,createDate,drugClass.drugClass,drugClass.id,id,name,profileName,references,therapy,updateDate
0,07/23/2014,BRAF Inhibitor,31,1,BRAF Inhibitor,BRAF V600E,"[{'id': 222, 'pubMedId': 21639808, 'title': 'Improved survival with vemurafenib in melanoma with BRAF V600E mutation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21639808'}, {'id': 467, 'pubMedId': 22608338, 'title': 'Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22608338'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,07/23/2014
0,07/23/2014,MEK1 Inhibitor,143,2,MEK1 Inhibitor,BRAF V600E,"[{'id': 468, 'pubMedId': 22663011, 'title': 'Improved survival with MEK inhibition in BRAF-mutated melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22663011'}]",,07/23/2014
0,07/23/2014,MEK2 Inhibitor,144,7,MEK2 Inhibitor,BRAF V600E,"[{'id': 468, 'pubMedId': 22663011, 'title': 'Improved survival with MEK inhibition in BRAF-mutated melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22663011'}]",,07/23/2014
0,08/08/2014,PARP Inhibitor (Pan),171,33,PARP Inhibitor (Pan),BRCA2 inact mut,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,08/08/2014
0,08/08/2014,PARP Inhibitor (Pan),171,36,PARP Inhibitor (Pan),BRCA1 inact mut,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,08/08/2014
0,08/08/2014,PARP Inhibitor (Pan),171,40,PARP Inhibitor (Pan),ATM inact mut,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",,08/08/2014
0,08/09/2014,PARP Inhibitor (Pan),171,42,PARP Inhibitor (Pan),ATM H1380Y,"[{'id': 514, 'pubMedId': 16556909, 'title': 'Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16556909'}]",,08/09/2014
0,08/09/2014,PARP Inhibitor (Pan),171,43,PARP Inhibitor (Pan),ATM dec exp,"[{'id': 520, 'pubMedId': 23881923, 'title': 'BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23881923'}]",,08/09/2014
0,08/12/2014,ALK Inhibitor,9,45,ALK Inhibitor,ALK F1174L,"[{'id': 527, 'pubMedId': 21838707, 'title': 'Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21838707'}]",,08/12/2014
0,08/12/2014,ALK Inhibitor,9,46,ALK Inhibitor,ALK G1128A,"[{'id': 527, 'pubMedId': 21838707, 'title': 'Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21838707'}]",,08/12/2014
0,08/12/2014,ALK Inhibitor,9,47,ALK Inhibitor,ALK I1171N,"[{'id': 527, 'pubMedId': 21838707, 'title': 'Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21838707'}]",,08/12/2014
0,08/12/2014,ALK Inhibitor,9,48,ALK Inhibitor,ALK F1245C,"[{'id': 527, 'pubMedId': 21838707, 'title': 'Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21838707'}]",,08/12/2014
0,08/12/2014,ALK Inhibitor,9,49,ALK Inhibitor,ALK R1192P,"[{'id': 527, 'pubMedId': 21838707, 'title': 'Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21838707'}]",,08/12/2014
0,08/12/2014,ALK Inhibitor,9,50,ALK Inhibitor,ALK R1275Q,"[{'id': 527, 'pubMedId': 21838707, 'title': 'Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21838707'}]",,08/12/2014
0,08/12/2014,PARP Inhibitor (Pan),171,51,PARP Inhibitor (Pan),ATM S1455R,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",,08/12/2014
0,08/12/2014,PARP Inhibitor (Pan),171,58,PARP Inhibitor (Pan),ATM S1403fs*3,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",,08/12/2014
0,08/13/2014,EGFR Inhibitor (Pan),74,69,EGFR Inhibitor (Pan),EGFR exon 19 del,"[{'id': 410, 'pubMedId': 16187797, 'title': 'Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16187797'}, {'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,08/13/2014
0,08/13/2014,EGFR Inhibitor 3rd gen,77,71,EGFR Inhibitor 3rd gen,EGFR T790M,"[{'id': 537, 'pubMedId': 24893891, 'title': 'AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24893891'}]",,08/13/2014
0,08/18/2014,HER2 Inhibitor,106,81,HER2 Inhibitor,ERBB2 act mut,"[{'id': 561, 'pubMedId': 22649146, 'title': 'HER2 mutations in non-small-cell lung cancer can be continually targeted.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22649146'}, {'id': 563, 'pubMedId': 21991949, 'title': 'Adjuvant trastuzumab in HER2-positive breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21991949'}, {'id': 564, 'pubMedId': 23801166, 'title': 'First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23801166'}]",,08/18/2014
0,08/18/2014,HER2 Inhibitor,106,82,HER2 Inhibitor,ERBB2 amp,"[{'id': 9560, 'pubMedId': 26260909, 'title': 'Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26260909'}, {'id': 9561, 'pubMedId': 24367169, 'title': 'Lapatinib: new opportunities for management of breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24367169'}]",,08/18/2014
0,08/26/2014,HER2 (ERBB2) Antibody,242,102,HER2 (ERBB2) Antibody,ERBB2 amp,"[{'id': 9557, 'pubMedId': 28520362, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28520362'}, {'id': 9558, 'pubMedId': 28520364, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28520364'}, {'id': 9559, 'pubMedId': 25398397, 'title': 'T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25398397'}]",,07/20/2017
0,09/08/2014,KIT Inhibitor,136,107,KIT Inhibitor,KIT N505I,"[{'id': 651, 'pubMedId': 24317392, 'title': 'A new KIT mutation (N505I) in acral melanoma confers constitutive signaling, favors tumorigenic properties, and is sensitive to imatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24317392'}]",,09/08/2014
0,09/18/2014,FLT3 Inhibitor,96,120,FLT3 Inhibitor,FLT3 L611_E612insCSSDNEYFYVDFREYEYDLKWEFPRENL,"[{'id': 705, 'pubMedId': 11756186, 'title': 'FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11756186'}]",,09/18/2014
0,09/18/2014,PARP Inhibitor (Pan),171,138,PARP Inhibitor (Pan),BRCA2 Q1037*,"[{'id': 770, 'pubMedId': 20609467, 'title': 'Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20609467'}]",,09/18/2014
0,10/20/2014,EGFR Inhibitor 1st gen,75,154,EGFR Inhibitor 1st gen,EGFR exon 19 del,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",,10/20/2014
0,11/01/2014,MET Inhibitor,147,159,MET Inhibitor,MET T1010I,"[{'id': 333, 'pubMedId': 17483355, 'title': 'An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17483355'}]",,11/01/2014
0,11/06/2014,mTOR Inhibitor,152,168,mTOR Inhibitor,PIK3CA E542K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,11/06/2014
0,11/13/2014,EGFR Inhibitor 3rd gen,77,170,EGFR Inhibitor 3rd gen,EGFR L858R EGFR T790M,"[{'id': 2493, 'pubMedId': 25668228, 'title': 'EGFR T790M resistance mutation in non small-cell lung carcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25668228'}]",,04/16/2015
0,01/30/2015,MEK1 Inhibitor,143,177,MEK1 Inhibitor,HRAS G12S,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,01/30/2015
0,01/30/2015,PI3K Inhibitor (Pan),181,178,PI3K Inhibitor (Pan),HRAS G12S,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,01/30/2015
0,01/30/2015,MEK2 Inhibitor,144,179,MEK2 Inhibitor,HRAS G12S,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,01/30/2015
0,02/06/2015,PIK3CG inhibitor,185,183,PIK3CG inhibitor,HRAS G12S,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,02/06/2015
0,02/06/2015,PIK3CD inhibitor,184,184,PIK3CD inhibitor,HRAS G12S,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,02/06/2015
0,02/06/2015,PIK3CB inhibitor,183,185,PIK3CB inhibitor,HRAS G12S,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,02/06/2015
0,02/06/2015,PIK3CA inhibitor,182,186,PIK3CA inhibitor,HRAS G12S,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,02/06/2015
0,02/06/2015,MEK inhibitor (Pan),142,187,MEK inhibitor (Pan),HRAS G12S,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,02/06/2015
0,02/08/2015,PI3K Inhibitor (Pan),181,188,PI3K Inhibitor (Pan),PIK3CA H1047R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,02/08/2015
0,02/08/2015,PIK3CA inhibitor,182,189,PIK3CA inhibitor,PIK3CA H1047R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,02/08/2015
0,02/08/2015,mTOR Inhibitor,152,190,mTOR Inhibitor,PIK3CA H1047R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,02/08/2015
0,02/08/2015,Akt Inhibitor (Pan),4,191,Akt Inhibitor (Pan),PIK3CA H1047R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,02/08/2015
0,02/08/2015,Akt Inhibitor (Pan),4,192,Akt Inhibitor (Pan),PIK3CA act mut,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,02/08/2015
0,02/08/2015,PI3K Inhibitor (Pan),181,193,PI3K Inhibitor (Pan),PIK3CA act mut,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,02/08/2015
0,02/08/2015,PIK3CA inhibitor,182,194,PIK3CA inhibitor,PIK3CA act mut,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,02/08/2015
0,02/08/2015,mTOR Inhibitor,152,195,mTOR Inhibitor,PIK3CA act mut,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,02/08/2015
0,02/09/2015,PI3K Inhibitor (Pan),181,203,PI3K Inhibitor (Pan),HRAS G12V,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,02/09/2015
0,02/09/2015,PIK3CA inhibitor,182,204,PIK3CA inhibitor,HRAS G12V,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,02/09/2015
0,02/09/2015,PIK3CB inhibitor,183,205,PIK3CB inhibitor,HRAS G12V,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,02/09/2015
0,02/09/2015,PIK3CD inhibitor,184,206,PIK3CD inhibitor,HRAS G12V,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,02/09/2015
0,02/09/2015,PIK3CG inhibitor,185,207,PIK3CG inhibitor,HRAS G12V,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,02/09/2015
0,02/09/2015,MEK2 Inhibitor,144,208,MEK2 Inhibitor,HRAS G12V,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,02/09/2015
0,02/09/2015,MEK1 Inhibitor,143,209,MEK1 Inhibitor,HRAS G12V,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,02/09/2015
0,02/09/2015,MEK inhibitor (Pan),142,210,MEK inhibitor (Pan),HRAS G12V,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,02/09/2015
0,02/09/2015,PI3K Inhibitor (Pan),181,211,PI3K Inhibitor (Pan),HRAS G13D,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,02/09/2015
0,02/09/2015,PIK3CA inhibitor,182,212,PIK3CA inhibitor,HRAS G13D,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,02/09/2015
0,02/09/2015,PIK3CB inhibitor,183,213,PIK3CB inhibitor,HRAS G13D,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,02/09/2015
0,02/09/2015,PIK3CD inhibitor,184,214,PIK3CD inhibitor,HRAS G13D,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,02/09/2015
0,02/09/2015,PIK3CG inhibitor,185,215,PIK3CG inhibitor,HRAS G13D,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,02/09/2015
0,02/09/2015,MEK inhibitor (Pan),142,216,MEK inhibitor (Pan),HRAS G13D,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,02/09/2015
0,02/09/2015,MEK1 Inhibitor,143,217,MEK1 Inhibitor,HRAS G13D,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,02/09/2015
0,02/09/2015,MEK2 Inhibitor,144,218,MEK2 Inhibitor,HRAS G13D,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,02/09/2015
0,02/09/2015,PI3K Inhibitor (Pan),181,219,PI3K Inhibitor (Pan),HRAS Q61K,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,02/09/2015
0,02/09/2015,PIK3CA inhibitor,182,220,PIK3CA inhibitor,HRAS Q61K,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,02/09/2015
0,02/09/2015,PIK3CB inhibitor,183,221,PIK3CB inhibitor,HRAS Q61K,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,02/09/2015
0,02/09/2015,PIK3CD inhibitor,184,222,PIK3CD inhibitor,HRAS Q61K,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,02/09/2015
0,02/09/2015,PIK3CG inhibitor,185,223,PIK3CG inhibitor,HRAS Q61K,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,02/09/2015
0,02/09/2015,MEK inhibitor (Pan),142,224,MEK inhibitor (Pan),HRAS Q61K,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,02/09/2015
0,02/09/2015,MEK1 Inhibitor,143,225,MEK1 Inhibitor,HRAS Q61K,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,02/09/2015
0,02/09/2015,MEK2 Inhibitor,144,226,MEK2 Inhibitor,HRAS Q61K,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,02/09/2015
0,02/09/2015,VEGFR2 Inhibitor,232,261,VEGFR2 Inhibitor,KDR Q472H,"[{'id': 217, 'pubMedId': 19723655, 'title': 'KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19723655'}, {'id': 1847, 'pubMedId': 25568876, 'title': 'Clinical advances in the development of novel VEGFR2 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25568876'}]",,02/09/2015
0,02/09/2015,EGFR Inhibitor 3rd gen,77,263,EGFR Inhibitor 3rd gen,EGFR exon 19 del,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,02/09/2015
0,02/09/2015,EGFR Inhibitor 2nd gen,76,264,EGFR Inhibitor 2nd gen,EGFR exon 19 del,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,02/09/2015
0,02/12/2015,VEGFR Inhibitor (Pan),230,270,VEGFR Inhibitor (Pan),KDR Q472H,"[{'id': 217, 'pubMedId': 19723655, 'title': 'KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19723655'}]",,02/12/2015
0,02/12/2015,VEGFR Inhibitor (Pan),230,271,VEGFR Inhibitor (Pan),KDR act mut,"[{'id': 217, 'pubMedId': 19723655, 'title': 'KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19723655'}]",,02/12/2015
0,02/12/2015,VEGFR2 Inhibitor,232,272,VEGFR2 Inhibitor,KDR act mut,"[{'id': 217, 'pubMedId': 19723655, 'title': 'KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19723655'}, {'id': 1847, 'pubMedId': 25568876, 'title': 'Clinical advances in the development of novel VEGFR2 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25568876'}]",,02/12/2015
0,02/12/2015,RET Inhibitor,199,273,RET Inhibitor,RET amp,"[{'id': 59, 'pubMedId': 22146228, 'title': 'Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22146228'}, {'id': 1869, 'pubMedId': 24705026, 'title': 'Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24705026'}, {'id': 1870, 'pubMedId': 21551259, 'title': 'In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21551259'}]",,02/12/2015
0,02/12/2015,RET Inhibitor,199,274,RET Inhibitor,RET Y791F,"[{'id': 59, 'pubMedId': 22146228, 'title': 'Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22146228'}, {'id': 1869, 'pubMedId': 24705026, 'title': 'Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24705026'}, {'id': 1870, 'pubMedId': 21551259, 'title': 'In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21551259'}]",,02/12/2015
0,02/12/2015,RET Inhibitor,199,275,RET Inhibitor,RET act mut,"[{'id': 59, 'pubMedId': 22146228, 'title': 'Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22146228'}, {'id': 1869, 'pubMedId': 24705026, 'title': 'Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24705026'}, {'id': 1870, 'pubMedId': 21551259, 'title': 'In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21551259'}]",,02/12/2015
0,02/16/2015,VEGFR2 Inhibitor,232,378,VEGFR2 Inhibitor,KDR D717V,"[{'id': 217, 'pubMedId': 19723655, 'title': 'KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19723655'}, {'id': 1847, 'pubMedId': 25568876, 'title': 'Clinical advances in the development of novel VEGFR2 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25568876'}]",,02/16/2015
0,02/16/2015,VEGFR Inhibitor (Pan),230,379,VEGFR Inhibitor (Pan),KDR D717V,"[{'id': 217, 'pubMedId': 19723655, 'title': 'KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19723655'}]",,02/16/2015
0,02/16/2015,RET Inhibitor,199,380,RET Inhibitor,RET C634R,"[{'id': 59, 'pubMedId': 22146228, 'title': 'Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22146228'}, {'id': 1869, 'pubMedId': 24705026, 'title': 'Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24705026'}, {'id': 1870, 'pubMedId': 21551259, 'title': 'In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21551259'}]",,02/16/2015
0,02/16/2015,RET Inhibitor,199,381,RET Inhibitor,RET V804L,"[{'id': 59, 'pubMedId': 22146228, 'title': 'Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22146228'}, {'id': 1869, 'pubMedId': 24705026, 'title': 'Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24705026'}, {'id': 1870, 'pubMedId': 21551259, 'title': 'In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21551259'}]",,02/16/2015
0,02/16/2015,RET Inhibitor,199,382,RET Inhibitor,RET V804M,"[{'id': 59, 'pubMedId': 22146228, 'title': 'Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22146228'}, {'id': 1869, 'pubMedId': 24705026, 'title': 'Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24705026'}, {'id': 1870, 'pubMedId': 21551259, 'title': 'In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21551259'}]",,02/16/2015
0,02/16/2015,FGFR Inhibitor (Pan),89,383,FGFR Inhibitor (Pan),FGFR1 act mut,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,02/16/2015
0,02/16/2015,FGFR1 Inhibitor,90,384,FGFR1 Inhibitor,FGFR1 act mut,"[{'id': 1901, 'pubMedId': 24980830, 'title': 'Discovery of novel non-ATP competitive FGFR1 inhibitors and evaluation of their anti-tumor activity in non-small cell lung cancer in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24980830'}]",,02/16/2015
0,02/16/2015,FGFR1 Inhibitor,90,385,FGFR1 Inhibitor,FGFR1 amp,"[{'id': 1901, 'pubMedId': 24980830, 'title': 'Discovery of novel non-ATP competitive FGFR1 inhibitors and evaluation of their anti-tumor activity in non-small cell lung cancer in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24980830'}]",,02/16/2015
0,02/16/2015,FGFR Inhibitor (Pan),89,386,FGFR Inhibitor (Pan),FGFR1 amp,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,02/16/2015
0,02/16/2015,Akt1 Inhibitor,6,389,Akt1 Inhibitor,PIK3CA act mut,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,02/16/2015
0,02/16/2015,Akt2 Inhibitor,7,390,Akt2 Inhibitor,PIK3CA act mut,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,02/16/2015
0,02/16/2015,Akt3 Inhibitor,8,391,Akt3 Inhibitor,PIK3CA act mut,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,02/16/2015
0,02/16/2015,mTOR Inhibitor,152,392,mTOR Inhibitor,PIK3CA C420R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,02/16/2015
0,02/16/2015,PIK3CA inhibitor,182,393,PIK3CA inhibitor,PIK3CA C420R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,02/16/2015
0,02/16/2015,PI3K Inhibitor (Pan),181,394,PI3K Inhibitor (Pan),PIK3CA C420R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,02/16/2015
0,02/16/2015,Akt3 Inhibitor,8,395,Akt3 Inhibitor,PIK3CA C420R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,02/16/2015
0,02/16/2015,Akt2 Inhibitor,7,396,Akt2 Inhibitor,PIK3CA C420R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,02/16/2015
0,02/16/2015,Akt1 Inhibitor,6,397,Akt1 Inhibitor,PIK3CA C420R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,02/16/2015
0,02/16/2015,Akt Inhibitor (Pan),4,398,Akt Inhibitor (Pan),PIK3CA C420R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,02/16/2015
0,02/16/2015,Akt Inhibitor (Pan),4,399,Akt Inhibitor (Pan),PIK3CA E542K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,02/16/2015
0,02/16/2015,Akt1 Inhibitor,6,400,Akt1 Inhibitor,PIK3CA E542K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,02/16/2015
0,02/16/2015,Akt2 Inhibitor,7,401,Akt2 Inhibitor,PIK3CA E542K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,02/16/2015
0,02/16/2015,Akt3 Inhibitor,8,402,Akt3 Inhibitor,PIK3CA E542K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,02/16/2015
0,02/16/2015,PI3K Inhibitor (Pan),181,403,PI3K Inhibitor (Pan),PIK3CA E542K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,02/16/2015
0,02/16/2015,PIK3CA inhibitor,182,404,PIK3CA inhibitor,PIK3CA E542K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,02/16/2015
0,02/16/2015,Akt Inhibitor (Pan),4,405,Akt Inhibitor (Pan),PIK3CA E545K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,02/16/2015
0,02/16/2015,Akt1 Inhibitor,6,406,Akt1 Inhibitor,PIK3CA E545K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,02/16/2015
0,02/16/2015,Akt2 Inhibitor,7,407,Akt2 Inhibitor,PIK3CA E545K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,02/16/2015
0,02/16/2015,Akt3 Inhibitor,8,408,Akt3 Inhibitor,PIK3CA E545K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,02/16/2015
0,02/16/2015,mTOR Inhibitor,152,409,mTOR Inhibitor,PIK3CA E545K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,02/16/2015
0,02/16/2015,PI3K Inhibitor (Pan),181,410,PI3K Inhibitor (Pan),PIK3CA E545K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,02/16/2015
0,02/16/2015,PIK3CA inhibitor,182,411,PIK3CA inhibitor,PIK3CA E545K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,02/16/2015
0,02/16/2015,Akt1 Inhibitor,6,412,Akt1 Inhibitor,PIK3CA H1047R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,02/16/2015
0,02/16/2015,Akt2 Inhibitor,7,413,Akt2 Inhibitor,PIK3CA H1047R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,02/16/2015
0,02/16/2015,Akt3 Inhibitor,8,414,Akt3 Inhibitor,PIK3CA H1047R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,02/16/2015
0,02/16/2015,FGFR Inhibitor (Pan),89,415,FGFR Inhibitor (Pan),FGFR2 act mut,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,02/16/2015
0,02/16/2015,FGFR2 Inhibitor,92,416,FGFR2 Inhibitor,FGFR2 act mut,"[{'id': 1903, 'pubMedId': 19212647, 'title': 'FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19212647'}]",,02/16/2015
0,02/16/2015,Akt Inhibitor (Pan),4,417,Akt Inhibitor (Pan),PIK3CA P539R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,02/16/2015
0,02/16/2015,Akt1 Inhibitor,6,418,Akt1 Inhibitor,PIK3CA P539R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,02/16/2015
0,02/16/2015,Akt2 Inhibitor,7,419,Akt2 Inhibitor,PIK3CA P539R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,02/16/2015
0,02/16/2015,Akt3 Inhibitor,8,420,Akt3 Inhibitor,PIK3CA P539R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,02/16/2015
0,02/16/2015,mTOR Inhibitor,152,421,mTOR Inhibitor,PIK3CA P539R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,02/16/2015
0,02/16/2015,PI3K Inhibitor (Pan),181,422,PI3K Inhibitor (Pan),PIK3CA P539R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,02/16/2015
0,02/16/2015,PIK3CA inhibitor,182,423,PIK3CA inhibitor,PIK3CA P539R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,02/16/2015
0,02/17/2015,Akt Inhibitor (Pan),4,430,Akt Inhibitor (Pan),AKT1 act mut,"[{'id': 104, 'pubMedId': 18504432, 'title': 'AKT1(E17K) in human solid tumours.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18504432'}, {'id': 8234, 'pubMedId': 26469692, 'title': 'Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26469692'}]",,02/17/2015
0,02/17/2015,FGFR Inhibitor (Pan),89,434,FGFR Inhibitor (Pan),FGFR3 act mut,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,02/17/2015
0,02/17/2015,FGFR3 Inhibitor,94,435,FGFR3 Inhibitor,FGFR3 act mut,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}, {'id': 1907, 'pubMedId': 20439987, 'title': 'NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20439987'}]",,02/17/2015
0,02/22/2015,RAS Inhibitor (Pan),198,447,RAS Inhibitor (Pan),HRAS Q61K,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,02/22/2015
0,02/22/2015,RAS Inhibitor (Pan),198,448,RAS Inhibitor (Pan),HRAS G12S,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,02/22/2015
0,02/23/2015,KIT Inhibitor,136,464,KIT Inhibitor,KIT act mut,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,02/23/2015
0,02/23/2015,KIT Inhibitor,136,465,KIT Inhibitor,KIT amp,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,02/23/2015
0,02/23/2015,RAF Inhibitor (Pan),197,466,RAF Inhibitor (Pan),BRAF V600E,"[{'id': 222, 'pubMedId': 21639808, 'title': 'Improved survival with vemurafenib in melanoma with BRAF V600E mutation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21639808'}, {'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,02/23/2015
0,02/23/2015,MEK inhibitor (Pan),142,467,MEK inhibitor (Pan),BRAF V600E,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,02/23/2015
0,02/23/2015,MEK2 Inhibitor,144,470,MEK2 Inhibitor,BRAF V600X,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}]",,02/23/2015
0,02/23/2015,MEK1 Inhibitor,143,471,MEK1 Inhibitor,BRAF V600X,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}]",,02/23/2015
0,02/23/2015,MEK inhibitor (Pan),142,472,MEK inhibitor (Pan),BRAF V600X,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}]",,02/23/2015
0,02/23/2015,RAF Inhibitor (Pan),197,473,RAF Inhibitor (Pan),BRAF V600X,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}]",,02/23/2015
0,02/23/2015,BRAF Inhibitor,31,474,BRAF Inhibitor,BRAF V600X,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}]",,02/23/2015
0,02/25/2015,MET Inhibitor,147,476,MET Inhibitor,MET act mut,"[{'id': 1994, 'pubMedId': 24045150, 'title': 'Met as a therapeutic target in HCC: facts and hopes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24045150'}]",,02/25/2015
0,02/25/2015,FGFR2 Inhibitor,92,477,FGFR2 Inhibitor,FGFR2 amp,"[{'id': 1903, 'pubMedId': 19212647, 'title': 'FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19212647'}]",,02/25/2015
0,02/25/2015,FGFR Inhibitor (Pan),89,478,FGFR Inhibitor (Pan),FGFR2 amp,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,02/25/2015
0,03/03/2015,Akt Inhibitor (Pan),4,497,Akt Inhibitor (Pan),AKT1 amp,"[{'id': 104, 'pubMedId': 18504432, 'title': 'AKT1(E17K) in human solid tumours.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18504432'}]",,03/03/2015
0,03/03/2015,Akt1 Inhibitor,6,498,Akt1 Inhibitor,AKT1 amp,"[{'id': 104, 'pubMedId': 18504432, 'title': 'AKT1(E17K) in human solid tumours.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18504432'}]",,03/03/2015
0,03/04/2015,MEK inhibitor (Pan),142,539,MEK inhibitor (Pan),GNAQ Q209P,"[{'id': 8672, 'pubMedId': 22515704, 'title': 'Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22515704'}, {'id': 8677, 'pubMedId': 22550165, 'title': 'Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22550165'}, {'id': 8679, 'pubMedId': 25113308, 'title': 'Biology of advanced uveal melanoma and next steps for clinical therapeutics.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25113308'}]",,03/04/2015
0,03/04/2015,PKC beta Inhibitor,191,543,PKC beta Inhibitor,GNAQ Q209P,"[{'id': 982, 'pubMedId': 22253748, 'title': 'The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22253748'}]",,03/04/2015
0,03/04/2015,PKC Inhibitor (Pan),192,544,PKC Inhibitor (Pan),GNAQ Q209P,"[{'id': 772, 'pubMedId': 24141786, 'title': 'Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24141786'}, {'id': 8663, 'pubMedId': 22653968, 'title': 'Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22653968'}]",,03/04/2015
0,03/04/2015,MEK inhibitor (Pan),142,605,MEK inhibitor (Pan),GNA11 Q209P,"[{'id': 8672, 'pubMedId': 22515704, 'title': 'Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22515704'}, {'id': 8679, 'pubMedId': 25113308, 'title': 'Biology of advanced uveal melanoma and next steps for clinical therapeutics.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25113308'}]",,03/04/2015
0,03/04/2015,PKC Inhibitor (Pan),192,610,PKC Inhibitor (Pan),GNA11 Q209P,"[{'id': 772, 'pubMedId': 24141786, 'title': 'Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24141786'}]",,03/04/2015
0,03/05/2015,KIT Inhibitor,136,703,KIT Inhibitor,KIT W557S,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/05/2015
0,03/05/2015,Akt Inhibitor (Pan),4,705,Akt Inhibitor (Pan),PIK3CA Q546K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/05/2015
0,03/05/2015,Akt1 Inhibitor,6,706,Akt1 Inhibitor,PIK3CA Q546K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/05/2015
0,03/05/2015,Akt2 Inhibitor,7,707,Akt2 Inhibitor,PIK3CA Q546K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/05/2015
0,03/05/2015,Akt3 Inhibitor,8,708,Akt3 Inhibitor,PIK3CA Q546K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/05/2015
0,03/05/2015,mTOR Inhibitor,152,709,mTOR Inhibitor,PIK3CA Q546K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/05/2015
0,03/05/2015,PI3K Inhibitor (Pan),181,710,PI3K Inhibitor (Pan),PIK3CA Q546K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/05/2015
0,03/05/2015,PIK3CA inhibitor,182,711,PIK3CA inhibitor,PIK3CA Q546K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/05/2015
0,03/05/2015,Akt Inhibitor (Pan),4,712,Akt Inhibitor (Pan),PIK3CA R88Q,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/05/2015
0,03/05/2015,Akt1 Inhibitor,6,713,Akt1 Inhibitor,PIK3CA R88Q,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/05/2015
0,03/05/2015,Akt2 Inhibitor,7,714,Akt2 Inhibitor,PIK3CA R88Q,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/05/2015
0,03/05/2015,Akt3 Inhibitor,8,715,Akt3 Inhibitor,PIK3CA R88Q,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/05/2015
0,03/05/2015,mTOR Inhibitor,152,716,mTOR Inhibitor,PIK3CA R88Q,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/05/2015
0,03/05/2015,PI3K Inhibitor (Pan),181,717,PI3K Inhibitor (Pan),PIK3CA R88Q,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/05/2015
0,03/05/2015,PIK3CA inhibitor,182,718,PIK3CA inhibitor,PIK3CA R88Q,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/05/2015
0,03/05/2015,KIT Inhibitor,136,726,KIT Inhibitor,KIT V825A,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/05/2015
0,03/05/2015,p53 Gene Therapy,167,727,p53 Gene Therapy,TP53 R248W,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,03/05/2015
0,03/05/2015,p53 Activator,166,728,p53 Activator,TP53 R248W,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,03/05/2015
0,03/05/2015,p53 Activator,166,729,p53 Activator,TP53 R249S,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,03/05/2015
0,03/05/2015,p53 Gene Therapy,167,730,p53 Gene Therapy,TP53 R249S,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,03/05/2015
0,03/05/2015,p53 Activator,166,731,p53 Activator,TP53 R175H,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,03/05/2015
0,03/05/2015,p53 Gene Therapy,167,732,p53 Gene Therapy,TP53 R175H,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,03/05/2015
0,03/05/2015,p53 Activator,166,733,p53 Activator,TP53 G245S,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,03/05/2015
0,03/05/2015,p53 Gene Therapy,167,734,p53 Gene Therapy,TP53 G245S,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,03/05/2015
0,03/05/2015,p53 Activator,166,735,p53 Activator,TP53 R273H,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,03/05/2015
0,03/05/2015,p53 Gene Therapy,167,736,p53 Gene Therapy,TP53 R273H,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,03/05/2015
0,03/07/2015,MEK inhibitor (Pan),142,900,MEK inhibitor (Pan),NRAS G12D,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,03/07/2015
0,03/07/2015,MEK1 Inhibitor,143,901,MEK1 Inhibitor,NRAS G12D,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,03/07/2015
0,03/07/2015,MEK2 Inhibitor,144,902,MEK2 Inhibitor,NRAS G12D,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,03/07/2015
0,03/07/2015,PI3K Inhibitor (Pan),181,903,PI3K Inhibitor (Pan),NRAS G12D,"[{'id': 28, 'pubMedId': 19629070, 'title': 'Targeting PI3K signalling in cancer: opportunities, challenges and limitations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19629070'}, {'id': 8051, 'pubMedId': 27307593, 'title': 'PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27307593'}]",,03/07/2015
0,03/07/2015,PIK3CA inhibitor,182,904,PIK3CA inhibitor,NRAS G12D,"[{'id': 28, 'pubMedId': 19629070, 'title': 'Targeting PI3K signalling in cancer: opportunities, challenges and limitations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19629070'}, {'id': 1145, 'pubMedId': 24608574, 'title': 'Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24608574'}]",,03/07/2015
0,03/07/2015,RAS Inhibitor (Pan),198,908,RAS Inhibitor (Pan),NRAS G12D,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,03/07/2015
0,03/07/2015,RAS Inhibitor (Pan),198,1175,RAS Inhibitor (Pan),HRAS G12V,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,03/07/2015
0,03/07/2015,MEK inhibitor (Pan),142,1176,MEK inhibitor (Pan),HRAS G12X,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/07/2015
0,03/07/2015,MEK1 Inhibitor,143,1177,MEK1 Inhibitor,HRAS G12X,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/07/2015
0,03/07/2015,MEK2 Inhibitor,144,1178,MEK2 Inhibitor,HRAS G12X,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/07/2015
0,03/07/2015,PI3K Inhibitor (Pan),181,1179,PI3K Inhibitor (Pan),HRAS G12X,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/07/2015
0,03/07/2015,PIK3CA inhibitor,182,1180,PIK3CA inhibitor,HRAS G12X,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/07/2015
0,03/07/2015,PIK3CB inhibitor,183,1181,PIK3CB inhibitor,HRAS G12X,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/07/2015
0,03/07/2015,PIK3CD inhibitor,184,1182,PIK3CD inhibitor,HRAS G12X,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/07/2015
0,03/07/2015,PIK3CG inhibitor,185,1183,PIK3CG inhibitor,HRAS G12X,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/07/2015
0,03/07/2015,RAS Inhibitor (Pan),198,1184,RAS Inhibitor (Pan),HRAS G12X,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,03/07/2015
0,03/07/2015,RAS Inhibitor (Pan),198,1185,RAS Inhibitor (Pan),HRAS G13D,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,03/07/2015
0,03/07/2015,MEK inhibitor (Pan),142,1186,MEK inhibitor (Pan),HRAS G13X,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/07/2015
0,03/07/2015,MEK1 Inhibitor,143,1187,MEK1 Inhibitor,HRAS G13X,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/07/2015
0,03/07/2015,MEK2 Inhibitor,144,1188,MEK2 Inhibitor,HRAS G13X,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/07/2015
0,03/07/2015,PI3K Inhibitor (Pan),181,1189,PI3K Inhibitor (Pan),HRAS G13X,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/07/2015
0,03/07/2015,PIK3CA inhibitor,182,1190,PIK3CA inhibitor,HRAS G13X,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/07/2015
0,03/07/2015,PIK3CB inhibitor,183,1191,PIK3CB inhibitor,HRAS G13X,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/07/2015
0,03/07/2015,PIK3CD inhibitor,184,1192,PIK3CD inhibitor,HRAS G13X,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/07/2015
0,03/07/2015,PIK3CG inhibitor,185,1193,PIK3CG inhibitor,HRAS G13X,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/07/2015
0,03/07/2015,RAS Inhibitor (Pan),198,1194,RAS Inhibitor (Pan),HRAS G13X,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,03/07/2015
0,03/07/2015,MEK inhibitor (Pan),142,1195,MEK inhibitor (Pan),HRAS Q61X,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/07/2015
0,03/07/2015,MEK1 Inhibitor,143,1196,MEK1 Inhibitor,HRAS Q61X,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/07/2015
0,03/07/2015,MEK2 Inhibitor,144,1197,MEK2 Inhibitor,HRAS Q61X,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/07/2015
0,03/07/2015,PI3K Inhibitor (Pan),181,1198,PI3K Inhibitor (Pan),HRAS Q61X,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/07/2015
0,03/07/2015,PIK3CA inhibitor,182,1199,PIK3CA inhibitor,HRAS Q61X,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/07/2015
0,03/07/2015,PIK3CB inhibitor,183,1200,PIK3CB inhibitor,HRAS Q61X,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/07/2015
0,03/07/2015,PIK3CD inhibitor,184,1201,PIK3CD inhibitor,HRAS Q61X,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/07/2015
0,03/07/2015,PIK3CG inhibitor,185,1202,PIK3CG inhibitor,HRAS Q61X,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/07/2015
0,03/07/2015,RAS Inhibitor (Pan),198,1203,RAS Inhibitor (Pan),HRAS Q61X,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,03/07/2015
0,03/10/2015,RET Inhibitor,199,1223,RET Inhibitor,RET C634W,"[{'id': 59, 'pubMedId': 22146228, 'title': 'Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22146228'}, {'id': 1869, 'pubMedId': 24705026, 'title': 'Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24705026'}, {'id': 1870, 'pubMedId': 21551259, 'title': 'In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21551259'}]",,03/10/2015
0,03/10/2015,PDGFR Inhibitor (Pan),175,1224,PDGFR Inhibitor (Pan),PDGFRA act mut,"[{'id': 2152, 'pubMedId': 20509775, 'title': 'Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20509775'}]",,03/10/2015
0,03/10/2015,PDGFR-alpha Inhibitor,176,1225,PDGFR-alpha Inhibitor,PDGFRA act mut,"[{'id': 1621, 'pubMedId': 24359404, 'title': 'Targeting the PDGF signaling pathway in tumor treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24359404'}]",,03/10/2015
0,03/10/2015,RET Inhibitor,199,1226,RET Inhibitor,RET M918T,"[{'id': 59, 'pubMedId': 22146228, 'title': 'Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22146228'}, {'id': 1869, 'pubMedId': 24705026, 'title': 'Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24705026'}, {'id': 1870, 'pubMedId': 21551259, 'title': 'In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21551259'}]",,03/10/2015
0,03/10/2015,RET Inhibitor,199,1227,RET Inhibitor,RET S891A,"[{'id': 59, 'pubMedId': 22146228, 'title': 'Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22146228'}, {'id': 1869, 'pubMedId': 24705026, 'title': 'Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24705026'}, {'id': 1870, 'pubMedId': 21551259, 'title': 'In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21551259'}]",,03/10/2015
0,03/10/2015,KIT Inhibitor,136,1228,KIT Inhibitor,KIT C443Y,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/10/2015
0,03/10/2015,KIT Inhibitor,136,1229,KIT Inhibitor,KIT A502_Y503insSA,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/10/2015
0,03/10/2015,KIT Inhibitor,136,1231,KIT Inhibitor,KIT D572A,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/10/2015
0,03/10/2015,KIT Inhibitor,136,1232,KIT Inhibitor,KIT D816A,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/10/2015
0,03/10/2015,KIT Inhibitor,136,1233,KIT Inhibitor,KIT D816E,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/10/2015
0,03/10/2015,KIT Inhibitor,136,1234,KIT Inhibitor,KIT D816F,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/10/2015
0,03/10/2015,PDGFR Inhibitor (Pan),175,1235,PDGFR Inhibitor (Pan),PDGFRA D842V,"[{'id': 2152, 'pubMedId': 20509775, 'title': 'Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20509775'}]",,03/10/2015
0,03/10/2015,PDGFR-alpha Inhibitor,176,1236,PDGFR-alpha Inhibitor,PDGFRA D842V,"[{'id': 1621, 'pubMedId': 24359404, 'title': 'Targeting the PDGF signaling pathway in tumor treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24359404'}]",,03/10/2015
0,03/10/2015,KIT Inhibitor,136,1237,KIT Inhibitor,KIT D816G,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/10/2015
0,03/10/2015,KIT Inhibitor,136,1239,KIT Inhibitor,KIT D816I,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/10/2015
0,03/10/2015,KIT Inhibitor,136,1241,KIT Inhibitor,KIT D816Y,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/10/2015
0,03/10/2015,p53 Activator,166,1242,p53 Activator,TP53 R248Q,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,03/10/2015
0,03/10/2015,p53 Gene Therapy,167,1243,p53 Gene Therapy,TP53 R248Q,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,03/10/2015
0,03/10/2015,PDGFR Inhibitor (Pan),175,1244,PDGFR Inhibitor (Pan),PDGFRA H650Q,"[{'id': 2152, 'pubMedId': 20509775, 'title': 'Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20509775'}]",,03/10/2015
0,03/10/2015,PDGFR-alpha Inhibitor,176,1245,PDGFR-alpha Inhibitor,PDGFRA H650Q,"[{'id': 1621, 'pubMedId': 24359404, 'title': 'Targeting the PDGF signaling pathway in tumor treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24359404'}]",,03/10/2015
0,03/11/2015,PDGFR Inhibitor (Pan),175,1246,PDGFR Inhibitor (Pan),PDGFRA V536E,"[{'id': 2152, 'pubMedId': 20509775, 'title': 'Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20509775'}]",,03/11/2015
0,03/11/2015,PDGFR-alpha Inhibitor,176,1247,PDGFR-alpha Inhibitor,PDGFRA V536E,"[{'id': 1621, 'pubMedId': 24359404, 'title': 'Targeting the PDGF signaling pathway in tumor treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24359404'}]",,03/11/2015
0,03/11/2015,PDGFR Inhibitor (Pan),175,1273,PDGFR Inhibitor (Pan),PDGFRA V561D,"[{'id': 2152, 'pubMedId': 20509775, 'title': 'Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20509775'}]",,03/11/2015
0,03/11/2015,PDGFR-alpha Inhibitor,176,1274,PDGFR-alpha Inhibitor,PDGFRA V561D,"[{'id': 1621, 'pubMedId': 24359404, 'title': 'Targeting the PDGF signaling pathway in tumor treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24359404'}]",,03/11/2015
0,03/12/2015,KIT Inhibitor,136,1472,KIT Inhibitor,KIT D820G,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/12/2015
0,03/12/2015,KIT Inhibitor,136,1473,KIT Inhibitor,KIT D820V,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/12/2015
0,03/12/2015,KIT Inhibitor,136,1474,KIT Inhibitor,KIT D820H,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/12/2015
0,03/12/2015,KIT Inhibitor,136,1475,KIT Inhibitor,KIT D820Y,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/12/2015
0,03/12/2015,KIT Inhibitor,136,1476,KIT Inhibitor,KIT F522C,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/12/2015
0,03/12/2015,KIT Inhibitor,136,1477,KIT Inhibitor,KIT H697Y,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/12/2015
0,03/12/2015,KIT Inhibitor,136,1480,KIT Inhibitor,KIT K509I,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/12/2015
0,03/12/2015,KIT Inhibitor,136,1481,KIT Inhibitor,KIT K550_K558del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/12/2015
0,03/12/2015,KIT Inhibitor,136,1482,KIT Inhibitor,KIT K550_V559del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/12/2015
0,03/12/2015,KIT Inhibitor,136,1483,KIT Inhibitor,KIT K558_E562del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/12/2015
0,03/12/2015,KIT Inhibitor,136,1484,KIT Inhibitor,KIT K558_N564del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/12/2015
0,03/12/2015,KIT Inhibitor,136,1485,KIT Inhibitor,KIT K558_V559del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/12/2015
0,03/12/2015,KIT Inhibitor,136,1486,KIT Inhibitor,KIT K558_V560del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/12/2015
0,03/12/2015,KIT Inhibitor,136,1488,KIT Inhibitor,KIT K642E,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/12/2015
0,03/12/2015,KIT Inhibitor,136,1489,KIT Inhibitor,KIT L576P,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/12/2015
0,03/12/2015,KIT Inhibitor,136,1491,KIT Inhibitor,KIT M552_Q556del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/12/2015
0,03/12/2015,KIT Inhibitor,136,1492,KIT Inhibitor,KIT M552_W557del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/12/2015
0,03/12/2015,KIT Inhibitor,136,1493,KIT Inhibitor,KIT A829P,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/12/2015
0,03/13/2015,MET Inhibitor,147,1509,MET Inhibitor,MET H1112Y,"[{'id': 1994, 'pubMedId': 24045150, 'title': 'Met as a therapeutic target in HCC: facts and hopes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24045150'}]",,03/13/2015
0,03/13/2015,MET Inhibitor,147,1510,MET Inhibitor,MET H1124D,"[{'id': 1994, 'pubMedId': 24045150, 'title': 'Met as a therapeutic target in HCC: facts and hopes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24045150'}]",,03/13/2015
0,03/13/2015,MET Inhibitor,147,1511,MET Inhibitor,MET H1112L,"[{'id': 1994, 'pubMedId': 24045150, 'title': 'Met as a therapeutic target in HCC: facts and hopes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24045150'}]",,03/13/2015
0,03/13/2015,MET Inhibitor,147,1513,MET Inhibitor,MET M1268T,"[{'id': 1994, 'pubMedId': 24045150, 'title': 'Met as a therapeutic target in HCC: facts and hopes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24045150'}]",,03/13/2015
0,03/13/2015,MET Inhibitor,147,1514,MET Inhibitor,MET N1118Y,"[{'id': 1994, 'pubMedId': 24045150, 'title': 'Met as a therapeutic target in HCC: facts and hopes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24045150'}]",,03/13/2015
0,03/13/2015,MET Inhibitor,147,1515,MET Inhibitor,MET V1110I,"[{'id': 1994, 'pubMedId': 24045150, 'title': 'Met as a therapeutic target in HCC: facts and hopes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24045150'}]",,03/13/2015
0,03/13/2015,MET Inhibitor,147,1516,MET Inhibitor,MET R988C,"[{'id': 1994, 'pubMedId': 24045150, 'title': 'Met as a therapeutic target in HCC: facts and hopes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24045150'}]",,03/13/2015
0,03/13/2015,MET Inhibitor,147,1517,MET Inhibitor,MET V1238I,"[{'id': 1994, 'pubMedId': 24045150, 'title': 'Met as a therapeutic target in HCC: facts and hopes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24045150'}]",,03/13/2015
0,03/13/2015,MET Inhibitor,147,1520,MET Inhibitor,MET Y1253D,"[{'id': 1994, 'pubMedId': 24045150, 'title': 'Met as a therapeutic target in HCC: facts and hopes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24045150'}]",,03/13/2015
0,03/13/2015,EGFR Inhibitor (Pan),74,1542,EGFR Inhibitor (Pan),EGFR E746_A750del,"[{'id': 410, 'pubMedId': 16187797, 'title': 'Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16187797'}, {'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,03/13/2015
0,03/13/2015,EGFR Inhibitor 1st gen,75,1543,EGFR Inhibitor 1st gen,EGFR E746_A750del,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",,03/13/2015
0,03/13/2015,EGFR Inhibitor 2nd gen,76,1544,EGFR Inhibitor 2nd gen,EGFR E746_A750del,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,03/13/2015
0,03/13/2015,EGFR Inhibitor 3rd gen,77,1545,EGFR Inhibitor 3rd gen,EGFR E746_A750del,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,03/13/2015
0,03/14/2015,MEK inhibitor (Pan),142,1576,MEK inhibitor (Pan),HRAS A59T,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/14/2015
0,03/14/2015,MEK1 Inhibitor,143,1577,MEK1 Inhibitor,HRAS A59T,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/14/2015
0,03/14/2015,MEK2 Inhibitor,144,1578,MEK2 Inhibitor,HRAS A59T,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/14/2015
0,03/14/2015,PI3K Inhibitor (Pan),181,1579,PI3K Inhibitor (Pan),HRAS A59T,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/14/2015
0,03/14/2015,PIK3CA inhibitor,182,1580,PIK3CA inhibitor,HRAS A59T,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/14/2015
0,03/14/2015,PIK3CB inhibitor,183,1581,PIK3CB inhibitor,HRAS A59T,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/14/2015
0,03/14/2015,PIK3CD inhibitor,184,1582,PIK3CD inhibitor,HRAS A59T,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/14/2015
0,03/14/2015,PIK3CG inhibitor,185,1583,PIK3CG inhibitor,HRAS A59T,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/14/2015
0,03/14/2015,RAS Inhibitor (Pan),198,1584,RAS Inhibitor (Pan),HRAS A59T,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,03/14/2015
0,03/14/2015,MEK inhibitor (Pan),142,1585,MEK inhibitor (Pan),HRAS G12A,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/14/2015
0,03/14/2015,MEK1 Inhibitor,143,1586,MEK1 Inhibitor,HRAS G12A,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/14/2015
0,03/14/2015,MEK2 Inhibitor,144,1587,MEK2 Inhibitor,HRAS G12A,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/14/2015
0,03/14/2015,PI3K Inhibitor (Pan),181,1588,PI3K Inhibitor (Pan),HRAS G12A,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/14/2015
0,03/14/2015,PIK3CA inhibitor,182,1589,PIK3CA inhibitor,HRAS G12A,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/14/2015
0,03/14/2015,PIK3CB inhibitor,183,1590,PIK3CB inhibitor,HRAS G12A,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/14/2015
0,03/14/2015,PIK3CD inhibitor,184,1591,PIK3CD inhibitor,HRAS G12A,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/14/2015
0,03/14/2015,PIK3CG inhibitor,185,1592,PIK3CG inhibitor,HRAS G12A,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/14/2015
0,03/14/2015,RAS Inhibitor (Pan),198,1593,RAS Inhibitor (Pan),HRAS G12A,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,03/14/2015
0,03/14/2015,MEK inhibitor (Pan),142,1594,MEK inhibitor (Pan),HRAS G12C,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/14/2015
0,03/14/2015,MEK1 Inhibitor,143,1595,MEK1 Inhibitor,HRAS G12C,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/14/2015
0,03/14/2015,MEK2 Inhibitor,144,1596,MEK2 Inhibitor,HRAS G12C,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/14/2015
0,03/14/2015,PI3K Inhibitor (Pan),181,1597,PI3K Inhibitor (Pan),HRAS G12C,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/14/2015
0,03/14/2015,PIK3CA inhibitor,182,1598,PIK3CA inhibitor,HRAS G12C,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/14/2015
0,03/14/2015,PIK3CB inhibitor,183,1599,PIK3CB inhibitor,HRAS G12C,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/14/2015
0,03/14/2015,PIK3CD inhibitor,184,1600,PIK3CD inhibitor,HRAS G12C,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/14/2015
0,03/14/2015,PIK3CG inhibitor,185,1601,PIK3CG inhibitor,HRAS G12C,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/14/2015
0,03/14/2015,RAS Inhibitor (Pan),198,1602,RAS Inhibitor (Pan),HRAS G12C,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,03/14/2015
0,03/14/2015,MEK inhibitor (Pan),142,1603,MEK inhibitor (Pan),HRAS G12D,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/14/2015
0,03/14/2015,MEK1 Inhibitor,143,1604,MEK1 Inhibitor,HRAS G12D,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/14/2015
0,03/14/2015,MEK2 Inhibitor,144,1605,MEK2 Inhibitor,HRAS G12D,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/14/2015
0,03/14/2015,PI3K Inhibitor (Pan),181,1606,PI3K Inhibitor (Pan),HRAS G12D,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/14/2015
0,03/14/2015,PIK3CA inhibitor,182,1607,PIK3CA inhibitor,HRAS G12D,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/14/2015
0,03/14/2015,PIK3CB inhibitor,183,1608,PIK3CB inhibitor,HRAS G12D,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/14/2015
0,03/14/2015,PIK3CD inhibitor,184,1609,PIK3CD inhibitor,HRAS G12D,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/14/2015
0,03/14/2015,PIK3CG inhibitor,185,1610,PIK3CG inhibitor,HRAS G12D,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/14/2015
0,03/14/2015,RAS Inhibitor (Pan),198,1611,RAS Inhibitor (Pan),HRAS G12D,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,03/14/2015
0,03/14/2015,MEK inhibitor (Pan),142,1612,MEK inhibitor (Pan),HRAS G12R,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/14/2015
0,03/14/2015,MEK1 Inhibitor,143,1613,MEK1 Inhibitor,HRAS G12R,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/14/2015
0,03/14/2015,MEK2 Inhibitor,144,1614,MEK2 Inhibitor,HRAS G12R,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/14/2015
0,03/14/2015,PI3K Inhibitor (Pan),181,1615,PI3K Inhibitor (Pan),HRAS G12R,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/14/2015
0,03/14/2015,PIK3CA inhibitor,182,1616,PIK3CA inhibitor,HRAS G12R,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/14/2015
0,03/14/2015,PIK3CB inhibitor,183,1617,PIK3CB inhibitor,HRAS G12R,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/14/2015
0,03/14/2015,PIK3CD inhibitor,184,1618,PIK3CD inhibitor,HRAS G12R,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/14/2015
0,03/14/2015,PIK3CG inhibitor,185,1619,PIK3CG inhibitor,HRAS G12R,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/14/2015
0,03/14/2015,RAS Inhibitor (Pan),198,1620,RAS Inhibitor (Pan),HRAS G12R,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,03/14/2015
0,03/14/2015,MEK inhibitor (Pan),142,1621,MEK inhibitor (Pan),HRAS G13R,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/14/2015
0,03/14/2015,MEK1 Inhibitor,143,1622,MEK1 Inhibitor,HRAS G13R,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/14/2015
0,03/14/2015,MEK2 Inhibitor,144,1623,MEK2 Inhibitor,HRAS G13R,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/14/2015
0,03/14/2015,PI3K Inhibitor (Pan),181,1624,PI3K Inhibitor (Pan),HRAS G13R,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/14/2015
0,03/14/2015,PIK3CA inhibitor,182,1625,PIK3CA inhibitor,HRAS G13R,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/14/2015
0,03/14/2015,PIK3CB inhibitor,183,1626,PIK3CB inhibitor,HRAS G13R,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/14/2015
0,03/14/2015,PIK3CD inhibitor,184,1627,PIK3CD inhibitor,HRAS G13R,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/14/2015
0,03/14/2015,PIK3CG inhibitor,185,1628,PIK3CG inhibitor,HRAS G13R,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/14/2015
0,03/14/2015,RAS Inhibitor (Pan),198,1629,RAS Inhibitor (Pan),HRAS G13R,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,03/14/2015
0,03/15/2015,PI3K Inhibitor (Pan),181,1630,PI3K Inhibitor (Pan),HRAS G13C,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/15/2015
0,03/15/2015,PIK3CA inhibitor,182,1631,PIK3CA inhibitor,HRAS G13C,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/15/2015
0,03/15/2015,PIK3CB inhibitor,183,1632,PIK3CB inhibitor,HRAS G13C,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/15/2015
0,03/15/2015,PIK3CD inhibitor,184,1633,PIK3CD inhibitor,HRAS G13C,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/15/2015
0,03/15/2015,PIK3CG inhibitor,185,1634,PIK3CG inhibitor,HRAS G13C,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/15/2015
0,03/15/2015,RAS Inhibitor (Pan),198,1635,RAS Inhibitor (Pan),HRAS G13C,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,03/15/2015
0,03/15/2015,MEK inhibitor (Pan),142,1636,MEK inhibitor (Pan),HRAS G13S,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/15/2015
0,03/15/2015,MEK1 Inhibitor,143,1637,MEK1 Inhibitor,HRAS G13S,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/15/2015
0,03/15/2015,MEK2 Inhibitor,144,1638,MEK2 Inhibitor,HRAS G13S,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/15/2015
0,03/15/2015,PI3K Inhibitor (Pan),181,1639,PI3K Inhibitor (Pan),HRAS G13S,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/15/2015
0,03/15/2015,PIK3CA inhibitor,182,1640,PIK3CA inhibitor,HRAS G13S,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/15/2015
0,03/15/2015,PIK3CB inhibitor,183,1641,PIK3CB inhibitor,HRAS G13S,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/15/2015
0,03/15/2015,PIK3CD inhibitor,184,1642,PIK3CD inhibitor,HRAS G13S,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/15/2015
0,03/15/2015,PIK3CG inhibitor,185,1643,PIK3CG inhibitor,HRAS G13S,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/15/2015
0,03/15/2015,RAS Inhibitor (Pan),198,1644,RAS Inhibitor (Pan),HRAS G13S,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,03/15/2015
0,03/15/2015,MEK inhibitor (Pan),142,1645,MEK inhibitor (Pan),HRAS G13C,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/15/2015
0,03/15/2015,MEK1 Inhibitor,143,1646,MEK1 Inhibitor,HRAS G13C,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/15/2015
0,03/15/2015,MEK2 Inhibitor,144,1647,MEK2 Inhibitor,HRAS G13C,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/15/2015
0,03/15/2015,MEK inhibitor (Pan),142,1661,MEK inhibitor (Pan),HRAS G13I,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/15/2015
0,03/15/2015,MEK1 Inhibitor,143,1662,MEK1 Inhibitor,HRAS G13I,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/15/2015
0,03/15/2015,MEK2 Inhibitor,144,1663,MEK2 Inhibitor,HRAS G13I,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/15/2015
0,03/15/2015,PI3K Inhibitor (Pan),181,1664,PI3K Inhibitor (Pan),HRAS G13I,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/15/2015
0,03/15/2015,PIK3CA inhibitor,182,1665,PIK3CA inhibitor,HRAS G13I,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/15/2015
0,03/15/2015,PIK3CB inhibitor,183,1666,PIK3CB inhibitor,HRAS G13I,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/15/2015
0,03/15/2015,PIK3CD inhibitor,184,1667,PIK3CD inhibitor,HRAS G13I,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/15/2015
0,03/15/2015,PIK3CG inhibitor,185,1668,PIK3CG inhibitor,HRAS G13I,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/15/2015
0,03/15/2015,RAS Inhibitor (Pan),198,1669,RAS Inhibitor (Pan),HRAS G13I,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,03/15/2015
0,03/15/2015,MEK inhibitor (Pan),142,1678,MEK inhibitor (Pan),HRAS G13V,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/15/2015
0,03/15/2015,MEK1 Inhibitor,143,1679,MEK1 Inhibitor,HRAS G13V,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/15/2015
0,03/15/2015,MEK2 Inhibitor,144,1680,MEK2 Inhibitor,HRAS G13V,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/15/2015
0,03/15/2015,PI3K Inhibitor (Pan),181,1681,PI3K Inhibitor (Pan),HRAS G13V,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/15/2015
0,03/15/2015,PIK3CA inhibitor,182,1682,PIK3CA inhibitor,HRAS G13V,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/15/2015
0,03/15/2015,PIK3CB inhibitor,183,1683,PIK3CB inhibitor,HRAS G13V,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/15/2015
0,03/15/2015,PIK3CD inhibitor,184,1684,PIK3CD inhibitor,HRAS G13V,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/15/2015
0,03/15/2015,PIK3CG inhibitor,185,1685,PIK3CG inhibitor,HRAS G13V,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/15/2015
0,03/15/2015,RAS Inhibitor (Pan),198,1686,RAS Inhibitor (Pan),HRAS G13V,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,03/15/2015
0,03/15/2015,MEK inhibitor (Pan),142,1687,MEK inhibitor (Pan),HRAS Q61H,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/15/2015
0,03/15/2015,MEK1 Inhibitor,143,1688,MEK1 Inhibitor,HRAS Q61H,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/15/2015
0,03/15/2015,MEK2 Inhibitor,144,1689,MEK2 Inhibitor,HRAS Q61H,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/15/2015
0,03/15/2015,PI3K Inhibitor (Pan),181,1690,PI3K Inhibitor (Pan),HRAS Q61H,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/15/2015
0,03/15/2015,PIK3CA inhibitor,182,1691,PIK3CA inhibitor,HRAS Q61H,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/15/2015
0,03/15/2015,PIK3CB inhibitor,183,1692,PIK3CB inhibitor,HRAS Q61H,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/15/2015
0,03/15/2015,PIK3CD inhibitor,184,1693,PIK3CD inhibitor,HRAS Q61H,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/15/2015
0,03/15/2015,PIK3CG inhibitor,185,1694,PIK3CG inhibitor,HRAS Q61H,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/15/2015
0,03/15/2015,RAS Inhibitor (Pan),198,1695,RAS Inhibitor (Pan),HRAS Q61H,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,03/15/2015
0,03/15/2015,MEK inhibitor (Pan),142,1696,MEK inhibitor (Pan),HRAS Q61L,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/15/2015
0,03/15/2015,MEK1 Inhibitor,143,1697,MEK1 Inhibitor,HRAS Q61L,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/15/2015
0,03/15/2015,MEK2 Inhibitor,144,1698,MEK2 Inhibitor,HRAS Q61L,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/15/2015
0,03/15/2015,PI3K Inhibitor (Pan),181,1699,PI3K Inhibitor (Pan),HRAS Q61L,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/15/2015
0,03/15/2015,PIK3CA inhibitor,182,1700,PIK3CA inhibitor,HRAS Q61L,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/15/2015
0,03/15/2015,PIK3CB inhibitor,183,1701,PIK3CB inhibitor,HRAS Q61L,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/15/2015
0,03/15/2015,PIK3CD inhibitor,184,1702,PIK3CD inhibitor,HRAS Q61L,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/15/2015
0,03/15/2015,PIK3CG inhibitor,185,1703,PIK3CG inhibitor,HRAS Q61L,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/15/2015
0,03/15/2015,RAS Inhibitor (Pan),198,1704,RAS Inhibitor (Pan),HRAS Q61L,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,03/15/2015
0,03/15/2015,MEK inhibitor (Pan),142,1705,MEK inhibitor (Pan),HRAS Q61R,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/15/2015
0,03/15/2015,MEK1 Inhibitor,143,1706,MEK1 Inhibitor,HRAS Q61R,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/15/2015
0,03/15/2015,MEK2 Inhibitor,144,1707,MEK2 Inhibitor,HRAS Q61R,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/15/2015
0,03/15/2015,PI3K Inhibitor (Pan),181,1708,PI3K Inhibitor (Pan),HRAS Q61R,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/15/2015
0,03/15/2015,PIK3CA inhibitor,182,1709,PIK3CA inhibitor,HRAS Q61R,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/15/2015
0,03/15/2015,PIK3CB inhibitor,183,1710,PIK3CB inhibitor,HRAS Q61R,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/15/2015
0,03/15/2015,PIK3CD inhibitor,184,1711,PIK3CD inhibitor,HRAS Q61R,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/15/2015
0,03/15/2015,PIK3CG inhibitor,185,1712,PIK3CG inhibitor,HRAS Q61R,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/15/2015
0,03/15/2015,RAS Inhibitor (Pan),198,1713,RAS Inhibitor (Pan),HRAS Q61R,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,03/15/2015
0,03/15/2015,MEK inhibitor (Pan),142,1722,MEK inhibitor (Pan),HRAS Q61P,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/15/2015
0,03/15/2015,MEK1 Inhibitor,143,1723,MEK1 Inhibitor,HRAS Q61P,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/15/2015
0,03/15/2015,MEK2 Inhibitor,144,1724,MEK2 Inhibitor,HRAS Q61P,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/15/2015
0,03/15/2015,PI3K Inhibitor (Pan),181,1725,PI3K Inhibitor (Pan),HRAS Q61P,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/15/2015
0,03/15/2015,PIK3CA inhibitor,182,1726,PIK3CA inhibitor,HRAS Q61P,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/15/2015
0,03/15/2015,PIK3CB inhibitor,183,1727,PIK3CB inhibitor,HRAS Q61P,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/15/2015
0,03/15/2015,PIK3CD inhibitor,184,1728,PIK3CD inhibitor,HRAS Q61P,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/15/2015
0,03/15/2015,PIK3CG inhibitor,185,1729,PIK3CG inhibitor,HRAS Q61P,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/15/2015
0,03/15/2015,RAS Inhibitor (Pan),198,1730,RAS Inhibitor (Pan),HRAS Q61P,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,03/15/2015
0,03/16/2015,Akt Inhibitor (Pan),4,1868,Akt Inhibitor (Pan),PIK3CA E453K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/16/2015
0,03/16/2015,Akt1 Inhibitor,6,1869,Akt1 Inhibitor,PIK3CA E453K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/16/2015
0,03/16/2015,Akt2 Inhibitor,7,1870,Akt2 Inhibitor,PIK3CA E453K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/16/2015
0,03/16/2015,Akt3 Inhibitor,8,1871,Akt3 Inhibitor,PIK3CA E453K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/16/2015
0,03/16/2015,mTOR Inhibitor,152,1872,mTOR Inhibitor,PIK3CA E453K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/16/2015
0,03/16/2015,PI3K Inhibitor (Pan),181,1873,PI3K Inhibitor (Pan),PIK3CA E453K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/16/2015
0,03/16/2015,PIK3CA inhibitor,182,1874,PIK3CA inhibitor,PIK3CA E453K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/16/2015
0,03/16/2015,Akt Inhibitor (Pan),4,1875,Akt Inhibitor (Pan),PIK3CA E453A,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/16/2015
0,03/16/2015,Akt1 Inhibitor,6,1876,Akt1 Inhibitor,PIK3CA E453A,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/16/2015
0,03/16/2015,Akt2 Inhibitor,7,1877,Akt2 Inhibitor,PIK3CA E453A,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/16/2015
0,03/16/2015,Akt3 Inhibitor,8,1878,Akt3 Inhibitor,PIK3CA E453A,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/16/2015
0,03/16/2015,mTOR Inhibitor,152,1879,mTOR Inhibitor,PIK3CA E453A,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/16/2015
0,03/16/2015,PI3K Inhibitor (Pan),181,1880,PI3K Inhibitor (Pan),PIK3CA E453A,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/16/2015
0,03/16/2015,PIK3CA inhibitor,182,1881,PIK3CA inhibitor,PIK3CA E453A,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/16/2015
0,03/16/2015,Akt Inhibitor (Pan),4,1882,Akt Inhibitor (Pan),PIK3CA E453Q,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/16/2015
0,03/16/2015,Akt1 Inhibitor,6,1883,Akt1 Inhibitor,PIK3CA E453Q,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/16/2015
0,03/16/2015,Akt2 Inhibitor,7,1884,Akt2 Inhibitor,PIK3CA E453Q,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/16/2015
0,03/16/2015,Akt3 Inhibitor,8,1885,Akt3 Inhibitor,PIK3CA E453Q,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/16/2015
0,03/16/2015,mTOR Inhibitor,152,1886,mTOR Inhibitor,PIK3CA E453Q,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/16/2015
0,03/16/2015,PI3K Inhibitor (Pan),181,1887,PI3K Inhibitor (Pan),PIK3CA E453Q,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/16/2015
0,03/16/2015,PIK3CA inhibitor,182,1888,PIK3CA inhibitor,PIK3CA E453Q,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/16/2015
0,03/16/2015,p53 Activator,166,1889,p53 Activator,TP53 R273C,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,03/16/2015
0,03/16/2015,p53 Gene Therapy,167,1890,p53 Gene Therapy,TP53 R273C,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,03/16/2015
0,03/16/2015,p53 Activator,166,1891,p53 Activator,TP53 R273L,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,03/16/2015
0,03/16/2015,p53 Gene Therapy,167,1892,p53 Gene Therapy,TP53 R273L,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,03/16/2015
0,03/16/2015,p53 Activator,166,1893,p53 Activator,TP53 R273S,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,03/16/2015
0,03/16/2015,p53 Gene Therapy,167,1894,p53 Gene Therapy,TP53 R273S,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,03/16/2015
0,03/16/2015,KIT Inhibitor,136,1895,KIT Inhibitor,KIT N822I,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/16/2015
0,03/16/2015,KIT Inhibitor,136,1896,KIT Inhibitor,KIT N655K,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/16/2015
0,03/16/2015,KIT Inhibitor,136,1897,KIT Inhibitor,KIT N822K,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/16/2015
0,03/16/2015,KIT Inhibitor,136,1898,KIT Inhibitor,KIT N822Y,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/16/2015
0,03/16/2015,KIT Inhibitor,136,1899,KIT Inhibitor,KIT P551_V555del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/16/2015
0,03/16/2015,KIT Inhibitor,136,1900,KIT Inhibitor,KIT S476I,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/16/2015
0,03/16/2015,KIT Inhibitor,136,1901,KIT Inhibitor,KIT T670I,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/16/2015
0,03/16/2015,KIT Inhibitor,136,1902,KIT Inhibitor,KIT V530I,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/16/2015
0,03/16/2015,KIT Inhibitor,136,1903,KIT Inhibitor,KIT V555_E562del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/16/2015
0,03/16/2015,KIT Inhibitor,136,1904,KIT Inhibitor,KIT V555_I571del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/16/2015
0,03/16/2015,KIT Inhibitor,136,1905,KIT Inhibitor,KIT V555_P573del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/16/2015
0,03/16/2015,KIT Inhibitor,136,1906,KIT Inhibitor,KIT V555_V559del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/16/2015
0,03/16/2015,KIT Inhibitor,136,1907,KIT Inhibitor,KIT V555_V560del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/16/2015
0,03/16/2015,KIT Inhibitor,136,1908,KIT Inhibitor,KIT V556_L576del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/16/2015
0,03/16/2015,KIT Inhibitor,136,1909,KIT Inhibitor,KIT V556_V560del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/16/2015
0,03/16/2015,KIT Inhibitor,136,1910,KIT Inhibitor,KIT V559del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/16/2015
0,03/16/2015,KIT Inhibitor,136,1911,KIT Inhibitor,KIT V559_E561del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/16/2015
0,03/16/2015,KIT Inhibitor,136,1912,KIT Inhibitor,KIT V559_G565del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/16/2015
0,03/16/2015,KIT Inhibitor,136,1913,KIT Inhibitor,KIT V559_V560del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/16/2015
0,03/16/2015,KIT Inhibitor,136,1914,KIT Inhibitor,KIT V560E,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/16/2015
0,03/16/2015,KIT Inhibitor,136,1915,KIT Inhibitor,KIT V560G,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/16/2015
0,03/16/2015,KIT Inhibitor,136,1916,KIT Inhibitor,KIT W557del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/16/2015
0,03/16/2015,KIT Inhibitor,136,1917,KIT Inhibitor,KIT W557G,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/16/2015
0,03/16/2015,KIT Inhibitor,136,1918,KIT Inhibitor,KIT W557R,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/16/2015
0,03/16/2015,SMO Inhibitor,208,1920,SMO Inhibitor,SMO act mut,"[{'id': 2241, 'pubMedId': 24202394, 'title': 'Unraveling the therapeutic potential of the Hedgehog pathway in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24202394'}]",,03/16/2015
0,03/16/2015,KIT Inhibitor,136,1921,KIT Inhibitor,KIT W557_E561del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/16/2015
0,03/16/2015,KIT Inhibitor,136,1922,KIT Inhibitor,KIT W557_K558del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/16/2015
0,03/16/2015,KIT Inhibitor,136,1923,KIT Inhibitor,KIT W557_V559del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/16/2015
0,03/16/2015,KIT Inhibitor,136,1924,KIT Inhibitor,KIT W557_V560del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/16/2015
0,03/16/2015,KIT Inhibitor,136,1926,KIT Inhibitor,KIT Y553_Q556del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/16/2015
0,03/16/2015,KIT Inhibitor,136,1928,KIT Inhibitor,KIT Y553_W557del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/16/2015
0,03/16/2015,KIT Inhibitor,136,1929,KIT Inhibitor,KIT Y578C,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/16/2015
0,03/16/2015,KIT Inhibitor,136,1930,KIT Inhibitor,KIT Y823D,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/16/2015
0,03/17/2015,PDGFR Inhibitor (Pan),175,1931,PDGFR Inhibitor (Pan),PDGFRA G853D,"[{'id': 2152, 'pubMedId': 20509775, 'title': 'Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20509775'}]",,03/17/2015
0,03/17/2015,PDGFR-alpha Inhibitor,176,1932,PDGFR-alpha Inhibitor,PDGFRA G853D,"[{'id': 1621, 'pubMedId': 24359404, 'title': 'Targeting the PDGF signaling pathway in tumor treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24359404'}]",,03/17/2015
0,03/17/2015,Akt Inhibitor (Pan),4,1938,Akt Inhibitor (Pan),PIK3CA E545G,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/17/2015
0,03/17/2015,Akt1 Inhibitor,6,1939,Akt1 Inhibitor,PIK3CA E545G,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/17/2015
0,03/17/2015,Akt2 Inhibitor,7,1940,Akt2 Inhibitor,PIK3CA E545G,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/17/2015
0,03/17/2015,Akt3 Inhibitor,8,1941,Akt3 Inhibitor,PIK3CA E545G,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/17/2015
0,03/17/2015,mTOR Inhibitor,152,1942,mTOR Inhibitor,PIK3CA E545G,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/17/2015
0,03/17/2015,PI3K Inhibitor (Pan),181,1943,PI3K Inhibitor (Pan),PIK3CA E545G,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/17/2015
0,03/17/2015,PIK3CA inhibitor,182,1944,PIK3CA inhibitor,PIK3CA E545G,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/17/2015
0,03/17/2015,Akt Inhibitor (Pan),4,1945,Akt Inhibitor (Pan),PIK3CA E545A,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/17/2015
0,03/17/2015,Akt1 Inhibitor,6,1946,Akt1 Inhibitor,PIK3CA E545A,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/17/2015
0,03/17/2015,Akt2 Inhibitor,7,1947,Akt2 Inhibitor,PIK3CA E545A,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/17/2015
0,03/17/2015,Akt3 Inhibitor,8,1948,Akt3 Inhibitor,PIK3CA E545A,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/17/2015
0,03/17/2015,mTOR Inhibitor,152,1949,mTOR Inhibitor,PIK3CA E545A,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/17/2015
0,03/17/2015,PI3K Inhibitor (Pan),181,1950,PI3K Inhibitor (Pan),PIK3CA E545A,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/17/2015
0,03/17/2015,PIK3CA inhibitor,182,1951,PIK3CA inhibitor,PIK3CA E545A,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/17/2015
0,03/17/2015,Akt Inhibitor (Pan),4,1952,Akt Inhibitor (Pan),PIK3CA G1049R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/17/2015
0,03/17/2015,Akt1 Inhibitor,6,1953,Akt1 Inhibitor,PIK3CA G1049R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/17/2015
0,03/17/2015,Akt2 Inhibitor,7,1954,Akt2 Inhibitor,PIK3CA G1049R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/17/2015
0,03/17/2015,Akt3 Inhibitor,8,1955,Akt3 Inhibitor,PIK3CA G1049R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/17/2015
0,03/17/2015,mTOR Inhibitor,152,1956,mTOR Inhibitor,PIK3CA G1049R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/17/2015
0,03/17/2015,PI3K Inhibitor (Pan),181,1957,PI3K Inhibitor (Pan),PIK3CA G1049R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/17/2015
0,03/17/2015,PIK3CA inhibitor,182,1958,PIK3CA inhibitor,PIK3CA G1049R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/17/2015
0,03/17/2015,Akt Inhibitor (Pan),4,1959,Akt Inhibitor (Pan),PIK3CA G106_R108del,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/17/2015
0,03/17/2015,Akt1 Inhibitor,6,1960,Akt1 Inhibitor,PIK3CA G106_R108del,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/17/2015
0,03/17/2015,Akt2 Inhibitor,7,1961,Akt2 Inhibitor,PIK3CA G106_R108del,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/17/2015
0,03/17/2015,Akt3 Inhibitor,8,1962,Akt3 Inhibitor,PIK3CA G106_R108del,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/17/2015
0,03/17/2015,mTOR Inhibitor,152,1963,mTOR Inhibitor,PIK3CA G106_R108del,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/17/2015
0,03/17/2015,PI3K Inhibitor (Pan),181,1964,PI3K Inhibitor (Pan),PIK3CA G106_R108del,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/17/2015
0,03/17/2015,PIK3CA inhibitor,182,1965,PIK3CA inhibitor,PIK3CA G106_R108del,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/17/2015
0,03/17/2015,Akt Inhibitor (Pan),4,1966,Akt Inhibitor (Pan),PIK3CA G118D,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/17/2015
0,03/17/2015,Akt1 Inhibitor,6,1967,Akt1 Inhibitor,PIK3CA G118D,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/17/2015
0,03/17/2015,Akt2 Inhibitor,7,1968,Akt2 Inhibitor,PIK3CA G118D,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/17/2015
0,03/17/2015,Akt3 Inhibitor,8,1969,Akt3 Inhibitor,PIK3CA G118D,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/17/2015
0,03/17/2015,mTOR Inhibitor,152,1970,mTOR Inhibitor,PIK3CA G118D,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/17/2015
0,03/17/2015,PI3K Inhibitor (Pan),181,1971,PI3K Inhibitor (Pan),PIK3CA G118D,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/17/2015
0,03/17/2015,PIK3CA inhibitor,182,1972,PIK3CA inhibitor,PIK3CA G118D,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/17/2015
0,03/17/2015,Akt Inhibitor (Pan),4,1973,Akt Inhibitor (Pan),PIK3CA H1047L,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/17/2015
0,03/17/2015,Akt1 Inhibitor,6,1974,Akt1 Inhibitor,PIK3CA H1047L,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/17/2015
0,03/17/2015,Akt2 Inhibitor,7,1975,Akt2 Inhibitor,PIK3CA H1047L,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/17/2015
0,03/17/2015,Akt3 Inhibitor,8,1976,Akt3 Inhibitor,PIK3CA H1047L,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/17/2015
0,03/17/2015,mTOR Inhibitor,152,1977,mTOR Inhibitor,PIK3CA H1047L,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/17/2015
0,03/17/2015,PI3K Inhibitor (Pan),181,1978,PI3K Inhibitor (Pan),PIK3CA H1047L,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/17/2015
0,03/17/2015,PIK3CA inhibitor,182,1979,PIK3CA inhibitor,PIK3CA H1047L,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/17/2015
0,03/17/2015,KIT Inhibitor,136,1980,KIT Inhibitor,KIT V559G,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/17/2015
0,03/17/2015,KIT Inhibitor,136,1981,KIT Inhibitor,KIT D579del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/17/2015
0,03/17/2015,KIT Inhibitor,136,1982,KIT Inhibitor,KIT V559A,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/17/2015
0,03/17/2015,KIT Inhibitor,136,1983,KIT Inhibitor,KIT V559D,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/17/2015
0,03/17/2015,KIT Inhibitor,136,1984,KIT Inhibitor,KIT V559I,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/17/2015
0,03/17/2015,KIT Inhibitor,136,1985,KIT Inhibitor,KIT V560D,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,03/17/2015
0,03/17/2015,PDPK1 Inhibitor,180,1986,PDPK1 Inhibitor,CTNNB1 act mut,"[{'id': 2220, 'pubMedId': 20028853, 'title': 'Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028853'}]",,03/02/2016
0,03/17/2015,CTNNB1 Inhibitor,60,1987,CTNNB1 Inhibitor,CTNNB1 act mut,"[{'id': 2251, 'pubMedId': 23258168, 'title': 'WNT signalling pathways as therapeutic targets in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23258168'}]",,03/17/2015
0,03/17/2015,MEK1 Inhibitor,143,1992,MEK1 Inhibitor,MAP2K1 act mut,"[{'id': 119, 'pubMedId': 18632602, 'title': 'Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18632602'}, {'id': 2253, 'pubMedId': 18223206, 'title': 'Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18223206'}]",,03/17/2015
0,03/17/2015,MEK inhibitor (Pan),142,1993,MEK inhibitor (Pan),MAP2K1 act mut,"[{'id': 119, 'pubMedId': 18632602, 'title': 'Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18632602'}, {'id': 2253, 'pubMedId': 18223206, 'title': 'Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18223206'}]",,03/17/2015
0,03/17/2015,MEK inhibitor (Pan),142,1998,MEK inhibitor (Pan),MAP2K1 amp,"[{'id': 119, 'pubMedId': 18632602, 'title': 'Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18632602'}, {'id': 2253, 'pubMedId': 18223206, 'title': 'Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18223206'}]",,03/17/2015
0,03/17/2015,MEK1 Inhibitor,143,1999,MEK1 Inhibitor,MAP2K1 amp,"[{'id': 119, 'pubMedId': 18632602, 'title': 'Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18632602'}, {'id': 2253, 'pubMedId': 18223206, 'title': 'Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18223206'}]",,03/17/2015
0,03/17/2015,MEK inhibitor (Pan),142,2000,MEK inhibitor (Pan),MAP2K1 D67N,"[{'id': 119, 'pubMedId': 18632602, 'title': 'Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18632602'}, {'id': 2253, 'pubMedId': 18223206, 'title': 'Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18223206'}]",,03/17/2015
0,03/17/2015,MEK1 Inhibitor,143,2001,MEK1 Inhibitor,MAP2K1 D67N,"[{'id': 119, 'pubMedId': 18632602, 'title': 'Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18632602'}, {'id': 2253, 'pubMedId': 18223206, 'title': 'Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18223206'}]",,03/17/2015
0,03/17/2015,PDGFR Inhibitor (Pan),175,2002,PDGFR Inhibitor (Pan),PDGFRA I843del,"[{'id': 2152, 'pubMedId': 20509775, 'title': 'Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20509775'}]",,03/17/2015
0,03/17/2015,PDGFR-alpha Inhibitor,176,2003,PDGFR-alpha Inhibitor,PDGFRA I843del,"[{'id': 1621, 'pubMedId': 24359404, 'title': 'Targeting the PDGF signaling pathway in tumor treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24359404'}]",,03/17/2015
0,03/17/2015,PDGFR Inhibitor (Pan),175,2004,PDGFR Inhibitor (Pan),PDGFRA I843_D846del,"[{'id': 2152, 'pubMedId': 20509775, 'title': 'Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20509775'}]",,03/17/2015
0,03/17/2015,PDGFR-alpha Inhibitor,176,2005,PDGFR-alpha Inhibitor,PDGFRA I843_D846del,"[{'id': 1621, 'pubMedId': 24359404, 'title': 'Targeting the PDGF signaling pathway in tumor treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24359404'}]",,03/17/2015
0,03/18/2015,MEK inhibitor (Pan),142,2040,MEK inhibitor (Pan),BRAF G464E,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,03/18/2015
0,03/18/2015,MEK1 Inhibitor,143,2041,MEK1 Inhibitor,BRAF G464E,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,03/18/2015
0,03/18/2015,MEK2 Inhibitor,144,2042,MEK2 Inhibitor,BRAF G464E,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,03/18/2015
0,03/18/2015,PDGFR Inhibitor (Pan),175,2153,PDGFR Inhibitor (Pan),PDGFRA N659K,"[{'id': 2152, 'pubMedId': 20509775, 'title': 'Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20509775'}]",,03/18/2015
0,03/18/2015,PDGFR-alpha Inhibitor,176,2154,PDGFR-alpha Inhibitor,PDGFRA N659K,"[{'id': 1621, 'pubMedId': 24359404, 'title': 'Targeting the PDGF signaling pathway in tumor treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24359404'}]",,03/18/2015
0,03/18/2015,BRAF Inhibitor,31,2188,BRAF Inhibitor,BRAF V600M,"[{'id': 222, 'pubMedId': 21639808, 'title': 'Improved survival with vemurafenib in melanoma with BRAF V600E mutation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21639808'}, {'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 467, 'pubMedId': 22608338, 'title': 'Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22608338'}]",,03/18/2015
0,03/18/2015,MEK inhibitor (Pan),142,2189,MEK inhibitor (Pan),BRAF V600M,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}]",,03/18/2015
0,03/18/2015,MEK1 Inhibitor,143,2190,MEK1 Inhibitor,BRAF V600M,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 468, 'pubMedId': 22663011, 'title': 'Improved survival with MEK inhibition in BRAF-mutated melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22663011'}]",,03/18/2015
0,03/18/2015,MEK2 Inhibitor,144,2191,MEK2 Inhibitor,BRAF V600M,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 468, 'pubMedId': 22663011, 'title': 'Improved survival with MEK inhibition in BRAF-mutated melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22663011'}]",,03/18/2015
0,03/18/2015,RAF Inhibitor (Pan),197,2192,RAF Inhibitor (Pan),BRAF V600M,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}]",,03/18/2015
0,03/18/2015,BRAF Inhibitor,31,2193,BRAF Inhibitor,BRAF V600Q,"[{'id': 222, 'pubMedId': 21639808, 'title': 'Improved survival with vemurafenib in melanoma with BRAF V600E mutation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21639808'}, {'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 467, 'pubMedId': 22608338, 'title': 'Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22608338'}]",,03/18/2015
0,03/18/2015,MEK inhibitor (Pan),142,2194,MEK inhibitor (Pan),BRAF V600Q,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}]",,03/18/2015
0,03/18/2015,MEK1 Inhibitor,143,2195,MEK1 Inhibitor,BRAF V600Q,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 468, 'pubMedId': 22663011, 'title': 'Improved survival with MEK inhibition in BRAF-mutated melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22663011'}]",,03/18/2015
0,03/18/2015,MEK2 Inhibitor,144,2196,MEK2 Inhibitor,BRAF V600Q,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 468, 'pubMedId': 22663011, 'title': 'Improved survival with MEK inhibition in BRAF-mutated melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22663011'}]",,03/18/2015
0,03/18/2015,RAF Inhibitor (Pan),197,2197,RAF Inhibitor (Pan),BRAF V600Q,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}]",,03/18/2015
0,03/18/2015,BRAF Inhibitor,31,2198,BRAF Inhibitor,BRAF V600R,"[{'id': 222, 'pubMedId': 21639808, 'title': 'Improved survival with vemurafenib in melanoma with BRAF V600E mutation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21639808'}, {'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 467, 'pubMedId': 22608338, 'title': 'Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22608338'}]",,03/18/2015
0,03/18/2015,MEK inhibitor (Pan),142,2199,MEK inhibitor (Pan),BRAF V600R,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}]",,03/18/2015
0,03/18/2015,MEK1 Inhibitor,143,2200,MEK1 Inhibitor,BRAF V600R,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 468, 'pubMedId': 22663011, 'title': 'Improved survival with MEK inhibition in BRAF-mutated melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22663011'}]",,03/18/2015
0,03/18/2015,MEK2 Inhibitor,144,2201,MEK2 Inhibitor,BRAF V600R,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}, {'id': 468, 'pubMedId': 22663011, 'title': 'Improved survival with MEK inhibition in BRAF-mutated melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22663011'}]",,03/18/2015
0,03/18/2015,RAF Inhibitor (Pan),197,2202,RAF Inhibitor (Pan),BRAF V600R,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}]",,03/18/2015
0,03/18/2015,PDGFR Inhibitor (Pan),175,2218,PDGFR Inhibitor (Pan),PDGFRA P577S,"[{'id': 2152, 'pubMedId': 20509775, 'title': 'Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20509775'}]",,03/18/2015
0,03/18/2015,PDGFR-alpha Inhibitor,176,2219,PDGFR-alpha Inhibitor,PDGFRA P577S,"[{'id': 1621, 'pubMedId': 24359404, 'title': 'Targeting the PDGF signaling pathway in tumor treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24359404'}]",,03/18/2015
0,03/18/2015,MEK inhibitor (Pan),142,2220,MEK inhibitor (Pan),MAP2K1 K57C,"[{'id': 119, 'pubMedId': 18632602, 'title': 'Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18632602'}, {'id': 2253, 'pubMedId': 18223206, 'title': 'Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18223206'}]",,03/18/2015
0,03/18/2015,MEK1 Inhibitor,143,2221,MEK1 Inhibitor,MAP2K1 K57C,"[{'id': 119, 'pubMedId': 18632602, 'title': 'Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18632602'}, {'id': 2253, 'pubMedId': 18223206, 'title': 'Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18223206'}]",,03/18/2015
0,03/18/2015,Akt Inhibitor (Pan),4,2229,Akt Inhibitor (Pan),PIK3CA K111N,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/18/2015
0,03/18/2015,Akt1 Inhibitor,6,2230,Akt1 Inhibitor,PIK3CA K111N,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/18/2015
0,03/18/2015,Akt2 Inhibitor,7,2231,Akt2 Inhibitor,PIK3CA K111N,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/18/2015
0,03/18/2015,Akt3 Inhibitor,8,2232,Akt3 Inhibitor,PIK3CA K111N,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/18/2015
0,03/18/2015,mTOR Inhibitor,152,2233,mTOR Inhibitor,PIK3CA K111N,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/18/2015
0,03/18/2015,PI3K Inhibitor (Pan),181,2234,PI3K Inhibitor (Pan),PIK3CA K111N,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/18/2015
0,03/18/2015,PIK3CA inhibitor,182,2235,PIK3CA inhibitor,PIK3CA K111N,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/18/2015
0,03/18/2015,Akt Inhibitor (Pan),4,2236,Akt Inhibitor (Pan),PIK3CA K111E,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/18/2015
0,03/18/2015,Akt1 Inhibitor,6,2237,Akt1 Inhibitor,PIK3CA K111E,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/18/2015
0,03/18/2015,Akt2 Inhibitor,7,2238,Akt2 Inhibitor,PIK3CA K111E,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/18/2015
0,03/18/2015,Akt3 Inhibitor,8,2239,Akt3 Inhibitor,PIK3CA K111E,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/18/2015
0,03/18/2015,mTOR Inhibitor,152,2240,mTOR Inhibitor,PIK3CA K111E,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/18/2015
0,03/18/2015,PI3K Inhibitor (Pan),181,2241,PI3K Inhibitor (Pan),PIK3CA K111E,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/18/2015
0,03/18/2015,PIK3CA inhibitor,182,2242,PIK3CA inhibitor,PIK3CA K111E,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/18/2015
0,03/18/2015,MEK inhibitor (Pan),142,2245,MEK inhibitor (Pan),MAP2K1 K57N,"[{'id': 119, 'pubMedId': 18632602, 'title': 'Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18632602'}, {'id': 2253, 'pubMedId': 18223206, 'title': 'Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18223206'}]",,03/18/2015
0,03/18/2015,MEK1 Inhibitor,143,2246,MEK1 Inhibitor,MAP2K1 K57N,"[{'id': 119, 'pubMedId': 18632602, 'title': 'Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18632602'}, {'id': 2253, 'pubMedId': 18223206, 'title': 'Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18223206'}]",,03/18/2015
0,03/18/2015,Akt Inhibitor (Pan),4,2247,Akt Inhibitor (Pan),PIK3CA M1043V,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/18/2015
0,03/18/2015,Akt1 Inhibitor,6,2248,Akt1 Inhibitor,PIK3CA M1043V,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/18/2015
0,03/18/2015,Akt2 Inhibitor,7,2249,Akt2 Inhibitor,PIK3CA M1043V,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/18/2015
0,03/18/2015,Akt3 Inhibitor,8,2250,Akt3 Inhibitor,PIK3CA M1043V,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/18/2015
0,03/18/2015,mTOR Inhibitor,152,2251,mTOR Inhibitor,PIK3CA M1043V,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/18/2015
0,03/18/2015,PI3K Inhibitor (Pan),181,2252,PI3K Inhibitor (Pan),PIK3CA M1043V,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/18/2015
0,03/18/2015,PIK3CA inhibitor,182,2253,PIK3CA inhibitor,PIK3CA M1043V,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/18/2015
0,03/18/2015,Akt Inhibitor (Pan),4,2254,Akt Inhibitor (Pan),PIK3CA N1068fs*4,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/18/2015
0,03/18/2015,Akt1 Inhibitor,6,2255,Akt1 Inhibitor,PIK3CA N1068fs*4,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/18/2015
0,03/18/2015,Akt2 Inhibitor,7,2256,Akt2 Inhibitor,PIK3CA N1068fs*4,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/18/2015
0,03/18/2015,Akt3 Inhibitor,8,2257,Akt3 Inhibitor,PIK3CA N1068fs*4,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/18/2015
0,03/18/2015,mTOR Inhibitor,152,2258,mTOR Inhibitor,PIK3CA N1068fs*4,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/18/2015
0,03/18/2015,PI3K Inhibitor (Pan),181,2259,PI3K Inhibitor (Pan),PIK3CA N1068fs*4,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/18/2015
0,03/18/2015,PIK3CA inhibitor,182,2260,PIK3CA inhibitor,PIK3CA N1068fs*4,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/18/2015
0,03/18/2015,Akt Inhibitor (Pan),4,2261,Akt Inhibitor (Pan),PIK3CA N345K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/18/2015
0,03/18/2015,Akt1 Inhibitor,6,2262,Akt1 Inhibitor,PIK3CA N345K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/18/2015
0,03/18/2015,Akt2 Inhibitor,7,2263,Akt2 Inhibitor,PIK3CA N345K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/18/2015
0,03/18/2015,Akt3 Inhibitor,8,2264,Akt3 Inhibitor,PIK3CA N345K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/18/2015
0,03/18/2015,mTOR Inhibitor,152,2265,mTOR Inhibitor,PIK3CA N345K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/18/2015
0,03/18/2015,PI3K Inhibitor (Pan),181,2266,PI3K Inhibitor (Pan),PIK3CA N345K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/18/2015
0,03/18/2015,PIK3CA inhibitor,182,2267,PIK3CA inhibitor,PIK3CA N345K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/18/2015
0,03/18/2015,PDGFR Inhibitor (Pan),175,2272,PDGFR Inhibitor (Pan),PDGFRA D842I,"[{'id': 2152, 'pubMedId': 20509775, 'title': 'Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20509775'}]",,03/18/2015
0,03/18/2015,PDGFR-alpha Inhibitor,176,2273,PDGFR-alpha Inhibitor,PDGFRA D842I,"[{'id': 1621, 'pubMedId': 24359404, 'title': 'Targeting the PDGF signaling pathway in tumor treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24359404'}]",,03/18/2015
0,03/18/2015,PDGFR Inhibitor (Pan),175,2274,PDGFR Inhibitor (Pan),PDGFRA D842Y,"[{'id': 2152, 'pubMedId': 20509775, 'title': 'Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20509775'}]",,03/18/2015
0,03/18/2015,PDGFR-alpha Inhibitor,176,2275,PDGFR-alpha Inhibitor,PDGFRA D842Y,"[{'id': 1621, 'pubMedId': 24359404, 'title': 'Targeting the PDGF signaling pathway in tumor treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24359404'}]",,03/18/2015
0,03/18/2015,PDGFR Inhibitor (Pan),175,2276,PDGFR Inhibitor (Pan),PDGFRA D846Y,"[{'id': 2152, 'pubMedId': 20509775, 'title': 'Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20509775'}]",,03/18/2015
0,03/18/2015,PDGFR-alpha Inhibitor,176,2277,PDGFR-alpha Inhibitor,PDGFRA D846Y,"[{'id': 1621, 'pubMedId': 24359404, 'title': 'Targeting the PDGF signaling pathway in tumor treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24359404'}]",,03/18/2015
0,03/18/2015,Akt Inhibitor (Pan),4,2278,Akt Inhibitor (Pan),PIK3CA R115L,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/18/2015
0,03/18/2015,Akt1 Inhibitor,6,2279,Akt1 Inhibitor,PIK3CA R115L,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/18/2015
0,03/18/2015,Akt2 Inhibitor,7,2280,Akt2 Inhibitor,PIK3CA R115L,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/18/2015
0,03/18/2015,Akt3 Inhibitor,8,2281,Akt3 Inhibitor,PIK3CA R115L,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/18/2015
0,03/18/2015,mTOR Inhibitor,152,2282,mTOR Inhibitor,PIK3CA R115L,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/18/2015
0,03/18/2015,PI3K Inhibitor (Pan),181,2283,PI3K Inhibitor (Pan),PIK3CA R115L,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/18/2015
0,03/18/2015,PIK3CA inhibitor,182,2284,PIK3CA inhibitor,PIK3CA R115L,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/18/2015
0,03/19/2015,PDGFR Inhibitor (Pan),175,2285,PDGFR Inhibitor (Pan),PDGFRA R841K,"[{'id': 2152, 'pubMedId': 20509775, 'title': 'Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20509775'}]",,03/19/2015
0,03/19/2015,PDGFR-alpha Inhibitor,176,2286,PDGFR-alpha Inhibitor,PDGFRA R841K,"[{'id': 1621, 'pubMedId': 24359404, 'title': 'Targeting the PDGF signaling pathway in tumor treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24359404'}]",,03/19/2015
0,03/19/2015,PDGFR Inhibitor (Pan),175,2287,PDGFR Inhibitor (Pan),PDGFRA V658A,"[{'id': 2152, 'pubMedId': 20509775, 'title': 'Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20509775'}]",,03/19/2015
0,03/19/2015,PDGFR-alpha Inhibitor,176,2288,PDGFR-alpha Inhibitor,PDGFRA V658A,"[{'id': 1621, 'pubMedId': 24359404, 'title': 'Targeting the PDGF signaling pathway in tumor treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24359404'}]",,03/19/2015
0,03/19/2015,Akt Inhibitor (Pan),4,2289,Akt Inhibitor (Pan),PIK3CA M1043I,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/19/2015
0,03/19/2015,Akt1 Inhibitor,6,2290,Akt1 Inhibitor,PIK3CA M1043I,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/19/2015
0,03/19/2015,Akt2 Inhibitor,7,2291,Akt2 Inhibitor,PIK3CA M1043I,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/19/2015
0,03/19/2015,Akt3 Inhibitor,8,2292,Akt3 Inhibitor,PIK3CA M1043I,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/19/2015
0,03/19/2015,mTOR Inhibitor,152,2293,mTOR Inhibitor,PIK3CA M1043I,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/19/2015
0,03/19/2015,PI3K Inhibitor (Pan),181,2294,PI3K Inhibitor (Pan),PIK3CA M1043I,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/19/2015
0,03/19/2015,PIK3CA inhibitor,182,2295,PIK3CA inhibitor,PIK3CA M1043I,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/19/2015
0,03/19/2015,Akt Inhibitor (Pan),4,2308,Akt Inhibitor (Pan),PTEN inact mut,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,03/19/2015
0,03/19/2015,PI3K Inhibitor (Pan),181,2309,PI3K Inhibitor (Pan),PTEN inact mut,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,03/19/2015
0,03/19/2015,Akt Inhibitor (Pan),4,2310,Akt Inhibitor (Pan),PIK3CA T1025S,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/19/2015
0,03/19/2015,Akt1 Inhibitor,6,2311,Akt1 Inhibitor,PIK3CA T1025S,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/19/2015
0,03/19/2015,Akt2 Inhibitor,7,2312,Akt2 Inhibitor,PIK3CA T1025S,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/19/2015
0,03/19/2015,Akt3 Inhibitor,8,2313,Akt3 Inhibitor,PIK3CA T1025S,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/19/2015
0,03/19/2015,mTOR Inhibitor,152,2314,mTOR Inhibitor,PIK3CA T1025S,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/19/2015
0,03/19/2015,PI3K Inhibitor (Pan),181,2315,PI3K Inhibitor (Pan),PIK3CA T1025S,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/19/2015
0,03/19/2015,PIK3CA inhibitor,182,2316,PIK3CA inhibitor,PIK3CA T1025S,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/19/2015
0,03/19/2015,RET Inhibitor,199,2317,RET Inhibitor,RET C618R,"[{'id': 59, 'pubMedId': 22146228, 'title': 'Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22146228'}, {'id': 1869, 'pubMedId': 24705026, 'title': 'Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24705026'}, {'id': 1870, 'pubMedId': 21551259, 'title': 'In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21551259'}]",,03/19/2015
0,03/19/2015,RET Inhibitor,199,2318,RET Inhibitor,RET C630R,"[{'id': 59, 'pubMedId': 22146228, 'title': 'Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22146228'}, {'id': 1869, 'pubMedId': 24705026, 'title': 'Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24705026'}, {'id': 1870, 'pubMedId': 21551259, 'title': 'In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21551259'}]",,03/19/2015
0,03/19/2015,RET Inhibitor,199,2319,RET Inhibitor,RET C634Y,"[{'id': 59, 'pubMedId': 22146228, 'title': 'Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22146228'}, {'id': 1869, 'pubMedId': 24705026, 'title': 'Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24705026'}, {'id': 1870, 'pubMedId': 21551259, 'title': 'In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21551259'}]",,03/19/2015
0,03/19/2015,PDGFR Inhibitor (Pan),175,2320,PDGFR Inhibitor (Pan),PDGFRA H845Y,"[{'id': 2152, 'pubMedId': 20509775, 'title': 'Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20509775'}]",,03/19/2015
0,03/19/2015,PDGFR-alpha Inhibitor,176,2321,PDGFR-alpha Inhibitor,PDGFRA H845Y,"[{'id': 1621, 'pubMedId': 24359404, 'title': 'Targeting the PDGF signaling pathway in tumor treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24359404'}]",,03/19/2015
0,03/19/2015,Akt1 Inhibitor,6,2322,Akt1 Inhibitor,PTEN inact mut,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,03/19/2015
0,03/19/2015,Akt2 Inhibitor,7,2323,Akt2 Inhibitor,PTEN inact mut,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,03/19/2015
0,03/23/2015,Akt Inhibitor (Pan),4,2356,Akt Inhibitor (Pan),PIK3CA Q546P,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/23/2015
0,03/23/2015,Akt1 Inhibitor,6,2357,Akt1 Inhibitor,PIK3CA Q546P,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/23/2015
0,03/23/2015,Akt2 Inhibitor,7,2358,Akt2 Inhibitor,PIK3CA Q546P,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/23/2015
0,03/23/2015,Akt3 Inhibitor,8,2359,Akt3 Inhibitor,PIK3CA Q546P,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/23/2015
0,03/23/2015,mTOR Inhibitor,152,2360,mTOR Inhibitor,PIK3CA Q546P,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/23/2015
0,03/23/2015,PI3K Inhibitor (Pan),181,2361,PI3K Inhibitor (Pan),PIK3CA Q546P,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/23/2015
0,03/23/2015,PIK3CA inhibitor,182,2362,PIK3CA inhibitor,PIK3CA Q546P,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/23/2015
0,03/23/2015,Akt Inhibitor (Pan),4,2363,Akt Inhibitor (Pan),PIK3CA R108H,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/23/2015
0,03/23/2015,Akt1 Inhibitor,6,2364,Akt1 Inhibitor,PIK3CA R108H,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/23/2015
0,03/23/2015,Akt2 Inhibitor,7,2365,Akt2 Inhibitor,PIK3CA R108H,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/23/2015
0,03/23/2015,Akt3 Inhibitor,8,2366,Akt3 Inhibitor,PIK3CA R108H,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/23/2015
0,03/23/2015,mTOR Inhibitor,152,2367,mTOR Inhibitor,PIK3CA R108H,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/23/2015
0,03/23/2015,PI3K Inhibitor (Pan),181,2368,PI3K Inhibitor (Pan),PIK3CA R108H,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/23/2015
0,03/23/2015,PIK3CA inhibitor,182,2369,PIK3CA inhibitor,PIK3CA R108H,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/23/2015
0,03/30/2015,EGFR Inhibitor (Pan),74,2548,EGFR Inhibitor (Pan),EGFR amp,"[{'id': 2348, 'pubMedId': 25559287, 'title': 'Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25559287'}]",,03/30/2015
0,03/30/2015,EGFR Antibody,73,2549,EGFR Antibody,EGFR amp,"[{'id': 973, 'pubMedId': 24141978, 'title': 'A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24141978'}, {'id': 2349, 'pubMedId': 23828214, 'title': 'Cetuximab promotes anticancer drug toxicity in rhabdomyosarcomas with EGFR amplification in vitro.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23828214'}, {'id': 2350, 'pubMedId': 22897982, 'title': 'EGFR gene copy number as a predictive biomarker for the treatment of metastatic colorectal cancer with anti-EGFR monoclonal antibodies: a meta-analysis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22897982'}]",,03/30/2015
0,03/30/2015,MET Inhibitor,147,2550,MET Inhibitor,MET amp,"[{'id': 1994, 'pubMedId': 24045150, 'title': 'Met as a therapeutic target in HCC: facts and hopes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24045150'}]",,03/30/2015
0,04/03/2015,PDGFR Inhibitor (Pan),175,2851,PDGFR Inhibitor (Pan),PDGFRA amp,"[{'id': 2152, 'pubMedId': 20509775, 'title': 'Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20509775'}]",,04/03/2015
0,04/03/2015,PDGFR-alpha Inhibitor,176,2852,PDGFR-alpha Inhibitor,PDGFRA amp,"[{'id': 1621, 'pubMedId': 24359404, 'title': 'Targeting the PDGF signaling pathway in tumor treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24359404'}]",,04/03/2015
0,04/03/2015,CTNNB1 Inhibitor,60,2861,CTNNB1 Inhibitor,APC E1309Afs*3,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,04/03/2015
0,04/03/2015,mTORC1 Inhibitor,153,2885,mTORC1 Inhibitor,PIK3CA act mut,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/03/2015
0,04/03/2015,mTORC2 Inhibitor,154,2886,mTORC2 Inhibitor,PIK3CA act mut,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/03/2015
0,04/03/2015,mTORC1 Inhibitor,153,2887,mTORC1 Inhibitor,PIK3CA C420R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/03/2015
0,04/03/2015,mTORC2 Inhibitor,154,2888,mTORC2 Inhibitor,PIK3CA C420R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/03/2015
0,04/03/2015,mTORC1 Inhibitor,153,2889,mTORC1 Inhibitor,PIK3CA E453A,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/03/2015
0,04/03/2015,mTORC2 Inhibitor,154,2890,mTORC2 Inhibitor,PIK3CA E453A,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/03/2015
0,04/03/2015,mTORC1 Inhibitor,153,2891,mTORC1 Inhibitor,PIK3CA E453K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/03/2015
0,04/03/2015,mTORC2 Inhibitor,154,2892,mTORC2 Inhibitor,PIK3CA E453K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/03/2015
0,04/03/2015,mTORC1 Inhibitor,153,2893,mTORC1 Inhibitor,PIK3CA E453Q,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/03/2015
0,04/03/2015,mTORC2 Inhibitor,154,2894,mTORC2 Inhibitor,PIK3CA E453Q,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/03/2015
0,04/03/2015,mTORC1 Inhibitor,153,2895,mTORC1 Inhibitor,PIK3CA E542K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/03/2015
0,04/03/2015,mTORC2 Inhibitor,154,2896,mTORC2 Inhibitor,PIK3CA E542K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/03/2015
0,04/03/2015,mTORC1 Inhibitor,153,2897,mTORC1 Inhibitor,PIK3CA E545A,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/03/2015
0,04/03/2015,mTORC2 Inhibitor,154,2898,mTORC2 Inhibitor,PIK3CA E545A,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/03/2015
0,04/05/2015,Akt Inhibitor (Pan),4,3009,Akt Inhibitor (Pan),PIK3CA E545D,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,Akt1 Inhibitor,6,3010,Akt1 Inhibitor,PIK3CA E545D,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,Akt2 Inhibitor,7,3011,Akt2 Inhibitor,PIK3CA E545D,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,Akt3 Inhibitor,8,3012,Akt3 Inhibitor,PIK3CA E545D,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,mTOR Inhibitor,152,3013,mTOR Inhibitor,PIK3CA E545D,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,mTORC1 Inhibitor,153,3014,mTORC1 Inhibitor,PIK3CA E545D,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,mTORC2 Inhibitor,154,3015,mTORC2 Inhibitor,PIK3CA E545D,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,PI3K Inhibitor (Pan),181,3016,PI3K Inhibitor (Pan),PIK3CA E545D,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,PIK3CA inhibitor,182,3017,PIK3CA inhibitor,PIK3CA E545D,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,Akt Inhibitor (Pan),4,3018,Akt Inhibitor (Pan),PIK3CA E545Q,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,Akt1 Inhibitor,6,3019,Akt1 Inhibitor,PIK3CA E545Q,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,Akt2 Inhibitor,7,3020,Akt2 Inhibitor,PIK3CA E545Q,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,Akt3 Inhibitor,8,3021,Akt3 Inhibitor,PIK3CA E545Q,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,mTOR Inhibitor,152,3022,mTOR Inhibitor,PIK3CA E545Q,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,mTORC1 Inhibitor,153,3023,mTORC1 Inhibitor,PIK3CA E545Q,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,mTORC2 Inhibitor,154,3024,mTORC2 Inhibitor,PIK3CA E545Q,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,PI3K Inhibitor (Pan),181,3025,PI3K Inhibitor (Pan),PIK3CA E545Q,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,PIK3CA inhibitor,182,3026,PIK3CA inhibitor,PIK3CA E545Q,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,Akt Inhibitor (Pan),4,3027,Akt Inhibitor (Pan),PIK3CA E545V,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,Akt1 Inhibitor,6,3028,Akt1 Inhibitor,PIK3CA E545V,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,Akt2 Inhibitor,7,3029,Akt2 Inhibitor,PIK3CA E545V,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,Akt3 Inhibitor,8,3030,Akt3 Inhibitor,PIK3CA E545V,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,mTOR Inhibitor,152,3031,mTOR Inhibitor,PIK3CA E545V,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,mTORC1 Inhibitor,153,3032,mTORC1 Inhibitor,PIK3CA E545V,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,mTORC2 Inhibitor,154,3033,mTORC2 Inhibitor,PIK3CA E545V,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,PI3K Inhibitor (Pan),181,3034,PI3K Inhibitor (Pan),PIK3CA E545V,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,PIK3CA inhibitor,182,3035,PIK3CA inhibitor,PIK3CA E545V,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,mTORC2 Inhibitor,154,3036,mTORC2 Inhibitor,PIK3CA E545G,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,mTORC1 Inhibitor,153,3037,mTORC1 Inhibitor,PIK3CA E545G,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,mTORC1 Inhibitor,153,3038,mTORC1 Inhibitor,PIK3CA E545K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,mTORC2 Inhibitor,154,3039,mTORC2 Inhibitor,PIK3CA E545K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,mTORC1 Inhibitor,153,3040,mTORC1 Inhibitor,PIK3CA G1049R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,mTORC2 Inhibitor,154,3041,mTORC2 Inhibitor,PIK3CA G1049R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,mTORC1 Inhibitor,153,3042,mTORC1 Inhibitor,PIK3CA G106_R108del,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,mTORC2 Inhibitor,154,3043,mTORC2 Inhibitor,PIK3CA G106_R108del,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,mTORC1 Inhibitor,153,3044,mTORC1 Inhibitor,PIK3CA G118D,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,mTORC2 Inhibitor,154,3045,mTORC2 Inhibitor,PIK3CA G118D,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,mTORC1 Inhibitor,153,3046,mTORC1 Inhibitor,PIK3CA H1047L,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,mTORC2 Inhibitor,154,3047,mTORC2 Inhibitor,PIK3CA H1047L,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,Akt Inhibitor (Pan),4,3048,Akt Inhibitor (Pan),PIK3CA H1047Q,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,Akt1 Inhibitor,6,3049,Akt1 Inhibitor,PIK3CA H1047Q,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,Akt2 Inhibitor,7,3050,Akt2 Inhibitor,PIK3CA H1047Q,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,Akt3 Inhibitor,8,3051,Akt3 Inhibitor,PIK3CA H1047Q,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,mTOR Inhibitor,152,3052,mTOR Inhibitor,PIK3CA H1047Q,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,mTORC1 Inhibitor,153,3053,mTORC1 Inhibitor,PIK3CA H1047Q,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,mTORC2 Inhibitor,154,3054,mTORC2 Inhibitor,PIK3CA H1047Q,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,PI3K Inhibitor (Pan),181,3055,PI3K Inhibitor (Pan),PIK3CA H1047Q,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,PIK3CA inhibitor,182,3056,PIK3CA inhibitor,PIK3CA H1047Q,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,mTORC1 Inhibitor,153,3057,mTORC1 Inhibitor,PIK3CA H1047R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,mTORC2 Inhibitor,154,3058,mTORC2 Inhibitor,PIK3CA H1047R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,mTORC1 Inhibitor,153,3059,mTORC1 Inhibitor,PIK3CA K111E,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,mTORC2 Inhibitor,154,3060,mTORC2 Inhibitor,PIK3CA K111E,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,mTORC1 Inhibitor,153,3061,mTORC1 Inhibitor,PIK3CA K111N,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,mTORC2 Inhibitor,154,3062,mTORC2 Inhibitor,PIK3CA K111N,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,mTORC1 Inhibitor,153,3063,mTORC1 Inhibitor,PIK3CA M1043I,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,mTORC2 Inhibitor,154,3064,mTORC2 Inhibitor,PIK3CA M1043I,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,mTORC1 Inhibitor,153,3065,mTORC1 Inhibitor,PIK3CA M1043V,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,mTORC2 Inhibitor,154,3066,mTORC2 Inhibitor,PIK3CA M1043V,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,mTORC1 Inhibitor,153,3067,mTORC1 Inhibitor,PIK3CA N1068fs*4,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,mTORC2 Inhibitor,154,3068,mTORC2 Inhibitor,PIK3CA N1068fs*4,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,mTORC1 Inhibitor,153,3069,mTORC1 Inhibitor,PIK3CA N345K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,mTORC2 Inhibitor,154,3070,mTORC2 Inhibitor,PIK3CA N345K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,mTORC1 Inhibitor,153,3071,mTORC1 Inhibitor,PIK3CA P539R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,mTORC2 Inhibitor,154,3072,mTORC2 Inhibitor,PIK3CA P539R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,mTORC1 Inhibitor,153,3073,mTORC1 Inhibitor,PIK3CA Q546K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,mTORC2 Inhibitor,154,3074,mTORC2 Inhibitor,PIK3CA Q546K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,mTORC1 Inhibitor,153,3075,mTORC1 Inhibitor,PIK3CA Q546P,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,mTORC2 Inhibitor,154,3076,mTORC2 Inhibitor,PIK3CA Q546P,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,mTORC1 Inhibitor,153,3077,mTORC1 Inhibitor,PIK3CA R108H,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,mTORC2 Inhibitor,154,3078,mTORC2 Inhibitor,PIK3CA R108H,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,mTORC1 Inhibitor,153,3079,mTORC1 Inhibitor,PIK3CA R115L,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,mTORC2 Inhibitor,154,3080,mTORC2 Inhibitor,PIK3CA R115L,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,mTORC1 Inhibitor,153,3081,mTORC1 Inhibitor,PIK3CA R88Q,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,mTORC2 Inhibitor,154,3082,mTORC2 Inhibitor,PIK3CA R88Q,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,mTORC1 Inhibitor,153,3083,mTORC1 Inhibitor,PIK3CA T1025S,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/05/2015,mTORC2 Inhibitor,154,3084,mTORC2 Inhibitor,PIK3CA T1025S,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/05/2015
0,04/06/2015,p53 Activator,166,3189,p53 Activator,TP53 R248L,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/06/2015
0,04/06/2015,p53 Gene Therapy,167,3190,p53 Gene Therapy,TP53 R248L,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/06/2015
0,04/09/2015,p53 Activator,166,3328,p53 Activator,TP53 R158L,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/09/2015
0,04/09/2015,p53 Gene Therapy,167,3329,p53 Gene Therapy,TP53 R158L,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/09/2015
0,04/12/2015,p53 Activator,166,3382,p53 Activator,TP53 inact mut,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/12/2015
0,04/12/2015,p53 Gene Therapy,167,3383,p53 Gene Therapy,TP53 inact mut,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/12/2015
0,04/15/2015,p53 Activator,166,3390,p53 Activator,TP53 R249M,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/15/2015
0,04/15/2015,p53 Gene Therapy,167,3391,p53 Gene Therapy,TP53 R249M,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/15/2015
0,04/15/2015,p53 Activator,166,3392,p53 Activator,TP53 R248P,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/15/2015
0,04/15/2015,p53 Gene Therapy,167,3393,p53 Gene Therapy,TP53 R248P,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/15/2015
0,04/15/2015,p53 Activator,166,3394,p53 Activator,TP53 R249G,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/15/2015
0,04/15/2015,p53 Gene Therapy,167,3395,p53 Gene Therapy,TP53 R249G,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/15/2015
0,04/15/2015,p53 Activator,166,3396,p53 Activator,TP53 Y234H,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/15/2015
0,04/15/2015,p53 Gene Therapy,167,3397,p53 Gene Therapy,TP53 Y234H,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/15/2015
0,04/15/2015,p53 Activator,166,3398,p53 Activator,TP53 R175A,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/15/2015
0,04/15/2015,p53 Gene Therapy,167,3399,p53 Gene Therapy,TP53 R175A,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/15/2015
0,04/15/2015,p53 Gene Therapy,167,3403,p53 Gene Therapy,TP53 R158fs*11,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/15/2015
0,04/15/2015,SRC Inhibitor,209,3408,SRC Inhibitor,SRC act mut,"[{'id': 2477, 'pubMedId': 25662515, 'title': 'Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25662515'}, {'id': 2478, 'pubMedId': 21776389, 'title': 'Regulation of SRC family kinases in human cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21776389'}, {'id': 2479, 'pubMedId': 21521831, 'title': 'Current status of SRC inhibitors in solid tumor malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21521831'}]",,04/15/2015
0,04/15/2015,p53 Activator,166,3409,p53 Activator,TP53 R175L,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/15/2015
0,04/15/2015,p53 Gene Therapy,167,3410,p53 Gene Therapy,TP53 R175L,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/15/2015
0,04/15/2015,p53 Activator,166,3411,p53 Activator,TP53 R249K,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/15/2015
0,04/15/2015,p53 Gene Therapy,167,3412,p53 Gene Therapy,TP53 R249K,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/15/2015
0,04/15/2015,p53 Activator,166,3413,p53 Activator,TP53 R249T,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/15/2015
0,04/15/2015,p53 Gene Therapy,167,3414,p53 Gene Therapy,TP53 R249T,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/15/2015
0,04/15/2015,p53 Activator,166,3415,p53 Activator,TP53 R248E,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/15/2015
0,04/15/2015,p53 Gene Therapy,167,3416,p53 Gene Therapy,TP53 R248E,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/15/2015
0,04/15/2015,p53 Activator,166,3417,p53 Activator,TP53 R248G,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/15/2015
0,04/15/2015,p53 Gene Therapy,167,3418,p53 Gene Therapy,TP53 R248G,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/15/2015
0,04/15/2015,p53 Activator,166,3419,p53 Activator,TP53 R249W,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/15/2015
0,04/15/2015,p53 Gene Therapy,167,3420,p53 Gene Therapy,TP53 R249W,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/15/2015
0,04/15/2015,p53 Activator,166,3421,p53 Activator,TP53 R273P,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/15/2015
0,04/15/2015,p53 Gene Therapy,167,3422,p53 Gene Therapy,TP53 R273P,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/15/2015
0,04/15/2015,p53 Activator,166,3423,p53 Activator,TP53 R282Q,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/15/2015
0,04/15/2015,p53 Gene Therapy,167,3424,p53 Gene Therapy,TP53 R282Q,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/15/2015
0,04/15/2015,p53 Activator,166,3425,p53 Activator,TP53 G245R,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/15/2015
0,04/15/2015,p53 Gene Therapy,167,3426,p53 Gene Therapy,TP53 G245R,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/15/2015
0,04/15/2015,p53 Activator,166,3427,p53 Activator,TP53 G245D,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/15/2015
0,04/15/2015,p53 Gene Therapy,167,3428,p53 Gene Therapy,TP53 G245D,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/15/2015
0,04/15/2015,p53 Activator,166,3429,p53 Activator,TP53 G245A,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/15/2015
0,04/15/2015,p53 Gene Therapy,167,3430,p53 Gene Therapy,TP53 G245A,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/15/2015
0,04/15/2015,p53 Activator,166,3431,p53 Activator,TP53 V274F,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/15/2015
0,04/15/2015,p53 Gene Therapy,167,3432,p53 Gene Therapy,TP53 V274F,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/15/2015
0,04/15/2015,p53 Activator,166,3433,p53 Activator,TP53 R282del,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/15/2015
0,04/15/2015,p53 Gene Therapy,167,3434,p53 Gene Therapy,TP53 R282del,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/15/2015
0,04/15/2015,Akt Inhibitor (Pan),4,3435,Akt Inhibitor (Pan),PIK3CA D1029Y,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/15/2015
0,04/15/2015,Akt1 Inhibitor,6,3436,Akt1 Inhibitor,PIK3CA D1029Y,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/15/2015
0,04/15/2015,Akt2 Inhibitor,7,3437,Akt2 Inhibitor,PIK3CA D1029Y,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/15/2015
0,04/15/2015,Akt3 Inhibitor,8,3438,Akt3 Inhibitor,PIK3CA D1029Y,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/15/2015
0,04/15/2015,mTOR Inhibitor,152,3439,mTOR Inhibitor,PIK3CA D1029Y,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/15/2015
0,04/15/2015,mTORC1 Inhibitor,153,3440,mTORC1 Inhibitor,PIK3CA D1029Y,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/15/2015
0,04/15/2015,mTORC2 Inhibitor,154,3441,mTORC2 Inhibitor,PIK3CA D1029Y,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/15/2015
0,04/15/2015,PI3K Inhibitor (Pan),181,3442,PI3K Inhibitor (Pan),PIK3CA D1029Y,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/15/2015
0,04/15/2015,PIK3CA inhibitor,182,3443,PIK3CA inhibitor,PIK3CA D1029Y,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/15/2015
0,04/16/2015,PARP-1 Inhibitor,172,3446,PARP-1 Inhibitor,BRCA1 inact mut,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/16/2015
0,04/16/2015,PARP Inhibitor (Pan),171,3447,PARP Inhibitor (Pan),BRCA1 V340*,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/16/2015
0,04/16/2015,PARP-1 Inhibitor,172,3448,PARP-1 Inhibitor,BRCA1 V340*,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/16/2015
0,04/16/2015,PARP-1 Inhibitor,172,3449,PARP-1 Inhibitor,BRCA2 inact mut,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/16/2015
0,04/16/2015,PARP Inhibitor (Pan),171,3450,PARP Inhibitor (Pan),BRCA2 L2080*,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/16/2015
0,04/16/2015,PARP-1 Inhibitor,172,3451,PARP-1 Inhibitor,BRCA2 L2080*,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/16/2015
0,04/16/2015,PARP Inhibitor (Pan),171,3452,PARP Inhibitor (Pan),BRCA2 loss,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/16/2015
0,04/16/2015,PARP-1 Inhibitor,172,3453,PARP-1 Inhibitor,BRCA2 loss,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/16/2015
0,04/16/2015,PARP-1 Inhibitor,172,3455,PARP-1 Inhibitor,BRCA2 Q1037*,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/16/2015
0,04/16/2015,EGFR Inhibitor (Pan),74,3482,EGFR Inhibitor (Pan),EGFR act mut,"[{'id': 410, 'pubMedId': 16187797, 'title': 'Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16187797'}, {'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,04/16/2015
0,04/16/2015,EGFR Inhibitor 1st gen,75,3483,EGFR Inhibitor 1st gen,EGFR act mut,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",,04/16/2015
0,04/16/2015,EGFR Inhibitor 2nd gen,76,3484,EGFR Inhibitor 2nd gen,EGFR act mut,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,04/16/2015
0,04/16/2015,EGFR Inhibitor 3rd gen,77,3485,EGFR Inhibitor 3rd gen,EGFR act mut,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,04/16/2015
0,04/17/2015,Akt Inhibitor (Pan),4,3489,Akt Inhibitor (Pan),PIK3CA H1047P,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/17/2015
0,04/17/2015,Akt1 Inhibitor,6,3490,Akt1 Inhibitor,PIK3CA H1047P,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/17/2015
0,04/17/2015,Akt2 Inhibitor,7,3491,Akt2 Inhibitor,PIK3CA H1047P,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/17/2015
0,04/17/2015,Akt3 Inhibitor,8,3492,Akt3 Inhibitor,PIK3CA H1047P,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/17/2015
0,04/17/2015,mTOR Inhibitor,152,3493,mTOR Inhibitor,PIK3CA H1047P,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/17/2015
0,04/17/2015,mTORC1 Inhibitor,153,3494,mTORC1 Inhibitor,PIK3CA H1047P,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/17/2015
0,04/17/2015,mTORC2 Inhibitor,154,3495,mTORC2 Inhibitor,PIK3CA H1047P,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/17/2015
0,04/17/2015,PI3K Inhibitor (Pan),181,3496,PI3K Inhibitor (Pan),PIK3CA H1047P,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/17/2015
0,04/17/2015,PIK3CA inhibitor,182,3497,PIK3CA inhibitor,PIK3CA H1047P,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/17/2015
0,04/17/2015,PARP Inhibitor (Pan),171,3498,PARP Inhibitor (Pan),BRCA1 loss,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/17/2015
0,04/17/2015,PARP-1 Inhibitor,172,3499,PARP-1 Inhibitor,BRCA1 loss,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/17/2015
0,04/17/2015,PARP Inhibitor (Pan),171,3500,PARP Inhibitor (Pan),BRCA2 I605fs,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/17/2015
0,04/17/2015,PARP-1 Inhibitor,172,3501,PARP-1 Inhibitor,BRCA2 I605fs,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/17/2015
0,04/20/2015,ALK Inhibitor,9,3577,ALK Inhibitor,ALK F1174S,"[{'id': 527, 'pubMedId': 21838707, 'title': 'Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21838707'}]",,04/20/2015
0,04/20/2015,,3720,PF-06747775  ,EGFR T790M,"[{'id': 287, 'pubMedId': None, 'title': '(NCI Drug Dictionary)', 'url': 'http://www.cancer.gov/drugdictionary'}]",2527,PF-06747775  ,04/20/2015
0,04/20/2015,,3727,Cetuximab,EGFR G724S,"[{'id': 1125, 'pubMedId': 24894453, 'title': 'Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24894453'}]",694,Cetuximab,04/20/2015
0,04/20/2015,PDGFR Inhibitor (Pan),175,3896,PDGFR Inhibitor (Pan),PDGFRA V561A,"[{'id': 2152, 'pubMedId': 20509775, 'title': 'Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20509775'}]",,04/20/2015
0,04/20/2015,PDGFR-alpha Inhibitor,176,3897,PDGFR-alpha Inhibitor,PDGFRA V561A,"[{'id': 1621, 'pubMedId': 24359404, 'title': 'Targeting the PDGF signaling pathway in tumor treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24359404'}]",,04/20/2015
0,04/21/2015,RET Inhibitor,199,3899,RET Inhibitor,RET C630S,"[{'id': 59, 'pubMedId': 22146228, 'title': 'Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22146228'}, {'id': 1869, 'pubMedId': 24705026, 'title': 'Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24705026'}, {'id': 1870, 'pubMedId': 21551259, 'title': 'In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21551259'}]",,04/21/2015
0,04/21/2015,RET Inhibitor,199,3900,RET Inhibitor,RET C630G,"[{'id': 59, 'pubMedId': 22146228, 'title': 'Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22146228'}, {'id': 1869, 'pubMedId': 24705026, 'title': 'Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24705026'}, {'id': 1870, 'pubMedId': 21551259, 'title': 'In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21551259'}]",,04/21/2015
0,04/21/2015,RET Inhibitor,199,3901,RET Inhibitor,RET E632_L633del,"[{'id': 59, 'pubMedId': 22146228, 'title': 'Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22146228'}, {'id': 1869, 'pubMedId': 24705026, 'title': 'Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24705026'}, {'id': 1870, 'pubMedId': 21551259, 'title': 'In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21551259'}]",,04/21/2015
0,04/21/2015,RET Inhibitor,199,3902,RET Inhibitor,RET C634G,"[{'id': 59, 'pubMedId': 22146228, 'title': 'Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22146228'}, {'id': 1869, 'pubMedId': 24705026, 'title': 'Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24705026'}, {'id': 1870, 'pubMedId': 21551259, 'title': 'In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21551259'}]",,04/21/2015
0,04/21/2015,RET Inhibitor,199,3903,RET Inhibitor,RET C634S,"[{'id': 59, 'pubMedId': 22146228, 'title': 'Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22146228'}, {'id': 1869, 'pubMedId': 24705026, 'title': 'Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24705026'}, {'id': 1870, 'pubMedId': 21551259, 'title': 'In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21551259'}]",,04/21/2015
0,04/21/2015,RET Inhibitor,199,3904,RET Inhibitor,RET C634F,"[{'id': 59, 'pubMedId': 22146228, 'title': 'Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22146228'}, {'id': 1869, 'pubMedId': 24705026, 'title': 'Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24705026'}, {'id': 1870, 'pubMedId': 21551259, 'title': 'In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21551259'}]",,04/21/2015
0,04/21/2015,KIT Inhibitor,136,3905,KIT Inhibitor,KIT D816N,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,04/21/2015
0,04/21/2015,MEK inhibitor (Pan),142,3906,MEK inhibitor (Pan),HRAS Q61E,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,04/21/2015
0,04/21/2015,MEK1 Inhibitor,143,3907,MEK1 Inhibitor,HRAS Q61E,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,04/21/2015
0,04/21/2015,MEK2 Inhibitor,144,3908,MEK2 Inhibitor,HRAS Q61E,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,04/21/2015
0,04/21/2015,PI3K Inhibitor (Pan),181,3909,PI3K Inhibitor (Pan),HRAS Q61E,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,04/21/2015
0,04/21/2015,PIK3CA inhibitor,182,3910,PIK3CA inhibitor,HRAS Q61E,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,04/21/2015
0,04/21/2015,PIK3CB inhibitor,183,3911,PIK3CB inhibitor,HRAS Q61E,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,04/21/2015
0,04/21/2015,PIK3CD inhibitor,184,3912,PIK3CD inhibitor,HRAS Q61E,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,04/21/2015
0,04/21/2015,PIK3CG inhibitor,185,3913,PIK3CG inhibitor,HRAS Q61E,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,04/21/2015
0,04/21/2015,RAS Inhibitor (Pan),198,3914,RAS Inhibitor (Pan),HRAS Q61E,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,04/21/2015
0,04/21/2015,KIT Inhibitor,136,3915,KIT Inhibitor,KIT Q556_V560del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,04/21/2015
0,04/21/2015,KIT Inhibitor,136,3916,KIT Inhibitor,KIT V560A,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,04/21/2015
0,04/21/2015,KIT Inhibitor,136,3917,KIT Inhibitor,KIT Y823N,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,04/21/2015
0,04/23/2015,FLT3 Inhibitor,96,3996,FLT3 Inhibitor,FLT3 act mut,"[{'id': 705, 'pubMedId': 11756186, 'title': 'FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11756186'}, {'id': 2547, 'pubMedId': 17124058, 'title': 'FLT3 mutations: biology and treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17124058'}, {'id': 2548, 'pubMedId': 25231999, 'title': 'Targeting FLT3 to treat leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25231999'}]",,04/23/2015
0,04/23/2015,FLT3 Inhibitor,96,3997,FLT3 Inhibitor,FLT3 amp,"[{'id': 705, 'pubMedId': 11756186, 'title': 'FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11756186'}, {'id': 2547, 'pubMedId': 17124058, 'title': 'FLT3 mutations: biology and treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17124058'}, {'id': 2548, 'pubMedId': 25231999, 'title': 'Targeting FLT3 to treat leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25231999'}]",,04/23/2015
0,04/23/2015,FLT3 Inhibitor,96,3998,FLT3 Inhibitor,FLT3 over exp,"[{'id': 705, 'pubMedId': 11756186, 'title': 'FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11756186'}, {'id': 2547, 'pubMedId': 17124058, 'title': 'FLT3 mutations: biology and treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17124058'}, {'id': 2548, 'pubMedId': 25231999, 'title': 'Targeting FLT3 to treat leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25231999'}]",,04/23/2015
0,04/23/2015,FLT3 Inhibitor,96,3999,FLT3 Inhibitor,FLT3 D835E,"[{'id': 705, 'pubMedId': 11756186, 'title': 'FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11756186'}, {'id': 2547, 'pubMedId': 17124058, 'title': 'FLT3 mutations: biology and treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17124058'}, {'id': 2548, 'pubMedId': 25231999, 'title': 'Targeting FLT3 to treat leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25231999'}]",,04/23/2015
0,04/23/2015,FLT3 Inhibitor,96,4000,FLT3 Inhibitor,FLT3 D835H,"[{'id': 705, 'pubMedId': 11756186, 'title': 'FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11756186'}, {'id': 2547, 'pubMedId': 17124058, 'title': 'FLT3 mutations: biology and treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17124058'}, {'id': 2548, 'pubMedId': 25231999, 'title': 'Targeting FLT3 to treat leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25231999'}]",,04/23/2015
0,04/23/2015,FLT3 Inhibitor,96,4001,FLT3 Inhibitor,FLT3 D835N,"[{'id': 705, 'pubMedId': 11756186, 'title': 'FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11756186'}, {'id': 2547, 'pubMedId': 17124058, 'title': 'FLT3 mutations: biology and treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17124058'}, {'id': 2548, 'pubMedId': 25231999, 'title': 'Targeting FLT3 to treat leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25231999'}]",,04/23/2015
0,04/23/2015,FLT3 Inhibitor,96,4002,FLT3 Inhibitor,FLT3 D835V,"[{'id': 705, 'pubMedId': 11756186, 'title': 'FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11756186'}, {'id': 2547, 'pubMedId': 17124058, 'title': 'FLT3 mutations: biology and treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17124058'}, {'id': 2548, 'pubMedId': 25231999, 'title': 'Targeting FLT3 to treat leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25231999'}]",,04/23/2015
0,04/23/2015,FLT3 Inhibitor,96,4003,FLT3 Inhibitor,FLT3 D835Y,"[{'id': 705, 'pubMedId': 11756186, 'title': 'FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11756186'}, {'id': 2547, 'pubMedId': 17124058, 'title': 'FLT3 mutations: biology and treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17124058'}, {'id': 2548, 'pubMedId': 25231999, 'title': 'Targeting FLT3 to treat leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25231999'}]",,04/23/2015
0,04/23/2015,FLT3 Inhibitor,96,4004,FLT3 Inhibitor,FLT3 E598_Y599insGLVQVTGSSDNEYFYVDFREYE,"[{'id': 705, 'pubMedId': 11756186, 'title': 'FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11756186'}, {'id': 2547, 'pubMedId': 17124058, 'title': 'FLT3 mutations: biology and treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17124058'}, {'id': 2548, 'pubMedId': 25231999, 'title': 'Targeting FLT3 to treat leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25231999'}]",,04/23/2015
0,04/23/2015,FLT3 Inhibitor,96,4005,FLT3 Inhibitor,FLT3 E612_F613insGYVDFREYEYDLKWEFRPRENLEF,"[{'id': 705, 'pubMedId': 11756186, 'title': 'FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11756186'}, {'id': 2547, 'pubMedId': 17124058, 'title': 'FLT3 mutations: biology and treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17124058'}, {'id': 2548, 'pubMedId': 25231999, 'title': 'Targeting FLT3 to treat leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25231999'}]",,04/23/2015
0,04/23/2015,FLT3 Inhibitor,96,4006,FLT3 Inhibitor,FLT3 L601_K602insREYEYDL,"[{'id': 705, 'pubMedId': 11756186, 'title': 'FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11756186'}, {'id': 2547, 'pubMedId': 17124058, 'title': 'FLT3 mutations: biology and treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17124058'}, {'id': 2548, 'pubMedId': 25231999, 'title': 'Targeting FLT3 to treat leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25231999'}]",,04/23/2015
0,04/23/2015,FLT3 Inhibitor,96,4007,FLT3 Inhibitor,FLT3 Y599_D600insGLYVDFREYEY,"[{'id': 705, 'pubMedId': 11756186, 'title': 'FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11756186'}, {'id': 2547, 'pubMedId': 17124058, 'title': 'FLT3 mutations: biology and treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17124058'}, {'id': 2548, 'pubMedId': 25231999, 'title': 'Targeting FLT3 to treat leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25231999'}]",,04/23/2015
0,04/23/2015,IDH Inhibitor (Pan),117,4015,IDH Inhibitor (Pan),IDH1 act mut,"[{'id': 2551, 'pubMedId': 25678837, 'title': 'New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25678837'}]",,04/23/2015
0,04/23/2015,IDH1 Inhibitor,118,4016,IDH1 Inhibitor,IDH1 act mut,"[{'id': 2551, 'pubMedId': 25678837, 'title': 'New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25678837'}, {'id': 2552, 'pubMedId': 23558169, 'title': 'An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23558169'}]",,04/23/2015
0,04/23/2015,IDH Inhibitor (Pan),117,4017,IDH Inhibitor (Pan),IDH1 amp,"[{'id': 2551, 'pubMedId': 25678837, 'title': 'New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25678837'}]",,04/23/2015
0,04/23/2015,IDH1 Inhibitor,118,4018,IDH1 Inhibitor,IDH1 amp,"[{'id': 2551, 'pubMedId': 25678837, 'title': 'New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25678837'}, {'id': 2552, 'pubMedId': 23558169, 'title': 'An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23558169'}]",,04/23/2015
0,04/23/2015,IDH Inhibitor (Pan),117,4019,IDH Inhibitor (Pan),IDH1 over exp,"[{'id': 2551, 'pubMedId': 25678837, 'title': 'New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25678837'}]",,04/23/2015
0,04/23/2015,IDH1 Inhibitor,118,4020,IDH1 Inhibitor,IDH1 over exp,"[{'id': 2551, 'pubMedId': 25678837, 'title': 'New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25678837'}, {'id': 2552, 'pubMedId': 23558169, 'title': 'An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23558169'}]",,04/23/2015
0,04/23/2015,IDH Inhibitor (Pan),117,4022,IDH Inhibitor (Pan),IDH1 R132G,"[{'id': 2551, 'pubMedId': 25678837, 'title': 'New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25678837'}]",,04/23/2015
0,04/23/2015,IDH1 Inhibitor,118,4023,IDH1 Inhibitor,IDH1 R132G,"[{'id': 2551, 'pubMedId': 25678837, 'title': 'New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25678837'}, {'id': 2552, 'pubMedId': 23558169, 'title': 'An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23558169'}]",,04/23/2015
0,04/23/2015,IDH Inhibitor (Pan),117,4024,IDH Inhibitor (Pan),IDH1 R132C,"[{'id': 2551, 'pubMedId': 25678837, 'title': 'New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25678837'}]",,04/23/2015
0,04/23/2015,IDH1 Inhibitor,118,4025,IDH1 Inhibitor,IDH1 R132C,"[{'id': 2551, 'pubMedId': 25678837, 'title': 'New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25678837'}, {'id': 2552, 'pubMedId': 23558169, 'title': 'An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23558169'}]",,04/23/2015
0,04/23/2015,IDH Inhibitor (Pan),117,4026,IDH Inhibitor (Pan),IDH1 R132H,"[{'id': 2551, 'pubMedId': 25678837, 'title': 'New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25678837'}]",,04/23/2015
0,04/23/2015,IDH1 Inhibitor,118,4027,IDH1 Inhibitor,IDH1 R132H,"[{'id': 2551, 'pubMedId': 25678837, 'title': 'New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25678837'}, {'id': 2552, 'pubMedId': 23558169, 'title': 'An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23558169'}]",,04/23/2015
0,04/23/2015,IDH Inhibitor (Pan),117,4028,IDH Inhibitor (Pan),IDH1 R132L,"[{'id': 2551, 'pubMedId': 25678837, 'title': 'New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25678837'}]",,04/23/2015
0,04/23/2015,IDH1 Inhibitor,118,4029,IDH1 Inhibitor,IDH1 R132L,"[{'id': 2551, 'pubMedId': 25678837, 'title': 'New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25678837'}, {'id': 2552, 'pubMedId': 23558169, 'title': 'An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23558169'}]",,04/23/2015
0,04/23/2015,IDH Inhibitor (Pan),117,4030,IDH Inhibitor (Pan),IDH1 R132S,"[{'id': 2551, 'pubMedId': 25678837, 'title': 'New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25678837'}]",,04/23/2015
0,04/23/2015,IDH1 Inhibitor,118,4031,IDH1 Inhibitor,IDH1 R132S,"[{'id': 2551, 'pubMedId': 25678837, 'title': 'New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25678837'}, {'id': 2552, 'pubMedId': 23558169, 'title': 'An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23558169'}]",,04/23/2015
0,04/23/2015,IDH Inhibitor (Pan),117,4036,IDH Inhibitor (Pan),IDH2 act mut,"[{'id': 2554, 'pubMedId': 25558173, 'title': 'Disease progression in iridocorneal angle tissues of BMP2-induced ocular hypertensive mice with optical coherence tomography.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25558173'}, {'id': 2555, 'pubMedId': 25251602, 'title': 'Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25251602'}]",,04/23/2015
0,04/23/2015,IDH2 Inhibitor,119,4037,IDH2 Inhibitor,IDH2 act mut,"[{'id': 2554, 'pubMedId': 25558173, 'title': 'Disease progression in iridocorneal angle tissues of BMP2-induced ocular hypertensive mice with optical coherence tomography.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25558173'}, {'id': 2555, 'pubMedId': 25251602, 'title': 'Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25251602'}]",,04/23/2015
0,04/23/2015,IDH Inhibitor (Pan),117,4038,IDH Inhibitor (Pan),IDH2 amp,"[{'id': 2554, 'pubMedId': 25558173, 'title': 'Disease progression in iridocorneal angle tissues of BMP2-induced ocular hypertensive mice with optical coherence tomography.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25558173'}, {'id': 2555, 'pubMedId': 25251602, 'title': 'Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25251602'}]",,04/23/2015
0,04/23/2015,IDH2 Inhibitor,119,4039,IDH2 Inhibitor,IDH2 amp,"[{'id': 2554, 'pubMedId': 25558173, 'title': 'Disease progression in iridocorneal angle tissues of BMP2-induced ocular hypertensive mice with optical coherence tomography.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25558173'}, {'id': 2555, 'pubMedId': 25251602, 'title': 'Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25251602'}]",,04/23/2015
0,04/23/2015,IDH Inhibitor (Pan),117,4040,IDH Inhibitor (Pan),IDH2 R140Q,"[{'id': 2554, 'pubMedId': 25558173, 'title': 'Disease progression in iridocorneal angle tissues of BMP2-induced ocular hypertensive mice with optical coherence tomography.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25558173'}, {'id': 2555, 'pubMedId': 25251602, 'title': 'Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25251602'}]",,04/23/2015
0,04/23/2015,IDH2 Inhibitor,119,4041,IDH2 Inhibitor,IDH2 R140Q,"[{'id': 2554, 'pubMedId': 25558173, 'title': 'Disease progression in iridocorneal angle tissues of BMP2-induced ocular hypertensive mice with optical coherence tomography.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25558173'}, {'id': 2555, 'pubMedId': 25251602, 'title': 'Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25251602'}]",,04/23/2015
0,04/23/2015,IDH Inhibitor (Pan),117,4042,IDH Inhibitor (Pan),IDH2 R172G,"[{'id': 2554, 'pubMedId': 25558173, 'title': 'Disease progression in iridocorneal angle tissues of BMP2-induced ocular hypertensive mice with optical coherence tomography.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25558173'}, {'id': 2555, 'pubMedId': 25251602, 'title': 'Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25251602'}]",,04/23/2015
0,04/23/2015,IDH2 Inhibitor,119,4043,IDH2 Inhibitor,IDH2 R172G,"[{'id': 2554, 'pubMedId': 25558173, 'title': 'Disease progression in iridocorneal angle tissues of BMP2-induced ocular hypertensive mice with optical coherence tomography.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25558173'}, {'id': 2555, 'pubMedId': 25251602, 'title': 'Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25251602'}]",,04/23/2015
0,04/23/2015,IDH Inhibitor (Pan),117,4044,IDH Inhibitor (Pan),IDH2 R172K,"[{'id': 2554, 'pubMedId': 25558173, 'title': 'Disease progression in iridocorneal angle tissues of BMP2-induced ocular hypertensive mice with optical coherence tomography.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25558173'}, {'id': 2555, 'pubMedId': 25251602, 'title': 'Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25251602'}]",,04/23/2015
0,04/23/2015,IDH2 Inhibitor,119,4045,IDH2 Inhibitor,IDH2 R172K,"[{'id': 2554, 'pubMedId': 25558173, 'title': 'Disease progression in iridocorneal angle tissues of BMP2-induced ocular hypertensive mice with optical coherence tomography.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25558173'}, {'id': 2555, 'pubMedId': 25251602, 'title': 'Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25251602'}]",,04/23/2015
0,04/23/2015,mTORC1 Inhibitor,153,4056,mTORC1 Inhibitor,FBXW7 inact mut,"[{'id': 571, 'pubMedId': 18787170, 'title': 'FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18787170'}, {'id': 2558, 'pubMedId': 24586741, 'title': 'FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24586741'}]",,04/23/2015
0,04/24/2015,mTORC1 Inhibitor,153,4075,mTORC1 Inhibitor,FBXW7 del,"[{'id': 571, 'pubMedId': 18787170, 'title': 'FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18787170'}, {'id': 2558, 'pubMedId': 24586741, 'title': 'FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24586741'}]",,04/24/2015
0,04/24/2015,mTORC1 Inhibitor,153,4076,mTORC1 Inhibitor,FBXW7 R465C,"[{'id': 571, 'pubMedId': 18787170, 'title': 'FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18787170'}, {'id': 2558, 'pubMedId': 24586741, 'title': 'FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24586741'}]",,04/24/2015
0,04/24/2015,mTORC1 Inhibitor,153,4077,mTORC1 Inhibitor,FBXW7 R465H,"[{'id': 571, 'pubMedId': 18787170, 'title': 'FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18787170'}, {'id': 2558, 'pubMedId': 24586741, 'title': 'FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24586741'}]",,04/24/2015
0,04/24/2015,mTORC1 Inhibitor,153,4078,mTORC1 Inhibitor,FBXW7 R479Q,"[{'id': 571, 'pubMedId': 18787170, 'title': 'FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18787170'}, {'id': 2558, 'pubMedId': 24586741, 'title': 'FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24586741'}]",,04/24/2015
0,04/24/2015,mTORC1 Inhibitor,153,4079,mTORC1 Inhibitor,FBXW7 R505C,"[{'id': 571, 'pubMedId': 18787170, 'title': 'FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18787170'}, {'id': 2558, 'pubMedId': 24586741, 'title': 'FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24586741'}]",,04/24/2015
0,04/24/2015,mTORC1 Inhibitor,153,4080,mTORC1 Inhibitor,FBXW7 R505L,"[{'id': 571, 'pubMedId': 18787170, 'title': 'FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18787170'}, {'id': 2558, 'pubMedId': 24586741, 'title': 'FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24586741'}]",,04/24/2015
0,04/24/2015,mTORC1 Inhibitor,153,4081,mTORC1 Inhibitor,FBXW7 loss,"[{'id': 571, 'pubMedId': 18787170, 'title': 'FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18787170'}, {'id': 2558, 'pubMedId': 24586741, 'title': 'FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24586741'}]",,04/24/2015
0,04/24/2015,mTORC1 Inhibitor,153,4082,mTORC1 Inhibitor,FBXW7 W486*,"[{'id': 571, 'pubMedId': 18787170, 'title': 'FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18787170'}, {'id': 2558, 'pubMedId': 24586741, 'title': 'FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24586741'}]",,04/24/2015
0,04/26/2015,PARP Inhibitor (Pan),171,4087,PARP Inhibitor (Pan),BRCA1 E23fs,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/26/2015
0,04/26/2015,PARP-1 Inhibitor,172,4088,PARP-1 Inhibitor,BRCA1 E23fs,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/26/2015
0,04/26/2015,PARP Inhibitor (Pan),171,4089,PARP Inhibitor (Pan),BRCA1 E23fs*17,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/26/2015
0,04/26/2015,PARP-1 Inhibitor,172,4090,PARP-1 Inhibitor,BRCA1 E23fs*17,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/26/2015
0,04/26/2015,PARP Inhibitor (Pan),171,4091,PARP Inhibitor (Pan),BRCA1 E577*,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/26/2015
0,04/26/2015,PARP-1 Inhibitor,172,4092,PARP-1 Inhibitor,BRCA1 E577*,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/26/2015
0,04/26/2015,PARP Inhibitor (Pan),171,4093,PARP Inhibitor (Pan),BRCA1 E673*,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/26/2015
0,04/26/2015,PARP-1 Inhibitor,172,4094,PARP-1 Inhibitor,BRCA1 E673*,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/26/2015
0,04/26/2015,PARP Inhibitor (Pan),171,4095,PARP Inhibitor (Pan),BRCA1 K339fs,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/26/2015
0,04/26/2015,PARP-1 Inhibitor,172,4096,PARP-1 Inhibitor,BRCA1 K339fs,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/26/2015
0,04/26/2015,PARP Inhibitor (Pan),171,4097,PARP Inhibitor (Pan),BRCA1 K654fs*47,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/26/2015
0,04/26/2015,PARP-1 Inhibitor,172,4098,PARP-1 Inhibitor,BRCA1 K654fs*47,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/26/2015
0,04/26/2015,PARP Inhibitor (Pan),171,4101,PARP Inhibitor (Pan),BRCA1 Q1756fs,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/26/2015
0,04/26/2015,PARP-1 Inhibitor,172,4102,PARP-1 Inhibitor,BRCA1 Q1756fs,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/26/2015
0,04/26/2015,PARP Inhibitor (Pan),171,4103,PARP Inhibitor (Pan),BRCA1 Q202*,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/26/2015
0,04/26/2015,PARP-1 Inhibitor,172,4104,PARP-1 Inhibitor,BRCA1 Q202*,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/26/2015
0,04/26/2015,PARP Inhibitor (Pan),171,4105,PARP Inhibitor (Pan),BRCA1 Q94*,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/26/2015
0,04/26/2015,PARP-1 Inhibitor,172,4106,PARP-1 Inhibitor,BRCA1 Q94*,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/26/2015
0,04/26/2015,PARP Inhibitor (Pan),171,4107,PARP Inhibitor (Pan),BRCA1 R1443*,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/26/2015
0,04/26/2015,PARP-1 Inhibitor,172,4108,PARP-1 Inhibitor,BRCA1 R1443*,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/26/2015
0,04/26/2015,PARP Inhibitor (Pan),171,4111,PARP Inhibitor (Pan),BRCA1 S1503*,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/26/2015
0,04/26/2015,PARP-1 Inhibitor,172,4112,PARP-1 Inhibitor,BRCA1 S1503*,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/26/2015
0,04/27/2015,mTORC1 Inhibitor,153,4113,mTORC1 Inhibitor,FBXW7 E369*,"[{'id': 571, 'pubMedId': 18787170, 'title': 'FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18787170'}, {'id': 2558, 'pubMedId': 24586741, 'title': 'FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24586741'}]",,04/27/2015
0,04/27/2015,PARP Inhibitor (Pan),171,4114,PARP Inhibitor (Pan),BRCA2 C1200fs,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/27/2015
0,04/27/2015,PARP-1 Inhibitor,172,4115,PARP-1 Inhibitor,BRCA2 C1200fs,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/27/2015
0,04/27/2015,PARP Inhibitor (Pan),171,4116,PARP Inhibitor (Pan),BRCA2 E1285fs,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/27/2015
0,04/27/2015,PARP-1 Inhibitor,172,4117,PARP-1 Inhibitor,BRCA2 E1285fs,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/27/2015
0,04/27/2015,PARP Inhibitor (Pan),171,4118,PARP Inhibitor (Pan),BRCA2 E1441*,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/27/2015
0,04/27/2015,PARP-1 Inhibitor,172,4119,PARP-1 Inhibitor,BRCA2 E1441*,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/27/2015
0,04/27/2015,PARP Inhibitor (Pan),171,4120,PARP Inhibitor (Pan),BRCA2 E2229*,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/27/2015
0,04/27/2015,PARP-1 Inhibitor,172,4121,PARP-1 Inhibitor,BRCA2 E2229*,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/27/2015
0,04/27/2015,PARP Inhibitor (Pan),171,4122,PARP Inhibitor (Pan),BRCA2 E2476*,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/27/2015
0,04/27/2015,PARP-1 Inhibitor,172,4123,PARP-1 Inhibitor,BRCA2 E2476*,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/27/2015
0,04/27/2015,PARP Inhibitor (Pan),171,4124,PARP Inhibitor (Pan),BRCA2 E49*,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/27/2015
0,04/27/2015,PARP-1 Inhibitor,172,4125,PARP-1 Inhibitor,BRCA2 E49*,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/27/2015
0,04/27/2015,PARP Inhibitor (Pan),171,4126,PARP Inhibitor (Pan),BRCA2 E510*,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/27/2015
0,04/27/2015,PARP-1 Inhibitor,172,4127,PARP-1 Inhibitor,BRCA2 E510*,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/27/2015
0,04/27/2015,PARP Inhibitor (Pan),171,4128,PARP Inhibitor (Pan),BRCA2 E897*,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/27/2015
0,04/27/2015,PARP-1 Inhibitor,172,4129,PARP-1 Inhibitor,BRCA2 E897*,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/27/2015
0,04/27/2015,PARP Inhibitor (Pan),171,4130,PARP Inhibitor (Pan),BRCA2 K1691fs*15,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/27/2015
0,04/27/2015,PARP-1 Inhibitor,172,4131,PARP-1 Inhibitor,BRCA2 K1691fs*15,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/27/2015
0,04/27/2015,PARP Inhibitor (Pan),171,4132,PARP Inhibitor (Pan),BRCA2 K604*,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/27/2015
0,04/27/2015,PARP-1 Inhibitor,172,4133,PARP-1 Inhibitor,BRCA2 K604*,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/27/2015
0,04/28/2015,PARP Inhibitor (Pan),171,4134,PARP Inhibitor (Pan),BRCA2 R2645fs*3,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/28/2015
0,04/28/2015,PARP-1 Inhibitor,172,4135,PARP-1 Inhibitor,BRCA2 R2645fs*3,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/28/2015
0,04/28/2015,PARP Inhibitor (Pan),171,4136,PARP Inhibitor (Pan),BRCA2 R2784Q,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/28/2015
0,04/28/2015,PARP-1 Inhibitor,172,4137,PARP-1 Inhibitor,BRCA2 R2784Q,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/28/2015
0,04/28/2015,PARP Inhibitor (Pan),171,4138,PARP Inhibitor (Pan),BRCA2 R2842C,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/28/2015
0,04/28/2015,PARP-1 Inhibitor,172,4139,PARP-1 Inhibitor,BRCA2 R2842C,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/28/2015
0,04/28/2015,PARP Inhibitor (Pan),171,4140,PARP Inhibitor (Pan),BRCA2 S1064*,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/28/2015
0,04/28/2015,PARP-1 Inhibitor,172,4141,PARP-1 Inhibitor,BRCA2 S1064*,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/28/2015
0,04/28/2015,PARP Inhibitor (Pan),171,4142,PARP Inhibitor (Pan),BRCA2 S1982fs,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/28/2015
0,04/28/2015,PARP-1 Inhibitor,172,4143,PARP-1 Inhibitor,BRCA2 S1982fs,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/28/2015
0,04/28/2015,PARP Inhibitor (Pan),171,4144,PARP Inhibitor (Pan),BRCA2 S1982fs*22,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/28/2015
0,04/28/2015,PARP-1 Inhibitor,172,4145,PARP-1 Inhibitor,BRCA2 S1982fs*22,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/28/2015
0,04/28/2015,mTORC1 Inhibitor,153,4146,mTORC1 Inhibitor,FBXW7 G423*,"[{'id': 571, 'pubMedId': 18787170, 'title': 'FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18787170'}, {'id': 2558, 'pubMedId': 24586741, 'title': 'FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24586741'}]",,04/28/2015
0,04/28/2015,PARP Inhibitor (Pan),171,4147,PARP Inhibitor (Pan),BRCA2 K1574fs,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/28/2015
0,04/28/2015,PARP-1 Inhibitor,172,4148,PARP-1 Inhibitor,BRCA2 K1574fs,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/28/2015
0,04/28/2015,PARP Inhibitor (Pan),171,4153,PARP Inhibitor (Pan),BRCA2 D2611G,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/28/2015
0,04/28/2015,PARP-1 Inhibitor,172,4154,PARP-1 Inhibitor,BRCA2 D2611G,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/28/2015
0,04/28/2015,PARP Inhibitor (Pan),171,4155,PARP Inhibitor (Pan),BRCA2 D2723A,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/28/2015
0,04/28/2015,PARP-1 Inhibitor,172,4156,PARP-1 Inhibitor,BRCA2 D2723A,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/28/2015
0,04/28/2015,PARP Inhibitor (Pan),171,4157,PARP Inhibitor (Pan),BRCA2 D2723G,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/28/2015
0,04/28/2015,PARP-1 Inhibitor,172,4158,PARP-1 Inhibitor,BRCA2 D2723G,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/28/2015
0,04/28/2015,PARP Inhibitor (Pan),171,4159,PARP Inhibitor (Pan),BRCA2 D2723H,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/28/2015
0,04/28/2015,PARP-1 Inhibitor,172,4160,PARP-1 Inhibitor,BRCA2 D2723H,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/28/2015
0,04/28/2015,PARP Inhibitor (Pan),171,4161,PARP Inhibitor (Pan),BRCA2 D3073G,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/28/2015
0,04/28/2015,PARP-1 Inhibitor,172,4162,PARP-1 Inhibitor,BRCA2 D3073G,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/28/2015
0,04/28/2015,PARP Inhibitor (Pan),171,4163,PARP Inhibitor (Pan),BRCA2 D3095E,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/28/2015
0,04/28/2015,PARP-1 Inhibitor,172,4164,PARP-1 Inhibitor,BRCA2 D3095E,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/28/2015
0,04/28/2015,PARP Inhibitor (Pan),171,4165,PARP Inhibitor (Pan),BRCA2 E1382del,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/28/2015
0,04/28/2015,PARP-1 Inhibitor,172,4166,PARP-1 Inhibitor,BRCA2 E1382del,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/28/2015
0,04/28/2015,PARP Inhibitor (Pan),171,4167,PARP Inhibitor (Pan),BRCA2 E3002D,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/28/2015
0,04/28/2015,PARP-1 Inhibitor,172,4168,PARP-1 Inhibitor,BRCA2 E3002D,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/28/2015
0,04/28/2015,PARP Inhibitor (Pan),171,4169,PARP Inhibitor (Pan),BRCA2 E3002K,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/28/2015
0,04/28/2015,PARP-1 Inhibitor,172,4170,PARP-1 Inhibitor,BRCA2 E3002K,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/28/2015
0,04/28/2015,PARP Inhibitor (Pan),171,4171,PARP Inhibitor (Pan),BRCA2 G2585R,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/28/2015
0,04/28/2015,PARP-1 Inhibitor,172,4172,PARP-1 Inhibitor,BRCA2 G2585R,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/28/2015
0,04/28/2015,PARP Inhibitor (Pan),171,4173,PARP Inhibitor (Pan),BRCA2 G2609D,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/28/2015
0,04/28/2015,PARP-1 Inhibitor,172,4174,PARP-1 Inhibitor,BRCA2 G2609D,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/28/2015
0,04/28/2015,PARP Inhibitor (Pan),171,4175,PARP Inhibitor (Pan),BRCA2 G2748D,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/28/2015
0,04/28/2015,PARP-1 Inhibitor,172,4176,PARP-1 Inhibitor,BRCA2 G2748D,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/28/2015
0,04/28/2015,PARP Inhibitor (Pan),171,4177,PARP Inhibitor (Pan),BRCA2 G2793E,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/28/2015
0,04/28/2015,PARP-1 Inhibitor,172,4178,PARP-1 Inhibitor,BRCA2 G2793E,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/28/2015
0,04/28/2015,PARP Inhibitor (Pan),171,4179,PARP Inhibitor (Pan),BRCA2 G2793R,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/28/2015
0,04/28/2015,PARP-1 Inhibitor,172,4180,PARP-1 Inhibitor,BRCA2 G2793R,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/28/2015
0,04/28/2015,PARP Inhibitor (Pan),171,4181,PARP Inhibitor (Pan),BRCA2 G2812E,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/28/2015
0,04/28/2015,PARP-1 Inhibitor,172,4182,PARP-1 Inhibitor,BRCA2 G2812E,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/28/2015
0,04/28/2015,PARP Inhibitor (Pan),171,4183,PARP Inhibitor (Pan),BRCA2 G3076E,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/28/2015
0,04/28/2015,PARP-1 Inhibitor,172,4184,PARP-1 Inhibitor,BRCA2 G3076E,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/28/2015
0,04/28/2015,PARP Inhibitor (Pan),171,4185,PARP Inhibitor (Pan),BRCA2 G3076V,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/28/2015
0,04/28/2015,PARP-1 Inhibitor,172,4186,PARP-1 Inhibitor,BRCA2 G3076V,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/28/2015
0,04/28/2015,PARP Inhibitor (Pan),171,4187,PARP Inhibitor (Pan),BRCA2 I2627F,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/28/2015
0,04/28/2015,PARP-1 Inhibitor,172,4188,PARP-1 Inhibitor,BRCA2 I2627F,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/28/2015
0,04/28/2015,PARP Inhibitor (Pan),171,4189,PARP Inhibitor (Pan),BRCA2 L2510P,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/28/2015
0,04/28/2015,PARP-1 Inhibitor,172,4190,PARP-1 Inhibitor,BRCA2 L2510P,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/28/2015
0,04/28/2015,PARP Inhibitor (Pan),171,4191,PARP Inhibitor (Pan),BRCA2 L2647P,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/28/2015
0,04/28/2015,PARP-1 Inhibitor,172,4192,PARP-1 Inhibitor,BRCA2 L2647P,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/28/2015
0,04/28/2015,PARP Inhibitor (Pan),171,4193,PARP Inhibitor (Pan),BRCA2 L2653P,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/28/2015
0,04/28/2015,PARP-1 Inhibitor,172,4194,PARP-1 Inhibitor,BRCA2 L2653P,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/28/2015
0,04/28/2015,PARP Inhibitor (Pan),171,4195,PARP Inhibitor (Pan),BRCA2 L2654P,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/28/2015
0,04/28/2015,PARP-1 Inhibitor,172,4196,PARP-1 Inhibitor,BRCA2 L2654P,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/28/2015
0,04/28/2015,PARP Inhibitor (Pan),171,4197,PARP Inhibitor (Pan),BRCA2 L2688P,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/28/2015
0,04/28/2015,PARP-1 Inhibitor,172,4198,PARP-1 Inhibitor,BRCA2 L2688P,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/28/2015
0,04/28/2015,PARP Inhibitor (Pan),171,4199,PARP Inhibitor (Pan),BRCA2 L2792P,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/28/2015
0,04/28/2015,PARP-1 Inhibitor,172,4200,PARP-1 Inhibitor,BRCA2 L2792P,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/28/2015
0,04/28/2015,PARP Inhibitor (Pan),171,4201,PARP Inhibitor (Pan),BRCA2 N3124I,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/28/2015
0,04/28/2015,PARP-1 Inhibitor,172,4202,PARP-1 Inhibitor,BRCA2 N3124I,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/28/2015
0,04/28/2015,PARP Inhibitor (Pan),171,4203,PARP Inhibitor (Pan),BRCA2 P2800R,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/28/2015
0,04/28/2015,PARP-1 Inhibitor,172,4204,PARP-1 Inhibitor,BRCA2 P2800R,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/28/2015
0,04/28/2015,PARP Inhibitor (Pan),171,4205,PARP Inhibitor (Pan),BRCA2 P2800S,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/28/2015
0,04/28/2015,PARP-1 Inhibitor,172,4206,PARP-1 Inhibitor,BRCA2 P2800S,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/28/2015
0,04/28/2015,PARP Inhibitor (Pan),171,4207,PARP Inhibitor (Pan),BRCA2 R2659G,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/28/2015
0,04/28/2015,PARP-1 Inhibitor,172,4208,PARP-1 Inhibitor,BRCA2 R2659G,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/28/2015
0,04/28/2015,PARP Inhibitor (Pan),171,4209,PARP Inhibitor (Pan),BRCA2 R2659K,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/28/2015
0,04/28/2015,PARP-1 Inhibitor,172,4210,PARP-1 Inhibitor,BRCA2 R2659K,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/28/2015
0,04/28/2015,PARP Inhibitor (Pan),171,4211,PARP Inhibitor (Pan),BRCA2 R2784W,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/28/2015
0,04/28/2015,PARP-1 Inhibitor,172,4212,PARP-1 Inhibitor,BRCA2 R2784W,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/28/2015
0,04/28/2015,PARP Inhibitor (Pan),171,4213,PARP Inhibitor (Pan),BRCA2 R2842L,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/28/2015
0,04/28/2015,PARP-1 Inhibitor,172,4214,PARP-1 Inhibitor,BRCA2 R2842L,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/28/2015
0,04/28/2015,PARP Inhibitor (Pan),171,4215,PARP Inhibitor (Pan),BRCA2 R3052W,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/28/2015
0,04/28/2015,PARP-1 Inhibitor,172,4216,PARP-1 Inhibitor,BRCA2 R3052W,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/28/2015
0,04/28/2015,PARP Inhibitor (Pan),171,4217,PARP Inhibitor (Pan),ATM A2067D,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",,04/28/2015
0,04/28/2015,PARP Inhibitor (Pan),171,4218,PARP Inhibitor (Pan),ATM V2424G,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",,04/28/2015
0,04/28/2015,PARP Inhibitor (Pan),171,4219,PARP Inhibitor (Pan),ATM N1650S,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",,04/28/2015
0,04/28/2015,PARP Inhibitor (Pan),171,4220,PARP Inhibitor (Pan),ATM E1072*,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",,04/28/2015
0,04/28/2015,PARP Inhibitor (Pan),171,4221,PARP Inhibitor (Pan),ATM W57*,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",,04/28/2015
0,04/28/2015,FLT3 Inhibitor,96,4222,FLT3 Inhibitor,FLT3 D835X,"[{'id': 705, 'pubMedId': 11756186, 'title': 'FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11756186'}, {'id': 2547, 'pubMedId': 17124058, 'title': 'FLT3 mutations: biology and treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17124058'}, {'id': 2548, 'pubMedId': 25231999, 'title': 'Targeting FLT3 to treat leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25231999'}]",,04/28/2015
0,04/29/2015,mTORC1 Inhibitor,153,4223,mTORC1 Inhibitor,FBXW7 H460R,"[{'id': 571, 'pubMedId': 18787170, 'title': 'FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18787170'}, {'id': 2558, 'pubMedId': 24586741, 'title': 'FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24586741'}]",,04/29/2015
0,04/30/2015,mTORC1 Inhibitor,153,4231,mTORC1 Inhibitor,FBXW7 K299fs,"[{'id': 571, 'pubMedId': 18787170, 'title': 'FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18787170'}, {'id': 2558, 'pubMedId': 24586741, 'title': 'FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24586741'}]",,04/30/2015
0,04/30/2015,MET Antibody,244,4232,MET Antibody,MET amp,"[{'id': 2627, 'pubMedId': 24959084, 'title': 'The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24959084'}]",,07/20/2017
0,04/30/2015,MET Antibody,244,4233,MET Antibody,MET over exp,"[{'id': 2627, 'pubMedId': 24959084, 'title': 'The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24959084'}]",,07/20/2017
0,04/30/2015,MET Inhibitor,147,4234,MET Inhibitor,MET over exp,"[{'id': 1994, 'pubMedId': 24045150, 'title': 'Met as a therapeutic target in HCC: facts and hopes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24045150'}]",,04/30/2015
0,04/30/2015,Akt Inhibitor (Pan),4,4255,Akt Inhibitor (Pan),PIK3CA R38C,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/30/2015
0,04/30/2015,Akt1 Inhibitor,6,4256,Akt1 Inhibitor,PIK3CA R38C,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/30/2015
0,04/30/2015,Akt2 Inhibitor,7,4257,Akt2 Inhibitor,PIK3CA R38C,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/30/2015
0,04/30/2015,Akt3 Inhibitor,8,4258,Akt3 Inhibitor,PIK3CA R38C,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/30/2015
0,04/30/2015,mTOR Inhibitor,152,4259,mTOR Inhibitor,PIK3CA R38C,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/30/2015
0,04/30/2015,mTORC1 Inhibitor,153,4260,mTORC1 Inhibitor,PIK3CA R38C,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/30/2015
0,04/30/2015,mTORC2 Inhibitor,154,4261,mTORC2 Inhibitor,PIK3CA R38C,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/30/2015
0,04/30/2015,PI3K Inhibitor (Pan),181,4262,PI3K Inhibitor (Pan),PIK3CA R38C,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/30/2015
0,04/30/2015,PIK3CA inhibitor,182,4263,PIK3CA inhibitor,PIK3CA R38C,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/30/2015
0,04/30/2015,Akt Inhibitor (Pan),4,4264,Akt Inhibitor (Pan),PIK3CA E365K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/30/2015
0,04/30/2015,Akt1 Inhibitor,6,4265,Akt1 Inhibitor,PIK3CA E365K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/30/2015
0,04/30/2015,Akt2 Inhibitor,7,4266,Akt2 Inhibitor,PIK3CA E365K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/30/2015
0,04/30/2015,Akt3 Inhibitor,8,4267,Akt3 Inhibitor,PIK3CA E365K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/30/2015
0,04/30/2015,mTOR Inhibitor,152,4268,mTOR Inhibitor,PIK3CA E365K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/30/2015
0,04/30/2015,mTORC1 Inhibitor,153,4269,mTORC1 Inhibitor,PIK3CA E365K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/30/2015
0,04/30/2015,mTORC2 Inhibitor,154,4270,mTORC2 Inhibitor,PIK3CA E365K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/30/2015
0,04/30/2015,PI3K Inhibitor (Pan),181,4271,PI3K Inhibitor (Pan),PIK3CA E365K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/30/2015
0,04/30/2015,PIK3CA inhibitor,182,4272,PIK3CA inhibitor,PIK3CA E365K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/30/2015
0,04/30/2015,mTORC1 Inhibitor,153,4289,mTORC1 Inhibitor,FBXW7 R224*,"[{'id': 571, 'pubMedId': 18787170, 'title': 'FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18787170'}, {'id': 2558, 'pubMedId': 24586741, 'title': 'FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24586741'}]",,04/30/2015
0,05/01/2015,mTORC1 Inhibitor,153,4290,mTORC1 Inhibitor,FBXW7 R367*,"[{'id': 571, 'pubMedId': 18787170, 'title': 'FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18787170'}, {'id': 2558, 'pubMedId': 24586741, 'title': 'FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24586741'}]",,05/01/2015
0,05/01/2015,mTORC1 Inhibitor,153,4291,mTORC1 Inhibitor,FBXW7 R393*,"[{'id': 571, 'pubMedId': 18787170, 'title': 'FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18787170'}, {'id': 2558, 'pubMedId': 24586741, 'title': 'FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24586741'}]",,05/01/2015
0,05/01/2015,mTORC1 Inhibitor,153,4292,mTORC1 Inhibitor,FBXW7 R465L,"[{'id': 571, 'pubMedId': 18787170, 'title': 'FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18787170'}, {'id': 2558, 'pubMedId': 24586741, 'title': 'FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24586741'}]",,05/01/2015
0,05/01/2015,mTORC1 Inhibitor,153,4293,mTORC1 Inhibitor,FBXW7 R465P,"[{'id': 571, 'pubMedId': 18787170, 'title': 'FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18787170'}, {'id': 2558, 'pubMedId': 24586741, 'title': 'FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24586741'}]",,05/01/2015
0,05/01/2015,mTORC1 Inhibitor,153,4294,mTORC1 Inhibitor,FBXW7 R465Y,"[{'id': 571, 'pubMedId': 18787170, 'title': 'FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18787170'}, {'id': 2558, 'pubMedId': 24586741, 'title': 'FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24586741'}]",,05/01/2015
0,05/01/2015,mTORC1 Inhibitor,153,4295,mTORC1 Inhibitor,FBXW7 R473fs,"[{'id': 571, 'pubMedId': 18787170, 'title': 'FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18787170'}, {'id': 2558, 'pubMedId': 24586741, 'title': 'FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24586741'}]",,05/01/2015
0,05/02/2015,mTORC1 Inhibitor,153,4296,mTORC1 Inhibitor,FBXW7 R473fs*25,"[{'id': 571, 'pubMedId': 18787170, 'title': 'FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18787170'}, {'id': 2558, 'pubMedId': 24586741, 'title': 'FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24586741'}]",,05/02/2015
0,05/02/2015,mTORC1 Inhibitor,153,4297,mTORC1 Inhibitor,FBXW7 R473fs*4,"[{'id': 571, 'pubMedId': 18787170, 'title': 'FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18787170'}, {'id': 2558, 'pubMedId': 24586741, 'title': 'FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24586741'}]",,05/02/2015
0,05/02/2015,mTORC1 Inhibitor,153,4298,mTORC1 Inhibitor,FBXW7 R479*,"[{'id': 571, 'pubMedId': 18787170, 'title': 'FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18787170'}, {'id': 2558, 'pubMedId': 24586741, 'title': 'FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24586741'}]",,05/02/2015
0,05/02/2015,mTORC1 Inhibitor,153,4299,mTORC1 Inhibitor,FBXW7 R479L,"[{'id': 571, 'pubMedId': 18787170, 'title': 'FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18787170'}, {'id': 2558, 'pubMedId': 24586741, 'title': 'FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24586741'}]",,05/02/2015
0,05/02/2015,mTORC1 Inhibitor,153,4300,mTORC1 Inhibitor,FBXW7 R479G,"[{'id': 571, 'pubMedId': 18787170, 'title': 'FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18787170'}, {'id': 2558, 'pubMedId': 24586741, 'title': 'FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24586741'}]",,05/02/2015
0,05/02/2015,mTORC1 Inhibitor,153,4301,mTORC1 Inhibitor,FBXW7 R479H,"[{'id': 571, 'pubMedId': 18787170, 'title': 'FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18787170'}, {'id': 2558, 'pubMedId': 24586741, 'title': 'FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24586741'}]",,05/02/2015
0,05/02/2015,mTORC1 Inhibitor,153,4302,mTORC1 Inhibitor,FBXW7 R479P,"[{'id': 571, 'pubMedId': 18787170, 'title': 'FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18787170'}, {'id': 2558, 'pubMedId': 24586741, 'title': 'FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24586741'}]",,05/02/2015
0,05/03/2015,PARP Inhibitor (Pan),171,4303,PARP Inhibitor (Pan),ATM A1742P,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",,05/03/2015
0,05/03/2015,PARP Inhibitor (Pan),171,4304,PARP Inhibitor (Pan),ATM C353fs*5,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",,05/03/2015
0,05/03/2015,PARP Inhibitor (Pan),171,4305,PARP Inhibitor (Pan),ATM D1682Y,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",,05/03/2015
0,05/03/2015,PARP Inhibitor (Pan),171,4312,PARP Inhibitor (Pan),BRCA2 T1302del,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,05/03/2015
0,05/03/2015,PARP-1 Inhibitor,172,4313,PARP-1 Inhibitor,BRCA2 T1302del,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,05/03/2015
0,05/03/2015,PARP Inhibitor (Pan),171,4314,PARP Inhibitor (Pan),BRCA2 T2515I,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,05/03/2015
0,05/03/2015,PARP-1 Inhibitor,172,4315,PARP-1 Inhibitor,BRCA2 T2515I,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,05/03/2015
0,05/03/2015,PARP Inhibitor (Pan),171,4316,PARP Inhibitor (Pan),BRCA2 T2722R,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,05/03/2015
0,05/03/2015,PARP-1 Inhibitor,172,4317,PARP-1 Inhibitor,BRCA2 T2722R,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,05/03/2015
0,05/03/2015,PARP Inhibitor (Pan),171,4318,PARP Inhibitor (Pan),BRCA2 T3030fs,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,05/03/2015
0,05/03/2015,PARP-1 Inhibitor,172,4319,PARP-1 Inhibitor,BRCA2 T3030fs,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,05/03/2015
0,05/03/2015,PARP Inhibitor (Pan),171,4320,PARP Inhibitor (Pan),BRCA2 T3033fs*29,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,05/03/2015
0,05/03/2015,PARP-1 Inhibitor,172,4321,PARP-1 Inhibitor,BRCA2 T3033fs*29,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,05/03/2015
0,05/03/2015,PARP Inhibitor (Pan),171,4322,PARP Inhibitor (Pan),BRCA2 T3033I,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,05/03/2015
0,05/03/2015,PARP-1 Inhibitor,172,4323,PARP-1 Inhibitor,BRCA2 T3033I,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,05/03/2015
0,05/03/2015,PARP Inhibitor (Pan),171,4324,PARP Inhibitor (Pan),BRCA2 W2626C,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,05/03/2015
0,05/03/2015,PARP-1 Inhibitor,172,4325,PARP-1 Inhibitor,BRCA2 W2626C,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,05/03/2015
0,05/03/2015,PARP Inhibitor (Pan),171,4326,PARP Inhibitor (Pan),BRCA2 Y2660D,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,05/03/2015
0,05/03/2015,PARP-1 Inhibitor,172,4327,PARP-1 Inhibitor,BRCA2 Y2660D,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,05/03/2015
0,05/03/2015,PARP Inhibitor (Pan),171,4328,PARP Inhibitor (Pan),BRCA2 Y2726C,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,05/03/2015
0,05/03/2015,PARP-1 Inhibitor,172,4329,PARP-1 Inhibitor,BRCA2 Y2726C,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,05/03/2015
0,05/03/2015,PARP Inhibitor (Pan),171,4330,PARP Inhibitor (Pan),BRCA2 Y2997*,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,05/03/2015
0,05/03/2015,PARP-1 Inhibitor,172,4331,PARP-1 Inhibitor,BRCA2 Y2997*,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,05/03/2015
0,05/03/2015,PARP Inhibitor (Pan),171,4332,PARP Inhibitor (Pan),BRCA2 Y3092S,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,05/03/2015
0,05/03/2015,PARP-1 Inhibitor,172,4333,PARP-1 Inhibitor,BRCA2 Y3092S,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,05/03/2015
0,05/03/2015,PARP Inhibitor (Pan),171,4334,PARP Inhibitor (Pan),BRCA2 Y42C,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,05/03/2015
0,05/03/2015,PARP-1 Inhibitor,172,4335,PARP-1 Inhibitor,BRCA2 Y42C,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,05/03/2015
0,05/04/2015,PARP Inhibitor (Pan),171,4336,PARP Inhibitor (Pan),ATM E1666*,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",,05/04/2015
0,05/04/2015,PARP Inhibitor (Pan),171,4337,PARP Inhibitor (Pan),ATM E2272*,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",,05/04/2015
0,05/04/2015,PARP Inhibitor (Pan),171,4338,PARP Inhibitor (Pan),ATM E390*,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",,05/04/2015
0,05/04/2015,PARP Inhibitor (Pan),171,4339,PARP Inhibitor (Pan),ATM E522*,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",,05/04/2015
0,05/04/2015,PARP Inhibitor (Pan),171,4340,PARP Inhibitor (Pan),ATM G2083*,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",,05/04/2015
0,05/04/2015,p53 Activator,166,4341,p53 Activator,TP53 G245C,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,05/04/2015
0,05/04/2015,p53 Gene Therapy,167,4342,p53 Gene Therapy,TP53 G245C,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,05/04/2015
0,05/04/2015,SRC Inhibitor,209,4343,SRC Inhibitor,SRC E527K,"[{'id': 2477, 'pubMedId': 25662515, 'title': 'Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25662515'}, {'id': 2478, 'pubMedId': 21776389, 'title': 'Regulation of SRC family kinases in human cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21776389'}, {'id': 2479, 'pubMedId': 21521831, 'title': 'Current status of SRC inhibitors in solid tumor malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21521831'}]",,05/04/2015
0,05/05/2015,PARP Inhibitor (Pan),171,4344,PARP Inhibitor (Pan),ATM I1681V,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",,05/05/2015
0,05/05/2015,p53 Activator,166,4345,p53 Activator,TP53 G245F,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,05/05/2015
0,05/05/2015,p53 Gene Therapy,167,4346,p53 Gene Therapy,TP53 G245F,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,05/05/2015
0,05/05/2015,p53 Activator,166,4347,p53 Activator,TP53 G245V,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,05/05/2015
0,05/05/2015,p53 Gene Therapy,167,4348,p53 Gene Therapy,TP53 G245V,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,05/05/2015
0,05/05/2015,IDH Inhibitor (Pan),117,4349,IDH Inhibitor (Pan),IDH1 G97D,"[{'id': 2551, 'pubMedId': 25678837, 'title': 'New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25678837'}]",,05/05/2015
0,05/05/2015,IDH1 Inhibitor,118,4350,IDH1 Inhibitor,IDH1 G97D,"[{'id': 2551, 'pubMedId': 25678837, 'title': 'New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25678837'}, {'id': 2552, 'pubMedId': 23558169, 'title': 'An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23558169'}]",,05/05/2015
0,05/05/2015,PARP Inhibitor (Pan),171,4353,PARP Inhibitor (Pan),ATM I1849fs,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",,05/05/2015
0,05/06/2015,PARP Inhibitor (Pan),171,4358,PARP Inhibitor (Pan),ATM K468fs*18,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",,05/06/2015
0,05/06/2015,PARP Inhibitor (Pan),171,4359,PARP Inhibitor (Pan),ATM L2427P,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",,05/06/2015
0,05/06/2015,PARP Inhibitor (Pan),171,4360,PARP Inhibitor (Pan),ATM L2890V,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",,05/06/2015
0,05/06/2015,p53 Activator,166,4361,p53 Activator,TP53 P151H,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,05/06/2015
0,05/06/2015,p53 Gene Therapy,167,4362,p53 Gene Therapy,TP53 P151H,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,05/06/2015
0,05/07/2015,PARP Inhibitor (Pan),171,4372,PARP Inhibitor (Pan),ATM Q1579fs,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",,05/07/2015
0,05/07/2015,PARP Inhibitor (Pan),171,4373,PARP Inhibitor (Pan),ATM R1466*,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",,05/07/2015
0,05/07/2015,PARP Inhibitor (Pan),171,4374,PARP Inhibitor (Pan),ATM R1730*,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",,05/07/2015
0,05/07/2015,PARP Inhibitor (Pan),171,4375,PARP Inhibitor (Pan),ATM R2034*,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",,05/07/2015
0,05/07/2015,PARP Inhibitor (Pan),171,4376,PARP Inhibitor (Pan),ATM R250*,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",,05/07/2015
0,05/07/2015,PARP Inhibitor (Pan),171,4377,PARP Inhibitor (Pan),ATM R2598*,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",,05/07/2015
0,05/07/2015,EGFR Inhibitor 3rd gen,77,4379,EGFR Inhibitor 3rd gen,EGFR del exon 19 EGFR T790M,"[{'id': 537, 'pubMedId': 24893891, 'title': 'AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24893891'}]",,05/07/2015
0,05/07/2015,KIT Inhibitor,136,4380,KIT Inhibitor,KIT Q556_K558del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,05/07/2015
0,05/08/2015,PARP Inhibitor (Pan),171,4381,PARP Inhibitor (Pan),ATM R2832C,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",,05/08/2015
0,05/08/2015,PARP Inhibitor (Pan),171,4382,PARP Inhibitor (Pan),ATM R3008C,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",,05/08/2015
0,05/08/2015,PARP Inhibitor (Pan),171,4383,PARP Inhibitor (Pan),ATM R3008H,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",,05/08/2015
0,05/08/2015,PARP Inhibitor (Pan),171,4384,PARP Inhibitor (Pan),ATM R377S,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",,05/08/2015
0,05/08/2015,PARP Inhibitor (Pan),171,4385,PARP Inhibitor (Pan),ATM R3047*,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",,05/08/2015
0,05/08/2015,PARP Inhibitor (Pan),171,4386,PARP Inhibitor (Pan),ATM R2993*,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",,05/08/2015
0,05/08/2015,PARP Inhibitor (Pan),171,4387,PARP Inhibitor (Pan),ATM R805*,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",,05/08/2015
0,05/08/2015,PARP Inhibitor (Pan),171,4388,PARP Inhibitor (Pan),ATM S131*,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",,05/08/2015
0,05/08/2015,KIT Inhibitor,136,4389,KIT Inhibitor,KIT S501_A502insSAY,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,05/08/2015
0,05/09/2015,PARP Inhibitor (Pan),171,4397,PARP Inhibitor (Pan),ATM S719*,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",,05/09/2015
0,05/09/2015,PARP Inhibitor (Pan),171,4398,PARP Inhibitor (Pan),ATM T2947S,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",,05/09/2015
0,05/09/2015,PARP Inhibitor (Pan),171,4399,PARP Inhibitor (Pan),ATM V1941L,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",,05/09/2015
0,05/10/2015,PARP Inhibitor (Pan),171,4400,PARP Inhibitor (Pan),ATM K2756*,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",,05/10/2015
0,05/11/2015,HER inhibitor (Pan),105,4434,HER inhibitor (Pan),ERBB4 amp,"[{'id': 2681, 'pubMedId': 20404484, 'title': 'A growing family: adding mutated Erbb4 as a novel cancer target.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20404484'}]",,05/11/2015
0,05/11/2015,HER inhibitor (Pan),105,4435,HER inhibitor (Pan),ERBB4 over exp,"[{'id': 2681, 'pubMedId': 20404484, 'title': 'A growing family: adding mutated Erbb4 as a novel cancer target.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20404484'}]",,05/11/2015
0,05/11/2015,HER inhibitor (Pan),105,4436,HER inhibitor (Pan),ERBB4 act mut,"[{'id': 2681, 'pubMedId': 20404484, 'title': 'A growing family: adding mutated Erbb4 as a novel cancer target.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20404484'}]",,05/11/2015
0,05/11/2015,HER inhibitor (Pan),105,4437,HER inhibitor (Pan),ERBB4 E542K,"[{'id': 2681, 'pubMedId': 20404484, 'title': 'A growing family: adding mutated Erbb4 as a novel cancer target.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20404484'}]",,05/11/2015
0,05/11/2015,PARP Inhibitor (Pan),171,4438,PARP Inhibitor (Pan),ATM R2849*,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",,05/11/2015
0,05/12/2015,HER inhibitor (Pan),105,4455,HER inhibitor (Pan),ERBB2 act mut,"[{'id': 2691, 'pubMedId': 25674538, 'title': 'The Potential of panHER Inhibition in Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25674538'}]",,05/12/2015
0,05/12/2015,HER inhibitor (Pan),105,4456,HER inhibitor (Pan),ERBB2 amp,"[{'id': 2691, 'pubMedId': 25674538, 'title': 'The Potential of panHER Inhibition in Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25674538'}]",,05/12/2015
0,05/12/2015,HER inhibitor (Pan),105,4457,HER inhibitor (Pan),ERBB2 Y772_A775dup,"[{'id': 2691, 'pubMedId': 25674538, 'title': 'The Potential of panHER Inhibition in Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25674538'}]",,05/12/2015
0,05/12/2015,HER2 Inhibitor,106,4458,HER2 Inhibitor,ERBB2 Y772_A775dup,"[{'id': 561, 'pubMedId': 22649146, 'title': 'HER2 mutations in non-small-cell lung cancer can be continually targeted.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22649146'}, {'id': 563, 'pubMedId': 21991949, 'title': 'Adjuvant trastuzumab in HER2-positive breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21991949'}, {'id': 564, 'pubMedId': 23801166, 'title': 'First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23801166'}]",,05/12/2015
0,05/12/2015,HER inhibitor (Pan),105,4459,HER inhibitor (Pan),ERBB2 D769H,"[{'id': 2691, 'pubMedId': 25674538, 'title': 'The Potential of panHER Inhibition in Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25674538'}]",,05/12/2015
0,05/12/2015,HER2 Inhibitor,106,4460,HER2 Inhibitor,ERBB2 D769H,"[{'id': 561, 'pubMedId': 22649146, 'title': 'HER2 mutations in non-small-cell lung cancer can be continually targeted.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22649146'}, {'id': 563, 'pubMedId': 21991949, 'title': 'Adjuvant trastuzumab in HER2-positive breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21991949'}, {'id': 564, 'pubMedId': 23801166, 'title': 'First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23801166'}]",,05/12/2015
0,05/12/2015,HER inhibitor (Pan),105,4461,HER inhibitor (Pan),ERBB2 D769Y,"[{'id': 2691, 'pubMedId': 25674538, 'title': 'The Potential of panHER Inhibition in Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25674538'}]",,05/12/2015
0,05/12/2015,HER2 Inhibitor,106,4462,HER2 Inhibitor,ERBB2 D769Y,"[{'id': 561, 'pubMedId': 22649146, 'title': 'HER2 mutations in non-small-cell lung cancer can be continually targeted.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22649146'}, {'id': 563, 'pubMedId': 21991949, 'title': 'Adjuvant trastuzumab in HER2-positive breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21991949'}, {'id': 564, 'pubMedId': 23801166, 'title': 'First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23801166'}]",,05/12/2015
0,05/12/2015,HER inhibitor (Pan),105,4463,HER inhibitor (Pan),ERBB2 E321G,"[{'id': 2691, 'pubMedId': 25674538, 'title': 'The Potential of panHER Inhibition in Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25674538'}]",,05/12/2015
0,05/12/2015,HER2 Inhibitor,106,4464,HER2 Inhibitor,ERBB2 E321G,"[{'id': 561, 'pubMedId': 22649146, 'title': 'HER2 mutations in non-small-cell lung cancer can be continually targeted.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22649146'}, {'id': 563, 'pubMedId': 21991949, 'title': 'Adjuvant trastuzumab in HER2-positive breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21991949'}, {'id': 564, 'pubMedId': 23801166, 'title': 'First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23801166'}]",,05/12/2015
0,05/12/2015,HER inhibitor (Pan),105,4465,HER inhibitor (Pan),ERBB2 G309A,"[{'id': 2691, 'pubMedId': 25674538, 'title': 'The Potential of panHER Inhibition in Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25674538'}]",,05/12/2015
0,05/12/2015,HER2 Inhibitor,106,4466,HER2 Inhibitor,ERBB2 G309A,"[{'id': 561, 'pubMedId': 22649146, 'title': 'HER2 mutations in non-small-cell lung cancer can be continually targeted.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22649146'}, {'id': 563, 'pubMedId': 21991949, 'title': 'Adjuvant trastuzumab in HER2-positive breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21991949'}, {'id': 564, 'pubMedId': 23801166, 'title': 'First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23801166'}]",,05/12/2015
0,05/12/2015,HER inhibitor (Pan),105,4467,HER inhibitor (Pan),ERBB2 G309E,"[{'id': 2691, 'pubMedId': 25674538, 'title': 'The Potential of panHER Inhibition in Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25674538'}]",,05/12/2015
0,05/12/2015,HER2 Inhibitor,106,4468,HER2 Inhibitor,ERBB2 G309E,"[{'id': 561, 'pubMedId': 22649146, 'title': 'HER2 mutations in non-small-cell lung cancer can be continually targeted.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22649146'}, {'id': 563, 'pubMedId': 21991949, 'title': 'Adjuvant trastuzumab in HER2-positive breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21991949'}, {'id': 564, 'pubMedId': 23801166, 'title': 'First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23801166'}]",,05/12/2015
0,05/12/2015,HER inhibitor (Pan),105,4469,HER inhibitor (Pan),ERBB2 G776S,"[{'id': 2691, 'pubMedId': 25674538, 'title': 'The Potential of panHER Inhibition in Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25674538'}]",,05/12/2015
0,05/12/2015,HER2 Inhibitor,106,4470,HER2 Inhibitor,ERBB2 G776S,"[{'id': 561, 'pubMedId': 22649146, 'title': 'HER2 mutations in non-small-cell lung cancer can be continually targeted.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22649146'}, {'id': 563, 'pubMedId': 21991949, 'title': 'Adjuvant trastuzumab in HER2-positive breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21991949'}, {'id': 564, 'pubMedId': 23801166, 'title': 'First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23801166'}]",,05/12/2015
0,05/12/2015,HER inhibitor (Pan),105,4471,HER inhibitor (Pan),ERBB2 G776_V777insYVMA,"[{'id': 2691, 'pubMedId': 25674538, 'title': 'The Potential of panHER Inhibition in Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25674538'}]",,05/12/2015
0,05/12/2015,HER2 Inhibitor,106,4472,HER2 Inhibitor,ERBB2 G776_V777insYVMA,"[{'id': 561, 'pubMedId': 22649146, 'title': 'HER2 mutations in non-small-cell lung cancer can be continually targeted.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22649146'}, {'id': 563, 'pubMedId': 21991949, 'title': 'Adjuvant trastuzumab in HER2-positive breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21991949'}, {'id': 564, 'pubMedId': 23801166, 'title': 'First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23801166'}]",,05/12/2015
0,05/12/2015,HER inhibitor (Pan),105,4473,HER inhibitor (Pan),ERBB2 I654V,"[{'id': 2691, 'pubMedId': 25674538, 'title': 'The Potential of panHER Inhibition in Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25674538'}]",,05/12/2015
0,05/12/2015,HER2 Inhibitor,106,4474,HER2 Inhibitor,ERBB2 I654V,"[{'id': 561, 'pubMedId': 22649146, 'title': 'HER2 mutations in non-small-cell lung cancer can be continually targeted.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22649146'}, {'id': 563, 'pubMedId': 21991949, 'title': 'Adjuvant trastuzumab in HER2-positive breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21991949'}, {'id': 564, 'pubMedId': 23801166, 'title': 'First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23801166'}]",,05/12/2015
0,05/12/2015,HER inhibitor (Pan),105,4477,HER inhibitor (Pan),ERBB2 L755P,"[{'id': 2691, 'pubMedId': 25674538, 'title': 'The Potential of panHER Inhibition in Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25674538'}]",,05/12/2015
0,05/12/2015,HER2 Inhibitor,106,4478,HER2 Inhibitor,ERBB2 L755P,"[{'id': 561, 'pubMedId': 22649146, 'title': 'HER2 mutations in non-small-cell lung cancer can be continually targeted.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22649146'}, {'id': 563, 'pubMedId': 21991949, 'title': 'Adjuvant trastuzumab in HER2-positive breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21991949'}, {'id': 564, 'pubMedId': 23801166, 'title': 'First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23801166'}]",,05/12/2015
0,05/12/2015,HER inhibitor (Pan),105,4479,HER inhibitor (Pan),ERBB2 L755S,"[{'id': 2691, 'pubMedId': 25674538, 'title': 'The Potential of panHER Inhibition in Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25674538'}]",,05/12/2015
0,05/12/2015,HER2 Inhibitor,106,4480,HER2 Inhibitor,ERBB2 L755S,"[{'id': 561, 'pubMedId': 22649146, 'title': 'HER2 mutations in non-small-cell lung cancer can be continually targeted.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22649146'}, {'id': 563, 'pubMedId': 21991949, 'title': 'Adjuvant trastuzumab in HER2-positive breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21991949'}, {'id': 564, 'pubMedId': 23801166, 'title': 'First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23801166'}]",,05/12/2015
0,05/12/2015,HER inhibitor (Pan),105,4481,HER inhibitor (Pan),ERBB2 M774_A775insAYVM,"[{'id': 2691, 'pubMedId': 25674538, 'title': 'The Potential of panHER Inhibition in Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25674538'}]",,05/12/2015
0,05/12/2015,HER2 Inhibitor,106,4482,HER2 Inhibitor,ERBB2 M774_A775insAYVM,"[{'id': 561, 'pubMedId': 22649146, 'title': 'HER2 mutations in non-small-cell lung cancer can be continually targeted.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22649146'}, {'id': 563, 'pubMedId': 21991949, 'title': 'Adjuvant trastuzumab in HER2-positive breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21991949'}, {'id': 564, 'pubMedId': 23801166, 'title': 'First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23801166'}]",,05/12/2015
0,05/12/2015,HER inhibitor (Pan),105,4483,HER inhibitor (Pan),ERBB2 G778_P780dup,"[{'id': 2691, 'pubMedId': 25674538, 'title': 'The Potential of panHER Inhibition in Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25674538'}]",,05/12/2015
0,05/12/2015,HER2 Inhibitor,106,4484,HER2 Inhibitor,ERBB2 G778_P780dup,"[{'id': 561, 'pubMedId': 22649146, 'title': 'HER2 mutations in non-small-cell lung cancer can be continually targeted.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22649146'}, {'id': 563, 'pubMedId': 21991949, 'title': 'Adjuvant trastuzumab in HER2-positive breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21991949'}, {'id': 564, 'pubMedId': 23801166, 'title': 'First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23801166'}]",,05/12/2015
0,05/12/2015,HER inhibitor (Pan),105,4485,HER inhibitor (Pan),ERBB2 R896C,"[{'id': 2691, 'pubMedId': 25674538, 'title': 'The Potential of panHER Inhibition in Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25674538'}]",,05/12/2015
0,05/12/2015,HER2 Inhibitor,106,4486,HER2 Inhibitor,ERBB2 R896C,"[{'id': 561, 'pubMedId': 22649146, 'title': 'HER2 mutations in non-small-cell lung cancer can be continually targeted.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22649146'}, {'id': 563, 'pubMedId': 21991949, 'title': 'Adjuvant trastuzumab in HER2-positive breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21991949'}, {'id': 564, 'pubMedId': 23801166, 'title': 'First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23801166'}]",,05/12/2015
0,05/12/2015,HER inhibitor (Pan),105,4487,HER inhibitor (Pan),ERBB2 S310F,"[{'id': 2691, 'pubMedId': 25674538, 'title': 'The Potential of panHER Inhibition in Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25674538'}]",,05/12/2015
0,05/12/2015,HER2 Inhibitor,106,4488,HER2 Inhibitor,ERBB2 S310F,"[{'id': 561, 'pubMedId': 22649146, 'title': 'HER2 mutations in non-small-cell lung cancer can be continually targeted.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22649146'}, {'id': 563, 'pubMedId': 21991949, 'title': 'Adjuvant trastuzumab in HER2-positive breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21991949'}, {'id': 564, 'pubMedId': 23801166, 'title': 'First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23801166'}]",,05/12/2015
0,05/12/2015,HER inhibitor (Pan),105,4489,HER inhibitor (Pan),ERBB2 S310Y,"[{'id': 2691, 'pubMedId': 25674538, 'title': 'The Potential of panHER Inhibition in Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25674538'}]",,05/12/2015
0,05/12/2015,HER2 Inhibitor,106,4490,HER2 Inhibitor,ERBB2 S310Y,"[{'id': 561, 'pubMedId': 22649146, 'title': 'HER2 mutations in non-small-cell lung cancer can be continually targeted.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22649146'}, {'id': 563, 'pubMedId': 21991949, 'title': 'Adjuvant trastuzumab in HER2-positive breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21991949'}, {'id': 564, 'pubMedId': 23801166, 'title': 'First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23801166'}]",,05/12/2015
0,05/12/2015,HER inhibitor (Pan),105,4491,HER inhibitor (Pan),ERBB2 T216S,"[{'id': 2691, 'pubMedId': 25674538, 'title': 'The Potential of panHER Inhibition in Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25674538'}]",,05/12/2015
0,05/12/2015,HER2 Inhibitor,106,4492,HER2 Inhibitor,ERBB2 T216S,"[{'id': 561, 'pubMedId': 22649146, 'title': 'HER2 mutations in non-small-cell lung cancer can be continually targeted.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22649146'}, {'id': 563, 'pubMedId': 21991949, 'title': 'Adjuvant trastuzumab in HER2-positive breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21991949'}, {'id': 564, 'pubMedId': 23801166, 'title': 'First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23801166'}]",,05/12/2015
0,05/12/2015,HER inhibitor (Pan),105,4493,HER inhibitor (Pan),ERBB2 T798M,"[{'id': 2691, 'pubMedId': 25674538, 'title': 'The Potential of panHER Inhibition in Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25674538'}]",,05/12/2015
0,05/12/2015,HER2 Inhibitor,106,4494,HER2 Inhibitor,ERBB2 T798M,"[{'id': 561, 'pubMedId': 22649146, 'title': 'HER2 mutations in non-small-cell lung cancer can be continually targeted.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22649146'}, {'id': 563, 'pubMedId': 21991949, 'title': 'Adjuvant trastuzumab in HER2-positive breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21991949'}, {'id': 564, 'pubMedId': 23801166, 'title': 'First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23801166'}]",,05/12/2015
0,05/12/2015,HER inhibitor (Pan),105,4495,HER inhibitor (Pan),ERBB2 V777L,"[{'id': 2691, 'pubMedId': 25674538, 'title': 'The Potential of panHER Inhibition in Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25674538'}]",,05/12/2015
0,05/12/2015,HER2 Inhibitor,106,4496,HER2 Inhibitor,ERBB2 V777L,"[{'id': 561, 'pubMedId': 22649146, 'title': 'HER2 mutations in non-small-cell lung cancer can be continually targeted.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22649146'}, {'id': 563, 'pubMedId': 21991949, 'title': 'Adjuvant trastuzumab in HER2-positive breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21991949'}, {'id': 564, 'pubMedId': 23801166, 'title': 'First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23801166'}]",,05/12/2015
0,05/12/2015,HER inhibitor (Pan),105,4497,HER inhibitor (Pan),ERBB2 V842I,"[{'id': 2691, 'pubMedId': 25674538, 'title': 'The Potential of panHER Inhibition in Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25674538'}]",,05/12/2015
0,05/12/2015,HER2 Inhibitor,106,4498,HER2 Inhibitor,ERBB2 V842I,"[{'id': 561, 'pubMedId': 22649146, 'title': 'HER2 mutations in non-small-cell lung cancer can be continually targeted.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22649146'}, {'id': 563, 'pubMedId': 21991949, 'title': 'Adjuvant trastuzumab in HER2-positive breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21991949'}, {'id': 564, 'pubMedId': 23801166, 'title': 'First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23801166'}]",,05/12/2015
0,05/12/2015,HER inhibitor (Pan),105,4499,HER inhibitor (Pan),ERBB2 positive,"[{'id': 2691, 'pubMedId': 25674538, 'title': 'The Potential of panHER Inhibition in Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25674538'}]",,05/12/2015
0,05/12/2015,HER2 Inhibitor,106,4500,HER2 Inhibitor,ERBB2 positive,"[{'id': 561, 'pubMedId': 22649146, 'title': 'HER2 mutations in non-small-cell lung cancer can be continually targeted.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22649146'}, {'id': 563, 'pubMedId': 21991949, 'title': 'Adjuvant trastuzumab in HER2-positive breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21991949'}, {'id': 564, 'pubMedId': 23801166, 'title': 'First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23801166'}]",,05/12/2015
0,05/13/2015,FLT3 Inhibitor,96,4524,FLT3 Inhibitor,FLT3 D835A,"[{'id': 705, 'pubMedId': 11756186, 'title': 'FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11756186'}, {'id': 2547, 'pubMedId': 17124058, 'title': 'FLT3 mutations: biology and treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17124058'}, {'id': 2548, 'pubMedId': 25231999, 'title': 'Targeting FLT3 to treat leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25231999'}]",,05/13/2015
0,05/13/2015,FLT3 Inhibitor,96,4525,FLT3 Inhibitor,FLT3 D839G,"[{'id': 705, 'pubMedId': 11756186, 'title': 'FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11756186'}, {'id': 2547, 'pubMedId': 17124058, 'title': 'FLT3 mutations: biology and treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17124058'}, {'id': 2548, 'pubMedId': 25231999, 'title': 'Targeting FLT3 to treat leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25231999'}]",,05/13/2015
0,05/13/2015,FLT3 Inhibitor,96,4526,FLT3 Inhibitor,FLT3 D835del,"[{'id': 705, 'pubMedId': 11756186, 'title': 'FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11756186'}, {'id': 2547, 'pubMedId': 17124058, 'title': 'FLT3 mutations: biology and treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17124058'}, {'id': 2548, 'pubMedId': 25231999, 'title': 'Targeting FLT3 to treat leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25231999'}]",,05/13/2015
0,05/15/2015,HDAC Inhibitor,104,4558,HDAC Inhibitor,RB1 inact mut,"[{'id': 2739, 'pubMedId': 22293180, 'title': 'Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22293180'}]",,05/15/2015
0,05/15/2015,HDAC Inhibitor,104,4559,HDAC Inhibitor,RB1 loss,"[{'id': 2739, 'pubMedId': 22293180, 'title': 'Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22293180'}]",,05/15/2015
0,05/15/2015,HDAC Inhibitor,104,4560,HDAC Inhibitor,RB1 A10fs*21,"[{'id': 2739, 'pubMedId': 22293180, 'title': 'Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22293180'}]",,05/15/2015
0,05/15/2015,HDAC Inhibitor,104,4561,HDAC Inhibitor,RB1 A11fs*20,"[{'id': 2739, 'pubMedId': 22293180, 'title': 'Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22293180'}]",,05/15/2015
0,05/15/2015,HDAC Inhibitor,104,4562,HDAC Inhibitor,RB1 C553*,"[{'id': 2739, 'pubMedId': 22293180, 'title': 'Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22293180'}]",,05/15/2015
0,05/15/2015,HDAC Inhibitor,104,4563,HDAC Inhibitor,RB1 Q266*,"[{'id': 2739, 'pubMedId': 22293180, 'title': 'Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22293180'}]",,05/15/2015
0,05/15/2015,HDAC Inhibitor,104,4564,HDAC Inhibitor,RB1 Q354*,"[{'id': 2739, 'pubMedId': 22293180, 'title': 'Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22293180'}]",,05/15/2015
0,05/15/2015,HDAC Inhibitor,104,4565,HDAC Inhibitor,RB1 Q504*,"[{'id': 2739, 'pubMedId': 22293180, 'title': 'Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22293180'}]",,05/15/2015
0,05/15/2015,HDAC Inhibitor,104,4566,HDAC Inhibitor,RB1 Q575*,"[{'id': 2739, 'pubMedId': 22293180, 'title': 'Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22293180'}]",,05/15/2015
0,05/15/2015,HDAC Inhibitor,104,4567,HDAC Inhibitor,RB1 Q639*,"[{'id': 2739, 'pubMedId': 22293180, 'title': 'Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22293180'}]",,05/15/2015
0,05/15/2015,HDAC Inhibitor,104,4568,HDAC Inhibitor,RB1 R251*,"[{'id': 2739, 'pubMedId': 22293180, 'title': 'Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22293180'}]",,05/15/2015
0,05/15/2015,HDAC Inhibitor,104,4569,HDAC Inhibitor,RB1 R255*,"[{'id': 2739, 'pubMedId': 22293180, 'title': 'Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22293180'}]",,05/15/2015
0,05/15/2015,HDAC Inhibitor,104,4570,HDAC Inhibitor,RB1 R320*,"[{'id': 2739, 'pubMedId': 22293180, 'title': 'Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22293180'}]",,05/15/2015
0,05/15/2015,HDAC Inhibitor,104,4571,HDAC Inhibitor,RB1 R358*,"[{'id': 2739, 'pubMedId': 22293180, 'title': 'Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22293180'}]",,05/15/2015
0,05/15/2015,HDAC Inhibitor,104,4572,HDAC Inhibitor,RB1 R445*,"[{'id': 2739, 'pubMedId': 22293180, 'title': 'Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22293180'}]",,05/15/2015
0,05/15/2015,HDAC Inhibitor,104,4573,HDAC Inhibitor,RB1 R467*,"[{'id': 2739, 'pubMedId': 22293180, 'title': 'Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22293180'}]",,05/15/2015
0,05/15/2015,HDAC Inhibitor,104,4574,HDAC Inhibitor,RB1 R552*,"[{'id': 2739, 'pubMedId': 22293180, 'title': 'Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22293180'}]",,05/15/2015
0,05/15/2015,HDAC Inhibitor,104,4575,HDAC Inhibitor,RB1 R566*,"[{'id': 2739, 'pubMedId': 22293180, 'title': 'Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22293180'}]",,05/15/2015
0,05/15/2015,HDAC Inhibitor,104,4576,HDAC Inhibitor,RB1 R621C,"[{'id': 2739, 'pubMedId': 22293180, 'title': 'Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22293180'}]",,05/15/2015
0,05/15/2015,HDAC Inhibitor,104,4578,HDAC Inhibitor,RB1 R689W,"[{'id': 2739, 'pubMedId': 22293180, 'title': 'Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22293180'}]",,05/15/2015
0,05/15/2015,HDAC Inhibitor,104,4579,HDAC Inhibitor,RB1 R787*,"[{'id': 2739, 'pubMedId': 22293180, 'title': 'Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22293180'}]",,05/15/2015
0,05/15/2015,HDAC Inhibitor,104,4580,HDAC Inhibitor,RB1 S634*,"[{'id': 2739, 'pubMedId': 22293180, 'title': 'Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22293180'}]",,05/15/2015
0,05/15/2015,HDAC Inhibitor,104,4581,HDAC Inhibitor,RB1 S816*,"[{'id': 2739, 'pubMedId': 22293180, 'title': 'Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22293180'}]",,05/15/2015
0,05/15/2015,HDAC Inhibitor,104,4582,HDAC Inhibitor,RB1 W99*,"[{'id': 2739, 'pubMedId': 22293180, 'title': 'Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22293180'}]",,05/15/2015
0,05/15/2015,HDAC Inhibitor,104,4583,HDAC Inhibitor,RB1 Y728*,"[{'id': 2739, 'pubMedId': 22293180, 'title': 'Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22293180'}]",,05/15/2015
0,05/15/2015,EZH2 inhibitor,84,4586,EZH2 inhibitor,EZH2 act mut,"[{'id': 149, 'pubMedId': 24362326, 'title': 'EZH2: biology, disease, and structure-based drug discovery.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24362326'}, {'id': 1237, 'pubMedId': 24183969, 'title': 'Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24183969'}]",,05/15/2015
0,05/15/2015,EZH2 inhibitor,84,4587,EZH2 inhibitor,EZH2 A677G,"[{'id': 149, 'pubMedId': 24362326, 'title': 'EZH2: biology, disease, and structure-based drug discovery.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24362326'}, {'id': 1237, 'pubMedId': 24183969, 'title': 'Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24183969'}]",,05/15/2015
0,05/15/2015,EZH2 inhibitor,84,4588,EZH2 inhibitor,EZH2 A687V,"[{'id': 149, 'pubMedId': 24362326, 'title': 'EZH2: biology, disease, and structure-based drug discovery.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24362326'}, {'id': 1237, 'pubMedId': 24183969, 'title': 'Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24183969'}]",,05/15/2015
0,05/15/2015,EZH2 inhibitor,84,4589,EZH2 inhibitor,EZH2 Y641C,"[{'id': 149, 'pubMedId': 24362326, 'title': 'EZH2: biology, disease, and structure-based drug discovery.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24362326'}, {'id': 1237, 'pubMedId': 24183969, 'title': 'Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24183969'}]",,05/15/2015
0,05/15/2015,EZH2 inhibitor,84,4590,EZH2 inhibitor,EZH2 Y641H,"[{'id': 149, 'pubMedId': 24362326, 'title': 'EZH2: biology, disease, and structure-based drug discovery.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24362326'}, {'id': 1237, 'pubMedId': 24183969, 'title': 'Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24183969'}]",,05/15/2015
0,05/15/2015,EZH2 inhibitor,84,4591,EZH2 inhibitor,EZH2 Y641N,"[{'id': 149, 'pubMedId': 24362326, 'title': 'EZH2: biology, disease, and structure-based drug discovery.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24362326'}, {'id': 1237, 'pubMedId': 24183969, 'title': 'Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24183969'}]",,05/15/2015
0,05/15/2015,EZH2 inhibitor,84,4592,EZH2 inhibitor,EZH2 Y641S,"[{'id': 149, 'pubMedId': 24362326, 'title': 'EZH2: biology, disease, and structure-based drug discovery.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24362326'}, {'id': 1237, 'pubMedId': 24183969, 'title': 'Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24183969'}]",,05/15/2015
0,05/15/2015,EZH2 inhibitor,84,4593,EZH2 inhibitor,EZH2 Y641X,"[{'id': 149, 'pubMedId': 24362326, 'title': 'EZH2: biology, disease, and structure-based drug discovery.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24362326'}, {'id': 1237, 'pubMedId': 24183969, 'title': 'Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24183969'}]",,05/15/2015
0,05/15/2015,EZH2 inhibitor,84,4594,EZH2 inhibitor,EZH2 Y646N,"[{'id': 149, 'pubMedId': 24362326, 'title': 'EZH2: biology, disease, and structure-based drug discovery.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24362326'}, {'id': 1237, 'pubMedId': 24183969, 'title': 'Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24183969'}]",,05/15/2015
0,05/15/2015,HER inhibitor (Pan),105,4595,HER inhibitor (Pan),EGFR act mut,"[{'id': 2746, 'pubMedId': 25806203, 'title': 'Irreversible EGFR-TKIs: dreaming perfection.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806203'}]",,05/15/2015
0,05/15/2015,HER inhibitor (Pan),105,4596,HER inhibitor (Pan),EGFR exon 19 del,"[{'id': 2746, 'pubMedId': 25806203, 'title': 'Irreversible EGFR-TKIs: dreaming perfection.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806203'}]",,05/15/2015
0,05/15/2015,HER inhibitor (Pan),105,4597,HER inhibitor (Pan),EGFR E746_A750del,"[{'id': 2746, 'pubMedId': 25806203, 'title': 'Irreversible EGFR-TKIs: dreaming perfection.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806203'}]",,05/15/2015
0,05/17/2015,IDH Inhibitor (Pan),117,4609,IDH Inhibitor (Pan),IDH2 R140L,"[{'id': 2554, 'pubMedId': 25558173, 'title': 'Disease progression in iridocorneal angle tissues of BMP2-induced ocular hypertensive mice with optical coherence tomography.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25558173'}, {'id': 2555, 'pubMedId': 25251602, 'title': 'Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25251602'}]",,05/17/2015
0,05/17/2015,IDH2 Inhibitor,119,4610,IDH2 Inhibitor,IDH2 R140L,"[{'id': 2554, 'pubMedId': 25558173, 'title': 'Disease progression in iridocorneal angle tissues of BMP2-induced ocular hypertensive mice with optical coherence tomography.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25558173'}, {'id': 2555, 'pubMedId': 25251602, 'title': 'Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25251602'}]",,05/17/2015
0,05/17/2015,IDH Inhibitor (Pan),117,4611,IDH Inhibitor (Pan),IDH2 R140W,"[{'id': 2554, 'pubMedId': 25558173, 'title': 'Disease progression in iridocorneal angle tissues of BMP2-induced ocular hypertensive mice with optical coherence tomography.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25558173'}, {'id': 2555, 'pubMedId': 25251602, 'title': 'Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25251602'}]",,05/17/2015
0,05/17/2015,IDH2 Inhibitor,119,4612,IDH2 Inhibitor,IDH2 R140W,"[{'id': 2554, 'pubMedId': 25558173, 'title': 'Disease progression in iridocorneal angle tissues of BMP2-induced ocular hypertensive mice with optical coherence tomography.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25558173'}, {'id': 2555, 'pubMedId': 25251602, 'title': 'Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25251602'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor (Pan),74,4613,EGFR Inhibitor (Pan),EGFR E709A,"[{'id': 410, 'pubMedId': 16187797, 'title': 'Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16187797'}, {'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 1st gen,75,4614,EGFR Inhibitor 1st gen,EGFR E709A,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 2nd gen,76,4615,EGFR Inhibitor 2nd gen,EGFR E709A,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 3rd gen,77,4616,EGFR Inhibitor 3rd gen,EGFR E709A,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,HER inhibitor (Pan),105,4617,HER inhibitor (Pan),EGFR E709A,"[{'id': 2746, 'pubMedId': 25806203, 'title': 'Irreversible EGFR-TKIs: dreaming perfection.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806203'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor (Pan),74,4618,EGFR Inhibitor (Pan),EGFR E709G,"[{'id': 410, 'pubMedId': 16187797, 'title': 'Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16187797'}, {'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 1st gen,75,4619,EGFR Inhibitor 1st gen,EGFR E709G,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 2nd gen,76,4620,EGFR Inhibitor 2nd gen,EGFR E709G,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 3rd gen,77,4621,EGFR Inhibitor 3rd gen,EGFR E709G,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,HER inhibitor (Pan),105,4622,HER inhibitor (Pan),EGFR E709G,"[{'id': 2746, 'pubMedId': 25806203, 'title': 'Irreversible EGFR-TKIs: dreaming perfection.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806203'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor (Pan),74,4623,EGFR Inhibitor (Pan),EGFR E709K,"[{'id': 410, 'pubMedId': 16187797, 'title': 'Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16187797'}, {'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 1st gen,75,4624,EGFR Inhibitor 1st gen,EGFR E709K,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 2nd gen,76,4625,EGFR Inhibitor 2nd gen,EGFR E709K,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 3rd gen,77,4626,EGFR Inhibitor 3rd gen,EGFR E709K,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,HER inhibitor (Pan),105,4627,HER inhibitor (Pan),EGFR E709K,"[{'id': 2746, 'pubMedId': 25806203, 'title': 'Irreversible EGFR-TKIs: dreaming perfection.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806203'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor (Pan),74,4628,EGFR Inhibitor (Pan),EGFR E734Q,"[{'id': 410, 'pubMedId': 16187797, 'title': 'Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16187797'}, {'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 1st gen,75,4629,EGFR Inhibitor 1st gen,EGFR E734Q,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 2nd gen,76,4630,EGFR Inhibitor 2nd gen,EGFR E734Q,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 3rd gen,77,4631,EGFR Inhibitor 3rd gen,EGFR E734Q,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,HER inhibitor (Pan),105,4632,HER inhibitor (Pan),EGFR E734Q,"[{'id': 2746, 'pubMedId': 25806203, 'title': 'Irreversible EGFR-TKIs: dreaming perfection.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806203'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor (Pan),74,4633,EGFR Inhibitor (Pan),EGFR G735S,"[{'id': 410, 'pubMedId': 16187797, 'title': 'Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16187797'}, {'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 1st gen,75,4634,EGFR Inhibitor 1st gen,EGFR G735S,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 2nd gen,76,4635,EGFR Inhibitor 2nd gen,EGFR G735S,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 3rd gen,77,4636,EGFR Inhibitor 3rd gen,EGFR G735S,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,HER inhibitor (Pan),105,4637,HER inhibitor (Pan),EGFR G735S,"[{'id': 2746, 'pubMedId': 25806203, 'title': 'Irreversible EGFR-TKIs: dreaming perfection.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806203'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor (Pan),74,4638,EGFR Inhibitor (Pan),EGFR L747_T751del,"[{'id': 410, 'pubMedId': 16187797, 'title': 'Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16187797'}, {'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 1st gen,75,4639,EGFR Inhibitor 1st gen,EGFR L747_T751del,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 2nd gen,76,4640,EGFR Inhibitor 2nd gen,EGFR L747_T751del,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 3rd gen,77,4641,EGFR Inhibitor 3rd gen,EGFR L747_T751del,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,HER inhibitor (Pan),105,4642,HER inhibitor (Pan),EGFR L747_T751del,"[{'id': 2746, 'pubMedId': 25806203, 'title': 'Irreversible EGFR-TKIs: dreaming perfection.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806203'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor (Pan),74,4643,EGFR Inhibitor (Pan),EGFR L747_P753delinsS,"[{'id': 410, 'pubMedId': 16187797, 'title': 'Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16187797'}, {'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 1st gen,75,4644,EGFR Inhibitor 1st gen,EGFR L747_P753delinsS,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 2nd gen,76,4645,EGFR Inhibitor 2nd gen,EGFR L747_P753delinsS,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 3rd gen,77,4646,EGFR Inhibitor 3rd gen,EGFR L747_P753delinsS,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,HER inhibitor (Pan),105,4647,HER inhibitor (Pan),EGFR L747_P753delinsS,"[{'id': 2746, 'pubMedId': 25806203, 'title': 'Irreversible EGFR-TKIs: dreaming perfection.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806203'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor (Pan),74,4648,EGFR Inhibitor (Pan),EGFR E746_E749del,"[{'id': 410, 'pubMedId': 16187797, 'title': 'Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16187797'}, {'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 1st gen,75,4649,EGFR Inhibitor 1st gen,EGFR E746_E749del,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 2nd gen,76,4650,EGFR Inhibitor 2nd gen,EGFR E746_E749del,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 3rd gen,77,4651,EGFR Inhibitor 3rd gen,EGFR E746_E749del,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,HER inhibitor (Pan),105,4652,HER inhibitor (Pan),EGFR E746_E749del,"[{'id': 2746, 'pubMedId': 25806203, 'title': 'Irreversible EGFR-TKIs: dreaming perfection.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806203'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor (Pan),74,4653,EGFR Inhibitor (Pan),EGFR E746_S752del,"[{'id': 410, 'pubMedId': 16187797, 'title': 'Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16187797'}, {'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 1st gen,75,4654,EGFR Inhibitor 1st gen,EGFR E746_S752del,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 2nd gen,76,4655,EGFR Inhibitor 2nd gen,EGFR E746_S752del,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 3rd gen,77,4656,EGFR Inhibitor 3rd gen,EGFR E746_S752del,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,HER inhibitor (Pan),105,4657,HER inhibitor (Pan),EGFR E746_S752del,"[{'id': 2746, 'pubMedId': 25806203, 'title': 'Irreversible EGFR-TKIs: dreaming perfection.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806203'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor (Pan),74,4658,EGFR Inhibitor (Pan),EGFR E746_T751del,"[{'id': 410, 'pubMedId': 16187797, 'title': 'Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16187797'}, {'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 1st gen,75,4659,EGFR Inhibitor 1st gen,EGFR E746_T751del,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 2nd gen,76,4660,EGFR Inhibitor 2nd gen,EGFR E746_T751del,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 3rd gen,77,4661,EGFR Inhibitor 3rd gen,EGFR E746_T751del,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,HER inhibitor (Pan),105,4662,HER inhibitor (Pan),EGFR E746_T751del,"[{'id': 2746, 'pubMedId': 25806203, 'title': 'Irreversible EGFR-TKIs: dreaming perfection.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806203'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor (Pan),74,4673,EGFR Inhibitor (Pan),EGFR K745_A750del,"[{'id': 410, 'pubMedId': 16187797, 'title': 'Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16187797'}, {'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 1st gen,75,4674,EGFR Inhibitor 1st gen,EGFR K745_A750del,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 2nd gen,76,4675,EGFR Inhibitor 2nd gen,EGFR K745_A750del,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 3rd gen,77,4676,EGFR Inhibitor 3rd gen,EGFR K745_A750del,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,HER inhibitor (Pan),105,4677,HER inhibitor (Pan),EGFR K745_A750del,"[{'id': 2746, 'pubMedId': 25806203, 'title': 'Irreversible EGFR-TKIs: dreaming perfection.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806203'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor (Pan),74,4678,EGFR Inhibitor (Pan),EGFR K745_E749del,"[{'id': 410, 'pubMedId': 16187797, 'title': 'Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16187797'}, {'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 1st gen,75,4679,EGFR Inhibitor 1st gen,EGFR K745_E749del,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 2nd gen,76,4680,EGFR Inhibitor 2nd gen,EGFR K745_E749del,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 3rd gen,77,4681,EGFR Inhibitor 3rd gen,EGFR K745_E749del,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,HER inhibitor (Pan),105,4682,HER inhibitor (Pan),EGFR K745_E749del,"[{'id': 2746, 'pubMedId': 25806203, 'title': 'Irreversible EGFR-TKIs: dreaming perfection.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806203'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor (Pan),74,4683,EGFR Inhibitor (Pan),EGFR L747_E749del,"[{'id': 410, 'pubMedId': 16187797, 'title': 'Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16187797'}, {'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 1st gen,75,4684,EGFR Inhibitor 1st gen,EGFR L747_E749del,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 2nd gen,76,4685,EGFR Inhibitor 2nd gen,EGFR L747_E749del,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 3rd gen,77,4686,EGFR Inhibitor 3rd gen,EGFR L747_E749del,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,HER inhibitor (Pan),105,4687,HER inhibitor (Pan),EGFR L747_E749del,"[{'id': 2746, 'pubMedId': 25806203, 'title': 'Irreversible EGFR-TKIs: dreaming perfection.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806203'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor (Pan),74,4688,EGFR Inhibitor (Pan),EGFR L747_S752del,"[{'id': 410, 'pubMedId': 16187797, 'title': 'Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16187797'}, {'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 1st gen,75,4689,EGFR Inhibitor 1st gen,EGFR L747_S752del,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 2nd gen,76,4690,EGFR Inhibitor 2nd gen,EGFR L747_S752del,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 3rd gen,77,4691,EGFR Inhibitor 3rd gen,EGFR L747_S752del,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,HER inhibitor (Pan),105,4692,HER inhibitor (Pan),EGFR L747_S752del,"[{'id': 2746, 'pubMedId': 25806203, 'title': 'Irreversible EGFR-TKIs: dreaming perfection.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806203'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor (Pan),74,4693,EGFR Inhibitor (Pan),EGFR L858K,"[{'id': 410, 'pubMedId': 16187797, 'title': 'Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16187797'}, {'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 1st gen,75,4694,EGFR Inhibitor 1st gen,EGFR L858K,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 2nd gen,76,4695,EGFR Inhibitor 2nd gen,EGFR L858K,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 3rd gen,77,4696,EGFR Inhibitor 3rd gen,EGFR L858K,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,HER inhibitor (Pan),105,4697,HER inhibitor (Pan),EGFR L858K,"[{'id': 2746, 'pubMedId': 25806203, 'title': 'Irreversible EGFR-TKIs: dreaming perfection.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806203'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor (Pan),74,4698,EGFR Inhibitor (Pan),EGFR L858M,"[{'id': 410, 'pubMedId': 16187797, 'title': 'Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16187797'}, {'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 1st gen,75,4699,EGFR Inhibitor 1st gen,EGFR L858M,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 2nd gen,76,4700,EGFR Inhibitor 2nd gen,EGFR L858M,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 3rd gen,77,4701,EGFR Inhibitor 3rd gen,EGFR L858M,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,HER inhibitor (Pan),105,4702,HER inhibitor (Pan),EGFR L858M,"[{'id': 2746, 'pubMedId': 25806203, 'title': 'Irreversible EGFR-TKIs: dreaming perfection.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806203'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor (Pan),74,4703,EGFR Inhibitor (Pan),EGFR L858Q,"[{'id': 410, 'pubMedId': 16187797, 'title': 'Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16187797'}, {'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 1st gen,75,4704,EGFR Inhibitor 1st gen,EGFR L858Q,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 2nd gen,76,4705,EGFR Inhibitor 2nd gen,EGFR L858Q,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 3rd gen,77,4706,EGFR Inhibitor 3rd gen,EGFR L858Q,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,HER inhibitor (Pan),105,4707,HER inhibitor (Pan),EGFR L858Q,"[{'id': 2746, 'pubMedId': 25806203, 'title': 'Irreversible EGFR-TKIs: dreaming perfection.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806203'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor (Pan),74,4708,EGFR Inhibitor (Pan),EGFR L861R,"[{'id': 410, 'pubMedId': 16187797, 'title': 'Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16187797'}, {'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 1st gen,75,4709,EGFR Inhibitor 1st gen,EGFR L861R,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 2nd gen,76,4710,EGFR Inhibitor 2nd gen,EGFR L861R,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 3rd gen,77,4711,EGFR Inhibitor 3rd gen,EGFR L861R,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,HER inhibitor (Pan),105,4712,HER inhibitor (Pan),EGFR L861R,"[{'id': 2746, 'pubMedId': 25806203, 'title': 'Irreversible EGFR-TKIs: dreaming perfection.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806203'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor (Pan),74,4713,EGFR Inhibitor (Pan),EGFR S752_I759del,"[{'id': 410, 'pubMedId': 16187797, 'title': 'Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16187797'}, {'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 1st gen,75,4714,EGFR Inhibitor 1st gen,EGFR S752_I759del,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 2nd gen,76,4715,EGFR Inhibitor 2nd gen,EGFR S752_I759del,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 3rd gen,77,4716,EGFR Inhibitor 3rd gen,EGFR S752_I759del,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,HER inhibitor (Pan),105,4717,HER inhibitor (Pan),EGFR S752_I759del,"[{'id': 2746, 'pubMedId': 25806203, 'title': 'Irreversible EGFR-TKIs: dreaming perfection.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806203'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor (Pan),74,4718,EGFR Inhibitor (Pan),EGFR T751_E758del,"[{'id': 410, 'pubMedId': 16187797, 'title': 'Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16187797'}, {'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 1st gen,75,4719,EGFR Inhibitor 1st gen,EGFR T751_E758del,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 2nd gen,76,4720,EGFR Inhibitor 2nd gen,EGFR T751_E758del,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 3rd gen,77,4721,EGFR Inhibitor 3rd gen,EGFR T751_E758del,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,HER inhibitor (Pan),105,4722,HER inhibitor (Pan),EGFR T751_E758del,"[{'id': 2746, 'pubMedId': 25806203, 'title': 'Irreversible EGFR-TKIs: dreaming perfection.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806203'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor (Pan),74,4723,EGFR Inhibitor (Pan),EGFR T751_I759del ,"[{'id': 410, 'pubMedId': 16187797, 'title': 'Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16187797'}, {'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 1st gen,75,4724,EGFR Inhibitor 1st gen,EGFR T751_I759del ,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 2nd gen,76,4725,EGFR Inhibitor 2nd gen,EGFR T751_I759del ,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 3rd gen,77,4726,EGFR Inhibitor 3rd gen,EGFR T751_I759del ,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,HER inhibitor (Pan),105,4727,HER inhibitor (Pan),EGFR T751_I759del ,"[{'id': 2746, 'pubMedId': 25806203, 'title': 'Irreversible EGFR-TKIs: dreaming perfection.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806203'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor (Pan),74,4733,EGFR Inhibitor (Pan),EGFR G598V,"[{'id': 410, 'pubMedId': 16187797, 'title': 'Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16187797'}, {'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 1st gen,75,4734,EGFR Inhibitor 1st gen,EGFR G598V,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 2nd gen,76,4735,EGFR Inhibitor 2nd gen,EGFR G598V,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 3rd gen,77,4736,EGFR Inhibitor 3rd gen,EGFR G598V,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,HER inhibitor (Pan),105,4737,HER inhibitor (Pan),EGFR G598V,"[{'id': 2746, 'pubMedId': 25806203, 'title': 'Irreversible EGFR-TKIs: dreaming perfection.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806203'}]",,05/17/2015
0,05/17/2015,HER inhibitor (Pan),105,4738,HER inhibitor (Pan),EGFR amp,"[{'id': 593, 'pubMedId': 22761403, 'title': 'Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22761403'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor (Pan),74,4739,EGFR Inhibitor (Pan),EGFR A750P,"[{'id': 410, 'pubMedId': 16187797, 'title': 'Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16187797'}, {'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 1st gen,75,4740,EGFR Inhibitor 1st gen,EGFR A750P,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 2nd gen,76,4741,EGFR Inhibitor 2nd gen,EGFR A750P,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 3rd gen,77,4742,EGFR Inhibitor 3rd gen,EGFR A750P,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,HER inhibitor (Pan),105,4743,HER inhibitor (Pan),EGFR A750P,"[{'id': 2746, 'pubMedId': 25806203, 'title': 'Irreversible EGFR-TKIs: dreaming perfection.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806203'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor (Pan),74,4744,EGFR Inhibitor (Pan),EGFR A763_Y764insFQEA,"[{'id': 410, 'pubMedId': 16187797, 'title': 'Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16187797'}, {'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 1st gen,75,4745,EGFR Inhibitor 1st gen,EGFR A763_Y764insFQEA,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 2nd gen,76,4746,EGFR Inhibitor 2nd gen,EGFR A763_Y764insFQEA,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 3rd gen,77,4747,EGFR Inhibitor 3rd gen,EGFR A763_Y764insFQEA,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,HER inhibitor (Pan),105,4748,HER inhibitor (Pan),EGFR A763_Y764insFQEA,"[{'id': 2746, 'pubMedId': 25806203, 'title': 'Irreversible EGFR-TKIs: dreaming perfection.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806203'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor (Pan),74,4749,EGFR Inhibitor (Pan),EGFR E868G,"[{'id': 410, 'pubMedId': 16187797, 'title': 'Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16187797'}, {'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 1st gen,75,4750,EGFR Inhibitor 1st gen,EGFR E868G,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 2nd gen,76,4751,EGFR Inhibitor 2nd gen,EGFR E868G,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 3rd gen,77,4752,EGFR Inhibitor 3rd gen,EGFR E868G,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,HER inhibitor (Pan),105,4753,HER inhibitor (Pan),EGFR E868G,"[{'id': 2746, 'pubMedId': 25806203, 'title': 'Irreversible EGFR-TKIs: dreaming perfection.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806203'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor (Pan),74,4754,EGFR Inhibitor (Pan),EGFR G810S,"[{'id': 410, 'pubMedId': 16187797, 'title': 'Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16187797'}, {'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 1st gen,75,4755,EGFR Inhibitor 1st gen,EGFR G810S,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 2nd gen,76,4756,EGFR Inhibitor 2nd gen,EGFR G810S,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 3rd gen,77,4757,EGFR Inhibitor 3rd gen,EGFR G810S,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,HER inhibitor (Pan),105,4758,HER inhibitor (Pan),EGFR G810S,"[{'id': 2746, 'pubMedId': 25806203, 'title': 'Irreversible EGFR-TKIs: dreaming perfection.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806203'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor (Pan),74,4759,EGFR Inhibitor (Pan),EGFR L858R,"[{'id': 410, 'pubMedId': 16187797, 'title': 'Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16187797'}, {'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 1st gen,75,4760,EGFR Inhibitor 1st gen,EGFR L858R,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 2nd gen,76,4761,EGFR Inhibitor 2nd gen,EGFR L858R,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 3rd gen,77,4762,EGFR Inhibitor 3rd gen,EGFR L858R,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,HER inhibitor (Pan),105,4763,HER inhibitor (Pan),EGFR L858R,"[{'id': 2746, 'pubMedId': 25806203, 'title': 'Irreversible EGFR-TKIs: dreaming perfection.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806203'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor (Pan),74,4764,EGFR Inhibitor (Pan),EGFR L861Q,"[{'id': 410, 'pubMedId': 16187797, 'title': 'Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16187797'}, {'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 1st gen,75,4765,EGFR Inhibitor 1st gen,EGFR L861Q,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 2nd gen,76,4766,EGFR Inhibitor 2nd gen,EGFR L861Q,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 3rd gen,77,4767,EGFR Inhibitor 3rd gen,EGFR L861Q,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,HER inhibitor (Pan),105,4768,HER inhibitor (Pan),EGFR L861Q,"[{'id': 2746, 'pubMedId': 25806203, 'title': 'Irreversible EGFR-TKIs: dreaming perfection.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806203'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor (Pan),74,4769,EGFR Inhibitor (Pan),EGFR R776C,"[{'id': 410, 'pubMedId': 16187797, 'title': 'Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16187797'}, {'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 1st gen,75,4770,EGFR Inhibitor 1st gen,EGFR R776C,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 2nd gen,76,4771,EGFR Inhibitor 2nd gen,EGFR R776C,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 3rd gen,77,4772,EGFR Inhibitor 3rd gen,EGFR R776C,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,HER inhibitor (Pan),105,4773,HER inhibitor (Pan),EGFR R776C,"[{'id': 2746, 'pubMedId': 25806203, 'title': 'Irreversible EGFR-TKIs: dreaming perfection.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806203'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor (Pan),74,4774,EGFR Inhibitor (Pan),EGFR R776H,"[{'id': 410, 'pubMedId': 16187797, 'title': 'Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16187797'}, {'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 1st gen,75,4775,EGFR Inhibitor 1st gen,EGFR R776H,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 2nd gen,76,4776,EGFR Inhibitor 2nd gen,EGFR R776H,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 3rd gen,77,4777,EGFR Inhibitor 3rd gen,EGFR R776H,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,HER inhibitor (Pan),105,4778,HER inhibitor (Pan),EGFR R776H,"[{'id': 2746, 'pubMedId': 25806203, 'title': 'Irreversible EGFR-TKIs: dreaming perfection.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806203'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor (Pan),74,4779,EGFR Inhibitor (Pan),EGFR S768I,"[{'id': 410, 'pubMedId': 16187797, 'title': 'Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16187797'}, {'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 1st gen,75,4780,EGFR Inhibitor 1st gen,EGFR S768I,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 2nd gen,76,4781,EGFR Inhibitor 2nd gen,EGFR S768I,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 3rd gen,77,4782,EGFR Inhibitor 3rd gen,EGFR S768I,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,HER inhibitor (Pan),105,4783,HER inhibitor (Pan),EGFR S768I,"[{'id': 2746, 'pubMedId': 25806203, 'title': 'Irreversible EGFR-TKIs: dreaming perfection.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806203'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor (Pan),74,4784,EGFR Inhibitor (Pan),EGFR S784F,"[{'id': 410, 'pubMedId': 16187797, 'title': 'Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16187797'}, {'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 1st gen,75,4785,EGFR Inhibitor 1st gen,EGFR S784F,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 2nd gen,76,4786,EGFR Inhibitor 2nd gen,EGFR S784F,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 3rd gen,77,4787,EGFR Inhibitor 3rd gen,EGFR S784F,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,HER inhibitor (Pan),105,4788,HER inhibitor (Pan),EGFR S784F,"[{'id': 2746, 'pubMedId': 25806203, 'title': 'Irreversible EGFR-TKIs: dreaming perfection.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806203'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor (Pan),74,4789,EGFR Inhibitor (Pan),EGFR V742A,"[{'id': 410, 'pubMedId': 16187797, 'title': 'Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16187797'}, {'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 1st gen,75,4790,EGFR Inhibitor 1st gen,EGFR V742A,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 2nd gen,76,4791,EGFR Inhibitor 2nd gen,EGFR V742A,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 3rd gen,77,4792,EGFR Inhibitor 3rd gen,EGFR V742A,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,HER inhibitor (Pan),105,4793,HER inhibitor (Pan),EGFR V742A,"[{'id': 2746, 'pubMedId': 25806203, 'title': 'Irreversible EGFR-TKIs: dreaming perfection.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806203'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor (Pan),74,4794,EGFR Inhibitor (Pan),EGFR R108K,"[{'id': 410, 'pubMedId': 16187797, 'title': 'Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16187797'}, {'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 1st gen,75,4795,EGFR Inhibitor 1st gen,EGFR R108K,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 2nd gen,76,4796,EGFR Inhibitor 2nd gen,EGFR R108K,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,EGFR Inhibitor 3rd gen,77,4797,EGFR Inhibitor 3rd gen,EGFR R108K,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,05/17/2015
0,05/17/2015,HER inhibitor (Pan),105,4798,HER inhibitor (Pan),EGFR R108K,"[{'id': 2746, 'pubMedId': 25806203, 'title': 'Irreversible EGFR-TKIs: dreaming perfection.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806203'}]",,05/17/2015
0,05/18/2015,IDH Inhibitor (Pan),117,4811,IDH Inhibitor (Pan),IDH2 R172S,"[{'id': 2554, 'pubMedId': 25558173, 'title': 'Disease progression in iridocorneal angle tissues of BMP2-induced ocular hypertensive mice with optical coherence tomography.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25558173'}, {'id': 2555, 'pubMedId': 25251602, 'title': 'Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25251602'}]",,05/18/2015
0,05/18/2015,IDH2 Inhibitor,119,4812,IDH2 Inhibitor,IDH2 R172S,"[{'id': 2554, 'pubMedId': 25558173, 'title': 'Disease progression in iridocorneal angle tissues of BMP2-induced ocular hypertensive mice with optical coherence tomography.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25558173'}, {'id': 2555, 'pubMedId': 25251602, 'title': 'Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25251602'}]",,05/18/2015
0,05/18/2015,IDH Inhibitor (Pan),117,4813,IDH Inhibitor (Pan),IDH2 R172M,"[{'id': 2554, 'pubMedId': 25558173, 'title': 'Disease progression in iridocorneal angle tissues of BMP2-induced ocular hypertensive mice with optical coherence tomography.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25558173'}, {'id': 2555, 'pubMedId': 25251602, 'title': 'Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25251602'}]",,05/18/2015
0,05/18/2015,IDH2 Inhibitor,119,4814,IDH2 Inhibitor,IDH2 R172M,"[{'id': 2554, 'pubMedId': 25558173, 'title': 'Disease progression in iridocorneal angle tissues of BMP2-induced ocular hypertensive mice with optical coherence tomography.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25558173'}, {'id': 2555, 'pubMedId': 25251602, 'title': 'Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25251602'}]",,05/18/2015
0,05/18/2015,IDH Inhibitor (Pan),117,4815,IDH Inhibitor (Pan),IDH2 R172W,"[{'id': 2554, 'pubMedId': 25558173, 'title': 'Disease progression in iridocorneal angle tissues of BMP2-induced ocular hypertensive mice with optical coherence tomography.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25558173'}, {'id': 2555, 'pubMedId': 25251602, 'title': 'Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25251602'}]",,05/18/2015
0,05/18/2015,IDH2 Inhibitor,119,4816,IDH2 Inhibitor,IDH2 R172W,"[{'id': 2554, 'pubMedId': 25558173, 'title': 'Disease progression in iridocorneal angle tissues of BMP2-induced ocular hypertensive mice with optical coherence tomography.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25558173'}, {'id': 2555, 'pubMedId': 25251602, 'title': 'Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25251602'}]",,05/18/2015
0,05/21/2015,EGFR Inhibitor 3rd gen,77,4856,EGFR Inhibitor 3rd gen,EGFR D761Y EGFR L858R,"[{'id': 537, 'pubMedId': 24893891, 'title': 'AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24893891'}]",,05/21/2015
0,05/21/2015,EGFR Inhibitor 3rd gen,77,4857,EGFR Inhibitor 3rd gen,EGFR L858R EGFR T854A,"[{'id': 537, 'pubMedId': 24893891, 'title': 'AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24893891'}]",,05/21/2015
0,05/22/2015,p53 Activator,166,4871,p53 Activator,TP53 Y163C,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,05/22/2015
0,05/22/2015,p53 Gene Therapy,167,4872,p53 Gene Therapy,TP53 Y163C,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,05/22/2015
0,05/26/2015,,4938,Ibrutinib,MYD88 L265P,"[{'id': 2810, 'pubMedId': 25853747, 'title': ""Ibrutinib in previously treated Waldenström's macroglobulinemia."", 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25853747'}]",768,Ibrutinib,05/26/2015
0,05/29/2015,FLT3 Inhibitor,96,5002,FLT3 Inhibitor,FLT3 I836del,"[{'id': 705, 'pubMedId': 11756186, 'title': 'FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11756186'}, {'id': 2547, 'pubMedId': 17124058, 'title': 'FLT3 mutations: biology and treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17124058'}, {'id': 2548, 'pubMedId': 25231999, 'title': 'Targeting FLT3 to treat leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25231999'}]",,05/29/2015
0,06/02/2015,DNMT inhibitor (Pan),68,5008,DNMT inhibitor (Pan),DNMT3A act mut,"[{'id': 1168, 'pubMedId': 24822169, 'title': 'DNA methyltransferases: a novel target for prevention and therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24822169'}]",,06/02/2015
0,06/02/2015,p53 Activator,166,5011,p53 Activator,TP53 V173A,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,06/02/2015
0,06/02/2015,p53 Gene Therapy,167,5012,p53 Gene Therapy,TP53 V173A,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,06/02/2015
0,06/02/2015,FLT3 Inhibitor,96,5025,FLT3 Inhibitor,FLT3 R834Q,"[{'id': 705, 'pubMedId': 11756186, 'title': 'FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11756186'}, {'id': 2547, 'pubMedId': 17124058, 'title': 'FLT3 mutations: biology and treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17124058'}, {'id': 2548, 'pubMedId': 25231999, 'title': 'Targeting FLT3 to treat leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25231999'}]",,06/02/2015
0,06/02/2015,FLT3 Inhibitor,96,5026,FLT3 Inhibitor,FLT3 Y842C,"[{'id': 705, 'pubMedId': 11756186, 'title': 'FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11756186'}, {'id': 2547, 'pubMedId': 17124058, 'title': 'FLT3 mutations: biology and treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17124058'}, {'id': 2548, 'pubMedId': 25231999, 'title': 'Targeting FLT3 to treat leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25231999'}]",,06/02/2015
0,06/02/2015,FLT3 Inhibitor,96,5027,FLT3 Inhibitor,FLT3 Y599_D600insPAPQIMSTSTLISENMNIA,"[{'id': 705, 'pubMedId': 11756186, 'title': 'FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11756186'}, {'id': 2547, 'pubMedId': 17124058, 'title': 'FLT3 mutations: biology and treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17124058'}, {'id': 2548, 'pubMedId': 25231999, 'title': 'Targeting FLT3 to treat leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25231999'}]",,06/02/2015
0,06/02/2015,FLT3 Inhibitor,96,5028,FLT3 Inhibitor,FLT3 Y599_D600insEYEYEYEY,"[{'id': 705, 'pubMedId': 11756186, 'title': 'FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11756186'}, {'id': 2547, 'pubMedId': 17124058, 'title': 'FLT3 mutations: biology and treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17124058'}, {'id': 2548, 'pubMedId': 25231999, 'title': 'Targeting FLT3 to treat leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25231999'}]",,06/02/2015
0,06/02/2015,FLT3 Inhibitor,96,5029,FLT3 Inhibitor,FLT3 Y572C,"[{'id': 705, 'pubMedId': 11756186, 'title': 'FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11756186'}, {'id': 2547, 'pubMedId': 17124058, 'title': 'FLT3 mutations: biology and treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17124058'}, {'id': 2548, 'pubMedId': 25231999, 'title': 'Targeting FLT3 to treat leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25231999'}]",,06/02/2015
0,06/02/2015,FLT3 Inhibitor,96,5030,FLT3 Inhibitor,FLT3 V592A,"[{'id': 705, 'pubMedId': 11756186, 'title': 'FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11756186'}, {'id': 2547, 'pubMedId': 17124058, 'title': 'FLT3 mutations: biology and treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17124058'}, {'id': 2548, 'pubMedId': 25231999, 'title': 'Targeting FLT3 to treat leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25231999'}]",,06/02/2015
0,06/03/2015,DNMT inhibitor (Pan),68,5032,DNMT inhibitor (Pan),DNMT3A amp,"[{'id': 1168, 'pubMedId': 24822169, 'title': 'DNA methyltransferases: a novel target for prevention and therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24822169'}]",,06/03/2015
0,06/03/2015,VEGFR2 Inhibitor,232,5033,VEGFR2 Inhibitor,VHL inact mut,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2901, 'pubMedId': 22105611, 'title': 'Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22105611'}]",,06/03/2015
0,06/03/2015,VEGFR Inhibitor (Pan),230,5034,VEGFR Inhibitor (Pan),VHL inact mut,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2902, 'pubMedId': 22931246, 'title': 'Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22931246'}]",,06/03/2015
0,06/03/2015,p53 Activator,166,5035,p53 Activator,TP53 E180K,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,06/03/2015
0,06/03/2015,p53 Gene Therapy,167,5036,p53 Gene Therapy,TP53 E180K,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,06/03/2015
0,06/04/2015,FLT3 Inhibitor,96,5037,FLT3 Inhibitor,FLT3 S451F,"[{'id': 705, 'pubMedId': 11756186, 'title': 'FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11756186'}, {'id': 2547, 'pubMedId': 17124058, 'title': 'FLT3 mutations: biology and treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17124058'}, {'id': 2548, 'pubMedId': 25231999, 'title': 'Targeting FLT3 to treat leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25231999'}]",,06/04/2015
0,06/04/2015,FLT3 Inhibitor,96,5045,FLT3 Inhibitor,FLT3 V592G,"[{'id': 705, 'pubMedId': 11756186, 'title': 'FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11756186'}, {'id': 2547, 'pubMedId': 17124058, 'title': 'FLT3 mutations: biology and treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17124058'}, {'id': 2548, 'pubMedId': 25231999, 'title': 'Targeting FLT3 to treat leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25231999'}]",,06/04/2015
0,06/05/2015,DNMT inhibitor (Pan),68,5050,DNMT inhibitor (Pan),DNMT3A over exp,"[{'id': 1168, 'pubMedId': 24822169, 'title': 'DNA methyltransferases: a novel target for prevention and therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24822169'}]",,06/05/2015
0,06/08/2015,JAK2 Inhibitor – ATP competitive,131,5147,JAK2 Inhibitor – ATP competitive,JAK2 act mut,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/08/2015
0,06/08/2015,JAK2 Inhibitor,130,5148,JAK2 Inhibitor,JAK2 act mut,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/08/2015
0,06/08/2015,JAK Inhibitor (Pan) – ATP competitive,127,5149,JAK Inhibitor (Pan) – ATP competitive,JAK2 act mut,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/08/2015
0,06/08/2015,JAK Inhibitor (Pan),126,5150,JAK Inhibitor (Pan),JAK2 act mut,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/08/2015
0,06/08/2015,JAK Inhibitor (Pan),126,5151,JAK Inhibitor (Pan),JAK2 G571S,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/08/2015
0,06/08/2015,JAK Inhibitor (Pan) – ATP competitive,127,5152,JAK Inhibitor (Pan) – ATP competitive,JAK2 G571S,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/08/2015
0,06/08/2015,JAK2 Inhibitor,130,5153,JAK2 Inhibitor,JAK2 G571S,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/08/2015
0,06/08/2015,JAK2 Inhibitor – ATP competitive,131,5154,JAK2 Inhibitor – ATP competitive,JAK2 G571S,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/08/2015
0,06/08/2015,JAK Inhibitor (Pan),126,5155,JAK Inhibitor (Pan),JAK2 P132A,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/08/2015
0,06/08/2015,JAK Inhibitor (Pan) – ATP competitive,127,5156,JAK Inhibitor (Pan) – ATP competitive,JAK2 P132A,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/08/2015
0,06/08/2015,JAK2 Inhibitor,130,5157,JAK2 Inhibitor,JAK2 P132A,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/08/2015
0,06/08/2015,JAK2 Inhibitor – ATP competitive,131,5158,JAK2 Inhibitor – ATP competitive,JAK2 P132A,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/08/2015
0,06/08/2015,JAK Inhibitor (Pan),126,5159,JAK Inhibitor (Pan),JAK2 V617F,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/08/2015
0,06/08/2015,JAK Inhibitor (Pan) – ATP competitive,127,5160,JAK Inhibitor (Pan) – ATP competitive,JAK2 V617F,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/08/2015
0,06/08/2015,JAK2 Inhibitor,130,5161,JAK2 Inhibitor,JAK2 V617F,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/08/2015
0,06/08/2015,JAK2 Inhibitor – ATP competitive,131,5162,JAK2 Inhibitor – ATP competitive,JAK2 V617F,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/08/2015
0,06/08/2015,JAK Inhibitor (Pan),126,5163,JAK Inhibitor (Pan),JAK2 Y931C,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/08/2015
0,06/08/2015,JAK2 Inhibitor,130,5164,JAK2 Inhibitor,JAK2 Y931C,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/08/2015
0,06/08/2015,JAK3 Inhibitor,132,5174,JAK3 Inhibitor,JAK3 act mut,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,06/08/2015
0,06/08/2015,JAK3 Inhibitor – ATP competitive,133,5175,JAK3 Inhibitor – ATP competitive,JAK3 act mut,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,06/08/2015
0,06/08/2015,JAK Inhibitor (Pan) – ATP competitive,127,5176,JAK Inhibitor (Pan) – ATP competitive,JAK3 act mut,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,06/08/2015
0,06/08/2015,JAK Inhibitor (Pan),126,5177,JAK Inhibitor (Pan),JAK3 act mut,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,06/08/2015
0,06/08/2015,JAK Inhibitor (Pan),126,5178,JAK Inhibitor (Pan),JAK3 A572V,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,06/08/2015
0,06/08/2015,JAK Inhibitor (Pan) – ATP competitive,127,5179,JAK Inhibitor (Pan) – ATP competitive,JAK3 A572V,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,06/08/2015
0,06/08/2015,JAK3 Inhibitor,132,5180,JAK3 Inhibitor,JAK3 A572V,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,06/08/2015
0,06/08/2015,JAK3 Inhibitor – ATP competitive,133,5181,JAK3 Inhibitor – ATP competitive,JAK3 A572V,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,06/08/2015
0,06/08/2015,JAK Inhibitor (Pan),126,5182,JAK Inhibitor (Pan),JAK3 A573V,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,06/08/2015
0,06/08/2015,JAK Inhibitor (Pan) – ATP competitive,127,5183,JAK Inhibitor (Pan) – ATP competitive,JAK3 A573V,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,06/08/2015
0,06/08/2015,JAK3 Inhibitor,132,5184,JAK3 Inhibitor,JAK3 A573V,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,06/08/2015
0,06/08/2015,JAK3 Inhibitor – ATP competitive,133,5185,JAK3 Inhibitor – ATP competitive,JAK3 A573V,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,06/08/2015
0,06/08/2015,JAK Inhibitor (Pan),126,5186,JAK Inhibitor (Pan),JAK3 I87T,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,06/08/2015
0,06/08/2015,JAK Inhibitor (Pan) – ATP competitive,127,5187,JAK Inhibitor (Pan) – ATP competitive,JAK3 I87T,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,06/08/2015
0,06/08/2015,JAK3 Inhibitor,132,5188,JAK3 Inhibitor,JAK3 I87T,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,06/08/2015
0,06/08/2015,JAK3 Inhibitor – ATP competitive,133,5189,JAK3 Inhibitor – ATP competitive,JAK3 I87T,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,06/08/2015
0,06/08/2015,JAK Inhibitor (Pan),126,5190,JAK Inhibitor (Pan),JAK3 P132A,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,06/08/2015
0,06/08/2015,JAK Inhibitor (Pan) – ATP competitive,127,5191,JAK Inhibitor (Pan) – ATP competitive,JAK3 P132A,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,06/08/2015
0,06/08/2015,JAK3 Inhibitor,132,5192,JAK3 Inhibitor,JAK3 P132A,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,06/08/2015
0,06/08/2015,JAK3 Inhibitor – ATP competitive,133,5193,JAK3 Inhibitor – ATP competitive,JAK3 P132A,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,06/08/2015
0,06/08/2015,JAK Inhibitor (Pan),126,5194,JAK Inhibitor (Pan),JAK3 Q501H,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,06/08/2015
0,06/08/2015,JAK Inhibitor (Pan) – ATP competitive,127,5195,JAK Inhibitor (Pan) – ATP competitive,JAK3 Q501H,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,06/08/2015
0,06/08/2015,JAK3 Inhibitor,132,5196,JAK3 Inhibitor,JAK3 Q501H,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,06/08/2015
0,06/08/2015,JAK3 Inhibitor – ATP competitive,133,5197,JAK3 Inhibitor – ATP competitive,JAK3 Q501H,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,06/08/2015
0,06/08/2015,JAK Inhibitor (Pan),126,5198,JAK Inhibitor (Pan),JAK3 R657Q,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,06/08/2015
0,06/08/2015,JAK Inhibitor (Pan) – ATP competitive,127,5199,JAK Inhibitor (Pan) – ATP competitive,JAK3 R657Q,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,06/08/2015
0,06/08/2015,JAK3 Inhibitor,132,5200,JAK3 Inhibitor,JAK3 R657Q,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,06/08/2015
0,06/08/2015,JAK3 Inhibitor – ATP competitive,133,5201,JAK3 Inhibitor – ATP competitive,JAK3 R657Q,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,06/08/2015
0,06/08/2015,JAK Inhibitor (Pan),126,5202,JAK Inhibitor (Pan),JAK3 V722I,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,06/08/2015
0,06/08/2015,JAK Inhibitor (Pan) – ATP competitive,127,5203,JAK Inhibitor (Pan) – ATP competitive,JAK3 V722I,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,06/08/2015
0,06/08/2015,JAK3 Inhibitor,132,5204,JAK3 Inhibitor,JAK3 V722I,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,06/08/2015
0,06/08/2015,JAK3 Inhibitor – ATP competitive,133,5205,JAK3 Inhibitor – ATP competitive,JAK3 V722I,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,06/08/2015
0,06/08/2015,JAK Inhibitor (Pan),126,5206,JAK Inhibitor (Pan),JAK3 V674A,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,06/08/2015
0,06/08/2015,JAK Inhibitor (Pan) – ATP competitive,127,5207,JAK Inhibitor (Pan) – ATP competitive,JAK3 V674A,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,06/08/2015
0,06/08/2015,JAK3 Inhibitor,132,5208,JAK3 Inhibitor,JAK3 V674A,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,06/08/2015
0,06/08/2015,JAK3 Inhibitor – ATP competitive,133,5209,JAK3 Inhibitor – ATP competitive,JAK3 V674A,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,06/08/2015
0,06/09/2015,mTORC1 Inhibitor,153,5263,mTORC1 Inhibitor,VHL inact mut,"[{'id': 2992, 'pubMedId': 16341243, 'title': 'Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16341243'}]",,06/09/2015
0,06/09/2015,mTORC1 Inhibitor,153,5264,mTORC1 Inhibitor,VHL loss,"[{'id': 2992, 'pubMedId': 16341243, 'title': 'Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16341243'}]",,06/09/2015
0,06/09/2015,VEGFR Inhibitor (Pan),230,5265,VEGFR Inhibitor (Pan),VHL loss,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2902, 'pubMedId': 22931246, 'title': 'Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22931246'}]",,06/09/2015
0,06/09/2015,VEGFR2 Inhibitor,232,5266,VEGFR2 Inhibitor,VHL loss,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2901, 'pubMedId': 22105611, 'title': 'Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22105611'}]",,06/09/2015
0,06/09/2015,mTORC1 Inhibitor,153,5267,mTORC1 Inhibitor,VHL P154L,"[{'id': 2992, 'pubMedId': 16341243, 'title': 'Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16341243'}]",,06/09/2015
0,06/09/2015,VEGFR Inhibitor (Pan),230,5268,VEGFR Inhibitor (Pan),VHL P154L,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2902, 'pubMedId': 22931246, 'title': 'Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22931246'}]",,06/09/2015
0,06/09/2015,VEGFR2 Inhibitor,232,5269,VEGFR2 Inhibitor,VHL P154L,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2901, 'pubMedId': 22105611, 'title': 'Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22105611'}]",,06/09/2015
0,06/09/2015,mTORC1 Inhibitor,153,5270,mTORC1 Inhibitor,VHL P81S,"[{'id': 2992, 'pubMedId': 16341243, 'title': 'Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16341243'}]",,06/09/2015
0,06/09/2015,VEGFR Inhibitor (Pan),230,5271,VEGFR Inhibitor (Pan),VHL P81S,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2902, 'pubMedId': 22931246, 'title': 'Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22931246'}]",,06/09/2015
0,06/09/2015,VEGFR2 Inhibitor,232,5272,VEGFR2 Inhibitor,VHL P81S,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2901, 'pubMedId': 22105611, 'title': 'Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22105611'}]",,06/09/2015
0,06/09/2015,mTORC1 Inhibitor,153,5273,mTORC1 Inhibitor,VHL S183L,"[{'id': 2992, 'pubMedId': 16341243, 'title': 'Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16341243'}]",,06/09/2015
0,06/09/2015,VEGFR Inhibitor (Pan),230,5274,VEGFR Inhibitor (Pan),VHL S183L,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2902, 'pubMedId': 22931246, 'title': 'Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22931246'}]",,06/09/2015
0,06/09/2015,VEGFR2 Inhibitor,232,5275,VEGFR2 Inhibitor,VHL S183L,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2901, 'pubMedId': 22105611, 'title': 'Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22105611'}]",,06/09/2015
0,06/09/2015,mTORC1 Inhibitor,153,5276,mTORC1 Inhibitor,VHL S65L,"[{'id': 2992, 'pubMedId': 16341243, 'title': 'Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16341243'}]",,06/09/2015
0,06/09/2015,VEGFR Inhibitor (Pan),230,5277,VEGFR Inhibitor (Pan),VHL S65L,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2902, 'pubMedId': 22931246, 'title': 'Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22931246'}]",,06/09/2015
0,06/09/2015,VEGFR2 Inhibitor,232,5278,VEGFR2 Inhibitor,VHL S65L,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2901, 'pubMedId': 22105611, 'title': 'Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22105611'}]",,06/09/2015
0,06/09/2015,mTORC1 Inhibitor,153,5279,mTORC1 Inhibitor,VHL H110Q,"[{'id': 2992, 'pubMedId': 16341243, 'title': 'Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16341243'}]",,06/09/2015
0,06/09/2015,VEGFR Inhibitor (Pan),230,5280,VEGFR Inhibitor (Pan),VHL H110Q,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2902, 'pubMedId': 22931246, 'title': 'Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22931246'}]",,06/09/2015
0,06/09/2015,VEGFR2 Inhibitor,232,5281,VEGFR2 Inhibitor,VHL H110Q,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2901, 'pubMedId': 22105611, 'title': 'Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22105611'}]",,06/09/2015
0,06/12/2015,JAK Inhibitor (Pan),126,5314,JAK Inhibitor (Pan),JAK2 E864K,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/12/2015
0,06/12/2015,JAK2 Inhibitor,130,5315,JAK2 Inhibitor,JAK2 E864K,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/12/2015
0,06/13/2015,JAK Inhibitor (Pan),126,5333,JAK Inhibitor (Pan),JAK2 G935R,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/13/2015
0,06/13/2015,JAK2 Inhibitor,130,5334,JAK2 Inhibitor,JAK2 G935R,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/13/2015
0,06/14/2015,JAK Inhibitor (Pan),126,5335,JAK Inhibitor (Pan),JAK2 M929I,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/14/2015
0,06/14/2015,JAK2 Inhibitor,130,5336,JAK2 Inhibitor,JAK2 M929I,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/14/2015
0,06/14/2015,JAK Inhibitor (Pan),126,5337,JAK Inhibitor (Pan),JAK3 M511I,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,06/14/2015
0,06/14/2015,JAK Inhibitor (Pan) – ATP competitive,127,5338,JAK Inhibitor (Pan) – ATP competitive,JAK3 M511I,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,06/14/2015
0,06/14/2015,JAK3 Inhibitor,132,5339,JAK3 Inhibitor,JAK3 M511I,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,06/14/2015
0,06/14/2015,JAK3 Inhibitor – ATP competitive,133,5340,JAK3 Inhibitor – ATP competitive,JAK3 M511I,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,06/14/2015
0,06/14/2015,JAK Inhibitor (Pan),126,5341,JAK Inhibitor (Pan),JAK2 N909K,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/14/2015
0,06/14/2015,JAK2 Inhibitor,130,5342,JAK2 Inhibitor,JAK2 N909K,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/14/2015
0,06/15/2015,p53 Activator,166,5343,p53 Activator,TP53 R282W,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,06/15/2015
0,06/15/2015,p53 Gene Therapy,167,5344,p53 Gene Therapy,TP53 R282W,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,06/15/2015
0,06/15/2015,JAK Inhibitor (Pan),126,5345,JAK Inhibitor (Pan),JAK2 R975G,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/15/2015
0,06/15/2015,JAK2 Inhibitor,130,5346,JAK2 Inhibitor,JAK2 R975G,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/15/2015
0,06/15/2015,JAK Inhibitor (Pan),126,5347,JAK Inhibitor (Pan),JAK2 V881A,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/15/2015
0,06/15/2015,JAK2 Inhibitor,130,5348,JAK2 Inhibitor,JAK2 V881A,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/15/2015
0,06/16/2015,JAK Inhibitor (Pan),126,5351,JAK Inhibitor (Pan),JAK3 A572T,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,06/16/2015
0,06/16/2015,JAK Inhibitor (Pan) – ATP competitive,127,5352,JAK Inhibitor (Pan) – ATP competitive,JAK3 A572T,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,06/16/2015
0,06/16/2015,JAK3 Inhibitor,132,5353,JAK3 Inhibitor,JAK3 A572T,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,06/16/2015
0,06/16/2015,JAK3 Inhibitor – ATP competitive,133,5354,JAK3 Inhibitor – ATP competitive,JAK3 A572T,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,06/16/2015
0,06/16/2015,JAK Inhibitor (Pan),126,5355,JAK Inhibitor (Pan),JAK3 L857Q,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,06/16/2015
0,06/16/2015,JAK Inhibitor (Pan) – ATP competitive,127,5356,JAK Inhibitor (Pan) – ATP competitive,JAK3 L857Q,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,06/16/2015
0,06/16/2015,JAK3 Inhibitor,132,5357,JAK3 Inhibitor,JAK3 L857Q,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,06/16/2015
0,06/16/2015,JAK3 Inhibitor – ATP competitive,133,5358,JAK3 Inhibitor – ATP competitive,JAK3 L857Q,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,06/16/2015
0,06/16/2015,JAK Inhibitor (Pan),126,5359,JAK Inhibitor (Pan),JAK3 R657W,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,06/16/2015
0,06/16/2015,JAK Inhibitor (Pan) – ATP competitive,127,5360,JAK Inhibitor (Pan) – ATP competitive,JAK3 R657W,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,06/16/2015
0,06/16/2015,JAK3 Inhibitor,132,5361,JAK3 Inhibitor,JAK3 R657W,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,06/16/2015
0,06/16/2015,JAK3 Inhibitor – ATP competitive,133,5362,JAK3 Inhibitor – ATP competitive,JAK3 R657W,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,06/16/2015
0,06/16/2015,JAK Inhibitor (Pan),126,5363,JAK Inhibitor (Pan),JAK3 V678M,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,06/16/2015
0,06/16/2015,JAK Inhibitor (Pan) – ATP competitive,127,5364,JAK Inhibitor (Pan) – ATP competitive,JAK3 V678M,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,06/16/2015
0,06/16/2015,JAK3 Inhibitor,132,5365,JAK3 Inhibitor,JAK3 V678M,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,06/16/2015
0,06/16/2015,JAK3 Inhibitor – ATP competitive,133,5366,JAK3 Inhibitor – ATP competitive,JAK3 V678M,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,06/16/2015
0,06/18/2015,CSF1R Inhibitor,59,5456,CSF1R Inhibitor,CSF1R L301S,"[{'id': 397, 'pubMedId': 18971950, 'title': 'Imatinib sensitivity as a consequence of a CSF1R-Y571D mutation and CSF1/CSF1R signaling abnormalities in the cell line GDM1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18971950'}, {'id': 3080, 'pubMedId': 24898549, 'title': 'Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24898549'}]",,06/18/2015
0,06/18/2015,CSF1R Inhibitor,59,5457,CSF1R Inhibitor,CSF1R Y571D,"[{'id': 397, 'pubMedId': 18971950, 'title': 'Imatinib sensitivity as a consequence of a CSF1R-Y571D mutation and CSF1/CSF1R signaling abnormalities in the cell line GDM1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18971950'}, {'id': 3080, 'pubMedId': 24898549, 'title': 'Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24898549'}]",,06/18/2015
0,06/18/2015,CSF1R Inhibitor,59,5458,CSF1R Inhibitor,CSF1R act mut,"[{'id': 397, 'pubMedId': 18971950, 'title': 'Imatinib sensitivity as a consequence of a CSF1R-Y571D mutation and CSF1/CSF1R signaling abnormalities in the cell line GDM1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18971950'}, {'id': 3080, 'pubMedId': 24898549, 'title': 'Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24898549'}]",,06/18/2015
0,06/18/2015,FLT3 Inhibitor,96,5486,FLT3 Inhibitor,FLT3 F594_R595insSDNEYFYVDF,"[{'id': 705, 'pubMedId': 11756186, 'title': 'FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11756186'}, {'id': 2547, 'pubMedId': 17124058, 'title': 'FLT3 mutations: biology and treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17124058'}, {'id': 2548, 'pubMedId': 25231999, 'title': 'Targeting FLT3 to treat leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25231999'}]",,06/18/2015
0,06/18/2015,FLT3 Inhibitor,96,5487,FLT3 Inhibitor,FLT3 D600_L601insFREYEYD,"[{'id': 705, 'pubMedId': 11756186, 'title': 'FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11756186'}, {'id': 2547, 'pubMedId': 17124058, 'title': 'FLT3 mutations: biology and treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17124058'}, {'id': 2548, 'pubMedId': 25231999, 'title': 'Targeting FLT3 to treat leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25231999'}]",,06/18/2015
0,06/18/2015,FLT3 Inhibitor,96,5488,FLT3 Inhibitor,FLT3 K602_W603insYEYDLK,"[{'id': 705, 'pubMedId': 11756186, 'title': 'FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11756186'}, {'id': 2547, 'pubMedId': 17124058, 'title': 'FLT3 mutations: biology and treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17124058'}, {'id': 2548, 'pubMedId': 25231999, 'title': 'Targeting FLT3 to treat leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25231999'}]",,06/18/2015
0,06/25/2015,,5837,IMO-8400,MYD88 L265P,"[{'id': 3125, 'pubMedId': None, 'title': 'Abstract 2570: IMO-8400, a selective antagonist of TLRs 7, 8 and 9, inhibits MYD88 L265P mutation-driven signaling and cell survival: A potential novel approach for treatment of B-cell lymphomas harboring MYD88 L265P mutation', 'url': 'http://cancerres.aacrjournals.org/content/74/19_Supplement/2570.short'}]",2866,IMO-8400,06/25/2015
0,07/06/2015,mTORC1 Inhibitor,153,5931,mTORC1 Inhibitor,FBXW7 T15_G16insP,"[{'id': 571, 'pubMedId': 18787170, 'title': 'FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18787170'}, {'id': 2558, 'pubMedId': 24586741, 'title': 'FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24586741'}]",,07/06/2015
0,07/07/2015,HDAC Inhibitor,104,5934,HDAC Inhibitor,RB1 C706F,"[{'id': 2739, 'pubMedId': 22293180, 'title': 'Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22293180'}]",,07/07/2015
0,07/07/2015,HDAC Inhibitor,104,5935,HDAC Inhibitor,RB1 E280*,"[{'id': 2739, 'pubMedId': 22293180, 'title': 'Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22293180'}]",,07/07/2015
0,07/07/2015,HDAC Inhibitor,104,5936,HDAC Inhibitor,RB1 E413*,"[{'id': 2739, 'pubMedId': 22293180, 'title': 'Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22293180'}]",,07/07/2015
0,07/07/2015,HDAC Inhibitor,104,5937,HDAC Inhibitor,RB1 E545*,"[{'id': 2739, 'pubMedId': 22293180, 'title': 'Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22293180'}]",,07/07/2015
0,07/07/2015,HDAC Inhibitor,104,5938,HDAC Inhibitor,RB1 E748*,"[{'id': 2739, 'pubMedId': 22293180, 'title': 'Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22293180'}]",,07/07/2015
0,07/07/2015,HDAC Inhibitor,104,5939,HDAC Inhibitor,RB1 K765*,"[{'id': 2739, 'pubMedId': 22293180, 'title': 'Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22293180'}]",,07/07/2015
0,07/09/2015,JAK Inhibitor (Pan),126,5959,JAK Inhibitor (Pan),MPL W515L,"[{'id': 263, 'pubMedId': 16834459, 'title': 'MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16834459'}]",,07/09/2015
0,07/09/2015,JAK Inhibitor (Pan) – ATP competitive,127,5960,JAK Inhibitor (Pan) – ATP competitive,MPL W515L,"[{'id': 263, 'pubMedId': 16834459, 'title': 'MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16834459'}]",,07/09/2015
0,07/09/2015,JAK2 Inhibitor,130,5961,JAK2 Inhibitor,MPL W515L,"[{'id': 836, 'pubMedId': 17541402, 'title': 'TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17541402'}, {'id': 837, 'pubMedId': 18354492, 'title': 'TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18354492'}]",,07/09/2015
0,07/09/2015,JAK2 Inhibitor – ATP competitive,131,5962,JAK2 Inhibitor – ATP competitive,MPL W515L,"[{'id': 836, 'pubMedId': 17541402, 'title': 'TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17541402'}, {'id': 837, 'pubMedId': 18354492, 'title': 'TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18354492'}]",,07/09/2015
0,07/09/2015,,5963,MK2206,MPL W515L,"[{'id': 839, 'pubMedId': 23748344, 'title': 'AKT is a therapeutic target in myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23748344'}]",816,MK2206,07/09/2015
0,07/09/2015,HDAC Inhibitor,104,5964,HDAC Inhibitor,RB1 L199*,"[{'id': 2739, 'pubMedId': 22293180, 'title': 'Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22293180'}]",,07/09/2015
0,07/09/2015,HDAC Inhibitor,104,5965,HDAC Inhibitor,RB1 Q217*,"[{'id': 2739, 'pubMedId': 22293180, 'title': 'Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22293180'}]",,07/09/2015
0,07/09/2015,HDAC Inhibitor,104,5966,HDAC Inhibitor,RB1 Q344*,"[{'id': 2739, 'pubMedId': 22293180, 'title': 'Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22293180'}]",,07/09/2015
0,07/10/2015,HDAC Inhibitor,104,5967,HDAC Inhibitor,RB1 Q344fs,"[{'id': 2739, 'pubMedId': 22293180, 'title': 'Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22293180'}]",,07/10/2015
0,07/10/2015,FGFR3 Antibody,93,5969,FGFR3 Antibody,FGFR3 over exp,"[{'id': 3211, 'pubMedId': 26078430, 'title': 'Targeting FGFR Signaling in Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26078430'}]",,07/10/2015
0,07/10/2015,FGFR Inhibitor (Pan),89,5970,FGFR Inhibitor (Pan),FGFR3 over exp,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,07/10/2015
0,07/10/2015,FGFR3 Inhibitor,94,5971,FGFR3 Inhibitor,FGFR3 over exp,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}, {'id': 1907, 'pubMedId': 20439987, 'title': 'NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20439987'}]",,07/10/2015
0,07/10/2015,FGFR Inhibitor (Pan),89,5977,FGFR Inhibitor (Pan),FGFR1 over exp,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,07/10/2015
0,07/10/2015,FGFR1 Inhibitor,90,5978,FGFR1 Inhibitor,FGFR1 over exp,"[{'id': 1901, 'pubMedId': 24980830, 'title': 'Discovery of novel non-ATP competitive FGFR1 inhibitors and evaluation of their anti-tumor activity in non-small cell lung cancer in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24980830'}]",,07/10/2015
0,07/10/2015,FGFR Inhibitor (Pan),89,5984,FGFR Inhibitor (Pan),FGFR2 over exp,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,07/10/2015
0,07/10/2015,FGFR2 Inhibitor,92,5985,FGFR2 Inhibitor,FGFR2 over exp,"[{'id': 1903, 'pubMedId': 19212647, 'title': 'FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19212647'}]",,07/10/2015
0,07/11/2015,HDAC Inhibitor,104,6008,HDAC Inhibitor,RB1 R556*,"[{'id': 2739, 'pubMedId': 22293180, 'title': 'Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22293180'}]",,07/11/2015
0,07/11/2015,HDAC Inhibitor,104,6009,HDAC Inhibitor,RB1 R552fs,"[{'id': 2739, 'pubMedId': 22293180, 'title': 'Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22293180'}]",,07/11/2015
0,07/12/2015,HDAC Inhibitor,104,6011,HDAC Inhibitor,RB1 W195*,"[{'id': 2739, 'pubMedId': 22293180, 'title': 'Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22293180'}]",,07/12/2015
0,07/12/2015,mTORC1 Inhibitor,153,6014,mTORC1 Inhibitor,VHL C162F,"[{'id': 2992, 'pubMedId': 16341243, 'title': 'Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16341243'}]",,07/12/2015
0,07/12/2015,VEGFR Inhibitor (Pan),230,6015,VEGFR Inhibitor (Pan),VHL C162F,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2902, 'pubMedId': 22931246, 'title': 'Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22931246'}]",,07/12/2015
0,07/12/2015,VEGFR2 Inhibitor,232,6016,VEGFR2 Inhibitor,VHL C162F,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2901, 'pubMedId': 22105611, 'title': 'Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22105611'}]",,07/12/2015
0,07/12/2015,mTORC1 Inhibitor,153,6023,mTORC1 Inhibitor,VHL F148fs,"[{'id': 2992, 'pubMedId': 16341243, 'title': 'Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16341243'}]",,07/12/2015
0,07/12/2015,VEGFR Inhibitor (Pan),230,6024,VEGFR Inhibitor (Pan),VHL F148fs,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2902, 'pubMedId': 22931246, 'title': 'Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22931246'}]",,07/12/2015
0,07/12/2015,VEGFR2 Inhibitor,232,6025,VEGFR2 Inhibitor,VHL F148fs,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2901, 'pubMedId': 22105611, 'title': 'Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22105611'}]",,07/12/2015
0,07/12/2015,mTORC1 Inhibitor,153,6029,mTORC1 Inhibitor,VHL L158P,"[{'id': 2992, 'pubMedId': 16341243, 'title': 'Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16341243'}]",,07/12/2015
0,07/12/2015,VEGFR Inhibitor (Pan),230,6030,VEGFR Inhibitor (Pan),VHL L158P,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2902, 'pubMedId': 22931246, 'title': 'Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22931246'}]",,07/12/2015
0,07/12/2015,VEGFR2 Inhibitor,232,6031,VEGFR2 Inhibitor,VHL L158P,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2901, 'pubMedId': 22105611, 'title': 'Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22105611'}]",,07/12/2015
0,07/13/2015,mTORC1 Inhibitor,153,6042,mTORC1 Inhibitor,VHL N78S,"[{'id': 2992, 'pubMedId': 16341243, 'title': 'Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16341243'}]",,07/13/2015
0,07/13/2015,VEGFR Inhibitor (Pan),230,6043,VEGFR Inhibitor (Pan),VHL N78S,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2902, 'pubMedId': 22931246, 'title': 'Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22931246'}]",,07/13/2015
0,07/13/2015,VEGFR2 Inhibitor,232,6044,VEGFR2 Inhibitor,VHL N78S,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2901, 'pubMedId': 22105611, 'title': 'Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22105611'}]",,07/13/2015
0,07/13/2015,mTORC1 Inhibitor,153,6045,mTORC1 Inhibitor,VHL N90I,"[{'id': 2992, 'pubMedId': 16341243, 'title': 'Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16341243'}]",,07/13/2015
0,07/13/2015,VEGFR Inhibitor (Pan),230,6046,VEGFR Inhibitor (Pan),VHL N90I,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2902, 'pubMedId': 22931246, 'title': 'Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22931246'}]",,07/13/2015
0,07/13/2015,VEGFR2 Inhibitor,232,6047,VEGFR2 Inhibitor,VHL N90I,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2901, 'pubMedId': 22105611, 'title': 'Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22105611'}]",,07/13/2015
0,07/13/2015,mTORC1 Inhibitor,153,6051,mTORC1 Inhibitor,VHL Q96*,"[{'id': 2992, 'pubMedId': 16341243, 'title': 'Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16341243'}]",,07/13/2015
0,07/13/2015,VEGFR Inhibitor (Pan),230,6052,VEGFR Inhibitor (Pan),VHL Q96*,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2902, 'pubMedId': 22931246, 'title': 'Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22931246'}]",,07/13/2015
0,07/13/2015,VEGFR2 Inhibitor,232,6053,VEGFR2 Inhibitor,VHL Q96*,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2901, 'pubMedId': 22105611, 'title': 'Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22105611'}]",,07/13/2015
0,07/13/2015,mTORC1 Inhibitor,153,6060,mTORC1 Inhibitor,VHL R167Q,"[{'id': 2992, 'pubMedId': 16341243, 'title': 'Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16341243'}]",,07/13/2015
0,07/13/2015,VEGFR Inhibitor (Pan),230,6061,VEGFR Inhibitor (Pan),VHL R167Q,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2902, 'pubMedId': 22931246, 'title': 'Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22931246'}]",,07/13/2015
0,07/13/2015,VEGFR2 Inhibitor,232,6062,VEGFR2 Inhibitor,VHL R167Q,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2901, 'pubMedId': 22105611, 'title': 'Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22105611'}]",,07/13/2015
0,07/13/2015,mTORC1 Inhibitor,153,6063,mTORC1 Inhibitor,VHL R167W,"[{'id': 2992, 'pubMedId': 16341243, 'title': 'Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16341243'}]",,07/13/2015
0,07/13/2015,VEGFR Inhibitor (Pan),230,6064,VEGFR Inhibitor (Pan),VHL R167W,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2902, 'pubMedId': 22931246, 'title': 'Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22931246'}]",,07/13/2015
0,07/13/2015,VEGFR2 Inhibitor,232,6065,VEGFR2 Inhibitor,VHL R167W,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2901, 'pubMedId': 22105611, 'title': 'Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22105611'}]",,07/13/2015
0,07/13/2015,mTORC1 Inhibitor,153,6069,mTORC1 Inhibitor,VHL R82P,"[{'id': 2992, 'pubMedId': 16341243, 'title': 'Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16341243'}]",,07/13/2015
0,07/13/2015,VEGFR Inhibitor (Pan),230,6070,VEGFR Inhibitor (Pan),VHL R82P,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2902, 'pubMedId': 22931246, 'title': 'Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22931246'}]",,07/13/2015
0,07/13/2015,VEGFR2 Inhibitor,232,6071,VEGFR2 Inhibitor,VHL R82P,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2901, 'pubMedId': 22105611, 'title': 'Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22105611'}]",,07/13/2015
0,07/13/2015,mTORC1 Inhibitor,153,6072,mTORC1 Inhibitor,VHL S111N,"[{'id': 2992, 'pubMedId': 16341243, 'title': 'Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16341243'}]",,07/13/2015
0,07/13/2015,VEGFR Inhibitor (Pan),230,6073,VEGFR Inhibitor (Pan),VHL S111N,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2902, 'pubMedId': 22931246, 'title': 'Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22931246'}]",,07/13/2015
0,07/13/2015,VEGFR2 Inhibitor,232,6074,VEGFR2 Inhibitor,VHL S111N,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2901, 'pubMedId': 22105611, 'title': 'Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22105611'}]",,07/13/2015
0,07/13/2015,mTORC1 Inhibitor,153,6075,mTORC1 Inhibitor,VHL S111R,"[{'id': 2992, 'pubMedId': 16341243, 'title': 'Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16341243'}]",,07/13/2015
0,07/13/2015,VEGFR Inhibitor (Pan),230,6076,VEGFR Inhibitor (Pan),VHL S111R,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2902, 'pubMedId': 22931246, 'title': 'Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22931246'}]",,07/13/2015
0,07/13/2015,VEGFR2 Inhibitor,232,6077,VEGFR2 Inhibitor,VHL S111R,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2901, 'pubMedId': 22105611, 'title': 'Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22105611'}]",,07/13/2015
0,07/13/2015,mTORC1 Inhibitor,153,6078,mTORC1 Inhibitor,VHL S65W,"[{'id': 2992, 'pubMedId': 16341243, 'title': 'Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16341243'}]",,07/13/2015
0,07/13/2015,VEGFR Inhibitor (Pan),230,6079,VEGFR Inhibitor (Pan),VHL S65W,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2902, 'pubMedId': 22931246, 'title': 'Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22931246'}]",,07/13/2015
0,07/13/2015,VEGFR2 Inhibitor,232,6080,VEGFR2 Inhibitor,VHL S65W,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2901, 'pubMedId': 22105611, 'title': 'Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22105611'}]",,07/13/2015
0,07/13/2015,mTORC1 Inhibitor,153,6081,mTORC1 Inhibitor,VHL S68*,"[{'id': 2992, 'pubMedId': 16341243, 'title': 'Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16341243'}]",,07/13/2015
0,07/13/2015,VEGFR Inhibitor (Pan),230,6082,VEGFR Inhibitor (Pan),VHL S68*,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2902, 'pubMedId': 22931246, 'title': 'Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22931246'}]",,07/13/2015
0,07/13/2015,VEGFR2 Inhibitor,232,6083,VEGFR2 Inhibitor,VHL S68*,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2901, 'pubMedId': 22105611, 'title': 'Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22105611'}]",,07/13/2015
0,07/13/2015,mTORC1 Inhibitor,153,6084,mTORC1 Inhibitor,VHL S68fs,"[{'id': 2992, 'pubMedId': 16341243, 'title': 'Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16341243'}]",,07/13/2015
0,07/13/2015,VEGFR Inhibitor (Pan),230,6085,VEGFR Inhibitor (Pan),VHL S68fs,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2902, 'pubMedId': 22931246, 'title': 'Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22931246'}]",,07/13/2015
0,07/13/2015,VEGFR2 Inhibitor,232,6086,VEGFR2 Inhibitor,VHL S68fs,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2901, 'pubMedId': 22105611, 'title': 'Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22105611'}]",,07/13/2015
0,07/13/2015,mTORC1 Inhibitor,153,6096,mTORC1 Inhibitor,VHL V62fs,"[{'id': 2992, 'pubMedId': 16341243, 'title': 'Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16341243'}]",,07/13/2015
0,07/13/2015,VEGFR Inhibitor (Pan),230,6097,VEGFR Inhibitor (Pan),VHL V62fs,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2902, 'pubMedId': 22931246, 'title': 'Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22931246'}]",,07/13/2015
0,07/13/2015,VEGFR2 Inhibitor,232,6098,VEGFR2 Inhibitor,VHL V62fs,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2901, 'pubMedId': 22105611, 'title': 'Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22105611'}]",,07/13/2015
0,07/13/2015,mTORC1 Inhibitor,153,6102,mTORC1 Inhibitor,VHL W88*,"[{'id': 2992, 'pubMedId': 16341243, 'title': 'Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16341243'}]",,07/13/2015
0,07/13/2015,VEGFR Inhibitor (Pan),230,6103,VEGFR Inhibitor (Pan),VHL W88*,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2902, 'pubMedId': 22931246, 'title': 'Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22931246'}]",,07/13/2015
0,07/13/2015,VEGFR2 Inhibitor,232,6104,VEGFR2 Inhibitor,VHL W88*,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2901, 'pubMedId': 22105611, 'title': 'Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22105611'}]",,07/13/2015
0,07/13/2015,mTORC1 Inhibitor,153,6105,mTORC1 Inhibitor,VHL D126N,"[{'id': 2992, 'pubMedId': 16341243, 'title': 'Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16341243'}]",,07/13/2015
0,07/13/2015,VEGFR Inhibitor (Pan),230,6106,VEGFR Inhibitor (Pan),VHL D126N,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2902, 'pubMedId': 22931246, 'title': 'Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22931246'}]",,07/13/2015
0,07/13/2015,VEGFR2 Inhibitor,232,6107,VEGFR2 Inhibitor,VHL D126N,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2901, 'pubMedId': 22105611, 'title': 'Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22105611'}]",,07/13/2015
0,07/14/2015,p53 Gene Therapy,167,6114,p53 Gene Therapy,TP53 R213*,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,07/14/2015
0,07/17/2015,SMO Inhibitor,208,6118,SMO Inhibitor,SMO amp,"[{'id': 2241, 'pubMedId': 24202394, 'title': 'Unraveling the therapeutic potential of the Hedgehog pathway in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24202394'}]",,07/17/2015
0,07/19/2015,PARP Inhibitor (Pan),171,6119,PARP Inhibitor (Pan),BRCA2 I1977fs,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,07/19/2015
0,07/19/2015,PARP-1 Inhibitor,172,6120,PARP-1 Inhibitor,BRCA2 I1977fs,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,07/19/2015
0,07/19/2015,PARP Inhibitor (Pan),171,6121,PARP Inhibitor (Pan),BRCA2 Q1782fs,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,07/19/2015
0,07/19/2015,PARP-1 Inhibitor,172,6122,PARP-1 Inhibitor,BRCA2 Q1782fs,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,07/19/2015
0,07/21/2015,,6123,BLU-285,KIT D816A,"[{'id': 3289, 'pubMedId': None, 'title': 'BLU-285, the first selective inhibitor of PDGFR? D842V and KIT Exon 17 mutants', 'url': 'http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=3682&sKey=d5b048e4-c58d-4458-b1d2-1d174261752c&cKey=6e17d4b2-c0e3-4430-a953-05575feec816&mKey=19573a54-ae8f-4e00-9c23-bd6d62268424'}]",2941,BLU-285,07/21/2015
0,07/21/2015,,6124,BLU-285,KIT D816E,"[{'id': 3289, 'pubMedId': None, 'title': 'BLU-285, the first selective inhibitor of PDGFR? D842V and KIT Exon 17 mutants', 'url': 'http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=3682&sKey=d5b048e4-c58d-4458-b1d2-1d174261752c&cKey=6e17d4b2-c0e3-4430-a953-05575feec816&mKey=19573a54-ae8f-4e00-9c23-bd6d62268424'}]",2941,BLU-285,07/21/2015
0,07/21/2015,,6125,BLU-285,KIT D816F,"[{'id': 3289, 'pubMedId': None, 'title': 'BLU-285, the first selective inhibitor of PDGFR? D842V and KIT Exon 17 mutants', 'url': 'http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=3682&sKey=d5b048e4-c58d-4458-b1d2-1d174261752c&cKey=6e17d4b2-c0e3-4430-a953-05575feec816&mKey=19573a54-ae8f-4e00-9c23-bd6d62268424'}]",2941,BLU-285,07/21/2015
0,07/21/2015,,6126,BLU-285,KIT D816G,"[{'id': 3289, 'pubMedId': None, 'title': 'BLU-285, the first selective inhibitor of PDGFR? D842V and KIT Exon 17 mutants', 'url': 'http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=3682&sKey=d5b048e4-c58d-4458-b1d2-1d174261752c&cKey=6e17d4b2-c0e3-4430-a953-05575feec816&mKey=19573a54-ae8f-4e00-9c23-bd6d62268424'}]",2941,BLU-285,07/21/2015
0,07/21/2015,,6127,BLU-285,KIT D816H,"[{'id': 3289, 'pubMedId': None, 'title': 'BLU-285, the first selective inhibitor of PDGFR? D842V and KIT Exon 17 mutants', 'url': 'http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=3682&sKey=d5b048e4-c58d-4458-b1d2-1d174261752c&cKey=6e17d4b2-c0e3-4430-a953-05575feec816&mKey=19573a54-ae8f-4e00-9c23-bd6d62268424'}]",2941,BLU-285,07/21/2015
0,07/21/2015,,6128,BLU-285,KIT D816I,"[{'id': 3289, 'pubMedId': None, 'title': 'BLU-285, the first selective inhibitor of PDGFR? D842V and KIT Exon 17 mutants', 'url': 'http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=3682&sKey=d5b048e4-c58d-4458-b1d2-1d174261752c&cKey=6e17d4b2-c0e3-4430-a953-05575feec816&mKey=19573a54-ae8f-4e00-9c23-bd6d62268424'}]",2941,BLU-285,07/21/2015
0,07/21/2015,,6129,BLU-285,KIT D816N,"[{'id': 3289, 'pubMedId': None, 'title': 'BLU-285, the first selective inhibitor of PDGFR? D842V and KIT Exon 17 mutants', 'url': 'http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=3682&sKey=d5b048e4-c58d-4458-b1d2-1d174261752c&cKey=6e17d4b2-c0e3-4430-a953-05575feec816&mKey=19573a54-ae8f-4e00-9c23-bd6d62268424'}]",2941,BLU-285,07/21/2015
0,07/21/2015,,6131,BLU-285,KIT D816Y,"[{'id': 3289, 'pubMedId': None, 'title': 'BLU-285, the first selective inhibitor of PDGFR? D842V and KIT Exon 17 mutants', 'url': 'http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=3682&sKey=d5b048e4-c58d-4458-b1d2-1d174261752c&cKey=6e17d4b2-c0e3-4430-a953-05575feec816&mKey=19573a54-ae8f-4e00-9c23-bd6d62268424'}]",2941,BLU-285,07/21/2015
0,07/21/2015,,6132,BLU-285,KIT N822K,"[{'id': 3289, 'pubMedId': None, 'title': 'BLU-285, the first selective inhibitor of PDGFR? D842V and KIT Exon 17 mutants', 'url': 'http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=3682&sKey=d5b048e4-c58d-4458-b1d2-1d174261752c&cKey=6e17d4b2-c0e3-4430-a953-05575feec816&mKey=19573a54-ae8f-4e00-9c23-bd6d62268424'}]",2941,BLU-285,07/21/2015
0,07/21/2015,,6133,BLU-285,PDGFRA D842V,"[{'id': 3289, 'pubMedId': None, 'title': 'BLU-285, the first selective inhibitor of PDGFR? D842V and KIT Exon 17 mutants', 'url': 'http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=3682&sKey=d5b048e4-c58d-4458-b1d2-1d174261752c&cKey=6e17d4b2-c0e3-4430-a953-05575feec816&mKey=19573a54-ae8f-4e00-9c23-bd6d62268424'}]",2941,BLU-285,07/21/2015
0,07/22/2015,FLT3 Inhibitor,96,6138,FLT3 Inhibitor,CBL R420Q,"[{'id': 3301, 'pubMedId': 25477533, 'title': 'Molecular pathways: cbl proteins in tumorigenesis and antitumor immunity-opportunities for cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25477533'}, {'id': 3302, 'pubMedId': 22990016, 'title': 'Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22990016'}]",,07/22/2015
0,07/22/2015,FLT3 Inhibitor,96,6139,FLT3 Inhibitor,CBL C379A,"[{'id': 3301, 'pubMedId': 25477533, 'title': 'Molecular pathways: cbl proteins in tumorigenesis and antitumor immunity-opportunities for cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25477533'}, {'id': 3302, 'pubMedId': 22990016, 'title': 'Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22990016'}]",,07/22/2015
0,07/22/2015,FLT3 Inhibitor,96,6140,FLT3 Inhibitor,CBL E366_K382del,"[{'id': 3301, 'pubMedId': 25477533, 'title': 'Molecular pathways: cbl proteins in tumorigenesis and antitumor immunity-opportunities for cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25477533'}, {'id': 3302, 'pubMedId': 22990016, 'title': 'Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22990016'}]",,07/22/2015
0,07/22/2015,FLT3 Inhibitor,96,6141,FLT3 Inhibitor,CBL Y371H,"[{'id': 3301, 'pubMedId': 25477533, 'title': 'Molecular pathways: cbl proteins in tumorigenesis and antitumor immunity-opportunities for cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25477533'}, {'id': 3302, 'pubMedId': 22990016, 'title': 'Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22990016'}]",,07/22/2015
0,07/23/2015,MEK inhibitor (Pan),142,6142,MEK inhibitor (Pan),HRAS K117E,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,07/23/2015
0,07/23/2015,MEK1 Inhibitor,143,6143,MEK1 Inhibitor,HRAS K117E,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,07/23/2015
0,07/23/2015,MEK2 Inhibitor,144,6144,MEK2 Inhibitor,HRAS K117E,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,07/23/2015
0,07/23/2015,PI3K Inhibitor (Pan),181,6145,PI3K Inhibitor (Pan),HRAS K117E,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,07/23/2015
0,07/23/2015,PIK3CA inhibitor,182,6146,PIK3CA inhibitor,HRAS K117E,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,07/23/2015
0,07/23/2015,PIK3CB inhibitor,183,6147,PIK3CB inhibitor,HRAS K117E,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,07/23/2015
0,07/23/2015,PIK3CD inhibitor,184,6148,PIK3CD inhibitor,HRAS K117E,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,07/23/2015
0,07/23/2015,PIK3CG inhibitor,185,6149,PIK3CG inhibitor,HRAS K117E,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,07/23/2015
0,07/23/2015,RAS Inhibitor (Pan),198,6150,RAS Inhibitor (Pan),HRAS K117E,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,07/23/2015
0,07/27/2015,EZH2 inhibitor,84,6207,EZH2 inhibitor,EZH2 A682G,"[{'id': 149, 'pubMedId': 24362326, 'title': 'EZH2: biology, disease, and structure-based drug discovery.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24362326'}, {'id': 1237, 'pubMedId': 24183969, 'title': 'Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24183969'}]",,07/27/2015
0,07/27/2015,EZH2 inhibitor,84,6208,EZH2 inhibitor,EZH2 A692V,"[{'id': 149, 'pubMedId': 24362326, 'title': 'EZH2: biology, disease, and structure-based drug discovery.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24362326'}, {'id': 1237, 'pubMedId': 24183969, 'title': 'Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24183969'}]",,07/27/2015
0,07/27/2015,FLT3 Inhibitor,96,6326,FLT3 Inhibitor,CBL C384R,"[{'id': 3301, 'pubMedId': 25477533, 'title': 'Molecular pathways: cbl proteins in tumorigenesis and antitumor immunity-opportunities for cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25477533'}, {'id': 3302, 'pubMedId': 22990016, 'title': 'Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22990016'}]",,07/27/2015
0,08/04/2015,KIT Inhibitor,136,6344,KIT Inhibitor,KIT M552_Y553del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,08/04/2015
0,08/04/2015,KIT Inhibitor,136,6345,KIT Inhibitor,KIT N564_L576del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,08/04/2015
0,08/04/2015,KIT Inhibitor,136,6346,KIT Inhibitor,KIT M552_E554del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,08/04/2015
0,08/04/2015,KIT Inhibitor,136,6347,KIT Inhibitor,KIT I571_L576del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,08/04/2015
0,08/04/2015,KIT Inhibitor,136,6348,KIT Inhibitor,KIT I563_L576del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,08/04/2015
0,08/04/2015,KIT Inhibitor,136,6349,KIT Inhibitor,KIT E554_K558del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,08/04/2015
0,08/04/2015,KIT Inhibitor,136,6350,KIT Inhibitor,KIT N564_Y578del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,08/04/2015
0,08/04/2015,KIT Inhibitor,136,6351,KIT Inhibitor,KIT V555_K558del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,08/04/2015
0,08/04/2015,KIT Inhibitor,136,6352,KIT Inhibitor,KIT V555_Q556del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,08/04/2015
0,08/05/2015,ALK Inhibitor,9,6353,ALK Inhibitor,EML4-ALK,"[{'id': 3386, 'pubMedId': 25806224, 'title': 'Targeting EML4-ALK driven non-small cell lung cancer (NSCLC).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806224'}]",,08/05/2015
0,08/05/2015,FGFR Inhibitor (Pan),89,6356,FGFR Inhibitor (Pan),FGFR3-TACC3,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}, {'id': 3392, 'pubMedId': 25294908, 'title': 'Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25294908'}]",,08/05/2015
0,08/05/2015,FGFR3 Inhibitor,94,6357,FGFR3 Inhibitor,FGFR3-TACC3,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}, {'id': 1907, 'pubMedId': 20439987, 'title': 'NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20439987'}]",,08/05/2015
0,08/20/2015,mTORC1 Inhibitor,153,6412,mTORC1 Inhibitor,FBXW7 S227A,"[{'id': 571, 'pubMedId': 18787170, 'title': 'FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18787170'}, {'id': 2558, 'pubMedId': 24586741, 'title': 'FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24586741'}]",,08/20/2015
0,08/23/2015,KIT Inhibitor,136,6413,KIT Inhibitor,KIT A502_Y503dup,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,08/23/2015
0,09/01/2015,HER inhibitor (Pan),105,6422,HER inhibitor (Pan),ERBB2 N857S,"[{'id': 2691, 'pubMedId': 25674538, 'title': 'The Potential of panHER Inhibition in Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25674538'}]",,09/01/2015
0,09/01/2015,HER2 Inhibitor,106,6423,HER2 Inhibitor,ERBB2 N857S,"[{'id': 561, 'pubMedId': 22649146, 'title': 'HER2 mutations in non-small-cell lung cancer can be continually targeted.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22649146'}, {'id': 563, 'pubMedId': 21991949, 'title': 'Adjuvant trastuzumab in HER2-positive breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21991949'}, {'id': 564, 'pubMedId': 23801166, 'title': 'First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23801166'}]",,09/01/2015
0,09/01/2015,HER inhibitor (Pan),105,6424,HER inhibitor (Pan),ERBB2 T862A,"[{'id': 2691, 'pubMedId': 25674538, 'title': 'The Potential of panHER Inhibition in Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25674538'}]",,09/01/2015
0,09/01/2015,HER2 Inhibitor,106,6425,HER2 Inhibitor,ERBB2 T862A,"[{'id': 561, 'pubMedId': 22649146, 'title': 'HER2 mutations in non-small-cell lung cancer can be continually targeted.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22649146'}, {'id': 563, 'pubMedId': 21991949, 'title': 'Adjuvant trastuzumab in HER2-positive breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21991949'}, {'id': 564, 'pubMedId': 23801166, 'title': 'First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23801166'}]",,09/01/2015
0,09/01/2015,HER inhibitor (Pan),105,6426,HER inhibitor (Pan),ERBB2 V773A,"[{'id': 2691, 'pubMedId': 25674538, 'title': 'The Potential of panHER Inhibition in Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25674538'}]",,09/01/2015
0,09/01/2015,HER2 Inhibitor,106,6427,HER2 Inhibitor,ERBB2 V773A,"[{'id': 561, 'pubMedId': 22649146, 'title': 'HER2 mutations in non-small-cell lung cancer can be continually targeted.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22649146'}, {'id': 563, 'pubMedId': 21991949, 'title': 'Adjuvant trastuzumab in HER2-positive breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21991949'}, {'id': 564, 'pubMedId': 23801166, 'title': 'First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23801166'}]",,09/01/2015
0,09/02/2015,PARP Inhibitor (Pan),171,6428,PARP Inhibitor (Pan),ATM loss,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",,09/02/2015
0,09/02/2015,HER inhibitor (Pan),105,6429,HER inhibitor (Pan),ERBB2 V659E,"[{'id': 2691, 'pubMedId': 25674538, 'title': 'The Potential of panHER Inhibition in Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25674538'}]",,09/02/2015
0,09/02/2015,HER2 Inhibitor,106,6430,HER2 Inhibitor,ERBB2 V659E,"[{'id': 561, 'pubMedId': 22649146, 'title': 'HER2 mutations in non-small-cell lung cancer can be continually targeted.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22649146'}, {'id': 563, 'pubMedId': 21991949, 'title': 'Adjuvant trastuzumab in HER2-positive breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21991949'}, {'id': 564, 'pubMedId': 23801166, 'title': 'First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23801166'}]",,09/02/2015
0,09/03/2015,EGFR Inhibitor (Pan),74,6431,EGFR Inhibitor (Pan),EGFR L747_T751delinsP,"[{'id': 410, 'pubMedId': 16187797, 'title': 'Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16187797'}, {'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,09/03/2015
0,09/03/2015,EGFR Inhibitor 1st gen,75,6432,EGFR Inhibitor 1st gen,EGFR L747_T751delinsP,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",,09/03/2015
0,09/03/2015,EGFR Inhibitor 2nd gen,76,6433,EGFR Inhibitor 2nd gen,EGFR L747_T751delinsP,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,09/03/2015
0,09/03/2015,EGFR Inhibitor 3rd gen,77,6434,EGFR Inhibitor 3rd gen,EGFR L747_T751delinsP,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,09/03/2015
0,09/03/2015,HER inhibitor (Pan),105,6435,HER inhibitor (Pan),EGFR L747_T751delinsP,"[{'id': 2746, 'pubMedId': 25806203, 'title': 'Irreversible EGFR-TKIs: dreaming perfection.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806203'}]",,09/03/2015
0,09/04/2015,ALK Inhibitor,9,6436,ALK Inhibitor,NPM1-ALK,"[{'id': 3598, 'pubMedId': 21474455, 'title': 'Targeting oncogenic ALK: a promising strategy for cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21474455'}]",,09/04/2015
0,09/06/2015,PARP Inhibitor (Pan),171,6437,PARP Inhibitor (Pan),ATM T2666A,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",,09/06/2015
0,09/06/2015,JAK Inhibitor (Pan),126,6438,JAK Inhibitor (Pan),MPL P106L,"[{'id': 263, 'pubMedId': 16834459, 'title': 'MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16834459'}]",,09/06/2015
0,09/06/2015,JAK Inhibitor (Pan) – ATP competitive,127,6439,JAK Inhibitor (Pan) – ATP competitive,MPL P106L,"[{'id': 263, 'pubMedId': 16834459, 'title': 'MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16834459'}]",,09/06/2015
0,09/06/2015,JAK2 Inhibitor,130,6440,JAK2 Inhibitor,MPL P106L,"[{'id': 836, 'pubMedId': 17541402, 'title': 'TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17541402'}, {'id': 837, 'pubMedId': 18354492, 'title': 'TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18354492'}]",,09/06/2015
0,09/06/2015,JAK2 Inhibitor – ATP competitive,131,6441,JAK2 Inhibitor – ATP competitive,MPL P106L,"[{'id': 836, 'pubMedId': 17541402, 'title': 'TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17541402'}, {'id': 837, 'pubMedId': 18354492, 'title': 'TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18354492'}]",,09/06/2015
0,09/10/2015,,6460,Cetuximab,EGFR L858R,"[{'id': 1846, 'pubMedId': 24063894, 'title': 'Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24063894'}]",694,Cetuximab,09/10/2015
0,09/17/2015,mTORC1 Inhibitor,153,6482,mTORC1 Inhibitor,FBXW7 M83*,"[{'id': 571, 'pubMedId': 18787170, 'title': 'FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18787170'}, {'id': 2558, 'pubMedId': 24586741, 'title': 'FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24586741'}]",,09/17/2015
0,09/22/2015,Tankyrase Inhibitor,215,6500,Tankyrase Inhibitor,APC E1309Afs*3,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/22/2015
0,09/22/2015,CTNNB1 Inhibitor,60,6502,CTNNB1 Inhibitor,APC inact mut,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/22/2015
0,09/22/2015,Tankyrase Inhibitor,215,6503,Tankyrase Inhibitor,APC inact mut,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/22/2015
0,09/22/2015,CTNNB1 Inhibitor,60,6504,CTNNB1 Inhibitor,APC K716*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/22/2015
0,09/22/2015,Tankyrase Inhibitor,215,6505,Tankyrase Inhibitor,APC K716*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/22/2015
0,09/22/2015,CTNNB1 Inhibitor,60,6506,CTNNB1 Inhibitor,APC A1351fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/22/2015
0,09/22/2015,Tankyrase Inhibitor,215,6507,Tankyrase Inhibitor,APC A1351fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/22/2015
0,09/22/2015,CTNNB1 Inhibitor,60,6510,CTNNB1 Inhibitor,APC A1492fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/22/2015
0,09/22/2015,Tankyrase Inhibitor,215,6511,Tankyrase Inhibitor,APC A1492fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/22/2015
0,09/22/2015,CTNNB1 Inhibitor,60,6512,CTNNB1 Inhibitor,APC E1295*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/22/2015
0,09/22/2015,Tankyrase Inhibitor,215,6513,Tankyrase Inhibitor,APC E1295*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/22/2015
0,09/22/2015,CTNNB1 Inhibitor,60,6514,CTNNB1 Inhibitor,APC E1306*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/22/2015
0,09/22/2015,Tankyrase Inhibitor,215,6515,Tankyrase Inhibitor,APC E1306*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/22/2015
0,09/22/2015,CTNNB1 Inhibitor,60,6516,CTNNB1 Inhibitor,APC E1309*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/22/2015
0,09/22/2015,Tankyrase Inhibitor,215,6517,Tankyrase Inhibitor,APC E1309*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/22/2015
0,09/22/2015,CTNNB1 Inhibitor,60,6518,CTNNB1 Inhibitor,APC E1309fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/22/2015
0,09/22/2015,Tankyrase Inhibitor,215,6519,Tankyrase Inhibitor,APC E1309fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/22/2015
0,09/22/2015,CTNNB1 Inhibitor,60,6522,CTNNB1 Inhibitor,APC E1317*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/22/2015
0,09/22/2015,Tankyrase Inhibitor,215,6523,Tankyrase Inhibitor,APC E1317*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/22/2015
0,09/22/2015,CTNNB1 Inhibitor,60,6524,CTNNB1 Inhibitor,APC E1345*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/22/2015
0,09/22/2015,Tankyrase Inhibitor,215,6525,Tankyrase Inhibitor,APC E1345*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/22/2015
0,09/22/2015,CTNNB1 Inhibitor,60,6526,CTNNB1 Inhibitor,APC E1322*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/22/2015
0,09/22/2015,Tankyrase Inhibitor,215,6527,Tankyrase Inhibitor,APC E1322*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/22/2015
0,09/22/2015,CTNNB1 Inhibitor,60,6528,CTNNB1 Inhibitor,APC E1353*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/22/2015
0,09/22/2015,Tankyrase Inhibitor,215,6529,Tankyrase Inhibitor,APC E1353*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/22/2015
0,09/22/2015,CTNNB1 Inhibitor,60,6530,CTNNB1 Inhibitor,APC E1397*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/22/2015
0,09/22/2015,Tankyrase Inhibitor,215,6531,Tankyrase Inhibitor,APC E1397*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/22/2015
0,09/22/2015,CTNNB1 Inhibitor,60,6532,CTNNB1 Inhibitor,APC E1379*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/22/2015
0,09/22/2015,Tankyrase Inhibitor,215,6533,Tankyrase Inhibitor,APC E1379*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/22/2015
0,09/22/2015,CTNNB1 Inhibitor,60,6534,CTNNB1 Inhibitor,APC E1374*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/22/2015
0,09/22/2015,Tankyrase Inhibitor,215,6535,Tankyrase Inhibitor,APC E1374*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/22/2015
0,09/22/2015,CTNNB1 Inhibitor,60,6536,CTNNB1 Inhibitor,APC E1451*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/22/2015
0,09/22/2015,Tankyrase Inhibitor,215,6537,Tankyrase Inhibitor,APC E1451*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/22/2015
0,09/22/2015,CTNNB1 Inhibitor,60,6538,CTNNB1 Inhibitor,APC E1461*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/22/2015
0,09/22/2015,Tankyrase Inhibitor,215,6539,Tankyrase Inhibitor,APC E1461*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/22/2015
0,09/22/2015,CTNNB1 Inhibitor,60,6540,CTNNB1 Inhibitor,APC E1464*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/22/2015
0,09/22/2015,Tankyrase Inhibitor,215,6541,Tankyrase Inhibitor,APC E1464*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/22/2015
0,09/22/2015,CTNNB1 Inhibitor,60,6542,CTNNB1 Inhibitor,APC E1464fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/22/2015
0,09/22/2015,Tankyrase Inhibitor,215,6543,Tankyrase Inhibitor,APC E1464fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/22/2015
0,09/22/2015,CTNNB1 Inhibitor,60,6544,CTNNB1 Inhibitor,APC E1494fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/22/2015
0,09/22/2015,Tankyrase Inhibitor,215,6545,Tankyrase Inhibitor,APC E1494fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/22/2015
0,09/22/2015,CTNNB1 Inhibitor,60,6548,CTNNB1 Inhibitor,APC E1513*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/22/2015
0,09/22/2015,Tankyrase Inhibitor,215,6549,Tankyrase Inhibitor,APC E1513*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/22/2015
0,09/22/2015,CTNNB1 Inhibitor,60,6550,CTNNB1 Inhibitor,APC E1547*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/22/2015
0,09/22/2015,Tankyrase Inhibitor,215,6551,Tankyrase Inhibitor,APC E1547*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/22/2015
0,09/22/2015,CTNNB1 Inhibitor,60,6552,CTNNB1 Inhibitor,APC E1544*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/22/2015
0,09/22/2015,Tankyrase Inhibitor,215,6553,Tankyrase Inhibitor,APC E1544*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/22/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6554,CTNNB1 Inhibitor,APC E1552*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6555,Tankyrase Inhibitor,APC E1552*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6556,CTNNB1 Inhibitor,APC E1554*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6557,Tankyrase Inhibitor,APC E1554*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6560,CTNNB1 Inhibitor,APC F1491fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6561,Tankyrase Inhibitor,APC F1491fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6562,CTNNB1 Inhibitor,APC G1312*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6563,Tankyrase Inhibitor,APC G1312*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6564,CTNNB1 Inhibitor,APC G1312fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6565,Tankyrase Inhibitor,APC G1312fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6566,CTNNB1 Inhibitor,APC G1357fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6567,Tankyrase Inhibitor,APC G1357fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6568,CTNNB1 Inhibitor,APC G1499*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6569,Tankyrase Inhibitor,APC G1499*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6570,CTNNB1 Inhibitor,APC H1375fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6571,Tankyrase Inhibitor,APC H1375fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6572,CTNNB1 Inhibitor,APC H1490fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6573,Tankyrase Inhibitor,APC H1490fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6576,CTNNB1 Inhibitor,APC I1307fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6577,Tankyrase Inhibitor,APC I1307fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6586,CTNNB1 Inhibitor,APC I1311fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6587,Tankyrase Inhibitor,APC I1311fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6590,CTNNB1 Inhibitor,APC I1557fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6591,Tankyrase Inhibitor,APC I1557fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6592,CTNNB1 Inhibitor,APC K1308*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6593,Tankyrase Inhibitor,APC K1308*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6594,CTNNB1 Inhibitor,APC K1310*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6595,Tankyrase Inhibitor,APC K1310*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6596,CTNNB1 Inhibitor,APC K1310fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6597,Tankyrase Inhibitor,APC K1310fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6598,CTNNB1 Inhibitor,APC K1350*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6599,Tankyrase Inhibitor,APC K1350*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6600,CTNNB1 Inhibitor,APC K1370*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6601,Tankyrase Inhibitor,APC K1370*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6602,CTNNB1 Inhibitor,APC K1449fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6603,Tankyrase Inhibitor,APC K1449fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6608,CTNNB1 Inhibitor,APC K1555fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6609,Tankyrase Inhibitor,APC K1555fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6610,CTNNB1 Inhibitor,APC L1488*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6611,Tankyrase Inhibitor,APC L1488*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6612,CTNNB1 Inhibitor,APC L1488fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6613,Tankyrase Inhibitor,APC L1488fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6618,CTNNB1 Inhibitor,APC L1489fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6619,Tankyrase Inhibitor,APC L1489fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6622,CTNNB1 Inhibitor,APC L1564*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6623,Tankyrase Inhibitor,APC L1564*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6624,CTNNB1 Inhibitor,APC M1431fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6625,Tankyrase Inhibitor,APC M1431fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6626,CTNNB1 Inhibitor,APC N1300fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6627,Tankyrase Inhibitor,APC N1300fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6630,CTNNB1 Inhibitor,APC N1455fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6631,Tankyrase Inhibitor,APC N1455fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6632,CTNNB1 Inhibitor,APC N869fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6633,Tankyrase Inhibitor,APC N869fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6634,CTNNB1 Inhibitor,APC P1319fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6635,Tankyrase Inhibitor,APC P1319fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6636,CTNNB1 Inhibitor,APC P1361fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6637,Tankyrase Inhibitor,APC P1361fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6638,CTNNB1 Inhibitor,APC P1372fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6639,Tankyrase Inhibitor,APC P1372fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6640,CTNNB1 Inhibitor,APC P1373fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6641,Tankyrase Inhibitor,APC P1373fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6646,CTNNB1 Inhibitor,APC P1440fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6647,Tankyrase Inhibitor,APC P1440fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6648,CTNNB1 Inhibitor,APC P1443fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6649,Tankyrase Inhibitor,APC P1443fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6650,CTNNB1 Inhibitor,APC P1453fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6651,Tankyrase Inhibitor,APC P1453fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6652,CTNNB1 Inhibitor,APC P1458fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6653,Tankyrase Inhibitor,APC P1458fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6654,CTNNB1 Inhibitor,APC P1497fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6655,Tankyrase Inhibitor,APC P1497fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6656,CTNNB1 Inhibitor,APC Q1096*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6657,Tankyrase Inhibitor,APC Q1096*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6658,CTNNB1 Inhibitor,APC Q1127*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6659,Tankyrase Inhibitor,APC Q1127*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6660,CTNNB1 Inhibitor,APC Q1291*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6661,Tankyrase Inhibitor,APC Q1291*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6662,CTNNB1 Inhibitor,APC Q1294*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6663,Tankyrase Inhibitor,APC Q1294*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6664,Tankyrase Inhibitor,CTNNB1 act mut,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 2299, 'pubMedId': 23621985, 'title': 'Evidence for tankyrases as antineoplastic targets in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23621985'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6665,CTNNB1 Inhibitor,APC Q1294fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6666,Tankyrase Inhibitor,APC Q1294fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6715,CTNNB1 Inhibitor,APC Q1303*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6716,Tankyrase Inhibitor,APC Q1303*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6717,CTNNB1 Inhibitor,APC Q1303fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6718,Tankyrase Inhibitor,APC Q1303fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6719,CTNNB1 Inhibitor,APC Q1338*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6720,Tankyrase Inhibitor,APC Q1338*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6721,CTNNB1 Inhibitor,APC Q1367*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6722,Tankyrase Inhibitor,APC Q1367*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6723,CTNNB1 Inhibitor,APC Q1378*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6724,Tankyrase Inhibitor,APC Q1378*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6725,CTNNB1 Inhibitor,APC Q1378fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6726,Tankyrase Inhibitor,APC Q1378fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6727,CTNNB1 Inhibitor,APC Q1406*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6728,Tankyrase Inhibitor,APC Q1406*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6729,CTNNB1 Inhibitor,APC Q1429*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6730,Tankyrase Inhibitor,APC Q1429*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6731,CTNNB1 Inhibitor,APC Q1444*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6732,Tankyrase Inhibitor,APC Q1444*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6736,CTNNB1 Inhibitor,APC Q1447*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6737,Tankyrase Inhibitor,APC Q1447*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6738,CTNNB1 Inhibitor,APC Q1469*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6739,Tankyrase Inhibitor,APC Q1469*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6740,CTNNB1 Inhibitor,APC Q886*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6741,Tankyrase Inhibitor,APC Q886*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6742,CTNNB1 Inhibitor,APC R1114*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6743,Tankyrase Inhibitor,APC R1114*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6744,CTNNB1 Inhibitor,APC R1314fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6745,Tankyrase Inhibitor,APC R1314fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6746,CTNNB1 Inhibitor,APC R1348fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6747,Tankyrase Inhibitor,APC R1348fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6748,CTNNB1 Inhibitor,APC R1435*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6749,Tankyrase Inhibitor,APC R1435*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6750,CTNNB1 Inhibitor,APC R1435fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6751,Tankyrase Inhibitor,APC R1435fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6752,CTNNB1 Inhibitor,APC R1450*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6753,Tankyrase Inhibitor,APC R1450*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6757,CTNNB1 Inhibitor,APC R213*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6758,Tankyrase Inhibitor,APC R213*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6762,CTNNB1 Inhibitor,APC R216*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6763,Tankyrase Inhibitor,APC R216*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6764,CTNNB1 Inhibitor,APC R232*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6765,Tankyrase Inhibitor,APC R232*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6766,CTNNB1 Inhibitor,APC R283*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6767,Tankyrase Inhibitor,APC R283*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6768,CTNNB1 Inhibitor,APC R302*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6769,Tankyrase Inhibitor,APC R302*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6770,CTNNB1 Inhibitor,APC R564*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6771,Tankyrase Inhibitor,APC R564*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6772,CTNNB1 Inhibitor,APC R858*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6773,Tankyrase Inhibitor,APC R858*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6774,CTNNB1 Inhibitor,APC R876*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6775,Tankyrase Inhibitor,APC R876*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6776,CTNNB1 Inhibitor,APC S1315*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6777,Tankyrase Inhibitor,APC S1315*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6778,CTNNB1 Inhibitor,APC S1315fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6779,Tankyrase Inhibitor,APC S1315fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6780,CTNNB1 Inhibitor,APC S1346*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6781,Tankyrase Inhibitor,APC S1346*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6788,CTNNB1 Inhibitor,APC S1355fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6789,Tankyrase Inhibitor,APC S1355fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6790,CTNNB1 Inhibitor,APC S1356*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6791,Tankyrase Inhibitor,APC S1356*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6792,CTNNB1 Inhibitor,APC S1356fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6793,Tankyrase Inhibitor,APC S1356fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6794,CTNNB1 Inhibitor,APC S1364fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6795,Tankyrase Inhibitor,APC S1364fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6796,CTNNB1 Inhibitor,APC S1436fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6797,Tankyrase Inhibitor,APC S1436fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6798,CTNNB1 Inhibitor,APC S1465fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6799,Tankyrase Inhibitor,APC S1465fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6802,CTNNB1 Inhibitor,APC S1495fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6803,Tankyrase Inhibitor,APC S1495fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6806,CTNNB1 Inhibitor,APC S31fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6807,Tankyrase Inhibitor,APC S31fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6808,CTNNB1 Inhibitor,APC T1301fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6809,Tankyrase Inhibitor,APC T1301fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6812,CTNNB1 Inhibitor,APC T1438fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6813,Tankyrase Inhibitor,APC T1438fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6816,CTNNB1 Inhibitor,APC T1445fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6817,Tankyrase Inhibitor,APC T1445fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6818,CTNNB1 Inhibitor,APC T1459fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6819,Tankyrase Inhibitor,APC T1459fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6824,CTNNB1 Inhibitor,APC T1556fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6825,Tankyrase Inhibitor,APC T1556fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/23/2015,CTNNB1 Inhibitor,60,6832,CTNNB1 Inhibitor,APC Y1376fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/23/2015
0,09/23/2015,Tankyrase Inhibitor,215,6833,Tankyrase Inhibitor,APC Y1376fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/23/2015
0,09/30/2015,RET Inhibitor,199,6909,RET Inhibitor,RET R833C,"[{'id': 59, 'pubMedId': 22146228, 'title': 'Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22146228'}, {'id': 1869, 'pubMedId': 24705026, 'title': 'Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24705026'}, {'id': 1870, 'pubMedId': 21551259, 'title': 'In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21551259'}]",,09/30/2015
0,09/30/2015,RET Inhibitor,199,6910,RET Inhibitor,RET A883T,"[{'id': 59, 'pubMedId': 22146228, 'title': 'Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22146228'}, {'id': 1869, 'pubMedId': 24705026, 'title': 'Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24705026'}, {'id': 1870, 'pubMedId': 21551259, 'title': 'In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21551259'}]",,09/30/2015
0,09/30/2015,RET Inhibitor,199,6911,RET Inhibitor,RET M848T,"[{'id': 59, 'pubMedId': 22146228, 'title': 'Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22146228'}, {'id': 1869, 'pubMedId': 24705026, 'title': 'Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24705026'}, {'id': 1870, 'pubMedId': 21551259, 'title': 'In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21551259'}]",,09/30/2015
0,09/30/2015,RET Inhibitor,199,6912,RET Inhibitor,RET M918V,"[{'id': 59, 'pubMedId': 22146228, 'title': 'Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22146228'}, {'id': 1869, 'pubMedId': 24705026, 'title': 'Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24705026'}, {'id': 1870, 'pubMedId': 21551259, 'title': 'In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21551259'}]",,09/30/2015
0,09/30/2015,RET Inhibitor,199,6913,RET Inhibitor,RET S904F,"[{'id': 59, 'pubMedId': 22146228, 'title': 'Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22146228'}, {'id': 1869, 'pubMedId': 24705026, 'title': 'Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24705026'}, {'id': 1870, 'pubMedId': 21551259, 'title': 'In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21551259'}]",,09/30/2015
0,10/01/2015,RET Inhibitor,199,6914,RET Inhibitor,RET A883F,"[{'id': 59, 'pubMedId': 22146228, 'title': 'Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22146228'}, {'id': 1869, 'pubMedId': 24705026, 'title': 'Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24705026'}, {'id': 1870, 'pubMedId': 21551259, 'title': 'In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21551259'}]",,10/01/2015
0,10/05/2015,Trk Receptor Inhibitor (Pan),226,6916,Trk Receptor Inhibitor (Pan),ETV6-NTRK3,"[{'id': 3183, 'pubMedId': 21148487, 'title': 'ETV6-NTRK3-mediated breast epithelial cell transformation is blocked by targeting the IGF1R signaling pathway.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21148487'}, {'id': 4250, 'pubMedId': 16258068, 'title': 'The ETV6-NTRK3 chimeric tyrosine kinase suppresses TGF-beta signaling by inactivating the TGF-beta type II receptor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16258068'}]",,10/05/2015
0,10/05/2015,,6917,Crizotinib,ETV6-NTRK3,"[{'id': 3695, 'pubMedId': 25207766, 'title': 'Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25207766'}]",706,Crizotinib,10/05/2015
0,10/08/2015,Akt Inhibitor (Pan),4,6939,Akt Inhibitor (Pan),PIK3CA E545X,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,10/08/2015
0,10/08/2015,Akt1 Inhibitor,6,6940,Akt1 Inhibitor,PIK3CA E545X,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,10/08/2015
0,10/08/2015,Akt2 Inhibitor,7,6941,Akt2 Inhibitor,PIK3CA E545X,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,10/08/2015
0,10/08/2015,Akt3 Inhibitor,8,6942,Akt3 Inhibitor,PIK3CA E545X,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,10/08/2015
0,10/08/2015,mTOR Inhibitor,152,6943,mTOR Inhibitor,PIK3CA E545X,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,10/08/2015
0,10/08/2015,mTORC1 Inhibitor,153,6944,mTORC1 Inhibitor,PIK3CA E545X,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,10/08/2015
0,10/08/2015,mTORC2 Inhibitor,154,6945,mTORC2 Inhibitor,PIK3CA E545X,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,10/08/2015
0,10/08/2015,PI3K Inhibitor (Pan),181,6946,PI3K Inhibitor (Pan),PIK3CA E545X,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,10/08/2015
0,10/08/2015,PIK3CA inhibitor,182,6947,PIK3CA inhibitor,PIK3CA E545X,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,10/08/2015
0,10/19/2015,FLT3 Inhibitor,96,6968,FLT3 Inhibitor,FLT3 S840_N841insGS,"[{'id': 705, 'pubMedId': 11756186, 'title': 'FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11756186'}, {'id': 2547, 'pubMedId': 17124058, 'title': 'FLT3 mutations: biology and treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17124058'}, {'id': 2548, 'pubMedId': 25231999, 'title': 'Targeting FLT3 to treat leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25231999'}]",,10/19/2015
0,10/19/2015,IDH Inhibitor (Pan),117,6969,IDH Inhibitor (Pan),IDH1 R132V,"[{'id': 2551, 'pubMedId': 25678837, 'title': 'New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25678837'}]",,10/19/2015
0,10/19/2015,IDH1 Inhibitor,118,6970,IDH1 Inhibitor,IDH1 R132V,"[{'id': 2551, 'pubMedId': 25678837, 'title': 'New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25678837'}, {'id': 2552, 'pubMedId': 23558169, 'title': 'An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23558169'}]",,10/19/2015
0,10/21/2015,FGFR2 Antibody,91,6979,FGFR2 Antibody,FGFR2 amp,"[{'id': 3277, 'pubMedId': None, 'title': 'Abstract 4766: Pharmacodynamic and stratification biomarker for the anti-FGFR2 antibody (BAY1179470) and the FGFR2-ADC', 'url': 'http://cancerres.aacrjournals.org/content/74/19_Supplement/4766.abstract'}]",,10/21/2015
0,10/25/2015,EGFR Inhibitor (Pan),74,6984,EGFR Inhibitor (Pan),EGFR E746K,"[{'id': 410, 'pubMedId': 16187797, 'title': 'Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16187797'}, {'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,10/25/2015
0,10/25/2015,EGFR Inhibitor 1st gen,75,6985,EGFR Inhibitor 1st gen,EGFR E746K,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",,10/25/2015
0,10/25/2015,EGFR Inhibitor 2nd gen,76,6986,EGFR Inhibitor 2nd gen,EGFR E746K,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,10/25/2015
0,10/25/2015,EGFR Inhibitor 3rd gen,77,6987,EGFR Inhibitor 3rd gen,EGFR E746K,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,10/25/2015
0,10/25/2015,HER inhibitor (Pan),105,6988,HER inhibitor (Pan),EGFR E746K,"[{'id': 2746, 'pubMedId': 25806203, 'title': 'Irreversible EGFR-TKIs: dreaming perfection.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806203'}]",,10/25/2015
0,10/28/2015,FLT3 Inhibitor,96,6995,FLT3 Inhibitor,FLT3 Y599_D600insSTDNEYFYVDFREYEY,"[{'id': 705, 'pubMedId': 11756186, 'title': 'FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11756186'}, {'id': 2547, 'pubMedId': 17124058, 'title': 'FLT3 mutations: biology and treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17124058'}, {'id': 2548, 'pubMedId': 25231999, 'title': 'Targeting FLT3 to treat leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25231999'}]",,10/28/2015
0,10/28/2015,CTNNB1 Inhibitor,60,6996,CTNNB1 Inhibitor,APC A1325fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,10/28/2015
0,10/28/2015,Tankyrase Inhibitor,215,6997,Tankyrase Inhibitor,APC A1325fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,10/28/2015
0,10/28/2015,CTNNB1 Inhibitor,60,6998,CTNNB1 Inhibitor,APC A1296fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,10/28/2015
0,10/28/2015,Tankyrase Inhibitor,215,6999,Tankyrase Inhibitor,APC A1296fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,10/28/2015
0,10/28/2015,CTNNB1 Inhibitor,60,7000,CTNNB1 Inhibitor,APC A1305fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,10/28/2015
0,10/28/2015,Tankyrase Inhibitor,215,7001,Tankyrase Inhibitor,APC A1305fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,10/28/2015
0,10/28/2015,CTNNB1 Inhibitor,60,7002,CTNNB1 Inhibitor,APC A1316fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,10/28/2015
0,10/28/2015,Tankyrase Inhibitor,215,7003,Tankyrase Inhibitor,APC A1316fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,10/28/2015
0,10/28/2015,CTNNB1 Inhibitor,60,7006,CTNNB1 Inhibitor,APC A1402fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,10/28/2015
0,10/28/2015,Tankyrase Inhibitor,215,7007,Tankyrase Inhibitor,APC A1402fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,10/28/2015
0,10/28/2015,CTNNB1 Inhibitor,60,7010,CTNNB1 Inhibitor,APC A1446fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,10/28/2015
0,10/28/2015,Tankyrase Inhibitor,215,7011,Tankyrase Inhibitor,APC A1446fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,10/28/2015
0,10/28/2015,CTNNB1 Inhibitor,60,7014,CTNNB1 Inhibitor,APC A1470fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,10/28/2015
0,10/28/2015,Tankyrase Inhibitor,215,7015,Tankyrase Inhibitor,APC A1470fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,10/28/2015
0,10/28/2015,CTNNB1 Inhibitor,60,7016,CTNNB1 Inhibitor,APC A1471fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,10/28/2015
0,10/28/2015,Tankyrase Inhibitor,215,7017,Tankyrase Inhibitor,APC A1471fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,10/28/2015
0,10/28/2015,CTNNB1 Inhibitor,60,7018,CTNNB1 Inhibitor,APC A1475fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,10/28/2015
0,10/28/2015,Tankyrase Inhibitor,215,7019,Tankyrase Inhibitor,APC A1475fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,10/28/2015
0,10/28/2015,CTNNB1 Inhibitor,60,7020,CTNNB1 Inhibitor,APC C1274fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,10/28/2015
0,10/28/2015,Tankyrase Inhibitor,215,7021,Tankyrase Inhibitor,APC C1274fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,10/28/2015
0,10/28/2015,CTNNB1 Inhibitor,60,7022,CTNNB1 Inhibitor,APC C1387*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,10/28/2015
0,10/28/2015,Tankyrase Inhibitor,215,7023,Tankyrase Inhibitor,APC C1387*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,10/28/2015
0,10/28/2015,CTNNB1 Inhibitor,60,7024,CTNNB1 Inhibitor,APC C1387fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,10/28/2015
0,10/28/2015,Tankyrase Inhibitor,215,7025,Tankyrase Inhibitor,APC C1387fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,10/28/2015
0,10/28/2015,CTNNB1 Inhibitor,60,7026,CTNNB1 Inhibitor,APC C1410*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,10/28/2015
0,10/28/2015,Tankyrase Inhibitor,215,7027,Tankyrase Inhibitor,APC C1410*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,10/28/2015
0,10/28/2015,CTNNB1 Inhibitor,60,7030,CTNNB1 Inhibitor,APC D1297fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,10/28/2015
0,10/28/2015,Tankyrase Inhibitor,215,7031,Tankyrase Inhibitor,APC D1297fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,10/28/2015
0,10/28/2015,CTNNB1 Inhibitor,60,7032,CTNNB1 Inhibitor,APC D1318fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,10/28/2015
0,10/28/2015,Tankyrase Inhibitor,215,7033,Tankyrase Inhibitor,APC D1318fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,10/28/2015
0,10/28/2015,CTNNB1 Inhibitor,60,7036,CTNNB1 Inhibitor,APC D1422fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,10/28/2015
0,10/28/2015,Tankyrase Inhibitor,215,7037,Tankyrase Inhibitor,APC D1422fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,10/28/2015
0,10/28/2015,CTNNB1 Inhibitor,60,7038,CTNNB1 Inhibitor,APC D1425fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,10/28/2015
0,10/28/2015,Tankyrase Inhibitor,215,7039,Tankyrase Inhibitor,APC D1425fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,10/28/2015
0,10/28/2015,CTNNB1 Inhibitor,60,7040,CTNNB1 Inhibitor,APC D1484fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,10/28/2015
0,10/28/2015,Tankyrase Inhibitor,215,7041,Tankyrase Inhibitor,APC D1484fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,10/28/2015
0,10/28/2015,CTNNB1 Inhibitor,60,7042,CTNNB1 Inhibitor,APC E1577*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,10/28/2015
0,10/28/2015,Tankyrase Inhibitor,215,7043,Tankyrase Inhibitor,APC E1577*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,10/28/2015
0,10/28/2015,CTNNB1 Inhibitor,60,7044,CTNNB1 Inhibitor,APC Y1376*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,10/28/2015
0,10/28/2015,Tankyrase Inhibitor,215,7045,Tankyrase Inhibitor,APC Y1376*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,10/28/2015
0,10/30/2015,mTORC1 Inhibitor,153,7047,mTORC1 Inhibitor,FBXW7 I435fs*9,"[{'id': 571, 'pubMedId': 18787170, 'title': 'FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18787170'}, {'id': 2558, 'pubMedId': 24586741, 'title': 'FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24586741'}]",,10/30/2015
0,10/30/2015,mTORC1 Inhibitor,153,7048,mTORC1 Inhibitor,FBXW7 K444fs*32,"[{'id': 571, 'pubMedId': 18787170, 'title': 'FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18787170'}, {'id': 2558, 'pubMedId': 24586741, 'title': 'FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24586741'}]",,10/30/2015
0,11/01/2015,JAK Inhibitor (Pan),126,7049,JAK Inhibitor (Pan),JAK2 R867Q,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,11/01/2015
0,11/01/2015,JAK Inhibitor (Pan) – ATP competitive,127,7050,JAK Inhibitor (Pan) – ATP competitive,JAK2 R867Q,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,11/01/2015
0,11/01/2015,JAK2 Inhibitor,130,7051,JAK2 Inhibitor,JAK2 R867Q,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,11/01/2015
0,11/01/2015,JAK2 Inhibitor – ATP competitive,131,7052,JAK2 Inhibitor – ATP competitive,JAK2 R867Q,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,11/01/2015
0,11/05/2015,,7054,Dasatinib,KIT D816H,"[{'id': 3822, 'pubMedId': 18024392, 'title': 'Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18024392'}]",717,Dasatinib,11/05/2015
0,11/05/2015,,7055,BLU-285,KIT D816V,"[{'id': 3289, 'pubMedId': None, 'title': 'BLU-285, the first selective inhibitor of PDGFR? D842V and KIT Exon 17 mutants', 'url': 'http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=3682&sKey=d5b048e4-c58d-4458-b1d2-1d174261752c&cKey=6e17d4b2-c0e3-4430-a953-05575feec816&mKey=19573a54-ae8f-4e00-9c23-bd6d62268424'}]",2941,BLU-285,11/05/2015
0,11/05/2015,,7056,Dasatinib,KIT D816V,"[{'id': 3822, 'pubMedId': 18024392, 'title': 'Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18024392'}]",717,Dasatinib,11/05/2015
0,11/10/2015,JAK Inhibitor (Pan),126,7057,JAK Inhibitor (Pan),MPL S505N,"[{'id': 263, 'pubMedId': 16834459, 'title': 'MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16834459'}]",,11/10/2015
0,11/10/2015,JAK Inhibitor (Pan) – ATP competitive,127,7058,JAK Inhibitor (Pan) – ATP competitive,MPL S505N,"[{'id': 263, 'pubMedId': 16834459, 'title': 'MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16834459'}]",,11/10/2015
0,11/10/2015,JAK2 Inhibitor,130,7059,JAK2 Inhibitor,MPL S505N,"[{'id': 836, 'pubMedId': 17541402, 'title': 'TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17541402'}, {'id': 837, 'pubMedId': 18354492, 'title': 'TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18354492'}]",,11/10/2015
0,11/10/2015,JAK2 Inhibitor – ATP competitive,131,7060,JAK2 Inhibitor – ATP competitive,MPL S505N,"[{'id': 836, 'pubMedId': 17541402, 'title': 'TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17541402'}, {'id': 837, 'pubMedId': 18354492, 'title': 'TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18354492'}]",,11/10/2015
0,11/12/2015,HDAC Inhibitor,104,7061,HDAC Inhibitor,RB1 R272*,"[{'id': 2739, 'pubMedId': 22293180, 'title': 'Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22293180'}]",,11/12/2015
0,11/13/2015,p53 Activator,166,7062,p53 Activator,TP53 R280I,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,11/13/2015
0,11/13/2015,p53 Gene Therapy,167,7063,p53 Gene Therapy,TP53 R280I,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,11/13/2015
0,11/16/2015,mTORC1 Inhibitor,153,7065,mTORC1 Inhibitor,VHL C77*,"[{'id': 2992, 'pubMedId': 16341243, 'title': 'Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16341243'}]",,11/16/2015
0,11/16/2015,VEGFR Inhibitor (Pan),230,7066,VEGFR Inhibitor (Pan),VHL C77*,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2902, 'pubMedId': 22931246, 'title': 'Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22931246'}]",,11/16/2015
0,11/16/2015,VEGFR2 Inhibitor,232,7067,VEGFR2 Inhibitor,VHL C77*,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2901, 'pubMedId': 22105611, 'title': 'Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22105611'}]",,11/16/2015
0,11/16/2015,mTORC1 Inhibitor,153,7068,mTORC1 Inhibitor,VHL L116fs,"[{'id': 2992, 'pubMedId': 16341243, 'title': 'Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16341243'}]",,11/16/2015
0,11/16/2015,VEGFR Inhibitor (Pan),230,7069,VEGFR Inhibitor (Pan),VHL L116fs,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2902, 'pubMedId': 22931246, 'title': 'Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22931246'}]",,11/16/2015
0,11/16/2015,VEGFR2 Inhibitor,232,7070,VEGFR2 Inhibitor,VHL L116fs,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2901, 'pubMedId': 22105611, 'title': 'Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22105611'}]",,11/16/2015
0,11/16/2015,mTORC1 Inhibitor,153,7071,mTORC1 Inhibitor,VHL N131fs,"[{'id': 2992, 'pubMedId': 16341243, 'title': 'Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16341243'}]",,11/16/2015
0,11/16/2015,VEGFR Inhibitor (Pan),230,7072,VEGFR Inhibitor (Pan),VHL N131fs,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2902, 'pubMedId': 22931246, 'title': 'Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22931246'}]",,11/16/2015
0,11/16/2015,VEGFR2 Inhibitor,232,7073,VEGFR2 Inhibitor,VHL N131fs,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2901, 'pubMedId': 22105611, 'title': 'Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22105611'}]",,11/16/2015
0,11/16/2015,mTORC1 Inhibitor,153,7074,mTORC1 Inhibitor,VHL Q132fs,"[{'id': 2992, 'pubMedId': 16341243, 'title': 'Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16341243'}]",,11/16/2015
0,11/16/2015,VEGFR Inhibitor (Pan),230,7075,VEGFR Inhibitor (Pan),VHL Q132fs,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2902, 'pubMedId': 22931246, 'title': 'Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22931246'}]",,11/16/2015
0,11/16/2015,VEGFR2 Inhibitor,232,7076,VEGFR2 Inhibitor,VHL Q132fs,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2901, 'pubMedId': 22105611, 'title': 'Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22105611'}]",,11/16/2015
0,11/16/2015,mTORC1 Inhibitor,153,7077,mTORC1 Inhibitor,VHL L158fs,"[{'id': 2992, 'pubMedId': 16341243, 'title': 'Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16341243'}]",,11/16/2015
0,11/16/2015,VEGFR Inhibitor (Pan),230,7078,VEGFR Inhibitor (Pan),VHL L158fs,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2902, 'pubMedId': 22931246, 'title': 'Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22931246'}]",,11/16/2015
0,11/16/2015,VEGFR2 Inhibitor,232,7079,VEGFR2 Inhibitor,VHL L158fs,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2901, 'pubMedId': 22105611, 'title': 'Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22105611'}]",,11/16/2015
0,11/18/2015,VEGFR Inhibitor (Pan),230,7081,VEGFR Inhibitor (Pan),KDR A1065T,"[{'id': 217, 'pubMedId': 19723655, 'title': 'KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19723655'}]",,11/18/2015
0,11/18/2015,VEGFR2 Inhibitor,232,7082,VEGFR2 Inhibitor,KDR A1065T,"[{'id': 217, 'pubMedId': 19723655, 'title': 'KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19723655'}, {'id': 1847, 'pubMedId': 25568876, 'title': 'Clinical advances in the development of novel VEGFR2 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25568876'}]",,11/18/2015
0,11/19/2015,JAK2 Inhibitor – ATP competitive,131,7086,JAK2 Inhibitor – ATP competitive,CALR act mut,"[{'id': 3953, 'pubMedId': 24325356, 'title': 'Somatic mutations of calreticulin in myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24325356'}, {'id': 3954, 'pubMedId': 24645956, 'title': 'JAK inhibitor in CALR-mutant myelofibrosis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24645956'}]",,11/19/2015
0,11/24/2015,p53 Activator,166,7098,p53 Activator,TP53 P98A,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,11/24/2015
0,11/24/2015,p53 Gene Therapy,167,7099,p53 Gene Therapy,TP53 P98A,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,11/24/2015
0,11/24/2015,p53 Gene Therapy,167,7101,p53 Gene Therapy,TP53 R282fs,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,11/24/2015
0,11/24/2015,p53 Activator,166,7102,p53 Activator,TP53 R335H,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,11/24/2015
0,11/24/2015,p53 Gene Therapy,167,7103,p53 Gene Therapy,TP53 R335H,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,11/24/2015
0,11/24/2015,p53 Activator,166,7104,p53 Activator,TP53 S240I,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,11/24/2015
0,11/24/2015,p53 Gene Therapy,167,7105,p53 Gene Therapy,TP53 S240I,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,11/24/2015
0,11/30/2015,mTORC1 Inhibitor,153,7106,mTORC1 Inhibitor,STK11 inact mut,"[{'id': 3134, 'pubMedId': 24387336, 'title': 'Targeting the LKB1 tumor suppressor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24387336'}]",,11/30/2015
0,11/30/2015,JAK Inhibitor (Pan) – ATP competitive,127,7114,JAK Inhibitor (Pan) – ATP competitive,CSF3R T615A,"[{'id': 3951, 'pubMedId': 23656643, 'title': 'Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23656643'}]",,11/30/2015
0,11/30/2015,JAK1 Inhibitor – ATP competitive,129,7115,JAK1 Inhibitor – ATP competitive,CSF3R T615A,"[{'id': 3951, 'pubMedId': 23656643, 'title': 'Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23656643'}]",,11/30/2015
0,11/30/2015,JAK2 Inhibitor – ATP competitive,131,7116,JAK2 Inhibitor – ATP competitive,CSF3R T615A,"[{'id': 3951, 'pubMedId': 23656643, 'title': 'Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23656643'}]",,11/30/2015
0,11/30/2015,JAK Inhibitor (Pan) – ATP competitive,127,7117,JAK Inhibitor (Pan) – ATP competitive,CSF3R T618I,"[{'id': 3951, 'pubMedId': 23656643, 'title': 'Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23656643'}]",,11/30/2015
0,11/30/2015,JAK1 Inhibitor – ATP competitive,129,7118,JAK1 Inhibitor – ATP competitive,CSF3R T618I,"[{'id': 3951, 'pubMedId': 23656643, 'title': 'Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23656643'}]",,11/30/2015
0,11/30/2015,JAK2 Inhibitor – ATP competitive,131,7119,JAK2 Inhibitor – ATP competitive,CSF3R T618I,"[{'id': 3951, 'pubMedId': 23656643, 'title': 'Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23656643'}]",,11/30/2015
0,12/01/2015,JAK Inhibitor (Pan) – ATP competitive,127,7132,JAK Inhibitor (Pan) – ATP competitive,CSF3R act mut,"[{'id': 3951, 'pubMedId': 23656643, 'title': 'Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23656643'}]",,12/01/2015
0,12/01/2015,JAK1 Inhibitor – ATP competitive,129,7133,JAK1 Inhibitor – ATP competitive,CSF3R act mut,"[{'id': 3951, 'pubMedId': 23656643, 'title': 'Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23656643'}]",,12/01/2015
0,12/01/2015,JAK2 Inhibitor – ATP competitive,131,7134,JAK2 Inhibitor – ATP competitive,CSF3R act mut,"[{'id': 3951, 'pubMedId': 23656643, 'title': 'Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23656643'}]",,12/01/2015
0,12/01/2015,SRC Inhibitor,209,7135,SRC Inhibitor,CSF3R inact mut,"[{'id': 3951, 'pubMedId': 23656643, 'title': 'Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23656643'}, {'id': 4003, 'pubMedId': 26366092, 'title': 'Chronic neutrophilic leukemia: a clinical perspective.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26366092'}]",,12/01/2015
0,12/01/2015,SRC Inhibitor,209,7136,SRC Inhibitor,CSF3R Q741*,"[{'id': 3951, 'pubMedId': 23656643, 'title': 'Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23656643'}, {'id': 4003, 'pubMedId': 26366092, 'title': 'Chronic neutrophilic leukemia: a clinical perspective.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26366092'}]",,12/01/2015
0,12/01/2015,SRC Inhibitor,209,7137,SRC Inhibitor,CSF3R S783fs,"[{'id': 3951, 'pubMedId': 23656643, 'title': 'Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23656643'}, {'id': 4003, 'pubMedId': 26366092, 'title': 'Chronic neutrophilic leukemia: a clinical perspective.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26366092'}]",,12/01/2015
0,12/04/2015,,7159,Neratinib,EGFR E709K,"[{'id': 4031, 'pubMedId': 26206867, 'title': 'EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26206867'}]",828,Neratinib,12/04/2015
0,12/04/2015,,7160,Neratinib,EGFR E709A,"[{'id': 4031, 'pubMedId': 26206867, 'title': 'EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26206867'}]",828,Neratinib,12/04/2015
0,12/04/2015,,7161,Neratinib,EGFR E709G,"[{'id': 4031, 'pubMedId': 26206867, 'title': 'EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26206867'}]",828,Neratinib,12/04/2015
0,12/04/2015,EGFR Inhibitor 3rd gen,77,7162,EGFR Inhibitor 3rd gen,EGFR G719S,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,12/04/2015
0,12/04/2015,EGFR Inhibitor 2nd gen,76,7163,EGFR Inhibitor 2nd gen,EGFR G719S,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,12/04/2015
0,12/04/2015,EGFR Inhibitor 1st gen,75,7164,EGFR Inhibitor 1st gen,EGFR G719S,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",,12/04/2015
0,12/04/2015,HER inhibitor (Pan),105,7165,HER inhibitor (Pan),EGFR G719S,"[{'id': 2746, 'pubMedId': 25806203, 'title': 'Irreversible EGFR-TKIs: dreaming perfection.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806203'}]",,12/04/2015
0,12/04/2015,,7166,Neratinib,EGFR G719S,"[{'id': 4031, 'pubMedId': 26206867, 'title': 'EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26206867'}]",828,Neratinib,12/04/2015
0,12/04/2015,EGFR Inhibitor (Pan),74,7167,EGFR Inhibitor (Pan),EGFR G719S,"[{'id': 410, 'pubMedId': 16187797, 'title': 'Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16187797'}, {'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,12/04/2015
0,12/04/2015,EGFR Inhibitor 2nd gen,76,7168,EGFR Inhibitor 2nd gen,EGFR G719A,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,12/04/2015
0,12/04/2015,,7169,Neratinib,EGFR G719A,"[{'id': 4031, 'pubMedId': 26206867, 'title': 'EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26206867'}]",828,Neratinib,12/04/2015
0,12/04/2015,HER inhibitor (Pan),105,7170,HER inhibitor (Pan),EGFR G719A,"[{'id': 2746, 'pubMedId': 25806203, 'title': 'Irreversible EGFR-TKIs: dreaming perfection.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806203'}]",,12/04/2015
0,12/04/2015,EGFR Inhibitor 3rd gen,77,7171,EGFR Inhibitor 3rd gen,EGFR G719A,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,12/04/2015
0,12/04/2015,EGFR Inhibitor (Pan),74,7172,EGFR Inhibitor (Pan),EGFR G719A,"[{'id': 410, 'pubMedId': 16187797, 'title': 'Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16187797'}, {'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,12/04/2015
0,12/04/2015,EGFR Inhibitor 1st gen,75,7173,EGFR Inhibitor 1st gen,EGFR G719A,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",,12/04/2015
0,12/04/2015,EGFR Inhibitor 1st gen,75,7174,EGFR Inhibitor 1st gen,EGFR G719C,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",,12/04/2015
0,12/04/2015,HER inhibitor (Pan),105,7175,HER inhibitor (Pan),EGFR G719C,"[{'id': 2746, 'pubMedId': 25806203, 'title': 'Irreversible EGFR-TKIs: dreaming perfection.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806203'}]",,12/04/2015
0,12/04/2015,EGFR Inhibitor 2nd gen,76,7176,EGFR Inhibitor 2nd gen,EGFR G719C,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,12/04/2015
0,12/04/2015,EGFR Inhibitor (Pan),74,7177,EGFR Inhibitor (Pan),EGFR G719C,"[{'id': 410, 'pubMedId': 16187797, 'title': 'Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16187797'}, {'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,12/04/2015
0,12/04/2015,EGFR Inhibitor 3rd gen,77,7178,EGFR Inhibitor 3rd gen,EGFR G719C,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,12/04/2015
0,12/04/2015,,7179,Neratinib,EGFR G719C,"[{'id': 4031, 'pubMedId': 26206867, 'title': 'EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26206867'}]",828,Neratinib,12/04/2015
0,12/04/2015,EGFR Inhibitor 3rd gen,77,7180,EGFR Inhibitor 3rd gen,EGFR G719X,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,12/04/2015
0,12/04/2015,EGFR Inhibitor (Pan),74,7181,EGFR Inhibitor (Pan),EGFR G719X,"[{'id': 410, 'pubMedId': 16187797, 'title': 'Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16187797'}, {'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,12/04/2015
0,12/04/2015,HER inhibitor (Pan),105,7182,HER inhibitor (Pan),EGFR G719X,"[{'id': 2746, 'pubMedId': 25806203, 'title': 'Irreversible EGFR-TKIs: dreaming perfection.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806203'}]",,12/04/2015
0,12/04/2015,,7183,Neratinib,EGFR G719X,"[{'id': 4031, 'pubMedId': 26206867, 'title': 'EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26206867'}]",828,Neratinib,12/04/2015
0,12/04/2015,EGFR Inhibitor 2nd gen,76,7184,EGFR Inhibitor 2nd gen,EGFR G719X,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,12/04/2015
0,12/04/2015,EGFR Inhibitor 1st gen,75,7185,EGFR Inhibitor 1st gen,EGFR G719X,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",,12/04/2015
0,12/04/2015,EGFR Inhibitor (Pan),74,7186,EGFR Inhibitor (Pan),EGFR G719D,"[{'id': 410, 'pubMedId': 16187797, 'title': 'Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16187797'}, {'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,12/04/2015
0,12/04/2015,HER inhibitor (Pan),105,7187,HER inhibitor (Pan),EGFR G719D,"[{'id': 2746, 'pubMedId': 25806203, 'title': 'Irreversible EGFR-TKIs: dreaming perfection.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806203'}]",,12/04/2015
0,12/04/2015,EGFR Inhibitor 2nd gen,76,7188,EGFR Inhibitor 2nd gen,EGFR G719D,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,12/04/2015
0,12/04/2015,EGFR Inhibitor 1st gen,75,7189,EGFR Inhibitor 1st gen,EGFR G719D,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",,12/04/2015
0,12/04/2015,EGFR Inhibitor 3rd gen,77,7190,EGFR Inhibitor 3rd gen,EGFR G719D,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,12/04/2015
0,12/04/2015,,7191,Neratinib,EGFR G719D,"[{'id': 4031, 'pubMedId': 26206867, 'title': 'EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26206867'}]",828,Neratinib,12/04/2015
0,12/18/2015,CTNNB1 Inhibitor,60,7223,CTNNB1 Inhibitor,APC T1488fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,12/18/2015
0,12/18/2015,Tankyrase Inhibitor,215,7224,Tankyrase Inhibitor,APC T1488fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,12/18/2015
0,12/18/2015,HER inhibitor (Pan),105,7226,HER inhibitor (Pan),ERBB2 H878Y,"[{'id': 2691, 'pubMedId': 25674538, 'title': 'The Potential of panHER Inhibition in Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25674538'}]",,12/18/2015
0,12/18/2015,HER2 Inhibitor,106,7227,HER2 Inhibitor,ERBB2 H878Y,"[{'id': 561, 'pubMedId': 22649146, 'title': 'HER2 mutations in non-small-cell lung cancer can be continually targeted.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22649146'}, {'id': 563, 'pubMedId': 21991949, 'title': 'Adjuvant trastuzumab in HER2-positive breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21991949'}, {'id': 564, 'pubMedId': 23801166, 'title': 'First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23801166'}]",,12/18/2015
0,12/24/2015,Akt Inhibitor (Pan),4,7239,Akt Inhibitor (Pan),PIK3CA C378R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,12/24/2015
0,12/24/2015,Akt1 Inhibitor,6,7240,Akt1 Inhibitor,PIK3CA C378R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,12/24/2015
0,12/24/2015,Akt2 Inhibitor,7,7241,Akt2 Inhibitor,PIK3CA C378R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,12/24/2015
0,12/24/2015,Akt3 Inhibitor,8,7242,Akt3 Inhibitor,PIK3CA C378R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,12/24/2015
0,12/24/2015,mTOR Inhibitor,152,7243,mTOR Inhibitor,PIK3CA C378R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,12/24/2015
0,12/24/2015,mTORC1 Inhibitor,153,7244,mTORC1 Inhibitor,PIK3CA C378R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,12/24/2015
0,12/24/2015,mTORC2 Inhibitor,154,7245,mTORC2 Inhibitor,PIK3CA C378R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,12/24/2015
0,12/24/2015,PI3K Inhibitor (Pan),181,7246,PI3K Inhibitor (Pan),PIK3CA C378R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,12/24/2015
0,12/24/2015,PIK3CA inhibitor,182,7247,PIK3CA inhibitor,PIK3CA C378R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,12/24/2015
0,12/24/2015,Akt Inhibitor (Pan),4,7248,Akt Inhibitor (Pan),PIK3CA D350G,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,12/24/2015
0,12/24/2015,Akt1 Inhibitor,6,7249,Akt1 Inhibitor,PIK3CA D350G,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,12/24/2015
0,12/24/2015,Akt2 Inhibitor,7,7250,Akt2 Inhibitor,PIK3CA D350G,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,12/24/2015
0,12/24/2015,Akt3 Inhibitor,8,7251,Akt3 Inhibitor,PIK3CA D350G,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,12/24/2015
0,12/24/2015,mTOR Inhibitor,152,7252,mTOR Inhibitor,PIK3CA D350G,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,12/24/2015
0,12/24/2015,mTORC1 Inhibitor,153,7253,mTORC1 Inhibitor,PIK3CA D350G,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,12/24/2015
0,12/24/2015,mTORC2 Inhibitor,154,7254,mTORC2 Inhibitor,PIK3CA D350G,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,12/24/2015
0,12/24/2015,PI3K Inhibitor (Pan),181,7255,PI3K Inhibitor (Pan),PIK3CA D350G,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,12/24/2015
0,12/24/2015,PIK3CA inhibitor,182,7256,PIK3CA inhibitor,PIK3CA D350G,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,12/24/2015
0,12/24/2015,Akt Inhibitor (Pan),4,7257,Akt Inhibitor (Pan),PIK3CA G364R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,12/24/2015
0,12/24/2015,Akt1 Inhibitor,6,7258,Akt1 Inhibitor,PIK3CA G364R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,12/24/2015
0,12/24/2015,Akt2 Inhibitor,7,7259,Akt2 Inhibitor,PIK3CA G364R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,12/24/2015
0,12/24/2015,Akt3 Inhibitor,8,7260,Akt3 Inhibitor,PIK3CA G364R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,12/24/2015
0,12/24/2015,mTOR Inhibitor,152,7261,mTOR Inhibitor,PIK3CA G364R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,12/24/2015
0,12/24/2015,mTORC1 Inhibitor,153,7262,mTORC1 Inhibitor,PIK3CA G364R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,12/24/2015
0,12/24/2015,mTORC2 Inhibitor,154,7263,mTORC2 Inhibitor,PIK3CA G364R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,12/24/2015
0,12/24/2015,PI3K Inhibitor (Pan),181,7264,PI3K Inhibitor (Pan),PIK3CA G364R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,12/24/2015
0,12/24/2015,PIK3CA inhibitor,182,7265,PIK3CA inhibitor,PIK3CA G364R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,12/24/2015
0,12/24/2015,Akt Inhibitor (Pan),4,7266,Akt Inhibitor (Pan),PIK3CA R93W,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,12/24/2015
0,12/24/2015,Akt1 Inhibitor,6,7267,Akt1 Inhibitor,PIK3CA R93W,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,12/24/2015
0,12/24/2015,Akt2 Inhibitor,7,7268,Akt2 Inhibitor,PIK3CA R93W,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,12/24/2015
0,12/24/2015,Akt3 Inhibitor,8,7269,Akt3 Inhibitor,PIK3CA R93W,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,12/24/2015
0,12/24/2015,mTOR Inhibitor,152,7270,mTOR Inhibitor,PIK3CA R93W,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,12/24/2015
0,12/24/2015,mTORC1 Inhibitor,153,7271,mTORC1 Inhibitor,PIK3CA R93W,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,12/24/2015
0,12/24/2015,mTORC2 Inhibitor,154,7272,mTORC2 Inhibitor,PIK3CA R93W,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,12/24/2015
0,12/24/2015,PI3K Inhibitor (Pan),181,7273,PI3K Inhibitor (Pan),PIK3CA R93W,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,12/24/2015
0,12/24/2015,PIK3CA inhibitor,182,7274,PIK3CA inhibitor,PIK3CA R93W,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,12/24/2015
0,12/30/2015,FLT3 Inhibitor,96,7280,FLT3 Inhibitor,CBL H398Y,"[{'id': 3301, 'pubMedId': 25477533, 'title': 'Molecular pathways: cbl proteins in tumorigenesis and antitumor immunity-opportunities for cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25477533'}, {'id': 3302, 'pubMedId': 22990016, 'title': 'Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22990016'}]",,12/30/2015
0,01/04/2016,SRC Inhibitor,209,7283,SRC Inhibitor,CSF3R Y752*,"[{'id': 3951, 'pubMedId': 23656643, 'title': 'Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23656643'}, {'id': 4003, 'pubMedId': 26366092, 'title': 'Chronic neutrophilic leukemia: a clinical perspective.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26366092'}]",,01/04/2016
0,01/08/2016,IGF-1R Inhibitor,120,7313,IGF-1R Inhibitor,ETV6-NTRK3,"[{'id': 3183, 'pubMedId': 21148487, 'title': 'ETV6-NTRK3-mediated breast epithelial cell transformation is blocked by targeting the IGF1R signaling pathway.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21148487'}, {'id': 4256, 'pubMedId': 21804605, 'title': 'A tripartite complex composed of ETV6-NTRK3, IRS1 and IGF1R is required for ETV6-NTRK3-mediated membrane localization and transformation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21804605'}]",,01/08/2016
0,01/10/2016,HDAC Inhibitor,104,7314,HDAC Inhibitor,RB1 K740*,"[{'id': 2739, 'pubMedId': 22293180, 'title': 'Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22293180'}]",,01/10/2016
0,01/10/2016,HDAC Inhibitor,104,7315,HDAC Inhibitor,RB1 L607I,"[{'id': 2739, 'pubMedId': 22293180, 'title': 'Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22293180'}]",,01/10/2016
0,01/10/2016,HDAC Inhibitor,104,7316,HDAC Inhibitor,RB1 E137*,"[{'id': 2739, 'pubMedId': 22293180, 'title': 'Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22293180'}]",,01/10/2016
0,01/10/2016,HDAC Inhibitor,104,7317,HDAC Inhibitor,RB1 R455*,"[{'id': 2739, 'pubMedId': 22293180, 'title': 'Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22293180'}]",,01/10/2016
0,01/10/2016,HDAC Inhibitor,104,7318,HDAC Inhibitor,RB1 R579*,"[{'id': 2739, 'pubMedId': 22293180, 'title': 'Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22293180'}]",,01/10/2016
0,01/10/2016,HDAC Inhibitor,104,7319,HDAC Inhibitor,RB1 E554*,"[{'id': 2739, 'pubMedId': 22293180, 'title': 'Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22293180'}]",,01/10/2016
0,01/10/2016,HDAC Inhibitor,104,7320,HDAC Inhibitor,RB1 Q62*,"[{'id': 2739, 'pubMedId': 22293180, 'title': 'Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22293180'}]",,01/10/2016
0,01/11/2016,GLI1/2 inhibitor,100,7321,GLI1/2 inhibitor,SMO act mut,"[{'id': 4281, 'pubMedId': 26080084, 'title': 'Digging a hole under Hedgehog: downstream inhibition as an emerging anticancer strategy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26080084'}]",,01/11/2016
0,01/13/2016,p53 Activator,166,7343,p53 Activator,TP53 I251S,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,01/13/2016
0,01/13/2016,p53 Gene Therapy,167,7344,p53 Gene Therapy,TP53 I251S,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,01/13/2016
0,01/13/2016,p53 Activator,166,7345,p53 Activator,TP53 Y327L,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,01/13/2016
0,01/13/2016,p53 Gene Therapy,167,7346,p53 Gene Therapy,TP53 Y327L,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,01/13/2016
0,01/13/2016,p53 Activator,166,7347,p53 Activator,TP53 Y234C,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,01/13/2016
0,01/13/2016,p53 Gene Therapy,167,7348,p53 Gene Therapy,TP53 Y234C,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,01/13/2016
0,01/14/2016,SHP2 Inhibitor,203,7349,SHP2 Inhibitor,PTPN11 act mut,"[{'id': 4299, 'pubMedId': 23825065, 'title': 'Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23825065'}, {'id': 4326, 'pubMedId': 25877780, 'title': 'Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in\u2005vitro and in\u2005vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25877780'}]",,01/14/2016
0,01/14/2016,SHP2 Inhibitor,203,7350,SHP2 Inhibitor,PTPN11 E76K,"[{'id': 4299, 'pubMedId': 23825065, 'title': 'Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23825065'}, {'id': 4326, 'pubMedId': 25877780, 'title': 'Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in\u2005vitro and in\u2005vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25877780'}]",,01/14/2016
0,01/14/2016,SHP2 Inhibitor,203,7351,SHP2 Inhibitor,PTPN11 A72D,"[{'id': 4299, 'pubMedId': 23825065, 'title': 'Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23825065'}, {'id': 4326, 'pubMedId': 25877780, 'title': 'Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in\u2005vitro and in\u2005vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25877780'}]",,01/14/2016
0,01/14/2016,SHP2 Inhibitor,203,7352,SHP2 Inhibitor,PTPN11 A72S,"[{'id': 4299, 'pubMedId': 23825065, 'title': 'Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23825065'}, {'id': 4326, 'pubMedId': 25877780, 'title': 'Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in\u2005vitro and in\u2005vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25877780'}]",,01/14/2016
0,01/14/2016,SHP2 Inhibitor,203,7353,SHP2 Inhibitor,PTPN11 A72V,"[{'id': 4299, 'pubMedId': 23825065, 'title': 'Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23825065'}, {'id': 4326, 'pubMedId': 25877780, 'title': 'Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in\u2005vitro and in\u2005vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25877780'}]",,01/14/2016
0,01/14/2016,SHP2 Inhibitor,203,7354,SHP2 Inhibitor,PTPN11 E69K,"[{'id': 4299, 'pubMedId': 23825065, 'title': 'Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23825065'}, {'id': 4326, 'pubMedId': 25877780, 'title': 'Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in\u2005vitro and in\u2005vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25877780'}]",,01/14/2016
0,01/14/2016,SHP2 Inhibitor,203,7355,SHP2 Inhibitor,PTPN11 E76G,"[{'id': 4299, 'pubMedId': 23825065, 'title': 'Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23825065'}, {'id': 4326, 'pubMedId': 25877780, 'title': 'Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in\u2005vitro and in\u2005vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25877780'}]",,01/14/2016
0,01/14/2016,SHP2 Inhibitor,203,7356,SHP2 Inhibitor,PTPN11 G503V,"[{'id': 4299, 'pubMedId': 23825065, 'title': 'Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23825065'}, {'id': 4326, 'pubMedId': 25877780, 'title': 'Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in\u2005vitro and in\u2005vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25877780'}]",,01/14/2016
0,01/14/2016,SHP2 Inhibitor,203,7357,SHP2 Inhibitor,PTPN11 G60R,"[{'id': 4299, 'pubMedId': 23825065, 'title': 'Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23825065'}, {'id': 4326, 'pubMedId': 25877780, 'title': 'Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in\u2005vitro and in\u2005vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25877780'}]",,01/14/2016
0,01/14/2016,SHP2 Inhibitor,203,7358,SHP2 Inhibitor,PTPN11 N308D,"[{'id': 4299, 'pubMedId': 23825065, 'title': 'Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23825065'}, {'id': 4326, 'pubMedId': 25877780, 'title': 'Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in\u2005vitro and in\u2005vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25877780'}]",,01/14/2016
0,01/14/2016,SHP2 Inhibitor,203,7359,SHP2 Inhibitor,PTPN11 N58S,"[{'id': 4299, 'pubMedId': 23825065, 'title': 'Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23825065'}, {'id': 4326, 'pubMedId': 25877780, 'title': 'Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in\u2005vitro and in\u2005vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25877780'}]",,01/14/2016
0,01/14/2016,Akt Inhibitor (Pan),4,7360,Akt Inhibitor (Pan),PIK3CA N1044K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,01/14/2016
0,01/14/2016,Akt1 Inhibitor,6,7361,Akt1 Inhibitor,PIK3CA N1044K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,01/14/2016
0,01/14/2016,Akt2 Inhibitor,7,7362,Akt2 Inhibitor,PIK3CA N1044K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,01/14/2016
0,01/14/2016,Akt3 Inhibitor,8,7363,Akt3 Inhibitor,PIK3CA N1044K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,01/14/2016
0,01/14/2016,mTOR Inhibitor,152,7364,mTOR Inhibitor,PIK3CA N1044K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,01/14/2016
0,01/14/2016,mTORC1 Inhibitor,153,7365,mTORC1 Inhibitor,PIK3CA N1044K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,01/14/2016
0,01/14/2016,mTORC2 Inhibitor,154,7366,mTORC2 Inhibitor,PIK3CA N1044K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,01/14/2016
0,01/14/2016,PI3K Inhibitor (Pan),181,7367,PI3K Inhibitor (Pan),PIK3CA N1044K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,01/14/2016
0,01/14/2016,PIK3CA inhibitor,182,7368,PIK3CA inhibitor,PIK3CA N1044K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,01/14/2016
0,01/14/2016,Akt Inhibitor (Pan),4,7369,Akt Inhibitor (Pan),PIK3CA N345I,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,01/14/2016
0,01/14/2016,Akt1 Inhibitor,6,7370,Akt1 Inhibitor,PIK3CA N345I,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,01/14/2016
0,01/14/2016,Akt2 Inhibitor,7,7371,Akt2 Inhibitor,PIK3CA N345I,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,01/14/2016
0,01/14/2016,Akt3 Inhibitor,8,7372,Akt3 Inhibitor,PIK3CA N345I,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,01/14/2016
0,01/14/2016,mTOR Inhibitor,152,7373,mTOR Inhibitor,PIK3CA N345I,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,01/14/2016
0,01/14/2016,mTORC1 Inhibitor,153,7374,mTORC1 Inhibitor,PIK3CA N345I,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,01/14/2016
0,01/14/2016,mTORC2 Inhibitor,154,7375,mTORC2 Inhibitor,PIK3CA N345I,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,01/14/2016
0,01/14/2016,PI3K Inhibitor (Pan),181,7376,PI3K Inhibitor (Pan),PIK3CA N345I,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,01/14/2016
0,01/14/2016,PIK3CA inhibitor,182,7377,PIK3CA inhibitor,PIK3CA N345I,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,01/14/2016
0,01/14/2016,Akt Inhibitor (Pan),4,7379,Akt Inhibitor (Pan),PIK3CA Q546R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,01/14/2016
0,01/14/2016,Akt1 Inhibitor,6,7380,Akt1 Inhibitor,PIK3CA Q546R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,01/14/2016
0,01/14/2016,Akt2 Inhibitor,7,7381,Akt2 Inhibitor,PIK3CA Q546R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,01/14/2016
0,01/14/2016,Akt3 Inhibitor,8,7382,Akt3 Inhibitor,PIK3CA Q546R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,01/14/2016
0,01/14/2016,mTOR Inhibitor,152,7383,mTOR Inhibitor,PIK3CA Q546R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,01/14/2016
0,01/14/2016,mTORC1 Inhibitor,153,7384,mTORC1 Inhibitor,PIK3CA Q546R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,01/14/2016
0,01/14/2016,mTORC2 Inhibitor,154,7385,mTORC2 Inhibitor,PIK3CA Q546R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,01/14/2016
0,01/14/2016,PI3K Inhibitor (Pan),181,7386,PI3K Inhibitor (Pan),PIK3CA Q546R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,01/14/2016
0,01/14/2016,PIK3CA inhibitor,182,7387,PIK3CA inhibitor,PIK3CA Q546R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,01/14/2016
0,01/14/2016,p53 Activator,166,7388,p53 Activator,TP53 P151S,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,01/14/2016
0,01/14/2016,p53 Gene Therapy,167,7389,p53 Gene Therapy,TP53 P151S,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,01/14/2016
0,01/14/2016,p53 Activator,166,7390,p53 Activator,TP53 P278S,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,01/14/2016
0,01/14/2016,p53 Gene Therapy,167,7391,p53 Gene Therapy,TP53 P278S,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,01/14/2016
0,01/14/2016,p53 Gene Therapy,167,7392,p53 Gene Therapy,TP53 R196*,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,01/14/2016
0,01/14/2016,p53 Activator,166,7393,p53 Activator,TP53 S241F,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,01/14/2016
0,01/14/2016,p53 Gene Therapy,167,7394,p53 Gene Therapy,TP53 S241F,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,01/14/2016
0,01/14/2016,p53 Activator,166,7395,p53 Activator,TP53 V272M,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,01/14/2016
0,01/14/2016,p53 Gene Therapy,167,7396,p53 Gene Therapy,TP53 V272M,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,01/14/2016
0,01/14/2016,p53 Gene Therapy,167,7397,p53 Gene Therapy,TP53 Y103*,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,01/14/2016
0,01/14/2016,p53 Gene Therapy,167,7398,p53 Gene Therapy,TP53 E198*,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,01/14/2016
0,01/14/2016,p53 Gene Therapy,167,7399,p53 Gene Therapy,TP53 F212fs*3,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,01/14/2016
0,01/15/2016,p53 Activator,166,7401,p53 Activator,TP53 H179N,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,01/15/2016
0,01/15/2016,p53 Gene Therapy,167,7402,p53 Gene Therapy,TP53 H179N,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,01/15/2016
0,01/18/2016,mTORC1 Inhibitor,153,7413,mTORC1 Inhibitor,FBXW7 G499Vfs*25,"[{'id': 571, 'pubMedId': 18787170, 'title': 'FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18787170'}, {'id': 2558, 'pubMedId': 24586741, 'title': 'FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24586741'}]",,01/18/2016
0,01/18/2016,FLT3 Inhibitor,96,7414,FLT3 Inhibitor,FLT3 D600_L601insDFREYEYD,"[{'id': 705, 'pubMedId': 11756186, 'title': 'FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11756186'}, {'id': 2547, 'pubMedId': 17124058, 'title': 'FLT3 mutations: biology and treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17124058'}, {'id': 2548, 'pubMedId': 25231999, 'title': 'Targeting FLT3 to treat leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25231999'}]",,01/18/2016
0,01/18/2016,EZH2 inhibitor,84,7417,EZH2 inhibitor,EZH2 Y641F,"[{'id': 149, 'pubMedId': 24362326, 'title': 'EZH2: biology, disease, and structure-based drug discovery.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24362326'}, {'id': 1237, 'pubMedId': 24183969, 'title': 'Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24183969'}]",,01/18/2016
0,01/18/2016,EZH2 inhibitor,84,7418,EZH2 inhibitor,EZH2 Y646F,"[{'id': 149, 'pubMedId': 24362326, 'title': 'EZH2: biology, disease, and structure-based drug discovery.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24362326'}, {'id': 1237, 'pubMedId': 24183969, 'title': 'Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24183969'}]",,01/18/2016
0,01/18/2016,EZH2 inhibitor,84,7419,EZH2 inhibitor,EZH2 Y646H,"[{'id': 149, 'pubMedId': 24362326, 'title': 'EZH2: biology, disease, and structure-based drug discovery.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24362326'}, {'id': 1237, 'pubMedId': 24183969, 'title': 'Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24183969'}]",,01/18/2016
0,01/18/2016,EZH2 inhibitor,84,7420,EZH2 inhibitor,EZH2 Y646S,"[{'id': 149, 'pubMedId': 24362326, 'title': 'EZH2: biology, disease, and structure-based drug discovery.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24362326'}, {'id': 1237, 'pubMedId': 24183969, 'title': 'Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24183969'}]",,01/18/2016
0,01/20/2016,CTNNB1 Inhibitor,60,7421,CTNNB1 Inhibitor,APC A1485fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,01/20/2016
0,01/20/2016,Tankyrase Inhibitor,215,7422,Tankyrase Inhibitor,APC A1485fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,01/20/2016
0,01/20/2016,CTNNB1 Inhibitor,60,7423,CTNNB1 Inhibitor,APC E658*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,01/20/2016
0,01/20/2016,Tankyrase Inhibitor,215,7424,Tankyrase Inhibitor,APC E658*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,01/20/2016
0,01/20/2016,CTNNB1 Inhibitor,60,7425,CTNNB1 Inhibitor,APC P1483fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,01/20/2016
0,01/20/2016,Tankyrase Inhibitor,215,7426,Tankyrase Inhibitor,APC P1483fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,01/20/2016
0,01/20/2016,CTNNB1 Inhibitor,60,7427,CTNNB1 Inhibitor,APC Q424*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,01/20/2016
0,01/20/2016,Tankyrase Inhibitor,215,7428,Tankyrase Inhibitor,APC Q424*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,01/20/2016
0,01/20/2016,CTNNB1 Inhibitor,60,7429,CTNNB1 Inhibitor,APC R405*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,01/20/2016
0,01/20/2016,Tankyrase Inhibitor,215,7430,Tankyrase Inhibitor,APC R405*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,01/20/2016
0,01/20/2016,CTNNB1 Inhibitor,60,7431,CTNNB1 Inhibitor,APC T1493fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,01/20/2016
0,01/20/2016,Tankyrase Inhibitor,215,7432,Tankyrase Inhibitor,APC T1493fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,01/20/2016
0,01/21/2016,PARP Inhibitor (Pan),171,7440,PARP Inhibitor (Pan),BRCA1 K654fs,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,01/21/2016
0,01/21/2016,PARP-1 Inhibitor,172,7441,PARP-1 Inhibitor,BRCA1 K654fs,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,01/21/2016
0,01/22/2016,,7443,U0126,FGFR3-TACC3,"[{'id': 3393, 'pubMedId': 23298836, 'title': 'The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23298836'}]",2427,U0126,01/22/2016
0,01/22/2016,FGFR Inhibitor (Pan),89,7444,FGFR Inhibitor (Pan),FGFR1 K656E,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/22/2016
0,01/22/2016,FGFR1 Inhibitor,90,7445,FGFR1 Inhibitor,FGFR1 K656E,"[{'id': 1901, 'pubMedId': 24980830, 'title': 'Discovery of novel non-ATP competitive FGFR1 inhibitors and evaluation of their anti-tumor activity in non-small cell lung cancer in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24980830'}]",,01/22/2016
0,01/22/2016,FGFR Inhibitor (Pan),89,7446,FGFR Inhibitor (Pan),FGFR1 P252S,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/22/2016
0,01/22/2016,FGFR1 Inhibitor,90,7447,FGFR1 Inhibitor,FGFR1 P252S,"[{'id': 1901, 'pubMedId': 24980830, 'title': 'Discovery of novel non-ATP competitive FGFR1 inhibitors and evaluation of their anti-tumor activity in non-small cell lung cancer in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24980830'}]",,01/22/2016
0,01/22/2016,FGFR1 Inhibitor,90,7448,FGFR1 Inhibitor,FGFR1 P252T,"[{'id': 1901, 'pubMedId': 24980830, 'title': 'Discovery of novel non-ATP competitive FGFR1 inhibitors and evaluation of their anti-tumor activity in non-small cell lung cancer in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24980830'}]",,01/22/2016
0,01/22/2016,FGFR Inhibitor (Pan),89,7449,FGFR Inhibitor (Pan),FGFR1 P252T,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/22/2016
0,01/22/2016,FGFR1 Inhibitor,90,7450,FGFR1 Inhibitor,FGFR1 N546K,"[{'id': 1901, 'pubMedId': 24980830, 'title': 'Discovery of novel non-ATP competitive FGFR1 inhibitors and evaluation of their anti-tumor activity in non-small cell lung cancer in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24980830'}]",,01/22/2016
0,01/22/2016,FGFR Inhibitor (Pan),89,7451,FGFR Inhibitor (Pan),FGFR1 N546K,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/22/2016
0,01/22/2016,FGFR1 Inhibitor,90,7452,FGFR1 Inhibitor,FGFR1-TACC1,"[{'id': 1901, 'pubMedId': 24980830, 'title': 'Discovery of novel non-ATP competitive FGFR1 inhibitors and evaluation of their anti-tumor activity in non-small cell lung cancer in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24980830'}]",,01/22/2016
0,01/22/2016,FGFR Inhibitor (Pan),89,7453,FGFR Inhibitor (Pan),FGFR1-TACC1,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/22/2016
0,01/22/2016,FGFR1 Inhibitor,90,7454,FGFR1 Inhibitor,FGFR1 V561M,"[{'id': 1901, 'pubMedId': 24980830, 'title': 'Discovery of novel non-ATP competitive FGFR1 inhibitors and evaluation of their anti-tumor activity in non-small cell lung cancer in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24980830'}]",,01/22/2016
0,01/22/2016,FGFR Inhibitor (Pan),89,7455,FGFR Inhibitor (Pan),FGFR1 V561M,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/22/2016
0,01/22/2016,FGFR2 Inhibitor,92,7456,FGFR2 Inhibitor,FGFR2 N549K,"[{'id': 1903, 'pubMedId': 19212647, 'title': 'FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19212647'}]",,01/22/2016
0,01/22/2016,FGFR Inhibitor (Pan),89,7457,FGFR Inhibitor (Pan),FGFR2 N549K,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/22/2016
0,01/22/2016,FGFR Inhibitor (Pan),89,7458,FGFR Inhibitor (Pan),FGFR2 C382R,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/22/2016
0,01/22/2016,FGFR2 Inhibitor,92,7459,FGFR2 Inhibitor,FGFR2 C382R,"[{'id': 1903, 'pubMedId': 19212647, 'title': 'FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19212647'}]",,01/22/2016
0,01/22/2016,FGFR2 Inhibitor,92,7460,FGFR2 Inhibitor,FGFR2 S373C,"[{'id': 1903, 'pubMedId': 19212647, 'title': 'FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19212647'}]",,01/22/2016
0,01/22/2016,FGFR Inhibitor (Pan),89,7461,FGFR Inhibitor (Pan),FGFR2 S373C,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/22/2016
0,01/22/2016,FGFR2 Inhibitor,92,7462,FGFR2 Inhibitor,FGFR2 D101Y,"[{'id': 1903, 'pubMedId': 19212647, 'title': 'FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19212647'}]",,01/22/2016
0,01/22/2016,FGFR Inhibitor (Pan),89,7463,FGFR Inhibitor (Pan),FGFR2 D101Y,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/22/2016
0,01/22/2016,FGFR Inhibitor (Pan),89,7464,FGFR Inhibitor (Pan),FGFR2 K660E,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/22/2016
0,01/22/2016,FGFR2 Inhibitor,92,7465,FGFR2 Inhibitor,FGFR2 K660E,"[{'id': 1903, 'pubMedId': 19212647, 'title': 'FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19212647'}]",,01/22/2016
0,01/22/2016,FGFR2 Inhibitor,92,7466,FGFR2 Inhibitor,FGFR2 L617F,"[{'id': 1903, 'pubMedId': 19212647, 'title': 'FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19212647'}]",,01/22/2016
0,01/22/2016,FGFR Inhibitor (Pan),89,7467,FGFR Inhibitor (Pan),FGFR2 L617F,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/22/2016
0,01/22/2016,FGFR Inhibitor (Pan),89,7468,FGFR Inhibitor (Pan),FGFR2 N550H,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/22/2016
0,01/22/2016,FGFR2 Inhibitor,92,7469,FGFR2 Inhibitor,FGFR2 N550H,"[{'id': 1903, 'pubMedId': 19212647, 'title': 'FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19212647'}]",,01/22/2016
0,01/22/2016,FGFR2 Inhibitor,92,7470,FGFR2 Inhibitor,FGFR2 N550K,"[{'id': 1903, 'pubMedId': 19212647, 'title': 'FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19212647'}]",,01/22/2016
0,01/22/2016,FGFR Inhibitor (Pan),89,7471,FGFR Inhibitor (Pan),FGFR2 N550K,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/22/2016
0,01/22/2016,FGFR2 Inhibitor,92,7472,FGFR2 Inhibitor,FGFR2 S252W,"[{'id': 1903, 'pubMedId': 19212647, 'title': 'FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19212647'}]",,01/22/2016
0,01/22/2016,FGFR Inhibitor (Pan),89,7473,FGFR Inhibitor (Pan),FGFR2 S252W,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/22/2016
0,01/22/2016,FGFR Inhibitor (Pan),89,7474,FGFR Inhibitor (Pan),FGFR2 Y376C,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/22/2016
0,01/22/2016,FGFR2 Inhibitor,92,7475,FGFR2 Inhibitor,FGFR2 Y376C,"[{'id': 1903, 'pubMedId': 19212647, 'title': 'FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19212647'}]",,01/22/2016
0,01/22/2016,FGFR2 Inhibitor,92,7476,FGFR2 Inhibitor,FGFR2 R203C,"[{'id': 1903, 'pubMedId': 19212647, 'title': 'FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19212647'}]",,01/22/2016
0,01/22/2016,FGFR Inhibitor (Pan),89,7477,FGFR Inhibitor (Pan),FGFR2 R203C,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/22/2016
0,01/22/2016,FGFR Inhibitor (Pan),89,7478,FGFR Inhibitor (Pan),FGFR2 W290C,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/22/2016
0,01/22/2016,FGFR2 Inhibitor,92,7479,FGFR2 Inhibitor,FGFR2 W290C,"[{'id': 1903, 'pubMedId': 19212647, 'title': 'FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19212647'}]",,01/22/2016
0,01/22/2016,FGFR Inhibitor (Pan),89,7480,FGFR Inhibitor (Pan),FGFR2 Y375C,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/22/2016
0,01/22/2016,FGFR2 Inhibitor,92,7481,FGFR2 Inhibitor,FGFR2 Y375C,"[{'id': 1903, 'pubMedId': 19212647, 'title': 'FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19212647'}]",,01/22/2016
0,01/22/2016,FGFR Inhibitor (Pan),89,7482,FGFR Inhibitor (Pan),FGFR2 C293R,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/22/2016
0,01/22/2016,FGFR2 Inhibitor,92,7483,FGFR2 Inhibitor,FGFR2 C293R,"[{'id': 1903, 'pubMedId': 19212647, 'title': 'FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19212647'}]",,01/22/2016
0,01/22/2016,FGFR Inhibitor (Pan),89,7484,FGFR Inhibitor (Pan),FGFR2 N460K,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/22/2016
0,01/22/2016,FGFR2 Inhibitor,92,7485,FGFR2 Inhibitor,FGFR2 N460K,"[{'id': 1903, 'pubMedId': 19212647, 'title': 'FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19212647'}]",,01/22/2016
0,01/22/2016,FGFR2 Inhibitor,92,7486,FGFR2 Inhibitor,FGFR2 N547K,"[{'id': 1903, 'pubMedId': 19212647, 'title': 'FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19212647'}]",,01/22/2016
0,01/22/2016,FGFR Inhibitor (Pan),89,7487,FGFR Inhibitor (Pan),FGFR2 N547K,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/22/2016
0,01/22/2016,FGFR2 Inhibitor,92,7488,FGFR2 Inhibitor,FGFR2 P164R,"[{'id': 1903, 'pubMedId': 19212647, 'title': 'FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19212647'}]",,01/22/2016
0,01/22/2016,FGFR Inhibitor (Pan),89,7489,FGFR Inhibitor (Pan),FGFR2 P164R,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/22/2016
0,01/22/2016,FGFR2 Inhibitor,92,7490,FGFR2 Inhibitor,FGFR2 N550S,"[{'id': 1903, 'pubMedId': 19212647, 'title': 'FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19212647'}]",,01/22/2016
0,01/22/2016,FGFR Inhibitor (Pan),89,7491,FGFR Inhibitor (Pan),FGFR2 N550S,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/22/2016
0,01/22/2016,FGFR2 Inhibitor,92,7492,FGFR2 Inhibitor,FGFR2 N550T,"[{'id': 1903, 'pubMedId': 19212647, 'title': 'FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19212647'}]",,01/22/2016
0,01/22/2016,FGFR Inhibitor (Pan),89,7493,FGFR Inhibitor (Pan),FGFR2 N550T,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/22/2016
0,01/22/2016,FGFR2 Inhibitor,92,7494,FGFR2 Inhibitor,FGFR2 E566G,"[{'id': 1903, 'pubMedId': 19212647, 'title': 'FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19212647'}]",,01/22/2016
0,01/22/2016,FGFR Inhibitor (Pan),89,7495,FGFR Inhibitor (Pan),FGFR2 E566G,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/22/2016
0,01/22/2016,FGFR Inhibitor (Pan),89,7496,FGFR Inhibitor (Pan),FGFR2 K642N,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/22/2016
0,01/22/2016,FGFR2 Inhibitor,92,7497,FGFR2 Inhibitor,FGFR2 K642N,"[{'id': 1903, 'pubMedId': 19212647, 'title': 'FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19212647'}]",,01/22/2016
0,01/22/2016,FGFR Inhibitor (Pan),89,7498,FGFR Inhibitor (Pan),FGFR2 M536I,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/22/2016
0,01/22/2016,FGFR2 Inhibitor,92,7499,FGFR2 Inhibitor,FGFR2 M536I,"[{'id': 1903, 'pubMedId': 19212647, 'title': 'FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19212647'}]",,01/22/2016
0,01/22/2016,FGFR2 Inhibitor,92,7500,FGFR2 Inhibitor,FGFR2 M538I,"[{'id': 1903, 'pubMedId': 19212647, 'title': 'FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19212647'}]",,01/22/2016
0,01/22/2016,FGFR Inhibitor (Pan),89,7501,FGFR Inhibitor (Pan),FGFR2 M538I,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/22/2016
0,01/22/2016,FGFR2 Inhibitor,92,7502,FGFR2 Inhibitor,FGFR2 I548V,"[{'id': 1903, 'pubMedId': 19212647, 'title': 'FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19212647'}]",,01/22/2016
0,01/22/2016,FGFR Inhibitor (Pan),89,7503,FGFR Inhibitor (Pan),FGFR2 I548V,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/22/2016
0,01/22/2016,FGFR Inhibitor (Pan),89,7504,FGFR Inhibitor (Pan),FGFR2 V565I,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/22/2016
0,01/22/2016,FGFR2 Inhibitor,92,7505,FGFR2 Inhibitor,FGFR2 V565I,"[{'id': 1903, 'pubMedId': 19212647, 'title': 'FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19212647'}]",,01/22/2016
0,01/22/2016,FGFR2 Inhibitor,92,7506,FGFR2 Inhibitor,FGFR2 L618M,"[{'id': 1903, 'pubMedId': 19212647, 'title': 'FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19212647'}]",,01/22/2016
0,01/22/2016,FGFR Inhibitor (Pan),89,7507,FGFR Inhibitor (Pan),FGFR2 L618M,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/22/2016
0,01/22/2016,FGFR2 Inhibitor,92,7508,FGFR2 Inhibitor,FGFR2 S267_D273dup,"[{'id': 1903, 'pubMedId': 19212647, 'title': 'FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19212647'}]",,01/22/2016
0,01/22/2016,FGFR Inhibitor (Pan),89,7509,FGFR Inhibitor (Pan),FGFR2 S267_D273dup,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/22/2016
0,01/22/2016,FGFR2 Inhibitor,92,7510,FGFR2 Inhibitor,FGFR2 - TACC3,"[{'id': 1903, 'pubMedId': 19212647, 'title': 'FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19212647'}]",,01/22/2016
0,01/22/2016,FGFR Inhibitor (Pan),89,7511,FGFR Inhibitor (Pan),FGFR2 - TACC3,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/22/2016
0,01/22/2016,FGFR2 Inhibitor,92,7512,FGFR2 Inhibitor,FGFR2 C383R,"[{'id': 1903, 'pubMedId': 19212647, 'title': 'FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19212647'}]",,01/22/2016
0,01/22/2016,FGFR Inhibitor (Pan),89,7513,FGFR Inhibitor (Pan),FGFR2 C383R,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/22/2016
0,01/22/2016,FGFR2 Inhibitor,92,7514,FGFR2 Inhibitor,FGFR2 P253R,"[{'id': 1903, 'pubMedId': 19212647, 'title': 'FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19212647'}]",,01/22/2016
0,01/22/2016,FGFR Inhibitor (Pan),89,7515,FGFR Inhibitor (Pan),FGFR2 P253R,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/22/2016
0,01/22/2016,FGFR2 Inhibitor,92,7516,FGFR2 Inhibitor,FGFR2 E566A,"[{'id': 1903, 'pubMedId': 19212647, 'title': 'FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19212647'}]",,01/22/2016
0,01/22/2016,FGFR Inhibitor (Pan),89,7517,FGFR Inhibitor (Pan),FGFR2 E566A,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/22/2016
0,01/22/2016,FGFR Inhibitor (Pan),89,7518,FGFR Inhibitor (Pan),FGFR2 W290_I291delinsC,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/22/2016
0,01/22/2016,FGFR2 Inhibitor,92,7519,FGFR2 Inhibitor,FGFR2 W290_I291delinsC,"[{'id': 1903, 'pubMedId': 19212647, 'title': 'FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19212647'}]",,01/22/2016
0,01/22/2016,FGFR Inhibitor (Pan),89,7520,FGFR Inhibitor (Pan),FGFR3 K652E,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/22/2016
0,01/22/2016,FGFR3 Inhibitor,94,7521,FGFR3 Inhibitor,FGFR3 K652E,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}, {'id': 1907, 'pubMedId': 20439987, 'title': 'NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20439987'}]",,01/22/2016
0,01/22/2016,FGFR3 Inhibitor,94,7522,FGFR3 Inhibitor,FGFR3 Y375C,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}, {'id': 1907, 'pubMedId': 20439987, 'title': 'NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20439987'}]",,01/22/2016
0,01/22/2016,FGFR Inhibitor (Pan),89,7523,FGFR Inhibitor (Pan),FGFR3 Y375C,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/22/2016
0,01/22/2016,FGFR3 Inhibitor,94,7524,FGFR3 Inhibitor,FGFR3 S249C,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}, {'id': 1907, 'pubMedId': 20439987, 'title': 'NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20439987'}]",,01/22/2016
0,01/22/2016,FGFR Inhibitor (Pan),89,7525,FGFR Inhibitor (Pan),FGFR3 S249C,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/22/2016
0,01/22/2016,FGFR3 Inhibitor,94,7526,FGFR3 Inhibitor,FGFR3 R248C,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}, {'id': 1907, 'pubMedId': 20439987, 'title': 'NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20439987'}]",,01/22/2016
0,01/22/2016,FGFR Inhibitor (Pan),89,7527,FGFR Inhibitor (Pan),FGFR3 R248C,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/22/2016
0,01/22/2016,FGFR3 Inhibitor,94,7528,FGFR3 Inhibitor,FGFR3 G372C,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}, {'id': 1907, 'pubMedId': 20439987, 'title': 'NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20439987'}]",,01/22/2016
0,01/22/2016,FGFR Inhibitor (Pan),89,7529,FGFR Inhibitor (Pan),FGFR3 G372C,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/22/2016
0,01/22/2016,FGFR Inhibitor (Pan),89,7530,FGFR Inhibitor (Pan),FGFR3 K650E,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/22/2016
0,01/22/2016,FGFR3 Inhibitor,94,7531,FGFR3 Inhibitor,FGFR3 K650E,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}, {'id': 1907, 'pubMedId': 20439987, 'title': 'NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20439987'}]",,01/22/2016
0,01/22/2016,FGFR Inhibitor (Pan),89,7532,FGFR Inhibitor (Pan),FGFR3 K650M,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/22/2016
0,01/22/2016,FGFR3 Inhibitor,94,7533,FGFR3 Inhibitor,FGFR3 K650M,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}, {'id': 1907, 'pubMedId': 20439987, 'title': 'NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20439987'}]",,01/22/2016
0,01/22/2016,FGFR Inhibitor (Pan),89,7534,FGFR Inhibitor (Pan),FGFR3 K650N,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/22/2016
0,01/22/2016,FGFR3 Inhibitor,94,7535,FGFR3 Inhibitor,FGFR3 K650N,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}, {'id': 1907, 'pubMedId': 20439987, 'title': 'NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20439987'}]",,01/22/2016
0,01/22/2016,FGFR3 Inhibitor,94,7536,FGFR3 Inhibitor,FGFR3 K650Q,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}, {'id': 1907, 'pubMedId': 20439987, 'title': 'NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20439987'}]",,01/22/2016
0,01/22/2016,FGFR Inhibitor (Pan),89,7537,FGFR Inhibitor (Pan),FGFR3 K650Q,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/22/2016
0,01/22/2016,FGFR3 Inhibitor,94,7538,FGFR3 Inhibitor,FGFR3 K650T,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}, {'id': 1907, 'pubMedId': 20439987, 'title': 'NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20439987'}]",,01/22/2016
0,01/22/2016,FGFR Inhibitor (Pan),89,7539,FGFR Inhibitor (Pan),FGFR3 K650T,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/22/2016
0,01/22/2016,FGFR Inhibitor (Pan),89,7540,FGFR Inhibitor (Pan),FGFR3 G370C,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/22/2016
0,01/22/2016,FGFR3 Inhibitor,94,7541,FGFR3 Inhibitor,FGFR3 G370C,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}, {'id': 1907, 'pubMedId': 20439987, 'title': 'NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20439987'}]",,01/22/2016
0,01/22/2016,FGFR3 Inhibitor,94,7542,FGFR3 Inhibitor,FGFR3 Y373C,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}, {'id': 1907, 'pubMedId': 20439987, 'title': 'NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20439987'}]",,01/22/2016
0,01/22/2016,FGFR Inhibitor (Pan),89,7543,FGFR Inhibitor (Pan),FGFR3 Y373C,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/22/2016
0,01/22/2016,FGFR Inhibitor (Pan),89,7544,FGFR Inhibitor (Pan),FGFR3 R200C,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/22/2016
0,01/22/2016,FGFR3 Inhibitor,94,7545,FGFR3 Inhibitor,FGFR3 R200C,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}, {'id': 1907, 'pubMedId': 20439987, 'title': 'NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20439987'}]",,01/22/2016
0,01/22/2016,FGFR3 Inhibitor,94,7546,FGFR3 Inhibitor,FGFR3 S371C,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}, {'id': 1907, 'pubMedId': 20439987, 'title': 'NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20439987'}]",,01/22/2016
0,01/22/2016,FGFR Inhibitor (Pan),89,7547,FGFR Inhibitor (Pan),FGFR3 S371C,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/22/2016
0,01/22/2016,FGFR3 Inhibitor,94,7548,FGFR3 Inhibitor,FGFR3 A391E,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}, {'id': 1907, 'pubMedId': 20439987, 'title': 'NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20439987'}]",,01/22/2016
0,01/22/2016,FGFR Inhibitor (Pan),89,7549,FGFR Inhibitor (Pan),FGFR3 A391E,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/22/2016
0,01/22/2016,FGFR3 Inhibitor,94,7550,FGFR3 Inhibitor,FGFR3 G380R,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}, {'id': 1907, 'pubMedId': 20439987, 'title': 'NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20439987'}]",,01/22/2016
0,01/22/2016,FGFR Inhibitor (Pan),89,7551,FGFR Inhibitor (Pan),FGFR3 G380R,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/22/2016
0,01/22/2016,FGFR Inhibitor (Pan),89,7554,FGFR Inhibitor (Pan),FGFR3 G382R,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/22/2016
0,01/22/2016,FGFR3 Inhibitor,94,7555,FGFR3 Inhibitor,FGFR3 G382R,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}, {'id': 1907, 'pubMedId': 20439987, 'title': 'NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20439987'}]",,01/22/2016
0,01/22/2016,FGFR3 Inhibitor,94,7556,FGFR3 Inhibitor,FGFR3-BAIAP2L1,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}, {'id': 1907, 'pubMedId': 20439987, 'title': 'NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20439987'}]",,01/22/2016
0,01/22/2016,FGFR Inhibitor (Pan),89,7557,FGFR Inhibitor (Pan),FGFR3-BAIAP2L1,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/22/2016
0,01/22/2016,FGFR Inhibitor (Pan),89,7558,FGFR Inhibitor (Pan),FGFR3 amp,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/22/2016
0,01/22/2016,FGFR3 Antibody,93,7559,FGFR3 Antibody,FGFR3 amp,"[{'id': 3211, 'pubMedId': 26078430, 'title': 'Targeting FGFR Signaling in Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26078430'}]",,01/22/2016
0,01/22/2016,FGFR3 Inhibitor,94,7560,FGFR3 Inhibitor,FGFR3 amp,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}, {'id': 1907, 'pubMedId': 20439987, 'title': 'NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20439987'}]",,01/22/2016
0,01/24/2016,PARP Inhibitor (Pan),171,7574,PARP Inhibitor (Pan),BRCA2 A1689fs,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,01/24/2016
0,01/24/2016,PARP-1 Inhibitor,172,7575,PARP-1 Inhibitor,BRCA2 A1689fs,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,01/24/2016
0,01/24/2016,PARP Inhibitor (Pan),171,7576,PARP Inhibitor (Pan),BRCA2 E350*,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,01/24/2016
0,01/24/2016,PARP-1 Inhibitor,172,7577,PARP-1 Inhibitor,BRCA2 E350*,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,01/24/2016
0,01/24/2016,KIT Inhibitor,136,7578,KIT Inhibitor,KIT L576del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,01/24/2016
0,01/24/2016,KIT Inhibitor,136,7579,KIT Inhibitor,KIT M551_W557del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,01/24/2016
0,01/25/2016,FGFR Inhibitor (Pan),89,7581,FGFR Inhibitor (Pan),FGFR2 K659E,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/25/2016
0,01/25/2016,FGFR2 Inhibitor,92,7582,FGFR2 Inhibitor,FGFR2 K659E,"[{'id': 1903, 'pubMedId': 19212647, 'title': 'FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19212647'}]",,01/25/2016
0,01/25/2016,HDAC Inhibitor,104,7592,HDAC Inhibitor,RB1 L797fs,"[{'id': 2739, 'pubMedId': 22293180, 'title': 'Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22293180'}]",,01/25/2016
0,01/25/2016,FGFR Inhibitor (Pan),89,7593,FGFR Inhibitor (Pan),FGFR2-BICC1,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/25/2016
0,01/25/2016,FGFR2 Inhibitor,92,7594,FGFR2 Inhibitor,FGFR2-BICC1,"[{'id': 1903, 'pubMedId': 19212647, 'title': 'FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19212647'}]",,01/25/2016
0,01/25/2016,FGFR Inhibitor (Pan),89,7595,FGFR Inhibitor (Pan),FGFR2-AHCYL1,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/25/2016
0,01/25/2016,FGFR2 Inhibitor,92,7596,FGFR2 Inhibitor,FGFR2-AHCYL1,"[{'id': 1903, 'pubMedId': 19212647, 'title': 'FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19212647'}]",,01/25/2016
0,01/25/2016,FGFR Inhibitor (Pan),89,7597,FGFR Inhibitor (Pan),FGFR2-CCDC6,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,01/25/2016
0,01/25/2016,FGFR2 Inhibitor,92,7598,FGFR2 Inhibitor,FGFR2-CCDC6,"[{'id': 1903, 'pubMedId': 19212647, 'title': 'FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19212647'}]",,01/25/2016
0,01/25/2016,p53 Gene Therapy,167,7599,p53 Gene Therapy,TP53 Y220C,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,01/25/2016
0,01/25/2016,p53 Activator,166,7600,p53 Activator,TP53 Y220C,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,01/25/2016
0,01/26/2016,p53 Activator,166,7606,p53 Activator,TP53 C176F,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,01/26/2016
0,01/26/2016,p53 Gene Therapy,167,7607,p53 Gene Therapy,TP53 C176F,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,01/26/2016
0,01/26/2016,p53 Activator,166,7610,p53 Activator,TP53 C135F,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,01/26/2016
0,01/26/2016,p53 Gene Therapy,167,7611,p53 Gene Therapy,TP53 C135F,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,01/26/2016
0,01/27/2016,p53 Activator,166,7612,p53 Activator,TP53 F134L,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,01/27/2016
0,01/27/2016,p53 Gene Therapy,167,7613,p53 Gene Therapy,TP53 F134L,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,01/27/2016
0,02/02/2016,KIT Inhibitor,136,7706,KIT Inhibitor,KIT V559K,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,02/02/2016
0,02/02/2016,KIT Inhibitor,136,7707,KIT Inhibitor,KIT V560_L576del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,02/02/2016
0,02/02/2016,KIT Inhibitor,136,7708,KIT Inhibitor,KIT V560del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,02/02/2016
0,02/02/2016,KIT Inhibitor,136,7709,KIT Inhibitor,KIT Y553_K558del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,02/02/2016
0,02/02/2016,KIT Inhibitor,136,7710,KIT Inhibitor,KIT Y570_L576del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,02/02/2016
0,02/02/2016,KIT Inhibitor,136,7711,KIT Inhibitor,KIT Y568_T574del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,02/02/2016
0,02/02/2016,KIT Inhibitor,136,7712,KIT Inhibitor,KIT Y578_D579del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,02/02/2016
0,02/04/2016,GLI1/2 inhibitor,100,7734,GLI1/2 inhibitor,SMO F460L,"[{'id': 4281, 'pubMedId': 26080084, 'title': 'Digging a hole under Hedgehog: downstream inhibition as an emerging anticancer strategy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26080084'}, {'id': 4523, 'pubMedId': 26053182, 'title': 'Targeting the Hedgehog signaling pathway in cancer: beyond Smoothened.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26053182'}]",,02/04/2016
0,02/04/2016,GLI1/2 inhibitor,100,7735,GLI1/2 inhibitor,SMO W535L,"[{'id': 4281, 'pubMedId': 26080084, 'title': 'Digging a hole under Hedgehog: downstream inhibition as an emerging anticancer strategy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26080084'}, {'id': 4523, 'pubMedId': 26053182, 'title': 'Targeting the Hedgehog signaling pathway in cancer: beyond Smoothened.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26053182'}]",,02/04/2016
0,02/04/2016,GLI1/2 inhibitor,100,7736,GLI1/2 inhibitor,SMO V321M,"[{'id': 4281, 'pubMedId': 26080084, 'title': 'Digging a hole under Hedgehog: downstream inhibition as an emerging anticancer strategy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26080084'}, {'id': 4523, 'pubMedId': 26053182, 'title': 'Targeting the Hedgehog signaling pathway in cancer: beyond Smoothened.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26053182'}]",,02/04/2016
0,02/04/2016,GLI1/2 inhibitor,100,7737,GLI1/2 inhibitor,SMO L412F,"[{'id': 4281, 'pubMedId': 26080084, 'title': 'Digging a hole under Hedgehog: downstream inhibition as an emerging anticancer strategy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26080084'}, {'id': 4523, 'pubMedId': 26053182, 'title': 'Targeting the Hedgehog signaling pathway in cancer: beyond Smoothened.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26053182'}]",,02/04/2016
0,02/08/2016,p53 Gene Therapy,167,7740,p53 Gene Therapy,TP53 R209fs,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,02/08/2016
0,02/09/2016,SRC Inhibitor,209,7743,SRC Inhibitor,SRC Q531*,"[{'id': 2477, 'pubMedId': 25662515, 'title': 'Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25662515'}, {'id': 2478, 'pubMedId': 21776389, 'title': 'Regulation of SRC family kinases in human cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21776389'}, {'id': 2479, 'pubMedId': 21521831, 'title': 'Current status of SRC inhibitors in solid tumor malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21521831'}]",,02/09/2016
0,02/11/2016,GLI1/2 inhibitor,100,7763,GLI1/2 inhibitor,SMO S533N,"[{'id': 4281, 'pubMedId': 26080084, 'title': 'Digging a hole under Hedgehog: downstream inhibition as an emerging anticancer strategy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26080084'}, {'id': 4523, 'pubMedId': 26053182, 'title': 'Targeting the Hedgehog signaling pathway in cancer: beyond Smoothened.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26053182'}]",,02/11/2016
0,02/12/2016,CDK6 Inhibitor,45,7816,CDK6 Inhibitor,CDKN2A loss,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,02/12/2016
0,02/12/2016,CDK Inhibitor (Pan),38,7817,CDK Inhibitor (Pan),CDKN2A loss,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,02/12/2016
0,02/12/2016,CDK4/6 Inhibitor,43,7818,CDK4/6 Inhibitor,CDKN2A loss,"[{'id': 2835, 'pubMedId': 24495407, 'title': 'Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24495407'}, {'id': 2948, 'pubMedId': 23898052, 'title': 'PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23898052'}]",,02/12/2016
0,02/12/2016,CDK4 Inhibitor,42,7819,CDK4 Inhibitor,CDKN2A loss,"[{'id': 2949, 'pubMedId': 18829975, 'title': 'The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18829975'}]",,02/12/2016
0,02/14/2016,CSF1R Inhibitor,59,7829,CSF1R Inhibitor,CSF1R D802V,"[{'id': 397, 'pubMedId': 18971950, 'title': 'Imatinib sensitivity as a consequence of a CSF1R-Y571D mutation and CSF1/CSF1R signaling abnormalities in the cell line GDM1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18971950'}, {'id': 3080, 'pubMedId': 24898549, 'title': 'Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24898549'}]",,02/14/2016
0,02/19/2016,EZH2 inhibitor,84,7856,EZH2 inhibitor,EZH2 S21D,"[{'id': 149, 'pubMedId': 24362326, 'title': 'EZH2: biology, disease, and structure-based drug discovery.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24362326'}, {'id': 1237, 'pubMedId': 24183969, 'title': 'Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24183969'}]",,02/19/2016
0,02/20/2016,IDH Inhibitor (Pan),117,7862,IDH Inhibitor (Pan),IDH1 Y139D,"[{'id': 2551, 'pubMedId': 25678837, 'title': 'New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25678837'}]",,02/20/2016
0,02/20/2016,IDH1 Inhibitor,118,7863,IDH1 Inhibitor,IDH1 Y139D,"[{'id': 2551, 'pubMedId': 25678837, 'title': 'New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25678837'}, {'id': 2552, 'pubMedId': 23558169, 'title': 'An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23558169'}]",,02/20/2016
0,02/23/2016,JAK Inhibitor (Pan) – ATP competitive,127,7874,JAK Inhibitor (Pan) – ATP competitive,CSF3R T640N,"[{'id': 3951, 'pubMedId': 23656643, 'title': 'Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23656643'}]",,02/23/2016
0,02/23/2016,JAK1 Inhibitor – ATP competitive,129,7875,JAK1 Inhibitor – ATP competitive,CSF3R T640N,"[{'id': 3951, 'pubMedId': 23656643, 'title': 'Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23656643'}]",,02/23/2016
0,02/23/2016,JAK2 Inhibitor – ATP competitive,131,7876,JAK2 Inhibitor – ATP competitive,CSF3R T640N,"[{'id': 3951, 'pubMedId': 23656643, 'title': 'Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23656643'}]",,02/23/2016
0,02/24/2016,p53 Activator,166,7882,p53 Activator,TP53 H168R,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,02/24/2016
0,02/24/2016,p53 Gene Therapy,167,7883,p53 Gene Therapy,TP53 H168R,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,02/24/2016
0,02/25/2016,FLT3 Inhibitor,96,7891,FLT3 Inhibitor,FLT3 N841I,"[{'id': 705, 'pubMedId': 11756186, 'title': 'FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11756186'}, {'id': 2547, 'pubMedId': 17124058, 'title': 'FLT3 mutations: biology and treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17124058'}, {'id': 2548, 'pubMedId': 25231999, 'title': 'Targeting FLT3 to treat leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25231999'}]",,02/25/2016
0,02/25/2016,FLT3 Inhibitor,96,7892,FLT3 Inhibitor,FLT3 F691L,"[{'id': 705, 'pubMedId': 11756186, 'title': 'FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11756186'}, {'id': 2547, 'pubMedId': 17124058, 'title': 'FLT3 mutations: biology and treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17124058'}, {'id': 2548, 'pubMedId': 25231999, 'title': 'Targeting FLT3 to treat leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25231999'}]",,02/25/2016
0,02/25/2016,MET Inhibitor,147,7893,MET Inhibitor,MET L1213V,"[{'id': 1994, 'pubMedId': 24045150, 'title': 'Met as a therapeutic target in HCC: facts and hopes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24045150'}]",,02/25/2016
0,02/25/2016,MET Inhibitor,147,7894,MET Inhibitor,MET Y1248H,"[{'id': 1994, 'pubMedId': 24045150, 'title': 'Met as a therapeutic target in HCC: facts and hopes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24045150'}]",,02/25/2016
0,02/25/2016,MET Inhibitor,147,7895,MET Inhibitor,MET V1206L,"[{'id': 1994, 'pubMedId': 24045150, 'title': 'Met as a therapeutic target in HCC: facts and hopes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24045150'}]",,02/25/2016
0,02/25/2016,MET Inhibitor,147,7896,MET Inhibitor,MET H1112R,"[{'id': 1994, 'pubMedId': 24045150, 'title': 'Met as a therapeutic target in HCC: facts and hopes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24045150'}]",,02/25/2016
0,02/25/2016,MET Inhibitor,147,7897,MET Inhibitor,MET Y1248C,"[{'id': 1994, 'pubMedId': 24045150, 'title': 'Met as a therapeutic target in HCC: facts and hopes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24045150'}]",,02/25/2016
0,02/25/2016,PARP Inhibitor (Pan),171,7898,PARP Inhibitor (Pan),ATM P2699S,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",,02/25/2016
0,02/25/2016,PARP Inhibitor (Pan),171,7899,PARP Inhibitor (Pan),ATM del,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",,02/25/2016
0,02/25/2016,GLI1/2 inhibitor,100,7900,GLI1/2 inhibitor,SMO K575M,"[{'id': 4281, 'pubMedId': 26080084, 'title': 'Digging a hole under Hedgehog: downstream inhibition as an emerging anticancer strategy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26080084'}]",,02/25/2016
0,02/25/2016,SMO Inhibitor,208,7901,SMO Inhibitor,SMO K575M,"[{'id': 2241, 'pubMedId': 24202394, 'title': 'Unraveling the therapeutic potential of the Hedgehog pathway in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24202394'}]",,02/25/2016
0,02/25/2016,MET Inhibitor,147,7902,MET Inhibitor,MET E168D,"[{'id': 1994, 'pubMedId': 24045150, 'title': 'Met as a therapeutic target in HCC: facts and hopes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24045150'}]",,02/25/2016
0,02/28/2016,FLT3 Inhibitor,96,7917,FLT3 Inhibitor,FLT3 N676K,"[{'id': 705, 'pubMedId': 11756186, 'title': 'FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11756186'}, {'id': 2547, 'pubMedId': 17124058, 'title': 'FLT3 mutations: biology and treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17124058'}, {'id': 2548, 'pubMedId': 25231999, 'title': 'Targeting FLT3 to treat leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25231999'}]",,02/28/2016
0,03/02/2016,CTNNB1 Inhibitor,60,7931,CTNNB1 Inhibitor,CTNNB1 H36P,"[{'id': 2251, 'pubMedId': 23258168, 'title': 'WNT signalling pathways as therapeutic targets in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23258168'}]",,03/02/2016
0,03/02/2016,PDPK1 Inhibitor,180,7932,PDPK1 Inhibitor,CTNNB1 H36P,"[{'id': 2220, 'pubMedId': 20028853, 'title': 'Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028853'}]",,03/02/2016
0,03/02/2016,Tankyrase Inhibitor,215,7933,Tankyrase Inhibitor,CTNNB1 H36P,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 2299, 'pubMedId': 23621985, 'title': 'Evidence for tankyrases as antineoplastic targets in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23621985'}]",,03/02/2016
0,03/02/2016,CTNNB1 Inhibitor,60,7934,CTNNB1 Inhibitor,CTNNB1 S45P,"[{'id': 2251, 'pubMedId': 23258168, 'title': 'WNT signalling pathways as therapeutic targets in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23258168'}]",,03/02/2016
0,03/02/2016,Tankyrase Inhibitor,215,7935,Tankyrase Inhibitor,CTNNB1 S45P,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 2299, 'pubMedId': 23621985, 'title': 'Evidence for tankyrases as antineoplastic targets in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23621985'}]",,03/02/2016
0,03/02/2016,PDPK1 Inhibitor,180,7936,PDPK1 Inhibitor,CTNNB1 S45P,"[{'id': 2220, 'pubMedId': 20028853, 'title': 'Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028853'}]",,03/02/2016
0,03/02/2016,PDPK1 Inhibitor,180,7937,PDPK1 Inhibitor,CTNNB1 D32N,"[{'id': 2220, 'pubMedId': 20028853, 'title': 'Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028853'}]",,03/02/2016
0,03/02/2016,CTNNB1 Inhibitor,60,7938,CTNNB1 Inhibitor,CTNNB1 D32N,"[{'id': 2251, 'pubMedId': 23258168, 'title': 'WNT signalling pathways as therapeutic targets in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23258168'}]",,03/02/2016
0,03/02/2016,Tankyrase Inhibitor,215,7939,Tankyrase Inhibitor,CTNNB1 D32N,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 2299, 'pubMedId': 23621985, 'title': 'Evidence for tankyrases as antineoplastic targets in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23621985'}]",,03/02/2016
0,03/02/2016,CTNNB1 Inhibitor,60,7940,CTNNB1 Inhibitor,CTNNB1 S45del,"[{'id': 2251, 'pubMedId': 23258168, 'title': 'WNT signalling pathways as therapeutic targets in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23258168'}]",,03/02/2016
0,03/02/2016,Tankyrase Inhibitor,215,7941,Tankyrase Inhibitor,CTNNB1 S45del,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 2299, 'pubMedId': 23621985, 'title': 'Evidence for tankyrases as antineoplastic targets in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23621985'}]",,03/02/2016
0,03/02/2016,PDPK1 Inhibitor,180,7942,PDPK1 Inhibitor,CTNNB1 S45del,"[{'id': 2220, 'pubMedId': 20028853, 'title': 'Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028853'}]",,03/02/2016
0,03/02/2016,Tankyrase Inhibitor,215,7943,Tankyrase Inhibitor,CTNNB1 E54K,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 2299, 'pubMedId': 23621985, 'title': 'Evidence for tankyrases as antineoplastic targets in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23621985'}]",,03/02/2016
0,03/02/2016,PDPK1 Inhibitor,180,7944,PDPK1 Inhibitor,CTNNB1 E54K,"[{'id': 2220, 'pubMedId': 20028853, 'title': 'Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028853'}]",,03/02/2016
0,03/02/2016,CTNNB1 Inhibitor,60,7945,CTNNB1 Inhibitor,CTNNB1 E54K,"[{'id': 2251, 'pubMedId': 23258168, 'title': 'WNT signalling pathways as therapeutic targets in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23258168'}]",,03/02/2016
0,03/02/2016,Tankyrase Inhibitor,215,7946,Tankyrase Inhibitor,CTNNB1 K335I,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 2299, 'pubMedId': 23621985, 'title': 'Evidence for tankyrases as antineoplastic targets in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23621985'}]",,03/02/2016
0,03/02/2016,PDPK1 Inhibitor,180,7947,PDPK1 Inhibitor,CTNNB1 K335I,"[{'id': 2220, 'pubMedId': 20028853, 'title': 'Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028853'}]",,03/02/2016
0,03/02/2016,CTNNB1 Inhibitor,60,7948,CTNNB1 Inhibitor,CTNNB1 K335I,"[{'id': 2251, 'pubMedId': 23258168, 'title': 'WNT signalling pathways as therapeutic targets in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23258168'}]",,03/02/2016
0,03/02/2016,CTNNB1 Inhibitor,60,7949,CTNNB1 Inhibitor,CTNNB1 W383R,"[{'id': 2251, 'pubMedId': 23258168, 'title': 'WNT signalling pathways as therapeutic targets in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23258168'}]",,03/02/2016
0,03/02/2016,Tankyrase Inhibitor,215,7950,Tankyrase Inhibitor,CTNNB1 W383R,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 2299, 'pubMedId': 23621985, 'title': 'Evidence for tankyrases as antineoplastic targets in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23621985'}]",,03/02/2016
0,03/02/2016,PDPK1 Inhibitor,180,7951,PDPK1 Inhibitor,CTNNB1 W383R,"[{'id': 2220, 'pubMedId': 20028853, 'title': 'Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028853'}]",,03/02/2016
0,03/02/2016,Tankyrase Inhibitor,215,7952,Tankyrase Inhibitor,CTNNB1 S37Y,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 2299, 'pubMedId': 23621985, 'title': 'Evidence for tankyrases as antineoplastic targets in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23621985'}]",,03/02/2016
0,03/02/2016,CTNNB1 Inhibitor,60,7953,CTNNB1 Inhibitor,CTNNB1 S37Y,"[{'id': 2251, 'pubMedId': 23258168, 'title': 'WNT signalling pathways as therapeutic targets in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23258168'}]",,03/02/2016
0,03/02/2016,PDPK1 Inhibitor,180,7954,PDPK1 Inhibitor,CTNNB1 S37Y,"[{'id': 2220, 'pubMedId': 20028853, 'title': 'Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028853'}]",,03/02/2016
0,03/02/2016,Tankyrase Inhibitor,215,7955,Tankyrase Inhibitor,CTNNB1 G48D,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 2299, 'pubMedId': 23621985, 'title': 'Evidence for tankyrases as antineoplastic targets in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23621985'}]",,03/02/2016
0,03/02/2016,CTNNB1 Inhibitor,60,7956,CTNNB1 Inhibitor,CTNNB1 G48D,"[{'id': 2251, 'pubMedId': 23258168, 'title': 'WNT signalling pathways as therapeutic targets in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23258168'}]",,03/02/2016
0,03/02/2016,PDPK1 Inhibitor,180,7957,PDPK1 Inhibitor,CTNNB1 G48D,"[{'id': 2220, 'pubMedId': 20028853, 'title': 'Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028853'}]",,03/02/2016
0,03/02/2016,Tankyrase Inhibitor,215,7958,Tankyrase Inhibitor,CTNNB1 A39T,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 2299, 'pubMedId': 23621985, 'title': 'Evidence for tankyrases as antineoplastic targets in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23621985'}]",,03/02/2016
0,03/02/2016,PDPK1 Inhibitor,180,7959,PDPK1 Inhibitor,CTNNB1 A39T,"[{'id': 2220, 'pubMedId': 20028853, 'title': 'Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028853'}]",,03/02/2016
0,03/02/2016,CTNNB1 Inhibitor,60,7960,CTNNB1 Inhibitor,CTNNB1 A39T,"[{'id': 2251, 'pubMedId': 23258168, 'title': 'WNT signalling pathways as therapeutic targets in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23258168'}]",,03/02/2016
0,03/02/2016,Tankyrase Inhibitor,215,7961,Tankyrase Inhibitor,CTNNB1 D32E,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 2299, 'pubMedId': 23621985, 'title': 'Evidence for tankyrases as antineoplastic targets in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23621985'}]",,03/02/2016
0,03/02/2016,CTNNB1 Inhibitor,60,7962,CTNNB1 Inhibitor,CTNNB1 D32E,"[{'id': 2251, 'pubMedId': 23258168, 'title': 'WNT signalling pathways as therapeutic targets in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23258168'}]",,03/02/2016
0,03/02/2016,PDPK1 Inhibitor,180,7963,PDPK1 Inhibitor,CTNNB1 D32E,"[{'id': 2220, 'pubMedId': 20028853, 'title': 'Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028853'}]",,03/02/2016
0,03/02/2016,PDPK1 Inhibitor,180,7964,PDPK1 Inhibitor,CTNNB1 E67K,"[{'id': 2220, 'pubMedId': 20028853, 'title': 'Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028853'}]",,03/02/2016
0,03/02/2016,CTNNB1 Inhibitor,60,7965,CTNNB1 Inhibitor,CTNNB1 E67K,"[{'id': 2251, 'pubMedId': 23258168, 'title': 'WNT signalling pathways as therapeutic targets in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23258168'}]",,03/02/2016
0,03/02/2016,Tankyrase Inhibitor,215,7966,Tankyrase Inhibitor,CTNNB1 E67K,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 2299, 'pubMedId': 23621985, 'title': 'Evidence for tankyrases as antineoplastic targets in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23621985'}]",,03/02/2016
0,03/02/2016,Tankyrase Inhibitor,215,7967,Tankyrase Inhibitor,CTNNB1 G34E,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 2299, 'pubMedId': 23621985, 'title': 'Evidence for tankyrases as antineoplastic targets in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23621985'}]",,03/02/2016
0,03/02/2016,PDPK1 Inhibitor,180,7968,PDPK1 Inhibitor,CTNNB1 G34E,"[{'id': 2220, 'pubMedId': 20028853, 'title': 'Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028853'}]",,03/02/2016
0,03/02/2016,CTNNB1 Inhibitor,60,7969,CTNNB1 Inhibitor,CTNNB1 G34E,"[{'id': 2251, 'pubMedId': 23258168, 'title': 'WNT signalling pathways as therapeutic targets in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23258168'}]",,03/02/2016
0,03/02/2016,PDPK1 Inhibitor,180,7970,PDPK1 Inhibitor,CTNNB1 S33A,"[{'id': 2220, 'pubMedId': 20028853, 'title': 'Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028853'}]",,03/02/2016
0,03/02/2016,Tankyrase Inhibitor,215,7971,Tankyrase Inhibitor,CTNNB1 S33A,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 2299, 'pubMedId': 23621985, 'title': 'Evidence for tankyrases as antineoplastic targets in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23621985'}]",,03/02/2016
0,03/02/2016,CTNNB1 Inhibitor,60,7972,CTNNB1 Inhibitor,CTNNB1 S33A,"[{'id': 2251, 'pubMedId': 23258168, 'title': 'WNT signalling pathways as therapeutic targets in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23258168'}]",,03/02/2016
0,03/02/2016,Tankyrase Inhibitor,215,7973,Tankyrase Inhibitor,CTNNB1 D32Y,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 2299, 'pubMedId': 23621985, 'title': 'Evidence for tankyrases as antineoplastic targets in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23621985'}]",,03/02/2016
0,03/02/2016,PDPK1 Inhibitor,180,7974,PDPK1 Inhibitor,CTNNB1 D32Y,"[{'id': 2220, 'pubMedId': 20028853, 'title': 'Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028853'}]",,03/02/2016
0,03/02/2016,CTNNB1 Inhibitor,60,7975,CTNNB1 Inhibitor,CTNNB1 D32Y,"[{'id': 2251, 'pubMedId': 23258168, 'title': 'WNT signalling pathways as therapeutic targets in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23258168'}]",,03/02/2016
0,03/02/2016,CTNNB1 Inhibitor,60,7976,CTNNB1 Inhibitor,CTNNB1 D32G,"[{'id': 2251, 'pubMedId': 23258168, 'title': 'WNT signalling pathways as therapeutic targets in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23258168'}]",,03/02/2016
0,03/02/2016,Tankyrase Inhibitor,215,7977,Tankyrase Inhibitor,CTNNB1 D32G,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 2299, 'pubMedId': 23621985, 'title': 'Evidence for tankyrases as antineoplastic targets in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23621985'}]",,03/02/2016
0,03/02/2016,PDPK1 Inhibitor,180,7978,PDPK1 Inhibitor,CTNNB1 D32G,"[{'id': 2220, 'pubMedId': 20028853, 'title': 'Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028853'}]",,03/02/2016
0,03/02/2016,PDPK1 Inhibitor,180,7979,PDPK1 Inhibitor,CTNNB1 D32H,"[{'id': 2220, 'pubMedId': 20028853, 'title': 'Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028853'}]",,03/02/2016
0,03/02/2016,Tankyrase Inhibitor,215,7980,Tankyrase Inhibitor,CTNNB1 D32H,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 2299, 'pubMedId': 23621985, 'title': 'Evidence for tankyrases as antineoplastic targets in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23621985'}]",,03/02/2016
0,03/02/2016,CTNNB1 Inhibitor,60,7981,CTNNB1 Inhibitor,CTNNB1 D32H,"[{'id': 2251, 'pubMedId': 23258168, 'title': 'WNT signalling pathways as therapeutic targets in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23258168'}]",,03/02/2016
0,03/02/2016,CTNNB1 Inhibitor,60,7982,CTNNB1 Inhibitor,CTNNB1 A13T,"[{'id': 2251, 'pubMedId': 23258168, 'title': 'WNT signalling pathways as therapeutic targets in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23258168'}]",,03/02/2016
0,03/02/2016,Tankyrase Inhibitor,215,7983,Tankyrase Inhibitor,CTNNB1 A13T,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 2299, 'pubMedId': 23621985, 'title': 'Evidence for tankyrases as antineoplastic targets in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23621985'}]",,03/02/2016
0,03/02/2016,PDPK1 Inhibitor,180,7984,PDPK1 Inhibitor,CTNNB1 A13T,"[{'id': 2220, 'pubMedId': 20028853, 'title': 'Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028853'}]",,03/02/2016
0,03/02/2016,CTNNB1 Inhibitor,60,7985,CTNNB1 Inhibitor,CTNNB1 A39G,"[{'id': 2251, 'pubMedId': 23258168, 'title': 'WNT signalling pathways as therapeutic targets in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23258168'}]",,03/02/2016
0,03/02/2016,Tankyrase Inhibitor,215,7986,Tankyrase Inhibitor,CTNNB1 A39G,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 2299, 'pubMedId': 23621985, 'title': 'Evidence for tankyrases as antineoplastic targets in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23621985'}]",,03/02/2016
0,03/02/2016,PDPK1 Inhibitor,180,7987,PDPK1 Inhibitor,CTNNB1 A39G,"[{'id': 2220, 'pubMedId': 20028853, 'title': 'Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028853'}]",,03/02/2016
0,03/02/2016,PDPK1 Inhibitor,180,7988,PDPK1 Inhibitor,CTNNB1 A43P,"[{'id': 2220, 'pubMedId': 20028853, 'title': 'Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028853'}]",,03/02/2016
0,03/02/2016,CTNNB1 Inhibitor,60,7989,CTNNB1 Inhibitor,CTNNB1 A43P,"[{'id': 2251, 'pubMedId': 23258168, 'title': 'WNT signalling pathways as therapeutic targets in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23258168'}]",,03/02/2016
0,03/02/2016,Tankyrase Inhibitor,215,7990,Tankyrase Inhibitor,CTNNB1 A43P,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 2299, 'pubMedId': 23621985, 'title': 'Evidence for tankyrases as antineoplastic targets in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23621985'}]",,03/02/2016
0,03/02/2016,CTNNB1 Inhibitor,60,7991,CTNNB1 Inhibitor,CTNNB1 A43T,"[{'id': 2251, 'pubMedId': 23258168, 'title': 'WNT signalling pathways as therapeutic targets in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23258168'}]",,03/02/2016
0,03/02/2016,PDPK1 Inhibitor,180,7992,PDPK1 Inhibitor,CTNNB1 A43T,"[{'id': 2220, 'pubMedId': 20028853, 'title': 'Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028853'}]",,03/02/2016
0,03/02/2016,Tankyrase Inhibitor,215,7993,Tankyrase Inhibitor,CTNNB1 A43T,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 2299, 'pubMedId': 23621985, 'title': 'Evidence for tankyrases as antineoplastic targets in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23621985'}]",,03/02/2016
0,03/02/2016,CTNNB1 Inhibitor,60,7994,CTNNB1 Inhibitor,CTNNB1 D32A,"[{'id': 2251, 'pubMedId': 23258168, 'title': 'WNT signalling pathways as therapeutic targets in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23258168'}]",,03/02/2016
0,03/02/2016,PDPK1 Inhibitor,180,7995,PDPK1 Inhibitor,CTNNB1 D32A,"[{'id': 2220, 'pubMedId': 20028853, 'title': 'Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028853'}]",,03/02/2016
0,03/02/2016,Tankyrase Inhibitor,215,7996,Tankyrase Inhibitor,CTNNB1 D32A,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 2299, 'pubMedId': 23621985, 'title': 'Evidence for tankyrases as antineoplastic targets in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23621985'}]",,03/02/2016
0,03/02/2016,PDPK1 Inhibitor,180,7997,PDPK1 Inhibitor,CTNNB1 D32V,"[{'id': 2220, 'pubMedId': 20028853, 'title': 'Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028853'}]",,03/02/2016
0,03/02/2016,Tankyrase Inhibitor,215,7998,Tankyrase Inhibitor,CTNNB1 D32V,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 2299, 'pubMedId': 23621985, 'title': 'Evidence for tankyrases as antineoplastic targets in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23621985'}]",,03/02/2016
0,03/02/2016,CTNNB1 Inhibitor,60,7999,CTNNB1 Inhibitor,CTNNB1 D32V,"[{'id': 2251, 'pubMedId': 23258168, 'title': 'WNT signalling pathways as therapeutic targets in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23258168'}]",,03/02/2016
0,03/02/2016,Tankyrase Inhibitor,215,8000,Tankyrase Inhibitor,CTNNB1 G34R,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 2299, 'pubMedId': 23621985, 'title': 'Evidence for tankyrases as antineoplastic targets in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23621985'}]",,03/02/2016
0,03/02/2016,CTNNB1 Inhibitor,60,8001,CTNNB1 Inhibitor,CTNNB1 G34R,"[{'id': 2251, 'pubMedId': 23258168, 'title': 'WNT signalling pathways as therapeutic targets in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23258168'}]",,03/02/2016
0,03/02/2016,PDPK1 Inhibitor,180,8002,PDPK1 Inhibitor,CTNNB1 G34R,"[{'id': 2220, 'pubMedId': 20028853, 'title': 'Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028853'}]",,03/02/2016
0,03/02/2016,Tankyrase Inhibitor,215,8003,Tankyrase Inhibitor,CTNNB1 G34V,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 2299, 'pubMedId': 23621985, 'title': 'Evidence for tankyrases as antineoplastic targets in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23621985'}]",,03/02/2016
0,03/02/2016,PDPK1 Inhibitor,180,8004,PDPK1 Inhibitor,CTNNB1 G34V,"[{'id': 2220, 'pubMedId': 20028853, 'title': 'Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028853'}]",,03/02/2016
0,03/02/2016,CTNNB1 Inhibitor,60,8005,CTNNB1 Inhibitor,CTNNB1 G34V,"[{'id': 2251, 'pubMedId': 23258168, 'title': 'WNT signalling pathways as therapeutic targets in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23258168'}]",,03/02/2016
0,03/02/2016,CTNNB1 Inhibitor,60,8006,CTNNB1 Inhibitor,CTNNB1 A21T,"[{'id': 2251, 'pubMedId': 23258168, 'title': 'WNT signalling pathways as therapeutic targets in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23258168'}]",,03/02/2016
0,03/02/2016,Tankyrase Inhibitor,215,8007,Tankyrase Inhibitor,CTNNB1 A21T,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 2299, 'pubMedId': 23621985, 'title': 'Evidence for tankyrases as antineoplastic targets in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23621985'}]",,03/02/2016
0,03/02/2016,PDPK1 Inhibitor,180,8008,PDPK1 Inhibitor,CTNNB1 A21T,"[{'id': 2220, 'pubMedId': 20028853, 'title': 'Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028853'}]",,03/02/2016
0,03/02/2016,CTNNB1 Inhibitor,60,8009,CTNNB1 Inhibitor,CTNNB1 G38P,"[{'id': 2251, 'pubMedId': 23258168, 'title': 'WNT signalling pathways as therapeutic targets in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23258168'}]",,03/02/2016
0,03/02/2016,PDPK1 Inhibitor,180,8010,PDPK1 Inhibitor,CTNNB1 G38P,"[{'id': 2220, 'pubMedId': 20028853, 'title': 'Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028853'}]",,03/02/2016
0,03/02/2016,Tankyrase Inhibitor,215,8011,Tankyrase Inhibitor,CTNNB1 G38P,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 2299, 'pubMedId': 23621985, 'title': 'Evidence for tankyrases as antineoplastic targets in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23621985'}]",,03/02/2016
0,03/02/2016,Tankyrase Inhibitor,215,8012,Tankyrase Inhibitor,CTNNB1 H36Y,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 2299, 'pubMedId': 23621985, 'title': 'Evidence for tankyrases as antineoplastic targets in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23621985'}]",,03/02/2016
0,03/02/2016,PDPK1 Inhibitor,180,8013,PDPK1 Inhibitor,CTNNB1 H36Y,"[{'id': 2220, 'pubMedId': 20028853, 'title': 'Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028853'}]",,03/02/2016
0,03/02/2016,CTNNB1 Inhibitor,60,8014,CTNNB1 Inhibitor,CTNNB1 H36Y,"[{'id': 2251, 'pubMedId': 23258168, 'title': 'WNT signalling pathways as therapeutic targets in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23258168'}]",,03/02/2016
0,03/02/2016,Tankyrase Inhibitor,215,8015,Tankyrase Inhibitor,CTNNB1 I35T,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 2299, 'pubMedId': 23621985, 'title': 'Evidence for tankyrases as antineoplastic targets in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23621985'}]",,03/02/2016
0,03/02/2016,CTNNB1 Inhibitor,60,8016,CTNNB1 Inhibitor,CTNNB1 I35T,"[{'id': 2251, 'pubMedId': 23258168, 'title': 'WNT signalling pathways as therapeutic targets in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23258168'}]",,03/02/2016
0,03/02/2016,PDPK1 Inhibitor,180,8017,PDPK1 Inhibitor,CTNNB1 I35T,"[{'id': 2220, 'pubMedId': 20028853, 'title': 'Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028853'}]",,03/02/2016
0,03/02/2016,PDPK1 Inhibitor,180,8018,PDPK1 Inhibitor,CTNNB1 P44A,"[{'id': 2220, 'pubMedId': 20028853, 'title': 'Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028853'}]",,03/02/2016
0,03/02/2016,CTNNB1 Inhibitor,60,8019,CTNNB1 Inhibitor,CTNNB1 P44A,"[{'id': 2251, 'pubMedId': 23258168, 'title': 'WNT signalling pathways as therapeutic targets in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23258168'}]",,03/02/2016
0,03/02/2016,Tankyrase Inhibitor,215,8020,Tankyrase Inhibitor,CTNNB1 P44A,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 2299, 'pubMedId': 23621985, 'title': 'Evidence for tankyrases as antineoplastic targets in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23621985'}]",,03/02/2016
0,03/02/2016,PDPK1 Inhibitor,180,8021,PDPK1 Inhibitor,CTNNB1 S33C,"[{'id': 2220, 'pubMedId': 20028853, 'title': 'Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028853'}]",,03/02/2016
0,03/02/2016,Tankyrase Inhibitor,215,8022,Tankyrase Inhibitor,CTNNB1 S33C,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 2299, 'pubMedId': 23621985, 'title': 'Evidence for tankyrases as antineoplastic targets in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23621985'}]",,03/02/2016
0,03/02/2016,CTNNB1 Inhibitor,60,8023,CTNNB1 Inhibitor,CTNNB1 S33C,"[{'id': 2251, 'pubMedId': 23258168, 'title': 'WNT signalling pathways as therapeutic targets in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23258168'}]",,03/02/2016
0,03/02/2016,CTNNB1 Inhibitor,60,8024,CTNNB1 Inhibitor,CTNNB1 S33Y,"[{'id': 2251, 'pubMedId': 23258168, 'title': 'WNT signalling pathways as therapeutic targets in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23258168'}]",,03/02/2016
0,03/02/2016,PDPK1 Inhibitor,180,8025,PDPK1 Inhibitor,CTNNB1 S33Y,"[{'id': 2220, 'pubMedId': 20028853, 'title': 'Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028853'}]",,03/02/2016
0,03/02/2016,Tankyrase Inhibitor,215,8026,Tankyrase Inhibitor,CTNNB1 S33Y,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 2299, 'pubMedId': 23621985, 'title': 'Evidence for tankyrases as antineoplastic targets in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23621985'}]",,03/02/2016
0,03/02/2016,CTNNB1 Inhibitor,60,8027,CTNNB1 Inhibitor,CTNNB1 S33F,"[{'id': 2251, 'pubMedId': 23258168, 'title': 'WNT signalling pathways as therapeutic targets in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23258168'}]",,03/02/2016
0,03/02/2016,PDPK1 Inhibitor,180,8028,PDPK1 Inhibitor,CTNNB1 S33F,"[{'id': 2220, 'pubMedId': 20028853, 'title': 'Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028853'}]",,03/02/2016
0,03/02/2016,Tankyrase Inhibitor,215,8029,Tankyrase Inhibitor,CTNNB1 S33F,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 2299, 'pubMedId': 23621985, 'title': 'Evidence for tankyrases as antineoplastic targets in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23621985'}]",,03/02/2016
0,03/02/2016,Tankyrase Inhibitor,215,8030,Tankyrase Inhibitor,CTNNB1 S33L,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 2299, 'pubMedId': 23621985, 'title': 'Evidence for tankyrases as antineoplastic targets in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23621985'}]",,03/02/2016
0,03/02/2016,CTNNB1 Inhibitor,60,8031,CTNNB1 Inhibitor,CTNNB1 S33L,"[{'id': 2251, 'pubMedId': 23258168, 'title': 'WNT signalling pathways as therapeutic targets in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23258168'}]",,03/02/2016
0,03/02/2016,PDPK1 Inhibitor,180,8032,PDPK1 Inhibitor,CTNNB1 S33L,"[{'id': 2220, 'pubMedId': 20028853, 'title': 'Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028853'}]",,03/02/2016
0,03/02/2016,Tankyrase Inhibitor,215,8033,Tankyrase Inhibitor,CTNNB1 S33N,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 2299, 'pubMedId': 23621985, 'title': 'Evidence for tankyrases as antineoplastic targets in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23621985'}]",,03/02/2016
0,03/02/2016,PDPK1 Inhibitor,180,8034,PDPK1 Inhibitor,CTNNB1 S33N,"[{'id': 2220, 'pubMedId': 20028853, 'title': 'Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028853'}]",,03/02/2016
0,03/02/2016,CTNNB1 Inhibitor,60,8035,CTNNB1 Inhibitor,CTNNB1 S33N,"[{'id': 2251, 'pubMedId': 23258168, 'title': 'WNT signalling pathways as therapeutic targets in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23258168'}]",,03/02/2016
0,03/02/2016,PDPK1 Inhibitor,180,8036,PDPK1 Inhibitor,CTNNB1 S33P,"[{'id': 2220, 'pubMedId': 20028853, 'title': 'Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028853'}]",,03/02/2016
0,03/02/2016,CTNNB1 Inhibitor,60,8037,CTNNB1 Inhibitor,CTNNB1 S33P,"[{'id': 2251, 'pubMedId': 23258168, 'title': 'WNT signalling pathways as therapeutic targets in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23258168'}]",,03/02/2016
0,03/02/2016,Tankyrase Inhibitor,215,8038,Tankyrase Inhibitor,CTNNB1 S33P,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 2299, 'pubMedId': 23621985, 'title': 'Evidence for tankyrases as antineoplastic targets in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23621985'}]",,03/02/2016
0,03/02/2016,CTNNB1 Inhibitor,60,8039,CTNNB1 Inhibitor,CTNNB1 S37A,"[{'id': 2251, 'pubMedId': 23258168, 'title': 'WNT signalling pathways as therapeutic targets in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23258168'}]",,03/02/2016
0,03/02/2016,PDPK1 Inhibitor,180,8040,PDPK1 Inhibitor,CTNNB1 S37A,"[{'id': 2220, 'pubMedId': 20028853, 'title': 'Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028853'}]",,03/02/2016
0,03/02/2016,Tankyrase Inhibitor,215,8041,Tankyrase Inhibitor,CTNNB1 S37A,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 2299, 'pubMedId': 23621985, 'title': 'Evidence for tankyrases as antineoplastic targets in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23621985'}]",,03/02/2016
0,03/02/2016,Tankyrase Inhibitor,215,8042,Tankyrase Inhibitor,CTNNB1 S37C,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 2299, 'pubMedId': 23621985, 'title': 'Evidence for tankyrases as antineoplastic targets in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23621985'}]",,03/02/2016
0,03/02/2016,PDPK1 Inhibitor,180,8043,PDPK1 Inhibitor,CTNNB1 S37C,"[{'id': 2220, 'pubMedId': 20028853, 'title': 'Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028853'}]",,03/02/2016
0,03/02/2016,CTNNB1 Inhibitor,60,8044,CTNNB1 Inhibitor,CTNNB1 S37C,"[{'id': 2251, 'pubMedId': 23258168, 'title': 'WNT signalling pathways as therapeutic targets in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23258168'}]",,03/02/2016
0,03/02/2016,CTNNB1 Inhibitor,60,8045,CTNNB1 Inhibitor,CTNNB1 S37F,"[{'id': 2251, 'pubMedId': 23258168, 'title': 'WNT signalling pathways as therapeutic targets in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23258168'}]",,03/02/2016
0,03/02/2016,Tankyrase Inhibitor,215,8046,Tankyrase Inhibitor,CTNNB1 S37F,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 2299, 'pubMedId': 23621985, 'title': 'Evidence for tankyrases as antineoplastic targets in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23621985'}]",,03/02/2016
0,03/02/2016,PDPK1 Inhibitor,180,8047,PDPK1 Inhibitor,CTNNB1 S37F,"[{'id': 2220, 'pubMedId': 20028853, 'title': 'Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028853'}]",,03/02/2016
0,03/02/2016,Tankyrase Inhibitor,215,8048,Tankyrase Inhibitor,CTNNB1 S37P,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 2299, 'pubMedId': 23621985, 'title': 'Evidence for tankyrases as antineoplastic targets in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23621985'}]",,03/02/2016
0,03/02/2016,PDPK1 Inhibitor,180,8049,PDPK1 Inhibitor,CTNNB1 S37P,"[{'id': 2220, 'pubMedId': 20028853, 'title': 'Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028853'}]",,03/02/2016
0,03/02/2016,CTNNB1 Inhibitor,60,8050,CTNNB1 Inhibitor,CTNNB1 S37P,"[{'id': 2251, 'pubMedId': 23258168, 'title': 'WNT signalling pathways as therapeutic targets in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23258168'}]",,03/02/2016
0,03/02/2016,PDPK1 Inhibitor,180,8051,PDPK1 Inhibitor,CTNNB1 S45C,"[{'id': 2220, 'pubMedId': 20028853, 'title': 'Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028853'}]",,03/02/2016
0,03/02/2016,CTNNB1 Inhibitor,60,8052,CTNNB1 Inhibitor,CTNNB1 S45C,"[{'id': 2251, 'pubMedId': 23258168, 'title': 'WNT signalling pathways as therapeutic targets in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23258168'}]",,03/02/2016
0,03/02/2016,Tankyrase Inhibitor,215,8053,Tankyrase Inhibitor,CTNNB1 S45C,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 2299, 'pubMedId': 23621985, 'title': 'Evidence for tankyrases as antineoplastic targets in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23621985'}]",,03/02/2016
0,03/02/2016,PDPK1 Inhibitor,180,8054,PDPK1 Inhibitor,CTNNB1 S45Y,"[{'id': 2220, 'pubMedId': 20028853, 'title': 'Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028853'}]",,03/02/2016
0,03/02/2016,Tankyrase Inhibitor,215,8055,Tankyrase Inhibitor,CTNNB1 S45Y,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 2299, 'pubMedId': 23621985, 'title': 'Evidence for tankyrases as antineoplastic targets in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23621985'}]",,03/02/2016
0,03/02/2016,CTNNB1 Inhibitor,60,8056,CTNNB1 Inhibitor,CTNNB1 S45Y,"[{'id': 2251, 'pubMedId': 23258168, 'title': 'WNT signalling pathways as therapeutic targets in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23258168'}]",,03/02/2016
0,03/02/2016,CTNNB1 Inhibitor,60,8057,CTNNB1 Inhibitor,CTNNB1 T41A,"[{'id': 2251, 'pubMedId': 23258168, 'title': 'WNT signalling pathways as therapeutic targets in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23258168'}]",,03/02/2016
0,03/02/2016,PDPK1 Inhibitor,180,8058,PDPK1 Inhibitor,CTNNB1 T41A,"[{'id': 2220, 'pubMedId': 20028853, 'title': 'Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028853'}]",,03/02/2016
0,03/02/2016,Tankyrase Inhibitor,215,8059,Tankyrase Inhibitor,CTNNB1 T41A,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 2299, 'pubMedId': 23621985, 'title': 'Evidence for tankyrases as antineoplastic targets in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23621985'}]",,03/02/2016
0,03/02/2016,PDPK1 Inhibitor,180,8060,PDPK1 Inhibitor,CTNNB1 T41I,"[{'id': 2220, 'pubMedId': 20028853, 'title': 'Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028853'}]",,03/02/2016
0,03/02/2016,CTNNB1 Inhibitor,60,8061,CTNNB1 Inhibitor,CTNNB1 T41I,"[{'id': 2251, 'pubMedId': 23258168, 'title': 'WNT signalling pathways as therapeutic targets in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23258168'}]",,03/02/2016
0,03/02/2016,Tankyrase Inhibitor,215,8062,Tankyrase Inhibitor,CTNNB1 T41I,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 2299, 'pubMedId': 23621985, 'title': 'Evidence for tankyrases as antineoplastic targets in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23621985'}]",,03/02/2016
0,03/02/2016,PDPK1 Inhibitor,180,8063,PDPK1 Inhibitor,CTNNB1 V22A,"[{'id': 2220, 'pubMedId': 20028853, 'title': 'Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028853'}]",,03/02/2016
0,03/02/2016,CTNNB1 Inhibitor,60,8064,CTNNB1 Inhibitor,CTNNB1 V22A,"[{'id': 2251, 'pubMedId': 23258168, 'title': 'WNT signalling pathways as therapeutic targets in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23258168'}]",,03/02/2016
0,03/02/2016,Tankyrase Inhibitor,215,8065,Tankyrase Inhibitor,CTNNB1 V22A,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 2299, 'pubMedId': 23621985, 'title': 'Evidence for tankyrases as antineoplastic targets in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23621985'}]",,03/02/2016
0,03/02/2016,PDPK1 Inhibitor,180,8066,PDPK1 Inhibitor,CTNNB1 W25_D32del,"[{'id': 2220, 'pubMedId': 20028853, 'title': 'Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028853'}]",,03/02/2016
0,03/02/2016,Tankyrase Inhibitor,215,8067,Tankyrase Inhibitor,CTNNB1 W25_D32del,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 2299, 'pubMedId': 23621985, 'title': 'Evidence for tankyrases as antineoplastic targets in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23621985'}]",,03/02/2016
0,03/02/2016,CTNNB1 Inhibitor,60,8068,CTNNB1 Inhibitor,CTNNB1 W25_D32del,"[{'id': 2251, 'pubMedId': 23258168, 'title': 'WNT signalling pathways as therapeutic targets in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23258168'}]",,03/02/2016
0,03/02/2016,CTNNB1 Inhibitor,60,8069,CTNNB1 Inhibitor,CTNNB1 S45F,"[{'id': 2251, 'pubMedId': 23258168, 'title': 'WNT signalling pathways as therapeutic targets in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23258168'}]",,03/02/2016
0,03/02/2016,Tankyrase Inhibitor,215,8070,Tankyrase Inhibitor,CTNNB1 S45F,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 2299, 'pubMedId': 23621985, 'title': 'Evidence for tankyrases as antineoplastic targets in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23621985'}]",,03/02/2016
0,03/02/2016,PDPK1 Inhibitor,180,8071,PDPK1 Inhibitor,CTNNB1 S45F,"[{'id': 2220, 'pubMedId': 20028853, 'title': 'Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028853'}]",,03/02/2016
0,03/02/2016,Tankyrase Inhibitor,215,8072,Tankyrase Inhibitor,CTNNB1 S45A,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 2299, 'pubMedId': 23621985, 'title': 'Evidence for tankyrases as antineoplastic targets in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23621985'}]",,03/02/2016
0,03/02/2016,PDPK1 Inhibitor,180,8073,PDPK1 Inhibitor,CTNNB1 S45A,"[{'id': 2220, 'pubMedId': 20028853, 'title': 'Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028853'}]",,03/02/2016
0,03/02/2016,CTNNB1 Inhibitor,60,8074,CTNNB1 Inhibitor,CTNNB1 S45A,"[{'id': 2251, 'pubMedId': 23258168, 'title': 'WNT signalling pathways as therapeutic targets in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23258168'}]",,03/02/2016
0,03/02/2016,Tankyrase Inhibitor,215,8075,Tankyrase Inhibitor,CTNNB1 I35N,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 2299, 'pubMedId': 23621985, 'title': 'Evidence for tankyrases as antineoplastic targets in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23621985'}]",,03/02/2016
0,03/02/2016,PDPK1 Inhibitor,180,8076,PDPK1 Inhibitor,CTNNB1 I35N,"[{'id': 2220, 'pubMedId': 20028853, 'title': 'Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028853'}]",,03/02/2016
0,03/02/2016,CTNNB1 Inhibitor,60,8077,CTNNB1 Inhibitor,CTNNB1 I35N,"[{'id': 2251, 'pubMedId': 23258168, 'title': 'WNT signalling pathways as therapeutic targets in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23258168'}]",,03/02/2016
0,03/02/2016,PDPK1 Inhibitor,180,8078,PDPK1 Inhibitor,CTNNB1 S33T,"[{'id': 2220, 'pubMedId': 20028853, 'title': 'Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028853'}]",,03/02/2016
0,03/02/2016,CTNNB1 Inhibitor,60,8079,CTNNB1 Inhibitor,CTNNB1 S33T,"[{'id': 2251, 'pubMedId': 23258168, 'title': 'WNT signalling pathways as therapeutic targets in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23258168'}]",,03/02/2016
0,03/02/2016,Tankyrase Inhibitor,215,8080,Tankyrase Inhibitor,CTNNB1 S33T,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 2299, 'pubMedId': 23621985, 'title': 'Evidence for tankyrases as antineoplastic targets in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23621985'}]",,03/02/2016
0,03/02/2016,Tankyrase Inhibitor,215,8081,Tankyrase Inhibitor,CTNNB1 S45T,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 2299, 'pubMedId': 23621985, 'title': 'Evidence for tankyrases as antineoplastic targets in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23621985'}]",,03/02/2016
0,03/02/2016,CTNNB1 Inhibitor,60,8082,CTNNB1 Inhibitor,CTNNB1 S45T,"[{'id': 2251, 'pubMedId': 23258168, 'title': 'WNT signalling pathways as therapeutic targets in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23258168'}]",,03/02/2016
0,03/02/2016,PDPK1 Inhibitor,180,8083,PDPK1 Inhibitor,CTNNB1 S45T,"[{'id': 2220, 'pubMedId': 20028853, 'title': 'Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028853'}]",,03/02/2016
0,03/02/2016,Tankyrase Inhibitor,215,8084,Tankyrase Inhibitor,CTNNB1 S37T,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 2299, 'pubMedId': 23621985, 'title': 'Evidence for tankyrases as antineoplastic targets in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23621985'}]",,03/02/2016
0,03/02/2016,CTNNB1 Inhibitor,60,8085,CTNNB1 Inhibitor,CTNNB1 S37T,"[{'id': 2251, 'pubMedId': 23258168, 'title': 'WNT signalling pathways as therapeutic targets in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23258168'}]",,03/02/2016
0,03/02/2016,PDPK1 Inhibitor,180,8086,PDPK1 Inhibitor,CTNNB1 S37T,"[{'id': 2220, 'pubMedId': 20028853, 'title': 'Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028853'}]",,03/02/2016
0,03/02/2016,PDPK1 Inhibitor,180,8087,PDPK1 Inhibitor,CTNNB1 P44_S45del,"[{'id': 2220, 'pubMedId': 20028853, 'title': 'Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028853'}]",,03/02/2016
0,03/02/2016,CTNNB1 Inhibitor,60,8088,CTNNB1 Inhibitor,CTNNB1 P44_S45del,"[{'id': 2251, 'pubMedId': 23258168, 'title': 'WNT signalling pathways as therapeutic targets in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23258168'}]",,03/02/2016
0,03/02/2016,Tankyrase Inhibitor,215,8089,Tankyrase Inhibitor,CTNNB1 P44_S45del,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 2299, 'pubMedId': 23621985, 'title': 'Evidence for tankyrases as antineoplastic targets in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23621985'}]",,03/02/2016
0,03/02/2016,PDPK1 Inhibitor,180,8090,PDPK1 Inhibitor,CTNNB1 S45N,"[{'id': 2220, 'pubMedId': 20028853, 'title': 'Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028853'}]",,03/02/2016
0,03/02/2016,CTNNB1 Inhibitor,60,8091,CTNNB1 Inhibitor,CTNNB1 S45N,"[{'id': 2251, 'pubMedId': 23258168, 'title': 'WNT signalling pathways as therapeutic targets in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23258168'}]",,03/02/2016
0,03/02/2016,Tankyrase Inhibitor,215,8092,Tankyrase Inhibitor,CTNNB1 S45N,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 2299, 'pubMedId': 23621985, 'title': 'Evidence for tankyrases as antineoplastic targets in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23621985'}]",,03/02/2016
0,03/04/2016,MET Inhibitor,147,8094,MET Inhibitor,MET Y1235D,"[{'id': 1994, 'pubMedId': 24045150, 'title': 'Met as a therapeutic target in HCC: facts and hopes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24045150'}]",,03/04/2016
0,03/06/2016,IDH Inhibitor (Pan),117,8095,IDH Inhibitor (Pan),IDH1 R100A,"[{'id': 2551, 'pubMedId': 25678837, 'title': 'New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25678837'}]",,03/06/2016
0,03/06/2016,IDH1 Inhibitor,118,8096,IDH1 Inhibitor,IDH1 R100A,"[{'id': 2551, 'pubMedId': 25678837, 'title': 'New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25678837'}, {'id': 2552, 'pubMedId': 23558169, 'title': 'An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23558169'}]",,03/06/2016
0,03/06/2016,JAK Inhibitor (Pan),126,8097,JAK Inhibitor (Pan),JAK2 E846D,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,03/06/2016
0,03/06/2016,JAK Inhibitor (Pan) – ATP competitive,127,8098,JAK Inhibitor (Pan) – ATP competitive,JAK2 E846D,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,03/06/2016
0,03/06/2016,JAK2 Inhibitor,130,8099,JAK2 Inhibitor,JAK2 E846D,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,03/06/2016
0,03/06/2016,JAK2 Inhibitor – ATP competitive,131,8100,JAK2 Inhibitor – ATP competitive,JAK2 E846D,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,03/06/2016
0,03/21/2016,Akt2 Inhibitor,7,8150,Akt2 Inhibitor,PIK3CA H1047Y,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/21/2016
0,03/21/2016,mTOR Inhibitor,152,8151,mTOR Inhibitor,PIK3CA H1047Y,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/21/2016
0,03/21/2016,mTORC2 Inhibitor,154,8152,mTORC2 Inhibitor,PIK3CA H1047Y,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/21/2016
0,03/21/2016,mTORC1 Inhibitor,153,8153,mTORC1 Inhibitor,PIK3CA H1047Y,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/21/2016
0,03/21/2016,Akt3 Inhibitor,8,8154,Akt3 Inhibitor,PIK3CA H1047Y,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/21/2016
0,03/21/2016,PIK3CA inhibitor,182,8155,PIK3CA inhibitor,PIK3CA H1047Y,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/21/2016
0,03/21/2016,Akt1 Inhibitor,6,8156,Akt1 Inhibitor,PIK3CA H1047Y,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/21/2016
0,03/21/2016,Akt Inhibitor (Pan),4,8157,Akt Inhibitor (Pan),PIK3CA H1047Y,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/21/2016
0,03/21/2016,PI3K Inhibitor (Pan),181,8158,PI3K Inhibitor (Pan),PIK3CA H1047Y,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/21/2016
0,03/21/2016,Akt3 Inhibitor,8,8159,Akt3 Inhibitor,PIK3CA H1047X,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/21/2016
0,03/21/2016,Akt Inhibitor (Pan),4,8160,Akt Inhibitor (Pan),PIK3CA H1047X,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/21/2016
0,03/21/2016,Akt2 Inhibitor,7,8161,Akt2 Inhibitor,PIK3CA H1047X,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/21/2016
0,03/21/2016,mTORC2 Inhibitor,154,8162,mTORC2 Inhibitor,PIK3CA H1047X,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/21/2016
0,03/21/2016,mTORC1 Inhibitor,153,8163,mTORC1 Inhibitor,PIK3CA H1047X,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/21/2016
0,03/21/2016,mTOR Inhibitor,152,8164,mTOR Inhibitor,PIK3CA H1047X,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/21/2016
0,03/21/2016,PIK3CA inhibitor,182,8165,PIK3CA inhibitor,PIK3CA H1047X,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/21/2016
0,03/21/2016,Akt1 Inhibitor,6,8166,Akt1 Inhibitor,PIK3CA H1047X,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/21/2016
0,03/21/2016,PI3K Inhibitor (Pan),181,8167,PI3K Inhibitor (Pan),PIK3CA H1047X,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/21/2016
0,03/21/2016,PIK3CA inhibitor,182,8168,PIK3CA inhibitor,PIK3CA Q546E,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/21/2016
0,03/21/2016,Akt1 Inhibitor,6,8169,Akt1 Inhibitor,PIK3CA Q546E,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/21/2016
0,03/21/2016,mTORC2 Inhibitor,154,8170,mTORC2 Inhibitor,PIK3CA Q546E,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/21/2016
0,03/21/2016,PI3K Inhibitor (Pan),181,8171,PI3K Inhibitor (Pan),PIK3CA Q546E,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/21/2016
0,03/21/2016,mTOR Inhibitor,152,8172,mTOR Inhibitor,PIK3CA Q546E,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/21/2016
0,03/21/2016,Akt Inhibitor (Pan),4,8173,Akt Inhibitor (Pan),PIK3CA Q546E,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/21/2016
0,03/21/2016,Akt2 Inhibitor,7,8174,Akt2 Inhibitor,PIK3CA Q546E,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/21/2016
0,03/21/2016,mTORC1 Inhibitor,153,8175,mTORC1 Inhibitor,PIK3CA Q546E,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/21/2016
0,03/21/2016,Akt3 Inhibitor,8,8176,Akt3 Inhibitor,PIK3CA Q546E,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,03/21/2016
0,03/21/2016,ALK Inhibitor,9,8252,ALK Inhibitor,ALK rearrange,"[{'id': 527, 'pubMedId': 21838707, 'title': 'Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21838707'}]",,03/21/2016
0,03/21/2016,ALK Inhibitor,9,8255,ALK Inhibitor,ALK fusion,"[{'id': 527, 'pubMedId': 21838707, 'title': 'Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21838707'}]",,03/21/2016
0,03/21/2016,ALK Inhibitor,9,8256,ALK Inhibitor,ALK F1174C,"[{'id': 527, 'pubMedId': 21838707, 'title': 'Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21838707'}]",,03/21/2016
0,03/21/2016,ALK Inhibitor,9,8257,ALK Inhibitor,ALK F1174I,"[{'id': 527, 'pubMedId': 21838707, 'title': 'Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21838707'}]",,03/21/2016
0,03/21/2016,ALK Inhibitor,9,8258,ALK Inhibitor,ALK F1174V,"[{'id': 527, 'pubMedId': 21838707, 'title': 'Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21838707'}]",,03/21/2016
0,03/21/2016,ALK Inhibitor,9,8259,ALK Inhibitor,ALK K1062M,"[{'id': 527, 'pubMedId': 21838707, 'title': 'Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21838707'}]",,03/21/2016
0,03/21/2016,ALK Inhibitor,9,8260,ALK Inhibitor,ALK G1201E,"[{'id': 527, 'pubMedId': 21838707, 'title': 'Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21838707'}]",,03/21/2016
0,03/21/2016,ALK Inhibitor,9,8261,ALK Inhibitor,ALK L1198F,"[{'id': 527, 'pubMedId': 21838707, 'title': 'Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21838707'}]",,03/21/2016
0,03/21/2016,ALK Inhibitor,9,8262,ALK Inhibitor,ALK act mut,"[{'id': 527, 'pubMedId': 21838707, 'title': 'Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21838707'}]",,03/21/2016
0,03/21/2016,Tankyrase Inhibitor,215,8264,Tankyrase Inhibitor,APC C1289fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,03/21/2016
0,03/21/2016,CTNNB1 Inhibitor,60,8265,CTNNB1 Inhibitor,APC C1289fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,03/21/2016
0,03/21/2016,HER inhibitor (Pan),105,8266,HER inhibitor (Pan),ERBB4 D595V,"[{'id': 2681, 'pubMedId': 20404484, 'title': 'A growing family: adding mutated Erbb4 as a novel cancer target.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20404484'}]",,03/21/2016
0,03/21/2016,HER inhibitor (Pan),105,8267,HER inhibitor (Pan),ERBB4 D931Y,"[{'id': 2681, 'pubMedId': 20404484, 'title': 'A growing family: adding mutated Erbb4 as a novel cancer target.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20404484'}]",,03/21/2016
0,03/21/2016,HER inhibitor (Pan),105,8268,HER inhibitor (Pan),ERBB4 K935I,"[{'id': 2681, 'pubMedId': 20404484, 'title': 'A growing family: adding mutated Erbb4 as a novel cancer target.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20404484'}]",,03/21/2016
0,03/21/2016,HER inhibitor (Pan),105,8269,HER inhibitor (Pan),ERBB4 Y285C,"[{'id': 2681, 'pubMedId': 20404484, 'title': 'A growing family: adding mutated Erbb4 as a novel cancer target.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20404484'}]",,03/21/2016
0,03/21/2016,HER inhibitor (Pan),105,8270,HER inhibitor (Pan),ERBB4 G936R,"[{'id': 2681, 'pubMedId': 20404484, 'title': 'A growing family: adding mutated Erbb4 as a novel cancer target.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20404484'}]",,03/21/2016
0,03/21/2016,HER inhibitor (Pan),105,8271,HER inhibitor (Pan),ERBB2 G778_S779insG,"[{'id': 2691, 'pubMedId': 25674538, 'title': 'The Potential of panHER Inhibition in Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25674538'}]",,03/21/2016
0,03/21/2016,HER2 Inhibitor,106,8272,HER2 Inhibitor,ERBB2 G778_S779insG,"[{'id': 561, 'pubMedId': 22649146, 'title': 'HER2 mutations in non-small-cell lung cancer can be continually targeted.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22649146'}, {'id': 563, 'pubMedId': 21991949, 'title': 'Adjuvant trastuzumab in HER2-positive breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21991949'}, {'id': 564, 'pubMedId': 23801166, 'title': 'First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23801166'}]",,03/21/2016
0,03/21/2016,HER2 Inhibitor,106,8273,HER2 Inhibitor,ERBB2 S779_P780insVGS,"[{'id': 561, 'pubMedId': 22649146, 'title': 'HER2 mutations in non-small-cell lung cancer can be continually targeted.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22649146'}, {'id': 563, 'pubMedId': 21991949, 'title': 'Adjuvant trastuzumab in HER2-positive breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21991949'}, {'id': 564, 'pubMedId': 23801166, 'title': 'First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23801166'}]",,03/21/2016
0,03/21/2016,HER inhibitor (Pan),105,8274,HER inhibitor (Pan),ERBB2 S779_P780insVGS,"[{'id': 2691, 'pubMedId': 25674538, 'title': 'The Potential of panHER Inhibition in Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25674538'}]",,03/21/2016
0,03/21/2016,HER inhibitor (Pan),105,8275,HER inhibitor (Pan),ERBB2 I624V,"[{'id': 2691, 'pubMedId': 25674538, 'title': 'The Potential of panHER Inhibition in Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25674538'}]",,03/21/2016
0,03/21/2016,HER2 Inhibitor,106,8276,HER2 Inhibitor,ERBB2 I624V,"[{'id': 561, 'pubMedId': 22649146, 'title': 'HER2 mutations in non-small-cell lung cancer can be continually targeted.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22649146'}, {'id': 563, 'pubMedId': 21991949, 'title': 'Adjuvant trastuzumab in HER2-positive breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21991949'}, {'id': 564, 'pubMedId': 23801166, 'title': 'First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23801166'}]",,03/21/2016
0,03/21/2016,HER inhibitor (Pan),105,8277,HER inhibitor (Pan),ERBB2 I639V,"[{'id': 2691, 'pubMedId': 25674538, 'title': 'The Potential of panHER Inhibition in Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25674538'}]",,03/21/2016
0,03/21/2016,HER2 Inhibitor,106,8278,HER2 Inhibitor,ERBB2 I639V,"[{'id': 561, 'pubMedId': 22649146, 'title': 'HER2 mutations in non-small-cell lung cancer can be continually targeted.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22649146'}, {'id': 563, 'pubMedId': 21991949, 'title': 'Adjuvant trastuzumab in HER2-positive breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21991949'}, {'id': 564, 'pubMedId': 23801166, 'title': 'First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23801166'}]",,03/21/2016
0,03/21/2016,IDH Inhibitor (Pan),117,8279,IDH Inhibitor (Pan),IDH1 R100Q,"[{'id': 2551, 'pubMedId': 25678837, 'title': 'New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25678837'}]",,03/21/2016
0,03/21/2016,IDH1 Inhibitor,118,8280,IDH1 Inhibitor,IDH1 R100Q,"[{'id': 2551, 'pubMedId': 25678837, 'title': 'New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25678837'}, {'id': 2552, 'pubMedId': 23558169, 'title': 'An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23558169'}]",,03/21/2016
0,03/21/2016,IDH1 Inhibitor,118,8281,IDH1 Inhibitor,IDH1 R132X,"[{'id': 2551, 'pubMedId': 25678837, 'title': 'New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25678837'}, {'id': 2552, 'pubMedId': 23558169, 'title': 'An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23558169'}]",,03/21/2016
0,03/21/2016,IDH Inhibitor (Pan),117,8282,IDH Inhibitor (Pan),IDH1 R132X,"[{'id': 2551, 'pubMedId': 25678837, 'title': 'New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25678837'}]",,03/21/2016
0,03/21/2016,PIK3CD inhibitor,184,8283,PIK3CD inhibitor,HRAS inact mut,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/21/2016
0,03/21/2016,PIK3CG inhibitor,185,8284,PIK3CG inhibitor,HRAS inact mut,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/21/2016
0,03/21/2016,PI3K Inhibitor (Pan),181,8285,PI3K Inhibitor (Pan),HRAS inact mut,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/21/2016
0,03/21/2016,MEK1 Inhibitor,143,8286,MEK1 Inhibitor,HRAS inact mut,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/21/2016
0,03/21/2016,PIK3CB inhibitor,183,8287,PIK3CB inhibitor,HRAS inact mut,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/21/2016
0,03/21/2016,PIK3CA inhibitor,182,8288,PIK3CA inhibitor,HRAS inact mut,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/21/2016
0,03/21/2016,MEK inhibitor (Pan),142,8289,MEK inhibitor (Pan),HRAS inact mut,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/21/2016
0,03/21/2016,MEK2 Inhibitor,144,8290,MEK2 Inhibitor,HRAS inact mut,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/21/2016
0,03/21/2016,RAS Inhibitor (Pan),198,8291,RAS Inhibitor (Pan),HRAS inact mut,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,03/21/2016
0,03/21/2016,PI3K Inhibitor (Pan),181,8292,PI3K Inhibitor (Pan),HRAS Y32*,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/21/2016
0,03/21/2016,MEK inhibitor (Pan),142,8293,MEK inhibitor (Pan),HRAS Y32*,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/21/2016
0,03/21/2016,RAS Inhibitor (Pan),198,8294,RAS Inhibitor (Pan),HRAS Y32*,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,03/21/2016
0,03/21/2016,PIK3CA inhibitor,182,8295,PIK3CA inhibitor,HRAS Y32*,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/21/2016
0,03/21/2016,MEK2 Inhibitor,144,8296,MEK2 Inhibitor,HRAS Y32*,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/21/2016
0,03/21/2016,PIK3CG inhibitor,185,8297,PIK3CG inhibitor,HRAS Y32*,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/21/2016
0,03/21/2016,MEK1 Inhibitor,143,8298,MEK1 Inhibitor,HRAS Y32*,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/21/2016
0,03/21/2016,PIK3CD inhibitor,184,8299,PIK3CD inhibitor,HRAS Y32*,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/21/2016
0,03/21/2016,PIK3CB inhibitor,183,8300,PIK3CB inhibitor,HRAS Y32*,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/21/2016
0,03/21/2016,mTORC1 Inhibitor,153,8310,mTORC1 Inhibitor,FBXW7 W244*,"[{'id': 571, 'pubMedId': 18787170, 'title': 'FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18787170'}, {'id': 2558, 'pubMedId': 24586741, 'title': 'FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24586741'}]",,03/21/2016
0,03/21/2016,mTORC1 Inhibitor,153,8311,mTORC1 Inhibitor,FBXW7 R222*,"[{'id': 571, 'pubMedId': 18787170, 'title': 'FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18787170'}, {'id': 2558, 'pubMedId': 24586741, 'title': 'FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24586741'}]",,03/21/2016
0,03/21/2016,mTORC1 Inhibitor,153,8312,mTORC1 Inhibitor,FBXW7 R278*,"[{'id': 571, 'pubMedId': 18787170, 'title': 'FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18787170'}, {'id': 2558, 'pubMedId': 24586741, 'title': 'FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24586741'}]",,03/21/2016
0,03/21/2016,mTORC1 Inhibitor,153,8313,mTORC1 Inhibitor,FBXW7 S282*,"[{'id': 571, 'pubMedId': 18787170, 'title': 'FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18787170'}, {'id': 2558, 'pubMedId': 24586741, 'title': 'FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24586741'}]",,03/21/2016
0,03/21/2016,mTORC1 Inhibitor,153,8314,mTORC1 Inhibitor,FBXW7 H420Y,"[{'id': 571, 'pubMedId': 18787170, 'title': 'FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18787170'}, {'id': 2558, 'pubMedId': 24586741, 'title': 'FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24586741'}]",,03/21/2016
0,03/21/2016,mTORC1 Inhibitor,153,8315,mTORC1 Inhibitor,FBXW7 W237*,"[{'id': 571, 'pubMedId': 18787170, 'title': 'FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18787170'}, {'id': 2558, 'pubMedId': 24586741, 'title': 'FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24586741'}]",,03/21/2016
0,03/21/2016,mTORC1 Inhibitor,153,8316,mTORC1 Inhibitor,FBXW7 T165fs,"[{'id': 571, 'pubMedId': 18787170, 'title': 'FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18787170'}, {'id': 2558, 'pubMedId': 24586741, 'title': 'FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24586741'}]",,03/21/2016
0,03/21/2016,VEGFR2 Inhibitor,232,8327,VEGFR2 Inhibitor,VHL G114R,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2901, 'pubMedId': 22105611, 'title': 'Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22105611'}]",,03/21/2016
0,03/21/2016,VEGFR Inhibitor (Pan),230,8328,VEGFR Inhibitor (Pan),VHL G114R,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2902, 'pubMedId': 22931246, 'title': 'Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22931246'}]",,03/21/2016
0,03/21/2016,mTORC1 Inhibitor,153,8329,mTORC1 Inhibitor,VHL G114R,"[{'id': 2992, 'pubMedId': 16341243, 'title': 'Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16341243'}]",,03/21/2016
0,03/21/2016,VEGFR2 Inhibitor,232,8351,VEGFR2 Inhibitor,VHL R79P,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2901, 'pubMedId': 22105611, 'title': 'Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22105611'}]",,03/21/2016
0,03/21/2016,mTORC1 Inhibitor,153,8352,mTORC1 Inhibitor,VHL R79P,"[{'id': 2992, 'pubMedId': 16341243, 'title': 'Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16341243'}]",,03/21/2016
0,03/21/2016,VEGFR Inhibitor (Pan),230,8353,VEGFR Inhibitor (Pan),VHL R79P,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2902, 'pubMedId': 22931246, 'title': 'Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22931246'}]",,03/21/2016
0,03/21/2016,VEGFR Inhibitor (Pan),230,8354,VEGFR Inhibitor (Pan),VHL S80I,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2902, 'pubMedId': 22931246, 'title': 'Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22931246'}]",,03/21/2016
0,03/21/2016,mTORC1 Inhibitor,153,8355,mTORC1 Inhibitor,VHL S80I,"[{'id': 2992, 'pubMedId': 16341243, 'title': 'Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16341243'}]",,03/21/2016
0,03/21/2016,VEGFR2 Inhibitor,232,8356,VEGFR2 Inhibitor,VHL S80I,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2901, 'pubMedId': 22105611, 'title': 'Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22105611'}]",,03/21/2016
0,03/21/2016,VEGFR2 Inhibitor,232,8357,VEGFR2 Inhibitor,VHL S80R,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2901, 'pubMedId': 22105611, 'title': 'Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22105611'}]",,03/21/2016
0,03/21/2016,VEGFR Inhibitor (Pan),230,8358,VEGFR Inhibitor (Pan),VHL S80R,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2902, 'pubMedId': 22931246, 'title': 'Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22931246'}]",,03/21/2016
0,03/21/2016,mTORC1 Inhibitor,153,8359,mTORC1 Inhibitor,VHL S80R,"[{'id': 2992, 'pubMedId': 16341243, 'title': 'Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16341243'}]",,03/21/2016
0,03/21/2016,VEGFR2 Inhibitor,232,8360,VEGFR2 Inhibitor,VHL V130F,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2901, 'pubMedId': 22105611, 'title': 'Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22105611'}]",,03/21/2016
0,03/21/2016,mTORC1 Inhibitor,153,8361,mTORC1 Inhibitor,VHL V130F,"[{'id': 2992, 'pubMedId': 16341243, 'title': 'Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16341243'}]",,03/21/2016
0,03/21/2016,VEGFR Inhibitor (Pan),230,8362,VEGFR Inhibitor (Pan),VHL V130F,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2902, 'pubMedId': 22931246, 'title': 'Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22931246'}]",,03/21/2016
0,03/21/2016,VEGFR2 Inhibitor,232,8363,VEGFR2 Inhibitor,VHL V74G,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2901, 'pubMedId': 22105611, 'title': 'Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22105611'}]",,03/21/2016
0,03/21/2016,VEGFR Inhibitor (Pan),230,8364,VEGFR Inhibitor (Pan),VHL V74G,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2902, 'pubMedId': 22931246, 'title': 'Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22931246'}]",,03/21/2016
0,03/21/2016,mTORC1 Inhibitor,153,8365,mTORC1 Inhibitor,VHL V74G,"[{'id': 2992, 'pubMedId': 16341243, 'title': 'Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16341243'}]",,03/21/2016
0,03/25/2016,MEK inhibitor (Pan),142,8374,MEK inhibitor (Pan),HRAS K117N,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/25/2016
0,03/25/2016,MEK1 Inhibitor,143,8375,MEK1 Inhibitor,HRAS K117N,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/25/2016
0,03/25/2016,MEK2 Inhibitor,144,8376,MEK2 Inhibitor,HRAS K117N,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,03/25/2016
0,03/25/2016,PI3K Inhibitor (Pan),181,8377,PI3K Inhibitor (Pan),HRAS K117N,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/25/2016
0,03/25/2016,PIK3CA inhibitor,182,8378,PIK3CA inhibitor,HRAS K117N,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/25/2016
0,03/25/2016,PIK3CB inhibitor,183,8379,PIK3CB inhibitor,HRAS K117N,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/25/2016
0,03/25/2016,PIK3CD inhibitor,184,8380,PIK3CD inhibitor,HRAS K117N,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/25/2016
0,03/25/2016,PIK3CG inhibitor,185,8381,PIK3CG inhibitor,HRAS K117N,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,03/25/2016
0,03/25/2016,RAS Inhibitor (Pan),198,8382,RAS Inhibitor (Pan),HRAS K117N,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,03/25/2016
0,03/28/2016,mTOR Inhibitor,152,8388,mTOR Inhibitor,STK11 inact mut,"[{'id': 5047, 'pubMedId': 25436981, 'title': 'Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25436981'}, {'id': 5053, 'pubMedId': 26574479, 'title': 'Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26574479'}]",,03/28/2016
0,03/28/2016,mTOR Inhibitor,152,8389,mTOR Inhibitor,STK11 loss,"[{'id': 5047, 'pubMedId': 25436981, 'title': 'Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25436981'}, {'id': 5053, 'pubMedId': 26574479, 'title': 'Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26574479'}]",,03/28/2016
0,03/28/2016,mTORC1 Inhibitor,153,8390,mTORC1 Inhibitor,STK11 loss,"[{'id': 3134, 'pubMedId': 24387336, 'title': 'Targeting the LKB1 tumor suppressor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24387336'}]",,03/28/2016
0,03/28/2016,mTORC1 Inhibitor,153,8391,mTORC1 Inhibitor,STK11 K78I,"[{'id': 3134, 'pubMedId': 24387336, 'title': 'Targeting the LKB1 tumor suppressor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24387336'}]",,03/28/2016
0,03/28/2016,mTOR Inhibitor,152,8392,mTOR Inhibitor,STK11 K78I,"[{'id': 5047, 'pubMedId': 25436981, 'title': 'Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25436981'}, {'id': 5053, 'pubMedId': 26574479, 'title': 'Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26574479'}]",,03/28/2016
0,03/28/2016,mTOR Inhibitor,152,8393,mTOR Inhibitor,STK11 Q100*,"[{'id': 5047, 'pubMedId': 25436981, 'title': 'Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25436981'}, {'id': 5053, 'pubMedId': 26574479, 'title': 'Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26574479'}]",,03/28/2016
0,03/28/2016,mTORC1 Inhibitor,153,8394,mTORC1 Inhibitor,STK11 Q100*,"[{'id': 3134, 'pubMedId': 24387336, 'title': 'Targeting the LKB1 tumor suppressor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24387336'}]",,03/28/2016
0,03/28/2016,mTOR Inhibitor,152,8395,mTOR Inhibitor,STK11 Q137*,"[{'id': 5047, 'pubMedId': 25436981, 'title': 'Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25436981'}, {'id': 5053, 'pubMedId': 26574479, 'title': 'Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26574479'}]",,03/28/2016
0,03/28/2016,mTORC1 Inhibitor,153,8396,mTORC1 Inhibitor,STK11 Q137*,"[{'id': 3134, 'pubMedId': 24387336, 'title': 'Targeting the LKB1 tumor suppressor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24387336'}]",,03/28/2016
0,03/28/2016,mTOR Inhibitor,152,8397,mTOR Inhibitor,STK11 D194Y,"[{'id': 5047, 'pubMedId': 25436981, 'title': 'Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25436981'}, {'id': 5053, 'pubMedId': 26574479, 'title': 'Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26574479'}]",,03/28/2016
0,03/28/2016,mTORC1 Inhibitor,153,8398,mTORC1 Inhibitor,STK11 D194Y,"[{'id': 3134, 'pubMedId': 24387336, 'title': 'Targeting the LKB1 tumor suppressor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24387336'}]",,03/28/2016
0,03/28/2016,mTOR Inhibitor,152,8399,mTOR Inhibitor,STK11 P281fs*6,"[{'id': 5047, 'pubMedId': 25436981, 'title': 'Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25436981'}, {'id': 5053, 'pubMedId': 26574479, 'title': 'Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26574479'}]",,03/28/2016
0,03/28/2016,mTORC1 Inhibitor,153,8400,mTORC1 Inhibitor,STK11 P281fs*6,"[{'id': 3134, 'pubMedId': 24387336, 'title': 'Targeting the LKB1 tumor suppressor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24387336'}]",,03/28/2016
0,03/28/2016,mTOR Inhibitor,152,8401,mTOR Inhibitor,STK11 Q123*,"[{'id': 5047, 'pubMedId': 25436981, 'title': 'Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25436981'}, {'id': 5053, 'pubMedId': 26574479, 'title': 'Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26574479'}]",,03/28/2016
0,03/28/2016,mTORC1 Inhibitor,153,8402,mTORC1 Inhibitor,STK11 Q123*,"[{'id': 3134, 'pubMedId': 24387336, 'title': 'Targeting the LKB1 tumor suppressor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24387336'}]",,03/28/2016
0,03/28/2016,mTORC1 Inhibitor,153,8403,mTORC1 Inhibitor,STK11 E70*,"[{'id': 3134, 'pubMedId': 24387336, 'title': 'Targeting the LKB1 tumor suppressor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24387336'}]",,03/28/2016
0,03/28/2016,mTOR Inhibitor,152,8404,mTOR Inhibitor,STK11 E70*,"[{'id': 5047, 'pubMedId': 25436981, 'title': 'Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25436981'}, {'id': 5053, 'pubMedId': 26574479, 'title': 'Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26574479'}]",,03/28/2016
0,03/28/2016,mTORC1 Inhibitor,153,8405,mTORC1 Inhibitor,STK11 D176N,"[{'id': 3134, 'pubMedId': 24387336, 'title': 'Targeting the LKB1 tumor suppressor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24387336'}]",,03/28/2016
0,03/28/2016,mTOR Inhibitor,152,8406,mTOR Inhibitor,STK11 D176N,"[{'id': 5047, 'pubMedId': 25436981, 'title': 'Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25436981'}, {'id': 5053, 'pubMedId': 26574479, 'title': 'Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26574479'}]",,03/28/2016
0,03/28/2016,mTOR Inhibitor,152,8407,mTOR Inhibitor,STK11 D53Tfs*11,"[{'id': 5047, 'pubMedId': 25436981, 'title': 'Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25436981'}, {'id': 5053, 'pubMedId': 26574479, 'title': 'Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26574479'}]",,03/28/2016
0,03/28/2016,mTORC1 Inhibitor,153,8408,mTORC1 Inhibitor,STK11 D53Tfs*11,"[{'id': 3134, 'pubMedId': 24387336, 'title': 'Targeting the LKB1 tumor suppressor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24387336'}]",,03/28/2016
0,03/28/2016,mTOR Inhibitor,152,8409,mTOR Inhibitor,STK11 G61Afs*3,"[{'id': 5047, 'pubMedId': 25436981, 'title': 'Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25436981'}, {'id': 5053, 'pubMedId': 26574479, 'title': 'Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26574479'}]",,03/28/2016
0,03/28/2016,mTORC1 Inhibitor,153,8410,mTORC1 Inhibitor,STK11 G61Afs*3,"[{'id': 3134, 'pubMedId': 24387336, 'title': 'Targeting the LKB1 tumor suppressor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24387336'}]",,03/28/2016
0,03/28/2016,mTORC1 Inhibitor,153,8411,mTORC1 Inhibitor,STK11 L285Q,"[{'id': 3134, 'pubMedId': 24387336, 'title': 'Targeting the LKB1 tumor suppressor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24387336'}]",,03/28/2016
0,03/28/2016,mTOR Inhibitor,152,8412,mTOR Inhibitor,STK11 L285Q,"[{'id': 5047, 'pubMedId': 25436981, 'title': 'Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25436981'}, {'id': 5053, 'pubMedId': 26574479, 'title': 'Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26574479'}]",,03/28/2016
0,03/28/2016,mTORC1 Inhibitor,153,8413,mTORC1 Inhibitor,STK11 Q159*,"[{'id': 3134, 'pubMedId': 24387336, 'title': 'Targeting the LKB1 tumor suppressor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24387336'}]",,03/28/2016
0,03/28/2016,mTOR Inhibitor,152,8414,mTOR Inhibitor,STK11 Q159*,"[{'id': 5047, 'pubMedId': 25436981, 'title': 'Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25436981'}, {'id': 5053, 'pubMedId': 26574479, 'title': 'Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26574479'}]",,03/28/2016
0,03/28/2016,mTOR Inhibitor,152,8415,mTOR Inhibitor,STK11 Q170*,"[{'id': 5047, 'pubMedId': 25436981, 'title': 'Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25436981'}, {'id': 5053, 'pubMedId': 26574479, 'title': 'Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26574479'}]",,03/28/2016
0,03/28/2016,mTORC1 Inhibitor,153,8416,mTORC1 Inhibitor,STK11 Q170*,"[{'id': 3134, 'pubMedId': 24387336, 'title': 'Targeting the LKB1 tumor suppressor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24387336'}]",,03/28/2016
0,03/28/2016,mTORC1 Inhibitor,153,8417,mTORC1 Inhibitor,STK11 Q37*,"[{'id': 3134, 'pubMedId': 24387336, 'title': 'Targeting the LKB1 tumor suppressor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24387336'}]",,03/28/2016
0,03/28/2016,mTOR Inhibitor,152,8418,mTOR Inhibitor,STK11 Q37*,"[{'id': 5047, 'pubMedId': 25436981, 'title': 'Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25436981'}, {'id': 5053, 'pubMedId': 26574479, 'title': 'Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26574479'}]",,03/28/2016
0,03/28/2016,mTOR Inhibitor,152,8419,mTOR Inhibitor,STK11 E120*,"[{'id': 5047, 'pubMedId': 25436981, 'title': 'Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25436981'}, {'id': 5053, 'pubMedId': 26574479, 'title': 'Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26574479'}]",,03/28/2016
0,03/28/2016,mTORC1 Inhibitor,153,8420,mTORC1 Inhibitor,STK11 E120*,"[{'id': 3134, 'pubMedId': 24387336, 'title': 'Targeting the LKB1 tumor suppressor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24387336'}]",,03/28/2016
0,03/28/2016,mTOR Inhibitor,152,8421,mTOR Inhibitor,STK11 S216F,"[{'id': 5047, 'pubMedId': 25436981, 'title': 'Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25436981'}, {'id': 5053, 'pubMedId': 26574479, 'title': 'Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26574479'}]",,03/28/2016
0,03/28/2016,mTORC1 Inhibitor,153,8422,mTORC1 Inhibitor,STK11 S216F,"[{'id': 3134, 'pubMedId': 24387336, 'title': 'Targeting the LKB1 tumor suppressor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24387336'}]",,03/28/2016
0,03/28/2016,mTOR Inhibitor,152,8423,mTOR Inhibitor,STK11 F157S,"[{'id': 5047, 'pubMedId': 25436981, 'title': 'Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25436981'}, {'id': 5053, 'pubMedId': 26574479, 'title': 'Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26574479'}]",,03/28/2016
0,03/28/2016,mTORC1 Inhibitor,153,8424,mTORC1 Inhibitor,STK11 F157S,"[{'id': 3134, 'pubMedId': 24387336, 'title': 'Targeting the LKB1 tumor suppressor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24387336'}]",,03/28/2016
0,03/28/2016,mTOR Inhibitor,152,8425,mTOR Inhibitor,STK11 Y60*,"[{'id': 5047, 'pubMedId': 25436981, 'title': 'Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25436981'}, {'id': 5053, 'pubMedId': 26574479, 'title': 'Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26574479'}]",,03/28/2016
0,03/28/2016,mTORC1 Inhibitor,153,8426,mTORC1 Inhibitor,STK11 Y60*,"[{'id': 3134, 'pubMedId': 24387336, 'title': 'Targeting the LKB1 tumor suppressor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24387336'}]",,03/28/2016
0,03/28/2016,mTOR Inhibitor,152,8427,mTOR Inhibitor,STK11 G163D,"[{'id': 5047, 'pubMedId': 25436981, 'title': 'Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25436981'}, {'id': 5053, 'pubMedId': 26574479, 'title': 'Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26574479'}]",,03/28/2016
0,03/28/2016,mTORC1 Inhibitor,153,8428,mTORC1 Inhibitor,STK11 G163D,"[{'id': 3134, 'pubMedId': 24387336, 'title': 'Targeting the LKB1 tumor suppressor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24387336'}]",,03/28/2016
0,03/28/2016,mTOR Inhibitor,152,8429,mTOR Inhibitor,STK11 Q170P,"[{'id': 5047, 'pubMedId': 25436981, 'title': 'Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25436981'}, {'id': 5053, 'pubMedId': 26574479, 'title': 'Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26574479'}]",,03/28/2016
0,03/28/2016,mTORC1 Inhibitor,153,8430,mTORC1 Inhibitor,STK11 Q170P,"[{'id': 3134, 'pubMedId': 24387336, 'title': 'Targeting the LKB1 tumor suppressor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24387336'}]",,03/28/2016
0,03/28/2016,mTOR Inhibitor,152,8431,mTOR Inhibitor,STK11 G171S,"[{'id': 5047, 'pubMedId': 25436981, 'title': 'Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25436981'}, {'id': 5053, 'pubMedId': 26574479, 'title': 'Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26574479'}]",,03/28/2016
0,03/28/2016,mTORC1 Inhibitor,153,8432,mTORC1 Inhibitor,STK11 G171S,"[{'id': 3134, 'pubMedId': 24387336, 'title': 'Targeting the LKB1 tumor suppressor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24387336'}]",,03/28/2016
0,03/28/2016,mTOR Inhibitor,152,8433,mTOR Inhibitor,STK11 H174R,"[{'id': 5047, 'pubMedId': 25436981, 'title': 'Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25436981'}, {'id': 5053, 'pubMedId': 26574479, 'title': 'Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26574479'}]",,03/28/2016
0,03/28/2016,mTORC1 Inhibitor,153,8434,mTORC1 Inhibitor,STK11 H174R,"[{'id': 3134, 'pubMedId': 24387336, 'title': 'Targeting the LKB1 tumor suppressor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24387336'}]",,03/28/2016
0,03/28/2016,mTORC1 Inhibitor,153,8435,mTORC1 Inhibitor,STK11 D176Y,"[{'id': 3134, 'pubMedId': 24387336, 'title': 'Targeting the LKB1 tumor suppressor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24387336'}]",,03/28/2016
0,03/28/2016,mTOR Inhibitor,152,8436,mTOR Inhibitor,STK11 D176Y,"[{'id': 5047, 'pubMedId': 25436981, 'title': 'Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25436981'}, {'id': 5053, 'pubMedId': 26574479, 'title': 'Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26574479'}]",,03/28/2016
0,03/28/2016,mTOR Inhibitor,152,8437,mTOR Inhibitor,STK11 I177N,"[{'id': 5047, 'pubMedId': 25436981, 'title': 'Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25436981'}, {'id': 5053, 'pubMedId': 26574479, 'title': 'Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26574479'}]",,03/28/2016
0,03/28/2016,mTORC1 Inhibitor,153,8438,mTORC1 Inhibitor,STK11 I177N,"[{'id': 3134, 'pubMedId': 24387336, 'title': 'Targeting the LKB1 tumor suppressor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24387336'}]",,03/28/2016
0,03/28/2016,mTORC1 Inhibitor,153,8439,mTORC1 Inhibitor,STK11 N181E,"[{'id': 3134, 'pubMedId': 24387336, 'title': 'Targeting the LKB1 tumor suppressor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24387336'}]",,03/28/2016
0,03/28/2016,mTOR Inhibitor,152,8440,mTOR Inhibitor,STK11 N181E,"[{'id': 5047, 'pubMedId': 25436981, 'title': 'Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25436981'}, {'id': 5053, 'pubMedId': 26574479, 'title': 'Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26574479'}]",,03/28/2016
0,03/28/2016,mTORC1 Inhibitor,153,8441,mTORC1 Inhibitor,STK11 E199K,"[{'id': 3134, 'pubMedId': 24387336, 'title': 'Targeting the LKB1 tumor suppressor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24387336'}]",,03/28/2016
0,03/28/2016,mTOR Inhibitor,152,8442,mTOR Inhibitor,STK11 E199K,"[{'id': 5047, 'pubMedId': 25436981, 'title': 'Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25436981'}, {'id': 5053, 'pubMedId': 26574479, 'title': 'Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26574479'}]",,03/28/2016
0,03/28/2016,mTORC1 Inhibitor,153,8443,mTORC1 Inhibitor,STK11 A205T,"[{'id': 3134, 'pubMedId': 24387336, 'title': 'Targeting the LKB1 tumor suppressor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24387336'}]",,03/28/2016
0,03/28/2016,mTOR Inhibitor,152,8444,mTOR Inhibitor,STK11 A205T,"[{'id': 5047, 'pubMedId': 25436981, 'title': 'Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25436981'}, {'id': 5053, 'pubMedId': 26574479, 'title': 'Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26574479'}]",,03/28/2016
0,03/28/2016,mTORC1 Inhibitor,153,8445,mTORC1 Inhibitor,STK11 E223V,"[{'id': 3134, 'pubMedId': 24387336, 'title': 'Targeting the LKB1 tumor suppressor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24387336'}]",,03/28/2016
0,03/28/2016,mTOR Inhibitor,152,8446,mTOR Inhibitor,STK11 E223V,"[{'id': 5047, 'pubMedId': 25436981, 'title': 'Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25436981'}, {'id': 5053, 'pubMedId': 26574479, 'title': 'Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26574479'}]",,03/28/2016
0,03/28/2016,mTOR Inhibitor,152,8447,mTOR Inhibitor,STK11 L245R,"[{'id': 5047, 'pubMedId': 25436981, 'title': 'Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25436981'}, {'id': 5053, 'pubMedId': 26574479, 'title': 'Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26574479'}]",,03/28/2016
0,03/28/2016,mTORC1 Inhibitor,153,8448,mTORC1 Inhibitor,STK11 L245R,"[{'id': 3134, 'pubMedId': 24387336, 'title': 'Targeting the LKB1 tumor suppressor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24387336'}]",,03/28/2016
0,03/28/2016,mTORC1 Inhibitor,153,8449,mTORC1 Inhibitor,STK11 T250P,"[{'id': 3134, 'pubMedId': 24387336, 'title': 'Targeting the LKB1 tumor suppressor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24387336'}]",,03/28/2016
0,03/28/2016,mTOR Inhibitor,152,8450,mTOR Inhibitor,STK11 T250P,"[{'id': 5047, 'pubMedId': 25436981, 'title': 'Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25436981'}, {'id': 5053, 'pubMedId': 26574479, 'title': 'Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26574479'}]",,03/28/2016
0,03/28/2016,mTORC1 Inhibitor,153,8451,mTORC1 Inhibitor,STK11 Y272H,"[{'id': 3134, 'pubMedId': 24387336, 'title': 'Targeting the LKB1 tumor suppressor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24387336'}]",,03/28/2016
0,03/28/2016,mTOR Inhibitor,152,8452,mTOR Inhibitor,STK11 Y272H,"[{'id': 5047, 'pubMedId': 25436981, 'title': 'Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25436981'}, {'id': 5053, 'pubMedId': 26574479, 'title': 'Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26574479'}]",,03/28/2016
0,03/28/2016,mTOR Inhibitor,152,8453,mTOR Inhibitor,STK11 D277Y,"[{'id': 5047, 'pubMedId': 25436981, 'title': 'Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25436981'}, {'id': 5053, 'pubMedId': 26574479, 'title': 'Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26574479'}]",,03/28/2016
0,03/28/2016,mTORC1 Inhibitor,153,8454,mTORC1 Inhibitor,STK11 D277Y,"[{'id': 3134, 'pubMedId': 24387336, 'title': 'Targeting the LKB1 tumor suppressor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24387336'}]",,03/28/2016
0,03/28/2016,mTORC1 Inhibitor,153,8455,mTORC1 Inhibitor,STK11 F354L,"[{'id': 3134, 'pubMedId': 24387336, 'title': 'Targeting the LKB1 tumor suppressor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24387336'}]",,03/28/2016
0,03/28/2016,mTOR Inhibitor,152,8456,mTOR Inhibitor,STK11 F354L,"[{'id': 5047, 'pubMedId': 25436981, 'title': 'Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25436981'}, {'id': 5053, 'pubMedId': 26574479, 'title': 'Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26574479'}]",,03/28/2016
0,03/28/2016,mTORC1 Inhibitor,153,8457,mTORC1 Inhibitor,STK11 K44*,"[{'id': 3134, 'pubMedId': 24387336, 'title': 'Targeting the LKB1 tumor suppressor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24387336'}]",,03/28/2016
0,03/28/2016,mTOR Inhibitor,152,8458,mTOR Inhibitor,STK11 K44*,"[{'id': 5047, 'pubMedId': 25436981, 'title': 'Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25436981'}, {'id': 5053, 'pubMedId': 26574479, 'title': 'Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26574479'}]",,03/28/2016
0,03/28/2016,mTOR Inhibitor,152,8459,mTOR Inhibitor,STK11 E165*,"[{'id': 5047, 'pubMedId': 25436981, 'title': 'Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25436981'}, {'id': 5053, 'pubMedId': 26574479, 'title': 'Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26574479'}]",,03/28/2016
0,03/28/2016,mTORC1 Inhibitor,153,8460,mTORC1 Inhibitor,STK11 E165*,"[{'id': 3134, 'pubMedId': 24387336, 'title': 'Targeting the LKB1 tumor suppressor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24387336'}]",,03/28/2016
0,03/28/2016,mTORC1 Inhibitor,153,8461,mTORC1 Inhibitor,STK11 E33*,"[{'id': 3134, 'pubMedId': 24387336, 'title': 'Targeting the LKB1 tumor suppressor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24387336'}]",,03/28/2016
0,03/28/2016,mTOR Inhibitor,152,8462,mTOR Inhibitor,STK11 E33*,"[{'id': 5047, 'pubMedId': 25436981, 'title': 'Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25436981'}, {'id': 5053, 'pubMedId': 26574479, 'title': 'Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26574479'}]",,03/28/2016
0,03/28/2016,mTOR Inhibitor,152,8463,mTOR Inhibitor,STK11 P281L,"[{'id': 5047, 'pubMedId': 25436981, 'title': 'Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25436981'}, {'id': 5053, 'pubMedId': 26574479, 'title': 'Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26574479'}]",,03/28/2016
0,03/28/2016,mTORC1 Inhibitor,153,8464,mTORC1 Inhibitor,STK11 P281L,"[{'id': 3134, 'pubMedId': 24387336, 'title': 'Targeting the LKB1 tumor suppressor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24387336'}]",,03/28/2016
0,03/28/2016,mTOR Inhibitor,152,8465,mTOR Inhibitor,STK11 K62Sfs*100,"[{'id': 5047, 'pubMedId': 25436981, 'title': 'Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25436981'}, {'id': 5053, 'pubMedId': 26574479, 'title': 'Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26574479'}]",,03/28/2016
0,03/28/2016,mTORC1 Inhibitor,153,8466,mTORC1 Inhibitor,STK11 K62Sfs*100,"[{'id': 3134, 'pubMedId': 24387336, 'title': 'Targeting the LKB1 tumor suppressor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24387336'}]",,03/28/2016
0,03/28/2016,mTORC1 Inhibitor,153,8467,mTORC1 Inhibitor,STK11 K62*,"[{'id': 3134, 'pubMedId': 24387336, 'title': 'Targeting the LKB1 tumor suppressor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24387336'}]",,03/28/2016
0,03/28/2016,mTOR Inhibitor,152,8468,mTOR Inhibitor,STK11 K62*,"[{'id': 5047, 'pubMedId': 25436981, 'title': 'Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25436981'}, {'id': 5053, 'pubMedId': 26574479, 'title': 'Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26574479'}]",,03/28/2016
0,03/28/2016,mTORC1 Inhibitor,153,8469,mTORC1 Inhibitor,STK11 G56Tfs*4,"[{'id': 3134, 'pubMedId': 24387336, 'title': 'Targeting the LKB1 tumor suppressor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24387336'}]",,03/28/2016
0,03/28/2016,mTOR Inhibitor,152,8470,mTOR Inhibitor,STK11 G56Tfs*4,"[{'id': 5047, 'pubMedId': 25436981, 'title': 'Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25436981'}, {'id': 5053, 'pubMedId': 26574479, 'title': 'Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26574479'}]",,03/28/2016
0,03/28/2016,mTOR Inhibitor,152,8471,mTOR Inhibitor,STK11 E57Sfs*107,"[{'id': 5047, 'pubMedId': 25436981, 'title': 'Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25436981'}, {'id': 5053, 'pubMedId': 26574479, 'title': 'Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26574479'}]",,03/28/2016
0,03/28/2016,mTORC1 Inhibitor,153,8472,mTORC1 Inhibitor,STK11 E57Sfs*107,"[{'id': 3134, 'pubMedId': 24387336, 'title': 'Targeting the LKB1 tumor suppressor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24387336'}]",,03/28/2016
0,03/29/2016,mTOR Inhibitor,152,8474,mTOR Inhibitor,STK11 D194E,"[{'id': 5047, 'pubMedId': 25436981, 'title': 'Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25436981'}, {'id': 5053, 'pubMedId': 26574479, 'title': 'Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26574479'}]",,03/29/2016
0,03/29/2016,mTORC1 Inhibitor,153,8475,mTORC1 Inhibitor,STK11 D194E,"[{'id': 3134, 'pubMedId': 24387336, 'title': 'Targeting the LKB1 tumor suppressor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24387336'}]",,03/29/2016
0,04/01/2016,Akt Inhibitor (Pan),4,8501,Akt Inhibitor (Pan),PIK3CA E81K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/01/2016
0,04/01/2016,Akt1 Inhibitor,6,8502,Akt1 Inhibitor,PIK3CA E81K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/01/2016
0,04/01/2016,Akt2 Inhibitor,7,8503,Akt2 Inhibitor,PIK3CA E81K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/01/2016
0,04/01/2016,Akt3 Inhibitor,8,8504,Akt3 Inhibitor,PIK3CA E81K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/01/2016
0,04/01/2016,mTOR Inhibitor,152,8505,mTOR Inhibitor,PIK3CA E81K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/01/2016
0,04/01/2016,mTORC1 Inhibitor,153,8506,mTORC1 Inhibitor,PIK3CA E81K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/01/2016
0,04/01/2016,mTORC2 Inhibitor,154,8507,mTORC2 Inhibitor,PIK3CA E81K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/01/2016
0,04/01/2016,PI3K Inhibitor (Pan),181,8508,PI3K Inhibitor (Pan),PIK3CA E81K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/01/2016
0,04/01/2016,PIK3CA inhibitor,182,8509,PIK3CA inhibitor,PIK3CA E81K,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,04/01/2016
0,04/06/2016,JAK2 Inhibitor – ATP competitive,131,8515,JAK2 Inhibitor – ATP competitive,CALR L367fs*46,"[{'id': 3953, 'pubMedId': 24325356, 'title': 'Somatic mutations of calreticulin in myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24325356'}, {'id': 3954, 'pubMedId': 24645956, 'title': 'JAK inhibitor in CALR-mutant myelofibrosis.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24645956'}]",,04/06/2016
0,04/06/2016,p53 Activator,166,8516,p53 Activator,TP53 D7A,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/06/2016
0,04/06/2016,p53 Gene Therapy,167,8517,p53 Gene Therapy,TP53 D7A,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/06/2016
0,04/08/2016,p53 Activator,166,8518,p53 Activator,TP53 N235D,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/08/2016
0,04/08/2016,p53 Gene Therapy,167,8519,p53 Gene Therapy,TP53 N235D,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/08/2016
0,04/08/2016,ALK Inhibitor,9,8520,ALK Inhibitor,ALK L1196M,"[{'id': 527, 'pubMedId': 21838707, 'title': 'Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21838707'}]",,04/08/2016
0,04/08/2016,ALK Inhibitor,9,8521,ALK Inhibitor,ALK L1196Q,"[{'id': 527, 'pubMedId': 21838707, 'title': 'Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21838707'}]",,04/08/2016
0,04/11/2016,MEK inhibitor (Pan),142,8526,MEK inhibitor (Pan),MAP2K1 F53L,"[{'id': 119, 'pubMedId': 18632602, 'title': 'Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18632602'}, {'id': 2253, 'pubMedId': 18223206, 'title': 'Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18223206'}]",,04/11/2016
0,04/11/2016,MEK1 Inhibitor,143,8527,MEK1 Inhibitor,MAP2K1 F53L,"[{'id': 119, 'pubMedId': 18632602, 'title': 'Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18632602'}, {'id': 2253, 'pubMedId': 18223206, 'title': 'Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18223206'}]",,04/11/2016
0,04/11/2016,MEK inhibitor (Pan),142,8528,MEK inhibitor (Pan),MAP2K1 E203K,"[{'id': 119, 'pubMedId': 18632602, 'title': 'Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18632602'}, {'id': 2253, 'pubMedId': 18223206, 'title': 'Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18223206'}]",,04/11/2016
0,04/11/2016,MEK1 Inhibitor,143,8529,MEK1 Inhibitor,MAP2K1 E203K,"[{'id': 119, 'pubMedId': 18632602, 'title': 'Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18632602'}, {'id': 2253, 'pubMedId': 18223206, 'title': 'Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18223206'}]",,04/11/2016
0,04/11/2016,MEK inhibitor (Pan),142,8530,MEK inhibitor (Pan),MAP2K1 R47Q,"[{'id': 119, 'pubMedId': 18632602, 'title': 'Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18632602'}, {'id': 2253, 'pubMedId': 18223206, 'title': 'Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18223206'}]",,04/11/2016
0,04/11/2016,MEK1 Inhibitor,143,8531,MEK1 Inhibitor,MAP2K1 R47Q,"[{'id': 119, 'pubMedId': 18632602, 'title': 'Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18632602'}, {'id': 2253, 'pubMedId': 18223206, 'title': 'Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18223206'}]",,04/11/2016
0,04/11/2016,p53 Activator,166,8532,p53 Activator,TP53 S241Y,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/11/2016
0,04/11/2016,p53 Gene Therapy,167,8533,p53 Gene Therapy,TP53 S241Y,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/11/2016
0,04/11/2016,p53 Activator,166,8534,p53 Activator,TP53 R158H,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/11/2016
0,04/11/2016,p53 Gene Therapy,167,8535,p53 Gene Therapy,TP53 R158H,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/11/2016
0,04/11/2016,p53 Activator,166,8536,p53 Activator,TP53 P219S,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/11/2016
0,04/11/2016,p53 Gene Therapy,167,8537,p53 Gene Therapy,TP53 P219S,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/11/2016
0,04/11/2016,p53 Activator,166,8538,p53 Activator,TP53 P152L,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/11/2016
0,04/11/2016,p53 Gene Therapy,167,8539,p53 Gene Therapy,TP53 P152L,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/11/2016
0,04/11/2016,p53 Activator,166,8540,p53 Activator,TP53 I254T,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/11/2016
0,04/11/2016,p53 Gene Therapy,167,8541,p53 Gene Therapy,TP53 I254T,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/11/2016
0,04/11/2016,p53 Activator,166,8542,p53 Activator,TP53 H193P,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/11/2016
0,04/11/2016,p53 Gene Therapy,167,8543,p53 Gene Therapy,TP53 H193P,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/11/2016
0,04/11/2016,p53 Activator,166,8544,p53 Activator,TP53 E285V,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/11/2016
0,04/11/2016,p53 Gene Therapy,167,8545,p53 Gene Therapy,TP53 E285V,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/11/2016
0,04/11/2016,p53 Gene Therapy,167,8547,p53 Gene Therapy,TP53 C275*,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/11/2016
0,04/13/2016,,8576,MRX34,SMARCB1 loss,"[{'id': 2815, 'pubMedId': 21173237, 'title': 'Therapeutically targeting cyclin D1 in primary tumors arising from loss of Ini1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21173237'}]",1035,MRX34,04/13/2016
0,04/13/2016,,8578,Fenretinide,SMARCB1 loss,"[{'id': 2822, 'pubMedId': 16302003, 'title': 'Targeting cyclin D1, a downstream effector of INI1/hSNF5, in rhabdoid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16302003'}]",2731,Fenretinide,04/13/2016
0,04/13/2016,EZH2 inhibitor,84,8580,EZH2 inhibitor,SMARCB1 loss,"[{'id': 2724, 'pubMedId': 23620515, 'title': 'Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23620515'}]",,04/13/2016
0,04/13/2016,MEK inhibitor (Pan),142,8581,MEK inhibitor (Pan),MAP2K1 Q56P,"[{'id': 119, 'pubMedId': 18632602, 'title': 'Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18632602'}, {'id': 2253, 'pubMedId': 18223206, 'title': 'Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18223206'}]",,04/13/2016
0,04/13/2016,MEK1 Inhibitor,143,8582,MEK1 Inhibitor,MAP2K1 Q56P,"[{'id': 119, 'pubMedId': 18632602, 'title': 'Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18632602'}, {'id': 2253, 'pubMedId': 18223206, 'title': 'Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18223206'}]",,04/13/2016
0,04/14/2016,JAK Inhibitor (Pan) – ATP competitive,127,8618,JAK Inhibitor (Pan) – ATP competitive,MPL E230G,"[{'id': 263, 'pubMedId': 16834459, 'title': 'MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16834459'}]",,04/14/2016
0,04/14/2016,JAK2 Inhibitor,130,8619,JAK2 Inhibitor,MPL E230G,"[{'id': 836, 'pubMedId': 17541402, 'title': 'TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17541402'}, {'id': 837, 'pubMedId': 18354492, 'title': 'TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18354492'}]",,04/14/2016
0,04/14/2016,JAK Inhibitor (Pan),126,8620,JAK Inhibitor (Pan),MPL E230G,"[{'id': 263, 'pubMedId': 16834459, 'title': 'MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16834459'}]",,04/14/2016
0,04/14/2016,JAK2 Inhibitor – ATP competitive,131,8621,JAK2 Inhibitor – ATP competitive,MPL E230G,"[{'id': 836, 'pubMedId': 17541402, 'title': 'TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17541402'}, {'id': 837, 'pubMedId': 18354492, 'title': 'TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18354492'}]",,04/14/2016
0,04/14/2016,JAK2 Inhibitor – ATP competitive,131,8622,JAK2 Inhibitor – ATP competitive,MPL R321W,"[{'id': 836, 'pubMedId': 17541402, 'title': 'TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17541402'}, {'id': 837, 'pubMedId': 18354492, 'title': 'TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18354492'}]",,04/14/2016
0,04/14/2016,JAK Inhibitor (Pan) – ATP competitive,127,8623,JAK Inhibitor (Pan) – ATP competitive,MPL R321W,"[{'id': 263, 'pubMedId': 16834459, 'title': 'MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16834459'}]",,04/14/2016
0,04/14/2016,JAK2 Inhibitor,130,8624,JAK2 Inhibitor,MPL R321W,"[{'id': 836, 'pubMedId': 17541402, 'title': 'TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17541402'}, {'id': 837, 'pubMedId': 18354492, 'title': 'TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18354492'}]",,04/14/2016
0,04/14/2016,JAK Inhibitor (Pan),126,8625,JAK Inhibitor (Pan),MPL R321W,"[{'id': 263, 'pubMedId': 16834459, 'title': 'MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16834459'}]",,04/14/2016
0,04/14/2016,JAK2 Inhibitor,130,8626,JAK2 Inhibitor,MPL S204F,"[{'id': 836, 'pubMedId': 17541402, 'title': 'TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17541402'}, {'id': 837, 'pubMedId': 18354492, 'title': 'TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18354492'}]",,04/14/2016
0,04/14/2016,JAK Inhibitor (Pan),126,8627,JAK Inhibitor (Pan),MPL S204F,"[{'id': 263, 'pubMedId': 16834459, 'title': 'MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16834459'}]",,04/14/2016
0,04/14/2016,JAK Inhibitor (Pan) – ATP competitive,127,8628,JAK Inhibitor (Pan) – ATP competitive,MPL S204F,"[{'id': 263, 'pubMedId': 16834459, 'title': 'MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16834459'}]",,04/14/2016
0,04/14/2016,JAK2 Inhibitor – ATP competitive,131,8629,JAK2 Inhibitor – ATP competitive,MPL S204F,"[{'id': 836, 'pubMedId': 17541402, 'title': 'TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17541402'}, {'id': 837, 'pubMedId': 18354492, 'title': 'TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18354492'}]",,04/14/2016
0,04/14/2016,JAK2 Inhibitor,130,8630,JAK2 Inhibitor,MPL S204P,"[{'id': 836, 'pubMedId': 17541402, 'title': 'TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17541402'}, {'id': 837, 'pubMedId': 18354492, 'title': 'TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18354492'}]",,04/14/2016
0,04/14/2016,JAK Inhibitor (Pan) – ATP competitive,127,8631,JAK Inhibitor (Pan) – ATP competitive,MPL S204P,"[{'id': 263, 'pubMedId': 16834459, 'title': 'MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16834459'}]",,04/14/2016
0,04/14/2016,JAK Inhibitor (Pan),126,8632,JAK Inhibitor (Pan),MPL S204P,"[{'id': 263, 'pubMedId': 16834459, 'title': 'MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16834459'}]",,04/14/2016
0,04/14/2016,JAK2 Inhibitor – ATP competitive,131,8633,JAK2 Inhibitor – ATP competitive,MPL S204P,"[{'id': 836, 'pubMedId': 17541402, 'title': 'TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17541402'}, {'id': 837, 'pubMedId': 18354492, 'title': 'TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18354492'}]",,04/14/2016
0,04/14/2016,JAK2 Inhibitor,130,8634,JAK2 Inhibitor,MPL T119I,"[{'id': 836, 'pubMedId': 17541402, 'title': 'TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17541402'}, {'id': 837, 'pubMedId': 18354492, 'title': 'TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18354492'}]",,04/14/2016
0,04/14/2016,JAK Inhibitor (Pan),126,8635,JAK Inhibitor (Pan),MPL T119I,"[{'id': 263, 'pubMedId': 16834459, 'title': 'MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16834459'}]",,04/14/2016
0,04/14/2016,JAK2 Inhibitor – ATP competitive,131,8636,JAK2 Inhibitor – ATP competitive,MPL T119I,"[{'id': 836, 'pubMedId': 17541402, 'title': 'TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17541402'}, {'id': 837, 'pubMedId': 18354492, 'title': 'TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18354492'}]",,04/14/2016
0,04/14/2016,JAK Inhibitor (Pan) – ATP competitive,127,8637,JAK Inhibitor (Pan) – ATP competitive,MPL T119I,"[{'id': 263, 'pubMedId': 16834459, 'title': 'MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16834459'}]",,04/14/2016
0,04/14/2016,JAK Inhibitor (Pan) – ATP competitive,127,8638,JAK Inhibitor (Pan) – ATP competitive,MPL V285E,"[{'id': 263, 'pubMedId': 16834459, 'title': 'MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16834459'}]",,04/14/2016
0,04/14/2016,JAK2 Inhibitor – ATP competitive,131,8639,JAK2 Inhibitor – ATP competitive,MPL V285E,"[{'id': 836, 'pubMedId': 17541402, 'title': 'TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17541402'}, {'id': 837, 'pubMedId': 18354492, 'title': 'TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18354492'}]",,04/14/2016
0,04/14/2016,JAK2 Inhibitor,130,8640,JAK2 Inhibitor,MPL V285E,"[{'id': 836, 'pubMedId': 17541402, 'title': 'TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17541402'}, {'id': 837, 'pubMedId': 18354492, 'title': 'TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18354492'}]",,04/14/2016
0,04/14/2016,JAK Inhibitor (Pan),126,8641,JAK Inhibitor (Pan),MPL V285E,"[{'id': 263, 'pubMedId': 16834459, 'title': 'MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16834459'}]",,04/14/2016
0,04/14/2016,JAK2 Inhibitor,130,8642,JAK2 Inhibitor,MPL Y591D,"[{'id': 836, 'pubMedId': 17541402, 'title': 'TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17541402'}, {'id': 837, 'pubMedId': 18354492, 'title': 'TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18354492'}]",,04/14/2016
0,04/14/2016,JAK Inhibitor (Pan),126,8643,JAK Inhibitor (Pan),MPL Y591D,"[{'id': 263, 'pubMedId': 16834459, 'title': 'MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16834459'}]",,04/14/2016
0,04/14/2016,JAK Inhibitor (Pan) – ATP competitive,127,8644,JAK Inhibitor (Pan) – ATP competitive,MPL Y591D,"[{'id': 263, 'pubMedId': 16834459, 'title': 'MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16834459'}]",,04/14/2016
0,04/14/2016,JAK2 Inhibitor – ATP competitive,131,8645,JAK2 Inhibitor – ATP competitive,MPL Y591D,"[{'id': 836, 'pubMedId': 17541402, 'title': 'TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17541402'}, {'id': 837, 'pubMedId': 18354492, 'title': 'TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18354492'}]",,04/14/2016
0,04/14/2016,JAK2 Inhibitor,130,8646,JAK2 Inhibitor,MPL W515Y,"[{'id': 836, 'pubMedId': 17541402, 'title': 'TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17541402'}, {'id': 837, 'pubMedId': 18354492, 'title': 'TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18354492'}]",,04/14/2016
0,04/14/2016,JAK2 Inhibitor – ATP competitive,131,8647,JAK2 Inhibitor – ATP competitive,MPL W515Y,"[{'id': 836, 'pubMedId': 17541402, 'title': 'TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17541402'}, {'id': 837, 'pubMedId': 18354492, 'title': 'TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18354492'}]",,04/14/2016
0,04/14/2016,JAK Inhibitor (Pan) – ATP competitive,127,8648,JAK Inhibitor (Pan) – ATP competitive,MPL W515Y,"[{'id': 263, 'pubMedId': 16834459, 'title': 'MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16834459'}]",,04/14/2016
0,04/14/2016,JAK Inhibitor (Pan),126,8649,JAK Inhibitor (Pan),MPL W515Y,"[{'id': 263, 'pubMedId': 16834459, 'title': 'MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16834459'}]",,04/14/2016
0,04/14/2016,JAK Inhibitor (Pan),126,8650,JAK Inhibitor (Pan),MPL W515F,"[{'id': 263, 'pubMedId': 16834459, 'title': 'MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16834459'}]",,04/14/2016
0,04/14/2016,JAK Inhibitor (Pan) – ATP competitive,127,8651,JAK Inhibitor (Pan) – ATP competitive,MPL W515F,"[{'id': 263, 'pubMedId': 16834459, 'title': 'MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16834459'}]",,04/14/2016
0,04/14/2016,JAK2 Inhibitor – ATP competitive,131,8652,JAK2 Inhibitor – ATP competitive,MPL W515F,"[{'id': 836, 'pubMedId': 17541402, 'title': 'TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17541402'}, {'id': 837, 'pubMedId': 18354492, 'title': 'TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18354492'}]",,04/14/2016
0,04/14/2016,JAK2 Inhibitor,130,8653,JAK2 Inhibitor,MPL W515F,"[{'id': 836, 'pubMedId': 17541402, 'title': 'TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17541402'}, {'id': 837, 'pubMedId': 18354492, 'title': 'TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18354492'}]",,04/14/2016
0,04/14/2016,JAK2 Inhibitor – ATP competitive,131,8654,JAK2 Inhibitor – ATP competitive,MPL W515M,"[{'id': 836, 'pubMedId': 17541402, 'title': 'TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17541402'}, {'id': 837, 'pubMedId': 18354492, 'title': 'TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18354492'}]",,04/14/2016
0,04/14/2016,JAK2 Inhibitor,130,8655,JAK2 Inhibitor,MPL W515M,"[{'id': 836, 'pubMedId': 17541402, 'title': 'TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17541402'}, {'id': 837, 'pubMedId': 18354492, 'title': 'TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18354492'}]",,04/14/2016
0,04/14/2016,JAK Inhibitor (Pan) – ATP competitive,127,8656,JAK Inhibitor (Pan) – ATP competitive,MPL W515M,"[{'id': 263, 'pubMedId': 16834459, 'title': 'MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16834459'}]",,04/14/2016
0,04/14/2016,JAK Inhibitor (Pan),126,8657,JAK Inhibitor (Pan),MPL W515M,"[{'id': 263, 'pubMedId': 16834459, 'title': 'MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16834459'}]",,04/14/2016
0,04/14/2016,JAK2 Inhibitor,130,8658,JAK2 Inhibitor,MPL W515I,"[{'id': 836, 'pubMedId': 17541402, 'title': 'TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17541402'}, {'id': 837, 'pubMedId': 18354492, 'title': 'TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18354492'}]",,04/14/2016
0,04/14/2016,JAK Inhibitor (Pan) – ATP competitive,127,8659,JAK Inhibitor (Pan) – ATP competitive,MPL W515I,"[{'id': 263, 'pubMedId': 16834459, 'title': 'MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16834459'}]",,04/14/2016
0,04/14/2016,JAK Inhibitor (Pan),126,8660,JAK Inhibitor (Pan),MPL W515I,"[{'id': 263, 'pubMedId': 16834459, 'title': 'MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16834459'}]",,04/14/2016
0,04/14/2016,JAK2 Inhibitor – ATP competitive,131,8661,JAK2 Inhibitor – ATP competitive,MPL W515I,"[{'id': 836, 'pubMedId': 17541402, 'title': 'TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17541402'}, {'id': 837, 'pubMedId': 18354492, 'title': 'TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18354492'}]",,04/14/2016
0,04/14/2016,JAK2 Inhibitor – ATP competitive,131,8662,JAK2 Inhibitor – ATP competitive,MPL W515V,"[{'id': 836, 'pubMedId': 17541402, 'title': 'TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17541402'}, {'id': 837, 'pubMedId': 18354492, 'title': 'TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18354492'}]",,04/14/2016
0,04/14/2016,JAK Inhibitor (Pan),126,8663,JAK Inhibitor (Pan),MPL W515V,"[{'id': 263, 'pubMedId': 16834459, 'title': 'MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16834459'}]",,04/14/2016
0,04/14/2016,JAK2 Inhibitor,130,8664,JAK2 Inhibitor,MPL W515V,"[{'id': 836, 'pubMedId': 17541402, 'title': 'TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17541402'}, {'id': 837, 'pubMedId': 18354492, 'title': 'TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18354492'}]",,04/14/2016
0,04/14/2016,JAK Inhibitor (Pan) – ATP competitive,127,8665,JAK Inhibitor (Pan) – ATP competitive,MPL W515V,"[{'id': 263, 'pubMedId': 16834459, 'title': 'MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16834459'}]",,04/14/2016
0,04/14/2016,JAK2 Inhibitor,130,8666,JAK2 Inhibitor,MPL W515A,"[{'id': 836, 'pubMedId': 17541402, 'title': 'TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17541402'}, {'id': 837, 'pubMedId': 18354492, 'title': 'TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18354492'}]",,04/14/2016
0,04/14/2016,JAK Inhibitor (Pan),126,8667,JAK Inhibitor (Pan),MPL W515A,"[{'id': 263, 'pubMedId': 16834459, 'title': 'MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16834459'}]",,04/14/2016
0,04/14/2016,JAK2 Inhibitor – ATP competitive,131,8668,JAK2 Inhibitor – ATP competitive,MPL W515A,"[{'id': 836, 'pubMedId': 17541402, 'title': 'TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17541402'}, {'id': 837, 'pubMedId': 18354492, 'title': 'TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18354492'}]",,04/14/2016
0,04/14/2016,JAK Inhibitor (Pan) – ATP competitive,127,8669,JAK Inhibitor (Pan) – ATP competitive,MPL W515A,"[{'id': 263, 'pubMedId': 16834459, 'title': 'MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16834459'}]",,04/14/2016
0,04/14/2016,JAK2 Inhibitor,130,8670,JAK2 Inhibitor,MPL W515G,"[{'id': 836, 'pubMedId': 17541402, 'title': 'TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17541402'}, {'id': 837, 'pubMedId': 18354492, 'title': 'TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18354492'}]",,04/14/2016
0,04/14/2016,JAK Inhibitor (Pan) – ATP competitive,127,8671,JAK Inhibitor (Pan) – ATP competitive,MPL W515G,"[{'id': 263, 'pubMedId': 16834459, 'title': 'MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16834459'}]",,04/14/2016
0,04/14/2016,JAK2 Inhibitor – ATP competitive,131,8672,JAK2 Inhibitor – ATP competitive,MPL W515G,"[{'id': 836, 'pubMedId': 17541402, 'title': 'TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17541402'}, {'id': 837, 'pubMedId': 18354492, 'title': 'TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18354492'}]",,04/14/2016
0,04/14/2016,JAK Inhibitor (Pan),126,8673,JAK Inhibitor (Pan),MPL W515G,"[{'id': 263, 'pubMedId': 16834459, 'title': 'MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16834459'}]",,04/14/2016
0,04/14/2016,JAK2 Inhibitor – ATP competitive,131,8674,JAK2 Inhibitor – ATP competitive,MPL W515D,"[{'id': 836, 'pubMedId': 17541402, 'title': 'TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17541402'}, {'id': 837, 'pubMedId': 18354492, 'title': 'TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18354492'}]",,04/14/2016
0,04/14/2016,JAK Inhibitor (Pan),126,8675,JAK Inhibitor (Pan),MPL W515D,"[{'id': 263, 'pubMedId': 16834459, 'title': 'MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16834459'}]",,04/14/2016
0,04/14/2016,JAK Inhibitor (Pan) – ATP competitive,127,8676,JAK Inhibitor (Pan) – ATP competitive,MPL W515D,"[{'id': 263, 'pubMedId': 16834459, 'title': 'MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16834459'}]",,04/14/2016
0,04/14/2016,JAK2 Inhibitor,130,8677,JAK2 Inhibitor,MPL W515D,"[{'id': 836, 'pubMedId': 17541402, 'title': 'TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17541402'}, {'id': 837, 'pubMedId': 18354492, 'title': 'TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18354492'}]",,04/14/2016
0,04/14/2016,JAK2 Inhibitor – ATP competitive,131,8678,JAK2 Inhibitor – ATP competitive,MPL W515E,"[{'id': 836, 'pubMedId': 17541402, 'title': 'TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17541402'}, {'id': 837, 'pubMedId': 18354492, 'title': 'TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18354492'}]",,04/14/2016
0,04/14/2016,JAK Inhibitor (Pan) – ATP competitive,127,8679,JAK Inhibitor (Pan) – ATP competitive,MPL W515E,"[{'id': 263, 'pubMedId': 16834459, 'title': 'MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16834459'}]",,04/14/2016
0,04/14/2016,JAK Inhibitor (Pan),126,8680,JAK Inhibitor (Pan),MPL W515E,"[{'id': 263, 'pubMedId': 16834459, 'title': 'MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16834459'}]",,04/14/2016
0,04/14/2016,JAK2 Inhibitor,130,8681,JAK2 Inhibitor,MPL W515E,"[{'id': 836, 'pubMedId': 17541402, 'title': 'TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17541402'}, {'id': 837, 'pubMedId': 18354492, 'title': 'TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18354492'}]",,04/14/2016
0,04/14/2016,JAK Inhibitor (Pan),126,8682,JAK Inhibitor (Pan),MPL W515R,"[{'id': 263, 'pubMedId': 16834459, 'title': 'MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16834459'}]",,04/14/2016
0,04/14/2016,JAK2 Inhibitor – ATP competitive,131,8683,JAK2 Inhibitor – ATP competitive,MPL W515R,"[{'id': 836, 'pubMedId': 17541402, 'title': 'TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17541402'}, {'id': 837, 'pubMedId': 18354492, 'title': 'TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18354492'}]",,04/14/2016
0,04/14/2016,JAK Inhibitor (Pan) – ATP competitive,127,8684,JAK Inhibitor (Pan) – ATP competitive,MPL W515R,"[{'id': 263, 'pubMedId': 16834459, 'title': 'MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16834459'}]",,04/14/2016
0,04/14/2016,JAK2 Inhibitor,130,8685,JAK2 Inhibitor,MPL W515R,"[{'id': 836, 'pubMedId': 17541402, 'title': 'TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17541402'}, {'id': 837, 'pubMedId': 18354492, 'title': 'TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18354492'}]",,04/14/2016
0,04/14/2016,JAK2 Inhibitor – ATP competitive,131,8686,JAK2 Inhibitor – ATP competitive,MPL W515H,"[{'id': 836, 'pubMedId': 17541402, 'title': 'TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17541402'}, {'id': 837, 'pubMedId': 18354492, 'title': 'TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18354492'}]",,04/14/2016
0,04/14/2016,JAK Inhibitor (Pan) – ATP competitive,127,8687,JAK Inhibitor (Pan) – ATP competitive,MPL W515H,"[{'id': 263, 'pubMedId': 16834459, 'title': 'MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16834459'}]",,04/14/2016
0,04/14/2016,JAK Inhibitor (Pan),126,8688,JAK Inhibitor (Pan),MPL W515H,"[{'id': 263, 'pubMedId': 16834459, 'title': 'MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16834459'}]",,04/14/2016
0,04/14/2016,JAK2 Inhibitor,130,8689,JAK2 Inhibitor,MPL W515H,"[{'id': 836, 'pubMedId': 17541402, 'title': 'TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17541402'}, {'id': 837, 'pubMedId': 18354492, 'title': 'TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18354492'}]",,04/14/2016
0,04/14/2016,JAK2 Inhibitor,130,8690,JAK2 Inhibitor,MPL W515S,"[{'id': 836, 'pubMedId': 17541402, 'title': 'TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17541402'}, {'id': 837, 'pubMedId': 18354492, 'title': 'TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18354492'}]",,04/14/2016
0,04/14/2016,JAK2 Inhibitor – ATP competitive,131,8691,JAK2 Inhibitor – ATP competitive,MPL W515S,"[{'id': 836, 'pubMedId': 17541402, 'title': 'TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17541402'}, {'id': 837, 'pubMedId': 18354492, 'title': 'TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18354492'}]",,04/14/2016
0,04/14/2016,JAK Inhibitor (Pan) – ATP competitive,127,8692,JAK Inhibitor (Pan) – ATP competitive,MPL W515S,"[{'id': 263, 'pubMedId': 16834459, 'title': 'MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16834459'}]",,04/14/2016
0,04/14/2016,JAK Inhibitor (Pan),126,8693,JAK Inhibitor (Pan),MPL W515S,"[{'id': 263, 'pubMedId': 16834459, 'title': 'MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16834459'}]",,04/14/2016
0,04/14/2016,JAK2 Inhibitor – ATP competitive,131,8694,JAK2 Inhibitor – ATP competitive,MPL W515T,"[{'id': 836, 'pubMedId': 17541402, 'title': 'TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17541402'}, {'id': 837, 'pubMedId': 18354492, 'title': 'TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18354492'}]",,04/14/2016
0,04/14/2016,JAK Inhibitor (Pan),126,8695,JAK Inhibitor (Pan),MPL W515T,"[{'id': 263, 'pubMedId': 16834459, 'title': 'MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16834459'}]",,04/14/2016
0,04/14/2016,JAK Inhibitor (Pan) – ATP competitive,127,8696,JAK Inhibitor (Pan) – ATP competitive,MPL W515T,"[{'id': 263, 'pubMedId': 16834459, 'title': 'MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16834459'}]",,04/14/2016
0,04/14/2016,JAK2 Inhibitor,130,8697,JAK2 Inhibitor,MPL W515T,"[{'id': 836, 'pubMedId': 17541402, 'title': 'TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17541402'}, {'id': 837, 'pubMedId': 18354492, 'title': 'TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18354492'}]",,04/14/2016
0,04/14/2016,JAK Inhibitor (Pan),126,8698,JAK Inhibitor (Pan),MPL W515N,"[{'id': 263, 'pubMedId': 16834459, 'title': 'MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16834459'}]",,04/14/2016
0,04/14/2016,JAK Inhibitor (Pan) – ATP competitive,127,8699,JAK Inhibitor (Pan) – ATP competitive,MPL W515N,"[{'id': 263, 'pubMedId': 16834459, 'title': 'MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16834459'}]",,04/14/2016
0,04/14/2016,JAK2 Inhibitor – ATP competitive,131,8700,JAK2 Inhibitor – ATP competitive,MPL W515N,"[{'id': 836, 'pubMedId': 17541402, 'title': 'TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17541402'}, {'id': 837, 'pubMedId': 18354492, 'title': 'TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18354492'}]",,04/14/2016
0,04/14/2016,JAK2 Inhibitor,130,8701,JAK2 Inhibitor,MPL W515N,"[{'id': 836, 'pubMedId': 17541402, 'title': 'TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17541402'}, {'id': 837, 'pubMedId': 18354492, 'title': 'TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18354492'}]",,04/14/2016
0,04/14/2016,JAK2 Inhibitor – ATP competitive,131,8702,JAK2 Inhibitor – ATP competitive,MPL W515Q,"[{'id': 836, 'pubMedId': 17541402, 'title': 'TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17541402'}, {'id': 837, 'pubMedId': 18354492, 'title': 'TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18354492'}]",,04/14/2016
0,04/14/2016,JAK Inhibitor (Pan),126,8703,JAK Inhibitor (Pan),MPL W515Q,"[{'id': 263, 'pubMedId': 16834459, 'title': 'MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16834459'}]",,04/14/2016
0,04/14/2016,JAK Inhibitor (Pan) – ATP competitive,127,8704,JAK Inhibitor (Pan) – ATP competitive,MPL W515Q,"[{'id': 263, 'pubMedId': 16834459, 'title': 'MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16834459'}]",,04/14/2016
0,04/14/2016,JAK2 Inhibitor,130,8705,JAK2 Inhibitor,MPL W515Q,"[{'id': 836, 'pubMedId': 17541402, 'title': 'TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17541402'}, {'id': 837, 'pubMedId': 18354492, 'title': 'TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18354492'}]",,04/14/2016
0,04/14/2016,JAK2 Inhibitor – ATP competitive,131,8706,JAK2 Inhibitor – ATP competitive,MPL W515_P518del,"[{'id': 836, 'pubMedId': 17541402, 'title': 'TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17541402'}, {'id': 837, 'pubMedId': 18354492, 'title': 'TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18354492'}]",,04/14/2016
0,04/14/2016,JAK Inhibitor (Pan),126,8707,JAK Inhibitor (Pan),MPL W515_P518del,"[{'id': 263, 'pubMedId': 16834459, 'title': 'MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16834459'}]",,04/14/2016
0,04/14/2016,JAK Inhibitor (Pan) – ATP competitive,127,8708,JAK Inhibitor (Pan) – ATP competitive,MPL W515_P518del,"[{'id': 263, 'pubMedId': 16834459, 'title': 'MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16834459'}]",,04/14/2016
0,04/14/2016,JAK2 Inhibitor,130,8709,JAK2 Inhibitor,MPL W515_P518del,"[{'id': 836, 'pubMedId': 17541402, 'title': 'TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17541402'}, {'id': 837, 'pubMedId': 18354492, 'title': 'TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18354492'}]",,04/14/2016
0,04/14/2016,JAK Inhibitor (Pan) – ATP competitive,127,8710,JAK Inhibitor (Pan) – ATP competitive,MPL W515K,"[{'id': 263, 'pubMedId': 16834459, 'title': 'MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16834459'}]",,04/14/2016
0,04/14/2016,JAK Inhibitor (Pan),126,8711,JAK Inhibitor (Pan),MPL W515K,"[{'id': 263, 'pubMedId': 16834459, 'title': 'MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16834459'}]",,04/14/2016
0,04/14/2016,JAK2 Inhibitor – ATP competitive,131,8712,JAK2 Inhibitor – ATP competitive,MPL W515K,"[{'id': 836, 'pubMedId': 17541402, 'title': 'TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17541402'}, {'id': 837, 'pubMedId': 18354492, 'title': 'TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18354492'}]",,04/14/2016
0,04/14/2016,JAK2 Inhibitor,130,8713,JAK2 Inhibitor,MPL W515K,"[{'id': 836, 'pubMedId': 17541402, 'title': 'TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17541402'}, {'id': 837, 'pubMedId': 18354492, 'title': 'TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18354492'}]",,04/14/2016
0,04/14/2016,JAK2 Inhibitor – ATP competitive,131,8714,JAK2 Inhibitor – ATP competitive,MPL T487A,"[{'id': 836, 'pubMedId': 17541402, 'title': 'TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17541402'}, {'id': 837, 'pubMedId': 18354492, 'title': 'TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18354492'}]",,04/14/2016
0,04/14/2016,JAK2 Inhibitor,130,8715,JAK2 Inhibitor,MPL T487A,"[{'id': 836, 'pubMedId': 17541402, 'title': 'TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17541402'}, {'id': 837, 'pubMedId': 18354492, 'title': 'TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18354492'}]",,04/14/2016
0,04/14/2016,JAK Inhibitor (Pan) – ATP competitive,127,8716,JAK Inhibitor (Pan) – ATP competitive,MPL T487A,"[{'id': 263, 'pubMedId': 16834459, 'title': 'MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16834459'}]",,04/14/2016
0,04/14/2016,JAK Inhibitor (Pan),126,8717,JAK Inhibitor (Pan),MPL T487A,"[{'id': 263, 'pubMedId': 16834459, 'title': 'MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16834459'}]",,04/14/2016
0,04/15/2016,p53 Activator,166,8718,p53 Activator,TP53 H179Q,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/15/2016
0,04/15/2016,p53 Gene Therapy,167,8719,p53 Gene Therapy,TP53 H179Q,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/15/2016
0,04/22/2016,HDAC Inhibitor,104,8744,HDAC Inhibitor,RB1 R698W,"[{'id': 2739, 'pubMedId': 22293180, 'title': 'Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22293180'}]",,04/22/2016
0,04/22/2016,IDH Inhibitor (Pan),117,8745,IDH Inhibitor (Pan),IDH2 R140X,"[{'id': 2554, 'pubMedId': 25558173, 'title': 'Disease progression in iridocorneal angle tissues of BMP2-induced ocular hypertensive mice with optical coherence tomography.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25558173'}, {'id': 2555, 'pubMedId': 25251602, 'title': 'Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25251602'}]",,04/22/2016
0,04/22/2016,IDH2 Inhibitor,119,8746,IDH2 Inhibitor,IDH2 R140X,"[{'id': 2554, 'pubMedId': 25558173, 'title': 'Disease progression in iridocorneal angle tissues of BMP2-induced ocular hypertensive mice with optical coherence tomography.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25558173'}, {'id': 2555, 'pubMedId': 25251602, 'title': 'Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25251602'}]",,04/22/2016
0,04/22/2016,IDH Inhibitor (Pan),117,8747,IDH Inhibitor (Pan),IDH2 R172X,"[{'id': 2554, 'pubMedId': 25558173, 'title': 'Disease progression in iridocorneal angle tissues of BMP2-induced ocular hypertensive mice with optical coherence tomography.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25558173'}, {'id': 2555, 'pubMedId': 25251602, 'title': 'Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25251602'}]",,04/22/2016
0,04/22/2016,IDH2 Inhibitor,119,8748,IDH2 Inhibitor,IDH2 R172X,"[{'id': 2554, 'pubMedId': 25558173, 'title': 'Disease progression in iridocorneal angle tissues of BMP2-induced ocular hypertensive mice with optical coherence tomography.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25558173'}, {'id': 2555, 'pubMedId': 25251602, 'title': 'Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25251602'}]",,04/22/2016
0,04/26/2016,p53 Gene Therapy,167,8759,p53 Gene Therapy,TP53 I195*,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/26/2016
0,04/26/2016,MEK inhibitor (Pan),142,8760,MEK inhibitor (Pan),MAP2K1 L37P,"[{'id': 119, 'pubMedId': 18632602, 'title': 'Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18632602'}, {'id': 2253, 'pubMedId': 18223206, 'title': 'Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18223206'}]",,04/26/2016
0,04/26/2016,MEK1 Inhibitor,143,8761,MEK1 Inhibitor,MAP2K1 L37P,"[{'id': 119, 'pubMedId': 18632602, 'title': 'Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18632602'}, {'id': 2253, 'pubMedId': 18223206, 'title': 'Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18223206'}]",,04/26/2016
0,04/26/2016,MEK inhibitor (Pan),142,8762,MEK inhibitor (Pan),MAP2K1 E144K,"[{'id': 119, 'pubMedId': 18632602, 'title': 'Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18632602'}, {'id': 2253, 'pubMedId': 18223206, 'title': 'Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18223206'}]",,04/26/2016
0,04/26/2016,MEK1 Inhibitor,143,8763,MEK1 Inhibitor,MAP2K1 E144K,"[{'id': 119, 'pubMedId': 18632602, 'title': 'Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18632602'}, {'id': 2253, 'pubMedId': 18223206, 'title': 'Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18223206'}]",,04/26/2016
0,04/26/2016,MEK inhibitor (Pan),142,8764,MEK inhibitor (Pan),MAP2K1 E120Q,"[{'id': 119, 'pubMedId': 18632602, 'title': 'Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18632602'}, {'id': 2253, 'pubMedId': 18223206, 'title': 'Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18223206'}]",,04/26/2016
0,04/26/2016,MEK1 Inhibitor,143,8765,MEK1 Inhibitor,MAP2K1 E120Q,"[{'id': 119, 'pubMedId': 18632602, 'title': 'Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18632602'}, {'id': 2253, 'pubMedId': 18223206, 'title': 'Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18223206'}]",,04/26/2016
0,04/26/2016,MEK inhibitor (Pan),142,8766,MEK inhibitor (Pan),MAP2K1 D65N,"[{'id': 119, 'pubMedId': 18632602, 'title': 'Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18632602'}, {'id': 2253, 'pubMedId': 18223206, 'title': 'Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18223206'}]",,04/26/2016
0,04/26/2016,MEK1 Inhibitor,143,8767,MEK1 Inhibitor,MAP2K1 D65N,"[{'id': 119, 'pubMedId': 18632602, 'title': 'Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18632602'}, {'id': 2253, 'pubMedId': 18223206, 'title': 'Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18223206'}]",,04/26/2016
0,04/26/2016,MEK inhibitor (Pan),142,8768,MEK inhibitor (Pan),MAP2K1 S123T,"[{'id': 119, 'pubMedId': 18632602, 'title': 'Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18632602'}, {'id': 2253, 'pubMedId': 18223206, 'title': 'Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18223206'}]",,04/26/2016
0,04/26/2016,MEK1 Inhibitor,143,8769,MEK1 Inhibitor,MAP2K1 S123T,"[{'id': 119, 'pubMedId': 18632602, 'title': 'Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18632602'}, {'id': 2253, 'pubMedId': 18223206, 'title': 'Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18223206'}]",,04/26/2016
0,04/26/2016,MEK inhibitor (Pan),142,8770,MEK inhibitor (Pan),MAP2K1 V60M,"[{'id': 119, 'pubMedId': 18632602, 'title': 'Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18632602'}, {'id': 2253, 'pubMedId': 18223206, 'title': 'Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18223206'}]",,04/26/2016
0,04/26/2016,MEK1 Inhibitor,143,8771,MEK1 Inhibitor,MAP2K1 V60M,"[{'id': 119, 'pubMedId': 18632602, 'title': 'Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18632602'}, {'id': 2253, 'pubMedId': 18223206, 'title': 'Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18223206'}]",,04/26/2016
0,04/26/2016,MEK inhibitor (Pan),142,8772,MEK inhibitor (Pan),MAP2K1 T28I,"[{'id': 119, 'pubMedId': 18632602, 'title': 'Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18632602'}, {'id': 2253, 'pubMedId': 18223206, 'title': 'Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18223206'}]",,04/26/2016
0,04/26/2016,MEK1 Inhibitor,143,8773,MEK1 Inhibitor,MAP2K1 T28I,"[{'id': 119, 'pubMedId': 18632602, 'title': 'Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18632602'}, {'id': 2253, 'pubMedId': 18223206, 'title': 'Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18223206'}]",,04/26/2016
0,04/26/2016,MEK inhibitor (Pan),142,8774,MEK inhibitor (Pan),MAP2K1 Q58_E62del,"[{'id': 119, 'pubMedId': 18632602, 'title': 'Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18632602'}, {'id': 2253, 'pubMedId': 18223206, 'title': 'Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18223206'}]",,04/26/2016
0,04/26/2016,MEK1 Inhibitor,143,8775,MEK1 Inhibitor,MAP2K1 Q58_E62del,"[{'id': 119, 'pubMedId': 18632602, 'title': 'Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18632602'}, {'id': 2253, 'pubMedId': 18223206, 'title': 'Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18223206'}]",,04/26/2016
0,05/01/2016,p53 Activator,166,8796,p53 Activator,TP53 R280A,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,05/01/2016
0,05/01/2016,p53 Gene Therapy,167,8797,p53 Gene Therapy,TP53 R280A,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,05/01/2016
0,05/01/2016,p53 Activator,166,8798,p53 Activator,TP53 R282D,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,05/01/2016
0,05/01/2016,p53 Gene Therapy,167,8799,p53 Gene Therapy,TP53 R282D,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,05/01/2016
0,05/01/2016,p53 Activator,166,8800,p53 Activator,TP53 R280D,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,05/01/2016
0,05/01/2016,p53 Gene Therapy,167,8801,p53 Gene Therapy,TP53 R280D,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,05/01/2016
0,05/01/2016,p53 Activator,166,8802,p53 Activator,TP53 E287A,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,05/01/2016
0,05/01/2016,p53 Gene Therapy,167,8803,p53 Gene Therapy,TP53 E287A,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,05/01/2016
0,05/10/2016,DOT1L Inhibitor,70,8838,DOT1L Inhibitor,KMT2A-MLLT10,"[{'id': 5485, 'pubMedId': 23138183, 'title': 'Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23138183'}]",,05/10/2016
0,05/12/2016,CDK4/6 Inhibitor,43,8839,CDK4/6 Inhibitor,SMARCB1 loss,"[{'id': 5148, 'pubMedId': 21871868, 'title': 'Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21871868'}]",,05/12/2016
0,05/12/2016,CDK Inhibitor (Pan),38,8840,CDK Inhibitor (Pan),SMARCB1 loss,"[{'id': 2815, 'pubMedId': 21173237, 'title': 'Therapeutically targeting cyclin D1 in primary tumors arising from loss of Ini1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21173237'}]",,05/12/2016
0,05/12/2016,EZH2 inhibitor,84,8841,EZH2 inhibitor,SMARCB1 E31V,"[{'id': 2724, 'pubMedId': 23620515, 'title': 'Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23620515'}]",,05/12/2016
0,05/12/2016,,8842,Fenretinide,SMARCB1 E31V,"[{'id': 2822, 'pubMedId': 16302003, 'title': 'Targeting cyclin D1, a downstream effector of INI1/hSNF5, in rhabdoid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16302003'}]",2731,Fenretinide,05/12/2016
0,05/12/2016,,8843,MRX34,SMARCB1 E31V,"[{'id': 2815, 'pubMedId': 21173237, 'title': 'Therapeutically targeting cyclin D1 in primary tumors arising from loss of Ini1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21173237'}]",1035,MRX34,05/12/2016
0,05/12/2016,CDK4/6 Inhibitor,43,8844,CDK4/6 Inhibitor,SMARCB1 E31V,"[{'id': 5148, 'pubMedId': 21871868, 'title': 'Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21871868'}]",,05/12/2016
0,05/12/2016,CDK Inhibitor (Pan),38,8845,CDK Inhibitor (Pan),SMARCB1 E31V,"[{'id': 2815, 'pubMedId': 21173237, 'title': 'Therapeutically targeting cyclin D1 in primary tumors arising from loss of Ini1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21173237'}]",,05/12/2016
0,05/12/2016,CDK4/6 Inhibitor,43,8846,CDK4/6 Inhibitor,SMARCB1 Q18*,"[{'id': 5148, 'pubMedId': 21871868, 'title': 'Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21871868'}]",,05/12/2016
0,05/12/2016,,8847,MRX34,SMARCB1 Q18*,"[{'id': 2815, 'pubMedId': 21173237, 'title': 'Therapeutically targeting cyclin D1 in primary tumors arising from loss of Ini1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21173237'}]",1035,MRX34,05/12/2016
0,05/12/2016,CDK Inhibitor (Pan),38,8848,CDK Inhibitor (Pan),SMARCB1 Q18*,"[{'id': 2815, 'pubMedId': 21173237, 'title': 'Therapeutically targeting cyclin D1 in primary tumors arising from loss of Ini1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21173237'}]",,05/12/2016
0,05/12/2016,EZH2 inhibitor,84,8849,EZH2 inhibitor,SMARCB1 Q18*,"[{'id': 2724, 'pubMedId': 23620515, 'title': 'Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23620515'}]",,05/12/2016
0,05/12/2016,,8850,Fenretinide,SMARCB1 Q18*,"[{'id': 2822, 'pubMedId': 16302003, 'title': 'Targeting cyclin D1, a downstream effector of INI1/hSNF5, in rhabdoid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16302003'}]",2731,Fenretinide,05/12/2016
0,05/12/2016,CDK Inhibitor (Pan),38,8851,CDK Inhibitor (Pan),SMARCB1 R53*,"[{'id': 2815, 'pubMedId': 21173237, 'title': 'Therapeutically targeting cyclin D1 in primary tumors arising from loss of Ini1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21173237'}]",,05/12/2016
0,05/12/2016,,8852,Fenretinide,SMARCB1 R53*,"[{'id': 2822, 'pubMedId': 16302003, 'title': 'Targeting cyclin D1, a downstream effector of INI1/hSNF5, in rhabdoid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16302003'}]",2731,Fenretinide,05/12/2016
0,05/12/2016,,8853,MRX34,SMARCB1 R53*,"[{'id': 2815, 'pubMedId': 21173237, 'title': 'Therapeutically targeting cyclin D1 in primary tumors arising from loss of Ini1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21173237'}]",1035,MRX34,05/12/2016
0,05/12/2016,EZH2 inhibitor,84,8854,EZH2 inhibitor,SMARCB1 R53*,"[{'id': 2724, 'pubMedId': 23620515, 'title': 'Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23620515'}]",,05/12/2016
0,05/12/2016,CDK4/6 Inhibitor,43,8855,CDK4/6 Inhibitor,SMARCB1 R53*,"[{'id': 5148, 'pubMedId': 21871868, 'title': 'Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21871868'}]",,05/12/2016
0,05/12/2016,CDK Inhibitor (Pan),38,8856,CDK Inhibitor (Pan),SMARCB1 T118Pfs*25,"[{'id': 2815, 'pubMedId': 21173237, 'title': 'Therapeutically targeting cyclin D1 in primary tumors arising from loss of Ini1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21173237'}]",,05/12/2016
0,05/12/2016,,8857,MRX34,SMARCB1 T118Pfs*25,"[{'id': 2815, 'pubMedId': 21173237, 'title': 'Therapeutically targeting cyclin D1 in primary tumors arising from loss of Ini1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21173237'}]",1035,MRX34,05/12/2016
0,05/12/2016,CDK4/6 Inhibitor,43,8858,CDK4/6 Inhibitor,SMARCB1 T118Pfs*25,"[{'id': 5148, 'pubMedId': 21871868, 'title': 'Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21871868'}]",,05/12/2016
0,05/12/2016,,8859,Fenretinide,SMARCB1 T118Pfs*25,"[{'id': 2822, 'pubMedId': 16302003, 'title': 'Targeting cyclin D1, a downstream effector of INI1/hSNF5, in rhabdoid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16302003'}]",2731,Fenretinide,05/12/2016
0,05/12/2016,EZH2 inhibitor,84,8860,EZH2 inhibitor,SMARCB1 T118Pfs*25,"[{'id': 2724, 'pubMedId': 23620515, 'title': 'Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23620515'}]",,05/12/2016
0,05/12/2016,,8861,MRX34,SMARCB1 T72Nfs*4,"[{'id': 2815, 'pubMedId': 21173237, 'title': 'Therapeutically targeting cyclin D1 in primary tumors arising from loss of Ini1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21173237'}]",1035,MRX34,05/12/2016
0,05/12/2016,,8862,Fenretinide,SMARCB1 T72Nfs*4,"[{'id': 2822, 'pubMedId': 16302003, 'title': 'Targeting cyclin D1, a downstream effector of INI1/hSNF5, in rhabdoid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16302003'}]",2731,Fenretinide,05/12/2016
0,05/12/2016,EZH2 inhibitor,84,8863,EZH2 inhibitor,SMARCB1 T72Nfs*4,"[{'id': 2724, 'pubMedId': 23620515, 'title': 'Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23620515'}]",,05/12/2016
0,05/12/2016,CDK Inhibitor (Pan),38,8864,CDK Inhibitor (Pan),SMARCB1 T72Nfs*4,"[{'id': 2815, 'pubMedId': 21173237, 'title': 'Therapeutically targeting cyclin D1 in primary tumors arising from loss of Ini1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21173237'}]",,05/12/2016
0,05/12/2016,CDK4/6 Inhibitor,43,8865,CDK4/6 Inhibitor,SMARCB1 T72Nfs*4,"[{'id': 5148, 'pubMedId': 21871868, 'title': 'Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21871868'}]",,05/12/2016
0,05/12/2016,EZH2 inhibitor,84,8866,EZH2 inhibitor,SMARCB1 T72Qfs*13,"[{'id': 2724, 'pubMedId': 23620515, 'title': 'Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23620515'}]",,05/12/2016
0,05/12/2016,,8867,MRX34,SMARCB1 T72Qfs*13,"[{'id': 2815, 'pubMedId': 21173237, 'title': 'Therapeutically targeting cyclin D1 in primary tumors arising from loss of Ini1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21173237'}]",1035,MRX34,05/12/2016
0,05/12/2016,CDK Inhibitor (Pan),38,8868,CDK Inhibitor (Pan),SMARCB1 T72Qfs*13,"[{'id': 2815, 'pubMedId': 21173237, 'title': 'Therapeutically targeting cyclin D1 in primary tumors arising from loss of Ini1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21173237'}]",,05/12/2016
0,05/12/2016,CDK4/6 Inhibitor,43,8869,CDK4/6 Inhibitor,SMARCB1 T72Qfs*13,"[{'id': 5148, 'pubMedId': 21871868, 'title': 'Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21871868'}]",,05/12/2016
0,05/12/2016,,8870,Fenretinide,SMARCB1 T72Qfs*13,"[{'id': 2822, 'pubMedId': 16302003, 'title': 'Targeting cyclin D1, a downstream effector of INI1/hSNF5, in rhabdoid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16302003'}]",2731,Fenretinide,05/12/2016
0,05/12/2016,EZH2 inhibitor,84,8871,EZH2 inhibitor,SMARCB1 del,"[{'id': 2724, 'pubMedId': 23620515, 'title': 'Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23620515'}]",,05/12/2016
0,05/12/2016,,8872,MRX34,SMARCB1 del,"[{'id': 2815, 'pubMedId': 21173237, 'title': 'Therapeutically targeting cyclin D1 in primary tumors arising from loss of Ini1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21173237'}]",1035,MRX34,05/12/2016
0,05/12/2016,CDK4/6 Inhibitor,43,8873,CDK4/6 Inhibitor,SMARCB1 del,"[{'id': 5148, 'pubMedId': 21871868, 'title': 'Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21871868'}]",,05/12/2016
0,05/12/2016,CDK Inhibitor (Pan),38,8874,CDK Inhibitor (Pan),SMARCB1 del,"[{'id': 2815, 'pubMedId': 21173237, 'title': 'Therapeutically targeting cyclin D1 in primary tumors arising from loss of Ini1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21173237'}]",,05/12/2016
0,05/12/2016,,8875,Fenretinide,SMARCB1 del,"[{'id': 2822, 'pubMedId': 16302003, 'title': 'Targeting cyclin D1, a downstream effector of INI1/hSNF5, in rhabdoid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16302003'}]",2731,Fenretinide,05/12/2016
0,05/18/2016,CTNNB1 Inhibitor,60,8881,CTNNB1 Inhibitor,CTNNB1 N387K,"[{'id': 2251, 'pubMedId': 23258168, 'title': 'WNT signalling pathways as therapeutic targets in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23258168'}]",,05/18/2016
0,05/18/2016,PDPK1 Inhibitor,180,8882,PDPK1 Inhibitor,CTNNB1 N387K,"[{'id': 2220, 'pubMedId': 20028853, 'title': 'Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028853'}]",,05/18/2016
0,05/18/2016,Tankyrase Inhibitor,215,8883,Tankyrase Inhibitor,CTNNB1 N387K,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 2299, 'pubMedId': 23621985, 'title': 'Evidence for tankyrases as antineoplastic targets in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23621985'}]",,05/18/2016
0,05/24/2016,HER inhibitor (Pan),105,8884,HER inhibitor (Pan),ERBB4 R306S,"[{'id': 2681, 'pubMedId': 20404484, 'title': 'A growing family: adding mutated Erbb4 as a novel cancer target.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20404484'}]",,05/24/2016
0,05/24/2016,HER inhibitor (Pan),105,8885,HER inhibitor (Pan),ERBB4 N181S,"[{'id': 2681, 'pubMedId': 20404484, 'title': 'A growing family: adding mutated Erbb4 as a novel cancer target.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20404484'}]",,05/24/2016
0,06/07/2016,KIT Inhibitor,136,8954,KIT Inhibitor,KIT P577_D579del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,06/07/2016
0,06/08/2016,FGFR Inhibitor (Pan),89,8957,FGFR Inhibitor (Pan),FGFR2 N549H,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,06/08/2016
0,06/08/2016,FGFR2 Inhibitor,92,8958,FGFR2 Inhibitor,FGFR2 N549H,"[{'id': 1903, 'pubMedId': 19212647, 'title': 'FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19212647'}]",,06/08/2016
0,06/08/2016,KIT Inhibitor,136,8959,KIT Inhibitor,KIT K550_W557del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,06/08/2016
0,06/08/2016,KIT Inhibitor,136,8960,KIT Inhibitor,KIT V560_Y578del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,06/08/2016
0,06/08/2016,KIT Inhibitor,136,8961,KIT Inhibitor,KIT E490K,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,06/08/2016
0,06/08/2016,KIT Inhibitor,136,8962,KIT Inhibitor,KIT T417_D419delinsI,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,06/08/2016
0,06/08/2016,KIT Inhibitor,136,8963,KIT Inhibitor,KIT D419del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,06/08/2016
0,06/08/2016,KIT Inhibitor,136,8964,KIT Inhibitor,KIT T417_D419delinsY,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,06/08/2016
0,06/08/2016,KIT Inhibitor,136,8965,KIT Inhibitor,KIT Y418_D419delinsS,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,06/08/2016
0,06/08/2016,KIT Inhibitor,136,8966,KIT Inhibitor,KIT T417_D419delinsRA,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,06/08/2016
0,06/08/2016,KIT Inhibitor,136,8967,KIT Inhibitor,KIT W557C,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,06/08/2016
0,06/09/2016,KIT Inhibitor,136,8971,KIT Inhibitor,KIT D60N,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,06/09/2016
0,06/09/2016,HER inhibitor (Pan),105,8972,HER inhibitor (Pan),ERBB2 I767M,"[{'id': 2691, 'pubMedId': 25674538, 'title': 'The Potential of panHER Inhibition in Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25674538'}]",,06/09/2016
0,06/09/2016,HER2 Inhibitor,106,8973,HER2 Inhibitor,ERBB2 I767M,"[{'id': 561, 'pubMedId': 22649146, 'title': 'HER2 mutations in non-small-cell lung cancer can be continually targeted.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22649146'}, {'id': 563, 'pubMedId': 21991949, 'title': 'Adjuvant trastuzumab in HER2-positive breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21991949'}, {'id': 564, 'pubMedId': 23801166, 'title': 'First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23801166'}]",,06/09/2016
0,06/09/2016,MEK inhibitor (Pan),142,8974,MEK inhibitor (Pan),MAP2K1 R49L,"[{'id': 119, 'pubMedId': 18632602, 'title': 'Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18632602'}, {'id': 2253, 'pubMedId': 18223206, 'title': 'Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18223206'}]",,06/09/2016
0,06/09/2016,MEK1 Inhibitor,143,8975,MEK1 Inhibitor,MAP2K1 R49L,"[{'id': 119, 'pubMedId': 18632602, 'title': 'Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18632602'}, {'id': 2253, 'pubMedId': 18223206, 'title': 'Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18223206'}]",,06/09/2016
0,06/09/2016,MEK inhibitor (Pan),142,8991,MEK inhibitor (Pan),MAP2K1 F53S,"[{'id': 119, 'pubMedId': 18632602, 'title': 'Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18632602'}, {'id': 2253, 'pubMedId': 18223206, 'title': 'Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18223206'}]",,06/09/2016
0,06/09/2016,MEK1 Inhibitor,143,8992,MEK1 Inhibitor,MAP2K1 F53S,"[{'id': 119, 'pubMedId': 18632602, 'title': 'Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18632602'}, {'id': 2253, 'pubMedId': 18223206, 'title': 'Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18223206'}]",,06/09/2016
0,06/09/2016,KIT Inhibitor,136,9073,KIT Inhibitor,KIT R634W,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,06/09/2016
0,06/09/2016,PARP Inhibitor (Pan),171,9076,PARP Inhibitor (Pan),BRCA1 E1114fs,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/09/2016
0,06/09/2016,PARP-1 Inhibitor,172,9077,PARP-1 Inhibitor,BRCA1 E1114fs,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/09/2016
0,06/10/2016,PARP Inhibitor (Pan),171,9078,PARP Inhibitor (Pan),BRCA2 R2845fs,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/10/2016
0,06/10/2016,PARP-1 Inhibitor,172,9079,PARP-1 Inhibitor,BRCA2 R2845fs,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/10/2016
0,06/12/2016,FGFR Inhibitor (Pan),89,9086,FGFR Inhibitor (Pan),FGFR2 K659N,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,06/12/2016
0,06/12/2016,FGFR2 Inhibitor,92,9087,FGFR2 Inhibitor,FGFR2 K659N,"[{'id': 1903, 'pubMedId': 19212647, 'title': 'FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19212647'}]",,06/12/2016
0,06/12/2016,FGFR Inhibitor (Pan),89,9088,FGFR Inhibitor (Pan),FGFR2 E731K,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,06/12/2016
0,06/12/2016,FGFR2 Inhibitor,92,9089,FGFR2 Inhibitor,FGFR2 E731K,"[{'id': 1903, 'pubMedId': 19212647, 'title': 'FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19212647'}]",,06/12/2016
0,06/12/2016,JAK Inhibitor (Pan),126,9090,JAK Inhibitor (Pan),JAK2 C618R,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/12/2016
0,06/12/2016,JAK Inhibitor (Pan) – ATP competitive,127,9091,JAK Inhibitor (Pan) – ATP competitive,JAK2 C618R,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/12/2016
0,06/12/2016,JAK2 Inhibitor,130,9092,JAK2 Inhibitor,JAK2 C618R,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/12/2016
0,06/12/2016,JAK2 Inhibitor – ATP competitive,131,9093,JAK2 Inhibitor – ATP competitive,JAK2 C618R,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/12/2016
0,06/12/2016,JAK Inhibitor (Pan),126,9094,JAK Inhibitor (Pan),JAK2 N542_E543del,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/12/2016
0,06/12/2016,JAK Inhibitor (Pan) – ATP competitive,127,9095,JAK Inhibitor (Pan) – ATP competitive,JAK2 N542_E543del,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/12/2016
0,06/12/2016,JAK2 Inhibitor,130,9096,JAK2 Inhibitor,JAK2 N542_E543del,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/12/2016
0,06/12/2016,JAK2 Inhibitor – ATP competitive,131,9097,JAK2 Inhibitor – ATP competitive,JAK2 N542_E543del,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/12/2016
0,06/12/2016,JAK Inhibitor (Pan),126,9098,JAK Inhibitor (Pan),JAK2 K539L,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/12/2016
0,06/12/2016,JAK Inhibitor (Pan) – ATP competitive,127,9099,JAK Inhibitor (Pan) – ATP competitive,JAK2 K539L,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/12/2016
0,06/12/2016,JAK2 Inhibitor,130,9100,JAK2 Inhibitor,JAK2 K539L,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/12/2016
0,06/12/2016,JAK2 Inhibitor – ATP competitive,131,9101,JAK2 Inhibitor – ATP competitive,JAK2 K539L,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/12/2016
0,06/12/2016,JAK Inhibitor (Pan),126,9102,JAK Inhibitor (Pan),JAK2 F537_K539delinsL,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/12/2016
0,06/12/2016,JAK Inhibitor (Pan) – ATP competitive,127,9103,JAK Inhibitor (Pan) – ATP competitive,JAK2 F537_K539delinsL,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/12/2016
0,06/12/2016,JAK2 Inhibitor,130,9104,JAK2 Inhibitor,JAK2 F537_K539delinsL,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/12/2016
0,06/12/2016,JAK2 Inhibitor – ATP competitive,131,9105,JAK2 Inhibitor – ATP competitive,JAK2 F537_K539delinsL,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/12/2016
0,06/13/2016,JAK Inhibitor (Pan),126,9106,JAK Inhibitor (Pan),JAK2 L611V,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/13/2016
0,06/13/2016,JAK Inhibitor (Pan) – ATP competitive,127,9107,JAK Inhibitor (Pan) – ATP competitive,JAK2 L611V,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/13/2016
0,06/13/2016,JAK2 Inhibitor,130,9108,JAK2 Inhibitor,JAK2 L611V,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/13/2016
0,06/13/2016,JAK2 Inhibitor – ATP competitive,131,9109,JAK2 Inhibitor – ATP competitive,JAK2 L611V,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/13/2016
0,06/13/2016,JAK Inhibitor (Pan),126,9110,JAK Inhibitor (Pan),JAK2 R683K,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/13/2016
0,06/13/2016,JAK Inhibitor (Pan) – ATP competitive,127,9111,JAK Inhibitor (Pan) – ATP competitive,JAK2 R683K,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/13/2016
0,06/13/2016,JAK2 Inhibitor,130,9112,JAK2 Inhibitor,JAK2 R683K,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/13/2016
0,06/13/2016,JAK2 Inhibitor – ATP competitive,131,9113,JAK2 Inhibitor – ATP competitive,JAK2 R683K,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/13/2016
0,06/13/2016,JAK Inhibitor (Pan),126,9114,JAK Inhibitor (Pan),JAK2 R683S,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/13/2016
0,06/13/2016,JAK Inhibitor (Pan) – ATP competitive,127,9115,JAK Inhibitor (Pan) – ATP competitive,JAK2 R683S,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/13/2016
0,06/13/2016,JAK2 Inhibitor,130,9116,JAK2 Inhibitor,JAK2 R683S,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/13/2016
0,06/13/2016,JAK2 Inhibitor – ATP competitive,131,9117,JAK2 Inhibitor – ATP competitive,JAK2 R683S,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/13/2016
0,06/13/2016,JAK Inhibitor (Pan),126,9118,JAK Inhibitor (Pan),JAK2 T875N,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/13/2016
0,06/13/2016,JAK Inhibitor (Pan) – ATP competitive,127,9119,JAK Inhibitor (Pan) – ATP competitive,JAK2 T875N,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/13/2016
0,06/13/2016,JAK2 Inhibitor,130,9120,JAK2 Inhibitor,JAK2 T875N,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/13/2016
0,06/13/2016,JAK2 Inhibitor – ATP competitive,131,9121,JAK2 Inhibitor – ATP competitive,JAK2 T875N,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,06/13/2016
0,06/14/2016,Akt Inhibitor (Pan),4,9282,Akt Inhibitor (Pan),PIK3CA C420G,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,06/14/2016
0,06/14/2016,Akt1 Inhibitor,6,9283,Akt1 Inhibitor,PIK3CA C420G,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,06/14/2016
0,06/14/2016,Akt2 Inhibitor,7,9284,Akt2 Inhibitor,PIK3CA C420G,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,06/14/2016
0,06/14/2016,Akt3 Inhibitor,8,9285,Akt3 Inhibitor,PIK3CA C420G,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,06/14/2016
0,06/14/2016,mTOR Inhibitor,152,9286,mTOR Inhibitor,PIK3CA C420G,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,06/14/2016
0,06/14/2016,mTORC1 Inhibitor,153,9287,mTORC1 Inhibitor,PIK3CA C420G,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,06/14/2016
0,06/14/2016,mTORC2 Inhibitor,154,9288,mTORC2 Inhibitor,PIK3CA C420G,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,06/14/2016
0,06/14/2016,PI3K Inhibitor (Pan),181,9289,PI3K Inhibitor (Pan),PIK3CA C420G,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,06/14/2016
0,06/14/2016,PIK3CA inhibitor,182,9290,PIK3CA inhibitor,PIK3CA C420G,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,06/14/2016
0,06/14/2016,Akt Inhibitor (Pan),4,9291,Akt Inhibitor (Pan),PIK3CA G106R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,06/14/2016
0,06/14/2016,Akt1 Inhibitor,6,9292,Akt1 Inhibitor,PIK3CA G106R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,06/14/2016
0,06/14/2016,Akt2 Inhibitor,7,9293,Akt2 Inhibitor,PIK3CA G106R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,06/14/2016
0,06/14/2016,Akt3 Inhibitor,8,9294,Akt3 Inhibitor,PIK3CA G106R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,06/14/2016
0,06/14/2016,mTOR Inhibitor,152,9295,mTOR Inhibitor,PIK3CA G106R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,06/14/2016
0,06/14/2016,mTORC1 Inhibitor,153,9296,mTORC1 Inhibitor,PIK3CA G106R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,06/14/2016
0,06/14/2016,mTORC2 Inhibitor,154,9297,mTORC2 Inhibitor,PIK3CA G106R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,06/14/2016
0,06/14/2016,PI3K Inhibitor (Pan),181,9298,PI3K Inhibitor (Pan),PIK3CA G106R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,06/14/2016
0,06/14/2016,PIK3CA inhibitor,182,9299,PIK3CA inhibitor,PIK3CA G106R,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,06/14/2016
0,06/14/2016,Akt Inhibitor (Pan),4,9300,Akt Inhibitor (Pan),PIK3CA G106V,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,06/14/2016
0,06/14/2016,Akt1 Inhibitor,6,9301,Akt1 Inhibitor,PIK3CA G106V,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,06/14/2016
0,06/14/2016,Akt2 Inhibitor,7,9302,Akt2 Inhibitor,PIK3CA G106V,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,06/14/2016
0,06/14/2016,Akt3 Inhibitor,8,9303,Akt3 Inhibitor,PIK3CA G106V,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,06/14/2016
0,06/14/2016,mTOR Inhibitor,152,9304,mTOR Inhibitor,PIK3CA G106V,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,06/14/2016
0,06/14/2016,mTORC1 Inhibitor,153,9305,mTORC1 Inhibitor,PIK3CA G106V,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,06/14/2016
0,06/14/2016,mTORC2 Inhibitor,154,9306,mTORC2 Inhibitor,PIK3CA G106V,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,06/14/2016
0,06/14/2016,PI3K Inhibitor (Pan),181,9307,PI3K Inhibitor (Pan),PIK3CA G106V,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,06/14/2016
0,06/14/2016,PIK3CA inhibitor,182,9308,PIK3CA inhibitor,PIK3CA G106V,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,06/14/2016
0,06/14/2016,Akt Inhibitor (Pan),4,9309,Akt Inhibitor (Pan),PIK3CA R38H,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,06/14/2016
0,06/14/2016,Akt1 Inhibitor,6,9310,Akt1 Inhibitor,PIK3CA R38H,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,06/14/2016
0,06/14/2016,Akt2 Inhibitor,7,9311,Akt2 Inhibitor,PIK3CA R38H,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,06/14/2016
0,06/14/2016,Akt3 Inhibitor,8,9312,Akt3 Inhibitor,PIK3CA R38H,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,06/14/2016
0,06/14/2016,mTOR Inhibitor,152,9313,mTOR Inhibitor,PIK3CA R38H,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,06/14/2016
0,06/14/2016,mTORC1 Inhibitor,153,9314,mTORC1 Inhibitor,PIK3CA R38H,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,06/14/2016
0,06/14/2016,mTORC2 Inhibitor,154,9315,mTORC2 Inhibitor,PIK3CA R38H,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,06/14/2016
0,06/14/2016,PI3K Inhibitor (Pan),181,9316,PI3K Inhibitor (Pan),PIK3CA R38H,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,06/14/2016
0,06/14/2016,PIK3CA inhibitor,182,9317,PIK3CA inhibitor,PIK3CA R38H,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,06/14/2016
0,06/15/2016,FLT3 Inhibitor,96,9349,FLT3 Inhibitor,CBL P417A,"[{'id': 3301, 'pubMedId': 25477533, 'title': 'Molecular pathways: cbl proteins in tumorigenesis and antitumor immunity-opportunities for cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25477533'}, {'id': 3302, 'pubMedId': 22990016, 'title': 'Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22990016'}]",,06/15/2016
0,06/15/2016,MEK inhibitor (Pan),142,9350,MEK inhibitor (Pan),MAP2K1 I204T,"[{'id': 119, 'pubMedId': 18632602, 'title': 'Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18632602'}, {'id': 2253, 'pubMedId': 18223206, 'title': 'Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18223206'}]",,06/15/2016
0,06/15/2016,MEK1 Inhibitor,143,9351,MEK1 Inhibitor,MAP2K1 I204T,"[{'id': 119, 'pubMedId': 18632602, 'title': 'Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18632602'}, {'id': 2253, 'pubMedId': 18223206, 'title': 'Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18223206'}]",,06/15/2016
0,06/15/2016,FLT3 Inhibitor,96,9363,FLT3 Inhibitor,CBL Q367P,"[{'id': 3301, 'pubMedId': 25477533, 'title': 'Molecular pathways: cbl proteins in tumorigenesis and antitumor immunity-opportunities for cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25477533'}, {'id': 3302, 'pubMedId': 22990016, 'title': 'Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22990016'}]",,06/15/2016
0,06/15/2016,MEK inhibitor (Pan),142,9364,MEK inhibitor (Pan),MAP2K1 S218D,"[{'id': 119, 'pubMedId': 18632602, 'title': 'Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18632602'}, {'id': 2253, 'pubMedId': 18223206, 'title': 'Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18223206'}]",,06/15/2016
0,06/15/2016,MEK1 Inhibitor,143,9365,MEK1 Inhibitor,MAP2K1 S218D,"[{'id': 119, 'pubMedId': 18632602, 'title': 'Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18632602'}, {'id': 2253, 'pubMedId': 18223206, 'title': 'Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18223206'}]",,06/15/2016
0,06/15/2016,MEK inhibitor (Pan),142,9366,MEK inhibitor (Pan),MAP2K1 P306H,"[{'id': 119, 'pubMedId': 18632602, 'title': 'Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18632602'}, {'id': 2253, 'pubMedId': 18223206, 'title': 'Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18223206'}]",,06/15/2016
0,06/15/2016,MEK1 Inhibitor,143,9367,MEK1 Inhibitor,MAP2K1 P306H,"[{'id': 119, 'pubMedId': 18632602, 'title': 'Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18632602'}, {'id': 2253, 'pubMedId': 18223206, 'title': 'Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18223206'}]",,06/15/2016
0,06/15/2016,FLT3 Inhibitor,96,9368,FLT3 Inhibitor,CBL R420P,"[{'id': 3301, 'pubMedId': 25477533, 'title': 'Molecular pathways: cbl proteins in tumorigenesis and antitumor immunity-opportunities for cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25477533'}, {'id': 3302, 'pubMedId': 22990016, 'title': 'Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22990016'}]",,06/15/2016
0,06/15/2016,FLT3 Inhibitor,96,9369,FLT3 Inhibitor,CBL S376F,"[{'id': 3301, 'pubMedId': 25477533, 'title': 'Molecular pathways: cbl proteins in tumorigenesis and antitumor immunity-opportunities for cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25477533'}, {'id': 3302, 'pubMedId': 22990016, 'title': 'Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22990016'}]",,06/15/2016
0,06/15/2016,MEK inhibitor (Pan),142,9370,MEK inhibitor (Pan),MAP2K1 Q56_V60del,"[{'id': 119, 'pubMedId': 18632602, 'title': 'Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18632602'}, {'id': 2253, 'pubMedId': 18223206, 'title': 'Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18223206'}]",,06/15/2016
0,06/15/2016,MEK1 Inhibitor,143,9371,MEK1 Inhibitor,MAP2K1 Q56_V60del,"[{'id': 119, 'pubMedId': 18632602, 'title': 'Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18632602'}, {'id': 2253, 'pubMedId': 18223206, 'title': 'Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18223206'}]",,06/15/2016
0,06/15/2016,FLT3 Inhibitor,96,9372,FLT3 Inhibitor,CBL Y371S,"[{'id': 3301, 'pubMedId': 25477533, 'title': 'Molecular pathways: cbl proteins in tumorigenesis and antitumor immunity-opportunities for cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25477533'}, {'id': 3302, 'pubMedId': 22990016, 'title': 'Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22990016'}]",,06/15/2016
0,06/15/2016,EGFR Inhibitor (Pan),74,9373,EGFR Inhibitor (Pan),EGFR E804G,"[{'id': 410, 'pubMedId': 16187797, 'title': 'Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16187797'}, {'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,06/15/2016
0,06/15/2016,EGFR Inhibitor 1st gen,75,9374,EGFR Inhibitor 1st gen,EGFR E804G,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",,06/15/2016
0,06/15/2016,EGFR Inhibitor 2nd gen,76,9375,EGFR Inhibitor 2nd gen,EGFR E804G,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,06/15/2016
0,06/15/2016,EGFR Inhibitor 3rd gen,77,9376,EGFR Inhibitor 3rd gen,EGFR E804G,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,06/15/2016
0,06/15/2016,HER inhibitor (Pan),105,9377,HER inhibitor (Pan),EGFR E804G,"[{'id': 2746, 'pubMedId': 25806203, 'title': 'Irreversible EGFR-TKIs: dreaming perfection.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806203'}]",,06/15/2016
0,06/15/2016,EGFR Inhibitor (Pan),74,9378,EGFR Inhibitor (Pan),EGFR G796S,"[{'id': 410, 'pubMedId': 16187797, 'title': 'Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16187797'}, {'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,06/15/2016
0,06/15/2016,EGFR Inhibitor 1st gen,75,9379,EGFR Inhibitor 1st gen,EGFR G796S,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",,06/15/2016
0,06/15/2016,EGFR Inhibitor 2nd gen,76,9380,EGFR Inhibitor 2nd gen,EGFR G796S,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,06/15/2016
0,06/15/2016,EGFR Inhibitor 3rd gen,77,9381,EGFR Inhibitor 3rd gen,EGFR G796S,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,06/15/2016
0,06/15/2016,HER inhibitor (Pan),105,9382,HER inhibitor (Pan),EGFR G796S,"[{'id': 2746, 'pubMedId': 25806203, 'title': 'Irreversible EGFR-TKIs: dreaming perfection.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806203'}]",,06/15/2016
0,06/15/2016,EGFR Inhibitor (Pan),74,9383,EGFR Inhibitor (Pan),EGFR E884K,"[{'id': 410, 'pubMedId': 16187797, 'title': 'Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16187797'}, {'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,06/15/2016
0,06/15/2016,EGFR Inhibitor 1st gen,75,9384,EGFR Inhibitor 1st gen,EGFR E884K,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",,06/15/2016
0,06/15/2016,EGFR Inhibitor 2nd gen,76,9385,EGFR Inhibitor 2nd gen,EGFR E884K,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,06/15/2016
0,06/15/2016,EGFR Inhibitor 3rd gen,77,9386,EGFR Inhibitor 3rd gen,EGFR E884K,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,06/15/2016
0,06/15/2016,HER inhibitor (Pan),105,9387,HER inhibitor (Pan),EGFR E884K,"[{'id': 2746, 'pubMedId': 25806203, 'title': 'Irreversible EGFR-TKIs: dreaming perfection.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806203'}]",,06/15/2016
0,06/16/2016,MEK1 Inhibitor,143,9408,MEK1 Inhibitor,MAP2K1 K59del,"[{'id': 119, 'pubMedId': 18632602, 'title': 'Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18632602'}, {'id': 2253, 'pubMedId': 18223206, 'title': 'Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18223206'}]",,06/16/2016
0,06/16/2016,MEK inhibitor (Pan),142,9409,MEK inhibitor (Pan),MAP2K1 K59del,"[{'id': 119, 'pubMedId': 18632602, 'title': 'Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18632602'}, {'id': 2253, 'pubMedId': 18223206, 'title': 'Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18223206'}]",,06/16/2016
0,06/16/2016,MEK inhibitor (Pan),142,9416,MEK inhibitor (Pan),HRAS A146T,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,06/16/2016
0,06/16/2016,MEK1 Inhibitor,143,9417,MEK1 Inhibitor,HRAS A146T,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,06/16/2016
0,06/16/2016,MEK2 Inhibitor,144,9418,MEK2 Inhibitor,HRAS A146T,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,06/16/2016
0,06/16/2016,PI3K Inhibitor (Pan),181,9419,PI3K Inhibitor (Pan),HRAS A146T,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,06/16/2016
0,06/16/2016,PIK3CA inhibitor,182,9420,PIK3CA inhibitor,HRAS A146T,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,06/16/2016
0,06/16/2016,PIK3CB inhibitor,183,9421,PIK3CB inhibitor,HRAS A146T,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,06/16/2016
0,06/16/2016,PIK3CD inhibitor,184,9422,PIK3CD inhibitor,HRAS A146T,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,06/16/2016
0,06/16/2016,PIK3CG inhibitor,185,9423,PIK3CG inhibitor,HRAS A146T,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,06/16/2016
0,06/16/2016,RAS Inhibitor (Pan),198,9424,RAS Inhibitor (Pan),HRAS A146T,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,06/16/2016
0,06/16/2016,MEK inhibitor (Pan),142,9425,MEK inhibitor (Pan),HRAS K117R,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,06/16/2016
0,06/16/2016,MEK1 Inhibitor,143,9426,MEK1 Inhibitor,HRAS K117R,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,06/16/2016
0,06/16/2016,MEK2 Inhibitor,144,9427,MEK2 Inhibitor,HRAS K117R,"[{'id': 445, 'pubMedId': 22805291, 'title': 'Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22805291'}]",,06/16/2016
0,06/16/2016,PI3K Inhibitor (Pan),181,9428,PI3K Inhibitor (Pan),HRAS K117R,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,06/16/2016
0,06/16/2016,PIK3CA inhibitor,182,9429,PIK3CA inhibitor,HRAS K117R,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,06/16/2016
0,06/16/2016,PIK3CB inhibitor,183,9430,PIK3CB inhibitor,HRAS K117R,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,06/16/2016
0,06/16/2016,PIK3CD inhibitor,184,9431,PIK3CD inhibitor,HRAS K117R,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,06/16/2016
0,06/16/2016,PIK3CG inhibitor,185,9432,PIK3CG inhibitor,HRAS K117R,"[{'id': 1790, 'pubMedId': 21831957, 'title': 'Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21831957'}]",,06/16/2016
0,06/16/2016,RAS Inhibitor (Pan),198,9433,RAS Inhibitor (Pan),HRAS K117R,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,06/16/2016
0,06/16/2016,EGFR Inhibitor (Pan),74,9434,EGFR Inhibitor (Pan),EGFR L838V,"[{'id': 410, 'pubMedId': 16187797, 'title': 'Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16187797'}, {'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,06/16/2016
0,06/16/2016,EGFR Inhibitor 1st gen,75,9435,EGFR Inhibitor 1st gen,EGFR L838V,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",,06/16/2016
0,06/16/2016,EGFR Inhibitor 2nd gen,76,9436,EGFR Inhibitor 2nd gen,EGFR L838V,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,06/16/2016
0,06/16/2016,EGFR Inhibitor 3rd gen,77,9437,EGFR Inhibitor 3rd gen,EGFR L838V,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,06/16/2016
0,06/16/2016,HER inhibitor (Pan),105,9438,HER inhibitor (Pan),EGFR L838V,"[{'id': 2746, 'pubMedId': 25806203, 'title': 'Irreversible EGFR-TKIs: dreaming perfection.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806203'}]",,06/16/2016
0,06/16/2016,MET Inhibitor,147,9439,MET Inhibitor,MET M1250T,"[{'id': 1994, 'pubMedId': 24045150, 'title': 'Met as a therapeutic target in HCC: facts and hopes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24045150'}]",,06/16/2016
0,06/16/2016,EGFR Inhibitor (Pan),74,9440,EGFR Inhibitor (Pan),EGFR R776G,"[{'id': 410, 'pubMedId': 16187797, 'title': 'Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16187797'}, {'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,06/16/2016
0,06/16/2016,EGFR Inhibitor 1st gen,75,9441,EGFR Inhibitor 1st gen,EGFR R776G,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",,06/16/2016
0,06/16/2016,EGFR Inhibitor 2nd gen,76,9442,EGFR Inhibitor 2nd gen,EGFR R776G,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,06/16/2016
0,06/16/2016,EGFR Inhibitor 3rd gen,77,9443,EGFR Inhibitor 3rd gen,EGFR R776G,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,06/16/2016
0,06/16/2016,HER inhibitor (Pan),105,9444,HER inhibitor (Pan),EGFR R776G,"[{'id': 2746, 'pubMedId': 25806203, 'title': 'Irreversible EGFR-TKIs: dreaming perfection.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806203'}]",,06/16/2016
0,06/16/2016,EGFR Inhibitor (Pan),74,9445,EGFR Inhibitor (Pan),EGFR R831H,"[{'id': 410, 'pubMedId': 16187797, 'title': 'Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16187797'}, {'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,06/16/2016
0,06/16/2016,EGFR Inhibitor 1st gen,75,9446,EGFR Inhibitor 1st gen,EGFR R831H,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",,06/16/2016
0,06/16/2016,EGFR Inhibitor 2nd gen,76,9447,EGFR Inhibitor 2nd gen,EGFR R831H,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,06/16/2016
0,06/16/2016,EGFR Inhibitor 3rd gen,77,9448,EGFR Inhibitor 3rd gen,EGFR R831H,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,06/16/2016
0,06/16/2016,HER inhibitor (Pan),105,9449,HER inhibitor (Pan),EGFR R831H,"[{'id': 2746, 'pubMedId': 25806203, 'title': 'Irreversible EGFR-TKIs: dreaming perfection.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806203'}]",,06/16/2016
0,06/20/2016,CTNNB1 Inhibitor,60,9458,CTNNB1 Inhibitor,APC N1026S,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,06/20/2016
0,06/20/2016,Tankyrase Inhibitor,215,9459,Tankyrase Inhibitor,APC N1026S,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,06/20/2016
0,06/21/2016,mTORC1 Inhibitor,153,9468,mTORC1 Inhibitor,FBXW7 K11R,"[{'id': 571, 'pubMedId': 18787170, 'title': 'FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18787170'}, {'id': 2558, 'pubMedId': 24586741, 'title': 'FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24586741'}]",,06/21/2016
0,06/21/2016,PARP Inhibitor (Pan),171,9469,PARP Inhibitor (Pan),BRCA1 A1708E,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/21/2016
0,06/21/2016,PARP-1 Inhibitor,172,9470,PARP-1 Inhibitor,BRCA1 A1708E,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/21/2016
0,06/21/2016,PARP Inhibitor (Pan),171,9471,PARP Inhibitor (Pan),BRCA1 A1708V,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/21/2016
0,06/21/2016,PARP-1 Inhibitor,172,9472,PARP-1 Inhibitor,BRCA1 A1708V,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/21/2016
0,06/21/2016,PARP Inhibitor (Pan),171,9473,PARP Inhibitor (Pan),BRCA1 A1752P,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/21/2016
0,06/21/2016,PARP-1 Inhibitor,172,9474,PARP-1 Inhibitor,BRCA1 A1752P,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/21/2016
0,06/21/2016,PARP Inhibitor (Pan),171,9475,PARP Inhibitor (Pan),BRCA1 A1843P,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/21/2016
0,06/21/2016,PARP-1 Inhibitor,172,9476,PARP-1 Inhibitor,BRCA1 A1843P,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/21/2016
0,06/21/2016,PARP Inhibitor (Pan),171,9477,PARP Inhibitor (Pan),BRCA1 C1697R,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/21/2016
0,06/21/2016,PARP-1 Inhibitor,172,9478,PARP-1 Inhibitor,BRCA1 C1697R,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/21/2016
0,06/21/2016,PARP Inhibitor (Pan),171,9479,PARP Inhibitor (Pan),BRCA1 D1692H,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/21/2016
0,06/21/2016,PARP-1 Inhibitor,172,9480,PARP-1 Inhibitor,BRCA1 D1692H,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/21/2016
0,06/21/2016,PARP Inhibitor (Pan),171,9481,PARP Inhibitor (Pan),BRCA1 D1692Y,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/21/2016
0,06/21/2016,PARP-1 Inhibitor,172,9482,PARP-1 Inhibitor,BRCA1 D1692Y,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/21/2016
0,06/21/2016,PARP Inhibitor (Pan),171,9483,PARP Inhibitor (Pan),BRCA1 D1739E,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/21/2016
0,06/21/2016,PARP-1 Inhibitor,172,9484,PARP-1 Inhibitor,BRCA1 D1739E,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/21/2016
0,06/21/2016,PARP Inhibitor (Pan),171,9485,PARP Inhibitor (Pan),BRCA1 D1739G,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/21/2016
0,06/21/2016,PARP-1 Inhibitor,172,9486,PARP-1 Inhibitor,BRCA1 D1739G,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/21/2016
0,06/21/2016,PARP Inhibitor (Pan),171,9487,PARP Inhibitor (Pan),BRCA1 D1739V,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/21/2016
0,06/21/2016,PARP-1 Inhibitor,172,9488,PARP-1 Inhibitor,BRCA1 D1739V,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/21/2016
0,06/21/2016,PARP Inhibitor (Pan),171,9489,PARP Inhibitor (Pan),BRCA1 D1739Y,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/21/2016
0,06/21/2016,PARP-1 Inhibitor,172,9490,PARP-1 Inhibitor,BRCA1 D1739Y,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/21/2016
0,06/21/2016,PARP Inhibitor (Pan),171,9491,PARP Inhibitor (Pan),BRCA1 G1706E,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/21/2016
0,06/21/2016,PARP-1 Inhibitor,172,9492,PARP-1 Inhibitor,BRCA1 G1706E,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/21/2016
0,06/21/2016,PARP Inhibitor (Pan),171,9493,PARP Inhibitor (Pan),BRCA1 G1738R,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/21/2016
0,06/21/2016,PARP-1 Inhibitor,172,9494,PARP-1 Inhibitor,BRCA1 G1738R,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/21/2016
0,06/21/2016,PARP Inhibitor (Pan),171,9495,PARP Inhibitor (Pan),BRCA1 G1738E,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/21/2016
0,06/21/2016,PARP-1 Inhibitor,172,9496,PARP-1 Inhibitor,BRCA1 G1738E,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/21/2016
0,06/21/2016,HER inhibitor (Pan),105,9497,HER inhibitor (Pan),ERBB2 L755_T759del,"[{'id': 2691, 'pubMedId': 25674538, 'title': 'The Potential of panHER Inhibition in Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25674538'}]",,06/21/2016
0,06/21/2016,HER2 Inhibitor,106,9498,HER2 Inhibitor,ERBB2 L755_T759del,"[{'id': 561, 'pubMedId': 22649146, 'title': 'HER2 mutations in non-small-cell lung cancer can be continually targeted.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22649146'}, {'id': 563, 'pubMedId': 21991949, 'title': 'Adjuvant trastuzumab in HER2-positive breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21991949'}, {'id': 564, 'pubMedId': 23801166, 'title': 'First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23801166'}]",,06/21/2016
0,06/21/2016,PARP Inhibitor (Pan),171,9499,PARP Inhibitor (Pan),BRCA1 G1763V,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/21/2016
0,06/21/2016,PARP-1 Inhibitor,172,9500,PARP-1 Inhibitor,BRCA1 G1763V,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/21/2016
0,06/21/2016,PARP Inhibitor (Pan),171,9501,PARP Inhibitor (Pan),BRCA1 G1788D,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/21/2016
0,06/21/2016,PARP-1 Inhibitor,172,9502,PARP-1 Inhibitor,BRCA1 G1788D,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/21/2016
0,06/21/2016,PARP Inhibitor (Pan),171,9503,PARP Inhibitor (Pan),BRCA1 G1788V,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/21/2016
0,06/21/2016,PARP-1 Inhibitor,172,9504,PARP-1 Inhibitor,BRCA1 G1788V,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/21/2016
0,06/21/2016,PARP Inhibitor (Pan),171,9505,PARP Inhibitor (Pan),BRCA1 G1803A,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/21/2016
0,06/21/2016,PARP-1 Inhibitor,172,9506,PARP-1 Inhibitor,BRCA1 G1803A,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/21/2016
0,06/21/2016,PARP Inhibitor (Pan),171,9507,PARP Inhibitor (Pan),BRCA1 H1746N,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/21/2016
0,06/21/2016,PARP-1 Inhibitor,172,9508,PARP-1 Inhibitor,BRCA1 H1746N,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/21/2016
0,06/21/2016,PARP Inhibitor (Pan),171,9509,PARP Inhibitor (Pan),BRCA1 I1766S,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/21/2016
0,06/21/2016,PARP-1 Inhibitor,172,9510,PARP-1 Inhibitor,BRCA1 I1766S,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/21/2016
0,06/21/2016,PARP Inhibitor (Pan),171,9511,PARP Inhibitor (Pan),BRCA1 L1764P,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/21/2016
0,06/21/2016,PARP-1 Inhibitor,172,9512,PARP-1 Inhibitor,BRCA1 L1764P,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/21/2016
0,06/21/2016,PARP Inhibitor (Pan),171,9513,PARP Inhibitor (Pan),BRCA1 L1780P,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/21/2016
0,06/21/2016,PARP-1 Inhibitor,172,9514,PARP-1 Inhibitor,BRCA1 L1780P,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/21/2016
0,06/21/2016,PARP Inhibitor (Pan),171,9515,PARP Inhibitor (Pan),BRCA1 L1844R,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/21/2016
0,06/21/2016,PARP-1 Inhibitor,172,9516,PARP-1 Inhibitor,BRCA1 L1844R,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/21/2016
0,06/21/2016,PARP Inhibitor (Pan),171,9517,PARP Inhibitor (Pan),BRCA1 M1689R,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/21/2016
0,06/21/2016,PARP-1 Inhibitor,172,9518,PARP-1 Inhibitor,BRCA1 M1689R,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/21/2016
0,06/21/2016,PARP Inhibitor (Pan),171,9519,PARP Inhibitor (Pan),BRCA1 M1689T,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/21/2016
0,06/21/2016,PARP-1 Inhibitor,172,9520,PARP-1 Inhibitor,BRCA1 M1689T,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/21/2016
0,06/21/2016,PARP Inhibitor (Pan),171,9521,PARP Inhibitor (Pan),BRCA1 M1775E,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/21/2016
0,06/21/2016,PARP-1 Inhibitor,172,9522,PARP-1 Inhibitor,BRCA1 M1775E,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/21/2016
0,06/21/2016,PARP Inhibitor (Pan),171,9523,PARP Inhibitor (Pan),BRCA1 M1775K,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/21/2016
0,06/21/2016,PARP-1 Inhibitor,172,9524,PARP-1 Inhibitor,BRCA1 M1775K,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/21/2016
0,06/21/2016,PARP Inhibitor (Pan),171,9525,PARP Inhibitor (Pan),BRCA1 M1775R,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/21/2016
0,06/21/2016,PARP-1 Inhibitor,172,9526,PARP-1 Inhibitor,BRCA1 M1775R,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/21/2016
0,06/21/2016,PARP Inhibitor (Pan),171,9527,PARP Inhibitor (Pan),BRCA1 M1783T,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/21/2016
0,06/21/2016,PARP-1 Inhibitor,172,9528,PARP-1 Inhibitor,BRCA1 M1783T,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/21/2016
0,06/21/2016,PARP Inhibitor (Pan),171,9529,PARP Inhibitor (Pan),BRCA1 P1749R,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/21/2016
0,06/21/2016,PARP-1 Inhibitor,172,9530,PARP-1 Inhibitor,BRCA1 P1749R,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/21/2016
0,06/21/2016,PARP Inhibitor (Pan),171,9531,PARP Inhibitor (Pan),BRCA1 P1771L,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/21/2016
0,06/21/2016,PARP-1 Inhibitor,172,9532,PARP-1 Inhibitor,BRCA1 P1771L,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/21/2016
0,06/21/2016,PARP Inhibitor (Pan),171,9533,PARP Inhibitor (Pan),BRCA1 P1771R,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/21/2016
0,06/21/2016,PARP-1 Inhibitor,172,9534,PARP-1 Inhibitor,BRCA1 P1771R,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/21/2016
0,06/21/2016,HER inhibitor (Pan),105,9535,HER inhibitor (Pan),ERBB2 G776delinsVC,"[{'id': 2691, 'pubMedId': 25674538, 'title': 'The Potential of panHER Inhibition in Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25674538'}]",,06/21/2016
0,06/21/2016,HER2 Inhibitor,106,9536,HER2 Inhibitor,ERBB2 G776delinsVC,"[{'id': 561, 'pubMedId': 22649146, 'title': 'HER2 mutations in non-small-cell lung cancer can be continually targeted.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22649146'}, {'id': 563, 'pubMedId': 21991949, 'title': 'Adjuvant trastuzumab in HER2-positive breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21991949'}, {'id': 564, 'pubMedId': 23801166, 'title': 'First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23801166'}]",,06/21/2016
0,06/21/2016,HER inhibitor (Pan),105,9537,HER inhibitor (Pan),ERBB2 G776delinsLC,"[{'id': 2691, 'pubMedId': 25674538, 'title': 'The Potential of panHER Inhibition in Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25674538'}]",,06/21/2016
0,06/21/2016,HER2 Inhibitor,106,9538,HER2 Inhibitor,ERBB2 G776delinsLC,"[{'id': 561, 'pubMedId': 22649146, 'title': 'HER2 mutations in non-small-cell lung cancer can be continually targeted.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22649146'}, {'id': 563, 'pubMedId': 21991949, 'title': 'Adjuvant trastuzumab in HER2-positive breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21991949'}, {'id': 564, 'pubMedId': 23801166, 'title': 'First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23801166'}]",,06/21/2016
0,06/21/2016,SHP2 Inhibitor,203,9539,SHP2 Inhibitor,PTPN11 D61Y,"[{'id': 4299, 'pubMedId': 23825065, 'title': 'Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23825065'}, {'id': 4326, 'pubMedId': 25877780, 'title': 'Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in\u2005vitro and in\u2005vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25877780'}]",,06/21/2016
0,06/21/2016,SHP2 Inhibitor,203,9540,SHP2 Inhibitor,PTPN11 D61N,"[{'id': 4299, 'pubMedId': 23825065, 'title': 'Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23825065'}, {'id': 4326, 'pubMedId': 25877780, 'title': 'Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in\u2005vitro and in\u2005vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25877780'}]",,06/21/2016
0,06/21/2016,SHP2 Inhibitor,203,9541,SHP2 Inhibitor,PTPN11 F71I,"[{'id': 4299, 'pubMedId': 23825065, 'title': 'Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23825065'}, {'id': 4326, 'pubMedId': 25877780, 'title': 'Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in\u2005vitro and in\u2005vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25877780'}]",,06/21/2016
0,06/21/2016,SHP2 Inhibitor,203,9542,SHP2 Inhibitor,PTPN11 T73I,"[{'id': 4299, 'pubMedId': 23825065, 'title': 'Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23825065'}, {'id': 4326, 'pubMedId': 25877780, 'title': 'Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in\u2005vitro and in\u2005vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25877780'}]",,06/21/2016
0,06/21/2016,SHP2 Inhibitor,203,9543,SHP2 Inhibitor,PTPN11 E76A,"[{'id': 4299, 'pubMedId': 23825065, 'title': 'Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23825065'}, {'id': 4326, 'pubMedId': 25877780, 'title': 'Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in\u2005vitro and in\u2005vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25877780'}]",,06/21/2016
0,06/21/2016,SHP2 Inhibitor,203,9544,SHP2 Inhibitor,PTPN11 I282V,"[{'id': 4299, 'pubMedId': 23825065, 'title': 'Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23825065'}, {'id': 4326, 'pubMedId': 25877780, 'title': 'Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in\u2005vitro and in\u2005vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25877780'}]",,06/21/2016
0,06/21/2016,SHP2 Inhibitor,203,9545,SHP2 Inhibitor,PTPN11 M504V,"[{'id': 4299, 'pubMedId': 23825065, 'title': 'Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23825065'}, {'id': 4326, 'pubMedId': 25877780, 'title': 'Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in\u2005vitro and in\u2005vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25877780'}]",,06/21/2016
0,06/21/2016,SHP2 Inhibitor,203,9546,SHP2 Inhibitor,PTPN11 T507K,"[{'id': 4299, 'pubMedId': 23825065, 'title': 'Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23825065'}, {'id': 4326, 'pubMedId': 25877780, 'title': 'Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in\u2005vitro and in\u2005vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25877780'}]",,06/21/2016
0,06/21/2016,SHP2 Inhibitor,203,9547,SHP2 Inhibitor,PTPN11 V45L,"[{'id': 4299, 'pubMedId': 23825065, 'title': 'Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23825065'}, {'id': 4326, 'pubMedId': 25877780, 'title': 'Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in\u2005vitro and in\u2005vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25877780'}]",,06/21/2016
0,06/21/2016,SHP2 Inhibitor,203,9548,SHP2 Inhibitor,PTPN11 Y62C,"[{'id': 4299, 'pubMedId': 23825065, 'title': 'Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23825065'}, {'id': 4326, 'pubMedId': 25877780, 'title': 'Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in\u2005vitro and in\u2005vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25877780'}]",,06/21/2016
0,06/21/2016,SHP2 Inhibitor,203,9549,SHP2 Inhibitor,PTPN11 Q79R,"[{'id': 4299, 'pubMedId': 23825065, 'title': 'Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23825065'}, {'id': 4326, 'pubMedId': 25877780, 'title': 'Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in\u2005vitro and in\u2005vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25877780'}]",,06/21/2016
0,06/21/2016,FLT3 Inhibitor,96,9550,FLT3 Inhibitor,FLT3 F590G,"[{'id': 705, 'pubMedId': 11756186, 'title': 'FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11756186'}, {'id': 2547, 'pubMedId': 17124058, 'title': 'FLT3 mutations: biology and treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17124058'}, {'id': 2548, 'pubMedId': 25231999, 'title': 'Targeting FLT3 to treat leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25231999'}]",,06/21/2016
0,06/21/2016,FLT3 Inhibitor,96,9551,FLT3 Inhibitor,FLT3 F594L,"[{'id': 705, 'pubMedId': 11756186, 'title': 'FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11756186'}, {'id': 2547, 'pubMedId': 17124058, 'title': 'FLT3 mutations: biology and treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17124058'}, {'id': 2548, 'pubMedId': 25231999, 'title': 'Targeting FLT3 to treat leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25231999'}]",,06/21/2016
0,06/21/2016,FLT3 Inhibitor,96,9552,FLT3 Inhibitor,FLT3 I867S,"[{'id': 705, 'pubMedId': 11756186, 'title': 'FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11756186'}, {'id': 2547, 'pubMedId': 17124058, 'title': 'FLT3 mutations: biology and treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17124058'}, {'id': 2548, 'pubMedId': 25231999, 'title': 'Targeting FLT3 to treat leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25231999'}]",,06/21/2016
0,06/21/2016,FLT3 Inhibitor,96,9553,FLT3 Inhibitor,FLT3 Y591D,"[{'id': 705, 'pubMedId': 11756186, 'title': 'FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11756186'}, {'id': 2547, 'pubMedId': 17124058, 'title': 'FLT3 mutations: biology and treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17124058'}, {'id': 2548, 'pubMedId': 25231999, 'title': 'Targeting FLT3 to treat leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25231999'}]",,06/21/2016
0,06/22/2016,HER inhibitor (Pan),105,9554,HER inhibitor (Pan),ERBB2 G660D,"[{'id': 2691, 'pubMedId': 25674538, 'title': 'The Potential of panHER Inhibition in Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25674538'}]",,06/22/2016
0,06/22/2016,HER2 Inhibitor,106,9555,HER2 Inhibitor,ERBB2 G660D,"[{'id': 561, 'pubMedId': 22649146, 'title': 'HER2 mutations in non-small-cell lung cancer can be continually targeted.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22649146'}, {'id': 563, 'pubMedId': 21991949, 'title': 'Adjuvant trastuzumab in HER2-positive breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21991949'}, {'id': 564, 'pubMedId': 23801166, 'title': 'First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23801166'}]",,06/22/2016
0,06/22/2016,HER inhibitor (Pan),105,9556,HER inhibitor (Pan),ERBB2 T733I,"[{'id': 2691, 'pubMedId': 25674538, 'title': 'The Potential of panHER Inhibition in Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25674538'}]",,06/22/2016
0,06/22/2016,HER2 Inhibitor,106,9557,HER2 Inhibitor,ERBB2 T733I,"[{'id': 561, 'pubMedId': 22649146, 'title': 'HER2 mutations in non-small-cell lung cancer can be continually targeted.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22649146'}, {'id': 563, 'pubMedId': 21991949, 'title': 'Adjuvant trastuzumab in HER2-positive breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21991949'}, {'id': 564, 'pubMedId': 23801166, 'title': 'First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23801166'}]",,06/22/2016
0,06/22/2016,HER inhibitor (Pan),105,9558,HER inhibitor (Pan),ERBB2 L726F,"[{'id': 2691, 'pubMedId': 25674538, 'title': 'The Potential of panHER Inhibition in Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25674538'}]",,06/22/2016
0,06/22/2016,HER2 Inhibitor,106,9559,HER2 Inhibitor,ERBB2 L726F,"[{'id': 561, 'pubMedId': 22649146, 'title': 'HER2 mutations in non-small-cell lung cancer can be continually targeted.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22649146'}, {'id': 563, 'pubMedId': 21991949, 'title': 'Adjuvant trastuzumab in HER2-positive breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21991949'}, {'id': 564, 'pubMedId': 23801166, 'title': 'First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23801166'}]",,06/22/2016
0,06/23/2016,SHP2 Inhibitor,203,9563,SHP2 Inhibitor,PTPN11 Y63C,"[{'id': 4299, 'pubMedId': 23825065, 'title': 'Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23825065'}, {'id': 4326, 'pubMedId': 25877780, 'title': 'Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in\u2005vitro and in\u2005vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25877780'}]",,06/23/2016
0,06/23/2016,SHP2 Inhibitor,203,9564,SHP2 Inhibitor,PTPN11 D106A,"[{'id': 4299, 'pubMedId': 23825065, 'title': 'Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23825065'}, {'id': 4326, 'pubMedId': 25877780, 'title': 'Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in\u2005vitro and in\u2005vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25877780'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9565,PARP Inhibitor (Pan),BRCA1 Q1811R,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9566,PARP-1 Inhibitor,BRCA1 Q1811R,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9567,PARP Inhibitor (Pan),BRCA1 R1751P,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9568,PARP-1 Inhibitor,BRCA1 R1751P,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9569,PARP Inhibitor (Pan),BRCA1 R1753T,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9570,PARP-1 Inhibitor,BRCA1 R1753T,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9571,PARP Inhibitor (Pan),BRCA1 S1655F,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9572,PARP-1 Inhibitor,BRCA1 S1655F,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9573,PARP Inhibitor (Pan),BRCA1 S1715C,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9574,PARP-1 Inhibitor,BRCA1 S1715C,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9575,PARP Inhibitor (Pan),BRCA1 S1715N,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9576,PARP-1 Inhibitor,BRCA1 S1715N,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9577,PARP Inhibitor (Pan),BRCA1 S1715R,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9578,PARP-1 Inhibitor,BRCA1 S1715R,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9579,PARP Inhibitor (Pan),BRCA1 S1722F,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9580,PARP-1 Inhibitor,BRCA1 S1722F,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9581,PARP Inhibitor (Pan),BRCA1 S1841N,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9582,PARP-1 Inhibitor,BRCA1 S1841N,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9583,PARP Inhibitor (Pan),BRCA1 T1685A,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9584,PARP-1 Inhibitor,BRCA1 T1685A,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9585,PARP Inhibitor (Pan),BRCA1 T1685I,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9586,PARP-1 Inhibitor,BRCA1 T1685I,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9587,PARP Inhibitor (Pan),BRCA1 T1691I,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9588,PARP-1 Inhibitor,BRCA1 T1691I,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9589,PARP Inhibitor (Pan),BRCA1 T1691K,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9590,PARP-1 Inhibitor,BRCA1 T1691K,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9591,PARP Inhibitor (Pan),BRCA1 T1700A,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9592,PARP-1 Inhibitor,BRCA1 T1700A,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9593,PARP Inhibitor (Pan),BRCA1 V1696L,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9594,PARP-1 Inhibitor,BRCA1 V1696L,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9595,PARP Inhibitor (Pan),BRCA1 V1714G,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9596,PARP-1 Inhibitor,BRCA1 V1714G,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9597,PARP Inhibitor (Pan),BRCA1 V1736A,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9598,PARP-1 Inhibitor,BRCA1 V1736A,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9599,PARP Inhibitor (Pan),BRCA1 V1736G,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9600,PARP-1 Inhibitor,BRCA1 V1736G,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9601,PARP Inhibitor (Pan),BRCA1 V1741G,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9602,PARP-1 Inhibitor,BRCA1 V1741G,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9603,PARP Inhibitor (Pan),BRCA1 V1809A,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9604,PARP-1 Inhibitor,BRCA1 V1809A,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9605,PARP Inhibitor (Pan),BRCA1 V1809F,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9606,PARP-1 Inhibitor,BRCA1 V1809F,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9607,PARP Inhibitor (Pan),BRCA1 V1810G,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9608,PARP-1 Inhibitor,BRCA1 V1810G,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9611,PARP Inhibitor (Pan),BRCA1 V1838E,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9612,PARP-1 Inhibitor,BRCA1 V1838E,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9613,PARP Inhibitor (Pan),BRCA1 W1718C,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9614,PARP-1 Inhibitor,BRCA1 W1718C,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9615,PARP Inhibitor (Pan),BRCA1 W1718S,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9616,PARP-1 Inhibitor,BRCA1 W1718S,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9617,PARP Inhibitor (Pan),BRCA1 W1837C,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9618,PARP-1 Inhibitor,BRCA1 W1837C,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9619,PARP Inhibitor (Pan),BRCA1 W1837G,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9620,PARP-1 Inhibitor,BRCA1 W1837G,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9621,PARP Inhibitor (Pan),BRCA1 W1837R,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9622,PARP-1 Inhibitor,BRCA1 W1837R,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9623,PARP Inhibitor (Pan),BRCA1 Y1853C,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9624,PARP-1 Inhibitor,BRCA1 Y1853C,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9625,PARP Inhibitor (Pan),BRCA1 A1752G,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9626,PARP-1 Inhibitor,BRCA1 A1752G,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9627,PARP Inhibitor (Pan),BRCA1 A1789T,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9628,PARP-1 Inhibitor,BRCA1 A1789T,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9629,PARP Inhibitor (Pan),BRCA1 A1843T,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9630,PARP-1 Inhibitor,BRCA1 A1843T,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,EGFR Inhibitor (Pan),74,9631,EGFR Inhibitor (Pan),EGFR V689M,"[{'id': 410, 'pubMedId': 16187797, 'title': 'Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16187797'}, {'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,06/23/2016
0,06/23/2016,EGFR Inhibitor 1st gen,75,9632,EGFR Inhibitor 1st gen,EGFR V689M,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",,06/23/2016
0,06/23/2016,EGFR Inhibitor 2nd gen,76,9633,EGFR Inhibitor 2nd gen,EGFR V689M,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,06/23/2016
0,06/23/2016,EGFR Inhibitor 3rd gen,77,9634,EGFR Inhibitor 3rd gen,EGFR V689M,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,06/23/2016
0,06/23/2016,HER inhibitor (Pan),105,9635,HER inhibitor (Pan),EGFR V689M,"[{'id': 2746, 'pubMedId': 25806203, 'title': 'Irreversible EGFR-TKIs: dreaming perfection.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806203'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9636,PARP Inhibitor (Pan),BRCA1 C24R,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9637,PARP-1 Inhibitor,BRCA1 C24R,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9638,PARP Inhibitor (Pan),BRCA1 M18T,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9639,PARP-1 Inhibitor,BRCA1 M18T,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9640,PARP Inhibitor (Pan),BRCA1 I21V,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9641,PARP-1 Inhibitor,BRCA1 I21V,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9642,PARP Inhibitor (Pan),BRCA1 C27A,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9643,PARP-1 Inhibitor,BRCA1 C27A,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9644,PARP Inhibitor (Pan),BRCA1 I31M,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9645,PARP-1 Inhibitor,BRCA1 I31M,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9646,PARP Inhibitor (Pan),BRCA1 T37R,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9647,PARP-1 Inhibitor,BRCA1 T37R,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9648,PARP Inhibitor (Pan),BRCA1 C39Y,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9649,PARP-1 Inhibitor,BRCA1 C39Y,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9650,PARP Inhibitor (Pan),BRCA1 H41R,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9651,PARP-1 Inhibitor,BRCA1 H41R,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9652,PARP Inhibitor (Pan),BRCA1 I42V,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9653,PARP-1 Inhibitor,BRCA1 I42V,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9654,PARP Inhibitor (Pan),BRCA1 C44F,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9655,PARP-1 Inhibitor,BRCA1 C44F,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9656,PARP Inhibitor (Pan),BRCA1 C47G,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9657,PARP-1 Inhibitor,BRCA1 C47G,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9658,PARP Inhibitor (Pan),BRCA1 L52F,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9659,PARP-1 Inhibitor,BRCA1 L52F,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9660,PARP Inhibitor (Pan),BRCA1 D67Y,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9661,PARP-1 Inhibitor,BRCA1 D67Y,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9662,PARP Inhibitor (Pan),BRCA1 C39R,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9663,PARP-1 Inhibitor,BRCA1 C39R,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9664,PARP Inhibitor (Pan),BRCA1 C39S,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9665,PARP-1 Inhibitor,BRCA1 C39S,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9666,PARP Inhibitor (Pan),BRCA1 C64G,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9667,PARP-1 Inhibitor,BRCA1 C64G,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9668,PARP Inhibitor (Pan),BRCA1 T826K,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9669,PARP-1 Inhibitor,BRCA1 T826K,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9670,PARP Inhibitor (Pan),BRCA1 E33A,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9671,PARP-1 Inhibitor,BRCA1 E33A,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9672,PARP Inhibitor (Pan),BRCA1 S1841A,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9673,PARP-1 Inhibitor,BRCA1 S1841A,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9674,PARP Inhibitor (Pan),BRCA1 E1660G,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9675,PARP-1 Inhibitor,BRCA1 E1660G,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9676,PARP Inhibitor (Pan),BRCA1 F1704S,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9677,PARP-1 Inhibitor,BRCA1 F1704S,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9678,PARP Inhibitor (Pan),BRCA1 F1734L,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9679,PARP-1 Inhibitor,BRCA1 F1734L,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9680,PARP Inhibitor (Pan),BRCA1 F1761I,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9681,PARP-1 Inhibitor,BRCA1 F1761I,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9682,PARP Inhibitor (Pan),BRCA1 F1761S,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9683,PARP-1 Inhibitor,BRCA1 F1761S,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9684,PARP Inhibitor (Pan),BRCA1 G1743R,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9685,PARP-1 Inhibitor,BRCA1 G1743R,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9686,PARP Inhibitor (Pan),BRCA1 H1686Q,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9687,PARP-1 Inhibitor,BRCA1 H1686Q,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9690,PARP Inhibitor (Pan),BRCA1 I1807S,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9691,PARP-1 Inhibitor,BRCA1 I1807S,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9692,PARP Inhibitor (Pan),BRCA1 L1657P,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9693,PARP-1 Inhibitor,BRCA1 L1657P,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9694,PARP Inhibitor (Pan),BRCA1 L1705P,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9695,PARP-1 Inhibitor,BRCA1 L1705P,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9696,PARP Inhibitor (Pan),BRCA1 M1652K,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9697,PARP-1 Inhibitor,BRCA1 M1652K,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/23/2016,PARP Inhibitor (Pan),171,9698,PARP Inhibitor (Pan),BRCA1 P1856T,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/23/2016
0,06/23/2016,PARP-1 Inhibitor,172,9699,PARP-1 Inhibitor,BRCA1 P1856T,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/23/2016
0,06/24/2016,HER inhibitor (Pan),105,9724,HER inhibitor (Pan),ERBB2 L866M,"[{'id': 2691, 'pubMedId': 25674538, 'title': 'The Potential of panHER Inhibition in Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25674538'}]",,06/24/2016
0,06/24/2016,HER2 Inhibitor,106,9725,HER2 Inhibitor,ERBB2 L866M,"[{'id': 561, 'pubMedId': 22649146, 'title': 'HER2 mutations in non-small-cell lung cancer can be continually targeted.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22649146'}, {'id': 563, 'pubMedId': 21991949, 'title': 'Adjuvant trastuzumab in HER2-positive breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21991949'}, {'id': 564, 'pubMedId': 23801166, 'title': 'First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23801166'}]",,06/24/2016
0,06/27/2016,PARP Inhibitor (Pan),171,9729,PARP Inhibitor (Pan),BRCA1 V1833E,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/27/2016
0,06/27/2016,PARP-1 Inhibitor,172,9730,PARP-1 Inhibitor,BRCA1 V1833E,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/27/2016
0,06/27/2016,PARP Inhibitor (Pan),171,9731,PARP Inhibitor (Pan),BRCA1 Y1703H,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/27/2016
0,06/27/2016,PARP-1 Inhibitor,172,9732,PARP-1 Inhibitor,BRCA1 Y1703H,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/27/2016
0,06/27/2016,PARP Inhibitor (Pan),171,9733,PARP Inhibitor (Pan),BRCA1 L1407P,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/27/2016
0,06/27/2016,PARP-1 Inhibitor,172,9734,PARP-1 Inhibitor,BRCA1 L1407P,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/27/2016
0,06/27/2016,PARP Inhibitor (Pan),171,9735,PARP Inhibitor (Pan),BRCA1 M1628V,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/27/2016
0,06/27/2016,PARP-1 Inhibitor,172,9736,PARP-1 Inhibitor,BRCA1 M1628V,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/27/2016
0,06/27/2016,PARP Inhibitor (Pan),171,9756,PARP Inhibitor (Pan),BRCA1 K45N,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/27/2016
0,06/27/2016,PARP-1 Inhibitor,172,9757,PARP-1 Inhibitor,BRCA1 K45N,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/27/2016
0,06/27/2016,PARP Inhibitor (Pan),171,9758,PARP Inhibitor (Pan),BRCA1 K45T,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/27/2016
0,06/27/2016,PARP-1 Inhibitor,172,9759,PARP-1 Inhibitor,BRCA1 K45T,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/27/2016
0,06/27/2016,PARP Inhibitor (Pan),171,9760,PARP Inhibitor (Pan),BRCA1 L63F,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/27/2016
0,06/27/2016,PARP-1 Inhibitor,172,9761,PARP-1 Inhibitor,BRCA1 L63F,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/27/2016
0,06/27/2016,PARP Inhibitor (Pan),171,9762,PARP Inhibitor (Pan),BRCA1 L82P,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/27/2016
0,06/27/2016,PARP-1 Inhibitor,172,9763,PARP-1 Inhibitor,BRCA1 L82P,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/27/2016
0,06/27/2016,PARP Inhibitor (Pan),171,9764,PARP Inhibitor (Pan),BRCA1 M18K,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/27/2016
0,06/27/2016,PARP-1 Inhibitor,172,9765,PARP-1 Inhibitor,BRCA1 M18K,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/27/2016
0,06/27/2016,PARP Inhibitor (Pan),171,9766,PARP Inhibitor (Pan),BRCA1 Q12Y,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/27/2016
0,06/27/2016,PARP-1 Inhibitor,172,9767,PARP-1 Inhibitor,BRCA1 Q12Y,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/27/2016
0,06/27/2016,PARP Inhibitor (Pan),171,9768,PARP Inhibitor (Pan),BRCA1 S59R,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/27/2016
0,06/27/2016,PARP-1 Inhibitor,172,9769,PARP-1 Inhibitor,BRCA1 S59R,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/27/2016
0,06/27/2016,PARP Inhibitor (Pan),171,9770,PARP Inhibitor (Pan),BRCA1 S72R,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/27/2016
0,06/27/2016,PARP-1 Inhibitor,172,9771,PARP-1 Inhibitor,BRCA1 S72R,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/27/2016
0,06/27/2016,PARP Inhibitor (Pan),171,9772,PARP Inhibitor (Pan),BRCA1 T77M,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/27/2016
0,06/27/2016,PARP-1 Inhibitor,172,9773,PARP-1 Inhibitor,BRCA1 T77M,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/27/2016
0,06/27/2016,PARP Inhibitor (Pan),171,9774,PARP Inhibitor (Pan),BRCA1 L1564P,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/27/2016
0,06/27/2016,PARP-1 Inhibitor,172,9775,PARP-1 Inhibitor,BRCA1 L1564P,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/27/2016
0,06/27/2016,PARP Inhibitor (Pan),171,9776,PARP Inhibitor (Pan),BRCA1 R1443G,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/27/2016
0,06/27/2016,PARP-1 Inhibitor,172,9777,PARP-1 Inhibitor,BRCA1 R1443G,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/27/2016
0,06/27/2016,PARP Inhibitor (Pan),171,9778,PARP Inhibitor (Pan),BRCA1 S1164I,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/27/2016
0,06/27/2016,PARP-1 Inhibitor,172,9779,PARP-1 Inhibitor,BRCA1 S1164I,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/27/2016
0,06/27/2016,PARP Inhibitor (Pan),171,9780,PARP Inhibitor (Pan),BRCA1 Y179C,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/27/2016
0,06/27/2016,PARP-1 Inhibitor,172,9781,PARP-1 Inhibitor,BRCA1 Y179C,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/27/2016
0,06/27/2016,PARP Inhibitor (Pan),171,9782,PARP Inhibitor (Pan),BRCA1 K1487R,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/27/2016
0,06/27/2016,PARP-1 Inhibitor,172,9783,PARP-1 Inhibitor,BRCA1 K1487R,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/27/2016
0,06/27/2016,PARP Inhibitor (Pan),171,9784,PARP Inhibitor (Pan),BRCA1 V1833M,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/27/2016
0,06/27/2016,PARP-1 Inhibitor,172,9785,PARP-1 Inhibitor,BRCA1 V1833M,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/27/2016
0,06/28/2016,PARP Inhibitor (Pan),171,9789,PARP Inhibitor (Pan),BRCA1 C47F,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/28/2016
0,06/28/2016,PARP-1 Inhibitor,172,9790,PARP-1 Inhibitor,BRCA1 C47F,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/28/2016
0,06/28/2016,PARP Inhibitor (Pan),171,9791,PARP Inhibitor (Pan),BRCA1 G1770V,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/28/2016
0,06/28/2016,PARP-1 Inhibitor,172,9792,PARP-1 Inhibitor,BRCA1 G1770V,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/28/2016
0,06/28/2016,PARP Inhibitor (Pan),171,9793,PARP Inhibitor (Pan),BRCA1 W1718L,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/28/2016
0,06/28/2016,PARP-1 Inhibitor,172,9794,PARP-1 Inhibitor,BRCA1 W1718L,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/28/2016
0,06/28/2016,PARP Inhibitor (Pan),171,9795,PARP Inhibitor (Pan),BRCA1 Y1703S,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/28/2016
0,06/28/2016,PARP-1 Inhibitor,172,9796,PARP-1 Inhibitor,BRCA1 Y1703S,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/28/2016
0,06/28/2016,PARP Inhibitor (Pan),171,9797,PARP Inhibitor (Pan),BRCA1 H1686R,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/28/2016
0,06/28/2016,PARP-1 Inhibitor,172,9798,PARP-1 Inhibitor,BRCA1 H1686R,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/28/2016
0,06/28/2016,PARP Inhibitor (Pan),171,9799,PARP Inhibitor (Pan),BRCA1 S1651P,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/28/2016
0,06/28/2016,PARP-1 Inhibitor,172,9800,PARP-1 Inhibitor,BRCA1 S1651P,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/28/2016
0,06/28/2016,PARP Inhibitor (Pan),171,9801,PARP Inhibitor (Pan),BRCA1 V1688del,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,06/28/2016
0,06/28/2016,PARP-1 Inhibitor,172,9802,PARP-1 Inhibitor,BRCA1 V1688del,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,06/28/2016
0,06/28/2016,HER inhibitor (Pan),105,9831,HER inhibitor (Pan),ERBB2 S653C,"[{'id': 2691, 'pubMedId': 25674538, 'title': 'The Potential of panHER Inhibition in Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25674538'}]",,06/28/2016
0,06/28/2016,HER2 Inhibitor,106,9832,HER2 Inhibitor,ERBB2 S653C,"[{'id': 561, 'pubMedId': 22649146, 'title': 'HER2 mutations in non-small-cell lung cancer can be continually targeted.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22649146'}, {'id': 563, 'pubMedId': 21991949, 'title': 'Adjuvant trastuzumab in HER2-positive breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21991949'}, {'id': 564, 'pubMedId': 23801166, 'title': 'First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23801166'}]",,06/28/2016
0,06/28/2016,mTOR Inhibitor,152,9851,mTOR Inhibitor,STK11 K78A,"[{'id': 5047, 'pubMedId': 25436981, 'title': 'Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25436981'}, {'id': 5053, 'pubMedId': 26574479, 'title': 'Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26574479'}]",,06/28/2016
0,06/28/2016,mTORC1 Inhibitor,153,9852,mTORC1 Inhibitor,STK11 K78A,"[{'id': 3134, 'pubMedId': 24387336, 'title': 'Targeting the LKB1 tumor suppressor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24387336'}]",,06/28/2016
0,06/28/2016,mTOR Inhibitor,152,9853,mTOR Inhibitor,STK11 L67P,"[{'id': 5047, 'pubMedId': 25436981, 'title': 'Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25436981'}, {'id': 5053, 'pubMedId': 26574479, 'title': 'Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26574479'}]",,06/28/2016
0,06/28/2016,mTORC1 Inhibitor,153,9854,mTORC1 Inhibitor,STK11 L67P,"[{'id': 3134, 'pubMedId': 24387336, 'title': 'Targeting the LKB1 tumor suppressor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24387336'}]",,06/28/2016
0,06/29/2016,mTOR Inhibitor,152,9855,mTOR Inhibitor,STK11 W308C,"[{'id': 5047, 'pubMedId': 25436981, 'title': 'Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25436981'}, {'id': 5053, 'pubMedId': 26574479, 'title': 'Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26574479'}]",,06/29/2016
0,06/29/2016,mTORC1 Inhibitor,153,9856,mTORC1 Inhibitor,STK11 W308C,"[{'id': 3134, 'pubMedId': 24387336, 'title': 'Targeting the LKB1 tumor suppressor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24387336'}]",,06/29/2016
0,06/29/2016,mTOR Inhibitor,152,9857,mTOR Inhibitor,STK11 R304W,"[{'id': 5047, 'pubMedId': 25436981, 'title': 'Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25436981'}, {'id': 5053, 'pubMedId': 26574479, 'title': 'Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26574479'}]",,06/29/2016
0,06/29/2016,mTORC1 Inhibitor,153,9858,mTORC1 Inhibitor,STK11 R304W,"[{'id': 3134, 'pubMedId': 24387336, 'title': 'Targeting the LKB1 tumor suppressor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24387336'}]",,06/29/2016
0,06/29/2016,mTOR Inhibitor,152,9859,mTOR Inhibitor,STK11 M136R,"[{'id': 5047, 'pubMedId': 25436981, 'title': 'Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25436981'}, {'id': 5053, 'pubMedId': 26574479, 'title': 'Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26574479'}]",,06/29/2016
0,06/29/2016,mTORC1 Inhibitor,153,9860,mTORC1 Inhibitor,STK11 M136R,"[{'id': 3134, 'pubMedId': 24387336, 'title': 'Targeting the LKB1 tumor suppressor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24387336'}]",,06/29/2016
0,06/29/2016,HER inhibitor (Pan),105,9861,HER inhibitor (Pan),ERBB4 E317K,"[{'id': 2681, 'pubMedId': 20404484, 'title': 'A growing family: adding mutated Erbb4 as a novel cancer target.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20404484'}]",,06/29/2016
0,06/29/2016,HER inhibitor (Pan),105,9862,HER inhibitor (Pan),ERBB4 E452K,"[{'id': 2681, 'pubMedId': 20404484, 'title': 'A growing family: adding mutated Erbb4 as a novel cancer target.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20404484'}]",,06/29/2016
0,06/29/2016,HER inhibitor (Pan),105,9863,HER inhibitor (Pan),ERBB4 E563K,"[{'id': 2681, 'pubMedId': 20404484, 'title': 'A growing family: adding mutated Erbb4 as a novel cancer target.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20404484'}]",,06/29/2016
0,06/29/2016,HER inhibitor (Pan),105,9864,HER inhibitor (Pan),ERBB4 E836K,"[{'id': 2681, 'pubMedId': 20404484, 'title': 'A growing family: adding mutated Erbb4 as a novel cancer target.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20404484'}]",,06/29/2016
0,06/29/2016,HER inhibitor (Pan),105,9865,HER inhibitor (Pan),ERBB4 E872K,"[{'id': 2681, 'pubMedId': 20404484, 'title': 'A growing family: adding mutated Erbb4 as a novel cancer target.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20404484'}]",,06/29/2016
0,06/29/2016,HER inhibitor (Pan),105,9866,HER inhibitor (Pan),ERBB4 R544W,"[{'id': 2681, 'pubMedId': 20404484, 'title': 'A growing family: adding mutated Erbb4 as a novel cancer target.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20404484'}]",,06/29/2016
0,06/29/2016,PDGFR Inhibitor (Pan),175,9867,PDGFR Inhibitor (Pan),PDGFRA C456_N468del,"[{'id': 2152, 'pubMedId': 20509775, 'title': 'Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20509775'}]",,06/29/2016
0,06/29/2016,PDGFR-alpha Inhibitor,176,9868,PDGFR-alpha Inhibitor,PDGFRA C456_N468del,"[{'id': 1621, 'pubMedId': 24359404, 'title': 'Targeting the PDGF signaling pathway in tumor treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24359404'}]",,06/29/2016
0,06/29/2016,PDGFR Inhibitor (Pan),175,9869,PDGFR Inhibitor (Pan),PDGFRA C456_R481del,"[{'id': 2152, 'pubMedId': 20509775, 'title': 'Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20509775'}]",,06/29/2016
0,06/29/2016,PDGFR-alpha Inhibitor,176,9870,PDGFR-alpha Inhibitor,PDGFRA C456_R481del,"[{'id': 1621, 'pubMedId': 24359404, 'title': 'Targeting the PDGF signaling pathway in tumor treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24359404'}]",,06/29/2016
0,06/29/2016,PDGFR Inhibitor (Pan),175,9871,PDGFR Inhibitor (Pan),PDGFRA E311_K312del,"[{'id': 2152, 'pubMedId': 20509775, 'title': 'Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20509775'}]",,06/29/2016
0,06/29/2016,PDGFR-alpha Inhibitor,176,9872,PDGFR-alpha Inhibitor,PDGFRA E311_K312del,"[{'id': 1621, 'pubMedId': 24359404, 'title': 'Targeting the PDGF signaling pathway in tumor treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24359404'}]",,06/29/2016
0,06/29/2016,PDGFR Inhibitor (Pan),175,9873,PDGFR Inhibitor (Pan),PDGFRA V544_L555insAVLVLLVIVIISLI,"[{'id': 2152, 'pubMedId': 20509775, 'title': 'Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20509775'}]",,06/29/2016
0,06/29/2016,PDGFR-alpha Inhibitor,176,9874,PDGFR-alpha Inhibitor,PDGFRA V544_L555insAVLVLLVIVIISLI,"[{'id': 1621, 'pubMedId': 24359404, 'title': 'Targeting the PDGF signaling pathway in tumor treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24359404'}]",,06/29/2016
0,06/29/2016,PDGFR Inhibitor (Pan),175,9875,PDGFR Inhibitor (Pan),PDGFRA C450_K451insMIEWMI,"[{'id': 2152, 'pubMedId': 20509775, 'title': 'Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20509775'}]",,06/29/2016
0,06/29/2016,PDGFR-alpha Inhibitor,176,9876,PDGFR-alpha Inhibitor,PDGFRA C450_K451insMIEWMI,"[{'id': 1621, 'pubMedId': 24359404, 'title': 'Targeting the PDGF signaling pathway in tumor treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24359404'}]",,06/29/2016
0,06/29/2016,PDGFR Inhibitor (Pan),175,9877,PDGFR Inhibitor (Pan),PDGFRA N848K,"[{'id': 2152, 'pubMedId': 20509775, 'title': 'Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20509775'}]",,06/29/2016
0,06/29/2016,PDGFR-alpha Inhibitor,176,9878,PDGFR-alpha Inhibitor,PDGFRA N848K,"[{'id': 1621, 'pubMedId': 24359404, 'title': 'Targeting the PDGF signaling pathway in tumor treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24359404'}]",,06/29/2016
0,06/29/2016,PDGFR Inhibitor (Pan),175,9879,PDGFR Inhibitor (Pan),PDGFRA Y894C,"[{'id': 2152, 'pubMedId': 20509775, 'title': 'Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20509775'}]",,06/29/2016
0,06/29/2016,PDGFR-alpha Inhibitor,176,9880,PDGFR-alpha Inhibitor,PDGFRA Y894C,"[{'id': 1621, 'pubMedId': 24359404, 'title': 'Targeting the PDGF signaling pathway in tumor treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24359404'}]",,06/29/2016
0,06/29/2016,PDGFR Inhibitor (Pan),175,9881,PDGFR Inhibitor (Pan),PDGFRA V561_I562insER,"[{'id': 2152, 'pubMedId': 20509775, 'title': 'Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20509775'}]",,06/29/2016
0,06/29/2016,PDGFR-alpha Inhibitor,176,9882,PDGFR-alpha Inhibitor,PDGFRA V561_I562insER,"[{'id': 1621, 'pubMedId': 24359404, 'title': 'Targeting the PDGF signaling pathway in tumor treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24359404'}]",,06/29/2016
0,06/29/2016,PDGFR Inhibitor (Pan),175,9883,PDGFR Inhibitor (Pan),PDGFRA Y375_K455del,"[{'id': 2152, 'pubMedId': 20509775, 'title': 'Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20509775'}]",,06/29/2016
0,06/29/2016,PDGFR-alpha Inhibitor,176,9884,PDGFR-alpha Inhibitor,PDGFRA Y375_K455del,"[{'id': 1621, 'pubMedId': 24359404, 'title': 'Targeting the PDGF signaling pathway in tumor treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24359404'}]",,06/29/2016
0,06/29/2016,PDGFR Inhibitor (Pan),175,9885,PDGFR Inhibitor (Pan),PDGFRA S566_E571delinsR,"[{'id': 2152, 'pubMedId': 20509775, 'title': 'Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20509775'}]",,06/29/2016
0,06/29/2016,PDGFR-alpha Inhibitor,176,9886,PDGFR-alpha Inhibitor,PDGFRA S566_E571delinsR,"[{'id': 1621, 'pubMedId': 24359404, 'title': 'Targeting the PDGF signaling pathway in tumor treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24359404'}]",,06/29/2016
0,06/29/2016,PDGFR Inhibitor (Pan),175,9887,PDGFR Inhibitor (Pan),PDGFRA R841_D842delinsKI,"[{'id': 2152, 'pubMedId': 20509775, 'title': 'Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20509775'}]",,06/29/2016
0,06/29/2016,PDGFR-alpha Inhibitor,176,9888,PDGFR-alpha Inhibitor,PDGFRA R841_D842delinsKI,"[{'id': 1621, 'pubMedId': 24359404, 'title': 'Targeting the PDGF signaling pathway in tumor treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24359404'}]",,06/29/2016
0,06/29/2016,PDGFR Inhibitor (Pan),175,9889,PDGFR Inhibitor (Pan),PDGFRA D842_I843delinsIM,"[{'id': 2152, 'pubMedId': 20509775, 'title': 'Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20509775'}]",,06/29/2016
0,06/29/2016,PDGFR-alpha Inhibitor,176,9890,PDGFR-alpha Inhibitor,PDGFRA D842_I843delinsIM,"[{'id': 1621, 'pubMedId': 24359404, 'title': 'Targeting the PDGF signaling pathway in tumor treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24359404'}]",,06/29/2016
0,06/29/2016,PDGFR Inhibitor (Pan),175,9891,PDGFR Inhibitor (Pan),PDGFRA H845_N848delinsP,"[{'id': 2152, 'pubMedId': 20509775, 'title': 'Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20509775'}]",,06/29/2016
0,06/29/2016,PDGFR-alpha Inhibitor,176,9892,PDGFR-alpha Inhibitor,PDGFRA H845_N848delinsP,"[{'id': 1621, 'pubMedId': 24359404, 'title': 'Targeting the PDGF signaling pathway in tumor treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24359404'}]",,06/29/2016
0,06/29/2016,PDGFR Inhibitor (Pan),175,9893,PDGFR Inhibitor (Pan),PDGFRA Y555C,"[{'id': 2152, 'pubMedId': 20509775, 'title': 'Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20509775'}]",,06/29/2016
0,06/29/2016,PDGFR-alpha Inhibitor,176,9894,PDGFR-alpha Inhibitor,PDGFRA Y555C,"[{'id': 1621, 'pubMedId': 24359404, 'title': 'Targeting the PDGF signaling pathway in tumor treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24359404'}]",,06/29/2016
0,06/29/2016,PDGFR Inhibitor (Pan),175,9895,PDGFR Inhibitor (Pan),PDGFRA N659S,"[{'id': 2152, 'pubMedId': 20509775, 'title': 'Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20509775'}]",,06/29/2016
0,06/29/2016,PDGFR-alpha Inhibitor,176,9896,PDGFR-alpha Inhibitor,PDGFRA N659S,"[{'id': 1621, 'pubMedId': 24359404, 'title': 'Targeting the PDGF signaling pathway in tumor treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24359404'}]",,06/29/2016
0,06/29/2016,PDGFR Inhibitor (Pan),175,9897,PDGFR Inhibitor (Pan),PDGFRA R748G,"[{'id': 2152, 'pubMedId': 20509775, 'title': 'Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20509775'}]",,06/29/2016
0,06/29/2016,PDGFR-alpha Inhibitor,176,9898,PDGFR-alpha Inhibitor,PDGFRA R748G,"[{'id': 1621, 'pubMedId': 24359404, 'title': 'Targeting the PDGF signaling pathway in tumor treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24359404'}]",,06/29/2016
0,06/29/2016,PDGFR Inhibitor (Pan),175,9899,PDGFR Inhibitor (Pan),PDGFRA Y849S,"[{'id': 2152, 'pubMedId': 20509775, 'title': 'Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20509775'}]",,06/29/2016
0,06/29/2016,PDGFR-alpha Inhibitor,176,9900,PDGFR-alpha Inhibitor,PDGFRA Y849S,"[{'id': 1621, 'pubMedId': 24359404, 'title': 'Targeting the PDGF signaling pathway in tumor treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24359404'}]",,06/29/2016
0,06/29/2016,RET Inhibitor,199,9901,RET Inhibitor,RET C609Y,"[{'id': 59, 'pubMedId': 22146228, 'title': 'Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22146228'}, {'id': 1869, 'pubMedId': 24705026, 'title': 'Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24705026'}, {'id': 1870, 'pubMedId': 21551259, 'title': 'In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21551259'}]",,06/29/2016
0,06/29/2016,RET Inhibitor,199,9902,RET Inhibitor,RET C611Y,"[{'id': 59, 'pubMedId': 22146228, 'title': 'Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22146228'}, {'id': 1869, 'pubMedId': 24705026, 'title': 'Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24705026'}, {'id': 1870, 'pubMedId': 21551259, 'title': 'In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21551259'}]",,06/29/2016
0,07/05/2016,VEGFR Inhibitor (Pan),230,9979,VEGFR Inhibitor (Pan),VHL Y98H,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2902, 'pubMedId': 22931246, 'title': 'Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22931246'}]",,07/05/2016
0,07/05/2016,mTORC1 Inhibitor,153,9980,mTORC1 Inhibitor,VHL Y98H,"[{'id': 2992, 'pubMedId': 16341243, 'title': 'Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16341243'}]",,07/05/2016
0,07/05/2016,VEGFR2 Inhibitor,232,9981,VEGFR2 Inhibitor,VHL Y98H,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2901, 'pubMedId': 22105611, 'title': 'Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22105611'}]",,07/05/2016
0,07/05/2016,VEGFR2 Inhibitor,232,9982,VEGFR2 Inhibitor,VHL Y98N,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2901, 'pubMedId': 22105611, 'title': 'Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22105611'}]",,07/05/2016
0,07/05/2016,mTORC1 Inhibitor,153,9983,mTORC1 Inhibitor,VHL Y98N,"[{'id': 2992, 'pubMedId': 16341243, 'title': 'Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16341243'}]",,07/05/2016
0,07/05/2016,VEGFR Inhibitor (Pan),230,9984,VEGFR Inhibitor (Pan),VHL Y98N,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2902, 'pubMedId': 22931246, 'title': 'Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22931246'}]",,07/05/2016
0,07/05/2016,VEGFR2 Inhibitor,232,9985,VEGFR2 Inhibitor,VHL Y112H,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2901, 'pubMedId': 22105611, 'title': 'Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22105611'}]",,07/05/2016
0,07/05/2016,VEGFR Inhibitor (Pan),230,9986,VEGFR Inhibitor (Pan),VHL Y112H,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2902, 'pubMedId': 22931246, 'title': 'Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22931246'}]",,07/05/2016
0,07/05/2016,mTORC1 Inhibitor,153,9987,mTORC1 Inhibitor,VHL Y112H,"[{'id': 2992, 'pubMedId': 16341243, 'title': 'Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16341243'}]",,07/05/2016
0,07/05/2016,VEGFR Inhibitor (Pan),230,9988,VEGFR Inhibitor (Pan),VHL P86H,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2902, 'pubMedId': 22931246, 'title': 'Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22931246'}]",,07/05/2016
0,07/05/2016,VEGFR2 Inhibitor,232,9989,VEGFR2 Inhibitor,VHL P86H,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2901, 'pubMedId': 22105611, 'title': 'Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22105611'}]",,07/05/2016
0,07/05/2016,mTORC1 Inhibitor,153,9990,mTORC1 Inhibitor,VHL P86H,"[{'id': 2992, 'pubMedId': 16341243, 'title': 'Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16341243'}]",,07/05/2016
0,07/05/2016,mTORC1 Inhibitor,153,9991,mTORC1 Inhibitor,VHL H115R,"[{'id': 2992, 'pubMedId': 16341243, 'title': 'Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16341243'}]",,07/05/2016
0,07/05/2016,VEGFR Inhibitor (Pan),230,9992,VEGFR Inhibitor (Pan),VHL H115R,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2902, 'pubMedId': 22931246, 'title': 'Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22931246'}]",,07/05/2016
0,07/05/2016,VEGFR2 Inhibitor,232,9993,VEGFR2 Inhibitor,VHL H115R,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2901, 'pubMedId': 22105611, 'title': 'Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22105611'}]",,07/05/2016
0,07/05/2016,mTORC1 Inhibitor,153,9994,mTORC1 Inhibitor,VHL W117C,"[{'id': 2992, 'pubMedId': 16341243, 'title': 'Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16341243'}]",,07/05/2016
0,07/05/2016,VEGFR Inhibitor (Pan),230,9995,VEGFR Inhibitor (Pan),VHL W117C,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2902, 'pubMedId': 22931246, 'title': 'Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22931246'}]",,07/05/2016
0,07/05/2016,VEGFR2 Inhibitor,232,9996,VEGFR2 Inhibitor,VHL W117C,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2901, 'pubMedId': 22105611, 'title': 'Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22105611'}]",,07/05/2016
0,07/09/2016,CTNNB1 Inhibitor,60,10017,CTNNB1 Inhibitor,APC D1394fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,07/09/2016
0,07/09/2016,Tankyrase Inhibitor,215,10018,Tankyrase Inhibitor,APC D1394fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,07/09/2016
0,07/09/2016,CTNNB1 Inhibitor,60,10019,CTNNB1 Inhibitor,APC K1462fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,07/09/2016
0,07/09/2016,Tankyrase Inhibitor,215,10020,Tankyrase Inhibitor,APC K1462fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,07/09/2016
0,07/09/2016,CTNNB1 Inhibitor,60,10021,CTNNB1 Inhibitor,APC K1817fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,07/09/2016
0,07/09/2016,Tankyrase Inhibitor,215,10022,Tankyrase Inhibitor,APC K1817fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,07/09/2016
0,07/10/2016,PARP Inhibitor (Pan),171,10050,PARP Inhibitor (Pan),BRCA2 I2672fs,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,07/10/2016
0,07/10/2016,PARP-1 Inhibitor,172,10051,PARP-1 Inhibitor,BRCA2 I2672fs,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,07/10/2016
0,07/14/2016,FGFR Inhibitor (Pan),89,10067,FGFR Inhibitor (Pan),FGFR2 K526E,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,07/14/2016
0,07/14/2016,FGFR2 Inhibitor,92,10068,FGFR2 Inhibitor,FGFR2 K526E,"[{'id': 1903, 'pubMedId': 19212647, 'title': 'FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19212647'}]",,07/14/2016
0,07/14/2016,FGFR Inhibitor (Pan),89,10069,FGFR Inhibitor (Pan),FGFR2 K641R,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,07/14/2016
0,07/14/2016,FGFR2 Inhibitor,92,10070,FGFR2 Inhibitor,FGFR2 K641R,"[{'id': 1903, 'pubMedId': 19212647, 'title': 'FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19212647'}]",,07/14/2016
0,07/15/2016,FGFR Inhibitor (Pan),89,10071,FGFR Inhibitor (Pan),FGFR2 M391R,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,07/15/2016
0,07/15/2016,FGFR2 Inhibitor,92,10072,FGFR2 Inhibitor,FGFR2 M391R,"[{'id': 1903, 'pubMedId': 19212647, 'title': 'FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19212647'}]",,07/15/2016
0,07/15/2016,Gamma secretase inhibitor,99,10278,Gamma secretase inhibitor,NOTCH1 A1552G,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}, {'id': 2522, 'pubMedId': 17317574, 'title': 'Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17317574'}]",,07/15/2016
0,07/15/2016,NOTCH1 Antibody,158,10280,NOTCH1 Antibody,NOTCH1 A1552G,"[{'id': 4206, 'pubMedId': 20393564, 'title': 'Therapeutic antibody targeting of individual Notch receptors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20393564'}]",,07/15/2016
0,07/15/2016,NOTCH Inhibitor (Pan),156,10281,NOTCH Inhibitor (Pan),NOTCH1 A1552G,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/15/2016
0,07/15/2016,NOTCH1 Inhibitor,159,10284,NOTCH1 Inhibitor,NOTCH1 A1552G,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/15/2016
0,07/15/2016,FGFR Inhibitor (Pan),89,10345,FGFR Inhibitor (Pan),FGFR2 T341P,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,07/15/2016
0,07/15/2016,FGFR2 Inhibitor,92,10346,FGFR2 Inhibitor,FGFR2 T341P,"[{'id': 1903, 'pubMedId': 19212647, 'title': 'FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19212647'}]",,07/15/2016
0,07/18/2016,FGFR Inhibitor (Pan),89,10347,FGFR Inhibitor (Pan),FGFR3 N540S,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,07/18/2016
0,07/18/2016,FGFR3 Inhibitor,94,10348,FGFR3 Inhibitor,FGFR3 N540S,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}, {'id': 1907, 'pubMedId': 20439987, 'title': 'NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20439987'}]",,07/18/2016
0,07/18/2016,FGFR Inhibitor (Pan),89,10349,FGFR Inhibitor (Pan),FGFR3 I538V,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,07/18/2016
0,07/18/2016,FGFR3 Inhibitor,94,10350,FGFR3 Inhibitor,FGFR3 I538V,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}, {'id': 1907, 'pubMedId': 20439987, 'title': 'NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20439987'}]",,07/18/2016
0,07/18/2016,FGFR Inhibitor (Pan),89,10351,FGFR Inhibitor (Pan),FGFR3 V555M,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,07/18/2016
0,07/18/2016,FGFR3 Inhibitor,94,10352,FGFR3 Inhibitor,FGFR3 V555M,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}, {'id': 1907, 'pubMedId': 20439987, 'title': 'NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20439987'}]",,07/18/2016
0,07/18/2016,FGFR Inhibitor (Pan),89,10353,FGFR Inhibitor (Pan),FGFR3 D641G,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,07/18/2016
0,07/18/2016,FGFR3 Inhibitor,94,10354,FGFR3 Inhibitor,FGFR3 D641G,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}, {'id': 1907, 'pubMedId': 20439987, 'title': 'NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20439987'}]",,07/18/2016
0,07/18/2016,FGFR Inhibitor (Pan),89,10355,FGFR Inhibitor (Pan),FGFR3 Y647C,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,07/18/2016
0,07/18/2016,FGFR3 Inhibitor,94,10356,FGFR3 Inhibitor,FGFR3 Y647C,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}, {'id': 1907, 'pubMedId': 20439987, 'title': 'NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20439987'}]",,07/18/2016
0,07/18/2016,FGFR Inhibitor (Pan),89,10357,FGFR Inhibitor (Pan),FGFR3 R669G,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,07/18/2016
0,07/18/2016,FGFR3 Inhibitor,94,10358,FGFR3 Inhibitor,FGFR3 R669G,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}, {'id': 1907, 'pubMedId': 20439987, 'title': 'NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20439987'}]",,07/18/2016
0,07/18/2016,FGFR Inhibitor (Pan),89,10359,FGFR Inhibitor (Pan),FGFR3 R669Q,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,07/18/2016
0,07/18/2016,FGFR3 Inhibitor,94,10360,FGFR3 Inhibitor,FGFR3 R669Q,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}, {'id': 1907, 'pubMedId': 20439987, 'title': 'NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20439987'}]",,07/18/2016
0,07/18/2016,FGFR Inhibitor (Pan),89,10361,FGFR Inhibitor (Pan),FGFR3 N540K,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,07/18/2016
0,07/18/2016,FGFR3 Inhibitor,94,10362,FGFR3 Inhibitor,FGFR3 N540K,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}, {'id': 1907, 'pubMedId': 20439987, 'title': 'NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20439987'}]",,07/18/2016
0,07/19/2016,SRC Inhibitor,209,10363,SRC Inhibitor,SRC T341I,"[{'id': 2477, 'pubMedId': 25662515, 'title': 'Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25662515'}, {'id': 2478, 'pubMedId': 21776389, 'title': 'Regulation of SRC family kinases in human cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21776389'}, {'id': 2479, 'pubMedId': 21521831, 'title': 'Current status of SRC inhibitors in solid tumor malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21521831'}]",,07/19/2016
0,07/19/2016,PARP Inhibitor (Pan),171,10364,PARP Inhibitor (Pan),ATM T2902fs,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",,07/19/2016
0,07/20/2016,FLT3 Inhibitor,96,10365,FLT3 Inhibitor,CBL Y371C,"[{'id': 3301, 'pubMedId': 25477533, 'title': 'Molecular pathways: cbl proteins in tumorigenesis and antitumor immunity-opportunities for cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25477533'}, {'id': 3302, 'pubMedId': 22990016, 'title': 'Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22990016'}]",,07/20/2016
0,07/20/2016,FLT3 Inhibitor,96,10366,FLT3 Inhibitor,CBL I383L,"[{'id': 3301, 'pubMedId': 25477533, 'title': 'Molecular pathways: cbl proteins in tumorigenesis and antitumor immunity-opportunities for cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25477533'}, {'id': 3302, 'pubMedId': 22990016, 'title': 'Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22990016'}]",,07/20/2016
0,07/20/2016,FLT3 Inhibitor,96,10367,FLT3 Inhibitor,CBL C384G,"[{'id': 3301, 'pubMedId': 25477533, 'title': 'Molecular pathways: cbl proteins in tumorigenesis and antitumor immunity-opportunities for cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25477533'}, {'id': 3302, 'pubMedId': 22990016, 'title': 'Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22990016'}]",,07/20/2016
0,07/20/2016,FLT3 Inhibitor,96,10368,FLT3 Inhibitor,CBL L399P,"[{'id': 3301, 'pubMedId': 25477533, 'title': 'Molecular pathways: cbl proteins in tumorigenesis and antitumor immunity-opportunities for cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25477533'}, {'id': 3302, 'pubMedId': 22990016, 'title': 'Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22990016'}]",,07/20/2016
0,07/20/2016,FLT3 Inhibitor,96,10369,FLT3 Inhibitor,CBL Q367K,"[{'id': 3301, 'pubMedId': 25477533, 'title': 'Molecular pathways: cbl proteins in tumorigenesis and antitumor immunity-opportunities for cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25477533'}, {'id': 3302, 'pubMedId': 22990016, 'title': 'Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22990016'}]",,07/20/2016
0,07/20/2016,JAK Inhibitor (Pan),126,10378,JAK Inhibitor (Pan),JAK3 L857P,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,07/20/2016
0,07/20/2016,JAK Inhibitor (Pan) – ATP competitive,127,10379,JAK Inhibitor (Pan) – ATP competitive,JAK3 L857P,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,07/20/2016
0,07/20/2016,JAK3 Inhibitor,132,10380,JAK3 Inhibitor,JAK3 L857P,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,07/20/2016
0,07/20/2016,JAK3 Inhibitor – ATP competitive,133,10381,JAK3 Inhibitor – ATP competitive,JAK3 L857P,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,07/20/2016
0,07/20/2016,JAK Inhibitor (Pan),126,10382,JAK Inhibitor (Pan),JAK3 L857H,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,07/20/2016
0,07/20/2016,JAK Inhibitor (Pan) – ATP competitive,127,10383,JAK Inhibitor (Pan) – ATP competitive,JAK3 L857H,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,07/20/2016
0,07/20/2016,JAK3 Inhibitor,132,10384,JAK3 Inhibitor,JAK3 L857H,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,07/20/2016
0,07/20/2016,JAK3 Inhibitor – ATP competitive,133,10385,JAK3 Inhibitor – ATP competitive,JAK3 L857H,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,07/20/2016
0,07/20/2016,JAK Inhibitor (Pan),126,10386,JAK Inhibitor (Pan),JAK3 P906S,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,07/20/2016
0,07/20/2016,JAK Inhibitor (Pan) – ATP competitive,127,10387,JAK Inhibitor (Pan) – ATP competitive,JAK3 P906S,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,07/20/2016
0,07/20/2016,JAK3 Inhibitor,132,10388,JAK3 Inhibitor,JAK3 P906S,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,07/20/2016
0,07/20/2016,JAK3 Inhibitor – ATP competitive,133,10389,JAK3 Inhibitor – ATP competitive,JAK3 P906S,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,07/20/2016
0,07/20/2016,JAK Inhibitor (Pan),126,10390,JAK Inhibitor (Pan),JAK3 E958K,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,07/20/2016
0,07/20/2016,JAK Inhibitor (Pan) – ATP competitive,127,10391,JAK Inhibitor (Pan) – ATP competitive,JAK3 E958K,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,07/20/2016
0,07/20/2016,JAK3 Inhibitor,132,10392,JAK3 Inhibitor,JAK3 E958K,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,07/20/2016
0,07/20/2016,JAK3 Inhibitor – ATP competitive,133,10393,JAK3 Inhibitor – ATP competitive,JAK3 E958K,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,07/20/2016
0,07/20/2016,JAK Inhibitor (Pan),126,10394,JAK Inhibitor (Pan),JAK3 T848A,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,07/20/2016
0,07/20/2016,JAK Inhibitor (Pan) – ATP competitive,127,10395,JAK Inhibitor (Pan) – ATP competitive,JAK3 T848A,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,07/20/2016
0,07/20/2016,JAK3 Inhibitor,132,10396,JAK3 Inhibitor,JAK3 T848A,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,07/20/2016
0,07/20/2016,JAK3 Inhibitor – ATP competitive,133,10397,JAK3 Inhibitor – ATP competitive,JAK3 T848A,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,07/20/2016
0,07/20/2016,PARP Inhibitor (Pan),171,10404,PARP Inhibitor (Pan),BRCA2 E2663V,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,07/20/2016
0,07/20/2016,PARP-1 Inhibitor,172,10405,PARP-1 Inhibitor,BRCA2 E2663V,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,07/20/2016
0,07/20/2016,PARP Inhibitor (Pan),171,10406,PARP Inhibitor (Pan),BRCA2 R2336H,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,07/20/2016
0,07/20/2016,PARP-1 Inhibitor,172,10407,PARP-1 Inhibitor,BRCA2 R2336H,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,07/20/2016
0,07/20/2016,PARP Inhibitor (Pan),171,10408,PARP Inhibitor (Pan),BRCA2 R2659T,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,07/20/2016
0,07/20/2016,PARP-1 Inhibitor,172,10409,PARP-1 Inhibitor,BRCA2 R2659T,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,07/20/2016
0,07/20/2016,PARP Inhibitor (Pan),171,10410,PARP Inhibitor (Pan),BRCA2 S196N,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,07/20/2016
0,07/20/2016,PARP-1 Inhibitor,172,10411,PARP-1 Inhibitor,BRCA2 S196N,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,07/20/2016
0,07/20/2016,PARP Inhibitor (Pan),171,10412,PARP Inhibitor (Pan),BRCA2 A75P,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,07/20/2016
0,07/20/2016,PARP-1 Inhibitor,172,10413,PARP-1 Inhibitor,BRCA2 A75P,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,07/20/2016
0,07/22/2016,CTNNB1 Inhibitor,60,10418,CTNNB1 Inhibitor,APC C207*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,07/22/2016
0,07/22/2016,Tankyrase Inhibitor,215,10419,Tankyrase Inhibitor,APC C207*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,07/22/2016
0,07/22/2016,CTNNB1 Inhibitor,60,10420,CTNNB1 Inhibitor,APC E190*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,07/22/2016
0,07/22/2016,Tankyrase Inhibitor,215,10421,Tankyrase Inhibitor,APC E190*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,07/22/2016
0,07/22/2016,CTNNB1 Inhibitor,60,10422,CTNNB1 Inhibitor,APC A928fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,07/22/2016
0,07/22/2016,Tankyrase Inhibitor,215,10423,Tankyrase Inhibitor,APC A928fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,07/22/2016
0,07/22/2016,PARP Inhibitor (Pan),171,10424,PARP Inhibitor (Pan),ATM E1978*,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",,07/22/2016
0,07/22/2016,PARP Inhibitor (Pan),171,10425,PARP Inhibitor (Pan),ATM C353fs,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",,07/22/2016
0,07/22/2016,PARP Inhibitor (Pan),171,10426,PARP Inhibitor (Pan),ATM K1410*,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",,07/22/2016
0,07/27/2016,ALK Inhibitor,9,10477,ALK Inhibitor,ALK Y1278S,"[{'id': 527, 'pubMedId': 21838707, 'title': 'Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21838707'}]",,07/27/2016
0,07/27/2016,PARP Inhibitor (Pan),171,10478,PARP Inhibitor (Pan),BRCA2 V211I,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,07/27/2016
0,07/27/2016,PARP-1 Inhibitor,172,10479,PARP-1 Inhibitor,BRCA2 V211I,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,07/27/2016
0,07/28/2016,p53 Activator,166,10484,p53 Activator,TP53 M246I,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,07/28/2016
0,07/28/2016,p53 Gene Therapy,167,10485,p53 Gene Therapy,TP53 M246I,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,07/28/2016
0,07/28/2016,p53 Activator,166,10486,p53 Activator,TP53 M246R,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,07/28/2016
0,07/28/2016,p53 Gene Therapy,167,10487,p53 Gene Therapy,TP53 M246R,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,07/28/2016
0,07/28/2016,mTORC1 Inhibitor,153,10488,mTORC1 Inhibitor,VHL R161P,"[{'id': 2992, 'pubMedId': 16341243, 'title': 'Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16341243'}]",,07/28/2016
0,07/28/2016,VEGFR Inhibitor (Pan),230,10489,VEGFR Inhibitor (Pan),VHL R161P,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2902, 'pubMedId': 22931246, 'title': 'Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22931246'}]",,07/28/2016
0,07/28/2016,VEGFR2 Inhibitor,232,10490,VEGFR2 Inhibitor,VHL R161P,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2901, 'pubMedId': 22105611, 'title': 'Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22105611'}]",,07/28/2016
0,07/28/2016,mTORC1 Inhibitor,153,10491,mTORC1 Inhibitor,VHL R161G,"[{'id': 2992, 'pubMedId': 16341243, 'title': 'Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16341243'}]",,07/28/2016
0,07/28/2016,VEGFR Inhibitor (Pan),230,10492,VEGFR Inhibitor (Pan),VHL R161G,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2902, 'pubMedId': 22931246, 'title': 'Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22931246'}]",,07/28/2016
0,07/28/2016,VEGFR2 Inhibitor,232,10493,VEGFR2 Inhibitor,VHL R161G,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2901, 'pubMedId': 22105611, 'title': 'Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22105611'}]",,07/28/2016
0,07/28/2016,mTOR Inhibitor,152,10494,mTOR Inhibitor,STK11 E138*,"[{'id': 5047, 'pubMedId': 25436981, 'title': 'Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25436981'}, {'id': 5053, 'pubMedId': 26574479, 'title': 'Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26574479'}]",,07/28/2016
0,07/28/2016,mTORC1 Inhibitor,153,10495,mTORC1 Inhibitor,STK11 E138*,"[{'id': 3134, 'pubMedId': 24387336, 'title': 'Targeting the LKB1 tumor suppressor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24387336'}]",,07/28/2016
0,07/28/2016,mTOR Inhibitor,152,10496,mTOR Inhibitor,STK11 I35Lfs*127,"[{'id': 5047, 'pubMedId': 25436981, 'title': 'Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25436981'}, {'id': 5053, 'pubMedId': 26574479, 'title': 'Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26574479'}]",,07/28/2016
0,07/28/2016,mTORC1 Inhibitor,153,10497,mTORC1 Inhibitor,STK11 I35Lfs*127,"[{'id': 3134, 'pubMedId': 24387336, 'title': 'Targeting the LKB1 tumor suppressor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24387336'}]",,07/28/2016
0,07/29/2016,PARP Inhibitor (Pan),171,10498,PARP Inhibitor (Pan),BRCA2 T582P,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,07/29/2016
0,07/29/2016,PARP-1 Inhibitor,172,10499,PARP-1 Inhibitor,BRCA2 T582P,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,07/29/2016
0,08/01/2016,,10505,Cetuximab,EGFR-RAD51,"[{'id': 6404, 'pubMedId': 27102076, 'title': 'EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27102076'}]",694,Cetuximab,08/01/2016
0,08/01/2016,,10506,Erlotinib,EGFR-PURB,"[{'id': 6404, 'pubMedId': 27102076, 'title': 'EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27102076'}]",4,Erlotinib,08/01/2016
0,08/01/2016,EGFR Inhibitor (Pan),74,10517,EGFR Inhibitor (Pan),EGFR-RAD51,"[{'id': 410, 'pubMedId': 16187797, 'title': 'Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16187797'}, {'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,08/01/2016
0,08/01/2016,EGFR Inhibitor 1st gen,75,10518,EGFR Inhibitor 1st gen,EGFR-RAD51,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",,08/01/2016
0,08/01/2016,EGFR Inhibitor 2nd gen,76,10519,EGFR Inhibitor 2nd gen,EGFR-RAD51,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,08/01/2016
0,08/01/2016,EGFR Inhibitor 3rd gen,77,10520,EGFR Inhibitor 3rd gen,EGFR-RAD51,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,08/01/2016
0,08/01/2016,HER inhibitor (Pan),105,10521,HER inhibitor (Pan),EGFR-RAD51,"[{'id': 2746, 'pubMedId': 25806203, 'title': 'Irreversible EGFR-TKIs: dreaming perfection.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806203'}]",,08/01/2016
0,08/03/2016,HER inhibitor (Pan),105,10527,HER inhibitor (Pan),ERBB2 A775_G776insYVMA,"[{'id': 2691, 'pubMedId': 25674538, 'title': 'The Potential of panHER Inhibition in Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25674538'}]",,08/03/2016
0,08/03/2016,HER2 Inhibitor,106,10528,HER2 Inhibitor,ERBB2 A775_G776insYVMA,"[{'id': 561, 'pubMedId': 22649146, 'title': 'HER2 mutations in non-small-cell lung cancer can be continually targeted.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22649146'}, {'id': 563, 'pubMedId': 21991949, 'title': 'Adjuvant trastuzumab in HER2-positive breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21991949'}, {'id': 564, 'pubMedId': 23801166, 'title': 'First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23801166'}]",,08/03/2016
0,08/03/2016,CTNNB1 Inhibitor,60,10529,CTNNB1 Inhibitor,CTNNB1 G34A,"[{'id': 2251, 'pubMedId': 23258168, 'title': 'WNT signalling pathways as therapeutic targets in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23258168'}]",,08/03/2016
0,08/03/2016,PDPK1 Inhibitor,180,10530,PDPK1 Inhibitor,CTNNB1 G34A,"[{'id': 2220, 'pubMedId': 20028853, 'title': 'Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028853'}]",,08/03/2016
0,08/03/2016,Tankyrase Inhibitor,215,10531,Tankyrase Inhibitor,CTNNB1 G34A,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 2299, 'pubMedId': 23621985, 'title': 'Evidence for tankyrases as antineoplastic targets in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23621985'}]",,08/03/2016
0,08/05/2016,KIT Inhibitor,136,10532,KIT Inhibitor,KIT V569_L576del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,08/05/2016
0,08/09/2016,Akt Inhibitor (Pan),4,10533,Akt Inhibitor (Pan),PIK3CA P449T,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/09/2016
0,08/09/2016,Akt1 Inhibitor,6,10534,Akt1 Inhibitor,PIK3CA P449T,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/09/2016
0,08/09/2016,Akt2 Inhibitor,7,10535,Akt2 Inhibitor,PIK3CA P449T,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/09/2016
0,08/09/2016,Akt3 Inhibitor,8,10536,Akt3 Inhibitor,PIK3CA P449T,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/09/2016
0,08/09/2016,mTOR Inhibitor,152,10537,mTOR Inhibitor,PIK3CA P449T,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/09/2016
0,08/09/2016,mTORC1 Inhibitor,153,10538,mTORC1 Inhibitor,PIK3CA P449T,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/09/2016
0,08/09/2016,mTORC2 Inhibitor,154,10539,mTORC2 Inhibitor,PIK3CA P449T,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/09/2016
0,08/09/2016,PI3K Inhibitor (Pan),181,10540,PI3K Inhibitor (Pan),PIK3CA P449T,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/09/2016
0,08/09/2016,PIK3CA inhibitor,182,10541,PIK3CA inhibitor,PIK3CA P449T,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/09/2016
0,08/10/2016,MEK inhibitor (Pan),142,10542,MEK inhibitor (Pan),MAP2K1 F129L,"[{'id': 119, 'pubMedId': 18632602, 'title': 'Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18632602'}, {'id': 2253, 'pubMedId': 18223206, 'title': 'Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18223206'}]",,08/10/2016
0,08/10/2016,MEK1 Inhibitor,143,10543,MEK1 Inhibitor,MAP2K1 F129L,"[{'id': 119, 'pubMedId': 18632602, 'title': 'Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18632602'}, {'id': 2253, 'pubMedId': 18223206, 'title': 'Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18223206'}]",,08/10/2016
0,08/12/2016,MEK2 Inhibitor,144,10544,MEK2 Inhibitor,KRAS G12D,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,08/12/2016
0,08/12/2016,RAS Inhibitor (Pan),198,10545,RAS Inhibitor (Pan),KRAS G12D,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,08/12/2016
0,08/12/2016,MEK inhibitor (Pan),142,10546,MEK inhibitor (Pan),KRAS G12D,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,08/12/2016
0,08/12/2016,PI3K Inhibitor (Pan),181,10548,PI3K Inhibitor (Pan),KRAS G12D,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,08/12/2016
0,08/12/2016,MEK1 Inhibitor,143,10550,MEK1 Inhibitor,KRAS G12D,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,08/12/2016
0,08/12/2016,PIK3CA inhibitor,182,10553,PIK3CA inhibitor,KRAS G12D,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,08/12/2016
0,08/14/2016,CTNNB1 Inhibitor,60,10554,CTNNB1 Inhibitor,APC E763*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,08/14/2016
0,08/14/2016,Tankyrase Inhibitor,215,10555,Tankyrase Inhibitor,APC E763*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,08/14/2016
0,08/14/2016,CTNNB1 Inhibitor,60,10556,CTNNB1 Inhibitor,APC F1354fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,08/14/2016
0,08/14/2016,Tankyrase Inhibitor,215,10557,Tankyrase Inhibitor,APC F1354fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,08/14/2016
0,08/14/2016,CTNNB1 Inhibitor,60,10558,CTNNB1 Inhibitor,APC I606fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,08/14/2016
0,08/14/2016,Tankyrase Inhibitor,215,10559,Tankyrase Inhibitor,APC I606fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,08/14/2016
0,08/14/2016,CTNNB1 Inhibitor,60,10560,CTNNB1 Inhibitor,APC Q1067*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,08/14/2016
0,08/14/2016,Tankyrase Inhibitor,215,10561,Tankyrase Inhibitor,APC Q1067*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,08/14/2016
0,08/14/2016,CTNNB1 Inhibitor,60,10562,CTNNB1 Inhibitor,APC R554*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,08/14/2016
0,08/14/2016,Tankyrase Inhibitor,215,10563,Tankyrase Inhibitor,APC R554*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,08/14/2016
0,08/14/2016,CTNNB1 Inhibitor,60,10564,CTNNB1 Inhibitor,APC S1400*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,08/14/2016
0,08/14/2016,Tankyrase Inhibitor,215,10565,Tankyrase Inhibitor,APC S1400*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,08/14/2016
0,08/14/2016,CTNNB1 Inhibitor,60,10566,CTNNB1 Inhibitor,APC V1377fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,08/14/2016
0,08/14/2016,Tankyrase Inhibitor,215,10567,Tankyrase Inhibitor,APC V1377fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,08/14/2016
0,08/14/2016,EGFR Inhibitor (Pan),74,10574,EGFR Inhibitor (Pan),EGFR D587H,"[{'id': 410, 'pubMedId': 16187797, 'title': 'Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16187797'}, {'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,08/14/2016
0,08/14/2016,EGFR Inhibitor 1st gen,75,10575,EGFR Inhibitor 1st gen,EGFR D587H,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",,08/14/2016
0,08/14/2016,EGFR Inhibitor 2nd gen,76,10576,EGFR Inhibitor 2nd gen,EGFR D587H,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,08/14/2016
0,08/14/2016,EGFR Inhibitor 3rd gen,77,10577,EGFR Inhibitor 3rd gen,EGFR D587H,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,08/14/2016
0,08/14/2016,HER inhibitor (Pan),105,10578,HER inhibitor (Pan),EGFR D587H,"[{'id': 2746, 'pubMedId': 25806203, 'title': 'Irreversible EGFR-TKIs: dreaming perfection.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806203'}]",,08/14/2016
0,08/14/2016,mTORC1 Inhibitor,153,10579,mTORC1 Inhibitor,FBXW7 Q47*,"[{'id': 571, 'pubMedId': 18787170, 'title': 'FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18787170'}, {'id': 2558, 'pubMedId': 24586741, 'title': 'FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24586741'}]",,08/14/2016
0,08/14/2016,FLT3 Inhibitor,96,10580,FLT3 Inhibitor,FLT3 E598_Y599insDVDFREYE,"[{'id': 705, 'pubMedId': 11756186, 'title': 'FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/11756186'}, {'id': 2547, 'pubMedId': 17124058, 'title': 'FLT3 mutations: biology and treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17124058'}, {'id': 2548, 'pubMedId': 25231999, 'title': 'Targeting FLT3 to treat leukemia.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25231999'}]",,08/14/2016
0,08/15/2016,p53 Activator,166,10581,p53 Activator,TP53 R110P,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,08/15/2016
0,08/15/2016,p53 Gene Therapy,167,10582,p53 Gene Therapy,TP53 R110P,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,08/15/2016
0,08/15/2016,HDAC Inhibitor,104,10583,HDAC Inhibitor,RB1 S463fs,"[{'id': 2739, 'pubMedId': 22293180, 'title': 'Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22293180'}]",,08/15/2016
0,08/18/2016,EGFR Inhibitor (Pan),74,10584,EGFR Inhibitor (Pan),EGFR T34_A289del,"[{'id': 410, 'pubMedId': 16187797, 'title': 'Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16187797'}, {'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,08/18/2016
0,08/18/2016,EGFR Inhibitor 1st gen,75,10585,EGFR Inhibitor 1st gen,EGFR T34_A289del,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",,08/18/2016
0,08/18/2016,EGFR Inhibitor 2nd gen,76,10586,EGFR Inhibitor 2nd gen,EGFR T34_A289del,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,08/18/2016
0,08/18/2016,EGFR Inhibitor 3rd gen,77,10587,EGFR Inhibitor 3rd gen,EGFR T34_A289del,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,08/18/2016
0,08/18/2016,HER inhibitor (Pan),105,10588,HER inhibitor (Pan),EGFR T34_A289del,"[{'id': 2746, 'pubMedId': 25806203, 'title': 'Irreversible EGFR-TKIs: dreaming perfection.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806203'}]",,08/18/2016
0,08/18/2016,SRC Inhibitor,209,10589,SRC Inhibitor,SRC T341M,"[{'id': 2477, 'pubMedId': 25662515, 'title': 'Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25662515'}, {'id': 2478, 'pubMedId': 21776389, 'title': 'Regulation of SRC family kinases in human cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21776389'}, {'id': 2479, 'pubMedId': 21521831, 'title': 'Current status of SRC inhibitors in solid tumor malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21521831'}]",,08/18/2016
0,08/18/2016,Tankyrase Inhibitor,215,10592,Tankyrase Inhibitor,APC C1578fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,08/18/2016
0,08/18/2016,CTNNB1 Inhibitor,60,10593,CTNNB1 Inhibitor,APC C1578fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,08/18/2016
0,08/18/2016,CTNNB1 Inhibitor,60,10594,CTNNB1 Inhibitor,APC R640G,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,08/18/2016
0,08/18/2016,Tankyrase Inhibitor,215,10595,Tankyrase Inhibitor,APC R640G,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,08/18/2016
0,08/18/2016,Tankyrase Inhibitor,215,10596,Tankyrase Inhibitor,APC N741fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,08/18/2016
0,08/18/2016,CTNNB1 Inhibitor,60,10597,CTNNB1 Inhibitor,APC N741fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,08/18/2016
0,08/19/2016,CDK Inhibitor (Pan),38,10598,CDK Inhibitor (Pan),CDKN2A del,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,08/19/2016
0,08/19/2016,CDK4 Inhibitor,42,10599,CDK4 Inhibitor,CDKN2A del,"[{'id': 2949, 'pubMedId': 18829975, 'title': 'The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18829975'}]",,08/19/2016
0,08/19/2016,CDK4/6 Inhibitor,43,10600,CDK4/6 Inhibitor,CDKN2A del,"[{'id': 2835, 'pubMedId': 24495407, 'title': 'Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24495407'}, {'id': 2948, 'pubMedId': 23898052, 'title': 'PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23898052'}]",,08/19/2016
0,08/19/2016,CDK6 Inhibitor,45,10601,CDK6 Inhibitor,CDKN2A del,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,08/19/2016
0,08/25/2016,p53 Gene Therapy,167,10602,p53 Gene Therapy,TP53 W53*,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,08/25/2016
0,08/30/2016,p53 Activator,166,10603,p53 Activator,TP53 V173M,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,08/30/2016
0,08/30/2016,p53 Gene Therapy,167,10604,p53 Gene Therapy,TP53 V173M,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,08/30/2016
0,09/15/2016,p53 Gene Therapy,167,10619,p53 Gene Therapy,TP53 A159fs,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,09/15/2016
0,09/16/2016,p53 Gene Therapy,167,10620,p53 Gene Therapy,TP53 M44fs,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,09/16/2016
0,09/16/2016,CTNNB1 Inhibitor,60,10621,CTNNB1 Inhibitor,APC G471*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,09/16/2016
0,09/16/2016,Tankyrase Inhibitor,215,10622,Tankyrase Inhibitor,APC G471*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,09/16/2016
0,09/18/2016,FGFR Inhibitor (Pan),89,10623,FGFR Inhibitor (Pan),FGFR2 K660N,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,09/18/2016
0,09/18/2016,FGFR2 Inhibitor,92,10624,FGFR2 Inhibitor,FGFR2 K660N,"[{'id': 1903, 'pubMedId': 19212647, 'title': 'FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19212647'}]",,09/18/2016
0,09/29/2016,p53 Gene Therapy,167,10633,p53 Gene Therapy,TP53 R273*,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,09/29/2016
0,09/30/2016,KIT Inhibitor,136,10634,KIT Inhibitor,KIT P551_V555delinsTL,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,09/30/2016
0,09/30/2016,KIT Inhibitor,136,10635,KIT Inhibitor,KIT V559_V560delinsS,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,09/30/2016
0,10/04/2016,p53 Gene Therapy,167,10636,p53 Gene Therapy,TP53 T118Qfs*5,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,10/04/2016
0,10/05/2016,PARP Inhibitor (Pan),171,10637,PARP Inhibitor (Pan),BRCA1 E23Vfs*17,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,10/05/2016
0,10/05/2016,PARP-1 Inhibitor,172,10638,PARP-1 Inhibitor,BRCA1 E23Vfs*17,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,10/05/2016
0,10/05/2016,PARP Inhibitor (Pan),171,10639,PARP Inhibitor (Pan),BRCA1 L1795Pfs*3,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,10/05/2016
0,10/05/2016,PARP-1 Inhibitor,172,10640,PARP-1 Inhibitor,BRCA1 L1795Pfs*3,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,10/05/2016
0,10/07/2016,,10641,Neratinib,ERBB2 K753E,"[{'id': 6720, 'pubMedId': 27697991, 'title': 'Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27697991'}]",828,Neratinib,10/07/2016
0,10/10/2016,HER inhibitor (Pan),105,10642,HER inhibitor (Pan),ERBB2 L768S,"[{'id': 2691, 'pubMedId': 25674538, 'title': 'The Potential of panHER Inhibition in Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25674538'}]",,10/10/2016
0,10/10/2016,HER2 Inhibitor,106,10643,HER2 Inhibitor,ERBB2 L768S,"[{'id': 561, 'pubMedId': 22649146, 'title': 'HER2 mutations in non-small-cell lung cancer can be continually targeted.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22649146'}, {'id': 563, 'pubMedId': 21991949, 'title': 'Adjuvant trastuzumab in HER2-positive breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21991949'}, {'id': 564, 'pubMedId': 23801166, 'title': 'First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23801166'}]",,10/10/2016
0,10/10/2016,HER inhibitor (Pan),105,10644,HER inhibitor (Pan),ERBB2 V773L,"[{'id': 2691, 'pubMedId': 25674538, 'title': 'The Potential of panHER Inhibition in Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25674538'}]",,10/10/2016
0,10/10/2016,HER2 Inhibitor,106,10645,HER2 Inhibitor,ERBB2 V773L,"[{'id': 561, 'pubMedId': 22649146, 'title': 'HER2 mutations in non-small-cell lung cancer can be continually targeted.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22649146'}, {'id': 563, 'pubMedId': 21991949, 'title': 'Adjuvant trastuzumab in HER2-positive breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21991949'}, {'id': 564, 'pubMedId': 23801166, 'title': 'First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23801166'}]",,10/10/2016
0,10/19/2016,MEK inhibitor (Pan),142,10672,MEK inhibitor (Pan),MAP2K1 Y130C,"[{'id': 119, 'pubMedId': 18632602, 'title': 'Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18632602'}, {'id': 2253, 'pubMedId': 18223206, 'title': 'Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18223206'}]",,10/19/2016
0,10/19/2016,MEK1 Inhibitor,143,10673,MEK1 Inhibitor,MAP2K1 Y130C,"[{'id': 119, 'pubMedId': 18632602, 'title': 'Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18632602'}, {'id': 2253, 'pubMedId': 18223206, 'title': 'Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18223206'}]",,10/19/2016
0,10/19/2016,JAK Inhibitor (Pan),126,10674,JAK Inhibitor (Pan),JAK2 H538_K539delinsQL,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,10/19/2016
0,10/19/2016,JAK Inhibitor (Pan) – ATP competitive,127,10675,JAK Inhibitor (Pan) – ATP competitive,JAK2 H538_K539delinsQL,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,10/19/2016
0,10/19/2016,JAK2 Inhibitor,130,10676,JAK2 Inhibitor,JAK2 H538_K539delinsQL,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,10/19/2016
0,10/19/2016,JAK2 Inhibitor – ATP competitive,131,10677,JAK2 Inhibitor – ATP competitive,JAK2 H538_K539delinsQL,"[{'id': 2981, 'pubMedId': 23670175, 'title': 'Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23670175'}]",,10/19/2016
0,10/19/2016,JAK Inhibitor (Pan),126,10678,JAK Inhibitor (Pan),JAK3 P132T,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,10/19/2016
0,10/19/2016,JAK Inhibitor (Pan) – ATP competitive,127,10679,JAK Inhibitor (Pan) – ATP competitive,JAK3 P132T,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,10/19/2016
0,10/19/2016,JAK3 Inhibitor,132,10680,JAK3 Inhibitor,JAK3 P132T,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,10/19/2016
0,10/19/2016,JAK3 Inhibitor – ATP competitive,133,10681,JAK3 Inhibitor – ATP competitive,JAK3 P132T,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,10/19/2016
0,10/19/2016,KIT Inhibitor,136,10682,KIT Inhibitor,KIT K550_E554del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,10/19/2016
0,10/19/2016,KIT Inhibitor,136,10683,KIT Inhibitor,KIT K550_V555delinsI,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,10/19/2016
0,10/19/2016,KIT Inhibitor,136,10684,KIT Inhibitor,KIT M552_D572del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,10/19/2016
0,10/19/2016,KIT Inhibitor,136,10685,KIT Inhibitor,KIT M552_E554delinsK,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,10/19/2016
0,10/19/2016,KIT Inhibitor,136,10686,KIT Inhibitor,KIT M552_V555del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,10/19/2016
0,10/19/2016,KIT Inhibitor,136,10687,KIT Inhibitor,KIT M552_V559delinsI,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,10/19/2016
0,10/19/2016,KIT Inhibitor,136,10688,KIT Inhibitor,KIT P551_E554del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,10/19/2016
0,10/19/2016,KIT Inhibitor,136,10689,KIT Inhibitor,KIT P551_M552delinsL,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,10/19/2016
0,10/19/2016,KIT Inhibitor,136,10690,KIT Inhibitor,KIT P551_Q556del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,10/19/2016
0,10/19/2016,KIT Inhibitor,136,10691,KIT Inhibitor,KIT E554_D572delinsA,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,10/19/2016
0,10/19/2016,KIT Inhibitor,136,10692,KIT Inhibitor,KIT K558_D572del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,10/19/2016
0,10/19/2016,KIT Inhibitor,136,10693,KIT Inhibitor,KIT K558_Y570delinsN,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,10/19/2016
0,10/19/2016,KIT Inhibitor,136,10694,KIT Inhibitor,KIT K558_Y570delinsR,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,10/19/2016
0,10/19/2016,KIT Inhibitor,136,10695,KIT Inhibitor,KIT K558_Y570delinsNP,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,10/19/2016
0,10/19/2016,KIT Inhibitor,136,10696,KIT Inhibitor,KIT N567_P573del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,10/19/2016
0,10/20/2016,KIT Inhibitor,136,10697,KIT Inhibitor,KIT Q556_V559del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,10/20/2016
0,10/20/2016,KIT Inhibitor,136,10698,KIT Inhibitor,KIT Q556_V559delinsH,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,10/20/2016
0,10/20/2016,KIT Inhibitor,136,10699,KIT Inhibitor,KIT Q556_W557del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,10/20/2016
0,10/20/2016,KIT Inhibitor,136,10700,KIT Inhibitor,KIT V559_T574del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,10/20/2016
0,10/20/2016,KIT Inhibitor,136,10701,KIT Inhibitor,KIT W557_K558delinsC,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,10/20/2016
0,10/20/2016,KIT Inhibitor,136,10702,KIT Inhibitor,KIT W557_K558delinsE,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,10/20/2016
0,10/20/2016,KIT Inhibitor,136,10703,KIT Inhibitor,KIT W557_K558delinsF,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,10/20/2016
0,10/20/2016,KIT Inhibitor,136,10704,KIT Inhibitor,KIT Y553_E561delinsLK,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,10/20/2016
0,10/20/2016,KIT Inhibitor,136,10705,KIT Inhibitor,KIT D579_H580insIDPTQLPYD,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,10/20/2016
0,10/20/2016,ALK Inhibitor,9,10706,ALK Inhibitor,ALK M1166R,"[{'id': 527, 'pubMedId': 21838707, 'title': 'Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21838707'}]",,10/20/2016
0,10/24/2016,CSF1R Inhibitor,59,10711,CSF1R Inhibitor,CSF1R Y969F,"[{'id': 397, 'pubMedId': 18971950, 'title': 'Imatinib sensitivity as a consequence of a CSF1R-Y571D mutation and CSF1/CSF1R signaling abnormalities in the cell line GDM1.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18971950'}, {'id': 3080, 'pubMedId': 24898549, 'title': 'Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24898549'}]",,10/24/2016
0,10/24/2016,HER inhibitor (Pan),105,10712,HER inhibitor (Pan),ERBB2 P780_Y781insGSP,"[{'id': 2691, 'pubMedId': 25674538, 'title': 'The Potential of panHER Inhibition in Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25674538'}]",,10/24/2016
0,10/24/2016,HER2 Inhibitor,106,10713,HER2 Inhibitor,ERBB2 P780_Y781insGSP,"[{'id': 561, 'pubMedId': 22649146, 'title': 'HER2 mutations in non-small-cell lung cancer can be continually targeted.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22649146'}, {'id': 563, 'pubMedId': 21991949, 'title': 'Adjuvant trastuzumab in HER2-positive breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21991949'}, {'id': 564, 'pubMedId': 23801166, 'title': 'First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23801166'}]",,10/24/2016
0,10/24/2016,FGFR Inhibitor (Pan),89,10714,FGFR Inhibitor (Pan),FGFR2 C342Y,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,10/24/2016
0,10/24/2016,FGFR2 Inhibitor,92,10715,FGFR2 Inhibitor,FGFR2 C342Y,"[{'id': 1903, 'pubMedId': 19212647, 'title': 'FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19212647'}]",,10/24/2016
0,10/24/2016,FGFR Inhibitor (Pan),89,10716,FGFR Inhibitor (Pan),FGFR2 E565A,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,10/24/2016
0,10/24/2016,FGFR2 Inhibitor,92,10717,FGFR2 Inhibitor,FGFR2 E565A,"[{'id': 1903, 'pubMedId': 19212647, 'title': 'FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19212647'}]",,10/24/2016
0,10/24/2016,FGFR Inhibitor (Pan),89,10718,FGFR Inhibitor (Pan),FGFR2 E565G,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,10/24/2016
0,10/24/2016,FGFR2 Inhibitor,92,10719,FGFR2 Inhibitor,FGFR2 E565G,"[{'id': 1903, 'pubMedId': 19212647, 'title': 'FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19212647'}]",,10/24/2016
0,10/24/2016,FGFR Inhibitor (Pan),89,10720,FGFR Inhibitor (Pan),FGFR2 K525E,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,10/24/2016
0,10/24/2016,FGFR2 Inhibitor,92,10721,FGFR2 Inhibitor,FGFR2 K525E,"[{'id': 1903, 'pubMedId': 19212647, 'title': 'FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19212647'}]",,10/24/2016
0,10/24/2016,FGFR Inhibitor (Pan),89,10722,FGFR Inhibitor (Pan),FGFR2 N549T,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,10/24/2016
0,10/24/2016,FGFR2 Inhibitor,92,10723,FGFR2 Inhibitor,FGFR2 N549T,"[{'id': 1903, 'pubMedId': 19212647, 'title': 'FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19212647'}]",,10/24/2016
0,10/24/2016,FGFR Inhibitor (Pan),89,10724,FGFR Inhibitor (Pan),FGFR2 G663E,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,10/24/2016
0,10/24/2016,FGFR2 Inhibitor,92,10725,FGFR2 Inhibitor,FGFR2 G663E,"[{'id': 1903, 'pubMedId': 19212647, 'title': 'FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19212647'}]",,10/24/2016
0,10/24/2016,FGFR Inhibitor (Pan),89,10726,FGFR Inhibitor (Pan),FGFR2 R678G,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,10/24/2016
0,10/24/2016,FGFR2 Inhibitor,92,10727,FGFR2 Inhibitor,FGFR2 R678G,"[{'id': 1903, 'pubMedId': 19212647, 'title': 'FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19212647'}]",,10/24/2016
0,10/25/2016,MET Inhibitor,147,10731,MET Inhibitor,MET Y1230H,"[{'id': 1994, 'pubMedId': 24045150, 'title': 'Met as a therapeutic target in HCC: facts and hopes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24045150'}]",,10/25/2016
0,10/25/2016,MET Inhibitor,147,10732,MET Inhibitor,MET Y1230C,"[{'id': 1994, 'pubMedId': 24045150, 'title': 'Met as a therapeutic target in HCC: facts and hopes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24045150'}]",,10/25/2016
0,10/25/2016,MET Inhibitor,147,10733,MET Inhibitor,MET D1228N,"[{'id': 1994, 'pubMedId': 24045150, 'title': 'Met as a therapeutic target in HCC: facts and hopes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24045150'}]",,10/25/2016
0,10/25/2016,MET Inhibitor,147,10734,MET Inhibitor,MET D1228H,"[{'id': 1994, 'pubMedId': 24045150, 'title': 'Met as a therapeutic target in HCC: facts and hopes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24045150'}]",,10/25/2016
0,10/25/2016,MET Inhibitor,147,10735,MET Inhibitor,MET L1195V,"[{'id': 1994, 'pubMedId': 24045150, 'title': 'Met as a therapeutic target in HCC: facts and hopes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24045150'}]",,10/25/2016
0,10/25/2016,MET Inhibitor,147,10736,MET Inhibitor,MET D1246H,"[{'id': 1994, 'pubMedId': 24045150, 'title': 'Met as a therapeutic target in HCC: facts and hopes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24045150'}]",,10/25/2016
0,10/25/2016,MET Inhibitor,147,10737,MET Inhibitor,MET M1149T,"[{'id': 1994, 'pubMedId': 24045150, 'title': 'Met as a therapeutic target in HCC: facts and hopes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24045150'}]",,10/25/2016
0,10/25/2016,CTNNB1 Inhibitor,60,10738,CTNNB1 Inhibitor,CTNNB1 I35S,"[{'id': 2251, 'pubMedId': 23258168, 'title': 'WNT signalling pathways as therapeutic targets in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23258168'}]",,10/25/2016
0,10/25/2016,PDPK1 Inhibitor,180,10739,PDPK1 Inhibitor,CTNNB1 I35S,"[{'id': 2220, 'pubMedId': 20028853, 'title': 'Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20028853'}]",,10/25/2016
0,10/25/2016,Tankyrase Inhibitor,215,10740,Tankyrase Inhibitor,CTNNB1 I35S,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 2299, 'pubMedId': 23621985, 'title': 'Evidence for tankyrases as antineoplastic targets in lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23621985'}]",,10/25/2016
0,10/26/2016,RET Inhibitor,199,10761,RET Inhibitor,RET E768D,"[{'id': 59, 'pubMedId': 22146228, 'title': 'Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22146228'}, {'id': 1869, 'pubMedId': 24705026, 'title': 'Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24705026'}, {'id': 1870, 'pubMedId': 21551259, 'title': 'In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21551259'}]",,10/26/2016
0,10/26/2016,PDGFR Inhibitor (Pan),175,10762,PDGFR Inhibitor (Pan),PDGFRA Y849C,"[{'id': 2152, 'pubMedId': 20509775, 'title': 'Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20509775'}]",,10/26/2016
0,10/26/2016,PDGFR-alpha Inhibitor,176,10763,PDGFR-alpha Inhibitor,PDGFRA Y849C,"[{'id': 1621, 'pubMedId': 24359404, 'title': 'Targeting the PDGF signaling pathway in tumor treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24359404'}]",,10/26/2016
0,10/26/2016,SRC Inhibitor,209,10772,SRC Inhibitor,SRC E378G,"[{'id': 2477, 'pubMedId': 25662515, 'title': 'Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25662515'}, {'id': 2478, 'pubMedId': 21776389, 'title': 'Regulation of SRC family kinases in human cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21776389'}, {'id': 2479, 'pubMedId': 21521831, 'title': 'Current status of SRC inhibitors in solid tumor malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21521831'}]",,10/26/2016
0,10/26/2016,SRC Inhibitor,209,10773,SRC Inhibitor,SRC Y530*,"[{'id': 2477, 'pubMedId': 25662515, 'title': 'Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25662515'}, {'id': 2478, 'pubMedId': 21776389, 'title': 'Regulation of SRC family kinases in human cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21776389'}, {'id': 2479, 'pubMedId': 21521831, 'title': 'Current status of SRC inhibitors in solid tumor malignancies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21521831'}]",,10/26/2016
0,10/26/2016,RET Inhibitor,199,10774,RET Inhibitor,RET C620Y,"[{'id': 59, 'pubMedId': 22146228, 'title': 'Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22146228'}, {'id': 1869, 'pubMedId': 24705026, 'title': 'Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24705026'}, {'id': 1870, 'pubMedId': 21551259, 'title': 'In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21551259'}]",,10/26/2016
0,10/26/2016,RET Inhibitor,199,10775,RET Inhibitor,RET Y606C,"[{'id': 59, 'pubMedId': 22146228, 'title': 'Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22146228'}, {'id': 1869, 'pubMedId': 24705026, 'title': 'Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24705026'}, {'id': 1870, 'pubMedId': 21551259, 'title': 'In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21551259'}]",,10/26/2016
0,10/26/2016,PDGFR Inhibitor (Pan),175,10776,PDGFR Inhibitor (Pan),PDGFRA S556_E571delinsR,"[{'id': 2152, 'pubMedId': 20509775, 'title': 'Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20509775'}]",,10/26/2016
0,10/26/2016,PDGFR-alpha Inhibitor,176,10777,PDGFR-alpha Inhibitor,PDGFRA S556_E571delinsR,"[{'id': 1621, 'pubMedId': 24359404, 'title': 'Targeting the PDGF signaling pathway in tumor treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24359404'}]",,10/26/2016
0,11/01/2016,CTNNB1 Inhibitor,60,10778,CTNNB1 Inhibitor,APC Q1131*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,11/01/2016
0,11/01/2016,Tankyrase Inhibitor,215,10779,Tankyrase Inhibitor,APC Q1131*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,11/01/2016
0,11/01/2016,CTNNB1 Inhibitor,60,10780,CTNNB1 Inhibitor,APC G1416*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,11/01/2016
0,11/01/2016,Tankyrase Inhibitor,215,10781,Tankyrase Inhibitor,APC G1416*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,11/01/2016
0,11/01/2016,CTNNB1 Inhibitor,60,10782,CTNNB1 Inhibitor,APC K1555*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,11/01/2016
0,11/01/2016,Tankyrase Inhibitor,215,10783,Tankyrase Inhibitor,APC K1555*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,11/01/2016
0,11/01/2016,p53 Activator,166,10784,p53 Activator,TP53 R196G,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,11/01/2016
0,11/01/2016,p53 Gene Therapy,167,10785,p53 Gene Therapy,TP53 R196G,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,11/01/2016
0,11/04/2016,p53 Activator,166,10786,p53 Activator,TP53 R337L,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,11/04/2016
0,11/04/2016,p53 Gene Therapy,167,10787,p53 Gene Therapy,TP53 R337L,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,11/04/2016
0,11/04/2016,p53 Activator,166,10788,p53 Activator,TP53 R337P,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,11/04/2016
0,11/04/2016,p53 Gene Therapy,167,10789,p53 Gene Therapy,TP53 R337P,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,11/04/2016
0,11/04/2016,p53 Activator,166,10790,p53 Activator,TP53 R337C,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,11/04/2016
0,11/04/2016,p53 Gene Therapy,167,10791,p53 Gene Therapy,TP53 R337C,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,11/04/2016
0,11/04/2016,PARP Inhibitor (Pan),171,10802,PARP Inhibitor (Pan),BRCA1 R1203*,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,11/04/2016
0,11/04/2016,PARP-1 Inhibitor,172,10803,PARP-1 Inhibitor,BRCA1 R1203*,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,11/04/2016
0,12/02/2016,Akt Inhibitor (Pan),4,10808,Akt Inhibitor (Pan),PIK3CA G363A,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,12/02/2016
0,12/02/2016,Akt1 Inhibitor,6,10809,Akt1 Inhibitor,PIK3CA G363A,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,12/02/2016
0,12/02/2016,Akt2 Inhibitor,7,10810,Akt2 Inhibitor,PIK3CA G363A,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,12/02/2016
0,12/02/2016,Akt3 Inhibitor,8,10811,Akt3 Inhibitor,PIK3CA G363A,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,12/02/2016
0,12/02/2016,mTOR Inhibitor,152,10812,mTOR Inhibitor,PIK3CA G363A,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,12/02/2016
0,12/02/2016,mTORC1 Inhibitor,153,10813,mTORC1 Inhibitor,PIK3CA G363A,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,12/02/2016
0,12/02/2016,mTORC2 Inhibitor,154,10814,mTORC2 Inhibitor,PIK3CA G363A,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,12/02/2016
0,12/02/2016,PI3K Inhibitor (Pan),181,10815,PI3K Inhibitor (Pan),PIK3CA G363A,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,12/02/2016
0,12/02/2016,PIK3CA inhibitor,182,10816,PIK3CA inhibitor,PIK3CA G363A,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,12/02/2016
0,12/06/2016,MET Inhibitor,147,10817,MET Inhibitor,MET del exon14,"[{'id': 6712, 'pubMedId': 25971938, 'title': 'Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25971938'}, {'id': 7249, 'pubMedId': 26798595, 'title': 'MET exon 14 deletion (METex14): finally, a frequent-enough actionable oncogenic driver mutation in non-small cell lung cancer to lead MET inhibitors out of ""40 years of wilderness"" and into a clear path of regulatory approval.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26798595'}]",,12/06/2016
0,12/13/2016,p53 Gene Therapy,167,10818,p53 Gene Therapy,TP53 N30fs*14,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,12/13/2016
0,12/28/2016,PARP Inhibitor (Pan),171,10820,PARP Inhibitor (Pan),ATM W412*,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",,12/28/2016
0,01/05/2017,Akt Inhibitor (Pan),4,10821,Akt Inhibitor (Pan),PIK3CA P447_L455del,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,01/05/2017
0,01/05/2017,Akt1 Inhibitor,6,10822,Akt1 Inhibitor,PIK3CA P447_L455del,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,01/05/2017
0,01/05/2017,Akt2 Inhibitor,7,10823,Akt2 Inhibitor,PIK3CA P447_L455del,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,01/05/2017
0,01/05/2017,Akt3 Inhibitor,8,10824,Akt3 Inhibitor,PIK3CA P447_L455del,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,01/05/2017
0,01/05/2017,mTOR Inhibitor,152,10825,mTOR Inhibitor,PIK3CA P447_L455del,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,01/05/2017
0,01/05/2017,mTORC1 Inhibitor,153,10826,mTORC1 Inhibitor,PIK3CA P447_L455del,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,01/05/2017
0,01/05/2017,mTORC2 Inhibitor,154,10827,mTORC2 Inhibitor,PIK3CA P447_L455del,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,01/05/2017
0,01/05/2017,PI3K Inhibitor (Pan),181,10828,PI3K Inhibitor (Pan),PIK3CA P447_L455del,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,01/05/2017
0,01/05/2017,PIK3CA inhibitor,182,10829,PIK3CA inhibitor,PIK3CA P447_L455del,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,01/05/2017
0,01/18/2017,Trk Receptor Inhibitor (Pan),226,10830,Trk Receptor Inhibitor (Pan),ETV6-NTRK2,"[{'id': 5130, 'pubMedId': 26939704, 'title': 'Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26939704'}, {'id': 6326, 'pubMedId': 26884591, 'title': 'What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26884591'}]",,01/18/2017
0,01/18/2017,ROS1 Inhibitor,201,10831,ROS1 Inhibitor,ETV6-ROS1,"[{'id': 5130, 'pubMedId': 26939704, 'title': 'Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26939704'}]",,01/18/2017
0,01/18/2017,ALK Inhibitor,9,10832,ALK Inhibitor,ETV6-ALK,"[{'id': 5130, 'pubMedId': 26939704, 'title': 'Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26939704'}]",,01/18/2017
0,01/19/2017,p53 Activator,166,10842,p53 Activator,TP53 C277F,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,01/19/2017
0,01/19/2017,p53 Gene Therapy,167,10843,p53 Gene Therapy,TP53 C277F,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,01/19/2017
0,01/20/2017,mTOR Inhibitor,152,10844,mTOR Inhibitor,STK11 K48fs*3,"[{'id': 5047, 'pubMedId': 25436981, 'title': 'Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25436981'}, {'id': 5053, 'pubMedId': 26574479, 'title': 'Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26574479'}]",,01/20/2017
0,01/20/2017,mTORC1 Inhibitor,153,10845,mTORC1 Inhibitor,STK11 K48fs*3,"[{'id': 3134, 'pubMedId': 24387336, 'title': 'Targeting the LKB1 tumor suppressor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24387336'}]",,01/20/2017
0,01/20/2017,mTOR Inhibitor,152,10848,mTOR Inhibitor,STK11 E199*,"[{'id': 5047, 'pubMedId': 25436981, 'title': 'Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25436981'}, {'id': 5053, 'pubMedId': 26574479, 'title': 'Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26574479'}]",,01/20/2017
0,01/20/2017,mTORC1 Inhibitor,153,10849,mTORC1 Inhibitor,STK11 E199*,"[{'id': 3134, 'pubMedId': 24387336, 'title': 'Targeting the LKB1 tumor suppressor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24387336'}]",,01/20/2017
0,01/22/2017,p53 Activator,166,10850,p53 Activator,TP53 L194R,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,01/22/2017
0,01/22/2017,p53 Gene Therapy,167,10851,p53 Gene Therapy,TP53 L194R,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,01/22/2017
0,01/23/2017,p53 Activator,166,10852,p53 Activator,TP53 L194F,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,01/23/2017
0,01/23/2017,p53 Gene Therapy,167,10853,p53 Gene Therapy,TP53 L194F,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,01/23/2017
0,01/23/2017,p53 Gene Therapy,167,10855,p53 Gene Therapy,TP53 C242fs,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,01/23/2017
0,01/23/2017,p53 Gene Therapy,167,10856,p53 Gene Therapy,TP53 C135fs,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,01/23/2017
0,01/23/2017,p53 Gene Therapy,167,10857,p53 Gene Therapy,TP53 C242fs*5,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,01/23/2017
0,01/23/2017,p53 Gene Therapy,167,10858,p53 Gene Therapy,TP53 P72fs,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,01/23/2017
0,01/23/2017,p53 Gene Therapy,167,10859,p53 Gene Therapy,TP53 S20fs,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,01/23/2017
0,01/23/2017,p53 Gene Therapy,167,10860,p53 Gene Therapy,TP53 S215fs,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,01/23/2017
0,01/23/2017,p53 Gene Therapy,167,10861,p53 Gene Therapy,TP53 R213fs,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,01/23/2017
0,02/02/2017,MEK inhibitor (Pan),142,10863,MEK inhibitor (Pan),MAP2K1 G128D,"[{'id': 119, 'pubMedId': 18632602, 'title': 'Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18632602'}, {'id': 2253, 'pubMedId': 18223206, 'title': 'Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18223206'}]",,02/02/2017
0,02/02/2017,MEK1 Inhibitor,143,10864,MEK1 Inhibitor,MAP2K1 G128D,"[{'id': 119, 'pubMedId': 18632602, 'title': 'Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18632602'}, {'id': 2253, 'pubMedId': 18223206, 'title': 'Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18223206'}]",,02/02/2017
0,02/10/2017,HDAC Inhibitor,104,10870,HDAC Inhibitor,RB1 Q257*,"[{'id': 2739, 'pubMedId': 22293180, 'title': 'Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22293180'}]",,02/10/2017
0,02/10/2017,mTORC1 Inhibitor,153,10877,mTORC1 Inhibitor,FBXW7 Q275*,"[{'id': 571, 'pubMedId': 18787170, 'title': 'FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18787170'}, {'id': 2558, 'pubMedId': 24586741, 'title': 'FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24586741'}]",,02/10/2017
0,02/14/2017,Akt Inhibitor (Pan),4,10878,Akt Inhibitor (Pan),PIK3CA E542V,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,02/14/2017
0,02/14/2017,Akt1 Inhibitor,6,10879,Akt1 Inhibitor,PIK3CA E542V,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,02/14/2017
0,02/14/2017,Akt2 Inhibitor,7,10880,Akt2 Inhibitor,PIK3CA E542V,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,02/14/2017
0,02/14/2017,Akt3 Inhibitor,8,10881,Akt3 Inhibitor,PIK3CA E542V,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,02/14/2017
0,02/14/2017,mTOR Inhibitor,152,10882,mTOR Inhibitor,PIK3CA E542V,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,02/14/2017
0,02/14/2017,mTORC1 Inhibitor,153,10883,mTORC1 Inhibitor,PIK3CA E542V,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,02/14/2017
0,02/14/2017,mTORC2 Inhibitor,154,10884,mTORC2 Inhibitor,PIK3CA E542V,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,02/14/2017
0,02/14/2017,PI3K Inhibitor (Pan),181,10885,PI3K Inhibitor (Pan),PIK3CA E542V,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,02/14/2017
0,02/14/2017,PIK3CA inhibitor,182,10886,PIK3CA inhibitor,PIK3CA E542V,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,02/14/2017
0,02/16/2017,MET Antibody,244,10891,MET Antibody,MET del exon14,"[{'id': 2006, 'pubMedId': 23882082, 'title': 'Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23882082'}, {'id': 7828, 'pubMedId': None, 'title': 'Abstract 1219: Sym015, a novel antibody mixture targeting non-overlapping epitopes of MET, effectively inhibits growth of MET dependent tumors and overcomes resistance to a single monoclonal antibody', 'url': 'http://cancerres.aacrjournals.org/content/76/14_Supplement/1219'}]",,07/20/2017
0,02/16/2017,MET Antibody,244,10892,MET Antibody,MET Y1003*,"[{'id': 2006, 'pubMedId': 23882082, 'title': 'Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23882082'}, {'id': 7828, 'pubMedId': None, 'title': 'Abstract 1219: Sym015, a novel antibody mixture targeting non-overlapping epitopes of MET, effectively inhibits growth of MET dependent tumors and overcomes resistance to a single monoclonal antibody', 'url': 'http://cancerres.aacrjournals.org/content/76/14_Supplement/1219'}]",,07/20/2017
0,02/16/2017,MET Inhibitor,147,10893,MET Inhibitor,MET Y1003*,"[{'id': 6712, 'pubMedId': 25971938, 'title': 'Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25971938'}, {'id': 7249, 'pubMedId': 26798595, 'title': 'MET exon 14 deletion (METex14): finally, a frequent-enough actionable oncogenic driver mutation in non-small cell lung cancer to lead MET inhibitors out of ""40 years of wilderness"" and into a clear path of regulatory approval.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26798595'}]",,02/16/2017
0,02/16/2017,MET Antibody,244,10894,MET Antibody,MET Y1003fs,"[{'id': 2006, 'pubMedId': 23882082, 'title': 'Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23882082'}, {'id': 7828, 'pubMedId': None, 'title': 'Abstract 1219: Sym015, a novel antibody mixture targeting non-overlapping epitopes of MET, effectively inhibits growth of MET dependent tumors and overcomes resistance to a single monoclonal antibody', 'url': 'http://cancerres.aacrjournals.org/content/76/14_Supplement/1219'}]",,07/20/2017
0,02/16/2017,MET Inhibitor,147,10895,MET Inhibitor,MET Y1003fs,"[{'id': 6712, 'pubMedId': 25971938, 'title': 'Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25971938'}, {'id': 7249, 'pubMedId': 26798595, 'title': 'MET exon 14 deletion (METex14): finally, a frequent-enough actionable oncogenic driver mutation in non-small cell lung cancer to lead MET inhibitors out of ""40 years of wilderness"" and into a clear path of regulatory approval.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26798595'}]",,02/16/2017
0,02/20/2017,p53 Gene Therapy,167,10898,p53 Gene Therapy,TP53 T118fs,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,02/20/2017
0,02/23/2017,EGFR Inhibitor (Pan),74,10899,EGFR Inhibitor (Pan),EGFR A871G,"[{'id': 410, 'pubMedId': 16187797, 'title': 'Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16187797'}, {'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,02/23/2017
0,02/23/2017,EGFR Inhibitor 1st gen,75,10900,EGFR Inhibitor 1st gen,EGFR A871G,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",,02/23/2017
0,02/23/2017,EGFR Inhibitor 2nd gen,76,10901,EGFR Inhibitor 2nd gen,EGFR A871G,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,02/23/2017
0,02/23/2017,EGFR Inhibitor 3rd gen,77,10902,EGFR Inhibitor 3rd gen,EGFR A871G,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,02/23/2017
0,02/23/2017,HER inhibitor (Pan),105,10903,HER inhibitor (Pan),EGFR A871G,"[{'id': 2746, 'pubMedId': 25806203, 'title': 'Irreversible EGFR-TKIs: dreaming perfection.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806203'}]",,02/23/2017
0,02/24/2017,p53 Activator,166,10904,p53 Activator,TP53 S215I,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,02/24/2017
0,02/24/2017,p53 Gene Therapy,167,10905,p53 Gene Therapy,TP53 S215I,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,02/24/2017
0,02/28/2017,MET Inhibitor,147,10906,MET Inhibitor,MET Y1230D,"[{'id': 1994, 'pubMedId': 24045150, 'title': 'Met as a therapeutic target in HCC: facts and hopes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24045150'}]",,02/28/2017
0,03/03/2017,mTORC1 Inhibitor,153,10923,mTORC1 Inhibitor,VHL C162W,"[{'id': 2992, 'pubMedId': 16341243, 'title': 'Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16341243'}]",,03/03/2017
0,03/03/2017,VEGFR Inhibitor (Pan),230,10924,VEGFR Inhibitor (Pan),VHL C162W,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2902, 'pubMedId': 22931246, 'title': 'Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22931246'}]",,03/03/2017
0,03/03/2017,VEGFR2 Inhibitor,232,10925,VEGFR2 Inhibitor,VHL C162W,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2901, 'pubMedId': 22105611, 'title': 'Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22105611'}]",,03/03/2017
0,03/06/2017,HER inhibitor (Pan),105,10926,HER inhibitor (Pan),ERBB2 A775_G776insSVMA,"[{'id': 2691, 'pubMedId': 25674538, 'title': 'The Potential of panHER Inhibition in Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25674538'}]",,03/06/2017
0,03/06/2017,HER2 Inhibitor,106,10927,HER2 Inhibitor,ERBB2 A775_G776insSVMA,"[{'id': 561, 'pubMedId': 22649146, 'title': 'HER2 mutations in non-small-cell lung cancer can be continually targeted.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22649146'}, {'id': 563, 'pubMedId': 21991949, 'title': 'Adjuvant trastuzumab in HER2-positive breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21991949'}, {'id': 564, 'pubMedId': 23801166, 'title': 'First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23801166'}]",,03/06/2017
0,03/07/2017,FGFR Inhibitor (Pan),89,10928,FGFR Inhibitor (Pan),FGFR2 V564F,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,03/07/2017
0,03/07/2017,FGFR2 Inhibitor,92,10929,FGFR2 Inhibitor,FGFR2 V564F,"[{'id': 1903, 'pubMedId': 19212647, 'title': 'FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19212647'}]",,03/07/2017
0,03/07/2017,FGFR Inhibitor (Pan),89,10930,FGFR Inhibitor (Pan),FGFR2 V564I,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,03/07/2017
0,03/07/2017,FGFR2 Inhibitor,92,10931,FGFR2 Inhibitor,FGFR2 V564I,"[{'id': 1903, 'pubMedId': 19212647, 'title': 'FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19212647'}]",,03/07/2017
0,03/07/2017,FGFR Inhibitor (Pan),89,10932,FGFR Inhibitor (Pan),FGFR2 V564L,"[{'id': 1832, 'pubMedId': 24265351, 'title': 'Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24265351'}]",,03/07/2017
0,03/07/2017,FGFR2 Inhibitor,92,10933,FGFR2 Inhibitor,FGFR2 V564L,"[{'id': 1903, 'pubMedId': 19212647, 'title': 'FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19212647'}]",,03/07/2017
0,03/17/2017,HDAC Inhibitor,104,10944,HDAC Inhibitor,RB1 K319Nfs*13,"[{'id': 2739, 'pubMedId': 22293180, 'title': 'Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22293180'}]",,03/17/2017
0,03/17/2017,HDAC Inhibitor,104,10945,HDAC Inhibitor,RB1 W681*,"[{'id': 2739, 'pubMedId': 22293180, 'title': 'Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22293180'}]",,03/17/2017
0,03/17/2017,HDAC Inhibitor,104,10946,HDAC Inhibitor,RB1 L523fs,"[{'id': 2739, 'pubMedId': 22293180, 'title': 'Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22293180'}]",,03/17/2017
0,03/27/2017,CTNNB1 Inhibitor,60,10947,CTNNB1 Inhibitor,APC E1554fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,03/27/2017
0,03/27/2017,Tankyrase Inhibitor,215,10948,Tankyrase Inhibitor,APC E1554fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,03/27/2017
0,03/27/2017,p53 Gene Therapy,167,10949,p53 Gene Therapy,TP53 S227fs,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,03/27/2017
0,04/03/2017,RET Inhibitor,199,10958,RET Inhibitor,RET D631Y,"[{'id': 59, 'pubMedId': 22146228, 'title': 'Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22146228'}, {'id': 1869, 'pubMedId': 24705026, 'title': 'Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24705026'}, {'id': 1870, 'pubMedId': 21551259, 'title': 'In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21551259'}]",,04/03/2017
0,04/03/2017,RET Inhibitor,199,10959,RET Inhibitor,RET C630Y,"[{'id': 59, 'pubMedId': 22146228, 'title': 'Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22146228'}, {'id': 1869, 'pubMedId': 24705026, 'title': 'Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24705026'}, {'id': 1870, 'pubMedId': 21551259, 'title': 'In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21551259'}]",,04/03/2017
0,04/03/2017,RET Inhibitor,199,10960,RET Inhibitor,RET L633_C634insCRT,"[{'id': 59, 'pubMedId': 22146228, 'title': 'Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22146228'}, {'id': 1869, 'pubMedId': 24705026, 'title': 'Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24705026'}, {'id': 1870, 'pubMedId': 21551259, 'title': 'In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21551259'}]",,04/03/2017
0,04/03/2017,RET Inhibitor,199,10961,RET Inhibitor,RET C634_R635insHELC,"[{'id': 59, 'pubMedId': 22146228, 'title': 'Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22146228'}, {'id': 1869, 'pubMedId': 24705026, 'title': 'Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24705026'}, {'id': 1870, 'pubMedId': 21551259, 'title': 'In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21551259'}]",,04/03/2017
0,04/03/2017,RET Inhibitor,199,10962,RET Inhibitor,RET V292M,"[{'id': 59, 'pubMedId': 22146228, 'title': 'Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22146228'}, {'id': 1869, 'pubMedId': 24705026, 'title': 'Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24705026'}, {'id': 1870, 'pubMedId': 21551259, 'title': 'In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21551259'}]",,04/03/2017
0,04/04/2017,HER inhibitor (Pan),105,10965,HER inhibitor (Pan),ERBB2 L869R,"[{'id': 2691, 'pubMedId': 25674538, 'title': 'The Potential of panHER Inhibition in Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25674538'}]",,04/04/2017
0,04/04/2017,HER2 Inhibitor,106,10966,HER2 Inhibitor,ERBB2 L869R,"[{'id': 561, 'pubMedId': 22649146, 'title': 'HER2 mutations in non-small-cell lung cancer can be continually targeted.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22649146'}, {'id': 563, 'pubMedId': 21991949, 'title': 'Adjuvant trastuzumab in HER2-positive breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21991949'}, {'id': 564, 'pubMedId': 23801166, 'title': 'First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23801166'}]",,04/04/2017
0,04/06/2017,PARP Inhibitor (Pan),171,11186,PARP Inhibitor (Pan),ATM V2119fs*8,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",,04/06/2017
0,04/07/2017,p53 Activator,166,11187,p53 Activator,TP53 Y205C,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/07/2017
0,04/07/2017,p53 Gene Therapy,167,11188,p53 Gene Therapy,TP53 Y205C,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/07/2017
0,04/12/2017,RET Inhibitor,199,11189,RET Inhibitor,RET C515S,"[{'id': 59, 'pubMedId': 22146228, 'title': 'Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22146228'}, {'id': 1869, 'pubMedId': 24705026, 'title': 'Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24705026'}, {'id': 1870, 'pubMedId': 21551259, 'title': 'In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21551259'}]",,04/12/2017
0,04/12/2017,RET Inhibitor,199,11190,RET Inhibitor,RET C609S,"[{'id': 59, 'pubMedId': 22146228, 'title': 'Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22146228'}, {'id': 1869, 'pubMedId': 24705026, 'title': 'Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24705026'}, {'id': 1870, 'pubMedId': 21551259, 'title': 'In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21551259'}]",,04/12/2017
0,04/12/2017,RET Inhibitor,199,11191,RET Inhibitor,RET C630F,"[{'id': 59, 'pubMedId': 22146228, 'title': 'Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22146228'}, {'id': 1869, 'pubMedId': 24705026, 'title': 'Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24705026'}, {'id': 1870, 'pubMedId': 21551259, 'title': 'In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21551259'}]",,04/12/2017
0,04/12/2017,RET Inhibitor,199,11192,RET Inhibitor,RET C634L,"[{'id': 59, 'pubMedId': 22146228, 'title': 'Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22146228'}, {'id': 1869, 'pubMedId': 24705026, 'title': 'Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24705026'}, {'id': 1870, 'pubMedId': 21551259, 'title': 'In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21551259'}]",,04/12/2017
0,04/12/2017,RET Inhibitor,199,11193,RET Inhibitor,RET K666E,"[{'id': 59, 'pubMedId': 22146228, 'title': 'Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22146228'}, {'id': 1869, 'pubMedId': 24705026, 'title': 'Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24705026'}, {'id': 1870, 'pubMedId': 21551259, 'title': 'In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21551259'}]",,04/12/2017
0,04/12/2017,RET Inhibitor,199,11194,RET Inhibitor,RET E805K,"[{'id': 59, 'pubMedId': 22146228, 'title': 'Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22146228'}, {'id': 1869, 'pubMedId': 24705026, 'title': 'Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24705026'}, {'id': 1870, 'pubMedId': 21551259, 'title': 'In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21551259'}]",,04/12/2017
0,04/12/2017,RET Inhibitor,199,11195,RET Inhibitor,RET E505_G506del,"[{'id': 59, 'pubMedId': 22146228, 'title': 'Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22146228'}, {'id': 1869, 'pubMedId': 24705026, 'title': 'Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24705026'}, {'id': 1870, 'pubMedId': 21551259, 'title': 'In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21551259'}]",,04/12/2017
0,04/13/2017,,11196,Dacomitinib,EGFR D770delinsGY,"[{'id': 8567, 'pubMedId': 28363995, 'title': 'Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28363995'}, {'id': 8568, 'pubMedId': 21220471, 'title': 'Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21220471'}]",714,Dacomitinib,04/13/2017
0,04/13/2017,HER inhibitor (Pan),105,11197,HER inhibitor (Pan),ERBB2 G778_S779insCPG,"[{'id': 8567, 'pubMedId': 28363995, 'title': 'Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28363995'}]",,04/13/2017
0,04/13/2017,HER2 Inhibitor,106,11198,HER2 Inhibitor,ERBB2 G778_S779insCPG,"[{'id': 8567, 'pubMedId': 28363995, 'title': 'Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28363995'}]",,04/13/2017
0,04/18/2017,mTOR Inhibitor,152,11199,mTOR Inhibitor,STK11 K48fs,"[{'id': 5047, 'pubMedId': 25436981, 'title': 'Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25436981'}, {'id': 5053, 'pubMedId': 26574479, 'title': 'Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26574479'}]",,04/18/2017
0,04/18/2017,mTORC1 Inhibitor,153,11200,mTORC1 Inhibitor,STK11 K48fs,"[{'id': 3134, 'pubMedId': 24387336, 'title': 'Targeting the LKB1 tumor suppressor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24387336'}]",,04/18/2017
0,04/18/2017,mTOR Inhibitor,152,11201,mTOR Inhibitor,STK11 E57fs,"[{'id': 5047, 'pubMedId': 25436981, 'title': 'Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25436981'}, {'id': 5053, 'pubMedId': 26574479, 'title': 'Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26574479'}]",,04/18/2017
0,04/18/2017,mTORC1 Inhibitor,153,11202,mTORC1 Inhibitor,STK11 E57fs,"[{'id': 3134, 'pubMedId': 24387336, 'title': 'Targeting the LKB1 tumor suppressor.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24387336'}]",,04/18/2017
0,04/18/2017,CTNNB1 Inhibitor,60,11203,CTNNB1 Inhibitor,APC S811*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,04/18/2017
0,04/18/2017,Tankyrase Inhibitor,215,11204,Tankyrase Inhibitor,APC S811*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,04/18/2017
0,04/18/2017,CTNNB1 Inhibitor,60,11205,CTNNB1 Inhibitor,APC S1278*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,04/18/2017
0,04/18/2017,Tankyrase Inhibitor,215,11206,Tankyrase Inhibitor,APC S1278*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,04/18/2017
0,04/18/2017,CTNNB1 Inhibitor,60,11207,CTNNB1 Inhibitor,APC S1197*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,04/18/2017
0,04/18/2017,Tankyrase Inhibitor,215,11208,Tankyrase Inhibitor,APC S1197*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,04/18/2017
0,04/18/2017,CTNNB1 Inhibitor,60,11209,CTNNB1 Inhibitor,APC E853*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,04/18/2017
0,04/18/2017,Tankyrase Inhibitor,215,11210,Tankyrase Inhibitor,APC E853*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,04/18/2017
0,04/18/2017,CTNNB1 Inhibitor,60,11211,CTNNB1 Inhibitor,APC L665*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,04/18/2017
0,04/18/2017,Tankyrase Inhibitor,215,11212,Tankyrase Inhibitor,APC L665*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,04/18/2017
0,04/18/2017,p53 Gene Therapy,167,11218,p53 Gene Therapy,TP53 S90fs*33,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/18/2017
0,04/19/2017,CTNNB1 Inhibitor,60,11219,CTNNB1 Inhibitor,APC I1164fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,04/19/2017
0,04/19/2017,Tankyrase Inhibitor,215,11220,Tankyrase Inhibitor,APC I1164fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,04/19/2017
0,04/19/2017,CTNNB1 Inhibitor,60,11221,CTNNB1 Inhibitor,APC W553*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,04/19/2017
0,04/19/2017,Tankyrase Inhibitor,215,11222,Tankyrase Inhibitor,APC W553*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,04/19/2017
0,04/19/2017,PARP Inhibitor (Pan),171,11223,PARP Inhibitor (Pan),ATM V278fs,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",,04/19/2017
0,04/19/2017,HDAC Inhibitor,104,11224,HDAC Inhibitor,RB1 E48*,"[{'id': 2739, 'pubMedId': 22293180, 'title': 'Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22293180'}]",,04/19/2017
0,04/19/2017,RET Inhibitor,199,11225,RET Inhibitor,RET C515W,"[{'id': 59, 'pubMedId': 22146228, 'title': 'Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22146228'}, {'id': 1869, 'pubMedId': 24705026, 'title': 'Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24705026'}, {'id': 1870, 'pubMedId': 21551259, 'title': 'In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21551259'}]",,04/19/2017
0,04/19/2017,RET Inhibitor,199,11226,RET Inhibitor,RET G533C,"[{'id': 59, 'pubMedId': 22146228, 'title': 'Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22146228'}, {'id': 1869, 'pubMedId': 24705026, 'title': 'Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24705026'}, {'id': 1870, 'pubMedId': 21551259, 'title': 'In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21551259'}]",,04/19/2017
0,04/21/2017,PARP Inhibitor (Pan),171,11229,PARP Inhibitor (Pan),ATM L804fs*4,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",,04/21/2017
0,04/21/2017,PARP Inhibitor (Pan),171,11230,PARP Inhibitor (Pan),ATM S978fs*12,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",,04/21/2017
0,04/21/2017,,11231,Verteporfin,GNAQ Q209P,"[{'id': 1808, 'pubMedId': 24882516, 'title': 'Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24882516'}, {'id': 8675, 'pubMedId': 27308390, 'title': 'YAP inhibition blocks uveal melanogenesis driven by GNAQ or GNA11 mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27308390'}]",3319,Verteporfin,04/21/2017
0,04/21/2017,PKC beta Inhibitor,191,11232,PKC beta Inhibitor,GNAQ Q209X,"[{'id': 982, 'pubMedId': 22253748, 'title': 'The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22253748'}]",,04/21/2017
0,04/21/2017,MEK inhibitor (Pan),142,11233,MEK inhibitor (Pan),GNAQ Q209X,"[{'id': 8672, 'pubMedId': 22515704, 'title': 'Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22515704'}, {'id': 8677, 'pubMedId': 22550165, 'title': 'Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22550165'}, {'id': 8679, 'pubMedId': 25113308, 'title': 'Biology of advanced uveal melanoma and next steps for clinical therapeutics.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25113308'}]",,04/21/2017
0,04/21/2017,PKC Inhibitor (Pan),192,11234,PKC Inhibitor (Pan),GNAQ Q209X,"[{'id': 772, 'pubMedId': 24141786, 'title': 'Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24141786'}, {'id': 8663, 'pubMedId': 22653968, 'title': 'Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22653968'}]",,04/21/2017
0,04/21/2017,,11235,Verteporfin,GNAQ Q209X,"[{'id': 1808, 'pubMedId': 24882516, 'title': 'Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24882516'}, {'id': 8675, 'pubMedId': 27308390, 'title': 'YAP inhibition blocks uveal melanogenesis driven by GNAQ or GNA11 mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27308390'}]",3319,Verteporfin,04/21/2017
0,04/21/2017,PKC Inhibitor (Pan),192,11236,PKC Inhibitor (Pan),GNAQ Q209L,"[{'id': 772, 'pubMedId': 24141786, 'title': 'Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24141786'}, {'id': 8663, 'pubMedId': 22653968, 'title': 'Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22653968'}]",,04/21/2017
0,04/21/2017,PKC beta Inhibitor,191,11237,PKC beta Inhibitor,GNAQ Q209L,"[{'id': 982, 'pubMedId': 22253748, 'title': 'The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22253748'}]",,04/21/2017
0,04/21/2017,,11238,Verteporfin,GNAQ Q209L,"[{'id': 1808, 'pubMedId': 24882516, 'title': 'Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24882516'}, {'id': 8675, 'pubMedId': 27308390, 'title': 'YAP inhibition blocks uveal melanogenesis driven by GNAQ or GNA11 mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27308390'}]",3319,Verteporfin,04/21/2017
0,04/21/2017,MEK inhibitor (Pan),142,11239,MEK inhibitor (Pan),GNAQ Q209L,"[{'id': 8672, 'pubMedId': 22515704, 'title': 'Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22515704'}, {'id': 8677, 'pubMedId': 22550165, 'title': 'Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22550165'}, {'id': 8679, 'pubMedId': 25113308, 'title': 'Biology of advanced uveal melanoma and next steps for clinical therapeutics.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25113308'}]",,04/21/2017
0,04/21/2017,MEK inhibitor (Pan),142,11240,MEK inhibitor (Pan),GNAQ Q209R,"[{'id': 8672, 'pubMedId': 22515704, 'title': 'Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22515704'}, {'id': 8677, 'pubMedId': 22550165, 'title': 'Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22550165'}, {'id': 8679, 'pubMedId': 25113308, 'title': 'Biology of advanced uveal melanoma and next steps for clinical therapeutics.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25113308'}]",,04/21/2017
0,04/21/2017,PKC beta Inhibitor,191,11241,PKC beta Inhibitor,GNAQ Q209R,"[{'id': 982, 'pubMedId': 22253748, 'title': 'The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22253748'}]",,04/21/2017
0,04/21/2017,,11242,Verteporfin,GNAQ Q209R,"[{'id': 1808, 'pubMedId': 24882516, 'title': 'Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24882516'}, {'id': 8675, 'pubMedId': 27308390, 'title': 'YAP inhibition blocks uveal melanogenesis driven by GNAQ or GNA11 mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27308390'}]",3319,Verteporfin,04/21/2017
0,04/21/2017,PKC Inhibitor (Pan),192,11243,PKC Inhibitor (Pan),GNAQ Q209R,"[{'id': 772, 'pubMedId': 24141786, 'title': 'Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24141786'}, {'id': 8663, 'pubMedId': 22653968, 'title': 'Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22653968'}]",,04/21/2017
0,04/21/2017,PKC Inhibitor (Pan),192,11244,PKC Inhibitor (Pan),GNAQ Q209H,"[{'id': 772, 'pubMedId': 24141786, 'title': 'Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24141786'}, {'id': 8663, 'pubMedId': 22653968, 'title': 'Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22653968'}]",,04/21/2017
0,04/21/2017,,11245,Verteporfin,GNAQ Q209H,"[{'id': 1808, 'pubMedId': 24882516, 'title': 'Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24882516'}, {'id': 8675, 'pubMedId': 27308390, 'title': 'YAP inhibition blocks uveal melanogenesis driven by GNAQ or GNA11 mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27308390'}]",3319,Verteporfin,04/21/2017
0,04/21/2017,PKC beta Inhibitor,191,11246,PKC beta Inhibitor,GNAQ Q209H,"[{'id': 982, 'pubMedId': 22253748, 'title': 'The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22253748'}]",,04/21/2017
0,04/21/2017,MEK inhibitor (Pan),142,11247,MEK inhibitor (Pan),GNAQ Q209H,"[{'id': 8672, 'pubMedId': 22515704, 'title': 'Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22515704'}, {'id': 8677, 'pubMedId': 22550165, 'title': 'Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22550165'}, {'id': 8679, 'pubMedId': 25113308, 'title': 'Biology of advanced uveal melanoma and next steps for clinical therapeutics.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25113308'}]",,04/21/2017
0,04/21/2017,,11248,Verteporfin,GNAQ Q209K,"[{'id': 1808, 'pubMedId': 24882516, 'title': 'Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24882516'}, {'id': 8675, 'pubMedId': 27308390, 'title': 'YAP inhibition blocks uveal melanogenesis driven by GNAQ or GNA11 mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27308390'}]",3319,Verteporfin,04/21/2017
0,04/21/2017,PKC Inhibitor (Pan),192,11249,PKC Inhibitor (Pan),GNAQ Q209K,"[{'id': 772, 'pubMedId': 24141786, 'title': 'Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24141786'}, {'id': 8663, 'pubMedId': 22653968, 'title': 'Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22653968'}]",,04/21/2017
0,04/21/2017,PKC beta Inhibitor,191,11250,PKC beta Inhibitor,GNAQ Q209K,"[{'id': 982, 'pubMedId': 22253748, 'title': 'The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22253748'}]",,04/21/2017
0,04/21/2017,MEK inhibitor (Pan),142,11251,MEK inhibitor (Pan),GNAQ Q209K,"[{'id': 8672, 'pubMedId': 22515704, 'title': 'Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22515704'}, {'id': 8677, 'pubMedId': 22550165, 'title': 'Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22550165'}, {'id': 8679, 'pubMedId': 25113308, 'title': 'Biology of advanced uveal melanoma and next steps for clinical therapeutics.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25113308'}]",,04/21/2017
0,04/21/2017,PKC beta Inhibitor,191,11252,PKC beta Inhibitor,GNAQ Q209Y,"[{'id': 982, 'pubMedId': 22253748, 'title': 'The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22253748'}]",,04/21/2017
0,04/21/2017,,11253,Verteporfin,GNAQ Q209Y,"[{'id': 1808, 'pubMedId': 24882516, 'title': 'Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24882516'}, {'id': 8675, 'pubMedId': 27308390, 'title': 'YAP inhibition blocks uveal melanogenesis driven by GNAQ or GNA11 mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27308390'}]",3319,Verteporfin,04/21/2017
0,04/21/2017,PKC Inhibitor (Pan),192,11254,PKC Inhibitor (Pan),GNAQ Q209Y,"[{'id': 772, 'pubMedId': 24141786, 'title': 'Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24141786'}, {'id': 8663, 'pubMedId': 22653968, 'title': 'Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22653968'}]",,04/21/2017
0,04/21/2017,MEK inhibitor (Pan),142,11255,MEK inhibitor (Pan),GNAQ Q209Y,"[{'id': 8672, 'pubMedId': 22515704, 'title': 'Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22515704'}, {'id': 8677, 'pubMedId': 22550165, 'title': 'Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22550165'}, {'id': 8679, 'pubMedId': 25113308, 'title': 'Biology of advanced uveal melanoma and next steps for clinical therapeutics.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25113308'}]",,04/21/2017
0,04/21/2017,MEK inhibitor (Pan),142,11256,MEK inhibitor (Pan),GNAQ R183X,"[{'id': 8672, 'pubMedId': 22515704, 'title': 'Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22515704'}, {'id': 8677, 'pubMedId': 22550165, 'title': 'Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22550165'}, {'id': 8679, 'pubMedId': 25113308, 'title': 'Biology of advanced uveal melanoma and next steps for clinical therapeutics.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25113308'}]",,04/21/2017
0,04/21/2017,PKC Inhibitor (Pan),192,11257,PKC Inhibitor (Pan),GNAQ R183X,"[{'id': 772, 'pubMedId': 24141786, 'title': 'Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24141786'}, {'id': 8663, 'pubMedId': 22653968, 'title': 'Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22653968'}]",,04/21/2017
0,04/21/2017,PKC beta Inhibitor,191,11258,PKC beta Inhibitor,GNAQ R183X,"[{'id': 982, 'pubMedId': 22253748, 'title': 'The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22253748'}]",,04/21/2017
0,04/21/2017,,11259,Verteporfin,GNAQ R183X,"[{'id': 1808, 'pubMedId': 24882516, 'title': 'Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24882516'}, {'id': 8675, 'pubMedId': 27308390, 'title': 'YAP inhibition blocks uveal melanogenesis driven by GNAQ or GNA11 mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27308390'}]",3319,Verteporfin,04/21/2017
0,04/21/2017,PKC Inhibitor (Pan),192,11260,PKC Inhibitor (Pan),GNAQ R183Q,"[{'id': 772, 'pubMedId': 24141786, 'title': 'Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24141786'}, {'id': 8663, 'pubMedId': 22653968, 'title': 'Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22653968'}]",,04/21/2017
0,04/21/2017,PKC beta Inhibitor,191,11261,PKC beta Inhibitor,GNAQ R183Q,"[{'id': 982, 'pubMedId': 22253748, 'title': 'The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22253748'}]",,04/21/2017
0,04/21/2017,MEK inhibitor (Pan),142,11262,MEK inhibitor (Pan),GNAQ R183Q,"[{'id': 8672, 'pubMedId': 22515704, 'title': 'Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22515704'}, {'id': 8677, 'pubMedId': 22550165, 'title': 'Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22550165'}, {'id': 8679, 'pubMedId': 25113308, 'title': 'Biology of advanced uveal melanoma and next steps for clinical therapeutics.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25113308'}]",,04/21/2017
0,04/21/2017,,11263,Verteporfin,GNAQ R183Q,"[{'id': 1808, 'pubMedId': 24882516, 'title': 'Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24882516'}, {'id': 8675, 'pubMedId': 27308390, 'title': 'YAP inhibition blocks uveal melanogenesis driven by GNAQ or GNA11 mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27308390'}]",3319,Verteporfin,04/21/2017
0,04/21/2017,MEK inhibitor (Pan),142,11264,MEK inhibitor (Pan),GNAQ inact mut,"[{'id': 8672, 'pubMedId': 22515704, 'title': 'Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22515704'}, {'id': 8677, 'pubMedId': 22550165, 'title': 'Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22550165'}, {'id': 8679, 'pubMedId': 25113308, 'title': 'Biology of advanced uveal melanoma and next steps for clinical therapeutics.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25113308'}]",,04/21/2017
0,04/21/2017,,11265,Verteporfin,GNAQ inact mut,"[{'id': 1808, 'pubMedId': 24882516, 'title': 'Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24882516'}, {'id': 8675, 'pubMedId': 27308390, 'title': 'YAP inhibition blocks uveal melanogenesis driven by GNAQ or GNA11 mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27308390'}]",3319,Verteporfin,04/21/2017
0,04/21/2017,PKC Inhibitor (Pan),192,11266,PKC Inhibitor (Pan),GNAQ inact mut,"[{'id': 772, 'pubMedId': 24141786, 'title': 'Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24141786'}, {'id': 8663, 'pubMedId': 22653968, 'title': 'Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22653968'}]",,04/21/2017
0,04/21/2017,PKC beta Inhibitor,191,11267,PKC beta Inhibitor,GNAQ inact mut,"[{'id': 982, 'pubMedId': 22253748, 'title': 'The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22253748'}]",,04/21/2017
0,04/21/2017,,11268,Verteporfin,GNA11 Q209P,"[{'id': 1808, 'pubMedId': 24882516, 'title': 'Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24882516'}]",3319,Verteporfin,04/21/2017
0,04/21/2017,MEK inhibitor (Pan),142,11269,MEK inhibitor (Pan),GNA11 Q209L,"[{'id': 8672, 'pubMedId': 22515704, 'title': 'Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22515704'}, {'id': 8679, 'pubMedId': 25113308, 'title': 'Biology of advanced uveal melanoma and next steps for clinical therapeutics.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25113308'}]",,04/21/2017
0,04/21/2017,PKC Inhibitor (Pan),192,11270,PKC Inhibitor (Pan),GNA11 Q209L,"[{'id': 772, 'pubMedId': 24141786, 'title': 'Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24141786'}]",,04/21/2017
0,04/21/2017,,11271,Verteporfin,GNA11 Q209L,"[{'id': 1808, 'pubMedId': 24882516, 'title': 'Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24882516'}]",3319,Verteporfin,04/21/2017
0,04/21/2017,PKC Inhibitor (Pan),192,11272,PKC Inhibitor (Pan),GNA11 Q209R,"[{'id': 772, 'pubMedId': 24141786, 'title': 'Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24141786'}]",,04/21/2017
0,04/21/2017,MEK inhibitor (Pan),142,11273,MEK inhibitor (Pan),GNA11 Q209R,"[{'id': 8672, 'pubMedId': 22515704, 'title': 'Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22515704'}, {'id': 8679, 'pubMedId': 25113308, 'title': 'Biology of advanced uveal melanoma and next steps for clinical therapeutics.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25113308'}]",,04/21/2017
0,04/21/2017,,11274,Verteporfin,GNA11 Q209R,"[{'id': 1808, 'pubMedId': 24882516, 'title': 'Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24882516'}]",3319,Verteporfin,04/21/2017
0,04/21/2017,MEK inhibitor (Pan),142,11275,MEK inhibitor (Pan),GNA11 Q209K,"[{'id': 8672, 'pubMedId': 22515704, 'title': 'Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22515704'}, {'id': 8679, 'pubMedId': 25113308, 'title': 'Biology of advanced uveal melanoma and next steps for clinical therapeutics.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25113308'}]",,04/21/2017
0,04/21/2017,,11276,Verteporfin,GNA11 Q209K,"[{'id': 1808, 'pubMedId': 24882516, 'title': 'Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24882516'}]",3319,Verteporfin,04/21/2017
0,04/21/2017,PKC Inhibitor (Pan),192,11277,PKC Inhibitor (Pan),GNA11 Q209K,"[{'id': 772, 'pubMedId': 24141786, 'title': 'Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24141786'}]",,04/21/2017
0,04/21/2017,PKC Inhibitor (Pan),192,11278,PKC Inhibitor (Pan),GNA11 Q209X,"[{'id': 772, 'pubMedId': 24141786, 'title': 'Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24141786'}]",,04/21/2017
0,04/21/2017,MEK inhibitor (Pan),142,11279,MEK inhibitor (Pan),GNA11 Q209X,"[{'id': 8672, 'pubMedId': 22515704, 'title': 'Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22515704'}, {'id': 8679, 'pubMedId': 25113308, 'title': 'Biology of advanced uveal melanoma and next steps for clinical therapeutics.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25113308'}]",,04/21/2017
0,04/21/2017,,11280,Verteporfin,GNA11 Q209X,"[{'id': 1808, 'pubMedId': 24882516, 'title': 'Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24882516'}]",3319,Verteporfin,04/21/2017
0,04/21/2017,PKC Inhibitor (Pan),192,11281,PKC Inhibitor (Pan),GNA11 R183Q,"[{'id': 772, 'pubMedId': 24141786, 'title': 'Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24141786'}]",,04/21/2017
0,04/21/2017,,11282,Verteporfin,GNA11 R183Q,"[{'id': 1808, 'pubMedId': 24882516, 'title': 'Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24882516'}]",3319,Verteporfin,04/21/2017
0,04/21/2017,MEK inhibitor (Pan),142,11283,MEK inhibitor (Pan),GNA11 R183Q,"[{'id': 8672, 'pubMedId': 22515704, 'title': 'Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22515704'}, {'id': 8679, 'pubMedId': 25113308, 'title': 'Biology of advanced uveal melanoma and next steps for clinical therapeutics.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25113308'}]",,04/21/2017
0,04/21/2017,PKC Inhibitor (Pan),192,11284,PKC Inhibitor (Pan),GNA11 R183H,"[{'id': 772, 'pubMedId': 24141786, 'title': 'Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24141786'}]",,04/21/2017
0,04/21/2017,MEK inhibitor (Pan),142,11285,MEK inhibitor (Pan),GNA11 R183H,"[{'id': 8672, 'pubMedId': 22515704, 'title': 'Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22515704'}, {'id': 8679, 'pubMedId': 25113308, 'title': 'Biology of advanced uveal melanoma and next steps for clinical therapeutics.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25113308'}]",,04/21/2017
0,04/21/2017,,11286,Verteporfin,GNA11 R183H,"[{'id': 1808, 'pubMedId': 24882516, 'title': 'Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24882516'}]",3319,Verteporfin,04/21/2017
0,04/21/2017,PKC Inhibitor (Pan),192,11287,PKC Inhibitor (Pan),GNA11 R183X,"[{'id': 772, 'pubMedId': 24141786, 'title': 'Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24141786'}]",,04/21/2017
0,04/21/2017,,11288,Verteporfin,GNA11 R183X,"[{'id': 1808, 'pubMedId': 24882516, 'title': 'Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24882516'}]",3319,Verteporfin,04/21/2017
0,04/21/2017,MEK inhibitor (Pan),142,11289,MEK inhibitor (Pan),GNA11 R183X,"[{'id': 8672, 'pubMedId': 22515704, 'title': 'Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22515704'}, {'id': 8679, 'pubMedId': 25113308, 'title': 'Biology of advanced uveal melanoma and next steps for clinical therapeutics.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25113308'}]",,04/21/2017
0,04/21/2017,,11290,Verteporfin,GNA11 R183C,"[{'id': 1808, 'pubMedId': 24882516, 'title': 'Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24882516'}]",3319,Verteporfin,04/21/2017
0,04/21/2017,MEK inhibitor (Pan),142,11291,MEK inhibitor (Pan),GNA11 R183C,"[{'id': 8672, 'pubMedId': 22515704, 'title': 'Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22515704'}, {'id': 8679, 'pubMedId': 25113308, 'title': 'Biology of advanced uveal melanoma and next steps for clinical therapeutics.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25113308'}]",,04/21/2017
0,04/21/2017,PKC Inhibitor (Pan),192,11292,PKC Inhibitor (Pan),GNA11 R183C,"[{'id': 772, 'pubMedId': 24141786, 'title': 'Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24141786'}]",,04/21/2017
0,04/21/2017,PKC Inhibitor (Pan),192,11293,PKC Inhibitor (Pan),GNA11 inact mut,"[{'id': 772, 'pubMedId': 24141786, 'title': 'Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24141786'}]",,04/21/2017
0,04/21/2017,MEK inhibitor (Pan),142,11294,MEK inhibitor (Pan),GNA11 inact mut,"[{'id': 8672, 'pubMedId': 22515704, 'title': 'Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22515704'}, {'id': 8679, 'pubMedId': 25113308, 'title': 'Biology of advanced uveal melanoma and next steps for clinical therapeutics.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25113308'}]",,04/21/2017
0,04/21/2017,,11295,Verteporfin,GNA11 inact mut,"[{'id': 1808, 'pubMedId': 24882516, 'title': 'Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24882516'}]",3319,Verteporfin,04/21/2017
0,04/24/2017,PARP Inhibitor (Pan),171,11299,PARP Inhibitor (Pan),BRCA2 N1784fs,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,04/24/2017
0,04/24/2017,PARP-1 Inhibitor,172,11300,PARP-1 Inhibitor,BRCA2 N1784fs,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,04/24/2017
0,04/25/2017,p53 Gene Therapy,167,11305,p53 Gene Therapy,TP53 C124fs,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/25/2017
0,04/29/2017,p53 Activator,166,11309,p53 Activator,TP53 P190S,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/29/2017
0,04/29/2017,p53 Gene Therapy,167,11310,p53 Gene Therapy,TP53 P190S,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,04/29/2017
0,05/01/2017,p53 Activator,166,11311,p53 Activator,TP53 R273W,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,05/01/2017
0,05/01/2017,p53 Gene Therapy,167,11312,p53 Gene Therapy,TP53 R273W,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,05/01/2017
0,05/10/2017,Akt1 Inhibitor,6,11422,Akt1 Inhibitor,AKT1 act mut,"[{'id': 6757, 'pubMedId': 27699769, 'title': 'BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27699769'}]",,05/10/2017
0,05/10/2017,Akt1 Inhibitor,6,11423,Akt1 Inhibitor,AKT1 E17K,"[{'id': 6757, 'pubMedId': 27699769, 'title': 'BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27699769'}]",,05/10/2017
0,05/10/2017,Akt Inhibitor (Pan),4,11424,Akt Inhibitor (Pan),AKT1 E17K,"[{'id': 104, 'pubMedId': 18504432, 'title': 'AKT1(E17K) in human solid tumours.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18504432'}, {'id': 8234, 'pubMedId': 26469692, 'title': 'Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26469692'}]",,05/10/2017
0,05/10/2017,Akt1 Inhibitor,6,11425,Akt1 Inhibitor,AKT1 E49K,"[{'id': 6757, 'pubMedId': 27699769, 'title': 'BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27699769'}]",,05/10/2017
0,05/10/2017,Akt Inhibitor (Pan),4,11426,Akt Inhibitor (Pan),AKT1 E49K,"[{'id': 104, 'pubMedId': 18504432, 'title': 'AKT1(E17K) in human solid tumours.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18504432'}, {'id': 8234, 'pubMedId': 26469692, 'title': 'Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26469692'}]",,05/10/2017
0,05/10/2017,Akt1 Inhibitor,6,11431,Akt1 Inhibitor,AKT1 D323H,"[{'id': 6757, 'pubMedId': 27699769, 'title': 'BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27699769'}]",,05/10/2017
0,05/10/2017,Akt Inhibitor (Pan),4,11432,Akt Inhibitor (Pan),AKT1 D323H,"[{'id': 104, 'pubMedId': 18504432, 'title': 'AKT1(E17K) in human solid tumours.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18504432'}, {'id': 8234, 'pubMedId': 26469692, 'title': 'Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26469692'}]",,05/10/2017
0,05/10/2017,Akt1 Inhibitor,6,11433,Akt1 Inhibitor,AKT1 K189N,"[{'id': 6757, 'pubMedId': 27699769, 'title': 'BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27699769'}]",,05/10/2017
0,05/10/2017,Akt Inhibitor (Pan),4,11434,Akt Inhibitor (Pan),AKT1 K189N,"[{'id': 104, 'pubMedId': 18504432, 'title': 'AKT1(E17K) in human solid tumours.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18504432'}, {'id': 8234, 'pubMedId': 26469692, 'title': 'Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26469692'}]",,05/10/2017
0,05/10/2017,Akt1 Inhibitor,6,11435,Akt1 Inhibitor,AKT1 L321A,"[{'id': 6757, 'pubMedId': 27699769, 'title': 'BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27699769'}]",,05/10/2017
0,05/10/2017,Akt Inhibitor (Pan),4,11436,Akt Inhibitor (Pan),AKT1 L321A,"[{'id': 104, 'pubMedId': 18504432, 'title': 'AKT1(E17K) in human solid tumours.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18504432'}, {'id': 8234, 'pubMedId': 26469692, 'title': 'Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26469692'}]",,05/10/2017
0,05/10/2017,Akt Inhibitor (Pan),4,11437,Akt Inhibitor (Pan),AKT1 L52R,"[{'id': 104, 'pubMedId': 18504432, 'title': 'AKT1(E17K) in human solid tumours.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18504432'}, {'id': 8234, 'pubMedId': 26469692, 'title': 'Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26469692'}]",,05/10/2017
0,05/10/2017,Akt1 Inhibitor,6,11438,Akt1 Inhibitor,AKT1 L52R,"[{'id': 6757, 'pubMedId': 27699769, 'title': 'BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27699769'}]",,05/10/2017
0,05/10/2017,Akt1 Inhibitor,6,11439,Akt1 Inhibitor,AKT1 Q79K,"[{'id': 6757, 'pubMedId': 27699769, 'title': 'BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27699769'}]",,05/10/2017
0,05/10/2017,Akt Inhibitor (Pan),4,11440,Akt Inhibitor (Pan),AKT1 Q79K,"[{'id': 104, 'pubMedId': 18504432, 'title': 'AKT1(E17K) in human solid tumours.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18504432'}, {'id': 8234, 'pubMedId': 26469692, 'title': 'Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26469692'}]",,05/10/2017
0,05/10/2017,Akt1 Inhibitor,6,11441,Akt1 Inhibitor,AKT1 F55Y,"[{'id': 6757, 'pubMedId': 27699769, 'title': 'BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27699769'}]",,05/10/2017
0,05/10/2017,Akt Inhibitor (Pan),4,11442,Akt Inhibitor (Pan),AKT1 F55Y,"[{'id': 104, 'pubMedId': 18504432, 'title': 'AKT1(E17K) in human solid tumours.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18504432'}, {'id': 8234, 'pubMedId': 26469692, 'title': 'Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26469692'}]",,05/10/2017
0,05/10/2017,Akt Inhibitor (Pan),4,11443,Akt Inhibitor (Pan),AKT1 T195I,"[{'id': 104, 'pubMedId': 18504432, 'title': 'AKT1(E17K) in human solid tumours.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18504432'}, {'id': 8234, 'pubMedId': 26469692, 'title': 'Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26469692'}]",,05/10/2017
0,05/10/2017,Akt1 Inhibitor,6,11444,Akt1 Inhibitor,AKT1 T195I,"[{'id': 6757, 'pubMedId': 27699769, 'title': 'BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27699769'}]",,05/10/2017
0,05/10/2017,Akt Inhibitor (Pan),4,11445,Akt Inhibitor (Pan),AKT1 D325A,"[{'id': 104, 'pubMedId': 18504432, 'title': 'AKT1(E17K) in human solid tumours.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18504432'}, {'id': 8234, 'pubMedId': 26469692, 'title': 'Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26469692'}]",,05/10/2017
0,05/10/2017,Akt1 Inhibitor,6,11446,Akt1 Inhibitor,AKT1 D325A,"[{'id': 6757, 'pubMedId': 27699769, 'title': 'BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27699769'}]",,05/10/2017
0,05/10/2017,Akt Inhibitor (Pan),4,11447,Akt Inhibitor (Pan),AKT1 E191A,"[{'id': 104, 'pubMedId': 18504432, 'title': 'AKT1(E17K) in human solid tumours.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18504432'}, {'id': 8234, 'pubMedId': 26469692, 'title': 'Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26469692'}]",,05/10/2017
0,05/10/2017,Akt1 Inhibitor,6,11448,Akt1 Inhibitor,AKT1 E191A,"[{'id': 6757, 'pubMedId': 27699769, 'title': 'BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27699769'}]",,05/10/2017
0,05/10/2017,Akt Inhibitor (Pan),4,11449,Akt Inhibitor (Pan),AKT1 L78T,"[{'id': 104, 'pubMedId': 18504432, 'title': 'AKT1(E17K) in human solid tumours.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18504432'}, {'id': 8234, 'pubMedId': 26469692, 'title': 'Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26469692'}]",,05/10/2017
0,05/10/2017,Akt1 Inhibitor,6,11450,Akt1 Inhibitor,AKT1 L78T,"[{'id': 6757, 'pubMedId': 27699769, 'title': 'BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27699769'}]",,05/10/2017
0,05/10/2017,Akt1 Inhibitor,6,11451,Akt1 Inhibitor,AKT1 N53A,"[{'id': 6757, 'pubMedId': 27699769, 'title': 'BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27699769'}]",,05/10/2017
0,05/10/2017,Akt Inhibitor (Pan),4,11452,Akt Inhibitor (Pan),AKT1 N53A,"[{'id': 104, 'pubMedId': 18504432, 'title': 'AKT1(E17K) in human solid tumours.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18504432'}, {'id': 8234, 'pubMedId': 26469692, 'title': 'Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26469692'}]",,05/10/2017
0,05/10/2017,Akt1 Inhibitor,6,11453,Akt1 Inhibitor,AKT1 Q79E,"[{'id': 6757, 'pubMedId': 27699769, 'title': 'BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27699769'}]",,05/10/2017
0,05/10/2017,Akt Inhibitor (Pan),4,11454,Akt Inhibitor (Pan),AKT1 Q79E,"[{'id': 104, 'pubMedId': 18504432, 'title': 'AKT1(E17K) in human solid tumours.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18504432'}, {'id': 8234, 'pubMedId': 26469692, 'title': 'Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26469692'}]",,05/10/2017
0,05/10/2017,Akt1 Inhibitor,6,11455,Akt1 Inhibitor,AKT1 R23A,"[{'id': 6757, 'pubMedId': 27699769, 'title': 'BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27699769'}]",,05/10/2017
0,05/10/2017,Akt Inhibitor (Pan),4,11456,Akt Inhibitor (Pan),AKT1 R23A,"[{'id': 104, 'pubMedId': 18504432, 'title': 'AKT1(E17K) in human solid tumours.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18504432'}, {'id': 8234, 'pubMedId': 26469692, 'title': 'Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26469692'}]",,05/10/2017
0,05/10/2017,Akt Inhibitor (Pan),4,11457,Akt Inhibitor (Pan),AKT1 R328A,"[{'id': 104, 'pubMedId': 18504432, 'title': 'AKT1(E17K) in human solid tumours.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18504432'}, {'id': 8234, 'pubMedId': 26469692, 'title': 'Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26469692'}]",,05/10/2017
0,05/10/2017,Akt1 Inhibitor,6,11458,Akt1 Inhibitor,AKT1 R328A,"[{'id': 6757, 'pubMedId': 27699769, 'title': 'BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27699769'}]",,05/10/2017
0,05/10/2017,Akt1 Inhibitor,6,11459,Akt1 Inhibitor,AKT1 V271A,"[{'id': 6757, 'pubMedId': 27699769, 'title': 'BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27699769'}]",,05/10/2017
0,05/10/2017,Akt Inhibitor (Pan),4,11460,Akt Inhibitor (Pan),AKT1 V271A,"[{'id': 104, 'pubMedId': 18504432, 'title': 'AKT1(E17K) in human solid tumours.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18504432'}, {'id': 8234, 'pubMedId': 26469692, 'title': 'Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26469692'}]",,05/10/2017
0,05/10/2017,Akt1 Inhibitor,6,11461,Akt1 Inhibitor,AKT1 V270A,"[{'id': 6757, 'pubMedId': 27699769, 'title': 'BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27699769'}]",,05/10/2017
0,05/10/2017,Akt Inhibitor (Pan),4,11462,Akt Inhibitor (Pan),AKT1 V270A,"[{'id': 104, 'pubMedId': 18504432, 'title': 'AKT1(E17K) in human solid tumours.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18504432'}, {'id': 8234, 'pubMedId': 26469692, 'title': 'Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26469692'}]",,05/10/2017
0,05/10/2017,Akt Inhibitor (Pan),4,11463,Akt Inhibitor (Pan),AKT1 W80A,"[{'id': 104, 'pubMedId': 18504432, 'title': 'AKT1(E17K) in human solid tumours.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18504432'}, {'id': 8234, 'pubMedId': 26469692, 'title': 'Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26469692'}]",,05/10/2017
0,05/10/2017,Akt1 Inhibitor,6,11464,Akt1 Inhibitor,AKT1 W80A,"[{'id': 6757, 'pubMedId': 27699769, 'title': 'BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27699769'}]",,05/10/2017
0,05/10/2017,Akt Inhibitor (Pan),4,11465,Akt Inhibitor (Pan),AKT1 E40K,"[{'id': 104, 'pubMedId': 18504432, 'title': 'AKT1(E17K) in human solid tumours.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18504432'}, {'id': 8234, 'pubMedId': 26469692, 'title': 'Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26469692'}]",,05/10/2017
0,05/10/2017,Akt1 Inhibitor,6,11466,Akt1 Inhibitor,AKT1 E40K,"[{'id': 6757, 'pubMedId': 27699769, 'title': 'BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27699769'}]",,05/10/2017
0,05/10/2017,Akt Inhibitor (Pan),4,11467,Akt Inhibitor (Pan),AKT1 E267G,"[{'id': 104, 'pubMedId': 18504432, 'title': 'AKT1(E17K) in human solid tumours.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18504432'}, {'id': 8234, 'pubMedId': 26469692, 'title': 'Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26469692'}]",,05/10/2017
0,05/10/2017,Akt1 Inhibitor,6,11468,Akt1 Inhibitor,AKT1 E267G,"[{'id': 6757, 'pubMedId': 27699769, 'title': 'BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27699769'}]",,05/10/2017
0,05/10/2017,Akt1 Inhibitor,6,11469,Akt1 Inhibitor,AKT1 R370C,"[{'id': 6757, 'pubMedId': 27699769, 'title': 'BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27699769'}]",,05/10/2017
0,05/10/2017,Akt Inhibitor (Pan),4,11470,Akt Inhibitor (Pan),AKT1 R370C,"[{'id': 104, 'pubMedId': 18504432, 'title': 'AKT1(E17K) in human solid tumours.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18504432'}, {'id': 8234, 'pubMedId': 26469692, 'title': 'Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26469692'}]",,05/10/2017
0,05/12/2017,CTNNB1 Inhibitor,60,11471,CTNNB1 Inhibitor,APC T1496fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,05/12/2017
0,05/12/2017,Tankyrase Inhibitor,215,11472,Tankyrase Inhibitor,APC T1496fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,05/12/2017
0,05/15/2017,Akt1 Inhibitor,6,11478,Akt1 Inhibitor,PTEN loss,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/15/2017
0,05/15/2017,Akt Inhibitor (Pan),4,11479,Akt Inhibitor (Pan),PTEN loss,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/15/2017
0,05/15/2017,Akt2 Inhibitor,7,11480,Akt2 Inhibitor,PTEN loss,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/15/2017
0,05/15/2017,PI3K Inhibitor (Pan),181,11481,PI3K Inhibitor (Pan),PTEN loss,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/15/2017
0,05/15/2017,p53 Gene Therapy,167,12406,p53 Gene Therapy,TP53 N131fs,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,05/15/2017
0,05/15/2017,Akt Inhibitor (Pan),4,12407,Akt Inhibitor (Pan),PIK3CA P449_L455del,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,05/15/2017
0,05/15/2017,Akt1 Inhibitor,6,12408,Akt1 Inhibitor,PIK3CA P449_L455del,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,05/15/2017
0,05/15/2017,Akt2 Inhibitor,7,12409,Akt2 Inhibitor,PIK3CA P449_L455del,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,05/15/2017
0,05/15/2017,Akt3 Inhibitor,8,12410,Akt3 Inhibitor,PIK3CA P449_L455del,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,05/15/2017
0,05/15/2017,mTOR Inhibitor,152,12411,mTOR Inhibitor,PIK3CA P449_L455del,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,05/15/2017
0,05/15/2017,mTORC1 Inhibitor,153,12412,mTORC1 Inhibitor,PIK3CA P449_L455del,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,05/15/2017
0,05/15/2017,mTORC2 Inhibitor,154,12413,mTORC2 Inhibitor,PIK3CA P449_L455del,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,05/15/2017
0,05/15/2017,PI3K Inhibitor (Pan),181,12414,PI3K Inhibitor (Pan),PIK3CA P449_L455del,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,05/15/2017
0,05/15/2017,PIK3CA inhibitor,182,12415,PIK3CA inhibitor,PIK3CA P449_L455del,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,05/15/2017
0,05/16/2017,PIK3CB inhibitor,183,12416,PIK3CB inhibitor,PTEN loss,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4117, 'pubMedId': 25514658, 'title': 'Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3Kβ and PI3Kδ for the treatment of PTEN-deficient cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25514658'}, {'id': 4556, 'pubMedId': 26645196, 'title': 'Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26645196'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12417,PIK3CB inhibitor,PTEN inact mut,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12418,Akt2 Inhibitor,PTEN R233*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12419,Akt1 Inhibitor,PTEN R233*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12420,PIK3CB inhibitor,PTEN R233*,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12421,Akt Inhibitor (Pan),PTEN R233*,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12422,PI3K Inhibitor (Pan),PTEN R233*,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12423,PI3K Inhibitor (Pan),PTEN R15S,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12424,Akt2 Inhibitor,PTEN R15S,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12425,Akt1 Inhibitor,PTEN R15S,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12426,Akt Inhibitor (Pan),PTEN R15S,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12427,PIK3CB inhibitor,PTEN R15S,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12428,Akt2 Inhibitor,PTEN V290*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12429,Akt1 Inhibitor,PTEN V290*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12430,Akt Inhibitor (Pan),PTEN V290*,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12431,PIK3CB inhibitor,PTEN V290*,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12432,PI3K Inhibitor (Pan),PTEN V290*,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12433,Akt2 Inhibitor,PTEN negative,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12434,Akt Inhibitor (Pan),PTEN negative,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12435,Akt1 Inhibitor,PTEN negative,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12436,PI3K Inhibitor (Pan),PTEN negative,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12437,PIK3CB inhibitor,PTEN negative,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12438,Akt2 Inhibitor,PTEN del,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12439,Akt Inhibitor (Pan),PTEN del,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12440,Akt1 Inhibitor,PTEN del,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12441,PIK3CB inhibitor,PTEN del,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12442,PI3K Inhibitor (Pan),PTEN del,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12443,Akt2 Inhibitor,PTEN D252Y,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12444,PIK3CB inhibitor,PTEN D252Y,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12445,Akt Inhibitor (Pan),PTEN D252Y,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12446,Akt1 Inhibitor,PTEN D252Y,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12447,PI3K Inhibitor (Pan),PTEN D252Y,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12448,PI3K Inhibitor (Pan),PTEN G127R,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12449,Akt2 Inhibitor,PTEN G127R,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12450,Akt1 Inhibitor,PTEN G127R,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12451,Akt Inhibitor (Pan),PTEN G127R,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12452,PIK3CB inhibitor,PTEN G127R,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12453,PIK3CB inhibitor,PTEN K289Nfs*8,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12454,Akt1 Inhibitor,PTEN K289Nfs*8,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12455,Akt Inhibitor (Pan),PTEN K289Nfs*8,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12456,PI3K Inhibitor (Pan),PTEN K289Nfs*8,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12457,Akt2 Inhibitor,PTEN K289Nfs*8,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12458,PI3K Inhibitor (Pan),PTEN A121E,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12459,PIK3CB inhibitor,PTEN A121E,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12460,Akt1 Inhibitor,PTEN A121E,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12461,Akt Inhibitor (Pan),PTEN A121E,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12462,Akt2 Inhibitor,PTEN A121E,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12463,PIK3CB inhibitor,PTEN A121P,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12464,Akt1 Inhibitor,PTEN A121P,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12465,Akt2 Inhibitor,PTEN A121P,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12466,Akt Inhibitor (Pan),PTEN A121P,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12467,PI3K Inhibitor (Pan),PTEN A121P,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12468,Akt1 Inhibitor,PTEN A126D,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12469,PI3K Inhibitor (Pan),PTEN A126D,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12470,Akt Inhibitor (Pan),PTEN A126D,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12471,PIK3CB inhibitor,PTEN A126D,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12472,Akt2 Inhibitor,PTEN A126D,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12473,PIK3CB inhibitor,PTEN A126S,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12474,Akt1 Inhibitor,PTEN A126S,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12475,PI3K Inhibitor (Pan),PTEN A126S,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12476,Akt2 Inhibitor,PTEN A126S,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12477,Akt Inhibitor (Pan),PTEN A126S,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12478,Akt2 Inhibitor,PTEN A126V,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12479,Akt1 Inhibitor,PTEN A126V,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12480,PI3K Inhibitor (Pan),PTEN A126V,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12481,Akt Inhibitor (Pan),PTEN A126V,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12482,PIK3CB inhibitor,PTEN A126V,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12483,Akt Inhibitor (Pan),PTEN C105F,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12484,PI3K Inhibitor (Pan),PTEN C105F,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12485,Akt2 Inhibitor,PTEN C105F,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12486,PIK3CB inhibitor,PTEN C105F,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12487,Akt1 Inhibitor,PTEN C105F,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12488,Akt2 Inhibitor,PTEN C124fs*10,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12489,PI3K Inhibitor (Pan),PTEN C124fs*10,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12490,Akt1 Inhibitor,PTEN C124fs*10,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12491,Akt Inhibitor (Pan),PTEN C124fs*10,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12492,PIK3CB inhibitor,PTEN C124fs*10,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12493,Akt1 Inhibitor,PTEN C124G,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12494,PIK3CB inhibitor,PTEN C124G,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12495,Akt2 Inhibitor,PTEN C124G,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12496,Akt Inhibitor (Pan),PTEN C124G,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12497,PI3K Inhibitor (Pan),PTEN C124G,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12498,Akt2 Inhibitor,PTEN C124R,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12499,Akt Inhibitor (Pan),PTEN C124R,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12500,PIK3CB inhibitor,PTEN C124R,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12501,Akt1 Inhibitor,PTEN C124R,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12502,PI3K Inhibitor (Pan),PTEN C124R,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12503,Akt2 Inhibitor,PTEN C124S,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12504,Akt Inhibitor (Pan),PTEN C124S,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12505,PI3K Inhibitor (Pan),PTEN C124S,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12506,Akt1 Inhibitor,PTEN C124S,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12507,PIK3CB inhibitor,PTEN C124S,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12508,PIK3CB inhibitor,PTEN C136R,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12509,Akt Inhibitor (Pan),PTEN C136R,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12510,Akt2 Inhibitor,PTEN C136R,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12511,PI3K Inhibitor (Pan),PTEN C136R,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12512,Akt1 Inhibitor,PTEN C136R,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12513,PI3K Inhibitor (Pan),PTEN C136Y,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12514,Akt1 Inhibitor,PTEN C136Y,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12515,PIK3CB inhibitor,PTEN C136Y,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12516,Akt2 Inhibitor,PTEN C136Y,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12517,Akt Inhibitor (Pan),PTEN C136Y,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12518,PI3K Inhibitor (Pan),PTEN C250fs*2,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12519,Akt Inhibitor (Pan),PTEN C250fs*2,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12520,Akt1 Inhibitor,PTEN C250fs*2,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12521,PIK3CB inhibitor,PTEN C250fs*2,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12522,Akt2 Inhibitor,PTEN C250fs*2,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12523,PIK3CB inhibitor,PTEN C71Y,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12524,Akt1 Inhibitor,PTEN C71Y,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12525,PI3K Inhibitor (Pan),PTEN C71Y,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12526,Akt Inhibitor (Pan),PTEN C71Y,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12527,Akt2 Inhibitor,PTEN C71Y,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12528,PIK3CB inhibitor,PTEN D107Y,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12529,Akt2 Inhibitor,PTEN D107Y,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12530,Akt Inhibitor (Pan),PTEN D107Y,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12531,PI3K Inhibitor (Pan),PTEN D107Y,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12532,Akt1 Inhibitor,PTEN D107Y,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12533,PI3K Inhibitor (Pan),PTEN D116fs*18,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12534,Akt1 Inhibitor,PTEN D116fs*18,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12535,Akt Inhibitor (Pan),PTEN D116fs*18,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12536,Akt2 Inhibitor,PTEN D116fs*18,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12537,PIK3CB inhibitor,PTEN D116fs*18,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12538,PI3K Inhibitor (Pan),PTEN D252G,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12539,Akt1 Inhibitor,PTEN D252G,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12540,Akt Inhibitor (Pan),PTEN D252G,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12541,PIK3CB inhibitor,PTEN D252G,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12542,Akt2 Inhibitor,PTEN D252G,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12543,Akt2 Inhibitor,PTEN D331fs*13,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12544,PI3K Inhibitor (Pan),PTEN D331fs*13,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12545,Akt Inhibitor (Pan),PTEN D331fs*13,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12546,PIK3CB inhibitor,PTEN D331fs*13,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12547,Akt1 Inhibitor,PTEN D331fs*13,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12548,Akt2 Inhibitor,PTEN D331G,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12549,PI3K Inhibitor (Pan),PTEN D331G,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12550,Akt1 Inhibitor,PTEN D331G,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12551,Akt Inhibitor (Pan),PTEN D331G,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12552,PIK3CB inhibitor,PTEN D331G,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12553,Akt Inhibitor (Pan),PTEN D92E,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12554,PIK3CB inhibitor,PTEN D92E,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12555,Akt2 Inhibitor,PTEN D92E,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12556,PI3K Inhibitor (Pan),PTEN D92E,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12557,Akt1 Inhibitor,PTEN D92E,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12558,PI3K Inhibitor (Pan),PTEN E201*,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12559,Akt1 Inhibitor,PTEN E201*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12560,PIK3CB inhibitor,PTEN E201*,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12561,Akt2 Inhibitor,PTEN E201*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12562,Akt Inhibitor (Pan),PTEN E201*,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12563,Akt2 Inhibitor,PTEN E235*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12564,Akt Inhibitor (Pan),PTEN E235*,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12565,Akt1 Inhibitor,PTEN E235*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12566,PI3K Inhibitor (Pan),PTEN E235*,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12567,PIK3CB inhibitor,PTEN E235*,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12568,Akt Inhibitor (Pan),PTEN E242*,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12569,Akt2 Inhibitor,PTEN E242*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12570,PI3K Inhibitor (Pan),PTEN E242*,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12571,Akt1 Inhibitor,PTEN E242*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12572,PIK3CB inhibitor,PTEN E242*,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12573,Akt1 Inhibitor,PTEN E242fs*1,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12574,Akt2 Inhibitor,PTEN E242fs*1,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12575,PI3K Inhibitor (Pan),PTEN E242fs*1,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12576,PIK3CB inhibitor,PTEN E242fs*1,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12577,Akt Inhibitor (Pan),PTEN E242fs*1,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12578,PI3K Inhibitor (Pan),PTEN E242fs*15,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12579,Akt2 Inhibitor,PTEN E242fs*15,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12580,PIK3CB inhibitor,PTEN E242fs*15,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12581,Akt1 Inhibitor,PTEN E242fs*15,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12582,Akt Inhibitor (Pan),PTEN E242fs*15,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12583,Akt1 Inhibitor,PTEN E284fs,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12584,PIK3CB inhibitor,PTEN E284fs,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12585,Akt Inhibitor (Pan),PTEN E284fs,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12586,PI3K Inhibitor (Pan),PTEN E284fs,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12587,Akt2 Inhibitor,PTEN E284fs,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12588,Akt2 Inhibitor,PTEN E285*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12589,PI3K Inhibitor (Pan),PTEN E285*,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12590,PIK3CB inhibitor,PTEN E285*,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12591,Akt1 Inhibitor,PTEN E285*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12592,Akt Inhibitor (Pan),PTEN E285*,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12593,PI3K Inhibitor (Pan),PTEN E288*,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12594,Akt1 Inhibitor,PTEN E288*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12595,PIK3CB inhibitor,PTEN E288*,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12596,Akt Inhibitor (Pan),PTEN E288*,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12597,Akt2 Inhibitor,PTEN E288*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12598,PI3K Inhibitor (Pan),PTEN E288fs,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12599,Akt2 Inhibitor,PTEN E288fs,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12600,Akt Inhibitor (Pan),PTEN E288fs,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12601,PIK3CB inhibitor,PTEN E288fs,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12602,Akt1 Inhibitor,PTEN E288fs,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12603,Akt Inhibitor (Pan),PTEN E288fs*3,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12604,PIK3CB inhibitor,PTEN E288fs*3,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12605,Akt2 Inhibitor,PTEN E288fs*3,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12606,Akt1 Inhibitor,PTEN E288fs*3,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12607,PI3K Inhibitor (Pan),PTEN E288fs*3,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12608,PI3K Inhibitor (Pan),PTEN E291*,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12609,Akt2 Inhibitor,PTEN E291*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12610,PIK3CB inhibitor,PTEN E291*,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12611,Akt Inhibitor (Pan),PTEN E291*,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12612,Akt1 Inhibitor,PTEN E291*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12613,Akt2 Inhibitor,PTEN E299*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12614,PIK3CB inhibitor,PTEN E299*,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12615,Akt1 Inhibitor,PTEN E299*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12616,Akt Inhibitor (Pan),PTEN E299*,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12617,PI3K Inhibitor (Pan),PTEN E299*,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12618,Akt Inhibitor (Pan),PTEN E7*,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12619,Akt1 Inhibitor,PTEN E7*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12620,PI3K Inhibitor (Pan),PTEN E7*,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12621,Akt2 Inhibitor,PTEN E7*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12622,PIK3CB inhibitor,PTEN E7*,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12623,PI3K Inhibitor (Pan),PTEN F337fs*6,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12624,Akt1 Inhibitor,PTEN F337fs*6,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12625,PIK3CB inhibitor,PTEN F337fs*6,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12626,Akt2 Inhibitor,PTEN F337fs*6,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12627,Akt Inhibitor (Pan),PTEN F337fs*6,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12628,PI3K Inhibitor (Pan),PTEN F337fs*7,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12629,Akt Inhibitor (Pan),PTEN F337fs*7,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12630,Akt2 Inhibitor,PTEN F337fs*7,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12631,PIK3CB inhibitor,PTEN F337fs*7,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12632,Akt1 Inhibitor,PTEN F337fs*7,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12633,Akt Inhibitor (Pan),PTEN F341V,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12634,PI3K Inhibitor (Pan),PTEN F341V,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12635,PIK3CB inhibitor,PTEN F341V,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12636,Akt2 Inhibitor,PTEN F341V,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12637,Akt1 Inhibitor,PTEN F341V,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12638,PI3K Inhibitor (Pan),PTEN G127E,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12639,Akt2 Inhibitor,PTEN G127E,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12640,Akt1 Inhibitor,PTEN G127E,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12641,Akt Inhibitor (Pan),PTEN G127E,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12642,PIK3CB inhibitor,PTEN G127E,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12643,PIK3CB inhibitor,PTEN G129*,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12644,Akt Inhibitor (Pan),PTEN G129*,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12645,Akt1 Inhibitor,PTEN G129*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12646,Akt2 Inhibitor,PTEN G129*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12647,PI3K Inhibitor (Pan),PTEN G129*,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12648,Akt2 Inhibitor,PTEN G129E,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12649,PI3K Inhibitor (Pan),PTEN G129E,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12650,Akt1 Inhibitor,PTEN G129E,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12651,Akt Inhibitor (Pan),PTEN G129E,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12652,PIK3CB inhibitor,PTEN G129E,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12653,Akt1 Inhibitor,PTEN G129R,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12654,PIK3CB inhibitor,PTEN G129R,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12655,PI3K Inhibitor (Pan),PTEN G129R,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12656,Akt2 Inhibitor,PTEN G129R,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12657,Akt Inhibitor (Pan),PTEN G129R,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12658,PIK3CB inhibitor,PTEN G129V,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12659,Akt Inhibitor (Pan),PTEN G129V,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12660,Akt2 Inhibitor,PTEN G129V,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12661,Akt1 Inhibitor,PTEN G129V,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12662,PI3K Inhibitor (Pan),PTEN G129V,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12663,Akt2 Inhibitor,PTEN G132S,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12664,PI3K Inhibitor (Pan),PTEN G132S,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12665,Akt1 Inhibitor,PTEN G132S,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12666,PIK3CB inhibitor,PTEN G132S,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12667,Akt Inhibitor (Pan),PTEN G132S,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12668,Akt Inhibitor (Pan),PTEN G165E,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12669,PI3K Inhibitor (Pan),PTEN G165E,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12670,Akt1 Inhibitor,PTEN G165E,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12671,Akt2 Inhibitor,PTEN G165E,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12672,PIK3CB inhibitor,PTEN G165E,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12673,Akt2 Inhibitor,PTEN G165R,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12674,PIK3CB inhibitor,PTEN G165R,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12675,Akt Inhibitor (Pan),PTEN G165R,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12676,PI3K Inhibitor (Pan),PTEN G165R,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12677,Akt1 Inhibitor,PTEN G165R,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12678,PI3K Inhibitor (Pan),PTEN G251C,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12679,Akt Inhibitor (Pan),PTEN G251C,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12680,Akt2 Inhibitor,PTEN G251C,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12681,PIK3CB inhibitor,PTEN G251C,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12682,Akt1 Inhibitor,PTEN G251C,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12683,PI3K Inhibitor (Pan),PTEN H123D,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12684,Akt1 Inhibitor,PTEN H123D,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12685,Akt2 Inhibitor,PTEN H123D,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12686,PIK3CB inhibitor,PTEN H123D,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12687,Akt Inhibitor (Pan),PTEN H123D,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12688,PIK3CB inhibitor,PTEN H123Y,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12689,Akt1 Inhibitor,PTEN H123Y,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12690,Akt Inhibitor (Pan),PTEN H123Y,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12691,PI3K Inhibitor (Pan),PTEN H123Y,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12692,Akt2 Inhibitor,PTEN H123Y,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12693,PIK3CB inhibitor,PTEN H61R,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12694,Akt Inhibitor (Pan),PTEN H61R,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12695,Akt2 Inhibitor,PTEN H61R,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12696,Akt1 Inhibitor,PTEN H61R,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12697,PI3K Inhibitor (Pan),PTEN H61R,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12698,Akt Inhibitor (Pan),PTEN K125E,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12699,Akt1 Inhibitor,PTEN K125E,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12700,Akt2 Inhibitor,PTEN K125E,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12701,PIK3CB inhibitor,PTEN K125E,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12702,PI3K Inhibitor (Pan),PTEN K125E,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12703,Akt Inhibitor (Pan),PTEN K13E,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12704,Akt1 Inhibitor,PTEN K13E,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12705,PIK3CB inhibitor,PTEN K13E,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12706,PI3K Inhibitor (Pan),PTEN K13E,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12707,Akt2 Inhibitor,PTEN K13E,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12708,PIK3CB inhibitor,PTEN L112P,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12709,PI3K Inhibitor (Pan),PTEN L112P,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12710,Akt Inhibitor (Pan),PTEN L112P,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12711,Akt1 Inhibitor,PTEN L112P,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12712,Akt2 Inhibitor,PTEN L112P,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12713,PI3K Inhibitor (Pan),PTEN L112R,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12714,PIK3CB inhibitor,PTEN L112R,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12715,Akt Inhibitor (Pan),PTEN L112R,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12716,Akt1 Inhibitor,PTEN L112R,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12717,Akt2 Inhibitor,PTEN L112R,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12718,Akt2 Inhibitor,PTEN V119fs*15,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12719,Akt Inhibitor (Pan),PTEN V119fs*15,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12720,PIK3CB inhibitor,PTEN V119fs*15,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12721,PI3K Inhibitor (Pan),PTEN V119fs*15,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12722,Akt1 Inhibitor,PTEN V119fs*15,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12723,Akt2 Inhibitor,PTEN L57W,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12724,PIK3CB inhibitor,PTEN L57W,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12725,Akt Inhibitor (Pan),PTEN L57W,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12726,Akt1 Inhibitor,PTEN L57W,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12727,PI3K Inhibitor (Pan),PTEN L57W,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12728,PIK3CB inhibitor,PTEN G127V,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12729,Akt2 Inhibitor,PTEN G127V,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12730,PI3K Inhibitor (Pan),PTEN G127V,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12731,Akt Inhibitor (Pan),PTEN G127V,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12732,Akt1 Inhibitor,PTEN G127V,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12733,PIK3CB inhibitor,PTEN G251D,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12734,Akt1 Inhibitor,PTEN G251D,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12735,Akt2 Inhibitor,PTEN G251D,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12736,Akt Inhibitor (Pan),PTEN G251D,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12737,PI3K Inhibitor (Pan),PTEN G251D,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12738,Akt1 Inhibitor,PTEN G293fs*14,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12739,PI3K Inhibitor (Pan),PTEN G293fs*14,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12740,Akt2 Inhibitor,PTEN G293fs*14,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12741,PIK3CB inhibitor,PTEN G293fs*14,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12742,Akt Inhibitor (Pan),PTEN G293fs*14,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12743,PIK3CB inhibitor,PTEN H118fs*8,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12744,Akt Inhibitor (Pan),PTEN H118fs*8,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12745,Akt2 Inhibitor,PTEN H118fs*8,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12746,Akt1 Inhibitor,PTEN H118fs*8,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12747,PI3K Inhibitor (Pan),PTEN H118fs*8,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12748,Akt Inhibitor (Pan),PTEN I122fs*2,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12749,Akt2 Inhibitor,PTEN I122fs*2,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12750,PIK3CB inhibitor,PTEN I122fs*2,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12751,PI3K Inhibitor (Pan),PTEN I122fs*2,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12752,Akt1 Inhibitor,PTEN I122fs*2,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12753,Akt Inhibitor (Pan),PTEN K125N,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12754,PI3K Inhibitor (Pan),PTEN K125N,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12755,PIK3CB inhibitor,PTEN K125N,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12756,Akt2 Inhibitor,PTEN K125N,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12757,Akt1 Inhibitor,PTEN K125N,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12758,PIK3CB inhibitor,PTEN K128_R130del,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12759,Akt2 Inhibitor,PTEN K128_R130del,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12760,Akt1 Inhibitor,PTEN K128_R130del,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12761,Akt Inhibitor (Pan),PTEN K128_R130del,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12762,PI3K Inhibitor (Pan),PTEN K128_R130del,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12763,Akt Inhibitor (Pan),PTEN K163fs,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12764,PIK3CB inhibitor,PTEN K163fs,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12765,Akt1 Inhibitor,PTEN K163fs,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12766,PI3K Inhibitor (Pan),PTEN K163fs,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12767,Akt2 Inhibitor,PTEN K163fs,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12768,Akt2 Inhibitor,PTEN K237fs*19,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12769,Akt Inhibitor (Pan),PTEN K237fs*19,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12770,PI3K Inhibitor (Pan),PTEN K237fs*19,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12771,Akt1 Inhibitor,PTEN K237fs*19,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12772,PIK3CB inhibitor,PTEN K237fs*19,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12773,PI3K Inhibitor (Pan),PTEN K254fs*42,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12774,PIK3CB inhibitor,PTEN K254fs*42,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12775,Akt1 Inhibitor,PTEN K254fs*42,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12776,Akt2 Inhibitor,PTEN K254fs*42,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12777,Akt Inhibitor (Pan),PTEN K254fs*42,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12778,PIK3CB inhibitor,PTEN K260fs*6,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12779,Akt Inhibitor (Pan),PTEN K260fs*6,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12780,Akt1 Inhibitor,PTEN K260fs*6,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12781,Akt2 Inhibitor,PTEN K260fs*6,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12782,PI3K Inhibitor (Pan),PTEN K260fs*6,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12783,Akt2 Inhibitor,PTEN K263*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12784,Akt Inhibitor (Pan),PTEN K263*,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12785,PIK3CB inhibitor,PTEN K263*,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12786,PI3K Inhibitor (Pan),PTEN K263*,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12787,Akt1 Inhibitor,PTEN K263*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12788,Akt1 Inhibitor,PTEN K267fs,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12789,Akt Inhibitor (Pan),PTEN K267fs,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12790,PIK3CB inhibitor,PTEN K267fs,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12791,PI3K Inhibitor (Pan),PTEN K267fs,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12792,Akt2 Inhibitor,PTEN K267fs,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12793,Akt Inhibitor (Pan),PTEN K267fs*9,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12794,PI3K Inhibitor (Pan),PTEN K267fs*9,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12795,PIK3CB inhibitor,PTEN K267fs*9,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12796,Akt2 Inhibitor,PTEN K267fs*9,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12797,Akt1 Inhibitor,PTEN K267fs*9,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12798,Akt Inhibitor (Pan),PTEN K60fs*39,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12799,PIK3CB inhibitor,PTEN K60fs*39,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12800,Akt2 Inhibitor,PTEN K60fs*39,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12801,PI3K Inhibitor (Pan),PTEN K60fs*39,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12802,Akt1 Inhibitor,PTEN K60fs*39,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12803,PI3K Inhibitor (Pan),PTEN K6fs*4,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12804,Akt Inhibitor (Pan),PTEN K6fs*4,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12805,Akt2 Inhibitor,PTEN K6fs*4,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12806,Akt1 Inhibitor,PTEN K6fs*4,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12807,PIK3CB inhibitor,PTEN K6fs*4,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12808,Akt2 Inhibitor,PTEN L182fs,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12809,PI3K Inhibitor (Pan),PTEN L182fs,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12810,Akt1 Inhibitor,PTEN L182fs,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12811,Akt Inhibitor (Pan),PTEN L182fs,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12812,PIK3CB inhibitor,PTEN L182fs,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12813,Akt Inhibitor (Pan),PTEN L265fs,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12814,PI3K Inhibitor (Pan),PTEN L265fs,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12815,Akt2 Inhibitor,PTEN L265fs,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12816,Akt1 Inhibitor,PTEN L265fs,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12817,PIK3CB inhibitor,PTEN L265fs,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12818,PIK3CB inhibitor,PTEN L318fs*2,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12819,Akt1 Inhibitor,PTEN L318fs*2,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12820,PI3K Inhibitor (Pan),PTEN L318fs*2,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12821,Akt2 Inhibitor,PTEN L318fs*2,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12822,Akt Inhibitor (Pan),PTEN L318fs*2,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12823,Akt1 Inhibitor,PTEN L57fs*6,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12824,Akt2 Inhibitor,PTEN L57fs*6,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12825,Akt Inhibitor (Pan),PTEN L57fs*6,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12826,PIK3CB inhibitor,PTEN L57fs*6,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12827,PI3K Inhibitor (Pan),PTEN L57fs*6,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12828,PIK3CB inhibitor,PTEN N323fs*2,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12829,Akt1 Inhibitor,PTEN N323fs*2,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12830,Akt Inhibitor (Pan),PTEN N323fs*2,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12831,PI3K Inhibitor (Pan),PTEN N323fs*2,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12832,Akt2 Inhibitor,PTEN N323fs*2,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12833,PIK3CB inhibitor,PTEN N323fs*21,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12834,PI3K Inhibitor (Pan),PTEN N323fs*21,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12835,Akt2 Inhibitor,PTEN N323fs*21,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12836,Akt Inhibitor (Pan),PTEN N323fs*21,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12837,Akt1 Inhibitor,PTEN N323fs*21,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12838,Akt1 Inhibitor,PTEN N329fs*14,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12839,Akt Inhibitor (Pan),PTEN N329fs*14,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12840,PI3K Inhibitor (Pan),PTEN N329fs*14,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12841,PIK3CB inhibitor,PTEN N329fs*14,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12842,Akt2 Inhibitor,PTEN N329fs*14,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12843,PI3K Inhibitor (Pan),PTEN N340fs,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12844,Akt Inhibitor (Pan),PTEN N340fs,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12845,Akt2 Inhibitor,PTEN N340fs,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12846,Akt1 Inhibitor,PTEN N340fs,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12847,PIK3CB inhibitor,PTEN N340fs,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12848,PIK3CB inhibitor,PTEN N63fs*10,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12849,Akt Inhibitor (Pan),PTEN N63fs*10,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12850,PI3K Inhibitor (Pan),PTEN N63fs*10,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12851,Akt1 Inhibitor,PTEN N63fs*10,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12852,Akt2 Inhibitor,PTEN N63fs*10,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12853,PIK3CB inhibitor,PTEN N63fs*36,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12854,Akt Inhibitor (Pan),PTEN N63fs*36,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12855,PI3K Inhibitor (Pan),PTEN N63fs*36,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12856,Akt1 Inhibitor,PTEN N63fs*36,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12857,Akt2 Inhibitor,PTEN N63fs*36,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12858,Akt1 Inhibitor,PTEN P246fs*10,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12859,PI3K Inhibitor (Pan),PTEN P246fs*10,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12860,Akt2 Inhibitor,PTEN P246fs*10,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12861,PIK3CB inhibitor,PTEN P246fs*10,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12862,Akt Inhibitor (Pan),PTEN P246fs*10,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12863,Akt Inhibitor (Pan),PTEN P248fs*5,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12864,Akt2 Inhibitor,PTEN P248fs*5,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12865,PIK3CB inhibitor,PTEN P248fs*5,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12866,PI3K Inhibitor (Pan),PTEN P248fs*5,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12867,Akt1 Inhibitor,PTEN P248fs*5,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12868,Akt1 Inhibitor,PTEN Q110*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12869,Akt Inhibitor (Pan),PTEN Q110*,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12870,PIK3CB inhibitor,PTEN Q110*,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12871,Akt2 Inhibitor,PTEN Q110*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12872,PI3K Inhibitor (Pan),PTEN Q110*,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12873,PI3K Inhibitor (Pan),PTEN Q17*,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12874,PIK3CB inhibitor,PTEN Q17*,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12875,Akt2 Inhibitor,PTEN Q17*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12876,Akt1 Inhibitor,PTEN Q17*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12877,Akt Inhibitor (Pan),PTEN Q17*,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12878,Akt Inhibitor (Pan),PTEN Q171*,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12879,Akt2 Inhibitor,PTEN Q171*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12880,Akt1 Inhibitor,PTEN Q171*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12881,PI3K Inhibitor (Pan),PTEN Q171*,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12882,PIK3CB inhibitor,PTEN Q171*,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12883,Akt Inhibitor (Pan),PTEN V133I,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12884,PI3K Inhibitor (Pan),PTEN V133I,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12885,Akt2 Inhibitor,PTEN V133I,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12886,PIK3CB inhibitor,PTEN V133I,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12887,Akt1 Inhibitor,PTEN V133I,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12888,Akt1 Inhibitor,PTEN V290fs*1,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12889,Akt2 Inhibitor,PTEN V290fs*1,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12890,Akt Inhibitor (Pan),PTEN V290fs*1,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12891,PIK3CB inhibitor,PTEN V290fs*1,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12892,PI3K Inhibitor (Pan),PTEN V290fs*1,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12893,PI3K Inhibitor (Pan),PTEN V317fs,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12894,Akt Inhibitor (Pan),PTEN V317fs,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12895,Akt2 Inhibitor,PTEN V317fs,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12896,Akt1 Inhibitor,PTEN V317fs,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12897,PIK3CB inhibitor,PTEN V317fs,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12898,PIK3CB inhibitor,PTEN V317fs*3,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12899,Akt1 Inhibitor,PTEN V317fs*3,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12900,Akt Inhibitor (Pan),PTEN V317fs*3,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12901,PI3K Inhibitor (Pan),PTEN V317fs*3,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12902,Akt2 Inhibitor,PTEN V317fs*3,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12903,PI3K Inhibitor (Pan),PTEN V317fs*6,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12904,Akt Inhibitor (Pan),PTEN V317fs*6,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12905,Akt2 Inhibitor,PTEN V317fs*6,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12906,PIK3CB inhibitor,PTEN V317fs*6,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12907,Akt1 Inhibitor,PTEN V317fs*6,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12908,PIK3CB inhibitor,PTEN W111*,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12909,PI3K Inhibitor (Pan),PTEN W111*,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12910,Akt2 Inhibitor,PTEN W111*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12911,Akt1 Inhibitor,PTEN W111*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12912,Akt Inhibitor (Pan),PTEN W111*,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12913,PIK3CB inhibitor,PTEN Y16fs*28,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12914,PI3K Inhibitor (Pan),PTEN Y16fs*28,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12915,Akt1 Inhibitor,PTEN Y16fs*28,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12916,Akt Inhibitor (Pan),PTEN Y16fs*28,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12917,Akt2 Inhibitor,PTEN Y16fs*28,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12918,Akt Inhibitor (Pan),PTEN Q219*,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12919,Akt1 Inhibitor,PTEN Q219*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12920,PI3K Inhibitor (Pan),PTEN Q219*,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12921,Akt2 Inhibitor,PTEN Q219*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12922,PIK3CB inhibitor,PTEN Q219*,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12923,PIK3CB inhibitor,PTEN R130*,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12924,Akt1 Inhibitor,PTEN R130*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12925,PI3K Inhibitor (Pan),PTEN R130*,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12926,Akt2 Inhibitor,PTEN R130*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12927,Akt Inhibitor (Pan),PTEN R130*,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12928,PI3K Inhibitor (Pan),PTEN Q245*,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12929,Akt2 Inhibitor,PTEN Q245*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12930,PIK3CB inhibitor,PTEN Q245*,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12931,Akt Inhibitor (Pan),PTEN Q245*,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12932,Akt1 Inhibitor,PTEN Q245*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12933,PIK3CB inhibitor,PTEN Q261*,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12934,PI3K Inhibitor (Pan),PTEN Q261*,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12935,Akt2 Inhibitor,PTEN Q261*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12936,Akt Inhibitor (Pan),PTEN Q261*,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12937,Akt1 Inhibitor,PTEN Q261*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12938,PI3K Inhibitor (Pan),PTEN Q298*,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12939,Akt1 Inhibitor,PTEN Q298*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12940,Akt2 Inhibitor,PTEN Q298*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12941,PIK3CB inhibitor,PTEN Q298*,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12942,Akt Inhibitor (Pan),PTEN Q298*,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12943,Akt1 Inhibitor,PTEN R130fs*4,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12944,PIK3CB inhibitor,PTEN R130fs*4,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12945,Akt2 Inhibitor,PTEN R130fs*4,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12946,PI3K Inhibitor (Pan),PTEN R130fs*4,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12947,Akt Inhibitor (Pan),PTEN R130fs*4,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12948,PI3K Inhibitor (Pan),PTEN Q214*,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12949,Akt Inhibitor (Pan),PTEN Q214*,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12950,PIK3CB inhibitor,PTEN Q214*,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12951,Akt1 Inhibitor,PTEN Q214*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12952,Akt2 Inhibitor,PTEN Q214*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12953,PI3K Inhibitor (Pan),PTEN R130G,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12954,PIK3CB inhibitor,PTEN R130G,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12955,Akt Inhibitor (Pan),PTEN R130G,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12956,Akt1 Inhibitor,PTEN R130G,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12957,Akt2 Inhibitor,PTEN R130G,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12958,Akt Inhibitor (Pan),PTEN R130Q,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12959,Akt2 Inhibitor,PTEN R130Q,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12960,Akt1 Inhibitor,PTEN R130Q,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12961,PI3K Inhibitor (Pan),PTEN R130Q,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12962,PIK3CB inhibitor,PTEN R130Q,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12963,PI3K Inhibitor (Pan),PTEN R130L,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12964,Akt1 Inhibitor,PTEN R130L,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12965,Akt2 Inhibitor,PTEN R130L,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12966,PIK3CB inhibitor,PTEN R130L,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12967,Akt Inhibitor (Pan),PTEN R130L,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12968,Akt Inhibitor (Pan),PTEN R130P,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12969,PIK3CB inhibitor,PTEN R130P,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12970,Akt2 Inhibitor,PTEN R130P,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12971,Akt1 Inhibitor,PTEN R130P,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12972,PI3K Inhibitor (Pan),PTEN R130P,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12973,Akt2 Inhibitor,PTEN R15I,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12974,Akt1 Inhibitor,PTEN R15I,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12975,PIK3CB inhibitor,PTEN R15I,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12976,Akt Inhibitor (Pan),PTEN R15I,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12977,PI3K Inhibitor (Pan),PTEN R15I,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12978,PI3K Inhibitor (Pan),PTEN R173C,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12979,Akt Inhibitor (Pan),PTEN R173C,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12980,Akt1 Inhibitor,PTEN R173C,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12981,Akt2 Inhibitor,PTEN R173C,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12982,PIK3CB inhibitor,PTEN R173C,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12983,PIK3CB inhibitor,PTEN R335*,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12984,Akt1 Inhibitor,PTEN R335*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12985,Akt2 Inhibitor,PTEN R335*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12986,Akt Inhibitor (Pan),PTEN R335*,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12987,PI3K Inhibitor (Pan),PTEN R335*,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12988,PIK3CB inhibitor,PTEN S170N,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12989,Akt1 Inhibitor,PTEN S170N,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12990,Akt2 Inhibitor,PTEN S170N,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12991,PI3K Inhibitor (Pan),PTEN S170N,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12992,Akt Inhibitor (Pan),PTEN S170N,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12993,PI3K Inhibitor (Pan),PTEN S59*,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,12994,Akt2 Inhibitor,PTEN S59*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12995,Akt1 Inhibitor,PTEN S59*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,12996,PIK3CB inhibitor,PTEN S59*,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,12997,Akt Inhibitor (Pan),PTEN S59*,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,12998,Akt1 Inhibitor,PTEN S287*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,12999,PI3K Inhibitor (Pan),PTEN S287*,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13000,PIK3CB inhibitor,PTEN S287*,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13001,Akt2 Inhibitor,PTEN S287*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13002,Akt Inhibitor (Pan),PTEN S287*,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13003,PI3K Inhibitor (Pan),PTEN S294fs*2,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13004,Akt1 Inhibitor,PTEN S294fs*2,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13005,Akt2 Inhibitor,PTEN S294fs*2,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13006,Akt Inhibitor (Pan),PTEN S294fs*2,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13007,PIK3CB inhibitor,PTEN S294fs*2,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13008,PIK3CB inhibitor,PTEN T167A,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13009,Akt2 Inhibitor,PTEN T167A,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13010,Akt Inhibitor (Pan),PTEN T167A,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13011,PI3K Inhibitor (Pan),PTEN T167A,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13012,Akt1 Inhibitor,PTEN T167A,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13013,PI3K Inhibitor (Pan),PTEN S170R,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13014,Akt2 Inhibitor,PTEN S170R,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13015,Akt Inhibitor (Pan),PTEN S170R,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13016,Akt1 Inhibitor,PTEN S170R,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13017,PIK3CB inhibitor,PTEN S170R,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13018,PIK3CB inhibitor,PTEN T319fs*1,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13019,PI3K Inhibitor (Pan),PTEN T319fs*1,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13020,Akt1 Inhibitor,PTEN T319fs*1,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13021,Akt2 Inhibitor,PTEN T319fs*1,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13022,Akt Inhibitor (Pan),PTEN T319fs*1,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13023,Akt Inhibitor (Pan),PTEN T319del,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13024,Akt1 Inhibitor,PTEN T319del,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13025,PIK3CB inhibitor,PTEN T319del,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13026,Akt2 Inhibitor,PTEN T319del,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13027,PI3K Inhibitor (Pan),PTEN T319del,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13028,PI3K Inhibitor (Pan),PTEN T131fs*3,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13029,Akt2 Inhibitor,PTEN T131fs*3,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13030,PIK3CB inhibitor,PTEN T131fs*3,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13031,Akt1 Inhibitor,PTEN T131fs*3,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13032,Akt Inhibitor (Pan),PTEN T131fs*3,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13033,Akt2 Inhibitor,PTEN T319fs*24,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13034,Akt Inhibitor (Pan),PTEN T319fs*24,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13035,PIK3CB inhibitor,PTEN T319fs*24,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13036,Akt1 Inhibitor,PTEN T319fs*24,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13037,PI3K Inhibitor (Pan),PTEN T319fs*24,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13038,Akt Inhibitor (Pan),PTEN T319fs*6,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13039,Akt1 Inhibitor,PTEN T319fs*6,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13040,PIK3CB inhibitor,PTEN T319fs*6,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13041,Akt2 Inhibitor,PTEN T319fs*6,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13042,PI3K Inhibitor (Pan),PTEN T319fs*6,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13043,Akt Inhibitor (Pan),PTEN T321fs*24,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13044,Akt1 Inhibitor,PTEN T321fs*24,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13045,PIK3CB inhibitor,PTEN T321fs*24,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13046,PI3K Inhibitor (Pan),PTEN T321fs*24,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13047,Akt2 Inhibitor,PTEN T321fs*24,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13048,Akt2 Inhibitor,PTEN T321fs*3,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13049,Akt1 Inhibitor,PTEN T321fs*3,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13050,Akt Inhibitor (Pan),PTEN T321fs*3,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13051,PIK3CB inhibitor,PTEN T321fs*3,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13052,PI3K Inhibitor (Pan),PTEN T321fs*3,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13053,PIK3CB inhibitor,PTEN Y336*,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13054,Akt Inhibitor (Pan),PTEN Y336*,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13055,PI3K Inhibitor (Pan),PTEN Y336*,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13056,Akt2 Inhibitor,PTEN Y336*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13057,Akt1 Inhibitor,PTEN Y336*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13058,Akt Inhibitor (Pan),PTEN Y65*,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13059,Akt2 Inhibitor,PTEN Y65*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13060,PIK3CB inhibitor,PTEN Y65*,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13061,PI3K Inhibitor (Pan),PTEN Y65*,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13062,Akt1 Inhibitor,PTEN Y65*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13063,PI3K Inhibitor (Pan),PTEN Y68C,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13064,Akt2 Inhibitor,PTEN Y68C,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13065,Akt1 Inhibitor,PTEN Y68C,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13066,PIK3CB inhibitor,PTEN Y68C,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13067,Akt Inhibitor (Pan),PTEN Y68C,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13068,PIK3CB inhibitor,PTEN Y68H,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13069,PI3K Inhibitor (Pan),PTEN Y68H,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13070,Akt2 Inhibitor,PTEN Y68H,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13071,Akt1 Inhibitor,PTEN Y68H,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13072,Akt Inhibitor (Pan),PTEN Y68H,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13073,Akt2 Inhibitor,PTEN Y68fs*5,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13074,PIK3CB inhibitor,PTEN Y68fs*5,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13075,Akt1 Inhibitor,PTEN Y68fs*5,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13076,PI3K Inhibitor (Pan),PTEN Y68fs*5,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13077,Akt Inhibitor (Pan),PTEN Y68fs*5,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13078,PIK3CB inhibitor,PTEN F347L,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13079,Akt1 Inhibitor,PTEN F347L,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13080,Akt2 Inhibitor,PTEN F347L,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13081,PI3K Inhibitor (Pan),PTEN F347L,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13082,Akt Inhibitor (Pan),PTEN F347L,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13083,Akt1 Inhibitor,PTEN G20E,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13084,PIK3CB inhibitor,PTEN G20E,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13085,PI3K Inhibitor (Pan),PTEN G20E,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13086,Akt2 Inhibitor,PTEN G20E,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13087,Akt Inhibitor (Pan),PTEN G20E,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13088,Akt2 Inhibitor,PTEN H93Y,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13089,Akt Inhibitor (Pan),PTEN H93Y,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13090,PI3K Inhibitor (Pan),PTEN H93Y,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13091,PIK3CB inhibitor,PTEN H93Y,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13092,Akt1 Inhibitor,PTEN H93Y,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13093,Akt1 Inhibitor,PTEN R173P,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13094,PI3K Inhibitor (Pan),PTEN R173P,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13095,Akt2 Inhibitor,PTEN R173P,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13096,PIK3CB inhibitor,PTEN R173P,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13097,Akt Inhibitor (Pan),PTEN R173P,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13098,Akt Inhibitor (Pan),PTEN M134L,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13099,Akt2 Inhibitor,PTEN M134L,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13100,Akt1 Inhibitor,PTEN M134L,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13101,PIK3CB inhibitor,PTEN M134L,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13102,PI3K Inhibitor (Pan),PTEN M134L,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13103,PI3K Inhibitor (Pan),PTEN Y155C,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13104,Akt1 Inhibitor,PTEN Y155C,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13105,Akt2 Inhibitor,PTEN Y155C,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13106,PIK3CB inhibitor,PTEN Y155C,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13107,Akt Inhibitor (Pan),PTEN Y155C,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13108,PIK3CB inhibitor,PTEN Y174N,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13109,Akt2 Inhibitor,PTEN Y174N,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13110,PI3K Inhibitor (Pan),PTEN Y174N,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13111,Akt Inhibitor (Pan),PTEN Y174N,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13112,Akt1 Inhibitor,PTEN Y174N,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13113,PI3K Inhibitor (Pan),PTEN Y27S,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13114,Akt Inhibitor (Pan),PTEN Y27S,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13115,Akt2 Inhibitor,PTEN Y27S,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13116,PIK3CB inhibitor,PTEN Y27S,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13117,Akt1 Inhibitor,PTEN Y27S,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13118,Akt2 Inhibitor,PTEN L345Q,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13119,PIK3CB inhibitor,PTEN L345Q,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13120,Akt Inhibitor (Pan),PTEN L345Q,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13121,Akt1 Inhibitor,PTEN L345Q,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13122,PI3K Inhibitor (Pan),PTEN L345Q,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13123,Akt2 Inhibitor,PTEN S227F,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13124,Akt1 Inhibitor,PTEN S227F,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13125,PIK3CB inhibitor,PTEN S227F,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13126,Akt Inhibitor (Pan),PTEN S227F,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13127,PI3K Inhibitor (Pan),PTEN S227F,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13128,PIK3CB inhibitor,PTEN V343E,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13129,Akt2 Inhibitor,PTEN V343E,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13130,PI3K Inhibitor (Pan),PTEN V343E,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13131,Akt1 Inhibitor,PTEN V343E,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13132,Akt Inhibitor (Pan),PTEN V343E,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13133,PIK3CB inhibitor,PTEN T321fs,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13134,Akt2 Inhibitor,PTEN T321fs,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13135,Akt Inhibitor (Pan),PTEN T321fs,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13136,Akt1 Inhibitor,PTEN T321fs,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13137,PI3K Inhibitor (Pan),PTEN T321fs,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13138,PIK3CB inhibitor,PTEN A126fs*8,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13139,Akt Inhibitor (Pan),PTEN A126fs*8,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13140,PI3K Inhibitor (Pan),PTEN A126fs*8,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13141,Akt2 Inhibitor,PTEN A126fs*8,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13142,Akt1 Inhibitor,PTEN A126fs*8,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13143,Akt2 Inhibitor,PTEN E256*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13144,Akt1 Inhibitor,PTEN E256*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13145,Akt Inhibitor (Pan),PTEN E256*,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13146,PIK3CB inhibitor,PTEN E256*,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13147,PI3K Inhibitor (Pan),PTEN E256*,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13148,Akt2 Inhibitor,PTEN G165*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13149,Akt Inhibitor (Pan),PTEN G165*,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13150,PI3K Inhibitor (Pan),PTEN G165*,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13151,PIK3CB inhibitor,PTEN G165*,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13152,Akt1 Inhibitor,PTEN G165*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13153,PIK3CB inhibitor,PTEN G165V,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13154,PI3K Inhibitor (Pan),PTEN G165V,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13155,Akt1 Inhibitor,PTEN G165V,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13156,Akt Inhibitor (Pan),PTEN G165V,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13157,Akt2 Inhibitor,PTEN G165V,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13158,PI3K Inhibitor (Pan),PTEN K125*,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13159,Akt2 Inhibitor,PTEN K125*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13160,Akt Inhibitor (Pan),PTEN K125*,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13161,Akt1 Inhibitor,PTEN K125*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13162,PIK3CB inhibitor,PTEN K125*,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13163,PIK3CB inhibitor,PTEN K13*,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13164,Akt Inhibitor (Pan),PTEN K13*,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13165,Akt1 Inhibitor,PTEN K13*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13166,PI3K Inhibitor (Pan),PTEN K13*,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13167,Akt2 Inhibitor,PTEN K13*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13168,Akt2 Inhibitor,PTEN K13Q,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13169,PI3K Inhibitor (Pan),PTEN K13Q,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13170,PIK3CB inhibitor,PTEN K13Q,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13171,Akt1 Inhibitor,PTEN K13Q,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13172,Akt Inhibitor (Pan),PTEN K13Q,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13173,PIK3CB inhibitor,PTEN K66fs*36,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13174,Akt2 Inhibitor,PTEN K66fs*36,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13175,Akt1 Inhibitor,PTEN K66fs*36,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13176,Akt Inhibitor (Pan),PTEN K66fs*36,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13177,PI3K Inhibitor (Pan),PTEN K66fs*36,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13178,PIK3CB inhibitor,PTEN L108P,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13179,Akt2 Inhibitor,PTEN L108P,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13180,Akt1 Inhibitor,PTEN L108P,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13181,PI3K Inhibitor (Pan),PTEN L108P,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13182,Akt Inhibitor (Pan),PTEN L108P,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13183,PI3K Inhibitor (Pan),PTEN L57fs*42,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13184,Akt2 Inhibitor,PTEN L57fs*42,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13185,Akt1 Inhibitor,PTEN L57fs*42,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13186,Akt Inhibitor (Pan),PTEN L57fs*42,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13187,PIK3CB inhibitor,PTEN L57fs*42,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13188,PI3K Inhibitor (Pan),PTEN Q298fs*9,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13189,Akt2 Inhibitor,PTEN Q298fs*9,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13190,Akt1 Inhibitor,PTEN Q298fs*9,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13191,Akt Inhibitor (Pan),PTEN Q298fs*9,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13192,PIK3CB inhibitor,PTEN Q298fs*9,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13193,PIK3CB inhibitor,PTEN R14fs*10,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13194,Akt1 Inhibitor,PTEN R14fs*10,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13195,Akt2 Inhibitor,PTEN R14fs*10,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13196,Akt Inhibitor (Pan),PTEN R14fs*10,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13197,PI3K Inhibitor (Pan),PTEN R14fs*10,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13198,PIK3CB inhibitor,PTEN R15K,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13199,Akt2 Inhibitor,PTEN R15K,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13200,PI3K Inhibitor (Pan),PTEN R15K,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13201,Akt1 Inhibitor,PTEN R15K,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13202,Akt Inhibitor (Pan),PTEN R15K,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13203,PI3K Inhibitor (Pan),PTEN T167P,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13204,Akt2 Inhibitor,PTEN T167P,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13205,PIK3CB inhibitor,PTEN T167P,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13206,Akt1 Inhibitor,PTEN T167P,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13207,Akt Inhibitor (Pan),PTEN T167P,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13208,PIK3CB inhibitor,PTEN Y16fs*1,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13209,PI3K Inhibitor (Pan),PTEN Y16fs*1,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13210,Akt2 Inhibitor,PTEN Y16fs*1,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13211,Akt Inhibitor (Pan),PTEN Y16fs*1,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13212,Akt1 Inhibitor,PTEN Y16fs*1,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13213,Akt Inhibitor (Pan),PTEN A72fs*5,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13214,PIK3CB inhibitor,PTEN A72fs*5,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13215,Akt2 Inhibitor,PTEN A72fs*5,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13216,PI3K Inhibitor (Pan),PTEN A72fs*5,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13217,Akt1 Inhibitor,PTEN A72fs*5,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13218,Akt Inhibitor (Pan),PTEN R173fs*10,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13219,Akt2 Inhibitor,PTEN R173fs*10,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13220,PI3K Inhibitor (Pan),PTEN R173fs*10,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13221,PIK3CB inhibitor,PTEN R173fs*10,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13222,Akt1 Inhibitor,PTEN R173fs*10,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13223,Akt1 Inhibitor,PTEN P248fs,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13224,PIK3CB inhibitor,PTEN P248fs,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13225,PI3K Inhibitor (Pan),PTEN P248fs,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13226,Akt2 Inhibitor,PTEN P248fs,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13227,Akt Inhibitor (Pan),PTEN P248fs,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13228,PIK3CB inhibitor,PTEN A126G,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13229,Akt2 Inhibitor,PTEN A126G,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13230,PI3K Inhibitor (Pan),PTEN A126G,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13231,Akt Inhibitor (Pan),PTEN A126G,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13232,Akt1 Inhibitor,PTEN A126G,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13233,PI3K Inhibitor (Pan),PTEN V54fs,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13234,PIK3CB inhibitor,PTEN V54fs,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13235,Akt1 Inhibitor,PTEN V54fs,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13236,Akt2 Inhibitor,PTEN V54fs,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13237,Akt Inhibitor (Pan),PTEN V54fs,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13238,Akt2 Inhibitor,PTEN A34D,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13239,PI3K Inhibitor (Pan),PTEN A34D,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13240,Akt1 Inhibitor,PTEN A34D,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13241,Akt Inhibitor (Pan),PTEN A34D,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13242,PIK3CB inhibitor,PTEN A34D,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13243,Akt2 Inhibitor,PTEN C124N,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13244,Akt Inhibitor (Pan),PTEN C124N,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13245,Akt1 Inhibitor,PTEN C124N,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13246,PI3K Inhibitor (Pan),PTEN C124N,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13247,PIK3CB inhibitor,PTEN C124N,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13248,PIK3CB inhibitor,PTEN D326N,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13249,Akt1 Inhibitor,PTEN D326N,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13250,Akt Inhibitor (Pan),PTEN D326N,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13251,PI3K Inhibitor (Pan),PTEN D326N,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13252,Akt2 Inhibitor,PTEN D326N,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13253,Akt1 Inhibitor,PTEN D92A,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13254,Akt Inhibitor (Pan),PTEN D92A,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13255,PIK3CB inhibitor,PTEN D92A,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13256,PI3K Inhibitor (Pan),PTEN D92A,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13257,Akt2 Inhibitor,PTEN D92A,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13258,Akt2 Inhibitor,PTEN D92G,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13259,Akt1 Inhibitor,PTEN D92G,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13260,PIK3CB inhibitor,PTEN D92G,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13261,PI3K Inhibitor (Pan),PTEN D92G,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13262,Akt Inhibitor (Pan),PTEN D92G,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13263,PI3K Inhibitor (Pan),PTEN D92H,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13264,Akt1 Inhibitor,PTEN D92H,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13265,PIK3CB inhibitor,PTEN D92H,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13266,Akt2 Inhibitor,PTEN D92H,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13267,Akt Inhibitor (Pan),PTEN D92H,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13268,Akt1 Inhibitor,PTEN D92V,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13269,PI3K Inhibitor (Pan),PTEN D92V,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13270,Akt Inhibitor (Pan),PTEN D92V,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13271,Akt2 Inhibitor,PTEN D92V,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13272,PIK3CB inhibitor,PTEN D92V,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13273,PI3K Inhibitor (Pan),PTEN E157G,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13274,Akt Inhibitor (Pan),PTEN E157G,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13275,Akt1 Inhibitor,PTEN E157G,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13276,Akt2 Inhibitor,PTEN E157G,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13277,PIK3CB inhibitor,PTEN E157G,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13278,Akt Inhibitor (Pan),PTEN F241S,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13279,PI3K Inhibitor (Pan),PTEN F241S,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13280,PIK3CB inhibitor,PTEN F241S,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13281,Akt2 Inhibitor,PTEN F241S,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13282,Akt1 Inhibitor,PTEN F241S,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13283,Akt Inhibitor (Pan),PTEN G127N,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13284,PIK3CB inhibitor,PTEN G127N,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13285,Akt2 Inhibitor,PTEN G127N,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13286,PI3K Inhibitor (Pan),PTEN G127N,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13287,Akt1 Inhibitor,PTEN G127N,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13288,Akt2 Inhibitor,PTEN G129D,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13289,Akt1 Inhibitor,PTEN G129D,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13290,Akt Inhibitor (Pan),PTEN G129D,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13291,PI3K Inhibitor (Pan),PTEN G129D,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13292,PIK3CB inhibitor,PTEN G129D,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13293,PI3K Inhibitor (Pan),PTEN G36R,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13294,Akt1 Inhibitor,PTEN G36R,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13295,PIK3CB inhibitor,PTEN G36R,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13296,Akt2 Inhibitor,PTEN G36R,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13297,Akt Inhibitor (Pan),PTEN G36R,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13298,PIK3CB inhibitor,PTEN G44D,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13299,Akt2 Inhibitor,PTEN G44D,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13300,Akt1 Inhibitor,PTEN G44D,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13301,PI3K Inhibitor (Pan),PTEN G44D,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13302,Akt Inhibitor (Pan),PTEN G44D,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13303,PI3K Inhibitor (Pan),PTEN H118P,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13304,PIK3CB inhibitor,PTEN H118P,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13305,Akt2 Inhibitor,PTEN H118P,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13306,Akt1 Inhibitor,PTEN H118P,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13307,Akt Inhibitor (Pan),PTEN H118P,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13308,PI3K Inhibitor (Pan),PTEN H123Q,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13309,Akt1 Inhibitor,PTEN H123Q,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13310,Akt2 Inhibitor,PTEN H123Q,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13311,Akt Inhibitor (Pan),PTEN H123Q,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13312,PIK3CB inhibitor,PTEN H123Q,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13313,PI3K Inhibitor (Pan),PTEN H61D,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13314,PIK3CB inhibitor,PTEN H61D,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13315,Akt1 Inhibitor,PTEN H61D,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13316,Akt2 Inhibitor,PTEN H61D,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13317,Akt Inhibitor (Pan),PTEN H61D,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13318,Akt1 Inhibitor,PTEN H93D,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13319,Akt Inhibitor (Pan),PTEN H93D,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13320,PI3K Inhibitor (Pan),PTEN H93D,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13321,PIK3CB inhibitor,PTEN H93D,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13322,Akt2 Inhibitor,PTEN H93D,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13323,PI3K Inhibitor (Pan),PTEN H93Q,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13324,Akt1 Inhibitor,PTEN H93Q,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13325,PIK3CB inhibitor,PTEN H93Q,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13326,Akt2 Inhibitor,PTEN H93Q,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13327,Akt Inhibitor (Pan),PTEN H93Q,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13328,Akt Inhibitor (Pan),PTEN I122L,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13329,PI3K Inhibitor (Pan),PTEN I122L,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13330,PIK3CB inhibitor,PTEN I122L,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13331,Akt2 Inhibitor,PTEN I122L,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13332,Akt1 Inhibitor,PTEN I122L,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13333,PI3K Inhibitor (Pan),PTEN I122S,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13334,PIK3CB inhibitor,PTEN I122S,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13335,Akt1 Inhibitor,PTEN I122S,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13336,Akt2 Inhibitor,PTEN I122S,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13337,Akt Inhibitor (Pan),PTEN I122S,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13338,PI3K Inhibitor (Pan),PTEN K125L,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13339,Akt Inhibitor (Pan),PTEN K125L,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13340,Akt1 Inhibitor,PTEN K125L,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13341,Akt2 Inhibitor,PTEN K125L,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13342,PIK3CB inhibitor,PTEN K125L,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13343,PI3K Inhibitor (Pan),PTEN K125M,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13344,PIK3CB inhibitor,PTEN K125M,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13345,Akt Inhibitor (Pan),PTEN K125M,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13346,Akt1 Inhibitor,PTEN K125M,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13347,Akt2 Inhibitor,PTEN K125M,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13348,PI3K Inhibitor (Pan),PTEN K128Q,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13349,Akt Inhibitor (Pan),PTEN K128Q,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13350,PIK3CB inhibitor,PTEN K128Q,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13351,Akt2 Inhibitor,PTEN K128Q,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13352,Akt1 Inhibitor,PTEN K128Q,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13353,Akt2 Inhibitor,PTEN L181P,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13354,PIK3CB inhibitor,PTEN L181P,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13355,PI3K Inhibitor (Pan),PTEN L181P,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13356,Akt Inhibitor (Pan),PTEN L181P,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13357,Akt1 Inhibitor,PTEN L181P,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13358,Akt2 Inhibitor,PTEN M35R,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13359,Akt1 Inhibitor,PTEN M35R,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13360,PI3K Inhibitor (Pan),PTEN M35R,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13361,Akt Inhibitor (Pan),PTEN M35R,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13362,PIK3CB inhibitor,PTEN M35R,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13363,Akt Inhibitor (Pan),PTEN N48K,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13364,PIK3CB inhibitor,PTEN N48K,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13365,Akt2 Inhibitor,PTEN N48K,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13366,Akt1 Inhibitor,PTEN N48K,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13367,PI3K Inhibitor (Pan),PTEN N48K,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13368,PIK3CB inhibitor,PTEN N94I,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13369,PI3K Inhibitor (Pan),PTEN N94I,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13370,Akt2 Inhibitor,PTEN N94I,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13371,Akt1 Inhibitor,PTEN N94I,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13372,Akt Inhibitor (Pan),PTEN N94I,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13373,PI3K Inhibitor (Pan),PTEN P95L,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13374,Akt2 Inhibitor,PTEN P95L,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13375,Akt1 Inhibitor,PTEN P95L,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13376,Akt Inhibitor (Pan),PTEN P95L,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13377,PIK3CB inhibitor,PTEN P95L,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13378,PI3K Inhibitor (Pan),PTEN P95S,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13379,Akt1 Inhibitor,PTEN P95S,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13380,Akt Inhibitor (Pan),PTEN P95S,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13381,PIK3CB inhibitor,PTEN P95S,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13382,Akt2 Inhibitor,PTEN P95S,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13383,Akt Inhibitor (Pan),PTEN P96Q,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13384,PIK3CB inhibitor,PTEN P96Q,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13385,Akt2 Inhibitor,PTEN P96Q,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13386,Akt1 Inhibitor,PTEN P96Q,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13387,PI3K Inhibitor (Pan),PTEN P96Q,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13388,PIK3CB inhibitor,PTEN R130A,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13389,PI3K Inhibitor (Pan),PTEN R130A,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13390,Akt1 Inhibitor,PTEN R130A,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13391,Akt2 Inhibitor,PTEN R130A,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13392,Akt Inhibitor (Pan),PTEN R130A,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13393,Akt1 Inhibitor,PTEN R130K,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13394,PI3K Inhibitor (Pan),PTEN R130K,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13395,Akt2 Inhibitor,PTEN R130K,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13396,PIK3CB inhibitor,PTEN R130K,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13397,Akt Inhibitor (Pan),PTEN R130K,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13398,PI3K Inhibitor (Pan),PTEN R161G,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13399,Akt2 Inhibitor,PTEN R161G,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13400,Akt1 Inhibitor,PTEN R161G,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13401,Akt Inhibitor (Pan),PTEN R161G,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13402,PIK3CB inhibitor,PTEN R161G,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13403,Akt Inhibitor (Pan),PTEN R335L,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13404,PI3K Inhibitor (Pan),PTEN R335L,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13405,Akt2 Inhibitor,PTEN R335L,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13406,PIK3CB inhibitor,PTEN R335L,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13407,Akt1 Inhibitor,PTEN R335L,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13408,Akt2 Inhibitor,PTEN T131I,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13409,PI3K Inhibitor (Pan),PTEN T131I,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13410,Akt1 Inhibitor,PTEN T131I,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13411,Akt Inhibitor (Pan),PTEN T131I,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13412,PIK3CB inhibitor,PTEN T131I,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13413,Akt2 Inhibitor,PTEN T131L,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13414,PI3K Inhibitor (Pan),PTEN T131L,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13415,PIK3CB inhibitor,PTEN T131L,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13416,Akt Inhibitor (Pan),PTEN T131L,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13417,Akt1 Inhibitor,PTEN T131L,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13418,PI3K Inhibitor (Pan),PTEN T160I,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13419,Akt1 Inhibitor,PTEN T160I,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13420,PIK3CB inhibitor,PTEN T160I,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13421,Akt Inhibitor (Pan),PTEN T160I,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13422,Akt2 Inhibitor,PTEN T160I,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13423,Akt Inhibitor (Pan),PTEN V217D,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13424,Akt1 Inhibitor,PTEN V217D,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13425,Akt2 Inhibitor,PTEN V217D,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13426,PI3K Inhibitor (Pan),PTEN V217D,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13427,PIK3CB inhibitor,PTEN V217D,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13428,Akt Inhibitor (Pan),PTEN V343L,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13429,PI3K Inhibitor (Pan),PTEN V343L,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13430,Akt1 Inhibitor,PTEN V343L,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13431,PIK3CB inhibitor,PTEN V343L,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13432,Akt2 Inhibitor,PTEN V343L,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13433,Akt Inhibitor (Pan),PTEN Y68D,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13434,Akt2 Inhibitor,PTEN Y68D,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13435,Akt1 Inhibitor,PTEN Y68D,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13436,PI3K Inhibitor (Pan),PTEN Y68D,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13437,PIK3CB inhibitor,PTEN Y68D,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13438,PI3K Inhibitor (Pan),PTEN A39P,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13439,Akt2 Inhibitor,PTEN A39P,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13440,PIK3CB inhibitor,PTEN A39P,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13441,Akt1 Inhibitor,PTEN A39P,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13442,Akt Inhibitor (Pan),PTEN A39P,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13443,PI3K Inhibitor (Pan),PTEN D24N,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13444,Akt2 Inhibitor,PTEN D24N,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13445,PIK3CB inhibitor,PTEN D24N,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13446,Akt Inhibitor (Pan),PTEN D24N,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13447,Akt1 Inhibitor,PTEN D24N,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13448,PI3K Inhibitor (Pan),PTEN D24Y,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13449,Akt2 Inhibitor,PTEN D24Y,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13450,Akt1 Inhibitor,PTEN D24Y,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13451,Akt Inhibitor (Pan),PTEN D24Y,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13452,PIK3CB inhibitor,PTEN D24Y,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13453,PI3K Inhibitor (Pan),PTEN F154L,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13454,PIK3CB inhibitor,PTEN F154L,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13455,Akt Inhibitor (Pan),PTEN F154L,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13456,Akt2 Inhibitor,PTEN F154L,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13457,Akt1 Inhibitor,PTEN F154L,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13458,Akt Inhibitor (Pan),PTEN F21A,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13459,PI3K Inhibitor (Pan),PTEN F21A,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13460,Akt2 Inhibitor,PTEN F21A,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13461,Akt1 Inhibitor,PTEN F21A,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13462,PIK3CB inhibitor,PTEN F21A,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13463,PI3K Inhibitor (Pan),PTEN K128T,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13464,Akt Inhibitor (Pan),PTEN K128T,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13465,Akt2 Inhibitor,PTEN K128T,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13466,PIK3CB inhibitor,PTEN K128T,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13467,Akt1 Inhibitor,PTEN K128T,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13468,Akt2 Inhibitor,PTEN K289E,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13469,Akt Inhibitor (Pan),PTEN K289E,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13470,PI3K Inhibitor (Pan),PTEN K289E,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13471,PIK3CB inhibitor,PTEN K289E,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13472,Akt1 Inhibitor,PTEN K289E,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13473,PIK3CB inhibitor,PTEN K62R,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13474,PI3K Inhibitor (Pan),PTEN K62R,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13475,Akt2 Inhibitor,PTEN K62R,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13476,Akt1 Inhibitor,PTEN K62R,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13477,Akt Inhibitor (Pan),PTEN K62R,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13478,PIK3CB inhibitor,PTEN L23F,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13479,Akt Inhibitor (Pan),PTEN L23F,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13480,Akt1 Inhibitor,PTEN L23F,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13481,PI3K Inhibitor (Pan),PTEN L23F,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13482,Akt2 Inhibitor,PTEN L23F,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13483,PIK3CB inhibitor,PTEN L325F,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13484,PI3K Inhibitor (Pan),PTEN L325F,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13485,Akt Inhibitor (Pan),PTEN L325F,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13486,Akt1 Inhibitor,PTEN L325F,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13487,Akt2 Inhibitor,PTEN L325F,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13488,PIK3CB inhibitor,PTEN L42R,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13489,PI3K Inhibitor (Pan),PTEN L42R,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13490,Akt Inhibitor (Pan),PTEN L42R,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13491,Akt1 Inhibitor,PTEN L42R,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13492,Akt2 Inhibitor,PTEN L42R,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13493,PI3K Inhibitor (Pan),PTEN M199del,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13494,Akt2 Inhibitor,PTEN M199del,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13495,PIK3CB inhibitor,PTEN M199del,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13496,Akt Inhibitor (Pan),PTEN M199del,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13497,Akt1 Inhibitor,PTEN M199del,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13498,Akt1 Inhibitor,PTEN Y65C,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13499,Akt2 Inhibitor,PTEN Y65C,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13500,PI3K Inhibitor (Pan),PTEN Y65C,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13501,PIK3CB inhibitor,PTEN Y65C,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13502,Akt Inhibitor (Pan),PTEN Y65C,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13503,PI3K Inhibitor (Pan),PTEN Y86fs,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13504,Akt Inhibitor (Pan),PTEN Y86fs,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13505,PIK3CB inhibitor,PTEN Y86fs,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13506,Akt1 Inhibitor,PTEN Y86fs,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13507,Akt2 Inhibitor,PTEN Y86fs,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13508,Akt1 Inhibitor,PTEN F56fs,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13509,Akt2 Inhibitor,PTEN F56fs,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13510,Akt Inhibitor (Pan),PTEN F56fs,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13511,PIK3CB inhibitor,PTEN F56fs,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13512,PI3K Inhibitor (Pan),PTEN F56fs,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13513,Akt2 Inhibitor,PTEN C218*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13514,PI3K Inhibitor (Pan),PTEN C218*,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13515,PIK3CB inhibitor,PTEN C218*,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13516,Akt Inhibitor (Pan),PTEN C218*,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13517,Akt1 Inhibitor,PTEN C218*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13518,PIK3CB inhibitor,PTEN N292fs,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13519,Akt1 Inhibitor,PTEN N292fs,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13520,Akt2 Inhibitor,PTEN N292fs,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13521,Akt Inhibitor (Pan),PTEN N292fs,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13522,PI3K Inhibitor (Pan),PTEN N292fs,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13523,Akt1 Inhibitor,PTEN Y27fs*1,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13524,Akt2 Inhibitor,PTEN Y27fs*1,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13525,Akt Inhibitor (Pan),PTEN Y27fs*1,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13526,PI3K Inhibitor (Pan),PTEN Y27fs*1,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13527,PIK3CB inhibitor,PTEN Y27fs*1,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13528,PIK3CB inhibitor,PTEN R55fs*1,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13529,Akt1 Inhibitor,PTEN R55fs*1,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13530,Akt Inhibitor (Pan),PTEN R55fs*1,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13531,PI3K Inhibitor (Pan),PTEN R55fs*1,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13532,Akt2 Inhibitor,PTEN R55fs*1,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13533,PIK3CB inhibitor,PTEN L70fs*7,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13534,PI3K Inhibitor (Pan),PTEN L70fs*7,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13535,Akt Inhibitor (Pan),PTEN L70fs*7,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13536,Akt2 Inhibitor,PTEN L70fs*7,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13537,Akt1 Inhibitor,PTEN L70fs*7,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13538,Akt2 Inhibitor,PTEN E284*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13539,Akt Inhibitor (Pan),PTEN E284*,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13540,PI3K Inhibitor (Pan),PTEN E284*,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13541,PIK3CB inhibitor,PTEN E284*,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13542,Akt1 Inhibitor,PTEN E284*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13543,PIK3CB inhibitor,PTEN K260*,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13544,Akt1 Inhibitor,PTEN K260*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13545,Akt Inhibitor (Pan),PTEN K260*,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13546,PI3K Inhibitor (Pan),PTEN K260*,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13547,Akt2 Inhibitor,PTEN K260*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13548,Akt2 Inhibitor,PTEN V275*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13549,Akt1 Inhibitor,PTEN V275*,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13550,PIK3CB inhibitor,PTEN V275*,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13551,Akt Inhibitor (Pan),PTEN V275*,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13552,PI3K Inhibitor (Pan),PTEN V275*,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13553,PIK3CB inhibitor,PTEN G143fs*4,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13554,Akt1 Inhibitor,PTEN G143fs*4,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13555,Akt Inhibitor (Pan),PTEN G143fs*4,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13556,Akt2 Inhibitor,PTEN G143fs*4,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13557,PI3K Inhibitor (Pan),PTEN G143fs*4,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13558,Akt1 Inhibitor,PTEN R130fs,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13559,PIK3CB inhibitor,PTEN R130fs,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13560,Akt2 Inhibitor,PTEN R130fs,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13561,PI3K Inhibitor (Pan),PTEN R130fs,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13562,Akt Inhibitor (Pan),PTEN R130fs,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13563,Akt2 Inhibitor,PTEN T321fs*23,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13564,PIK3CB inhibitor,PTEN T321fs*23,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13565,Akt1 Inhibitor,PTEN T321fs*23,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13566,PI3K Inhibitor (Pan),PTEN T321fs*23,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13567,Akt Inhibitor (Pan),PTEN T321fs*23,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PI3K Inhibitor (Pan),181,13568,PI3K Inhibitor (Pan),PTEN Y155fs,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,05/16/2017
0,05/16/2017,Akt Inhibitor (Pan),4,13569,Akt Inhibitor (Pan),PTEN Y155fs,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt1 Inhibitor,6,13570,Akt1 Inhibitor,PTEN Y155fs,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,Akt2 Inhibitor,7,13571,Akt2 Inhibitor,PTEN Y155fs,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,05/16/2017
0,05/16/2017,PIK3CB inhibitor,183,13572,PIK3CB inhibitor,PTEN Y155fs,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,05/16/2017
0,05/16/2017,KIT Inhibitor,136,13573,KIT Inhibitor,KIT exon 11 del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,05/16/2017
0,05/18/2017,JAK Inhibitor (Pan),126,13574,JAK Inhibitor (Pan),JAK3 R172Q,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,05/18/2017
0,05/18/2017,JAK Inhibitor (Pan) – ATP competitive,127,13575,JAK Inhibitor (Pan) – ATP competitive,JAK3 R172Q,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,05/18/2017
0,05/18/2017,JAK3 Inhibitor,132,13576,JAK3 Inhibitor,JAK3 R172Q,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,05/18/2017
0,05/18/2017,JAK3 Inhibitor – ATP competitive,133,13577,JAK3 Inhibitor – ATP competitive,JAK3 R172Q,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,05/18/2017
0,05/18/2017,JAK Inhibitor (Pan),126,13578,JAK Inhibitor (Pan),JAK3 E183G,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,05/18/2017
0,05/18/2017,JAK Inhibitor (Pan) – ATP competitive,127,13579,JAK Inhibitor (Pan) – ATP competitive,JAK3 E183G,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,05/18/2017
0,05/18/2017,JAK3 Inhibitor,132,13580,JAK3 Inhibitor,JAK3 E183G,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,05/18/2017
0,05/18/2017,JAK3 Inhibitor – ATP competitive,133,13581,JAK3 Inhibitor – ATP competitive,JAK3 E183G,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,05/18/2017
0,05/18/2017,JAK Inhibitor (Pan),126,13582,JAK Inhibitor (Pan),JAK3 L156P,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,05/18/2017
0,05/18/2017,JAK Inhibitor (Pan) – ATP competitive,127,13583,JAK Inhibitor (Pan) – ATP competitive,JAK3 L156P,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,05/18/2017
0,05/18/2017,JAK3 Inhibitor,132,13584,JAK3 Inhibitor,JAK3 L156P,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,05/18/2017
0,05/18/2017,JAK3 Inhibitor – ATP competitive,133,13585,JAK3 Inhibitor – ATP competitive,JAK3 L156P,"[{'id': 2985, 'pubMedId': 22819198, 'title': 'Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22819198'}]",,05/18/2017
0,06/01/2017,FLT3 Inhibitor,96,13586,FLT3 Inhibitor,CBL Y371D,"[{'id': 3301, 'pubMedId': 25477533, 'title': 'Molecular pathways: cbl proteins in tumorigenesis and antitumor immunity-opportunities for cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25477533'}, {'id': 3302, 'pubMedId': 22990016, 'title': 'Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22990016'}]",,06/01/2017
0,06/26/2017,EGFR Inhibitor (Pan),74,13599,EGFR Inhibitor (Pan),EGFR E746_T751delinsVA,"[{'id': 410, 'pubMedId': 16187797, 'title': 'Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16187797'}, {'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,06/26/2017
0,06/26/2017,EGFR Inhibitor 1st gen,75,13600,EGFR Inhibitor 1st gen,EGFR E746_T751delinsVA,"[{'id': 286, 'pubMedId': None, 'title': 'FDA.gov', 'url': 'http://www.fda.gov/'}]",,06/26/2017
0,06/26/2017,EGFR Inhibitor 2nd gen,76,13601,EGFR Inhibitor 2nd gen,EGFR E746_T751delinsVA,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,06/26/2017
0,06/26/2017,EGFR Inhibitor 3rd gen,77,13602,EGFR Inhibitor 3rd gen,EGFR E746_T751delinsVA,"[{'id': 447, 'pubMedId': 24857124, 'title': 'Management and future directions in non-small cell lung cancer with known activating mutations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24857124'}]",,06/26/2017
0,06/26/2017,HER inhibitor (Pan),105,13603,HER inhibitor (Pan),EGFR E746_T751delinsVA,"[{'id': 2746, 'pubMedId': 25806203, 'title': 'Irreversible EGFR-TKIs: dreaming perfection.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25806203'}]",,06/26/2017
0,06/27/2017,IDH Inhibitor (Pan),117,13604,IDH Inhibitor (Pan),IDH1 R132I,"[{'id': 2551, 'pubMedId': 25678837, 'title': 'New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25678837'}]",,06/27/2017
0,06/27/2017,IDH1 Inhibitor,118,13605,IDH1 Inhibitor,IDH1 R132I,"[{'id': 2551, 'pubMedId': 25678837, 'title': 'New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25678837'}, {'id': 2552, 'pubMedId': 23558169, 'title': 'An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23558169'}]",,06/27/2017
0,06/27/2017,IDH Inhibitor (Pan),117,13606,IDH Inhibitor (Pan),IDH1 R132P,"[{'id': 2551, 'pubMedId': 25678837, 'title': 'New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25678837'}]",,06/27/2017
0,06/27/2017,IDH1 Inhibitor,118,13607,IDH1 Inhibitor,IDH1 R132P,"[{'id': 2551, 'pubMedId': 25678837, 'title': 'New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25678837'}, {'id': 2552, 'pubMedId': 23558169, 'title': 'An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23558169'}]",,06/27/2017
0,07/13/2017,NOTCH Inhibitor (Pan),156,13809,NOTCH Inhibitor (Pan),NOTCH1 V1676I,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,NOTCH1 Inhibitor,159,13810,NOTCH1 Inhibitor,NOTCH1 V1676I,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,NOTCH1 Antibody,158,13811,NOTCH1 Antibody,NOTCH1 V1676I,"[{'id': 4206, 'pubMedId': 20393564, 'title': 'Therapeutic antibody targeting of individual Notch receptors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20393564'}]",,07/13/2017
0,07/13/2017,Gamma secretase inhibitor,99,13812,Gamma secretase inhibitor,NOTCH1 V1676I,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}, {'id': 2522, 'pubMedId': 17317574, 'title': 'Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17317574'}]",,07/13/2017
0,07/13/2017,NOTCH Inhibitor (Pan),156,13813,NOTCH Inhibitor (Pan),NOTCH1 act mut,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,Gamma secretase inhibitor,99,13814,Gamma secretase inhibitor,NOTCH1 act mut,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}, {'id': 2522, 'pubMedId': 17317574, 'title': 'Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17317574'}]",,07/13/2017
0,07/13/2017,NOTCH1 Inhibitor,159,13815,NOTCH1 Inhibitor,NOTCH1 act mut,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,NOTCH1 Antibody,158,13816,NOTCH1 Antibody,NOTCH1 act mut,"[{'id': 4206, 'pubMedId': 20393564, 'title': 'Therapeutic antibody targeting of individual Notch receptors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20393564'}]",,07/13/2017
0,07/13/2017,NOTCH1 Inhibitor,159,13821,NOTCH1 Inhibitor,NOTCH1 H2428fs*36,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,NOTCH Inhibitor (Pan),156,13822,NOTCH Inhibitor (Pan),NOTCH1 H2428fs*36,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,NOTCH1 Antibody,158,13823,NOTCH1 Antibody,NOTCH1 H2428fs*36,"[{'id': 4206, 'pubMedId': 20393564, 'title': 'Therapeutic antibody targeting of individual Notch receptors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20393564'}]",,07/13/2017
0,07/13/2017,Gamma secretase inhibitor,99,13824,Gamma secretase inhibitor,NOTCH1 H2428fs*36,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}, {'id': 2522, 'pubMedId': 17317574, 'title': 'Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17317574'}]",,07/13/2017
0,07/13/2017,NOTCH1 Antibody,158,13825,NOTCH1 Antibody,NOTCH1 P2475fs*4,"[{'id': 4206, 'pubMedId': 20393564, 'title': 'Therapeutic antibody targeting of individual Notch receptors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20393564'}]",,07/13/2017
0,07/13/2017,NOTCH Inhibitor (Pan),156,13826,NOTCH Inhibitor (Pan),NOTCH1 P2475fs*4,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,NOTCH1 Inhibitor,159,13827,NOTCH1 Inhibitor,NOTCH1 P2475fs*4,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,Gamma secretase inhibitor,99,13828,Gamma secretase inhibitor,NOTCH1 P2475fs*4,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}, {'id': 2522, 'pubMedId': 17317574, 'title': 'Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17317574'}]",,07/13/2017
0,07/13/2017,NOTCH1 Inhibitor,159,13841,NOTCH1 Inhibitor,NOTCH1 V2443fs,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,NOTCH1 Antibody,158,13842,NOTCH1 Antibody,NOTCH1 V2443fs,"[{'id': 4206, 'pubMedId': 20393564, 'title': 'Therapeutic antibody targeting of individual Notch receptors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20393564'}]",,07/13/2017
0,07/13/2017,Gamma secretase inhibitor,99,13843,Gamma secretase inhibitor,NOTCH1 V2443fs,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}, {'id': 2522, 'pubMedId': 17317574, 'title': 'Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17317574'}]",,07/13/2017
0,07/13/2017,NOTCH Inhibitor (Pan),156,13844,NOTCH Inhibitor (Pan),NOTCH1 V2443fs,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,NOTCH1 Inhibitor,159,13845,NOTCH1 Inhibitor,NOTCH1 L1575P,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,NOTCH1 Antibody,158,13846,NOTCH1 Antibody,NOTCH1 L1575P,"[{'id': 4206, 'pubMedId': 20393564, 'title': 'Therapeutic antibody targeting of individual Notch receptors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20393564'}]",,07/13/2017
0,07/13/2017,Gamma secretase inhibitor,99,13847,Gamma secretase inhibitor,NOTCH1 L1575P,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}, {'id': 2522, 'pubMedId': 17317574, 'title': 'Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17317574'}]",,07/13/2017
0,07/13/2017,NOTCH Inhibitor (Pan),156,13848,NOTCH Inhibitor (Pan),NOTCH1 L1575P,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,NOTCH1 Antibody,158,13849,NOTCH1 Antibody,NOTCH1 L1594P,"[{'id': 4206, 'pubMedId': 20393564, 'title': 'Therapeutic antibody targeting of individual Notch receptors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20393564'}]",,07/13/2017
0,07/13/2017,NOTCH1 Inhibitor,159,13850,NOTCH1 Inhibitor,NOTCH1 L1594P,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,Gamma secretase inhibitor,99,13851,Gamma secretase inhibitor,NOTCH1 L1594P,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}, {'id': 2522, 'pubMedId': 17317574, 'title': 'Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17317574'}]",,07/13/2017
0,07/13/2017,NOTCH Inhibitor (Pan),156,13852,NOTCH Inhibitor (Pan),NOTCH1 L1594P,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,NOTCH Inhibitor (Pan),156,13853,NOTCH Inhibitor (Pan),NOTCH1 L1601P,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,NOTCH1 Antibody,158,13854,NOTCH1 Antibody,NOTCH1 L1601P,"[{'id': 4206, 'pubMedId': 20393564, 'title': 'Therapeutic antibody targeting of individual Notch receptors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20393564'}]",,07/13/2017
0,07/13/2017,Gamma secretase inhibitor,99,13855,Gamma secretase inhibitor,NOTCH1 L1601P,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}, {'id': 2522, 'pubMedId': 17317574, 'title': 'Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17317574'}]",,07/13/2017
0,07/13/2017,NOTCH1 Inhibitor,159,13856,NOTCH1 Inhibitor,NOTCH1 L1601P,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,NOTCH1 Antibody,158,13857,NOTCH1 Antibody,NOTCH1 A1701P,"[{'id': 4206, 'pubMedId': 20393564, 'title': 'Therapeutic antibody targeting of individual Notch receptors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20393564'}]",,07/13/2017
0,07/13/2017,NOTCH1 Inhibitor,159,13858,NOTCH1 Inhibitor,NOTCH1 A1701P,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,NOTCH Inhibitor (Pan),156,13859,NOTCH Inhibitor (Pan),NOTCH1 A1701P,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,Gamma secretase inhibitor,99,13860,Gamma secretase inhibitor,NOTCH1 A1701P,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}, {'id': 2522, 'pubMedId': 17317574, 'title': 'Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17317574'}]",,07/13/2017
0,07/13/2017,NOTCH1 Inhibitor,159,13861,NOTCH1 Inhibitor,NOTCH1 A1707T,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,Gamma secretase inhibitor,99,13862,Gamma secretase inhibitor,NOTCH1 A1707T,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}, {'id': 2522, 'pubMedId': 17317574, 'title': 'Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17317574'}]",,07/13/2017
0,07/13/2017,NOTCH1 Antibody,158,13863,NOTCH1 Antibody,NOTCH1 A1707T,"[{'id': 4206, 'pubMedId': 20393564, 'title': 'Therapeutic antibody targeting of individual Notch receptors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20393564'}]",,07/13/2017
0,07/13/2017,NOTCH Inhibitor (Pan),156,13864,NOTCH Inhibitor (Pan),NOTCH1 A1707T,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,NOTCH1 Inhibitor,159,13865,NOTCH1 Inhibitor,NOTCH1 F1592S,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,NOTCH Inhibitor (Pan),156,13866,NOTCH Inhibitor (Pan),NOTCH1 F1592S,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,NOTCH1 Antibody,158,13867,NOTCH1 Antibody,NOTCH1 F1592S,"[{'id': 4206, 'pubMedId': 20393564, 'title': 'Therapeutic antibody targeting of individual Notch receptors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20393564'}]",,07/13/2017
0,07/13/2017,Gamma secretase inhibitor,99,13868,Gamma secretase inhibitor,NOTCH1 F1592S,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}, {'id': 2522, 'pubMedId': 17317574, 'title': 'Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17317574'}]",,07/13/2017
0,07/13/2017,NOTCH1 Inhibitor,159,13869,NOTCH1 Inhibitor,NOTCH1 L1574P,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,Gamma secretase inhibitor,99,13870,Gamma secretase inhibitor,NOTCH1 L1574P,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}, {'id': 2522, 'pubMedId': 17317574, 'title': 'Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17317574'}]",,07/13/2017
0,07/13/2017,NOTCH1 Antibody,158,13871,NOTCH1 Antibody,NOTCH1 L1574P,"[{'id': 4206, 'pubMedId': 20393564, 'title': 'Therapeutic antibody targeting of individual Notch receptors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20393564'}]",,07/13/2017
0,07/13/2017,NOTCH Inhibitor (Pan),156,13872,NOTCH Inhibitor (Pan),NOTCH1 L1574P,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,NOTCH1 Inhibitor,159,13873,NOTCH1 Inhibitor,NOTCH1 L1593P,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,Gamma secretase inhibitor,99,13874,Gamma secretase inhibitor,NOTCH1 L1593P,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}, {'id': 2522, 'pubMedId': 17317574, 'title': 'Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17317574'}]",,07/13/2017
0,07/13/2017,NOTCH1 Antibody,158,13875,NOTCH1 Antibody,NOTCH1 L1593P,"[{'id': 4206, 'pubMedId': 20393564, 'title': 'Therapeutic antibody targeting of individual Notch receptors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20393564'}]",,07/13/2017
0,07/13/2017,NOTCH Inhibitor (Pan),156,13876,NOTCH Inhibitor (Pan),NOTCH1 L1593P,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,NOTCH1 Antibody,158,13877,NOTCH1 Antibody,NOTCH1 L1600P,"[{'id': 4206, 'pubMedId': 20393564, 'title': 'Therapeutic antibody targeting of individual Notch receptors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20393564'}]",,07/13/2017
0,07/13/2017,Gamma secretase inhibitor,99,13878,Gamma secretase inhibitor,NOTCH1 L1600P,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}, {'id': 2522, 'pubMedId': 17317574, 'title': 'Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17317574'}]",,07/13/2017
0,07/13/2017,NOTCH1 Inhibitor,159,13879,NOTCH1 Inhibitor,NOTCH1 L1600P,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,NOTCH Inhibitor (Pan),156,13880,NOTCH Inhibitor (Pan),NOTCH1 L1600P,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,NOTCH Inhibitor (Pan),156,13881,NOTCH Inhibitor (Pan),NOTCH1 L1678P,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,Gamma secretase inhibitor,99,13882,Gamma secretase inhibitor,NOTCH1 L1678P,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}, {'id': 2522, 'pubMedId': 17317574, 'title': 'Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17317574'}]",,07/13/2017
0,07/13/2017,NOTCH1 Inhibitor,159,13883,NOTCH1 Inhibitor,NOTCH1 L1678P,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,NOTCH1 Antibody,158,13884,NOTCH1 Antibody,NOTCH1 L1678P,"[{'id': 4206, 'pubMedId': 20393564, 'title': 'Therapeutic antibody targeting of individual Notch receptors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20393564'}]",,07/13/2017
0,07/13/2017,NOTCH1 Inhibitor,159,13885,NOTCH1 Inhibitor,NOTCH1 L1596H ,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,Gamma secretase inhibitor,99,13886,Gamma secretase inhibitor,NOTCH1 L1596H ,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}, {'id': 2522, 'pubMedId': 17317574, 'title': 'Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17317574'}]",,07/13/2017
0,07/13/2017,NOTCH1 Antibody,158,13887,NOTCH1 Antibody,NOTCH1 L1596H ,"[{'id': 4206, 'pubMedId': 20393564, 'title': 'Therapeutic antibody targeting of individual Notch receptors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20393564'}]",,07/13/2017
0,07/13/2017,NOTCH Inhibitor (Pan),156,13888,NOTCH Inhibitor (Pan),NOTCH1 L1596H ,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,Gamma secretase inhibitor,99,13889,Gamma secretase inhibitor,NOTCH1 P2462fs*15 ,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}, {'id': 2522, 'pubMedId': 17317574, 'title': 'Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17317574'}]",,07/13/2017
0,07/13/2017,NOTCH1 Inhibitor,159,13890,NOTCH1 Inhibitor,NOTCH1 P2462fs*15 ,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,NOTCH Inhibitor (Pan),156,13891,NOTCH Inhibitor (Pan),NOTCH1 P2462fs*15 ,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,NOTCH1 Antibody,158,13892,NOTCH1 Antibody,NOTCH1 P2462fs*15 ,"[{'id': 4206, 'pubMedId': 20393564, 'title': 'Therapeutic antibody targeting of individual Notch receptors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20393564'}]",,07/13/2017
0,07/13/2017,NOTCH1 Inhibitor,159,13893,NOTCH1 Inhibitor,NOTCH1 Q2440*,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,NOTCH Inhibitor (Pan),156,13894,NOTCH Inhibitor (Pan),NOTCH1 Q2440*,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,NOTCH1 Antibody,158,13895,NOTCH1 Antibody,NOTCH1 Q2440*,"[{'id': 4206, 'pubMedId': 20393564, 'title': 'Therapeutic antibody targeting of individual Notch receptors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20393564'}]",,07/13/2017
0,07/13/2017,Gamma secretase inhibitor,99,13896,Gamma secretase inhibitor,NOTCH1 Q2440*,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}, {'id': 2522, 'pubMedId': 17317574, 'title': 'Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17317574'}]",,07/13/2017
0,07/13/2017,Gamma secretase inhibitor,99,13897,Gamma secretase inhibitor,NOTCH1 Q2459*,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}, {'id': 2522, 'pubMedId': 17317574, 'title': 'Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17317574'}]",,07/13/2017
0,07/13/2017,NOTCH1 Antibody,158,13898,NOTCH1 Antibody,NOTCH1 Q2459*,"[{'id': 4206, 'pubMedId': 20393564, 'title': 'Therapeutic antibody targeting of individual Notch receptors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20393564'}]",,07/13/2017
0,07/13/2017,NOTCH1 Inhibitor,159,13899,NOTCH1 Inhibitor,NOTCH1 Q2459*,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,NOTCH Inhibitor (Pan),156,13900,NOTCH Inhibitor (Pan),NOTCH1 Q2459*,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,Gamma secretase inhibitor,99,13901,Gamma secretase inhibitor,NOTCH1 R1598P,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}, {'id': 2522, 'pubMedId': 17317574, 'title': 'Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17317574'}]",,07/13/2017
0,07/13/2017,NOTCH Inhibitor (Pan),156,13902,NOTCH Inhibitor (Pan),NOTCH1 R1598P,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,NOTCH1 Antibody,158,13903,NOTCH1 Antibody,NOTCH1 R1598P,"[{'id': 4206, 'pubMedId': 20393564, 'title': 'Therapeutic antibody targeting of individual Notch receptors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20393564'}]",,07/13/2017
0,07/13/2017,NOTCH1 Inhibitor,159,13904,NOTCH1 Inhibitor,NOTCH1 R1598P,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,NOTCH1 Antibody,158,13905,NOTCH1 Antibody,NOTCH1 S2467*,"[{'id': 4206, 'pubMedId': 20393564, 'title': 'Therapeutic antibody targeting of individual Notch receptors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20393564'}]",,07/13/2017
0,07/13/2017,NOTCH Inhibitor (Pan),156,13906,NOTCH Inhibitor (Pan),NOTCH1 S2467*,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,NOTCH1 Inhibitor,159,13907,NOTCH1 Inhibitor,NOTCH1 S2467*,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,Gamma secretase inhibitor,99,13908,Gamma secretase inhibitor,NOTCH1 S2467*,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}, {'id': 2522, 'pubMedId': 17317574, 'title': 'Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17317574'}]",,07/13/2017
0,07/13/2017,NOTCH1 Antibody,158,13909,NOTCH1 Antibody,NOTCH1 S2467fs*11,"[{'id': 4206, 'pubMedId': 20393564, 'title': 'Therapeutic antibody targeting of individual Notch receptors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20393564'}]",,07/13/2017
0,07/13/2017,NOTCH1 Inhibitor,159,13910,NOTCH1 Inhibitor,NOTCH1 S2467fs*11,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,NOTCH Inhibitor (Pan),156,13911,NOTCH Inhibitor (Pan),NOTCH1 S2467fs*11,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,Gamma secretase inhibitor,99,13912,Gamma secretase inhibitor,NOTCH1 S2467fs*11,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}, {'id': 2522, 'pubMedId': 17317574, 'title': 'Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17317574'}]",,07/13/2017
0,07/13/2017,NOTCH1 Antibody,158,13913,NOTCH1 Antibody,NOTCH1 V1576E ,"[{'id': 4206, 'pubMedId': 20393564, 'title': 'Therapeutic antibody targeting of individual Notch receptors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20393564'}]",,07/13/2017
0,07/13/2017,NOTCH Inhibitor (Pan),156,13914,NOTCH Inhibitor (Pan),NOTCH1 V1576E ,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,Gamma secretase inhibitor,99,13915,Gamma secretase inhibitor,NOTCH1 V1576E ,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}, {'id': 2522, 'pubMedId': 17317574, 'title': 'Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17317574'}]",,07/13/2017
0,07/13/2017,NOTCH1 Inhibitor,159,13916,NOTCH1 Inhibitor,NOTCH1 V1576E ,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,Gamma secretase inhibitor,99,13917,Gamma secretase inhibitor,NOTCH1 V1676D,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}, {'id': 2522, 'pubMedId': 17317574, 'title': 'Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17317574'}]",,07/13/2017
0,07/13/2017,NOTCH Inhibitor (Pan),156,13918,NOTCH Inhibitor (Pan),NOTCH1 V1676D,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,NOTCH1 Antibody,158,13919,NOTCH1 Antibody,NOTCH1 V1676D,"[{'id': 4206, 'pubMedId': 20393564, 'title': 'Therapeutic antibody targeting of individual Notch receptors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20393564'}]",,07/13/2017
0,07/13/2017,NOTCH1 Inhibitor,159,13920,NOTCH1 Inhibitor,NOTCH1 V1676D,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,NOTCH Inhibitor (Pan),156,13921,NOTCH Inhibitor (Pan),NOTCH1 V2443fs*35,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,NOTCH1 Antibody,158,13922,NOTCH1 Antibody,NOTCH1 V2443fs*35,"[{'id': 4206, 'pubMedId': 20393564, 'title': 'Therapeutic antibody targeting of individual Notch receptors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20393564'}]",,07/13/2017
0,07/13/2017,Gamma secretase inhibitor,99,13923,Gamma secretase inhibitor,NOTCH1 V2443fs*35,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}, {'id': 2522, 'pubMedId': 17317574, 'title': 'Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17317574'}]",,07/13/2017
0,07/13/2017,NOTCH1 Inhibitor,159,13924,NOTCH1 Inhibitor,NOTCH1 V2443fs*35,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,NOTCH1 Antibody,158,13925,NOTCH1 Antibody,NOTCH1 S2449fs,"[{'id': 4206, 'pubMedId': 20393564, 'title': 'Therapeutic antibody targeting of individual Notch receptors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20393564'}]",,07/13/2017
0,07/13/2017,Gamma secretase inhibitor,99,13926,Gamma secretase inhibitor,NOTCH1 S2449fs,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}, {'id': 2522, 'pubMedId': 17317574, 'title': 'Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17317574'}]",,07/13/2017
0,07/13/2017,NOTCH Inhibitor (Pan),156,13927,NOTCH Inhibitor (Pan),NOTCH1 S2449fs,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,NOTCH1 Inhibitor,159,13928,NOTCH1 Inhibitor,NOTCH1 S2449fs,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,Gamma secretase inhibitor,99,13929,Gamma secretase inhibitor,NOTCH1 I1680S,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}, {'id': 2522, 'pubMedId': 17317574, 'title': 'Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17317574'}]",,07/13/2017
0,07/13/2017,NOTCH1 Inhibitor,159,13930,NOTCH1 Inhibitor,NOTCH1 I1680S,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,NOTCH1 Antibody,158,13931,NOTCH1 Antibody,NOTCH1 I1680S,"[{'id': 4206, 'pubMedId': 20393564, 'title': 'Therapeutic antibody targeting of individual Notch receptors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20393564'}]",,07/13/2017
0,07/13/2017,NOTCH Inhibitor (Pan),156,13932,NOTCH Inhibitor (Pan),NOTCH1 I1680S,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,NOTCH1 Inhibitor,159,13933,NOTCH1 Inhibitor,NOTCH1 A1552V,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,NOTCH1 Antibody,158,13934,NOTCH1 Antibody,NOTCH1 A1552V,"[{'id': 4206, 'pubMedId': 20393564, 'title': 'Therapeutic antibody targeting of individual Notch receptors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20393564'}]",,07/13/2017
0,07/13/2017,Gamma secretase inhibitor,99,13935,Gamma secretase inhibitor,NOTCH1 A1552V,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}, {'id': 2522, 'pubMedId': 17317574, 'title': 'Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17317574'}]",,07/13/2017
0,07/13/2017,NOTCH Inhibitor (Pan),156,13936,NOTCH Inhibitor (Pan),NOTCH1 A1552V,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,NOTCH1 Antibody,158,13937,NOTCH1 Antibody,NOTCH1 A1570G,"[{'id': 4206, 'pubMedId': 20393564, 'title': 'Therapeutic antibody targeting of individual Notch receptors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20393564'}]",,07/13/2017
0,07/13/2017,NOTCH Inhibitor (Pan),156,13938,NOTCH Inhibitor (Pan),NOTCH1 A1570G,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,Gamma secretase inhibitor,99,13939,Gamma secretase inhibitor,NOTCH1 A1570G,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}, {'id': 2522, 'pubMedId': 17317574, 'title': 'Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17317574'}]",,07/13/2017
0,07/13/2017,NOTCH1 Inhibitor,159,13940,NOTCH1 Inhibitor,NOTCH1 A1570G,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,Gamma secretase inhibitor,99,13941,Gamma secretase inhibitor,NOTCH1 R1627L,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}, {'id': 2522, 'pubMedId': 17317574, 'title': 'Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17317574'}]",,07/13/2017
0,07/13/2017,NOTCH1 Antibody,158,13942,NOTCH1 Antibody,NOTCH1 R1627L,"[{'id': 4206, 'pubMedId': 20393564, 'title': 'Therapeutic antibody targeting of individual Notch receptors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20393564'}]",,07/13/2017
0,07/13/2017,NOTCH1 Inhibitor,159,13943,NOTCH1 Inhibitor,NOTCH1 R1627L,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,NOTCH Inhibitor (Pan),156,13944,NOTCH Inhibitor (Pan),NOTCH1 R1627L,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,Gamma secretase inhibitor,99,13945,Gamma secretase inhibitor,NOTCH1 V1575A,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}, {'id': 2522, 'pubMedId': 17317574, 'title': 'Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17317574'}]",,07/13/2017
0,07/13/2017,NOTCH Inhibitor (Pan),156,13946,NOTCH Inhibitor (Pan),NOTCH1 V1575A,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,NOTCH1 Inhibitor,159,13947,NOTCH1 Inhibitor,NOTCH1 V1575A,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,NOTCH1 Antibody,158,13948,NOTCH1 Antibody,NOTCH1 V1575A,"[{'id': 4206, 'pubMedId': 20393564, 'title': 'Therapeutic antibody targeting of individual Notch receptors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20393564'}]",,07/13/2017
0,07/13/2017,NOTCH1 Antibody,158,13949,NOTCH1 Antibody,NOTCH1 V1599M,"[{'id': 4206, 'pubMedId': 20393564, 'title': 'Therapeutic antibody targeting of individual Notch receptors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20393564'}]",,07/13/2017
0,07/13/2017,NOTCH Inhibitor (Pan),156,13950,NOTCH Inhibitor (Pan),NOTCH1 V1599M,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,Gamma secretase inhibitor,99,13951,Gamma secretase inhibitor,NOTCH1 V1599M,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}, {'id': 2522, 'pubMedId': 17317574, 'title': 'Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17317574'}]",,07/13/2017
0,07/13/2017,NOTCH1 Inhibitor,159,13952,NOTCH1 Inhibitor,NOTCH1 V1599M,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,NOTCH Inhibitor (Pan),156,13953,NOTCH Inhibitor (Pan),NOTCH1 R1683W,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,NOTCH1 Inhibitor,159,13954,NOTCH1 Inhibitor,NOTCH1 R1683W,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,NOTCH1 Antibody,158,13955,NOTCH1 Antibody,NOTCH1 R1683W,"[{'id': 4206, 'pubMedId': 20393564, 'title': 'Therapeutic antibody targeting of individual Notch receptors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20393564'}]",,07/13/2017
0,07/13/2017,Gamma secretase inhibitor,99,13956,Gamma secretase inhibitor,NOTCH1 R1683W,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}, {'id': 2522, 'pubMedId': 17317574, 'title': 'Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17317574'}]",,07/13/2017
0,07/13/2017,Gamma secretase inhibitor,99,13961,Gamma secretase inhibitor,NOTCH1 amp,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}, {'id': 2522, 'pubMedId': 17317574, 'title': 'Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17317574'}]",,07/13/2017
0,07/13/2017,NOTCH Inhibitor (Pan),156,13962,NOTCH Inhibitor (Pan),NOTCH1 amp,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,NOTCH1 Antibody,158,13963,NOTCH1 Antibody,NOTCH1 amp,"[{'id': 4206, 'pubMedId': 20393564, 'title': 'Therapeutic antibody targeting of individual Notch receptors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20393564'}]",,07/13/2017
0,07/13/2017,NOTCH1 Inhibitor,159,13964,NOTCH1 Inhibitor,NOTCH1 amp,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,Gamma secretase inhibitor,99,13997,Gamma secretase inhibitor,NOTCH1 over exp,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}, {'id': 2522, 'pubMedId': 17317574, 'title': 'Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17317574'}]",,07/13/2017
0,07/13/2017,NOTCH Inhibitor (Pan),156,13998,NOTCH Inhibitor (Pan),NOTCH1 over exp,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,NOTCH1 Antibody,158,13999,NOTCH1 Antibody,NOTCH1 over exp,"[{'id': 4206, 'pubMedId': 20393564, 'title': 'Therapeutic antibody targeting of individual Notch receptors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20393564'}]",,07/13/2017
0,07/13/2017,NOTCH1 Inhibitor,159,14000,NOTCH1 Inhibitor,NOTCH1 over exp,"[{'id': 2498, 'pubMedId': 24781550, 'title': 'Therapeutic modulation of Notch signalling--are we there yet?', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24781550'}]",,07/13/2017
0,07/13/2017,,14001,GSK3052230,FGFR1 amp,"[{'id': 9409, 'pubMedId': 23536011, 'title': 'Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23536011'}, {'id': 9410, 'pubMedId': 27223434, 'title': 'Inhibition of FGF/FGFR autocrine signaling in mesothelioma with the FGF ligand trap, FP-1039/GSK3052230.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27223434'}]",2899,GSK3052230,07/13/2017
0,07/13/2017,,14002,GSK3052230,FGFR1 over exp,"[{'id': 9409, 'pubMedId': 23536011, 'title': 'Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23536011'}, {'id': 9410, 'pubMedId': 27223434, 'title': 'Inhibition of FGF/FGFR autocrine signaling in mesothelioma with the FGF ligand trap, FP-1039/GSK3052230.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27223434'}]",2899,GSK3052230,07/13/2017
0,07/13/2017,,14003,GSK3052230,FGFR2 over exp,"[{'id': 9410, 'pubMedId': 27223434, 'title': 'Inhibition of FGF/FGFR autocrine signaling in mesothelioma with the FGF ligand trap, FP-1039/GSK3052230.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27223434'}]",2899,GSK3052230,07/13/2017
0,07/13/2017,,14004,GSK3052230,FGFR2 S252W,"[{'id': 9409, 'pubMedId': 23536011, 'title': 'Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23536011'}]",2899,GSK3052230,07/13/2017
0,07/20/2017,HER2 (ERBB2) Vaccine,251,14006,HER2 (ERBB2) Vaccine,ERBB2 amp,"[{'id': 4894, 'pubMedId': 18536917, 'title': 'The E75 HER2/neu peptide vaccine.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18536917'}]",,07/20/2017
0,07/20/2017,HGF Antibody,252,14009,HGF Antibody,MET amp,"[{'id': 2627, 'pubMedId': 24959084, 'title': 'The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24959084'}]",,07/20/2017
0,07/20/2017,HGF Antibody,252,14012,HGF Antibody,MET over exp,"[{'id': 2627, 'pubMedId': 24959084, 'title': 'The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24959084'}]",,07/20/2017
0,07/25/2017,HER inhibitor (Pan),105,14016,HER inhibitor (Pan),ERBB2 over exp,"[{'id': 2691, 'pubMedId': 25674538, 'title': 'The Potential of panHER Inhibition in Cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25674538'}]",,07/25/2017
0,07/25/2017,HER2 (ERBB2) Antibody,242,14017,HER2 (ERBB2) Antibody,ERBB2 over exp,"[{'id': 9557, 'pubMedId': 28520362, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28520362'}, {'id': 9558, 'pubMedId': 28520364, 'title': '', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28520364'}, {'id': 9559, 'pubMedId': 25398397, 'title': 'T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25398397'}]",,07/25/2017
0,07/25/2017,HER2 (ERBB2) Vaccine,251,14018,HER2 (ERBB2) Vaccine,ERBB2 over exp,"[{'id': 4894, 'pubMedId': 18536917, 'title': 'The E75 HER2/neu peptide vaccine.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18536917'}]",,07/25/2017
0,07/25/2017,HER2 Inhibitor,106,14019,HER2 Inhibitor,ERBB2 over exp,"[{'id': 9560, 'pubMedId': 26260909, 'title': 'Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26260909'}, {'id': 9561, 'pubMedId': 24367169, 'title': 'Lapatinib: new opportunities for management of breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24367169'}]",,07/25/2017
0,07/26/2017,HER2 (ERBB2) Immune Cell Therapy,250,14020,HER2 (ERBB2) Immune Cell Therapy,ERBB2 over exp,"[{'id': 9563, 'pubMedId': 25800760, 'title': 'Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25800760'}, {'id': 9587, 'pubMedId': 28710747, 'title': 'Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28710747'}, {'id': 9588, 'pubMedId': 28284008, 'title': 'Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28284008'}]",,07/26/2017
0,07/26/2017,HER2 (ERBB2) Immune Cell Therapy,250,14021,HER2 (ERBB2) Immune Cell Therapy,ERBB2 amp,"[{'id': 9588, 'pubMedId': 28284008, 'title': 'Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28284008'}]",,07/26/2017
0,07/28/2017,CTNNB1 Inhibitor,60,14022,CTNNB1 Inhibitor,APC P1439fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,07/28/2017
0,07/28/2017,Tankyrase Inhibitor,215,14023,Tankyrase Inhibitor,APC P1439fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,07/28/2017
0,07/28/2017,p53 Gene Therapy,167,14024,p53 Gene Therapy,TP53 L111fs,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,07/28/2017
0,08/16/2017,Akt Inhibitor (Pan),4,14054,Akt Inhibitor (Pan),PIK3CA K944N,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/16/2017
0,08/16/2017,Akt1 Inhibitor,6,14055,Akt1 Inhibitor,PIK3CA K944N,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/16/2017
0,08/16/2017,Akt2 Inhibitor,7,14056,Akt2 Inhibitor,PIK3CA K944N,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/16/2017
0,08/16/2017,Akt3 Inhibitor,8,14057,Akt3 Inhibitor,PIK3CA K944N,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/16/2017
0,08/16/2017,mTOR Inhibitor,152,14058,mTOR Inhibitor,PIK3CA K944N,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/16/2017
0,08/16/2017,mTORC1 Inhibitor,153,14059,mTORC1 Inhibitor,PIK3CA K944N,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/16/2017
0,08/16/2017,mTORC2 Inhibitor,154,14060,mTORC2 Inhibitor,PIK3CA K944N,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/16/2017
0,08/16/2017,PI3K Inhibitor (Pan),181,14061,PI3K Inhibitor (Pan),PIK3CA K944N,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/16/2017
0,08/16/2017,PIK3CA inhibitor,182,14062,PIK3CA inhibitor,PIK3CA K944N,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/16/2017
0,08/16/2017,Akt Inhibitor (Pan),4,14063,Akt Inhibitor (Pan),PIK3CA V955G,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/16/2017
0,08/16/2017,Akt1 Inhibitor,6,14064,Akt1 Inhibitor,PIK3CA V955G,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/16/2017
0,08/16/2017,Akt2 Inhibitor,7,14065,Akt2 Inhibitor,PIK3CA V955G,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/16/2017
0,08/16/2017,Akt3 Inhibitor,8,14066,Akt3 Inhibitor,PIK3CA V955G,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/16/2017
0,08/16/2017,mTOR Inhibitor,152,14067,mTOR Inhibitor,PIK3CA V955G,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/16/2017
0,08/16/2017,mTORC1 Inhibitor,153,14068,mTORC1 Inhibitor,PIK3CA V955G,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/16/2017
0,08/16/2017,mTORC2 Inhibitor,154,14069,mTORC2 Inhibitor,PIK3CA V955G,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/16/2017
0,08/16/2017,PI3K Inhibitor (Pan),181,14070,PI3K Inhibitor (Pan),PIK3CA V955G,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/16/2017
0,08/16/2017,PIK3CA inhibitor,182,14071,PIK3CA inhibitor,PIK3CA V955G,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/16/2017
0,08/16/2017,Akt Inhibitor (Pan),4,14072,Akt Inhibitor (Pan),PIK3CA V955I,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/16/2017
0,08/16/2017,Akt1 Inhibitor,6,14073,Akt1 Inhibitor,PIK3CA V955I,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/16/2017
0,08/16/2017,Akt2 Inhibitor,7,14074,Akt2 Inhibitor,PIK3CA V955I,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/16/2017
0,08/16/2017,Akt3 Inhibitor,8,14075,Akt3 Inhibitor,PIK3CA V955I,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/16/2017
0,08/16/2017,mTOR Inhibitor,152,14076,mTOR Inhibitor,PIK3CA V955I,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/16/2017
0,08/16/2017,mTORC1 Inhibitor,153,14077,mTORC1 Inhibitor,PIK3CA V955I,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/16/2017
0,08/16/2017,mTORC2 Inhibitor,154,14078,mTORC2 Inhibitor,PIK3CA V955I,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/16/2017
0,08/16/2017,PI3K Inhibitor (Pan),181,14079,PI3K Inhibitor (Pan),PIK3CA V955I,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/16/2017
0,08/16/2017,PIK3CA inhibitor,182,14080,PIK3CA inhibitor,PIK3CA V955I,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/16/2017
0,08/16/2017,Akt Inhibitor (Pan),4,14081,Akt Inhibitor (Pan),PIK3CA K966E,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/16/2017
0,08/16/2017,Akt1 Inhibitor,6,14082,Akt1 Inhibitor,PIK3CA K966E,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/16/2017
0,08/16/2017,Akt2 Inhibitor,7,14083,Akt2 Inhibitor,PIK3CA K966E,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/16/2017
0,08/16/2017,Akt3 Inhibitor,8,14084,Akt3 Inhibitor,PIK3CA K966E,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/16/2017
0,08/16/2017,mTOR Inhibitor,152,14085,mTOR Inhibitor,PIK3CA K966E,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/16/2017
0,08/16/2017,mTORC1 Inhibitor,153,14086,mTORC1 Inhibitor,PIK3CA K966E,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/16/2017
0,08/16/2017,mTORC2 Inhibitor,154,14087,mTORC2 Inhibitor,PIK3CA K966E,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/16/2017
0,08/16/2017,PI3K Inhibitor (Pan),181,14088,PI3K Inhibitor (Pan),PIK3CA K966E,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/16/2017
0,08/16/2017,PIK3CA inhibitor,182,14089,PIK3CA inhibitor,PIK3CA K966E,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/16/2017
0,08/17/2017,Akt Inhibitor (Pan),4,14090,Akt Inhibitor (Pan),PIK3CA F930S,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/17/2017
0,08/17/2017,Akt1 Inhibitor,6,14091,Akt1 Inhibitor,PIK3CA F930S,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/17/2017
0,08/17/2017,Akt2 Inhibitor,7,14092,Akt2 Inhibitor,PIK3CA F930S,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/17/2017
0,08/17/2017,Akt3 Inhibitor,8,14093,Akt3 Inhibitor,PIK3CA F930S,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/17/2017
0,08/17/2017,mTOR Inhibitor,152,14094,mTOR Inhibitor,PIK3CA F930S,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/17/2017
0,08/17/2017,mTORC1 Inhibitor,153,14095,mTORC1 Inhibitor,PIK3CA F930S,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/17/2017
0,08/17/2017,mTORC2 Inhibitor,154,14096,mTORC2 Inhibitor,PIK3CA F930S,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/17/2017
0,08/17/2017,PI3K Inhibitor (Pan),181,14097,PI3K Inhibitor (Pan),PIK3CA F930S,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/17/2017
0,08/17/2017,PIK3CA inhibitor,182,14098,PIK3CA inhibitor,PIK3CA F930S,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/17/2017
0,08/17/2017,Akt Inhibitor (Pan),4,14099,Akt Inhibitor (Pan),PIK3CA V952A,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/17/2017
0,08/17/2017,Akt1 Inhibitor,6,14100,Akt1 Inhibitor,PIK3CA V952A,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/17/2017
0,08/17/2017,Akt2 Inhibitor,7,14101,Akt2 Inhibitor,PIK3CA V952A,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/17/2017
0,08/17/2017,Akt3 Inhibitor,8,14102,Akt3 Inhibitor,PIK3CA V952A,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/17/2017
0,08/17/2017,mTOR Inhibitor,152,14103,mTOR Inhibitor,PIK3CA V952A,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/17/2017
0,08/17/2017,mTORC1 Inhibitor,153,14104,mTORC1 Inhibitor,PIK3CA V952A,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/17/2017
0,08/17/2017,mTORC2 Inhibitor,154,14105,mTORC2 Inhibitor,PIK3CA V952A,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/17/2017
0,08/17/2017,PI3K Inhibitor (Pan),181,14106,PI3K Inhibitor (Pan),PIK3CA V952A,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/17/2017
0,08/17/2017,PIK3CA inhibitor,182,14107,PIK3CA inhibitor,PIK3CA V952A,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/17/2017
0,08/17/2017,Akt Inhibitor (Pan),4,14108,Akt Inhibitor (Pan),PIK3CA L938*,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/17/2017
0,08/17/2017,Akt1 Inhibitor,6,14109,Akt1 Inhibitor,PIK3CA L938*,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/17/2017
0,08/17/2017,Akt2 Inhibitor,7,14110,Akt2 Inhibitor,PIK3CA L938*,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/17/2017
0,08/17/2017,Akt3 Inhibitor,8,14111,Akt3 Inhibitor,PIK3CA L938*,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/17/2017
0,08/17/2017,mTOR Inhibitor,152,14112,mTOR Inhibitor,PIK3CA L938*,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/17/2017
0,08/17/2017,mTORC1 Inhibitor,153,14113,mTORC1 Inhibitor,PIK3CA L938*,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/17/2017
0,08/17/2017,mTORC2 Inhibitor,154,14114,mTORC2 Inhibitor,PIK3CA L938*,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/17/2017
0,08/17/2017,PI3K Inhibitor (Pan),181,14115,PI3K Inhibitor (Pan),PIK3CA L938*,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/17/2017
0,08/17/2017,PIK3CA inhibitor,182,14116,PIK3CA inhibitor,PIK3CA L938*,"[{'id': 1038, 'pubMedId': 23248156, 'title': 'PIK3CA mutations in advanced cancers: characteristics and outcomes.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23248156'}]",,08/17/2017
0,08/17/2017,,14294,LY3009120,BRAF G464E,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14295,MEK1 Inhibitor,BRAF G469A,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14296,LY3009120,BRAF G469A,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14297,MEK2 Inhibitor,BRAF G469A,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14298,MEK inhibitor (Pan),BRAF G469A,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14299,MEK2 Inhibitor,BRAF K601E,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14300,MEK1 Inhibitor,BRAF K601E,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14301,MEK inhibitor (Pan),BRAF K601E,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14302,LY3009120,BRAF K601E,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14303,MEK2 Inhibitor,BRAF L597V,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14304,LY3009120,BRAF L597V,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14305,MEK1 Inhibitor,BRAF L597V,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14306,MEK inhibitor (Pan),BRAF L597V,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14307,MEK inhibitor (Pan),BRAF G464V,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14308,LY3009120,BRAF G464V,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14309,MEK2 Inhibitor,BRAF G464V,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14310,MEK1 Inhibitor,BRAF G464V,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14311,MEK2 Inhibitor,BRAF G469E,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14312,MEK inhibitor (Pan),BRAF G469E,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14313,LY3009120,BRAF G469E,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14314,MEK1 Inhibitor,BRAF G469E,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14315,MEK inhibitor (Pan),BRAF G466V,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14316,MEK2 Inhibitor,BRAF G466V,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14317,MEK1 Inhibitor,BRAF G466V,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14318,LY3009120,BRAF G466V,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14319,MEK inhibitor (Pan),BRAF act mut,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14320,LY3009120,BRAF act mut,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14321,MEK1 Inhibitor,BRAF act mut,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14322,MEK2 Inhibitor,BRAF act mut,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14323,MEK1 Inhibitor,BRAF R347*,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14324,MEK2 Inhibitor,BRAF R347*,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14325,MEK inhibitor (Pan),BRAF R347*,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14326,LY3009120,BRAF R347*,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14327,MEK1 Inhibitor,BRAF Y472C,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14328,MEK inhibitor (Pan),BRAF Y472C,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14329,LY3009120,BRAF Y472C,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14330,MEK2 Inhibitor,BRAF Y472C,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14351,MEK2 Inhibitor,BRAF L597R,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14352,MEK inhibitor (Pan),BRAF L597R,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14353,LY3009120,BRAF L597R,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14354,MEK1 Inhibitor,BRAF L597R,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14355,LY3009120,BRAF L597Q,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14356,MEK1 Inhibitor,BRAF L597Q,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14357,MEK2 Inhibitor,BRAF L597Q,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14358,MEK inhibitor (Pan),BRAF L597Q,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14359,MEK1 Inhibitor,BRAF L597S,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14360,MEK2 Inhibitor,BRAF L597S,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14361,LY3009120,BRAF L597S,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14362,MEK inhibitor (Pan),BRAF L597S,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14371,MEK1 Inhibitor,BRAF G469V,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14372,MEK2 Inhibitor,BRAF G469V,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14373,MEK inhibitor (Pan),BRAF G469V,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14374,LY3009120,BRAF G469V,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14379,MEK1 Inhibitor,BRAF T241P,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14380,MEK2 Inhibitor,BRAF T241P,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14381,LY3009120,BRAF T241P,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14382,MEK inhibitor (Pan),BRAF T241P,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14383,MEK2 Inhibitor,BRAF E586K,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14384,MEK1 Inhibitor,BRAF E586K,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14385,LY3009120,BRAF E586K,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14386,MEK inhibitor (Pan),BRAF E586K,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14387,MEK inhibitor (Pan),BRAF G596R,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14388,LY3009120,BRAF G596R,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14389,MEK1 Inhibitor,BRAF G596R,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14390,MEK2 Inhibitor,BRAF G596R,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14395,MEK2 Inhibitor,BRAF K601N,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14396,MEK inhibitor (Pan),BRAF K601N,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14397,MEK1 Inhibitor,BRAF K601N,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14398,LY3009120,BRAF K601N,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14399,MEK inhibitor (Pan),BRAF K601I,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14400,LY3009120,BRAF K601I,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14401,MEK2 Inhibitor,BRAF K601I,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14402,MEK1 Inhibitor,BRAF K601I,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14403,MEK inhibitor (Pan),BRAF T599R,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14404,MEK2 Inhibitor,BRAF T599R,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14405,LY3009120,BRAF T599R,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14406,MEK1 Inhibitor,BRAF T599R,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14407,MEK inhibitor (Pan),BRAF K601Q,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14408,LY3009120,BRAF K601Q,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14409,MEK2 Inhibitor,BRAF K601Q,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14410,MEK1 Inhibitor,BRAF K601Q,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14411,MEK2 Inhibitor,BRAF G466R,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14412,MEK1 Inhibitor,BRAF G466R,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14413,LY3009120,BRAF G466R,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14414,MEK inhibitor (Pan),BRAF G466R,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14415,MEK1 Inhibitor,BRAF L505H,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14416,MEK2 Inhibitor,BRAF L505H,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14417,MEK inhibitor (Pan),BRAF L505H,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14418,LY3009120,BRAF L505H,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14419,MEK1 Inhibitor,BRAF A598_T599insV,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14420,LY3009120,BRAF A598_T599insV,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14421,MEK inhibitor (Pan),BRAF A598_T599insV,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14422,MEK2 Inhibitor,BRAF A598_T599insV,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14423,MEK inhibitor (Pan),BRAF A598V,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14424,MEK1 Inhibitor,BRAF A598V,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14425,LY3009120,BRAF A598V,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14426,MEK2 Inhibitor,BRAF A598V,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14427,LY3009120,BRAF G464R,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14428,MEK2 Inhibitor,BRAF G464R,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14429,MEK1 Inhibitor,BRAF G464R,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14430,MEK inhibitor (Pan),BRAF G464R,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14431,MEK inhibitor (Pan),BRAF G469S,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14432,LY3009120,BRAF G469S,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14433,MEK2 Inhibitor,BRAF G469S,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14434,MEK1 Inhibitor,BRAF G469S,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14439,LY3009120,BRAF T599I,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14440,MEK inhibitor (Pan),BRAF T599I,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14441,MEK2 Inhibitor,BRAF T599I,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14442,MEK1 Inhibitor,BRAF T599I,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14443,MEK1 Inhibitor,BRAF T599_V600insT,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14444,MEK2 Inhibitor,BRAF T599_V600insT,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14445,MEK inhibitor (Pan),BRAF T599_V600insT,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14446,LY3009120,BRAF T599_V600insT,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14447,MEK2 Inhibitor,BRAF T599_V600insTT,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14448,MEK1 Inhibitor,BRAF T599_V600insTT,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14449,MEK inhibitor (Pan),BRAF T599_V600insTT,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14450,LY3009120,BRAF T599_V600insTT,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14451,MEK1 Inhibitor,BRAF V471F,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14452,LY3009120,BRAF V471F,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14453,MEK inhibitor (Pan),BRAF V471F,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14454,MEK2 Inhibitor,BRAF V471F,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14455,MEK inhibitor (Pan),BRAF V600delinsYM,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14456,MEK1 Inhibitor,BRAF V600delinsYM,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14457,LY3009120,BRAF V600delinsYM,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14458,MEK2 Inhibitor,BRAF V600delinsYM,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14463,MEK inhibitor (Pan),BRAF G466A,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14464,MEK1 Inhibitor,BRAF G466A,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14465,MEK2 Inhibitor,BRAF G466A,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14466,LY3009120,BRAF G466A,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14467,MEK2 Inhibitor,BRAF G466E,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14468,MEK inhibitor (Pan),BRAF G466E,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14469,MEK1 Inhibitor,BRAF G466E,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14470,LY3009120,BRAF G466E,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14471,MEK1 Inhibitor,BRAF I463S,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14472,MEK2 Inhibitor,BRAF I463S,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14473,LY3009120,BRAF I463S,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14474,MEK inhibitor (Pan),BRAF I463S,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14475,LY3009120,BRAF N581S,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14476,MEK2 Inhibitor,BRAF N581S,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14477,MEK1 Inhibitor,BRAF N581S,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14478,MEK inhibitor (Pan),BRAF N581S,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14479,MEK1 Inhibitor,BRAF R462I,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14480,MEK2 Inhibitor,BRAF R462I,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14481,LY3009120,BRAF R462I,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14482,MEK inhibitor (Pan),BRAF R462I,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14487,MEK1 Inhibitor,BRAF V600_K601delinsE,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14488,LY3009120,BRAF V600_K601delinsE,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14489,MEK inhibitor (Pan),BRAF V600_K601delinsE,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14490,MEK2 Inhibitor,BRAF V600_K601delinsE,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14491,MEK inhibitor (Pan),BRAF K601T,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14492,MEK1 Inhibitor,BRAF K601T,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14493,LY3009120,BRAF K601T,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14494,MEK2 Inhibitor,BRAF K601T,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14495,MEK1 Inhibitor,BRAF G469R,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14496,MEK inhibitor (Pan),BRAF G469R,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14497,LY3009120,BRAF G469R,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14498,MEK2 Inhibitor,BRAF G469R,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14499,MEK2 Inhibitor,BRAF D594A,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14500,MEK1 Inhibitor,BRAF D594A,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14501,MEK inhibitor (Pan),BRAF D594A,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14503,MEK inhibitor (Pan),BRAF G469L,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14504,LY3009120,BRAF G469L,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14505,MEK1 Inhibitor,BRAF G469L,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14506,MEK2 Inhibitor,BRAF G469L,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14511,LY3009120,BRAF L597P,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14512,MEK2 Inhibitor,BRAF L597P,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14513,MEK inhibitor (Pan),BRAF L597P,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14514,MEK1 Inhibitor,BRAF L597P,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14515,MEK1 Inhibitor,BRAF N581I,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14516,LY3009120,BRAF N581I,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14517,MEK inhibitor (Pan),BRAF N581I,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14518,MEK2 Inhibitor,BRAF N581I,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14519,LY3009120,BRAF T599_V600insDFGLAT ,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14520,MEK2 Inhibitor,BRAF T599_V600insDFGLAT ,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14521,MEK inhibitor (Pan),BRAF T599_V600insDFGLAT ,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14522,MEK1 Inhibitor,BRAF T599_V600insDFGLAT ,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14523,LY3009120,BRAF T599_V600insEAT,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14524,MEK2 Inhibitor,BRAF T599_V600insEAT,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14525,MEK1 Inhibitor,BRAF T599_V600insEAT,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14526,MEK inhibitor (Pan),BRAF T599_V600insEAT,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14527,LY3009120,BRAF T599_V600insETT,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14528,MEK2 Inhibitor,BRAF T599_V600insETT,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14529,MEK inhibitor (Pan),BRAF T599_V600insETT,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14530,MEK1 Inhibitor,BRAF T599_V600insETT,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14539,MEK1 Inhibitor,BRAF R506_K507insVLR,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14540,MEK2 Inhibitor,BRAF R506_K507insVLR,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14541,LY3009120,BRAF R506_K507insVLR,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14542,MEK inhibitor (Pan),BRAF R506_K507insVLR,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14547,MEK2 Inhibitor,BRAF N486_P490del,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14548,MEK1 Inhibitor,BRAF N486_P490del,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14549,MEK inhibitor (Pan),BRAF N486_P490del,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14550,LY3009120,BRAF N486_P490del,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14551,MEK1 Inhibitor,BRAF V487_P492delinsA,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14552,LY3009120,BRAF V487_P492delinsA,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14553,MEK2 Inhibitor,BRAF V487_P492delinsA,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14554,MEK inhibitor (Pan),BRAF V487_P492delinsA,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14555,LY3009120,BRAF L485_P490delinsY,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14556,MEK inhibitor (Pan),BRAF L485_P490delinsY,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14557,MEK1 Inhibitor,BRAF L485_P490delinsY,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14558,MEK2 Inhibitor,BRAF L485_P490delinsY,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14559,MEK1 Inhibitor,BRAF L485_P490delinsF,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14560,MEK inhibitor (Pan),BRAF L485_P490delinsF,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14561,MEK2 Inhibitor,BRAF L485_P490delinsF,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14562,LY3009120,BRAF L485_P490delinsF,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14563,MEK inhibitor (Pan),BRAF P490_Q494del,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14564,MEK1 Inhibitor,BRAF P490_Q494del,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14565,MEK2 Inhibitor,BRAF P490_Q494del,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14566,LY3009120,BRAF P490_Q494del,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14567,MEK2 Inhibitor,BRAF T488_P492del,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14568,MEK inhibitor (Pan),BRAF T488_P492del,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14569,MEK1 Inhibitor,BRAF T488_P492del,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14570,LY3009120,BRAF T488_P492del,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,,14571,LY3009120,BRAF T488_Q493delinsK,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14572,MEK2 Inhibitor,BRAF T488_Q493delinsK,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14573,MEK inhibitor (Pan),BRAF T488_Q493delinsK,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14574,MEK1 Inhibitor,BRAF T488_Q493delinsK,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14579,LY3009120,BRAF A728V,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14580,MEK1 Inhibitor,BRAF A728V,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14581,MEK2 Inhibitor,BRAF A728V,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14582,MEK inhibitor (Pan),BRAF A728V,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14591,MEK2 Inhibitor,BRAF F468C,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14592,MEK1 Inhibitor,BRAF F468C,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14593,MEK inhibitor (Pan),BRAF F468C,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14594,LY3009120,BRAF F468C,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14595,MEK1 Inhibitor,BRAF G469del,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14596,MEK2 Inhibitor,BRAF G469del,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14597,LY3009120,BRAF G469del,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14598,MEK inhibitor (Pan),BRAF G469del,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14599,LY3009120,BRAF G596V,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14600,MEK2 Inhibitor,BRAF G596V,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14601,MEK1 Inhibitor,BRAF G596V,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14602,MEK inhibitor (Pan),BRAF G596V,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14607,MEK1 Inhibitor,BRAF K499E,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14608,LY3009120,BRAF K499E,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14609,MEK inhibitor (Pan),BRAF K499E,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14610,MEK2 Inhibitor,BRAF K499E,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14611,MEK2 Inhibitor,BRAF L485_Q494del,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14612,MEK1 Inhibitor,BRAF L485_Q494del,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14613,MEK inhibitor (Pan),BRAF L485_Q494del,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14614,LY3009120,BRAF L485_Q494del,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14615,MEK2 Inhibitor,BRAF L485_P490del,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14616,MEK1 Inhibitor,BRAF L485_P490del,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14617,MEK inhibitor (Pan),BRAF L485_P490del,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14618,LY3009120,BRAF L485_P490del,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14619,MEK1 Inhibitor,BRAF Q257R,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14620,MEK inhibitor (Pan),BRAF Q257R,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14621,LY3009120,BRAF Q257R,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14622,MEK2 Inhibitor,BRAF Q257R,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14623,MEK1 Inhibitor,BRAF S467A,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14624,LY3009120,BRAF S467A,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14625,MEK2 Inhibitor,BRAF S467A,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14626,MEK inhibitor (Pan),BRAF S467A,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14639,MEK2 Inhibitor,BRAF T599dup,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14640,MEK1 Inhibitor,BRAF T599dup,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14641,LY3009120,BRAF T599dup,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14642,MEK inhibitor (Pan),BRAF T599dup,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14643,MEK2 Inhibitor,BRAF A598_T599insARC,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14644,MEK1 Inhibitor,BRAF A598_T599insARC,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14645,LY3009120,BRAF A598_T599insARC,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14646,MEK inhibitor (Pan),BRAF A598_T599insARC,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14647,LY3009120,BRAF L485Y,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14648,MEK2 Inhibitor,BRAF L485Y,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14649,MEK inhibitor (Pan),BRAF L485Y,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14650,MEK1 Inhibitor,BRAF L485Y,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14651,MEK2 Inhibitor,BRAF L485F,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14652,MEK inhibitor (Pan),BRAF L485F,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,,14653,LY3009120,BRAF L485F,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14654,MEK1 Inhibitor,BRAF L485F,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,BRAF Inhibitor,31,14660,BRAF Inhibitor,BRAF V600L,"[{'id': 222, 'pubMedId': 21639808, 'title': 'Improved survival with vemurafenib in melanoma with BRAF V600E mutation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21639808'}, {'id': 467, 'pubMedId': 22608338, 'title': 'Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22608338'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14661,MEK inhibitor (Pan),BRAF V600L,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14662,MEK1 Inhibitor,BRAF V600L,"[{'id': 468, 'pubMedId': 22663011, 'title': 'Improved survival with MEK inhibition in BRAF-mutated melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22663011'}]",,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14663,MEK2 Inhibitor,BRAF V600L,"[{'id': 468, 'pubMedId': 22663011, 'title': 'Improved survival with MEK inhibition in BRAF-mutated melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22663011'}]",,08/17/2017
0,08/17/2017,RAF Inhibitor (Pan),197,14664,RAF Inhibitor (Pan),BRAF V600L,"[{'id': 222, 'pubMedId': 21639808, 'title': 'Improved survival with vemurafenib in melanoma with BRAF V600E mutation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21639808'}, {'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,BRAF Inhibitor,31,14665,BRAF Inhibitor,BRAF V600K,"[{'id': 222, 'pubMedId': 21639808, 'title': 'Improved survival with vemurafenib in melanoma with BRAF V600E mutation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21639808'}, {'id': 467, 'pubMedId': 22608338, 'title': 'Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22608338'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14666,MEK inhibitor (Pan),BRAF V600K,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14667,MEK1 Inhibitor,BRAF V600K,"[{'id': 468, 'pubMedId': 22663011, 'title': 'Improved survival with MEK inhibition in BRAF-mutated melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22663011'}]",,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14668,MEK2 Inhibitor,BRAF V600K,"[{'id': 468, 'pubMedId': 22663011, 'title': 'Improved survival with MEK inhibition in BRAF-mutated melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22663011'}]",,08/17/2017
0,08/17/2017,RAF Inhibitor (Pan),197,14669,RAF Inhibitor (Pan),BRAF V600K,"[{'id': 222, 'pubMedId': 21639808, 'title': 'Improved survival with vemurafenib in melanoma with BRAF V600E mutation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21639808'}, {'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,BRAF Inhibitor,31,14670,BRAF Inhibitor,BRAF V600G,"[{'id': 222, 'pubMedId': 21639808, 'title': 'Improved survival with vemurafenib in melanoma with BRAF V600E mutation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21639808'}, {'id': 467, 'pubMedId': 22608338, 'title': 'Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22608338'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14671,MEK inhibitor (Pan),BRAF V600G,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14672,MEK1 Inhibitor,BRAF V600G,"[{'id': 468, 'pubMedId': 22663011, 'title': 'Improved survival with MEK inhibition in BRAF-mutated melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22663011'}]",,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14673,MEK2 Inhibitor,BRAF V600G,"[{'id': 468, 'pubMedId': 22663011, 'title': 'Improved survival with MEK inhibition in BRAF-mutated melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22663011'}]",,08/17/2017
0,08/17/2017,RAF Inhibitor (Pan),197,14674,RAF Inhibitor (Pan),BRAF V600G,"[{'id': 222, 'pubMedId': 21639808, 'title': 'Improved survival with vemurafenib in melanoma with BRAF V600E mutation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21639808'}, {'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,BRAF Inhibitor,31,14675,BRAF Inhibitor,BRAF V600E/K,"[{'id': 222, 'pubMedId': 21639808, 'title': 'Improved survival with vemurafenib in melanoma with BRAF V600E mutation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21639808'}, {'id': 467, 'pubMedId': 22608338, 'title': 'Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22608338'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14676,MEK inhibitor (Pan),BRAF V600E/K,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14677,MEK1 Inhibitor,BRAF V600E/K,"[{'id': 468, 'pubMedId': 22663011, 'title': 'Improved survival with MEK inhibition in BRAF-mutated melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22663011'}]",,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14678,MEK2 Inhibitor,BRAF V600E/K,"[{'id': 468, 'pubMedId': 22663011, 'title': 'Improved survival with MEK inhibition in BRAF-mutated melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22663011'}]",,08/17/2017
0,08/17/2017,RAF Inhibitor (Pan),197,14679,RAF Inhibitor (Pan),BRAF V600E/K,"[{'id': 222, 'pubMedId': 21639808, 'title': 'Improved survival with vemurafenib in melanoma with BRAF V600E mutation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21639808'}, {'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,BRAF Inhibitor,31,14680,BRAF Inhibitor,BRAF V600D,"[{'id': 222, 'pubMedId': 21639808, 'title': 'Improved survival with vemurafenib in melanoma with BRAF V600E mutation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21639808'}, {'id': 467, 'pubMedId': 22608338, 'title': 'Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22608338'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK inhibitor (Pan),142,14681,MEK inhibitor (Pan),BRAF V600D,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/17/2017,MEK1 Inhibitor,143,14682,MEK1 Inhibitor,BRAF V600D,"[{'id': 468, 'pubMedId': 22663011, 'title': 'Improved survival with MEK inhibition in BRAF-mutated melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22663011'}]",,08/17/2017
0,08/17/2017,MEK2 Inhibitor,144,14683,MEK2 Inhibitor,BRAF V600D,"[{'id': 468, 'pubMedId': 22663011, 'title': 'Improved survival with MEK inhibition in BRAF-mutated melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22663011'}]",,08/17/2017
0,08/17/2017,RAF Inhibitor (Pan),197,14684,RAF Inhibitor (Pan),BRAF V600D,"[{'id': 222, 'pubMedId': 21639808, 'title': 'Improved survival with vemurafenib in melanoma with BRAF V600E mutation.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21639808'}, {'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/17/2017
0,08/22/2017,p53 Gene Therapy,167,14686,p53 Gene Therapy,TP53 P98fs,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,08/22/2017
0,08/22/2017,p53 Activator,166,14687,p53 Activator,TP53 A159V,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,08/22/2017
0,08/22/2017,p53 Gene Therapy,167,14688,p53 Gene Therapy,TP53 A159V,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,08/22/2017
0,08/22/2017,p53 Activator,166,14689,p53 Activator,TP53 S215G,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,08/22/2017
0,08/22/2017,p53 Gene Therapy,167,14690,p53 Gene Therapy,TP53 S215G,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,08/22/2017
0,08/22/2017,p53 Gene Therapy,167,14691,p53 Gene Therapy,TP53 Y163*,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,08/22/2017
0,08/22/2017,p53 Gene Therapy,167,14692,p53 Gene Therapy,TP53 L114fs,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,08/22/2017
0,08/22/2017,p53 Gene Therapy,167,14693,p53 Gene Therapy,TP53 V157fs,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,08/22/2017
0,08/23/2017,MEK inhibitor (Pan),142,14698,MEK inhibitor (Pan),BRAF D287H,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/23/2017
0,08/23/2017,MEK1 Inhibitor,143,14699,MEK1 Inhibitor,BRAF D287H,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/23/2017
0,08/23/2017,MEK2 Inhibitor,144,14700,MEK2 Inhibitor,BRAF D287H,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/23/2017
0,08/23/2017,MEK inhibitor (Pan),142,14701,MEK inhibitor (Pan),BRAF V459L,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/23/2017
0,08/23/2017,MEK1 Inhibitor,143,14702,MEK1 Inhibitor,BRAF V459L,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/23/2017
0,08/23/2017,MEK2 Inhibitor,144,14703,MEK2 Inhibitor,BRAF V459L,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,08/23/2017
0,08/24/2017,PDGFR Inhibitor (Pan),175,14712,PDGFR Inhibitor (Pan),PDGFRA D842_H845del,"[{'id': 2152, 'pubMedId': 20509775, 'title': 'Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20509775'}]",,08/24/2017
0,08/24/2017,PDGFR-alpha Inhibitor,176,14713,PDGFR-alpha Inhibitor,PDGFRA D842_H845del,"[{'id': 1621, 'pubMedId': 24359404, 'title': 'Targeting the PDGF signaling pathway in tumor treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24359404'}]",,08/24/2017
0,08/24/2017,PDGFR Inhibitor (Pan),175,14714,PDGFR Inhibitor (Pan),PDGFRA D842_D846del,"[{'id': 2152, 'pubMedId': 20509775, 'title': 'Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20509775'}]",,08/24/2017
0,08/24/2017,PDGFR-alpha Inhibitor,176,14715,PDGFR-alpha Inhibitor,PDGFRA D842_D846del,"[{'id': 1621, 'pubMedId': 24359404, 'title': 'Targeting the PDGF signaling pathway in tumor treatment.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24359404'}]",,08/24/2017
0,08/29/2017,CTNNB1 Inhibitor,60,14716,CTNNB1 Inhibitor,APC Q1480*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,08/29/2017
0,08/29/2017,Tankyrase Inhibitor,215,14717,Tankyrase Inhibitor,APC Q1480*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,08/29/2017
0,08/29/2017,PARP Inhibitor (Pan),171,14718,PARP Inhibitor (Pan),ATM S2407*,"[{'id': 137, 'pubMedId': 20739657, 'title': 'The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20739657'}]",,08/29/2017
0,08/29/2017,p53 Gene Therapy,167,14719,p53 Gene Therapy,TP53 E204fs,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,08/29/2017
0,09/05/2017,KIT Inhibitor,136,14721,KIT Inhibitor,KIT M552_V559del,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}]",,09/05/2017
0,09/06/2017,KIT Inhibitor,136,14722,KIT Inhibitor,KIT S628N,"[{'id': 1964, 'pubMedId': 23127174, 'title': 'Therapeutic targeting of c-KIT in cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23127174'}, {'id': 1965, 'pubMedId': 23775962, 'title': 'Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23775962'}, {'id': 9868, 'pubMedId': 25317746, 'title': 'Characterization of S628N: a novel KIT mutation found in a metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25317746'}]",,09/06/2017
0,09/06/2017,,14724,LY3009120,BRAF G596D,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,09/06/2017
0,09/06/2017,MEK2 Inhibitor,144,14725,MEK2 Inhibitor,BRAF G596D,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,09/06/2017
0,09/06/2017,MEK inhibitor (Pan),142,14726,MEK inhibitor (Pan),BRAF G596D,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,09/06/2017
0,09/06/2017,MEK1 Inhibitor,143,14727,MEK1 Inhibitor,BRAF G596D,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,09/06/2017
0,09/06/2017,MEK inhibitor (Pan),142,14728,MEK inhibitor (Pan),BRAF F247L,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,09/06/2017
0,09/06/2017,MEK2 Inhibitor,144,14729,MEK2 Inhibitor,BRAF F247L,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,09/06/2017
0,09/06/2017,MEK1 Inhibitor,143,14730,MEK1 Inhibitor,BRAF F247L,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,09/06/2017
0,09/06/2017,,14731,LY3009120,BRAF F247L,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,09/06/2017
0,09/06/2017,MEK1 Inhibitor,143,14736,MEK1 Inhibitor,BRAF D594N,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,09/06/2017
0,09/06/2017,MEK2 Inhibitor,144,14737,MEK2 Inhibitor,BRAF D594N,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,09/06/2017
0,09/06/2017,MEK inhibitor (Pan),142,14738,MEK inhibitor (Pan),BRAF D594N,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,09/06/2017
0,09/06/2017,MEK1 Inhibitor,143,14739,MEK1 Inhibitor,BRAF D594H,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,09/06/2017
0,09/06/2017,MEK inhibitor (Pan),142,14740,MEK inhibitor (Pan),BRAF D594H,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,09/06/2017
0,09/06/2017,MEK2 Inhibitor,144,14741,MEK2 Inhibitor,BRAF D594H,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,09/06/2017
0,09/06/2017,MEK2 Inhibitor,144,14742,MEK2 Inhibitor,BRAF D594G,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,09/06/2017
0,09/06/2017,MEK inhibitor (Pan),142,14743,MEK inhibitor (Pan),BRAF D594G,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,09/06/2017
0,09/06/2017,MEK1 Inhibitor,143,14744,MEK1 Inhibitor,BRAF D594G,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,09/06/2017
0,09/06/2017,MEK inhibitor (Pan),142,14748,MEK inhibitor (Pan),BRAF D594E,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,09/06/2017
0,09/06/2017,MEK1 Inhibitor,143,14749,MEK1 Inhibitor,BRAF D594E,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,09/06/2017
0,09/06/2017,MEK2 Inhibitor,144,14750,MEK2 Inhibitor,BRAF D594E,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,09/06/2017
0,09/06/2017,MEK inhibitor (Pan),142,14751,MEK inhibitor (Pan),BRAF F595L,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,09/06/2017
0,09/06/2017,MEK2 Inhibitor,144,14752,MEK2 Inhibitor,BRAF F595L,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,09/06/2017
0,09/06/2017,MEK1 Inhibitor,143,14753,MEK1 Inhibitor,BRAF F595L,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,09/06/2017
0,09/06/2017,MEK1 Inhibitor,143,14754,MEK1 Inhibitor,BRAF D594Y,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,09/06/2017
0,09/06/2017,MEK inhibitor (Pan),142,14755,MEK inhibitor (Pan),BRAF D594Y,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,09/06/2017
0,09/06/2017,MEK2 Inhibitor,144,14756,MEK2 Inhibitor,BRAF D594Y,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,09/06/2017
0,09/07/2017,MEK inhibitor (Pan),142,14757,MEK inhibitor (Pan),BRAF G596C,"[{'id': 1968, 'pubMedId': 25653539, 'title': 'BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25653539'}, {'id': 9692, 'pubMedId': 28783719, 'title': 'Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28783719'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,09/07/2017
0,09/07/2017,MEK1 Inhibitor,143,14758,MEK1 Inhibitor,BRAF G596C,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,09/07/2017
0,09/07/2017,MEK2 Inhibitor,144,14759,MEK2 Inhibitor,BRAF G596C,"[{'id': 7324, 'pubMedId': 25706985, 'title': 'Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25706985'}, {'id': 9743, 'pubMedId': 28203297, 'title': 'Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28203297'}]",,09/07/2017
0,09/07/2017,,14760,LY3009120,BRAF G596C,"[{'id': 4801, 'pubMedId': 26732095, 'title': 'Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26732095'}]",3268,LY3009120,09/07/2017
0,09/08/2017,PARP Inhibitor (Pan),171,14761,PARP Inhibitor (Pan),BRCA1 L392Qfs*5,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,09/08/2017
0,09/08/2017,PARP-1 Inhibitor,172,14762,PARP-1 Inhibitor,BRCA1 L392Qfs*5,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,09/08/2017
0,09/08/2017,PARP Inhibitor (Pan),171,14763,PARP Inhibitor (Pan),BRCA1 W1782*,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,09/08/2017
0,09/08/2017,PARP-1 Inhibitor,172,14764,PARP-1 Inhibitor,BRCA1 W1782*,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,09/08/2017
0,09/08/2017,PARP Inhibitor (Pan),171,14765,PARP Inhibitor (Pan),BRCA1 L631Qfs*4,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,09/08/2017
0,09/08/2017,PARP-1 Inhibitor,172,14766,PARP-1 Inhibitor,BRCA1 L631Qfs*4,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,09/08/2017
0,09/08/2017,PARP Inhibitor (Pan),171,14767,PARP Inhibitor (Pan),BRCA1 N682*,"[{'id': 510, 'pubMedId': 21821475, 'title': 'The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21821475'}]",,09/08/2017
0,09/08/2017,PARP-1 Inhibitor,172,14768,PARP-1 Inhibitor,BRCA1 N682*,"[{'id': 2494, 'pubMedId': 25614115, 'title': 'Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25614115'}]",,09/08/2017
0,09/21/2017,Akt Inhibitor (Pan),4,14828,Akt Inhibitor (Pan),PTEN S10N,"[{'id': 1148, 'pubMedId': 22932669, 'title': 'Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22932669'}, {'id': 2270, 'pubMedId': 22487539, 'title': 'Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22487539'}, {'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,09/21/2017
0,09/21/2017,Akt1 Inhibitor,6,14829,Akt1 Inhibitor,PTEN S10N,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,09/21/2017
0,09/21/2017,Akt2 Inhibitor,7,14830,Akt2 Inhibitor,PTEN S10N,"[{'id': 2278, 'pubMedId': 20085938, 'title': 'The PI3K pathway as drug target in human cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/20085938'}]",,09/21/2017
0,09/21/2017,PI3K Inhibitor (Pan),181,14831,PI3K Inhibitor (Pan),PTEN S10N,"[{'id': 348, 'pubMedId': 22662154, 'title': 'Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22662154'}]",,09/21/2017
0,09/21/2017,PIK3CB inhibitor,183,14832,PIK3CB inhibitor,PTEN S10N,"[{'id': 3345, 'pubMedId': 23674493, 'title': 'PI3K pathway dependencies in endometrioid endometrial cancer cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23674493'}, {'id': 4876, 'pubMedId': 25544636, 'title': 'Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25544636'}]",,09/21/2017
0,09/22/2017,,15267,AZD4785,KRAS G12D,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,15764,MEK1 Inhibitor,KRAS G13D,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,15765,PI3K Inhibitor (Pan),KRAS G13D,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,,15766,AZD4785,KRAS G13D,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,15767,MEK2 Inhibitor,KRAS G13D,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,15768,RAS Inhibitor (Pan),KRAS G13D,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,15769,PIK3CA inhibitor,KRAS G13D,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,15770,MEK inhibitor (Pan),KRAS G13D,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,15771,PI3K Inhibitor (Pan),KRAS L19F,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,,15772,AZD4785,KRAS L19F,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,15773,MEK2 Inhibitor,KRAS L19F,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,15774,RAS Inhibitor (Pan),KRAS L19F,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,15775,PIK3CA inhibitor,KRAS L19F,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,15776,MEK1 Inhibitor,KRAS L19F,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,15777,MEK inhibitor (Pan),KRAS L19F,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,15778,MEK1 Inhibitor,KRAS G12C,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,,15779,AZD4785,KRAS G12C,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,15780,PI3K Inhibitor (Pan),KRAS G12C,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,15781,MEK2 Inhibitor,KRAS G12C,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,15782,MEK inhibitor (Pan),KRAS G12C,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,15783,RAS Inhibitor (Pan),KRAS G12C,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,15784,PIK3CA inhibitor,KRAS G12C,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,15785,MEK2 Inhibitor,KRAS G12V,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,15786,RAS Inhibitor (Pan),KRAS G12V,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,15787,PIK3CA inhibitor,KRAS G12V,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,15788,PI3K Inhibitor (Pan),KRAS G12V,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,15789,MEK1 Inhibitor,KRAS G12V,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,15790,MEK inhibitor (Pan),KRAS G12V,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,,15791,AZD4785,KRAS G12V,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,15792,RAS Inhibitor (Pan),KRAS G12S,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,15793,PIK3CA inhibitor,KRAS G12S,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,,15794,AZD4785,KRAS G12S,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,15795,PI3K Inhibitor (Pan),KRAS G12S,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,15796,MEK2 Inhibitor,KRAS G12S,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,15797,MEK inhibitor (Pan),KRAS G12S,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,15798,MEK1 Inhibitor,KRAS G12S,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,,15799,AZD4785,KRAS G12X,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,15800,MEK2 Inhibitor,KRAS G12X,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,15801,MEK inhibitor (Pan),KRAS G12X,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,15802,PIK3CA inhibitor,KRAS G12X,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,15803,RAS Inhibitor (Pan),KRAS G12X,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,15804,PI3K Inhibitor (Pan),KRAS G12X,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,15805,MEK1 Inhibitor,KRAS G12X,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,15806,PIK3CA inhibitor,KRAS G13X,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,15807,MEK inhibitor (Pan),KRAS G13X,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,,15808,AZD4785,KRAS G13X,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,15809,PI3K Inhibitor (Pan),KRAS G13X,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,15810,MEK1 Inhibitor,KRAS G13X,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,15811,RAS Inhibitor (Pan),KRAS G13X,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,15812,MEK2 Inhibitor,KRAS G13X,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,15813,RAS Inhibitor (Pan),KRAS Q61X,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,,15814,AZD4785,KRAS Q61X,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,15815,PI3K Inhibitor (Pan),KRAS Q61X,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,15816,PIK3CA inhibitor,KRAS Q61X,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,15817,MEK2 Inhibitor,KRAS Q61X,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,15818,MEK1 Inhibitor,KRAS Q61X,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,15819,MEK inhibitor (Pan),KRAS Q61X,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,15820,RAS Inhibitor (Pan),KRAS G13V,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,15821,MEK1 Inhibitor,KRAS G13V,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,15822,MEK inhibitor (Pan),KRAS G13V,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,15823,PI3K Inhibitor (Pan),KRAS G13V,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,15824,MEK2 Inhibitor,KRAS G13V,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,15825,PIK3CA inhibitor,KRAS G13V,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,,15826,AZD4785,KRAS G13V,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,15827,MEK inhibitor (Pan),KRAS G13A,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,15828,PIK3CA inhibitor,KRAS G13A,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,15829,PI3K Inhibitor (Pan),KRAS G13A,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,15830,MEK2 Inhibitor,KRAS G13A,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,,15831,AZD4785,KRAS G13A,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,15832,RAS Inhibitor (Pan),KRAS G13A,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,15833,MEK1 Inhibitor,KRAS G13A,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,15834,MEK1 Inhibitor,KRAS G13S,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,15835,RAS Inhibitor (Pan),KRAS G13S,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,15836,PIK3CA inhibitor,KRAS G13S,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,15837,MEK2 Inhibitor,KRAS G13S,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,,15838,AZD4785,KRAS G13S,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,15839,MEK inhibitor (Pan),KRAS G13S,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,15840,PI3K Inhibitor (Pan),KRAS G13S,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,15841,MEK inhibitor (Pan),KRAS G13C,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,15842,MEK2 Inhibitor,KRAS G13C,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,,15843,AZD4785,KRAS G13C,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,15844,RAS Inhibitor (Pan),KRAS G13C,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,15845,PIK3CA inhibitor,KRAS G13C,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,15846,MEK1 Inhibitor,KRAS G13C,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,15847,PI3K Inhibitor (Pan),KRAS G13C,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,15848,PIK3CA inhibitor,KRAS V14I,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,15849,PI3K Inhibitor (Pan),KRAS V14I,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,15850,RAS Inhibitor (Pan),KRAS V14I,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,15851,MEK2 Inhibitor,KRAS V14I,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,15852,MEK1 Inhibitor,KRAS V14I,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,15853,MEK inhibitor (Pan),KRAS V14I,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,,15854,AZD4785,KRAS V14I,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,15855,PIK3CA inhibitor,KRAS T74P,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,15856,MEK inhibitor (Pan),KRAS T74P,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,15857,MEK2 Inhibitor,KRAS T74P,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,,15858,AZD4785,KRAS T74P,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,15859,RAS Inhibitor (Pan),KRAS T74P,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,15860,PI3K Inhibitor (Pan),KRAS T74P,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,15861,MEK1 Inhibitor,KRAS T74P,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,15862,MEK1 Inhibitor,KRAS A146T,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,15863,RAS Inhibitor (Pan),KRAS A146T,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,,15864,AZD4785,KRAS A146T,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,15865,PIK3CA inhibitor,KRAS A146T,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,15866,MEK2 Inhibitor,KRAS A146T,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,15867,PI3K Inhibitor (Pan),KRAS A146T,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,15868,MEK inhibitor (Pan),KRAS A146T,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,15869,MEK2 Inhibitor,KRAS G12R,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,,15870,AZD4785,KRAS G12R,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,15871,MEK1 Inhibitor,KRAS G12R,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,15872,PI3K Inhibitor (Pan),KRAS G12R,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,15873,RAS Inhibitor (Pan),KRAS G12R,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,15874,PIK3CA inhibitor,KRAS G12R,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,15875,MEK inhibitor (Pan),KRAS G12R,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,15876,PI3K Inhibitor (Pan),KRAS F156L,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,,15877,AZD4785,KRAS F156L,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,15878,MEK1 Inhibitor,KRAS F156L,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,15879,MEK inhibitor (Pan),KRAS F156L,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,15880,PIK3CA inhibitor,KRAS F156L,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,15881,RAS Inhibitor (Pan),KRAS F156L,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,15882,MEK2 Inhibitor,KRAS F156L,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,15883,PIK3CA inhibitor,KRAS Q22K,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,15884,MEK1 Inhibitor,KRAS Q22K,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,15885,MEK inhibitor (Pan),KRAS Q22K,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,,15886,AZD4785,KRAS Q22K,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,15887,MEK2 Inhibitor,KRAS Q22K,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,15888,PI3K Inhibitor (Pan),KRAS Q22K,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,15889,RAS Inhibitor (Pan),KRAS Q22K,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,15890,RAS Inhibitor (Pan),KRAS P34R,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,15891,PI3K Inhibitor (Pan),KRAS P34R,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,15892,PIK3CA inhibitor,KRAS P34R,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,,15893,AZD4785,KRAS P34R,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,15894,MEK1 Inhibitor,KRAS P34R,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,15895,MEK inhibitor (Pan),KRAS P34R,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,15896,MEK2 Inhibitor,KRAS P34R,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,15897,RAS Inhibitor (Pan),KRAS D153V,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,,15898,AZD4785,KRAS D153V,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,15899,MEK1 Inhibitor,KRAS D153V,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,15900,MEK2 Inhibitor,KRAS D153V,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,15901,PIK3CA inhibitor,KRAS D153V,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,15902,MEK inhibitor (Pan),KRAS D153V,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,15903,PI3K Inhibitor (Pan),KRAS D153V,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,15904,MEK2 Inhibitor,KRAS T58I,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,15905,MEK1 Inhibitor,KRAS T58I,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,15906,PI3K Inhibitor (Pan),KRAS T58I,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,15907,RAS Inhibitor (Pan),KRAS T58I,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,15908,PIK3CA inhibitor,KRAS T58I,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,15909,MEK inhibitor (Pan),KRAS T58I,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,,15910,AZD4785,KRAS T58I,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,15911,MEK inhibitor (Pan),KRAS Q61H,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,15912,RAS Inhibitor (Pan),KRAS Q61H,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,15913,PIK3CA inhibitor,KRAS Q61H,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,15914,MEK2 Inhibitor,KRAS Q61H,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,,15915,AZD4785,KRAS Q61H,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,15916,MEK1 Inhibitor,KRAS Q61H,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,15917,PI3K Inhibitor (Pan),KRAS Q61H,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,15918,MEK inhibitor (Pan),KRAS Q61L,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,15919,MEK2 Inhibitor,KRAS Q61L,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,,15920,AZD4785,KRAS Q61L,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,15921,RAS Inhibitor (Pan),KRAS Q61L,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,15922,MEK1 Inhibitor,KRAS Q61L,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,15923,PI3K Inhibitor (Pan),KRAS Q61L,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,15924,PIK3CA inhibitor,KRAS Q61L,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,15925,PI3K Inhibitor (Pan),KRAS Q61K,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,,15926,AZD4785,KRAS Q61K,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,15927,RAS Inhibitor (Pan),KRAS Q61K,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,15928,PIK3CA inhibitor,KRAS Q61K,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,15929,MEK1 Inhibitor,KRAS Q61K,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,15930,MEK inhibitor (Pan),KRAS Q61K,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,15931,MEK2 Inhibitor,KRAS Q61K,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,15932,MEK2 Inhibitor,KRAS Q61R,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,15933,PI3K Inhibitor (Pan),KRAS Q61R,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,15934,RAS Inhibitor (Pan),KRAS Q61R,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,15935,PIK3CA inhibitor,KRAS Q61R,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,15936,MEK1 Inhibitor,KRAS Q61R,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,15937,MEK inhibitor (Pan),KRAS Q61R,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,,15938,AZD4785,KRAS Q61R,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,15939,PIK3CA inhibitor,KRAS N116S,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,15940,RAS Inhibitor (Pan),KRAS N116S,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,15941,PI3K Inhibitor (Pan),KRAS N116S,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,15942,MEK inhibitor (Pan),KRAS N116S,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,,15943,AZD4785,KRAS N116S,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,15944,MEK1 Inhibitor,KRAS N116S,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,15945,MEK2 Inhibitor,KRAS N116S,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,,15946,AZD4785,KRAS K117N,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,15947,MEK inhibitor (Pan),KRAS K117N,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,15948,MEK2 Inhibitor,KRAS K117N,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,15949,MEK1 Inhibitor,KRAS K117N,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,15950,RAS Inhibitor (Pan),KRAS K117N,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,15951,PI3K Inhibitor (Pan),KRAS K117N,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,15952,PIK3CA inhibitor,KRAS K117N,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,,15953,AZD4785,KRAS A146V,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,15954,PIK3CA inhibitor,KRAS A146V,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,15955,MEK inhibitor (Pan),KRAS A146V,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,15956,RAS Inhibitor (Pan),KRAS A146V,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,15957,MEK1 Inhibitor,KRAS A146V,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,15958,PI3K Inhibitor (Pan),KRAS A146V,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,15959,MEK2 Inhibitor,KRAS A146V,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,15960,RAS Inhibitor (Pan),KRAS A146P,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,15961,PIK3CA inhibitor,KRAS A146P,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,15962,MEK2 Inhibitor,KRAS A146P,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,15963,MEK1 Inhibitor,KRAS A146P,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,15964,PI3K Inhibitor (Pan),KRAS A146P,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,15965,MEK inhibitor (Pan),KRAS A146P,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,,15966,AZD4785,KRAS A146P,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,15967,MEK inhibitor (Pan),KRAS G12A,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,,15968,AZD4785,KRAS G12A,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,15969,PI3K Inhibitor (Pan),KRAS G12A,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,15970,MEK1 Inhibitor,KRAS G12A,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,15971,RAS Inhibitor (Pan),KRAS G12A,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,15972,PIK3CA inhibitor,KRAS G12A,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,15973,MEK2 Inhibitor,KRAS G12A,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,15974,MEK inhibitor (Pan),KRAS P34L,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,15975,MEK2 Inhibitor,KRAS P34L,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,15976,MEK1 Inhibitor,KRAS P34L,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,15977,PIK3CA inhibitor,KRAS P34L,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,,15978,AZD4785,KRAS P34L,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,15979,PI3K Inhibitor (Pan),KRAS P34L,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,15980,RAS Inhibitor (Pan),KRAS P34L,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,15981,PIK3CA inhibitor,KRAS G60R,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,15982,RAS Inhibitor (Pan),KRAS G60R,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,15983,MEK2 Inhibitor,KRAS G60R,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,15984,PI3K Inhibitor (Pan),KRAS G60R,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,15985,MEK inhibitor (Pan),KRAS G60R,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,15986,MEK1 Inhibitor,KRAS G60R,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,,15987,AZD4785,KRAS G60R,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,15988,RAS Inhibitor (Pan),KRAS Q22R,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,15989,PIK3CA inhibitor,KRAS Q22R,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,15990,PI3K Inhibitor (Pan),KRAS Q22R,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,15991,MEK1 Inhibitor,KRAS Q22R,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,15992,MEK2 Inhibitor,KRAS Q22R,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,15993,MEK inhibitor (Pan),KRAS Q22R,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,,15994,AZD4785,KRAS Q22R,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,15995,RAS Inhibitor (Pan),KRAS Q22E,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,15996,PIK3CA inhibitor,KRAS Q22E,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,15997,MEK1 Inhibitor,KRAS Q22E,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,15998,PI3K Inhibitor (Pan),KRAS Q22E,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,15999,MEK inhibitor (Pan),KRAS Q22E,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,,16000,AZD4785,KRAS Q22E,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,16001,MEK2 Inhibitor,KRAS Q22E,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,,16002,AZD4785,KRAS K5N,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,16003,PIK3CA inhibitor,KRAS K5N,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,16004,MEK1 Inhibitor,KRAS K5N,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,16005,PI3K Inhibitor (Pan),KRAS K5N,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,16006,MEK2 Inhibitor,KRAS K5N,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,16007,MEK inhibitor (Pan),KRAS K5N,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,16008,RAS Inhibitor (Pan),KRAS K5N,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,16009,MEK1 Inhibitor,KRAS V14L,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,,16010,AZD4785,KRAS V14L,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,16011,MEK2 Inhibitor,KRAS V14L,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,16012,MEK inhibitor (Pan),KRAS V14L,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,16013,PIK3CA inhibitor,KRAS V14L,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,16014,PI3K Inhibitor (Pan),KRAS V14L,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,16015,RAS Inhibitor (Pan),KRAS V14L,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,,16016,AZD4785,KRAS Q61E,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,16017,RAS Inhibitor (Pan),KRAS Q61E,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,16018,MEK2 Inhibitor,KRAS Q61E,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,16019,MEK1 Inhibitor,KRAS Q61E,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,16020,PIK3CA inhibitor,KRAS Q61E,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,16021,PI3K Inhibitor (Pan),KRAS Q61E,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,16022,MEK inhibitor (Pan),KRAS Q61E,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,16023,PI3K Inhibitor (Pan),KRAS Q61P,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,,16024,AZD4785,KRAS Q61P,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,16025,MEK2 Inhibitor,KRAS Q61P,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,16026,MEK1 Inhibitor,KRAS Q61P,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,16027,PIK3CA inhibitor,KRAS Q61P,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,16028,MEK inhibitor (Pan),KRAS Q61P,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,16029,RAS Inhibitor (Pan),KRAS Q61P,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,16030,MEK inhibitor (Pan),KRAS A59G,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,16031,MEK2 Inhibitor,KRAS A59G,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,16032,RAS Inhibitor (Pan),KRAS A59G,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,16033,MEK1 Inhibitor,KRAS A59G,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,16034,PI3K Inhibitor (Pan),KRAS A59G,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,16035,PIK3CA inhibitor,KRAS A59G,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,,16036,AZD4785,KRAS A59G,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,16037,MEK1 Inhibitor,KRAS D119N,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,16038,PIK3CA inhibitor,KRAS D119N,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,,16039,AZD4785,KRAS D119N,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,16040,MEK inhibitor (Pan),KRAS D119N,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,16041,RAS Inhibitor (Pan),KRAS D119N,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,16042,MEK2 Inhibitor,KRAS D119N,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,16043,PI3K Inhibitor (Pan),KRAS D119N,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,16044,PI3K Inhibitor (Pan),KRAS E62K,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,16045,MEK1 Inhibitor,KRAS E62K,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,16046,PIK3CA inhibitor,KRAS E62K,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,16047,MEK2 Inhibitor,KRAS E62K,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,16048,RAS Inhibitor (Pan),KRAS E62K,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,16049,MEK inhibitor (Pan),KRAS E62K,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,,16050,AZD4785,KRAS E62K,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,16051,PI3K Inhibitor (Pan),KRAS A11_G12insGA,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,16052,MEK2 Inhibitor,KRAS A11_G12insGA,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,,16053,AZD4785,KRAS A11_G12insGA,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,16054,PIK3CA inhibitor,KRAS A11_G12insGA,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,16055,MEK1 Inhibitor,KRAS A11_G12insGA,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,16056,RAS Inhibitor (Pan),KRAS A11_G12insGA,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,16057,MEK inhibitor (Pan),KRAS A11_G12insGA,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,16058,MEK1 Inhibitor,KRAS G10dup,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,16059,MEK2 Inhibitor,KRAS G10dup,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,,16060,AZD4785,KRAS G10dup,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,16061,RAS Inhibitor (Pan),KRAS G10dup,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,16062,PIK3CA inhibitor,KRAS G10dup,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,16063,MEK inhibitor (Pan),KRAS G10dup,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,16064,PI3K Inhibitor (Pan),KRAS G10dup,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,16065,RAS Inhibitor (Pan),KRAS G12E,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,16066,MEK inhibitor (Pan),KRAS G12E,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,16067,PI3K Inhibitor (Pan),KRAS G12E,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,16068,MEK1 Inhibitor,KRAS G12E,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,16069,PIK3CA inhibitor,KRAS G12E,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,16070,MEK2 Inhibitor,KRAS G12E,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,,16071,AZD4785,KRAS G12E,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,16072,RAS Inhibitor (Pan),KRAS G12F,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,16073,PI3K Inhibitor (Pan),KRAS G12F,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,16074,MEK inhibitor (Pan),KRAS G12F,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,16075,PIK3CA inhibitor,KRAS G12F,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,16076,MEK1 Inhibitor,KRAS G12F,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,16077,MEK2 Inhibitor,KRAS G12F,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,,16078,AZD4785,KRAS G12F,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,16079,MEK1 Inhibitor,KRAS G12Y,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,16080,PI3K Inhibitor (Pan),KRAS G12Y,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,16081,MEK2 Inhibitor,KRAS G12Y,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,16082,PIK3CA inhibitor,KRAS G12Y,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,16083,MEK inhibitor (Pan),KRAS G12Y,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,,16084,AZD4785,KRAS G12Y,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,16085,RAS Inhibitor (Pan),KRAS G12Y,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,16086,MEK2 Inhibitor,KRAS G12I,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,16087,PIK3CA inhibitor,KRAS G12I,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,16088,RAS Inhibitor (Pan),KRAS G12I,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,16089,PI3K Inhibitor (Pan),KRAS G12I,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,16090,MEK inhibitor (Pan),KRAS G12I,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,,16091,AZD4785,KRAS G12I,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,16092,MEK1 Inhibitor,KRAS G12I,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,16093,MEK inhibitor (Pan),KRAS G12W,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,16094,PI3K Inhibitor (Pan),KRAS G12W,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,16095,MEK2 Inhibitor,KRAS G12W,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,,16096,AZD4785,KRAS G12W,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,16097,PIK3CA inhibitor,KRAS G12W,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,16098,MEK1 Inhibitor,KRAS G12W,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,16099,RAS Inhibitor (Pan),KRAS G12W,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,16100,PIK3CA inhibitor,KRAS G12L,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,,16101,AZD4785,KRAS G12L,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,16102,PI3K Inhibitor (Pan),KRAS G12L,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,16103,RAS Inhibitor (Pan),KRAS G12L,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,16104,MEK1 Inhibitor,KRAS G12L,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,16105,MEK2 Inhibitor,KRAS G12L,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,16106,MEK inhibitor (Pan),KRAS G12L,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,16107,PI3K Inhibitor (Pan),KRAS V41I,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,16108,MEK1 Inhibitor,KRAS V41I,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,,16109,AZD4785,KRAS V41I,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,16110,PIK3CA inhibitor,KRAS V41I,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,16111,MEK2 Inhibitor,KRAS V41I,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,16112,RAS Inhibitor (Pan),KRAS V41I,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,16113,MEK inhibitor (Pan),KRAS V41I,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,16114,RAS Inhibitor (Pan),KRAS G13R,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,16115,PI3K Inhibitor (Pan),KRAS G13R,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,,16116,AZD4785,KRAS G13R,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,16117,MEK1 Inhibitor,KRAS G13R,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,16118,MEK inhibitor (Pan),KRAS G13R,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,16119,MEK2 Inhibitor,KRAS G13R,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,16120,PIK3CA inhibitor,KRAS G13R,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,16121,MEK1 Inhibitor,KRAS G12N,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,16122,MEK2 Inhibitor,KRAS G12N,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,16123,PI3K Inhibitor (Pan),KRAS G12N,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,16124,RAS Inhibitor (Pan),KRAS G12N,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,,16125,AZD4785,KRAS G12N,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,16126,PIK3CA inhibitor,KRAS G12N,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,16127,MEK inhibitor (Pan),KRAS G12N,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,16128,PIK3CA inhibitor,KRAS G13E,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,16129,MEK1 Inhibitor,KRAS G13E,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,16130,PI3K Inhibitor (Pan),KRAS G13E,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,16131,MEK inhibitor (Pan),KRAS G13E,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,,16132,AZD4785,KRAS G13E,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,16133,RAS Inhibitor (Pan),KRAS G13E,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,16134,MEK2 Inhibitor,KRAS G13E,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,16135,PIK3CA inhibitor,KRAS D33E,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,16136,MEK1 Inhibitor,KRAS D33E,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,16137,RAS Inhibitor (Pan),KRAS D33E,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,16138,PI3K Inhibitor (Pan),KRAS D33E,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,16139,MEK inhibitor (Pan),KRAS D33E,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,16140,MEK2 Inhibitor,KRAS D33E,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,,16141,AZD4785,KRAS D33E,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,16142,PIK3CA inhibitor,KRAS E63K,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,,16143,AZD4785,KRAS E63K,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,16144,RAS Inhibitor (Pan),KRAS E63K,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,16145,MEK1 Inhibitor,KRAS E63K,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,16146,MEK2 Inhibitor,KRAS E63K,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,16147,PI3K Inhibitor (Pan),KRAS E63K,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,16148,MEK inhibitor (Pan),KRAS E63K,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,16149,RAS Inhibitor (Pan),KRAS I24N,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,16150,MEK1 Inhibitor,KRAS I24N,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,16151,PIK3CA inhibitor,KRAS I24N,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,16152,PI3K Inhibitor (Pan),KRAS I24N,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,,16153,AZD4785,KRAS I24N,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,16154,MEK inhibitor (Pan),KRAS I24N,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,16155,MEK2 Inhibitor,KRAS I24N,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,16156,RAS Inhibitor (Pan),KRAS F28L,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,16157,PI3K Inhibitor (Pan),KRAS F28L,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,16158,MEK2 Inhibitor,KRAS F28L,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,,16159,AZD4785,KRAS F28L,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,16160,MEK inhibitor (Pan),KRAS F28L,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,16161,MEK1 Inhibitor,KRAS F28L,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,16162,PIK3CA inhibitor,KRAS F28L,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,16163,MEK2 Inhibitor,KRAS K147E,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,16164,MEK1 Inhibitor,KRAS K147E,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,16165,MEK inhibitor (Pan),KRAS K147E,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,16166,PIK3CA inhibitor,KRAS K147E,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,16167,RAS Inhibitor (Pan),KRAS K147E,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,,16168,AZD4785,KRAS K147E,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,16169,PI3K Inhibitor (Pan),KRAS K147E,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,16170,MEK1 Inhibitor,KRAS Q61A,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,16171,MEK2 Inhibitor,KRAS Q61A,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,16172,MEK inhibitor (Pan),KRAS Q61A,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,,16173,AZD4785,KRAS Q61A,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,16174,RAS Inhibitor (Pan),KRAS Q61A,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,16175,PIK3CA inhibitor,KRAS Q61A,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,16176,PI3K Inhibitor (Pan),KRAS Q61A,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,16177,PIK3CA inhibitor,KRAS Y32S,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,16178,PI3K Inhibitor (Pan),KRAS Y32S,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,,16179,AZD4785,KRAS Y32S,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,16180,MEK1 Inhibitor,KRAS Y32S,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,16181,MEK inhibitor (Pan),KRAS Y32S,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,16182,MEK2 Inhibitor,KRAS Y32S,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,16183,RAS Inhibitor (Pan),KRAS Y32S,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,16184,PIK3CA inhibitor,KRAS Y40A,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,16185,MEK inhibitor (Pan),KRAS Y40A,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,,16186,AZD4785,KRAS Y40A,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,16187,MEK1 Inhibitor,KRAS Y40A,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,16188,PI3K Inhibitor (Pan),KRAS Y40A,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,16189,RAS Inhibitor (Pan),KRAS Y40A,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,16190,MEK2 Inhibitor,KRAS Y40A,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,,16191,AZD4785,KRAS Y71H,"[{'id': 9180, 'pubMedId': 28615361, 'title': 'Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/28615361'}]",5914,AZD4785,09/22/2017
0,09/22/2017,RAS Inhibitor (Pan),198,16192,RAS Inhibitor (Pan),KRAS Y71H,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,09/22/2017
0,09/22/2017,MEK2 Inhibitor,144,16193,MEK2 Inhibitor,KRAS Y71H,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,MEK1 Inhibitor,143,16194,MEK1 Inhibitor,KRAS Y71H,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}]",,09/22/2017
0,09/22/2017,PIK3CA inhibitor,182,16195,PIK3CA inhibitor,KRAS Y71H,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 9976, 'pubMedId': 27602501, 'title': 'Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27602501'}]",,09/22/2017
0,09/22/2017,MEK inhibitor (Pan),142,16196,MEK inhibitor (Pan),KRAS Y71H,"[{'id': 187, 'pubMedId': 23934108, 'title': 'Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23934108'}, {'id': 541, 'pubMedId': None, 'title': '', 'url': 'http://meetinglibrary.asco.org/content/105634-133'}, {'id': 542, 'pubMedId': 23200175, 'title': 'Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23200175'}]",,09/22/2017
0,09/22/2017,PI3K Inhibitor (Pan),181,16197,PI3K Inhibitor (Pan),KRAS Y71H,"[{'id': 1891, 'pubMedId': 23360111, 'title': 'Targeting the RAS oncogene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23360111'}, {'id': 4619, 'pubMedId': 26715098, 'title': 'Targeting the PI3K signaling pathway in KRAS mutant colon cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26715098'}]",,09/22/2017
0,09/25/2017,CDK4/6 Inhibitor,43,16198,CDK4/6 Inhibitor,CDKN2A E33fs,"[{'id': 2835, 'pubMedId': 24495407, 'title': 'Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24495407'}, {'id': 2948, 'pubMedId': 23898052, 'title': 'PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23898052'}]",,09/25/2017
0,09/25/2017,CDK Inhibitor (Pan),38,16199,CDK Inhibitor (Pan),CDKN2A E33fs,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK6 Inhibitor,45,16200,CDK6 Inhibitor,CDKN2A E33fs,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK4 Inhibitor,42,16201,CDK4 Inhibitor,CDKN2A E33fs,"[{'id': 2949, 'pubMedId': 18829975, 'title': 'The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18829975'}]",,09/25/2017
0,09/25/2017,CDK6 Inhibitor,45,16202,CDK6 Inhibitor,CDKN2A A68fs,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK Inhibitor (Pan),38,16203,CDK Inhibitor (Pan),CDKN2A A68fs,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK4 Inhibitor,42,16204,CDK4 Inhibitor,CDKN2A A68fs,"[{'id': 2949, 'pubMedId': 18829975, 'title': 'The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18829975'}]",,09/25/2017
0,09/25/2017,CDK4/6 Inhibitor,43,16205,CDK4/6 Inhibitor,CDKN2A A68fs,"[{'id': 2835, 'pubMedId': 24495407, 'title': 'Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24495407'}, {'id': 2948, 'pubMedId': 23898052, 'title': 'PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23898052'}]",,09/25/2017
0,09/25/2017,CDK4 Inhibitor,42,16206,CDK4 Inhibitor,CDKN2A A76fs,"[{'id': 2949, 'pubMedId': 18829975, 'title': 'The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18829975'}]",,09/25/2017
0,09/25/2017,CDK4/6 Inhibitor,43,16207,CDK4/6 Inhibitor,CDKN2A A76fs,"[{'id': 2835, 'pubMedId': 24495407, 'title': 'Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24495407'}, {'id': 2948, 'pubMedId': 23898052, 'title': 'PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23898052'}]",,09/25/2017
0,09/25/2017,CDK6 Inhibitor,45,16208,CDK6 Inhibitor,CDKN2A A76fs,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK Inhibitor (Pan),38,16209,CDK Inhibitor (Pan),CDKN2A A76fs,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK4 Inhibitor,42,16210,CDK4 Inhibitor,CDKN2A A80fs,"[{'id': 2949, 'pubMedId': 18829975, 'title': 'The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18829975'}]",,09/25/2017
0,09/25/2017,CDK Inhibitor (Pan),38,16211,CDK Inhibitor (Pan),CDKN2A A80fs,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK6 Inhibitor,45,16212,CDK6 Inhibitor,CDKN2A A80fs,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK4/6 Inhibitor,43,16213,CDK4/6 Inhibitor,CDKN2A A80fs,"[{'id': 2835, 'pubMedId': 24495407, 'title': 'Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24495407'}, {'id': 2948, 'pubMedId': 23898052, 'title': 'PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23898052'}]",,09/25/2017
0,09/25/2017,CDK6 Inhibitor,45,16214,CDK6 Inhibitor,CDKN2A C72fs,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK Inhibitor (Pan),38,16215,CDK Inhibitor (Pan),CDKN2A C72fs,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK4 Inhibitor,42,16216,CDK4 Inhibitor,CDKN2A C72fs,"[{'id': 2949, 'pubMedId': 18829975, 'title': 'The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18829975'}]",,09/25/2017
0,09/25/2017,CDK4/6 Inhibitor,43,16217,CDK4/6 Inhibitor,CDKN2A C72fs,"[{'id': 2835, 'pubMedId': 24495407, 'title': 'Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24495407'}, {'id': 2948, 'pubMedId': 23898052, 'title': 'PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23898052'}]",,09/25/2017
0,09/25/2017,CDK Inhibitor (Pan),38,16218,CDK Inhibitor (Pan),CDKN2A F90fs,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK4 Inhibitor,42,16219,CDK4 Inhibitor,CDKN2A F90fs,"[{'id': 2949, 'pubMedId': 18829975, 'title': 'The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18829975'}]",,09/25/2017
0,09/25/2017,CDK4/6 Inhibitor,43,16220,CDK4/6 Inhibitor,CDKN2A F90fs,"[{'id': 2835, 'pubMedId': 24495407, 'title': 'Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24495407'}, {'id': 2948, 'pubMedId': 23898052, 'title': 'PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23898052'}]",,09/25/2017
0,09/25/2017,CDK6 Inhibitor,45,16221,CDK6 Inhibitor,CDKN2A F90fs,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK6 Inhibitor,45,16222,CDK6 Inhibitor,CDKN2A L16fs,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK4 Inhibitor,42,16223,CDK4 Inhibitor,CDKN2A L16fs,"[{'id': 2949, 'pubMedId': 18829975, 'title': 'The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18829975'}]",,09/25/2017
0,09/25/2017,CDK Inhibitor (Pan),38,16224,CDK Inhibitor (Pan),CDKN2A L16fs,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK4/6 Inhibitor,43,16225,CDK4/6 Inhibitor,CDKN2A L16fs,"[{'id': 2835, 'pubMedId': 24495407, 'title': 'Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24495407'}, {'id': 2948, 'pubMedId': 23898052, 'title': 'PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23898052'}]",,09/25/2017
0,09/25/2017,CDK4 Inhibitor,42,16226,CDK4 Inhibitor,CDKN2A L78fs,"[{'id': 2949, 'pubMedId': 18829975, 'title': 'The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18829975'}]",,09/25/2017
0,09/25/2017,CDK4/6 Inhibitor,43,16227,CDK4/6 Inhibitor,CDKN2A L78fs,"[{'id': 2835, 'pubMedId': 24495407, 'title': 'Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24495407'}, {'id': 2948, 'pubMedId': 23898052, 'title': 'PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23898052'}]",,09/25/2017
0,09/25/2017,CDK6 Inhibitor,45,16228,CDK6 Inhibitor,CDKN2A L78fs,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK Inhibitor (Pan),38,16229,CDK Inhibitor (Pan),CDKN2A L78fs,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK Inhibitor (Pan),38,16230,CDK Inhibitor (Pan),CDKN2A M52fs,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK6 Inhibitor,45,16231,CDK6 Inhibitor,CDKN2A M52fs,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK4 Inhibitor,42,16232,CDK4 Inhibitor,CDKN2A M52fs,"[{'id': 2949, 'pubMedId': 18829975, 'title': 'The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18829975'}]",,09/25/2017
0,09/25/2017,CDK4/6 Inhibitor,43,16233,CDK4/6 Inhibitor,CDKN2A M52fs,"[{'id': 2835, 'pubMedId': 24495407, 'title': 'Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24495407'}, {'id': 2948, 'pubMedId': 23898052, 'title': 'PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23898052'}]",,09/25/2017
0,09/25/2017,CDK6 Inhibitor,45,16234,CDK6 Inhibitor,CDKN2A P81fs,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK4 Inhibitor,42,16235,CDK4 Inhibitor,CDKN2A P81fs,"[{'id': 2949, 'pubMedId': 18829975, 'title': 'The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18829975'}]",,09/25/2017
0,09/25/2017,CDK4/6 Inhibitor,43,16236,CDK4/6 Inhibitor,CDKN2A P81fs,"[{'id': 2835, 'pubMedId': 24495407, 'title': 'Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24495407'}, {'id': 2948, 'pubMedId': 23898052, 'title': 'PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23898052'}]",,09/25/2017
0,09/25/2017,CDK Inhibitor (Pan),38,16237,CDK Inhibitor (Pan),CDKN2A P81fs,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK6 Inhibitor,45,16238,CDK6 Inhibitor,CDKN2A Q50fs,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK4 Inhibitor,42,16239,CDK4 Inhibitor,CDKN2A Q50fs,"[{'id': 2949, 'pubMedId': 18829975, 'title': 'The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18829975'}]",,09/25/2017
0,09/25/2017,CDK Inhibitor (Pan),38,16240,CDK Inhibitor (Pan),CDKN2A Q50fs,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK4/6 Inhibitor,43,16241,CDK4/6 Inhibitor,CDKN2A Q50fs,"[{'id': 2835, 'pubMedId': 24495407, 'title': 'Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24495407'}, {'id': 2948, 'pubMedId': 23898052, 'title': 'PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23898052'}]",,09/25/2017
0,09/25/2017,CDK4 Inhibitor,42,16242,CDK4 Inhibitor,CDKN2A R58fs,"[{'id': 2949, 'pubMedId': 18829975, 'title': 'The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18829975'}]",,09/25/2017
0,09/25/2017,CDK4/6 Inhibitor,43,16243,CDK4/6 Inhibitor,CDKN2A R58fs,"[{'id': 2835, 'pubMedId': 24495407, 'title': 'Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24495407'}, {'id': 2948, 'pubMedId': 23898052, 'title': 'PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23898052'}]",,09/25/2017
0,09/25/2017,CDK Inhibitor (Pan),38,16244,CDK Inhibitor (Pan),CDKN2A R58fs,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK6 Inhibitor,45,16245,CDK6 Inhibitor,CDKN2A R58fs,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK6 Inhibitor,45,16246,CDK6 Inhibitor,CDKN2A S56fs,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK4/6 Inhibitor,43,16247,CDK4/6 Inhibitor,CDKN2A S56fs,"[{'id': 2835, 'pubMedId': 24495407, 'title': 'Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24495407'}, {'id': 2948, 'pubMedId': 23898052, 'title': 'PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23898052'}]",,09/25/2017
0,09/25/2017,CDK Inhibitor (Pan),38,16248,CDK Inhibitor (Pan),CDKN2A S56fs,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK4 Inhibitor,42,16249,CDK4 Inhibitor,CDKN2A S56fs,"[{'id': 2949, 'pubMedId': 18829975, 'title': 'The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18829975'}]",,09/25/2017
0,09/25/2017,CDK6 Inhibitor,45,16250,CDK6 Inhibitor,CDKN2A T72fs,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK Inhibitor (Pan),38,16251,CDK Inhibitor (Pan),CDKN2A T72fs,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK4 Inhibitor,42,16252,CDK4 Inhibitor,CDKN2A T72fs,"[{'id': 2949, 'pubMedId': 18829975, 'title': 'The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18829975'}]",,09/25/2017
0,09/25/2017,CDK4/6 Inhibitor,43,16253,CDK4/6 Inhibitor,CDKN2A T72fs,"[{'id': 2835, 'pubMedId': 24495407, 'title': 'Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24495407'}, {'id': 2948, 'pubMedId': 23898052, 'title': 'PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23898052'}]",,09/25/2017
0,09/25/2017,CDK4/6 Inhibitor,43,16254,CDK4/6 Inhibitor,CDKN2A T77fs,"[{'id': 2835, 'pubMedId': 24495407, 'title': 'Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24495407'}, {'id': 2948, 'pubMedId': 23898052, 'title': 'PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23898052'}]",,09/25/2017
0,09/25/2017,CDK4 Inhibitor,42,16255,CDK4 Inhibitor,CDKN2A T77fs,"[{'id': 2949, 'pubMedId': 18829975, 'title': 'The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18829975'}]",,09/25/2017
0,09/25/2017,CDK6 Inhibitor,45,16256,CDK6 Inhibitor,CDKN2A T77fs,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK Inhibitor (Pan),38,16257,CDK Inhibitor (Pan),CDKN2A T77fs,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK4/6 Inhibitor,43,16258,CDK4/6 Inhibitor,CDKN2A T79fs,"[{'id': 2835, 'pubMedId': 24495407, 'title': 'Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24495407'}, {'id': 2948, 'pubMedId': 23898052, 'title': 'PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23898052'}]",,09/25/2017
0,09/25/2017,CDK6 Inhibitor,45,16259,CDK6 Inhibitor,CDKN2A T79fs,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK4 Inhibitor,42,16260,CDK4 Inhibitor,CDKN2A T79fs,"[{'id': 2949, 'pubMedId': 18829975, 'title': 'The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18829975'}]",,09/25/2017
0,09/25/2017,CDK Inhibitor (Pan),38,16261,CDK Inhibitor (Pan),CDKN2A T79fs,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK Inhibitor (Pan),38,16262,CDK Inhibitor (Pan),CDKN2A V82fs,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK6 Inhibitor,45,16263,CDK6 Inhibitor,CDKN2A V82fs,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK4/6 Inhibitor,43,16264,CDK4/6 Inhibitor,CDKN2A V82fs,"[{'id': 2835, 'pubMedId': 24495407, 'title': 'Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24495407'}, {'id': 2948, 'pubMedId': 23898052, 'title': 'PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23898052'}]",,09/25/2017
0,09/25/2017,CDK4 Inhibitor,42,16265,CDK4 Inhibitor,CDKN2A V82fs,"[{'id': 2949, 'pubMedId': 18829975, 'title': 'The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18829975'}]",,09/25/2017
0,09/25/2017,CDK4/6 Inhibitor,43,16266,CDK4/6 Inhibitor,CDKN2A W110fs,"[{'id': 2835, 'pubMedId': 24495407, 'title': 'Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24495407'}, {'id': 2948, 'pubMedId': 23898052, 'title': 'PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23898052'}]",,09/25/2017
0,09/25/2017,CDK6 Inhibitor,45,16267,CDK6 Inhibitor,CDKN2A W110fs,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK4 Inhibitor,42,16268,CDK4 Inhibitor,CDKN2A W110fs,"[{'id': 2949, 'pubMedId': 18829975, 'title': 'The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18829975'}]",,09/25/2017
0,09/25/2017,CDK Inhibitor (Pan),38,16269,CDK Inhibitor (Pan),CDKN2A W110fs,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK6 Inhibitor,45,16270,CDK6 Inhibitor,CDKN2A W15fs,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK4 Inhibitor,42,16271,CDK4 Inhibitor,CDKN2A W15fs,"[{'id': 2949, 'pubMedId': 18829975, 'title': 'The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18829975'}]",,09/25/2017
0,09/25/2017,CDK4/6 Inhibitor,43,16272,CDK4/6 Inhibitor,CDKN2A W15fs,"[{'id': 2835, 'pubMedId': 24495407, 'title': 'Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24495407'}, {'id': 2948, 'pubMedId': 23898052, 'title': 'PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23898052'}]",,09/25/2017
0,09/25/2017,CDK Inhibitor (Pan),38,16273,CDK Inhibitor (Pan),CDKN2A W15fs,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK4/6 Inhibitor,43,16274,CDK4/6 Inhibitor,CDKN2A Y44fs,"[{'id': 2835, 'pubMedId': 24495407, 'title': 'Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24495407'}, {'id': 2948, 'pubMedId': 23898052, 'title': 'PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23898052'}]",,09/25/2017
0,09/25/2017,CDK4 Inhibitor,42,16275,CDK4 Inhibitor,CDKN2A Y44fs,"[{'id': 2949, 'pubMedId': 18829975, 'title': 'The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18829975'}]",,09/25/2017
0,09/25/2017,CDK Inhibitor (Pan),38,16276,CDK Inhibitor (Pan),CDKN2A Y44fs,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK6 Inhibitor,45,16277,CDK6 Inhibitor,CDKN2A Y44fs,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK6 Inhibitor,45,16278,CDK6 Inhibitor,CDKN2A G23fs,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK4/6 Inhibitor,43,16279,CDK4/6 Inhibitor,CDKN2A G23fs,"[{'id': 2835, 'pubMedId': 24495407, 'title': 'Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24495407'}, {'id': 2948, 'pubMedId': 23898052, 'title': 'PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23898052'}]",,09/25/2017
0,09/25/2017,CDK Inhibitor (Pan),38,16280,CDK Inhibitor (Pan),CDKN2A G23fs,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK4 Inhibitor,42,16281,CDK4 Inhibitor,CDKN2A G23fs,"[{'id': 2949, 'pubMedId': 18829975, 'title': 'The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18829975'}]",,09/25/2017
0,09/25/2017,CDK6 Inhibitor,45,16282,CDK6 Inhibitor,CDKN2A A102fs,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK4/6 Inhibitor,43,16283,CDK4/6 Inhibitor,CDKN2A A102fs,"[{'id': 2835, 'pubMedId': 24495407, 'title': 'Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24495407'}, {'id': 2948, 'pubMedId': 23898052, 'title': 'PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23898052'}]",,09/25/2017
0,09/25/2017,CDK4 Inhibitor,42,16284,CDK4 Inhibitor,CDKN2A A102fs,"[{'id': 2949, 'pubMedId': 18829975, 'title': 'The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18829975'}]",,09/25/2017
0,09/25/2017,CDK Inhibitor (Pan),38,16285,CDK Inhibitor (Pan),CDKN2A A102fs,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK4 Inhibitor,42,16286,CDK4 Inhibitor,CDKN2A C72*,"[{'id': 2949, 'pubMedId': 18829975, 'title': 'The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18829975'}]",,09/25/2017
0,09/25/2017,CDK4/6 Inhibitor,43,16287,CDK4/6 Inhibitor,CDKN2A C72*,"[{'id': 2835, 'pubMedId': 24495407, 'title': 'Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24495407'}, {'id': 2948, 'pubMedId': 23898052, 'title': 'PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23898052'}]",,09/25/2017
0,09/25/2017,CDK Inhibitor (Pan),38,16288,CDK Inhibitor (Pan),CDKN2A C72*,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK6 Inhibitor,45,16289,CDK6 Inhibitor,CDKN2A C72*,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK4 Inhibitor,42,16290,CDK4 Inhibitor,CDKN2A E120*,"[{'id': 2949, 'pubMedId': 18829975, 'title': 'The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18829975'}]",,09/25/2017
0,09/25/2017,CDK6 Inhibitor,45,16291,CDK6 Inhibitor,CDKN2A E120*,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK Inhibitor (Pan),38,16292,CDK Inhibitor (Pan),CDKN2A E120*,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK4/6 Inhibitor,43,16293,CDK4/6 Inhibitor,CDKN2A E120*,"[{'id': 2835, 'pubMedId': 24495407, 'title': 'Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24495407'}, {'id': 2948, 'pubMedId': 23898052, 'title': 'PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23898052'}]",,09/25/2017
0,09/25/2017,CDK6 Inhibitor,45,16294,CDK6 Inhibitor,CDKN2A E119*,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK4/6 Inhibitor,43,16295,CDK4/6 Inhibitor,CDKN2A E119*,"[{'id': 2835, 'pubMedId': 24495407, 'title': 'Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24495407'}, {'id': 2948, 'pubMedId': 23898052, 'title': 'PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23898052'}]",,09/25/2017
0,09/25/2017,CDK Inhibitor (Pan),38,16296,CDK Inhibitor (Pan),CDKN2A E119*,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK4 Inhibitor,42,16297,CDK4 Inhibitor,CDKN2A E119*,"[{'id': 2949, 'pubMedId': 18829975, 'title': 'The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18829975'}]",,09/25/2017
0,09/25/2017,CDK4 Inhibitor,42,16298,CDK4 Inhibitor,CDKN2A E69*,"[{'id': 2949, 'pubMedId': 18829975, 'title': 'The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18829975'}]",,09/25/2017
0,09/25/2017,CDK4/6 Inhibitor,43,16299,CDK4/6 Inhibitor,CDKN2A E69*,"[{'id': 2835, 'pubMedId': 24495407, 'title': 'Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24495407'}, {'id': 2948, 'pubMedId': 23898052, 'title': 'PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23898052'}]",,09/25/2017
0,09/25/2017,CDK Inhibitor (Pan),38,16300,CDK Inhibitor (Pan),CDKN2A E69*,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK6 Inhibitor,45,16301,CDK6 Inhibitor,CDKN2A E69*,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK4/6 Inhibitor,43,16302,CDK4/6 Inhibitor,CDKN2A E88*,"[{'id': 2835, 'pubMedId': 24495407, 'title': 'Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24495407'}, {'id': 2948, 'pubMedId': 23898052, 'title': 'PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23898052'}]",,09/25/2017
0,09/25/2017,CDK Inhibitor (Pan),38,16303,CDK Inhibitor (Pan),CDKN2A E88*,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK4 Inhibitor,42,16304,CDK4 Inhibitor,CDKN2A E88*,"[{'id': 2949, 'pubMedId': 18829975, 'title': 'The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18829975'}]",,09/25/2017
0,09/25/2017,CDK6 Inhibitor,45,16305,CDK6 Inhibitor,CDKN2A E88*,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK4 Inhibitor,42,16306,CDK4 Inhibitor,CDKN2A Q50*,"[{'id': 2949, 'pubMedId': 18829975, 'title': 'The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18829975'}]",,09/25/2017
0,09/25/2017,CDK6 Inhibitor,45,16307,CDK6 Inhibitor,CDKN2A Q50*,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK4/6 Inhibitor,43,16308,CDK4/6 Inhibitor,CDKN2A Q50*,"[{'id': 2835, 'pubMedId': 24495407, 'title': 'Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24495407'}, {'id': 2948, 'pubMedId': 23898052, 'title': 'PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23898052'}]",,09/25/2017
0,09/25/2017,CDK Inhibitor (Pan),38,16309,CDK Inhibitor (Pan),CDKN2A Q50*,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK6 Inhibitor,45,16310,CDK6 Inhibitor,CDKN2A R58*,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK4 Inhibitor,42,16311,CDK4 Inhibitor,CDKN2A R58*,"[{'id': 2949, 'pubMedId': 18829975, 'title': 'The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18829975'}]",,09/25/2017
0,09/25/2017,CDK Inhibitor (Pan),38,16312,CDK Inhibitor (Pan),CDKN2A R58*,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK4/6 Inhibitor,43,16313,CDK4/6 Inhibitor,CDKN2A R58*,"[{'id': 2835, 'pubMedId': 24495407, 'title': 'Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24495407'}, {'id': 2948, 'pubMedId': 23898052, 'title': 'PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23898052'}]",,09/25/2017
0,09/25/2017,CDK6 Inhibitor,45,16314,CDK6 Inhibitor,CDKN2A R80*,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK4/6 Inhibitor,43,16315,CDK4/6 Inhibitor,CDKN2A R80*,"[{'id': 2835, 'pubMedId': 24495407, 'title': 'Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24495407'}, {'id': 2948, 'pubMedId': 23898052, 'title': 'PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23898052'}]",,09/25/2017
0,09/25/2017,CDK4 Inhibitor,42,16316,CDK4 Inhibitor,CDKN2A R80*,"[{'id': 2949, 'pubMedId': 18829975, 'title': 'The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18829975'}]",,09/25/2017
0,09/25/2017,CDK Inhibitor (Pan),38,16317,CDK Inhibitor (Pan),CDKN2A R80*,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK Inhibitor (Pan),38,16318,CDK Inhibitor (Pan),CDKN2A S12*,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK6 Inhibitor,45,16319,CDK6 Inhibitor,CDKN2A S12*,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK4 Inhibitor,42,16320,CDK4 Inhibitor,CDKN2A S12*,"[{'id': 2949, 'pubMedId': 18829975, 'title': 'The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18829975'}]",,09/25/2017
0,09/25/2017,CDK4/6 Inhibitor,43,16321,CDK4/6 Inhibitor,CDKN2A S12*,"[{'id': 2835, 'pubMedId': 24495407, 'title': 'Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24495407'}, {'id': 2948, 'pubMedId': 23898052, 'title': 'PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23898052'}]",,09/25/2017
0,09/25/2017,CDK Inhibitor (Pan),38,16322,CDK Inhibitor (Pan),CDKN2A W110*,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK4 Inhibitor,42,16323,CDK4 Inhibitor,CDKN2A W110*,"[{'id': 2949, 'pubMedId': 18829975, 'title': 'The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18829975'}]",,09/25/2017
0,09/25/2017,CDK6 Inhibitor,45,16324,CDK6 Inhibitor,CDKN2A W110*,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK4/6 Inhibitor,43,16325,CDK4/6 Inhibitor,CDKN2A W110*,"[{'id': 2835, 'pubMedId': 24495407, 'title': 'Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24495407'}, {'id': 2948, 'pubMedId': 23898052, 'title': 'PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23898052'}]",,09/25/2017
0,09/25/2017,CDK Inhibitor (Pan),38,16326,CDK Inhibitor (Pan),CDKN2A W15*,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK4/6 Inhibitor,43,16327,CDK4/6 Inhibitor,CDKN2A W15*,"[{'id': 2835, 'pubMedId': 24495407, 'title': 'Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24495407'}, {'id': 2948, 'pubMedId': 23898052, 'title': 'PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23898052'}]",,09/25/2017
0,09/25/2017,CDK6 Inhibitor,45,16328,CDK6 Inhibitor,CDKN2A W15*,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK4 Inhibitor,42,16329,CDK4 Inhibitor,CDKN2A W15*,"[{'id': 2949, 'pubMedId': 18829975, 'title': 'The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18829975'}]",,09/25/2017
0,09/25/2017,CDK6 Inhibitor,45,16330,CDK6 Inhibitor,CDKN2A Y44*,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK4 Inhibitor,42,16331,CDK4 Inhibitor,CDKN2A Y44*,"[{'id': 2949, 'pubMedId': 18829975, 'title': 'The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/18829975'}]",,09/25/2017
0,09/25/2017,CDK Inhibitor (Pan),38,16332,CDK Inhibitor (Pan),CDKN2A Y44*,"[{'id': 2838, 'pubMedId': 12777976, 'title': 'The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/12777976'}]",,09/25/2017
0,09/25/2017,CDK4/6 Inhibitor,43,16333,CDK4/6 Inhibitor,CDKN2A Y44*,"[{'id': 2835, 'pubMedId': 24495407, 'title': 'Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24495407'}, {'id': 2948, 'pubMedId': 23898052, 'title': 'PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23898052'}]",,09/25/2017
0,10/04/2017,p53 Activator,166,16335,p53 Activator,TP53 C242Y,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,10/04/2017
0,10/04/2017,p53 Gene Therapy,167,16336,p53 Gene Therapy,TP53 C242Y,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,10/04/2017
0,10/04/2017,p53 Activator,166,16337,p53 Activator,TP53 D281E,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,10/04/2017
0,10/04/2017,p53 Gene Therapy,167,16338,p53 Gene Therapy,TP53 D281E,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,10/04/2017
0,10/04/2017,p53 Activator,166,16339,p53 Activator,TP53 R181P,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,10/04/2017
0,10/04/2017,p53 Gene Therapy,167,16340,p53 Gene Therapy,TP53 R181P,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,10/04/2017
0,10/04/2017,p53 Activator,166,16341,p53 Activator,TP53 G266R,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,10/04/2017
0,10/04/2017,p53 Gene Therapy,167,16342,p53 Gene Therapy,TP53 G266R,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,10/04/2017
0,10/04/2017,p53 Activator,166,16343,p53 Activator,TP53 V143A,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,10/04/2017
0,10/04/2017,p53 Gene Therapy,167,16344,p53 Gene Therapy,TP53 V143A,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,10/04/2017
0,10/04/2017,p53 Activator,166,16345,p53 Activator,TP53 Y236C,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,10/04/2017
0,10/04/2017,p53 Gene Therapy,167,16346,p53 Gene Therapy,TP53 Y236C,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,10/04/2017
0,10/04/2017,p53 Activator,166,16347,p53 Activator,TP53 C135S,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,10/04/2017
0,10/04/2017,p53 Gene Therapy,167,16348,p53 Gene Therapy,TP53 C135S,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,10/04/2017
0,10/05/2017,p53 Activator,166,16349,p53 Activator,TP53 R280T,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,10/05/2017
0,10/05/2017,p53 Gene Therapy,167,16350,p53 Gene Therapy,TP53 R280T,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,10/05/2017
0,10/05/2017,CTNNB1 Inhibitor,60,16351,CTNNB1 Inhibitor,APC E1408*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,10/05/2017
0,10/05/2017,Tankyrase Inhibitor,215,16352,Tankyrase Inhibitor,APC E1408*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,10/05/2017
0,10/05/2017,CTNNB1 Inhibitor,60,16353,CTNNB1 Inhibitor,APC R499*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,10/05/2017
0,10/05/2017,Tankyrase Inhibitor,215,16354,Tankyrase Inhibitor,APC R499*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,10/05/2017
0,10/05/2017,p53 Gene Therapy,167,16355,p53 Gene Therapy,TP53 P152fs,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,10/05/2017
0,10/05/2017,CTNNB1 Inhibitor,60,16356,CTNNB1 Inhibitor,APC S1411fs,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,10/05/2017
0,10/05/2017,Tankyrase Inhibitor,215,16357,Tankyrase Inhibitor,APC S1411fs,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,10/05/2017
0,10/05/2017,mTORC1 Inhibitor,153,16358,mTORC1 Inhibitor,VHL H115Q,"[{'id': 2992, 'pubMedId': 16341243, 'title': 'Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16341243'}]",,10/05/2017
0,10/05/2017,VEGFR Inhibitor (Pan),230,16359,VEGFR Inhibitor (Pan),VHL H115Q,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2902, 'pubMedId': 22931246, 'title': 'Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22931246'}]",,10/05/2017
0,10/05/2017,VEGFR2 Inhibitor,232,16360,VEGFR2 Inhibitor,VHL H115Q,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2901, 'pubMedId': 22105611, 'title': 'Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22105611'}]",,10/05/2017
0,10/06/2017,CTNNB1 Inhibitor,60,16361,CTNNB1 Inhibitor,APC Y935*,"[{'id': 1921, 'pubMedId': 17881494, 'title': 'Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/17881494'}, {'id': 2389, 'pubMedId': 24200292, 'title': 'Exploiting APC function as a novel cancer therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24200292'}]",,10/06/2017
0,10/06/2017,Tankyrase Inhibitor,215,16362,Tankyrase Inhibitor,APC Y935*,"[{'id': 2223, 'pubMedId': 22440753, 'title': 'A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22440753'}, {'id': 3387, 'pubMedId': 23539443, 'title': 'A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/23539443'}]",,10/06/2017
0,10/06/2017,p53 Activator,166,16363,p53 Activator,TP53 H179Y,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,10/06/2017
0,10/06/2017,p53 Gene Therapy,167,16364,p53 Gene Therapy,TP53 H179Y,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,10/06/2017
0,10/06/2017,p53 Activator,166,16365,p53 Activator,TP53 H179L,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,10/06/2017
0,10/06/2017,p53 Gene Therapy,167,16366,p53 Gene Therapy,TP53 H179L,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,10/06/2017
0,10/06/2017,p53 Gene Therapy,167,16367,p53 Gene Therapy,TP53 G244fs,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,10/06/2017
0,10/06/2017,p53 Gene Therapy,167,16368,p53 Gene Therapy,TP53 G154fs,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,10/06/2017
0,10/10/2017,p53 Activator,166,16369,p53 Activator,TP53 C141Y,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,10/10/2017
0,10/10/2017,p53 Gene Therapy,167,16370,p53 Gene Therapy,TP53 C141Y,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,10/10/2017
0,10/10/2017,p53 Activator,166,16371,p53 Activator,TP53 A138T,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,10/10/2017
0,10/10/2017,p53 Gene Therapy,167,16372,p53 Gene Therapy,TP53 A138T,"[{'id': 2108, 'pubMedId': 25455730, 'title': 'p53 as a target for the treatment of cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25455730'}]",,10/10/2017
0,10/11/2017,mTORC1 Inhibitor,153,16373,mTORC1 Inhibitor,VHL L184P,"[{'id': 2992, 'pubMedId': 16341243, 'title': 'Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16341243'}]",,10/11/2017
0,10/11/2017,VEGFR Inhibitor (Pan),230,16374,VEGFR Inhibitor (Pan),VHL L184P,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2902, 'pubMedId': 22931246, 'title': 'Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22931246'}]",,10/11/2017
0,10/11/2017,VEGFR2 Inhibitor,232,16375,VEGFR2 Inhibitor,VHL L184P,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2901, 'pubMedId': 22105611, 'title': 'Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22105611'}]",,10/11/2017
0,10/11/2017,mTORC1 Inhibitor,153,16376,mTORC1 Inhibitor,VHL V155fs,"[{'id': 2992, 'pubMedId': 16341243, 'title': 'Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16341243'}]",,10/11/2017
0,10/11/2017,VEGFR Inhibitor (Pan),230,16377,VEGFR Inhibitor (Pan),VHL V155fs,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2902, 'pubMedId': 22931246, 'title': 'Tumor microvasculature with endothelial fenestrations in VHL null clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22931246'}]",,10/11/2017
0,10/11/2017,VEGFR2 Inhibitor,232,16378,VEGFR2 Inhibitor,VHL V155fs,"[{'id': 2900, 'pubMedId': 25533676, 'title': 'VHL, the story of a tumour suppressor gene.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/25533676'}, {'id': 2901, 'pubMedId': 22105611, 'title': 'Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22105611'}]",,10/11/2017
0,10/16/2017,MEK1 Inhibitor,143,16379,MEK1 Inhibitor,NRAS Q61K,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,PIK3CA inhibitor,182,16380,PIK3CA inhibitor,NRAS Q61K,"[{'id': 28, 'pubMedId': 19629070, 'title': 'Targeting PI3K signalling in cancer: opportunities, challenges and limitations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19629070'}, {'id': 1145, 'pubMedId': 24608574, 'title': 'Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24608574'}]",,10/16/2017
0,10/16/2017,PI3K Inhibitor (Pan),181,16381,PI3K Inhibitor (Pan),NRAS Q61K,"[{'id': 28, 'pubMedId': 19629070, 'title': 'Targeting PI3K signalling in cancer: opportunities, challenges and limitations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19629070'}, {'id': 8051, 'pubMedId': 27307593, 'title': 'PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27307593'}]",,10/16/2017
0,10/16/2017,RAS Inhibitor (Pan),198,16382,RAS Inhibitor (Pan),NRAS Q61K,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,10/16/2017
0,10/16/2017,MEK2 Inhibitor,144,16383,MEK2 Inhibitor,NRAS Q61K,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,MEK inhibitor (Pan),142,16384,MEK inhibitor (Pan),NRAS Q61K,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,PI3K Inhibitor (Pan),181,16385,PI3K Inhibitor (Pan),NRAS Q61X,"[{'id': 28, 'pubMedId': 19629070, 'title': 'Targeting PI3K signalling in cancer: opportunities, challenges and limitations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19629070'}, {'id': 8051, 'pubMedId': 27307593, 'title': 'PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27307593'}]",,10/16/2017
0,10/16/2017,MEK2 Inhibitor,144,16386,MEK2 Inhibitor,NRAS Q61X,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,PIK3CA inhibitor,182,16387,PIK3CA inhibitor,NRAS Q61X,"[{'id': 28, 'pubMedId': 19629070, 'title': 'Targeting PI3K signalling in cancer: opportunities, challenges and limitations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19629070'}, {'id': 1145, 'pubMedId': 24608574, 'title': 'Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24608574'}]",,10/16/2017
0,10/16/2017,MEK inhibitor (Pan),142,16388,MEK inhibitor (Pan),NRAS Q61X,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,RAS Inhibitor (Pan),198,16389,RAS Inhibitor (Pan),NRAS Q61X,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,10/16/2017
0,10/16/2017,MEK1 Inhibitor,143,16390,MEK1 Inhibitor,NRAS Q61X,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,RAS Inhibitor (Pan),198,16391,RAS Inhibitor (Pan),NRAS G60E,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,10/16/2017
0,10/16/2017,MEK2 Inhibitor,144,16392,MEK2 Inhibitor,NRAS G60E,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,PI3K Inhibitor (Pan),181,16393,PI3K Inhibitor (Pan),NRAS G60E,"[{'id': 28, 'pubMedId': 19629070, 'title': 'Targeting PI3K signalling in cancer: opportunities, challenges and limitations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19629070'}, {'id': 8051, 'pubMedId': 27307593, 'title': 'PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27307593'}]",,10/16/2017
0,10/16/2017,MEK inhibitor (Pan),142,16394,MEK inhibitor (Pan),NRAS G60E,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,PIK3CA inhibitor,182,16395,PIK3CA inhibitor,NRAS G60E,"[{'id': 28, 'pubMedId': 19629070, 'title': 'Targeting PI3K signalling in cancer: opportunities, challenges and limitations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19629070'}, {'id': 1145, 'pubMedId': 24608574, 'title': 'Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24608574'}]",,10/16/2017
0,10/16/2017,MEK1 Inhibitor,143,16396,MEK1 Inhibitor,NRAS G60E,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,MEK inhibitor (Pan),142,16397,MEK inhibitor (Pan),NRAS G12S,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,MEK1 Inhibitor,143,16398,MEK1 Inhibitor,NRAS G12S,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,PI3K Inhibitor (Pan),181,16399,PI3K Inhibitor (Pan),NRAS G12S,"[{'id': 28, 'pubMedId': 19629070, 'title': 'Targeting PI3K signalling in cancer: opportunities, challenges and limitations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19629070'}, {'id': 8051, 'pubMedId': 27307593, 'title': 'PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27307593'}]",,10/16/2017
0,10/16/2017,MEK2 Inhibitor,144,16400,MEK2 Inhibitor,NRAS G12S,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,RAS Inhibitor (Pan),198,16401,RAS Inhibitor (Pan),NRAS G12S,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,10/16/2017
0,10/16/2017,PIK3CA inhibitor,182,16402,PIK3CA inhibitor,NRAS G12S,"[{'id': 28, 'pubMedId': 19629070, 'title': 'Targeting PI3K signalling in cancer: opportunities, challenges and limitations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19629070'}, {'id': 1145, 'pubMedId': 24608574, 'title': 'Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24608574'}]",,10/16/2017
0,10/16/2017,RAS Inhibitor (Pan),198,16403,RAS Inhibitor (Pan),NRAS Q61R,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,10/16/2017
0,10/16/2017,MEK1 Inhibitor,143,16404,MEK1 Inhibitor,NRAS Q61R,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,PI3K Inhibitor (Pan),181,16405,PI3K Inhibitor (Pan),NRAS Q61R,"[{'id': 28, 'pubMedId': 19629070, 'title': 'Targeting PI3K signalling in cancer: opportunities, challenges and limitations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19629070'}, {'id': 8051, 'pubMedId': 27307593, 'title': 'PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27307593'}]",,10/16/2017
0,10/16/2017,MEK2 Inhibitor,144,16406,MEK2 Inhibitor,NRAS Q61R,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,MEK inhibitor (Pan),142,16407,MEK inhibitor (Pan),NRAS Q61R,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,PIK3CA inhibitor,182,16408,PIK3CA inhibitor,NRAS Q61R,"[{'id': 28, 'pubMedId': 19629070, 'title': 'Targeting PI3K signalling in cancer: opportunities, challenges and limitations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19629070'}, {'id': 1145, 'pubMedId': 24608574, 'title': 'Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24608574'}]",,10/16/2017
0,10/16/2017,PIK3CA inhibitor,182,16409,PIK3CA inhibitor,NRAS S65C,"[{'id': 28, 'pubMedId': 19629070, 'title': 'Targeting PI3K signalling in cancer: opportunities, challenges and limitations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19629070'}, {'id': 1145, 'pubMedId': 24608574, 'title': 'Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24608574'}]",,10/16/2017
0,10/16/2017,PI3K Inhibitor (Pan),181,16410,PI3K Inhibitor (Pan),NRAS S65C,"[{'id': 28, 'pubMedId': 19629070, 'title': 'Targeting PI3K signalling in cancer: opportunities, challenges and limitations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19629070'}, {'id': 8051, 'pubMedId': 27307593, 'title': 'PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27307593'}]",,10/16/2017
0,10/16/2017,RAS Inhibitor (Pan),198,16411,RAS Inhibitor (Pan),NRAS S65C,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,10/16/2017
0,10/16/2017,MEK1 Inhibitor,143,16412,MEK1 Inhibitor,NRAS S65C,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,MEK inhibitor (Pan),142,16413,MEK inhibitor (Pan),NRAS S65C,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,MEK2 Inhibitor,144,16414,MEK2 Inhibitor,NRAS S65C,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,MEK2 Inhibitor,144,16415,MEK2 Inhibitor,NRAS G12C,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,RAS Inhibitor (Pan),198,16416,RAS Inhibitor (Pan),NRAS G12C,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,10/16/2017
0,10/16/2017,PI3K Inhibitor (Pan),181,16417,PI3K Inhibitor (Pan),NRAS G12C,"[{'id': 28, 'pubMedId': 19629070, 'title': 'Targeting PI3K signalling in cancer: opportunities, challenges and limitations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19629070'}, {'id': 8051, 'pubMedId': 27307593, 'title': 'PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27307593'}]",,10/16/2017
0,10/16/2017,PIK3CA inhibitor,182,16418,PIK3CA inhibitor,NRAS G12C,"[{'id': 28, 'pubMedId': 19629070, 'title': 'Targeting PI3K signalling in cancer: opportunities, challenges and limitations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19629070'}, {'id': 1145, 'pubMedId': 24608574, 'title': 'Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24608574'}]",,10/16/2017
0,10/16/2017,MEK inhibitor (Pan),142,16419,MEK inhibitor (Pan),NRAS G12C,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,MEK1 Inhibitor,143,16420,MEK1 Inhibitor,NRAS G12C,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,RAS Inhibitor (Pan),198,16421,RAS Inhibitor (Pan),NRAS G12A,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,10/16/2017
0,10/16/2017,MEK1 Inhibitor,143,16422,MEK1 Inhibitor,NRAS G12A,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,MEK inhibitor (Pan),142,16423,MEK inhibitor (Pan),NRAS G12A,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,MEK2 Inhibitor,144,16424,MEK2 Inhibitor,NRAS G12A,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,PIK3CA inhibitor,182,16425,PIK3CA inhibitor,NRAS G12A,"[{'id': 28, 'pubMedId': 19629070, 'title': 'Targeting PI3K signalling in cancer: opportunities, challenges and limitations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19629070'}, {'id': 1145, 'pubMedId': 24608574, 'title': 'Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24608574'}]",,10/16/2017
0,10/16/2017,PI3K Inhibitor (Pan),181,16426,PI3K Inhibitor (Pan),NRAS G12A,"[{'id': 28, 'pubMedId': 19629070, 'title': 'Targeting PI3K signalling in cancer: opportunities, challenges and limitations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19629070'}, {'id': 8051, 'pubMedId': 27307593, 'title': 'PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27307593'}]",,10/16/2017
0,10/16/2017,MEK inhibitor (Pan),142,16427,MEK inhibitor (Pan),NRAS A146T,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,MEK1 Inhibitor,143,16428,MEK1 Inhibitor,NRAS A146T,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,PIK3CA inhibitor,182,16429,PIK3CA inhibitor,NRAS A146T,"[{'id': 28, 'pubMedId': 19629070, 'title': 'Targeting PI3K signalling in cancer: opportunities, challenges and limitations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19629070'}, {'id': 1145, 'pubMedId': 24608574, 'title': 'Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24608574'}]",,10/16/2017
0,10/16/2017,MEK2 Inhibitor,144,16430,MEK2 Inhibitor,NRAS A146T,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,RAS Inhibitor (Pan),198,16431,RAS Inhibitor (Pan),NRAS A146T,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,10/16/2017
0,10/16/2017,PI3K Inhibitor (Pan),181,16432,PI3K Inhibitor (Pan),NRAS A146T,"[{'id': 28, 'pubMedId': 19629070, 'title': 'Targeting PI3K signalling in cancer: opportunities, challenges and limitations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19629070'}, {'id': 8051, 'pubMedId': 27307593, 'title': 'PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27307593'}]",,10/16/2017
0,10/16/2017,PIK3CA inhibitor,182,16433,PIK3CA inhibitor,NRAS G12N,"[{'id': 28, 'pubMedId': 19629070, 'title': 'Targeting PI3K signalling in cancer: opportunities, challenges and limitations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19629070'}, {'id': 1145, 'pubMedId': 24608574, 'title': 'Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24608574'}]",,10/16/2017
0,10/16/2017,RAS Inhibitor (Pan),198,16434,RAS Inhibitor (Pan),NRAS G12N,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,10/16/2017
0,10/16/2017,PI3K Inhibitor (Pan),181,16435,PI3K Inhibitor (Pan),NRAS G12N,"[{'id': 28, 'pubMedId': 19629070, 'title': 'Targeting PI3K signalling in cancer: opportunities, challenges and limitations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19629070'}, {'id': 8051, 'pubMedId': 27307593, 'title': 'PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27307593'}]",,10/16/2017
0,10/16/2017,MEK2 Inhibitor,144,16436,MEK2 Inhibitor,NRAS G12N,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,MEK inhibitor (Pan),142,16437,MEK inhibitor (Pan),NRAS G12N,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,MEK1 Inhibitor,143,16438,MEK1 Inhibitor,NRAS G12N,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,RAS Inhibitor (Pan),198,16439,RAS Inhibitor (Pan),NRAS G12R,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,10/16/2017
0,10/16/2017,MEK1 Inhibitor,143,16440,MEK1 Inhibitor,NRAS G12R,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,MEK2 Inhibitor,144,16441,MEK2 Inhibitor,NRAS G12R,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,MEK inhibitor (Pan),142,16442,MEK inhibitor (Pan),NRAS G12R,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,PIK3CA inhibitor,182,16443,PIK3CA inhibitor,NRAS G12R,"[{'id': 28, 'pubMedId': 19629070, 'title': 'Targeting PI3K signalling in cancer: opportunities, challenges and limitations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19629070'}, {'id': 1145, 'pubMedId': 24608574, 'title': 'Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24608574'}]",,10/16/2017
0,10/16/2017,PI3K Inhibitor (Pan),181,16444,PI3K Inhibitor (Pan),NRAS G12R,"[{'id': 28, 'pubMedId': 19629070, 'title': 'Targeting PI3K signalling in cancer: opportunities, challenges and limitations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19629070'}, {'id': 8051, 'pubMedId': 27307593, 'title': 'PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27307593'}]",,10/16/2017
0,10/16/2017,RAS Inhibitor (Pan),198,16445,RAS Inhibitor (Pan),NRAS G12V,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,10/16/2017
0,10/16/2017,MEK inhibitor (Pan),142,16446,MEK inhibitor (Pan),NRAS G12V,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,MEK2 Inhibitor,144,16447,MEK2 Inhibitor,NRAS G12V,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,PI3K Inhibitor (Pan),181,16448,PI3K Inhibitor (Pan),NRAS G12V,"[{'id': 28, 'pubMedId': 19629070, 'title': 'Targeting PI3K signalling in cancer: opportunities, challenges and limitations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19629070'}, {'id': 8051, 'pubMedId': 27307593, 'title': 'PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27307593'}]",,10/16/2017
0,10/16/2017,MEK1 Inhibitor,143,16449,MEK1 Inhibitor,NRAS G12V,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,PIK3CA inhibitor,182,16450,PIK3CA inhibitor,NRAS G12V,"[{'id': 28, 'pubMedId': 19629070, 'title': 'Targeting PI3K signalling in cancer: opportunities, challenges and limitations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19629070'}, {'id': 1145, 'pubMedId': 24608574, 'title': 'Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24608574'}]",,10/16/2017
0,10/16/2017,PI3K Inhibitor (Pan),181,16451,PI3K Inhibitor (Pan),NRAS G13D,"[{'id': 28, 'pubMedId': 19629070, 'title': 'Targeting PI3K signalling in cancer: opportunities, challenges and limitations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19629070'}, {'id': 8051, 'pubMedId': 27307593, 'title': 'PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27307593'}]",,10/16/2017
0,10/16/2017,RAS Inhibitor (Pan),198,16452,RAS Inhibitor (Pan),NRAS G13D,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,10/16/2017
0,10/16/2017,MEK2 Inhibitor,144,16453,MEK2 Inhibitor,NRAS G13D,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,PIK3CA inhibitor,182,16454,PIK3CA inhibitor,NRAS G13D,"[{'id': 28, 'pubMedId': 19629070, 'title': 'Targeting PI3K signalling in cancer: opportunities, challenges and limitations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19629070'}, {'id': 1145, 'pubMedId': 24608574, 'title': 'Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24608574'}]",,10/16/2017
0,10/16/2017,MEK inhibitor (Pan),142,16455,MEK inhibitor (Pan),NRAS G13D,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,MEK1 Inhibitor,143,16456,MEK1 Inhibitor,NRAS G13D,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,MEK inhibitor (Pan),142,16457,MEK inhibitor (Pan),NRAS G13R,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,MEK2 Inhibitor,144,16458,MEK2 Inhibitor,NRAS G13R,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,RAS Inhibitor (Pan),198,16459,RAS Inhibitor (Pan),NRAS G13R,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,10/16/2017
0,10/16/2017,MEK1 Inhibitor,143,16460,MEK1 Inhibitor,NRAS G13R,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,PIK3CA inhibitor,182,16461,PIK3CA inhibitor,NRAS G13R,"[{'id': 28, 'pubMedId': 19629070, 'title': 'Targeting PI3K signalling in cancer: opportunities, challenges and limitations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19629070'}, {'id': 1145, 'pubMedId': 24608574, 'title': 'Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24608574'}]",,10/16/2017
0,10/16/2017,PI3K Inhibitor (Pan),181,16462,PI3K Inhibitor (Pan),NRAS G13R,"[{'id': 28, 'pubMedId': 19629070, 'title': 'Targeting PI3K signalling in cancer: opportunities, challenges and limitations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19629070'}, {'id': 8051, 'pubMedId': 27307593, 'title': 'PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27307593'}]",,10/16/2017
0,10/16/2017,MEK2 Inhibitor,144,16463,MEK2 Inhibitor,NRAS G13V,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,RAS Inhibitor (Pan),198,16464,RAS Inhibitor (Pan),NRAS G13V,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,10/16/2017
0,10/16/2017,MEK inhibitor (Pan),142,16465,MEK inhibitor (Pan),NRAS G13V,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,MEK1 Inhibitor,143,16466,MEK1 Inhibitor,NRAS G13V,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,PI3K Inhibitor (Pan),181,16467,PI3K Inhibitor (Pan),NRAS G13V,"[{'id': 28, 'pubMedId': 19629070, 'title': 'Targeting PI3K signalling in cancer: opportunities, challenges and limitations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19629070'}, {'id': 8051, 'pubMedId': 27307593, 'title': 'PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27307593'}]",,10/16/2017
0,10/16/2017,PIK3CA inhibitor,182,16468,PIK3CA inhibitor,NRAS G13V,"[{'id': 28, 'pubMedId': 19629070, 'title': 'Targeting PI3K signalling in cancer: opportunities, challenges and limitations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19629070'}, {'id': 1145, 'pubMedId': 24608574, 'title': 'Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24608574'}]",,10/16/2017
0,10/16/2017,MEK inhibitor (Pan),142,16469,MEK inhibitor (Pan),NRAS G13S,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,MEK1 Inhibitor,143,16470,MEK1 Inhibitor,NRAS G13S,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,RAS Inhibitor (Pan),198,16471,RAS Inhibitor (Pan),NRAS G13S,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,10/16/2017
0,10/16/2017,MEK2 Inhibitor,144,16472,MEK2 Inhibitor,NRAS G13S,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,PIK3CA inhibitor,182,16473,PIK3CA inhibitor,NRAS G13S,"[{'id': 28, 'pubMedId': 19629070, 'title': 'Targeting PI3K signalling in cancer: opportunities, challenges and limitations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19629070'}, {'id': 1145, 'pubMedId': 24608574, 'title': 'Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24608574'}]",,10/16/2017
0,10/16/2017,PI3K Inhibitor (Pan),181,16474,PI3K Inhibitor (Pan),NRAS G13S,"[{'id': 28, 'pubMedId': 19629070, 'title': 'Targeting PI3K signalling in cancer: opportunities, challenges and limitations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19629070'}, {'id': 8051, 'pubMedId': 27307593, 'title': 'PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27307593'}]",,10/16/2017
0,10/16/2017,RAS Inhibitor (Pan),198,16475,RAS Inhibitor (Pan),NRAS G13C,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,10/16/2017
0,10/16/2017,MEK1 Inhibitor,143,16476,MEK1 Inhibitor,NRAS G13C,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,MEK inhibitor (Pan),142,16477,MEK inhibitor (Pan),NRAS G13C,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,PIK3CA inhibitor,182,16478,PIK3CA inhibitor,NRAS G13C,"[{'id': 28, 'pubMedId': 19629070, 'title': 'Targeting PI3K signalling in cancer: opportunities, challenges and limitations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19629070'}, {'id': 1145, 'pubMedId': 24608574, 'title': 'Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24608574'}]",,10/16/2017
0,10/16/2017,PI3K Inhibitor (Pan),181,16479,PI3K Inhibitor (Pan),NRAS G13C,"[{'id': 28, 'pubMedId': 19629070, 'title': 'Targeting PI3K signalling in cancer: opportunities, challenges and limitations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19629070'}, {'id': 8051, 'pubMedId': 27307593, 'title': 'PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27307593'}]",,10/16/2017
0,10/16/2017,MEK2 Inhibitor,144,16480,MEK2 Inhibitor,NRAS G13C,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,MEK2 Inhibitor,144,16481,MEK2 Inhibitor,NRAS G13A,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,MEK inhibitor (Pan),142,16482,MEK inhibitor (Pan),NRAS G13A,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,PIK3CA inhibitor,182,16483,PIK3CA inhibitor,NRAS G13A,"[{'id': 28, 'pubMedId': 19629070, 'title': 'Targeting PI3K signalling in cancer: opportunities, challenges and limitations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19629070'}, {'id': 1145, 'pubMedId': 24608574, 'title': 'Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24608574'}]",,10/16/2017
0,10/16/2017,PI3K Inhibitor (Pan),181,16484,PI3K Inhibitor (Pan),NRAS G13A,"[{'id': 28, 'pubMedId': 19629070, 'title': 'Targeting PI3K signalling in cancer: opportunities, challenges and limitations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19629070'}, {'id': 8051, 'pubMedId': 27307593, 'title': 'PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27307593'}]",,10/16/2017
0,10/16/2017,MEK1 Inhibitor,143,16485,MEK1 Inhibitor,NRAS G13A,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,RAS Inhibitor (Pan),198,16486,RAS Inhibitor (Pan),NRAS G13A,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,10/16/2017
0,10/16/2017,MEK inhibitor (Pan),142,16487,MEK inhibitor (Pan),NRAS Q61E,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,PI3K Inhibitor (Pan),181,16488,PI3K Inhibitor (Pan),NRAS Q61E,"[{'id': 28, 'pubMedId': 19629070, 'title': 'Targeting PI3K signalling in cancer: opportunities, challenges and limitations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19629070'}, {'id': 8051, 'pubMedId': 27307593, 'title': 'PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27307593'}]",,10/16/2017
0,10/16/2017,MEK1 Inhibitor,143,16489,MEK1 Inhibitor,NRAS Q61E,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,MEK2 Inhibitor,144,16490,MEK2 Inhibitor,NRAS Q61E,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,PIK3CA inhibitor,182,16491,PIK3CA inhibitor,NRAS Q61E,"[{'id': 28, 'pubMedId': 19629070, 'title': 'Targeting PI3K signalling in cancer: opportunities, challenges and limitations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19629070'}, {'id': 1145, 'pubMedId': 24608574, 'title': 'Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24608574'}]",,10/16/2017
0,10/16/2017,RAS Inhibitor (Pan),198,16492,RAS Inhibitor (Pan),NRAS Q61E,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,10/16/2017
0,10/16/2017,PIK3CA inhibitor,182,16493,PIK3CA inhibitor,NRAS Q61H,"[{'id': 28, 'pubMedId': 19629070, 'title': 'Targeting PI3K signalling in cancer: opportunities, challenges and limitations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19629070'}, {'id': 1145, 'pubMedId': 24608574, 'title': 'Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24608574'}]",,10/16/2017
0,10/16/2017,PI3K Inhibitor (Pan),181,16494,PI3K Inhibitor (Pan),NRAS Q61H,"[{'id': 28, 'pubMedId': 19629070, 'title': 'Targeting PI3K signalling in cancer: opportunities, challenges and limitations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19629070'}, {'id': 8051, 'pubMedId': 27307593, 'title': 'PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27307593'}]",,10/16/2017
0,10/16/2017,RAS Inhibitor (Pan),198,16495,RAS Inhibitor (Pan),NRAS Q61H,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,10/16/2017
0,10/16/2017,MEK1 Inhibitor,143,16496,MEK1 Inhibitor,NRAS Q61H,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,MEK inhibitor (Pan),142,16497,MEK inhibitor (Pan),NRAS Q61H,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,MEK2 Inhibitor,144,16498,MEK2 Inhibitor,NRAS Q61H,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,PI3K Inhibitor (Pan),181,16499,PI3K Inhibitor (Pan),NRAS Q61L,"[{'id': 28, 'pubMedId': 19629070, 'title': 'Targeting PI3K signalling in cancer: opportunities, challenges and limitations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19629070'}, {'id': 8051, 'pubMedId': 27307593, 'title': 'PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27307593'}]",,10/16/2017
0,10/16/2017,MEK1 Inhibitor,143,16500,MEK1 Inhibitor,NRAS Q61L,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,RAS Inhibitor (Pan),198,16501,RAS Inhibitor (Pan),NRAS Q61L,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,10/16/2017
0,10/16/2017,PIK3CA inhibitor,182,16502,PIK3CA inhibitor,NRAS Q61L,"[{'id': 28, 'pubMedId': 19629070, 'title': 'Targeting PI3K signalling in cancer: opportunities, challenges and limitations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19629070'}, {'id': 1145, 'pubMedId': 24608574, 'title': 'Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24608574'}]",,10/16/2017
0,10/16/2017,MEK inhibitor (Pan),142,16503,MEK inhibitor (Pan),NRAS Q61L,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,MEK2 Inhibitor,144,16504,MEK2 Inhibitor,NRAS Q61L,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,PIK3CA inhibitor,182,16505,PIK3CA inhibitor,NRAS Q61P,"[{'id': 28, 'pubMedId': 19629070, 'title': 'Targeting PI3K signalling in cancer: opportunities, challenges and limitations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19629070'}, {'id': 1145, 'pubMedId': 24608574, 'title': 'Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24608574'}]",,10/16/2017
0,10/16/2017,MEK2 Inhibitor,144,16506,MEK2 Inhibitor,NRAS Q61P,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,RAS Inhibitor (Pan),198,16507,RAS Inhibitor (Pan),NRAS Q61P,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,10/16/2017
0,10/16/2017,PI3K Inhibitor (Pan),181,16508,PI3K Inhibitor (Pan),NRAS Q61P,"[{'id': 28, 'pubMedId': 19629070, 'title': 'Targeting PI3K signalling in cancer: opportunities, challenges and limitations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19629070'}, {'id': 8051, 'pubMedId': 27307593, 'title': 'PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27307593'}]",,10/16/2017
0,10/16/2017,MEK1 Inhibitor,143,16509,MEK1 Inhibitor,NRAS Q61P,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,MEK inhibitor (Pan),142,16510,MEK inhibitor (Pan),NRAS Q61P,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,PIK3CA inhibitor,182,16511,PIK3CA inhibitor,NRAS G12Y,"[{'id': 28, 'pubMedId': 19629070, 'title': 'Targeting PI3K signalling in cancer: opportunities, challenges and limitations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19629070'}, {'id': 1145, 'pubMedId': 24608574, 'title': 'Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24608574'}]",,10/16/2017
0,10/16/2017,RAS Inhibitor (Pan),198,16512,RAS Inhibitor (Pan),NRAS G12Y,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,10/16/2017
0,10/16/2017,MEK1 Inhibitor,143,16513,MEK1 Inhibitor,NRAS G12Y,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,MEK2 Inhibitor,144,16514,MEK2 Inhibitor,NRAS G12Y,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,PI3K Inhibitor (Pan),181,16515,PI3K Inhibitor (Pan),NRAS G12Y,"[{'id': 28, 'pubMedId': 19629070, 'title': 'Targeting PI3K signalling in cancer: opportunities, challenges and limitations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19629070'}, {'id': 8051, 'pubMedId': 27307593, 'title': 'PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27307593'}]",,10/16/2017
0,10/16/2017,MEK inhibitor (Pan),142,16516,MEK inhibitor (Pan),NRAS G12Y,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,MEK2 Inhibitor,144,16517,MEK2 Inhibitor,NRAS E63K,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,PIK3CA inhibitor,182,16518,PIK3CA inhibitor,NRAS E63K,"[{'id': 28, 'pubMedId': 19629070, 'title': 'Targeting PI3K signalling in cancer: opportunities, challenges and limitations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19629070'}, {'id': 1145, 'pubMedId': 24608574, 'title': 'Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24608574'}]",,10/16/2017
0,10/16/2017,MEK inhibitor (Pan),142,16519,MEK inhibitor (Pan),NRAS E63K,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,RAS Inhibitor (Pan),198,16520,RAS Inhibitor (Pan),NRAS E63K,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,10/16/2017
0,10/16/2017,PI3K Inhibitor (Pan),181,16521,PI3K Inhibitor (Pan),NRAS E63K,"[{'id': 28, 'pubMedId': 19629070, 'title': 'Targeting PI3K signalling in cancer: opportunities, challenges and limitations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19629070'}, {'id': 8051, 'pubMedId': 27307593, 'title': 'PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27307593'}]",,10/16/2017
0,10/16/2017,MEK1 Inhibitor,143,16522,MEK1 Inhibitor,NRAS E63K,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,MEK inhibitor (Pan),142,16523,MEK inhibitor (Pan),NRAS T50I,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,MEK2 Inhibitor,144,16524,MEK2 Inhibitor,NRAS T50I,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,MEK1 Inhibitor,143,16525,MEK1 Inhibitor,NRAS T50I,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,PIK3CA inhibitor,182,16526,PIK3CA inhibitor,NRAS T50I,"[{'id': 28, 'pubMedId': 19629070, 'title': 'Targeting PI3K signalling in cancer: opportunities, challenges and limitations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19629070'}, {'id': 1145, 'pubMedId': 24608574, 'title': 'Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24608574'}]",,10/16/2017
0,10/16/2017,RAS Inhibitor (Pan),198,16527,RAS Inhibitor (Pan),NRAS T50I,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,10/16/2017
0,10/16/2017,PI3K Inhibitor (Pan),181,16528,PI3K Inhibitor (Pan),NRAS T50I,"[{'id': 28, 'pubMedId': 19629070, 'title': 'Targeting PI3K signalling in cancer: opportunities, challenges and limitations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19629070'}, {'id': 8051, 'pubMedId': 27307593, 'title': 'PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27307593'}]",,10/16/2017
0,10/16/2017,MEK inhibitor (Pan),142,16529,MEK inhibitor (Pan),NRAS G12X,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,MEK1 Inhibitor,143,16530,MEK1 Inhibitor,NRAS G12X,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,MEK2 Inhibitor,144,16531,MEK2 Inhibitor,NRAS G12X,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,PI3K Inhibitor (Pan),181,16532,PI3K Inhibitor (Pan),NRAS G12X,"[{'id': 28, 'pubMedId': 19629070, 'title': 'Targeting PI3K signalling in cancer: opportunities, challenges and limitations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19629070'}, {'id': 8051, 'pubMedId': 27307593, 'title': 'PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27307593'}]",,10/16/2017
0,10/16/2017,PIK3CA inhibitor,182,16533,PIK3CA inhibitor,NRAS G12X,"[{'id': 28, 'pubMedId': 19629070, 'title': 'Targeting PI3K signalling in cancer: opportunities, challenges and limitations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19629070'}, {'id': 1145, 'pubMedId': 24608574, 'title': 'Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24608574'}]",,10/16/2017
0,10/16/2017,RAS Inhibitor (Pan),198,16534,RAS Inhibitor (Pan),NRAS G12X,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,10/16/2017
0,10/16/2017,MEK inhibitor (Pan),142,16535,MEK inhibitor (Pan),NRAS G13X,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,MEK1 Inhibitor,143,16536,MEK1 Inhibitor,NRAS G13X,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,MEK2 Inhibitor,144,16537,MEK2 Inhibitor,NRAS G13X,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,PI3K Inhibitor (Pan),181,16538,PI3K Inhibitor (Pan),NRAS G13X,"[{'id': 28, 'pubMedId': 19629070, 'title': 'Targeting PI3K signalling in cancer: opportunities, challenges and limitations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19629070'}, {'id': 8051, 'pubMedId': 27307593, 'title': 'PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27307593'}]",,10/16/2017
0,10/16/2017,PIK3CA inhibitor,182,16539,PIK3CA inhibitor,NRAS G13X,"[{'id': 28, 'pubMedId': 19629070, 'title': 'Targeting PI3K signalling in cancer: opportunities, challenges and limitations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19629070'}, {'id': 1145, 'pubMedId': 24608574, 'title': 'Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24608574'}]",,10/16/2017
0,10/16/2017,RAS Inhibitor (Pan),198,16540,RAS Inhibitor (Pan),NRAS G13X,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,10/16/2017
0,10/16/2017,MEK inhibitor (Pan),142,16541,MEK inhibitor (Pan),NRAS T58I,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,MEK1 Inhibitor,143,16542,MEK1 Inhibitor,NRAS T58I,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,MEK2 Inhibitor,144,16543,MEK2 Inhibitor,NRAS T58I,"[{'id': 1839, 'pubMedId': 24419498, 'title': 'The role of MEK inhibitors in the treatment of metastatic melanoma.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24419498'}]",,10/16/2017
0,10/16/2017,PI3K Inhibitor (Pan),181,16544,PI3K Inhibitor (Pan),NRAS T58I,"[{'id': 28, 'pubMedId': 19629070, 'title': 'Targeting PI3K signalling in cancer: opportunities, challenges and limitations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19629070'}, {'id': 8051, 'pubMedId': 27307593, 'title': 'PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/27307593'}]",,10/16/2017
0,10/16/2017,PIK3CA inhibitor,182,16545,PIK3CA inhibitor,NRAS T58I,"[{'id': 28, 'pubMedId': 19629070, 'title': 'Targeting PI3K signalling in cancer: opportunities, challenges and limitations.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/19629070'}, {'id': 1145, 'pubMedId': 24608574, 'title': 'Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24608574'}]",,10/16/2017
0,10/16/2017,RAS Inhibitor (Pan),198,16546,RAS Inhibitor (Pan),NRAS T58I,"[{'id': 212, 'pubMedId': 16774045, 'title': 'Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/16774045'}]",,10/16/2017
